<SEC-DOCUMENT>0000950170-24-021074.txt : 20240227
<SEC-HEADER>0000950170-24-021074.hdr.sgml : 20240227
<ACCEPTANCE-DATETIME>20240227160155
ACCESSION NUMBER:		0000950170-24-021074
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240227
DATE AS OF CHANGE:		20240227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Fulcrum Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001680581
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				474839948
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38978
		FILM NUMBER:		24686353

	BUSINESS ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-651-8851

	MAIL ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fulc-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:fulc="http://www.fulcrumtx.com/20231231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a151601b-25e5-4dce-a7af-59adc7c0046e" name="dei:EntityCentralIndexKey" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c">0001680581</ix:nonNumeric><ix:nonNumeric id="F_418f39dc-1c32-4f25-a4ea-883e4e1ecce1" name="dei:AmendmentFlag" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_147a6ca8-da94-428a-949b-b233bda25635" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="C_f027d984-8450-4048-9d00-1f28f5700faa" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction><ix:nonNumeric id="F_7ea1fc65-b56a-4dfb-832a-ef4cfbdfdbe6" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_2fbda0dc-8dce-4255-a8df-39239cbf99b4">true</ix:nonNumeric><ix:nonNumeric id="F_6b56879a-8609-407b-a0e6-9933f8568a75" name="dei:DocumentFiscalPeriodFocus" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c">FY</ix:nonNumeric><ix:nonFraction id="F_1a1e02a0-4db7-4a97-ad0d-1f182f01916f" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="C_30e3fda8-1f2a-42d1-bbf1-8d7c093ac7d6" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction><ix:nonNumeric id="F_5371ab0a-259c-42e8-a3f8-9e6fae93b21c" name="dei:CurrentFiscalYearEndDate" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c">--12-31</ix:nonNumeric><ix:nonFraction id="F_f5f1606d-dc3f-4973-a9fa-9933609a1b1d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_766f3400-711f-4ffa-babd-fbc7095320eb" name="us-gaap:CommitmentsAndContingencies" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1a68b880-8a0c-4fb5-9af0-f610de17e8b2" name="us-gaap:NumberOfOperatingSegments" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_34f687fe-c7b7-4d4d-a574-1aceb3c54fb6" name="us-gaap:OpenTaxYear" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c">2016 2017 2018 2019 2020</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fulc-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_bc43a13b-90f8-4ef8-89c3-5e47e6633f21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30e3fda8-1f2a-42d1-bbf1-8d7c093ac7d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b2cb0ed-bc13-4280-b556-83c472d55900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b63474af-44cc-4faf-b216-6548e22c9832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_830548a4-6251-494e-acc6-0972515e7069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5fa44bd-3098-4335-bd36-e6a28c5c81f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:Camp4AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98a6da6d-074f-41ab-bfc4-6a2ea10c4c2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17ffb108-fe7e-476c-83d5-3f1c63e048af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b517f554-4042-404a-9af4-f3387f4737b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwothousandtwentytwoinducementstockincentiveplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_375efc5e-e60e-4b9b-bf98-fb370dc4734f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62175780-5393-425b-aa05-cee4f721a128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79eda3da-f82b-42a7-9282-e10d0fdfbdf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-02</xbrli:startDate><xbrli:endDate>2019-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_630894ba-94c3-4b2d-a63f-cbe1dd1d4533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_331bbcc1-90e8-4bf6-9dcd-ca73f84cc749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e910a3d-1e4f-4b7c-85cc-e29372e692ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ce2bbff-4474-45cb-9d57-0f72591eb0e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3bf28ad-b304-4305-a570-1122422d798b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3e57f9c-5c4a-427a-ae13-ff85b90fbe11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f962abd-0c59-46b0-942a-62bedb1c8907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9395349-8914-4a65-9d57-bc8e29bb62e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-31</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5418e51c-11bd-4ab1-86e5-58e2085729af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3a948e1-3f74-4748-b84d-2b0696114a7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_874dc0df-15d5-4f39-8253-51d6179f2225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1553121b-ab45-495e-b5a0-c6324fbe71f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef714543-18c5-47fb-aabb-747b27cc8411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsUnderTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d813c32-3ade-4f1e-a7d9-3519e68f4cac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63c6c909-d955-4771-8848-2cdb7bda457f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b2a8270-a42f-4a33-8218-0bc08d831c80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a2cdb21-6525-45f5-bf28-66b9a5ce67b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d0c7846-78b1-4df1-8b8d-1b707923fa89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandAndTwentyTwoInducementStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98d7485a-ca98-4800-86e5-94959550472d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb5c742b-1082-4c9f-adea-cdf8661b486d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e35e38c-6f43-4880-aab5-7ba1d31d8d24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ba2348b-df57-42f0-b766-38e72c616f8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a3bad76-7c81-4609-ae81-f7496ee21338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edc3b5c0-37a2-4a67-b22d-a8f24b1a6030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94054f0d-7eb4-4308-b9a8-6595c31dccc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_000f7fb2-957c-4f01-b3cf-38256d89b74f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22c69f38-8bae-4283-a815-fd207b1f78a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">fulc:LegalProceedingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94104f8d-cdd1-47a0-bd4b-ab3238e5307d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_465c59ff-4b61-4b2d-8eaa-5ac890630a2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a87177cb-5bc3-41bf-971c-4854bb97a946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1084719-244f-4e97-8f34-58c058846345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwothousandtwentytwoinducementstockincentiveplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a8b9b58-5d94-486d-a1c0-5e1919ae1ab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e373bc4-17ca-40e0-beff-f412a277967e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_343e6c36-f77a-4689-8990-03e75af7256f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddb6c423-a9fc-4d5d-b7bc-80dc1e5b3113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c3c4af6-ca10-4044-9408-a2cfdd8766f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:LandsdowneStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a79a27de-8391-4e03-935a-a5b39db9ffc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67ea3264-4f09-49a3-8fab-3cdfe1108e54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fae73cbe-4594-47e0-a56a-d04732d2b464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddc92748-af69-48e3-ad4c-c0752140c842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5df36d60-952e-4b70-a43a-be90787573aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2034a62c-8291-4271-afc4-d4d11578f7a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f46423a4-6cae-4566-b0b3-c4344e7e0ddc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71bc03af-5035-47a1-a103-ae996647c88e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a8da089-33c9-42b0-ba2e-0a03c031f084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd317054-d5af-4b47-89c2-049b6bdcf482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:Camp4AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1db948c7-31b2-4309-a481-9cda796e4d8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51307bed-9fb2-4853-8cce-0c34673cf5f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69b9c54c-e52c-4afc-b0d8-7b44074f2ffe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85e16b30-1163-467d-8e7c-c5891589de08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40257969-ac48-44c3-9ca7-ffe11592ae76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4f28692-ee59-4c99-998d-16b6c76ed96d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:CorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b18d8319-eea3-4201-bf6f-cdbb16015369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_508a96d8-65ca-4e37-92e2-530cc3c9b8b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19b2e307-2653-4c2d-ac68-2e2064f71c76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e7d6101-2b2e-4757-966e-e38a693e1fe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9320667-4317-4880-b542-adec903ee354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e746306c-e757-4570-81a1-01d41ff4c7c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:LandsdowneStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8a31241-faea-4738-8c70-9704d5b4aa96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbda6a93-4094-47c4-ac19-6cebaec8a93d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_990c5530-0921-4d0d-abca-bc365950858b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7d85ad2-5aaa-4c27-af4c-3ddc57509e92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e04dd368-3fa8-45c2-825d-2725b8979f16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45f470b7-37af-4351-8f8c-c8ecfdfc36bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_184f93c0-caca-423f-93d2-bab19e3e2a1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f634eef-7981-4392-81a6-c6c15de65892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbc1c709-9a9f-4ee8-ae35-e6e93fd2f8f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbd2599a-812b-4ac3-94fe-e6eac2633ccd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fbda0dc-8dce-4255-a8df-39239cbf99b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">fulc:CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cca8e9eb-dd24-4750-983a-2de55f115638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98e7f3b2-a03a-4688-bc57-f63c93ac0609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsUnderTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb406b69-1f55-4cbb-aacf-ebebc94b8c0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandAndTwentyTwoInducementStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5854b7db-5036-4f5d-b484-aa8238657b18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c4254ea-de8b-4774-8083-9eb5cd87bb6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a18d155f-7a8d-4b6c-9a25-f1314028d766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b05eccd-bd38-4e74-aadd-9cd13b5c1a5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:CorporateBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf9e5807-85a6-4487-b3cc-e06892d1b91c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fb06a81-59b1-410a-943c-d31a633e10ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4c94a63-164c-46e2-af94-f4aa5ed3dad5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fulc:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ccff940-b46f-49f2-a0ba-1cf5bf8580ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_542d5873-acb9-4a0a-8e2d-dac0c67b8056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ddbacbc-0594-4cc9-a6ac-745a13b49459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb41ec6a-6f90-42d8-a1d9-14d1685b4dbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5298f167-d10a-434d-ac4b-5d0e08769dd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwothousandtwentytwoinducementstockincentiveplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ba02dc0-884d-416e-855c-afa71a9532cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_884143a7-2e26-4a93-ac13-566cb4dd0eaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0663cabf-5a8c-4583-a6b8-7af5d48c1798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a1f01be-46f9-44b7-9528-8152dca6e10e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea0f142c-6216-4014-90e1-aa57c23c6c6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fulc:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2846897-76a3-4206-9f4d-846065573bee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fulc:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1189e0ad-3433-423c-b4a2-785ddc505de5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2704081c-8b8e-46dd-97fd-b538434d0d04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7354e229-40c7-40da-a524-c89e5cf4d63b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11995c32-99cc-441f-9c07-7fd5a7ad4859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e7c4269-98eb-4914-9616-c8e3cd7260bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2062e16-6f62-4e3b-89f8-c083e9ea8bfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfcc2344-b6f1-4e48-98ac-862abef9fa95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18e2c630-6ac6-421f-9bc1-23e2b22a1afb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwothousandtwentytwoinducementstockincentiveplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43ee8347-1c34-42ba-9abd-dcdc1b5cbd11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34147407-27d4-48db-9e5a-99ff76257ddc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-02</xbrli:startDate><xbrli:endDate>2019-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_848b9802-2af7-4a3a-b897-56f5907cf9a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a247c0da-5748-4ee1-809e-b40ff34a7c07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf990f8e-d292-4776-92bd-5fa5305cf788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4c8c6c6-98f6-489e-a40d-a5ff2e15f073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37fbfbef-7505-46ab-bce6-acf025a24bb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f027d984-8450-4048-9d00-1f28f5700faa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3409faec-0230-4835-b5e3-04aae93d50b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc2dcbed-a530-47fe-b591-af8023e6e6ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fulc:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:GSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91aa4910-0766-4281-855f-db89fadd437e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:GSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0796c66-5faa-42cb-bb2a-9806d8b59cc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f435b74c-2ffc-441d-adc0-12a5eda8264a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa1479d0-71e2-465d-899e-3a286e2d39c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1a6601c-64be-4399-85ae-db7867216139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa92b40b-ab4d-458f-9b44-218ef3a76113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6c403c7-c450-4827-9fce-058e2ee7e5b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae3bba65-b6cd-4d0b-9844-04bfbfe465a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_307f7d91-6fab-4f2c-b389-665c233bce30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:LandsdowneStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_944dfc71-acfe-4731-851c-eec85eb1064c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9eb8757-a555-4809-8e7b-95ed236c0f69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:GSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87e20816-2f34-485e-b3e4-7088d4e8e968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78fb4e2e-0240-4074-b54f-749132177dc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:CorporateBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36c5b7d8-3257-4975-88e1-ef21c0684b9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96c49986-10b9-4fb3-ac44-74df5efad901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:LandsdowneStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84b31042-326d-4a8d-bb3a-1fab245f12f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55fd13cf-5a49-4af6-b31e-8f8a1b4bf952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea348ed2-fdcc-4579-91c5-808f2dfce003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c1be40a-0714-4b4f-8656-46ec78f32fc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16f0f75c-5dfd-4809-a32b-10469163a156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3376273-a29c-48cf-8511-32060db0b560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:CorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5186a5a2-f3b1-4be3-90f3-23ff2a2bd44a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7022a87d-e56e-48d8-8868-7ed1b8f6cd32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fulc:ResearchMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3d54fc7-6a3d-43de-9e32-8e241187c233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7baf9985-59a2-4afb-b460-9750260fe38c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fulc:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_909e565e-556f-4785-a3a2-94aa703eda4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8919af49-dcdf-4a7e-89e1-427cdf1d9a7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96906aae-d485-4fa9-8d8d-c0baeaee0dc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da574656-31f4-41eb-8cfa-bc58b33e0fa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_477d49f1-72c7-42b4-91d0-1ea14d3bf239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e83c356b-9ff3-413e-a403-598979417ee5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04824925-8561-4f56-bff5-d30316c83058"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57f214bc-60d6-4c5d-b206-28aa46d3644a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ce307f7-639d-48f2-8416-d63934e3040e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_749e2b12-a6eb-4d72-8bf1-bab5c1af0594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bca61fa2-7113-472f-975c-b0f57452da67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bf64331-d750-4ee0-8b5b-6d241408072d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680581</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>fulc:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_SquareFeet"><xbrli:measure>fulc:SquareFeet</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>fulc:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea02c8c4-74f6-4c6c-ba67-e49aeccd869f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a89f8b5-5c7f-497b-9df0-d9f41a6e0852" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff152776-33ac-4a4a-a6ab-30d9d7488525" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ab3f932-7b6f-4ac6-8b88-91f0986571e9" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e47c69cf-a8a4-4725-8c1c-59b4ca56992e" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744; </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                     </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7320a356-58b6-49f9-9ba9-462b5b258261" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-38978</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7b6be00-5567-45e5-9746-0eba9e60b7e4" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">FULCRUM THERAPEUTICS, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b00fc233-2eb9-4126-ad43-c070c59d143d" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_adfdcee4-e6e6-4ed9-9ff2-a8ed88ec8306" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47-4839948</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2d77796c-a243-465c-95b3-bdf03720c16d" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">26 Landsdowne Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_f7d08653-1ffa-451c-8a41-62f8290c3fe8" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_1f8c0526-220d-46cb-b2e1-8e60414c0a78" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_829ccd6b-53cd-4c25-9403-e96122c78c5b" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02139</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_599de067-e50f-4a35-85d1-020a837e3f1c" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af1201bf-c545-4a78-9e4f-2a7ed191ff6b" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">651-8851</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;"/>
    <td style="width:1%;"/>
    <td style="width:18%;"/>
    <td style="width:1%;"/>
    <td style="width:40%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_211cb59a-e998-4fa7-b8c7-acd162b218a2" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e0be92d4-8d3a-405f-b015-dd4485c25916" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FULC</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9bd99d7c-a040-4916-8a18-18e5645e475f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_609aff12-9a82-49b3-9043-315404895ec8" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb737feb-d0ee-467f-b0c5-73e737631413" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4e5857c-60c6-4ede-b90d-5543307eff1f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> NO </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79537463-18ea-4257-b0da-8529c29ca72c" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> NO </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.04%;"/>
    <td style="width:1%;"/>
    <td style="width:54.62%;"/>
    <td style="width:1%;"/>
    <td style="width:20.28%;"/>
    <td style="width:1%;"/>
    <td style="width:2.06%;"/>
   </tr>
   <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fcbba139-ee28-44e6-a4c5-a36f6fff78f5" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_857e8a1b-86aa-44b7-a626-894265036687" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_942de826-59ea-46a3-85a7-faba090f5fe3" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5e3c961-6d00-42a3-b185-16b303871160" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_178de865-d60a-4c98-aadb-9a15650e01ed" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87b34972-5fd8-4459-b715-23ea697d54c6" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> NO</span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3faba763-610e-484d-b59b-25ba0a54d6ba" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant, based on the closing price of the shares of common stock on the Nasdaq Global Market on June 30, 2023, was approximately $</span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_617fa759-1985-45f6-9924-4b2a673e232a" contextRef="C_1189e0ad-3433-423c-b4a2-785ddc505de5" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,559,530</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of registrant&#8217;s common stock outstanding as of February 20, 2024 was </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88c457a9-3246-435d-9714-1efbdb85ffa6" contextRef="C_3e373bc4-17ca-40e0-beff-f412a277967e" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,935,171</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70b38388-17d0-4c8d-906a-5c6bf79ec10e" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2024 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:82.82%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_foreign_jurisdiction"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In this Annual Report on Form 10-K, unless otherwise stated or as the context otherwise requires, references to &#8220;Fulcrum,&#8221; &#8220;Fulcrum Therapeutics,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Fulcrum Therapeutics, Inc. together with its consolidated subsidiary.  The Fulcrum Therapeutics logo and other trademarks or service marks of Fulcrum Therapeutics, Inc. appearing in this Annual Report on Form 10-K are the property of Fulcrum Therapeutics, Inc. This Annual Report on Form 10-K also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," &#8220;outlook,&#8221; "plan," "potential," "predict," "project," "should," "target," "would," and the negative version of these words and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words and include, among other statements, statements regarding:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ongoing clinical trials of losmapimod and pociredir (formerly known as FTX-6058), including the effects of the revised inclusion and exclusion criteria on our trial of pociredir; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of our organizational streamlining and realignment of resources, including our anticipated cash runway;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, timing, progress and results of our drug target discovery screening programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans to develop and, if approved, subsequently commercialize losmapimod, pociredir and any other product candidates, including in combination with other drugs and therapies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for losmapimod, pociredir and any other product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and marketable securities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential advantages of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of our products, if our product candidates are approved; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding the potential market opportunity for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities and strategy; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intellectual property position; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress and results of our collaboration with MyoKardia, Inc., or MyoKardia, a wholly-owned subsidiary of Bristol-Myers Squibb Company, or under our exclusive global license agreement with CAMP4 Therapeutics Corp., or CAMP4; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding expenses, future revenue, timing of any future revenue, capital requirements and needs for additional financing; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of government laws and regulations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of a pandemic or an outbreak of highly infectious or contagious disease, such as the COVID-19 pandemic, on our business and operations, including our clinical trials and development plans, as well as our future financial results;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitive position; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments relating to our competitors and our industry;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain and establish collaborations or obtain additional funding; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company or a smaller reporting company as defined under the federal securities laws.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="page_dm10801_1_68"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to various risks and uncertainties. Actual results or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the "Risk Factors" section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments we may make or enter into.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Annual Report on Form 10-K involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to a number of risks that if realized could materially affect our business, financial condition, results of operations, cash flows and access to liquidity. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. Our principal risks include the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant losses since our inception. Our net loss was $97.3 million for the year ended December 31, 2023 and $109.9 million for the year ended December 31, 2022. We expect to incur losses over the next several years and may never achieve or maintain profitability. As of December 31, 2023, we had an accumulated deficit of $509.7 million.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we continue our clinical trials of losmapimod and pociredir and continue research and development and initiate additional clinical trials of, and seek regulatory approval for, these and other product candidates.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are early in our development efforts, and we only have two product candidates in clinical trials. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. The results of preclinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience further delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we are developing some of our product candidates for the treatment of diseases in which there is limited clinical experience and, in some cases, using new endpoints or methodologies, the U.S. Food and Drug Administration, or FDA, or other regulatory authorities may not consider the endpoints of our clinical trials to predict or provide clinically meaningful results.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If serious adverse events or unacceptable side effects are identified during the development of our product candidates, including others&#8217; product candidates in the same class of drugs, we may need to abandon or limit our development of some of our product candidates.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in our efforts to use our discovery approach to build a pipeline of product candidates.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on contract manufacturing organizations, or CMOs, to manufacture our product candidates. If we are unable to enter into such arrangements as expected or if such organizations do not meet our supply requirements, development and/or commercialization of our product candidates may be delayed.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may harm our business.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into, and may in the future enter into, collaborations and license agreements with third parties for the discovery, development or commercialization of product candidates, including our collaboration with MyoKardia and our license agreement with CAMP4. If our collaboration is not successful or we are not able to develop product candidates that we license-in, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain, maintain, enforce and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and financial condition and results of operations.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business was negatively impacted by the COVID-19 pandemic and may in the future be impacted by any future pandemics, as well as other geopolitical events that can impact our clinical trials or the supply chain, such as the Russian invasion of Ukraine or recent hostilities in Israel and the Gaza Strip. These events may continue to, and any future pandemics may, adversely impact economies worldwide, which could result in adverse effects on our business and operations.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i_1_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business_1_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Bu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">siness.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Our most advanced clinical-stage product candidate, losmapimod, is being developed for the potential treatment of facioscapulohumeral muscular dystrophy, or FSHD. Our other clinical-stage product candidate is pociredir, formerly known as FTX-6058, which is being developed for the potential treatment of sickle cell disease, or SCD. We</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiated REACH, a randomized, double-blind, placebo-controlled, multi-national Phase 3 clinical trial of losmapimod in the second quarter of 2022 and we completed enrollment during September 2023. The trial enrolled 260 patients. We expect to report topline data from REACH in the fourth quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we announced interim data from our Phase 1b clinical trial of pociredir in SCD. We completed enrollment in the 6 mg and 2 mg dose cohorts, and we do not plan to enroll additional subjects in these cohorts. Although we commenced enrollment in the 12 mg dose cohort, in February 2023 the U.S. Food and Drug Administration, or FDA, placed a full clinical hold on the Investigational New Drug, or IND, application for pociredir for SCD, which was lifted in August 2023. The Phase 1b clinical trial is being re-initiated at the 12 mg once daily dose level, with that cohort expected to enroll approximately 10 patients, and will be followed by an additional cohort of approximately 10 patients at the 20 mg once daily dose level. Following the clinical hold, we amended the protocol to revise the inclusion and exclusion criteria for the Phase 1b clinical trial to target patients with higher disease severity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to product candidate development, we have developed a drug discovery approach that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. Our discovery approach led to the identification of both losmapimod for FSHD and pociredir for SCD, as well as a robust discovery pipeline. With our priorities focused on the development and potential commercialization of our two clinical-stage assets, losmapimod and pociredir, and ongoing work on our preclinical programs in hematology and muscle diseases, we are realigning our strategy and resources accordingly and will be winding down certain exploratory activities from our discovery efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Using our discovery approach, we have generated a pipeline of potentially disease-modifying therapies that address the known root causes of rare genetic diseases. The following chart summarizes key information about our pipeline of clinical stage and pre-clinical programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span><img src="img44875045_0.jpg" alt="img44875045_0.jpg" style="width:672px;height:292px;"/></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through our focus on the development of small molecules, including our product candidates for the treatment of FSHD and SCD, our aim is to address unmet need in patients with genetically defined rare diseases that are debilitating and, in the case of SCD, life-threatening. The key components of our strategy include:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rapidly develop losmapimod for the treatment of FSHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We aim to rapidly complete the clinical development of losmapimod for the treatment of FSHD to support regulatory approval. In the second quarter of 2022, we initiated REACH, a randomized, double-blind, placebo-controlled, 48-week Phase 3 clinical trial to evaluate the efficacy and safety of losmapimod for the treatment of FSHD. We completed enrollment in September 2023 and expect to report topline data in the fourth quarter of 2024.</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rapidly develop pociredir for the treatment of SCD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We aim to rapidly complete the clinical development of pociredir for the treatment of SCD to support regulatory approval. We are currently reinitiating the Phase 1b clinical trial at the 12 mg once daily dose level, with that cohort expected to enroll approximately 10 patients, which will be followed by an additional cohort of approximately 10 patients at the 20 mg once daily dose level.</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continue to apply our discovery efforts to grow our portfolio of product candidates for the treatment of genetically defined rare diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have developed a discovery approach that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases, with a focus on muscle and hematology diseases. We also seek to explore opportunities to acquire or in-license complementary technologies or therapies, such as our recent exclusive global license agreement with CAMP4 Therapeutics Corp., or CAMP4. </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Maximize the commercial potential of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have retained all rights to our lead product candidates focused on rare genetically defined diseases, and we plan to commercialize any approved product for such rare genetically defined diseases using a targeted sales infrastructure. We may in the future pursue commercialization partnerships for certain product candidates and/or markets outside the United States. </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selectively enter into strategic partnerships to maximize the value of our discovery approach and pipeline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Given the breadth of opportunities for our discovery approach to discover drug targets and develop product candidates for genetically defined diseases, we may enter into strategic partnerships for certain drug targets, product candidates or disease areas, such as our collaboration and license agreement with MyoKardia, a wholly-owned subsidiary of Bristol Myers Squibb. Partnerships may provide an attractive avenue for expanding the impact of our discovery efforts. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Lead Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have used our discovery approach and screening efforts to identify drug targets for our lead product candidates and currently have two product candidates in clinical trials, as shown in the following chart.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img44875045_1.jpg" alt="img44875045_1.jpg" style="width:672px;height:119px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Losmapimod</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of Facioscapulohumeral Muscular Dystrophy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facioscapulohumeral muscular dystrophy is a rare, progressive and disabling disease for which there are no approved treatments. FSHD is one of the most common forms of muscular dystrophy and affects both sexes equally, with onset typically in teens and young adults. FSHD is characterized by progressive skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms and trunk and progresses to weakness in muscles in lower extremities and the pelvic girdle. Skeletal muscle weakness results in significant physical limitations, including progressive loss of independence, including impacts to facial muscles that can cause problems with communication, difficulty using arms for activities of daily living and difficulty getting out of bed, with many patients ultimately becoming dependent upon the use of a wheelchair for daily mobility activities. The majority of patients with FSHD also report experiencing chronic pain, anxiety and depression. The diagnosis and treatment of patients with FSHD is typically performed by neurologists.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on an estimated prevalence of approximately 1 in 8,000 people to 1 in 20,000 people (Jia et al, 2021, Neuromuscular Disorders) and a U.S. population of approximately 333 million people, we estimate that the FSHD patient population is approximately 30,000 individuals in the United States. We believe that there may be additional patients who are not formally diagnosed due to a perceived difficulty of obtaining a diagnosis and the fact that there are no approved treatments. Approximately two-thirds of FSHD cases are familial-inherited in an autosomal dominant fashion and one-third of cases are sporadic. FSHD affects all ethnic groups with similar incidence and prevalence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current treatment of FSHD is limited to symptomatic management including physical/ occupational therapy, low-intensity aerobic exercise tailored to the patient&#8217;s distribution of weakness, and general pain management, which may provide limited beneficial effect. Limited range of motion in the shoulder girdle can stem from periscapular muscle weakness leading to scapular winging and in such cases, surgical scapular fixation can result in some functional improvement for certain patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FSHD Biology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FSHD is caused by aberrant expression of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in skeletal muscle resulting in the inappropriate presence of DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">protein, a transcription factor causing the expression of other genes. Normally, DUX4-driven gene expression is limited to early embryonic development, after which time the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene is silenced. In patients with FSHD, aberrant production of DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">protein in skeletal muscle regulates other genes encoding proteins, some of which are toxic to the muscle. The result of aberrant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expression in FSHD is death of muscle and its replacement by fat, resulting in skeletal muscle weakness and progressive disability. We believe that reducing expression of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene and its downstream transcriptional program could provide a disease-modifying therapeutic approach for the treatment of FSHD at its root cause. Published preclinical and human data, in addition to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> experiments that we have conducted, suggest that any reduction in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expression may be beneficial for patients. In preclinical studies, we have demonstrated that there is a direct relationship between muscle cell death (apoptosis) and the level of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expression, and a reduction in DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">leads to a concomitant decrease in apoptosis. As illustrated in the graphic below, in animal models where expression of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in skeletal muscle is induced, a corresponding loss of function is observed with increasing levels of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expression. In these animal models where low levels of DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are expressed, the animals performed similarly to healthy animals in a mobility assessment, suggesting that complete DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduction is not required for a functional benefit. Data from human muscle biopsies likewise indicated that increased DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">activity is related to worsening muscle pathology.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44875045_2.jpg" alt="img44875045_2.jpg" style="width:328px;height:200px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">***: P-value = &lt;0.001</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In all patients with FSHD, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene is unsilenced, or de-repressed, as a result of one of two different types of genetic alterations, leading to FSHD1 or FSHD2; both FSHD1 and FSHD2 converge on a common downstream pathway</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">resulting in a clinically indistinguishable phenotype. Approximately 95% of patients have FSHD1 and approximately 5% of patients have FSHD2. FSHD1 is caused by the contraction of an array of DNA, known as a D4Z4 repeat, from greater than ten repeat units to nine or fewer units. This contraction causes de-repression of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Patients with FSHD2 do not have meaningful D4Z4 repeat contraction, but have mutations in regulatory genes, primarily the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SMCHD1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene, which normally contribute to the repression of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene via DNA methylation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Identification of the Drug Target for FSHD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilized patient-derived FSHD1 muscle cells, known as myotubes, and screened them with our small molecule probe library to identify drug targets that reduced </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expression. While we identified several potential drug targets, the modulation of the majority of the targets adversely affected the health or differentiation of muscle cells. However, one drug target that we identified from our screening efforts for which we did not observe adverse cell health consequences was p38&#945;/&#223;, which had been studied extensively in other diseases but had not been reported to be linked to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expression or FSHD until we conducted our screening efforts. We evaluated multiple small molecule p38&#945;/&#223; inhibitors and observed a consistent reduction of both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expression and DUX4-driven gene transcripts with each p38&#945;/&#223; inhibitor. We conducted further validation experiments to confirm that inhibition of p38&#945; using genetic approaches such as siRNA and CRISPR single-guide RNAs also led to a reduction in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expression. Additionally, researchers from Saint Louis University independently published the results of a study that concluded that inhibitors of p38&#945;/&#223;, including losmapimod, suppressed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expression in cellular and animal FSHD models.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Losmapimod Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After identifying p38&#945;/&#223; as a potential drug target, we evaluated multiple small molecule inhibitors of p38&#945;/&#223;. Each of these inhibitors had previously been evaluated in clinical trials for the treatment of various diseases but never in muscle disorders. As a result of our evaluation and relative to other p38&#945;/&#223; inhibitors, we identified losmapimod as the preferred development candidate based on substantial and attractive preclinical and clinical data regarding safety, pharmacokinetics, or PK, and target inhibition, and its advanced stage of development. Losmapimod was originally evaluated by GSK plc, or GSK, in nearly 3,500 subjects in clinical trials across multiple indications and in multiple countries. GSK did not evaluate losmapimod in FSHD or in any other muscle disorder. Although GSK did not pursue regulatory approval in the indications evaluated, losmapimod demonstrated an attractive PK, pharmacodynamics, or PD, safety and tolerability profile, including in chronic dosing. Additionally, we observed in preclinical studies using losmapimod that inhibition of the p38&#945;/&#223; pathway reduced </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expression and downstream gene expression. After identifying losmapimod, we in-licensed the molecule from GSK because we believed that its existing safety data and pharmacology history would significantly expedite our development plan and enhance our future regulatory submissions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, we reported full data from the randomized, double-blind placebo-controlled multicenter international Phase 2b clinical trial, or ReDUX4. Although the primary endpoint was not met, we demonstrated slowing of disease progression and improved function in FSHD patients treated with losmapimod compared to placebo. In October 2022, we presented data through 96 weeks from the open label extension portion of ReDUX4, which showed that patients in the initial treatment-arm who continued to receive losmapimod experienced maintenance of effect through 96 weeks as measured by reachable workspace, or RWS, mean change from baseline. Additionally, patients who crossed over from placebo to losmapimod after the initial 48 week trial period showed improvement and slowing of disease progression as measured by RWS mean change from baseline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the second quarter of 2022, we initiated REACH, a randomized, double-blind, placebo-controlled, 48-week Phase 3 clinical trial to evaluate the efficacy of losmapimod for the treatment of FSHD. We completed enrollment in September 2023 and expect to report topline data in the fourth quarter of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, the FDA granted orphan drug designation to losmapimod for the treatment of FSHD. In March 2020, the EMA granted orphan drug designation to losmapimod for the treatment of FSHD. In May 2021, the FDA granted fast track designation to losmapimod for the treatment of FSHD.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial: Phase 2b (ReDUX4)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, we presented full data from our randomized, double-blind, placebo-controlled multicenter international Phase 2b clinical trial, the ReDUX4 trial, in 80 patients with FSHD1 and clinical severity scores of two to four on the Ricci</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scale. In this trial, we evaluated treatment with 15 mg of losmapimod or placebo tablets twice per day over a 24 or 48-week period. Patients were randomized 1:1 between the treatment and placebo arms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary endpoint was the change in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-driven gene expression in affected skeletal muscle at 16 or 36 weeks, which was included as an experimental biomarker. The trial was also designed to capture a wide range of data relating to FSHD progression in addition to safety, target engagement and PK data. The secondary endpoints were evaluation of safety and tolerability in FSHD patients, PK in blood, losmapimod concentration in skeletal muscle biopsies, target engagement in blood and in muscle biopsies, and efficacy based on the whole-body skeletal muscle MRI biomarker. The whole-body MRI scans evaluated changes in muscle fat infiltration, or MFI, muscle fat fraction, or MFF and lean muscle volume, or LMV. The muscles evaluated in the trial were classified as normal appearing (not affected by disease), intermediate (clearly affected by disease but not so severely fat-replaced to have lost all function) or end stage (severely fat-replaced and have lost most if not all function). The exploratory endpoints included RWS, timed up and go, or TUG test, an optimized timed up and go test for FSHD, or FSHD TUG, muscle strength measured by hand-held dynamometry, other muscle function measures and patient reported outcomes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The original design of ReDUX4 included a muscle biopsy at week 16 during the 24-week treatment period followed by an open label extension. Sixteen of the 80 subjects in the trial completed the 24-week treatment period and rolled over to the open label extension portion of the trial. As a result of the impact of the COVID-19 pandemic on clinical site visits, we extended the ReDUX4 treatment period from 24 to 48 weeks through a protocol amendment to ensure the safety of the subjects and to allow for the opportunity for a biopsy either at week 16 as originally intended or at week 36. Approximately 64 subjects who did not complete the original 24-week treatment period continued in the 48-week treatment period in the randomized portion of the trial. The extension from 24 to 48 weeks also allowed for a longer assessment in a placebo-controlled design of the skeletal muscle MRI secondary endpoint and the various exploratory clinical endpoints, such as RWS, optimized FSHD TUG test, muscle function measures and patient reported outcomes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ReDUX4 did not meet the primary endpoint, which was change from baseline in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-driven gene expression in affected skeletal muscle at Week 16 or Week 36. Secondary and exploratory endpoints showed clinically relevant and nominally statistically significant benefits in the losmapimod treated group versus placebo on multiple measures of structural and functional FSHD progression and patient reported outcomes at 48 weeks. As the primary endpoint was not met, all comparative analyses were reported with nominal statistical p-values.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment with losmapimod was shown to slow the rate of decline and improve accessible surface area in RWS measures (p&lt;0.05). RWS, operationalized as relative surface area, or RSA, assessed over five quadrants, is a measure of function that assesses upper extremity range of motion. Prior studies have shown that RWS correlates with changes in the ability of patients to independently perform activities of daily living. Based on published results, RWS is an important measure of independence. FSHD tends to progress from the upper body down, and loss of shoulder movement leads to loss of mobility. Over the 48-week placebo-controlled treatment period, losmapimod resulted in significant improvements in total RSA (assessed with a 500 gram wrist weight) compared with placebo, measured on a 0-1.25 scale, with 1.25 being the greatest RSA. Based on the average of both arms, the total arm RSA was 0.020 for the losmapimod group and and -0.027 for the placebo group, reflecting a difference of 0.047, with a 95% confidence interval of 0.010 and 0.084, respectively (p=0.014).</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Losmapimod-treated participants showed decreased progression in the treatment efficacy composite measure of MFI as measured in intermediate muscles, those most likely to show change over the duration of the study (p=0.01). Normal appearing muscles appeared to be preserved in the losmapimod group versus placebo based on a post hoc analysis. MFI is a measure of diffuse fatty infiltration in lean muscle tissue that is correlated with disease severity in FSHD. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Losmapimod-treated participants showed improved patient-reported outcomes compared to placebo through the PGIC assessment (p=0.02). PGIC, a measure of self-reported change in how a patient feels and functions, shows whether participants were able to recognize improvements after 48 weeks of treatment. More participants in the losmapimod group reported improvement at 48 weeks compared to placebo. Four times more losmapimod participants reported improvement over time as compared to participants treated with placebo. Importantly, fewer losmapimod participants reported worsening as compared to placebo, and no losmapimod participants reported being &#8220;much worse&#8221; as compared to more than 13% of placebo participants, who reported that their disease had become &#8220;much worse.&#8221;</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional secondary and exploratory endpoints measuring disease progression and function demonstrated differences between losmapimod and placebo at week 48. In a post hoc analysis, losmapimod-treated participants showed improvement or less worsening in muscle strength of the shoulder abductors (~ +18% to ~ -4%) and ankle dorsiflexors (~ +13% to ~ +27%), two muscle groups particularly affected in FSHD, as measured by maximum percent change dynamometry, versus subjects in the placebo group who lost strength in shoulder abductors (~ -13% to ~ &#8211; 17%) and ankle dorsiflexors (~-26% to ~-10%). Functional scales including RWS and TUG showed improvements in limb function consistent with dynamometry</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results. Two recently designed scales (FSHD TUG, and FSHD Health Index), did not demonstrate changes from baseline in either group or differences between losmapimod and placebo groups, suggesting that these tests are not sensitive to change over the 48-week time period. Motor function measure also showed no changes in either group or differences between the groups over 48 weeks. There was no difference in MFF or LMV between losmapimod and placebo groups at 48 weeks in intermediate muscles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Safety and tolerability data were consistent with previously reported results with no drug-related serious adverse events, or SAEs, reported. Losmapimod was generally well-tolerated and the majority of treatment emergent adverse events, or TEAEs, were deemed unlikely related or not related to study drug by the investigator. There were three SAEs (post-op wound infection, alcohol poisoning and a suicide attempt) reported in two participants in the losmapimod group, each assessed as unrelated to losmapimod. There were no deaths or discontinuations due to adverse events. Losmapimod has been evaluated in over 3,600 subjects in clinical trials across multiple indications, including FSHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2020 we initiated an open label extension of the ReDUX4 trial to enable patients who completed the 24-week or 48-week treatment period with losmapimod or placebo in ReDUX4 to receive long term treatment with losmapimod. This open label extension, which is ongoing, includes clinical assessments of safety every three months. Subsequent to week 168, patients will only be monitored for safety and tolerability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2022, we presented data through 96 weeks from the open label extension portion of ReDUX4. Data presented showed that patients in the initial treatment-arm who continued to receive losmapimod experienced maintenance of effect through 96 weeks as measured by RWS mean change from baseline. Additionally, patients who crossed over from placebo to losmapimod after the initial 48-week trial period showed improvement and slowing of disease progression as measured by RWS mean change from baseline. Losmapimod continued to demonstrate an encouraging safety profile and was generally well-tolerated. 97% of participants in the initial 48 week study remained in the open label extension at week 96. The figure below illustrates annualized percentage change of average total RSA with 500 gram weights.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44875045_3.jpg" alt="img44875045_3.jpg" style="width:374px;height:318px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">REACH, a Phase 3 Registrational Trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initiated REACH, a Phase 3 trial of losmapimod in FSHD, in the second quarter of 2022 and we completed enrollment in September 2023. We expect to report topline data in the fourth quarter of 2024. Based on data from ReDUX4, we engaged with U.S. and EU regulatory agencies, including the FDA, to discuss key aspects of the design of a Phase 3 trial intended to support a full approval. REACH is a randomized, double-blind, placebo-controlled, multi-national trial to evaluate the efficacy and safety of losmapimod for the treatment of FSHD. The trial enrolled 260 adults with FSHD. Patients are randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or placebo, and are evaluated over a 48-week treatment period. The primary endpoint of the study is the absolute change from baseline in RWS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Secondary endpoints include MFI, shoulder dynamometry, PGIC, and Neuro QoL UE. The trial also includes patient-centered assessments of healthcare utilization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the 48-week treatment period with losmapimod or placebo, patients may elect to continue in an open label extension of REACH to receive long term treatment with losmapimod, which is ongoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial: Phase 2 Open Label Study Trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In parallel with the ReDUX4 Phase 2b clinical trial, we also initiated an open label, single center Phase 2 clinical trial of losmapimod in up to 16 patients with FSHD and clinical severity scores of two to four on the Ricci scale. In the first part of the trial, patients received tablets containing 15 mg of losmapimod twice per day for up to 52 weeks. The treatment period was preceded by eight weeks of pre-treatment assessments to establish a baseline for musculoskeletal MRI biomarkers and clinical outcome assessments. We also performed an outpatient mobility assessment using wearable sensors. After the 52-week treatment period, participants had the option to elect to continue in an extension of the study, which is ongoing. We are conducting the trial at a single center in the Netherlands.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary objective is to investigate the safety and tolerability of losmapimod for chronic dosing in FSHD patients. The primary endpoints are to assess safety and tolerability over the 52-week period. The secondary endpoints are the change from baseline in pHSP27 and the ratio of pHSP27 to total HSP27 in blood and muscle for assessment of the inhibition of p38&#945;/&#223; during the dosing period. This trial is also designed to provide initial data regarding changes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-driven gene expression, MRI biomarkers, objective clinical outcome assessments and patient-reported outcomes that may occur at various times following initiation of treatment with losmapimod relative to the pre-treatment period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the initial 52-week treatment period, we measured </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DUX4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-driven gene expression before and during treatment using muscle needle biopsies in affected muscles. Patients underwent muscle biopsy pre-treatment, and then a second biopsy on-treatment at either Week 4 or Week 8.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measured potential losmapimod treatment effects on shoulder and upper arm function and mobility/ambulation, as well as on muscle strength and function and quality of life and activities of daily living, similar to the assessments in the Phase 2b clinical trial. The clinical outcome assessments were RWS, FSHD-TUG, muscle strength, motor function ability and generic and FSHD-specific patient reports of quality of life and activities of daily living. Other exploratory assessments included the six minute walk test, spirometry, and muscle ultrasound. There was also an assessment of day-to-day mobility using wearable sensors. Subsequent to Week 156, this open label extension only includes clinical assessments of safety every three months.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Natural History Studies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD, or ReSOLVE study, is an ongoing natural history study funded by the NIH with additional support from industry (including our company) to help identify the patient population, efficacy biomarker and clinical outcome assessments for future FSHD drug trials. The study is being coordinated by the University of Rochester and University of Kansas Medical Center and enrolled the first subject in April 2018. The study has enrolled 235 subjects (158 in the U.S. and 77 in Europe) across a network of eleven U.S. clinical centers and three European clinical centers and evaluates multiple biomarkers and clinical outcome assessments that may be suitable for clinical trials and  patient selection criteria based on genetic, demographic or clinical characteristics. We also believe that this study may provide valuable insights into the timeline for disease progression and functional changes in FSHD in the absence of treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A third-party study (Hatch et al, 2019, Neuromuscular Disorders) assessed changes in RWS for 18 subjects with FSHD for up to five years. As illustrated in the figure below, the study concluded that the RWS measure is able to detect slow declines in upper extremity function in subjects with FSHD as early as 1 year. The study also found that the most notable declines in RWS were in above-the-shoulder level quadrants with no significant changes in lower quadrants and that RWS declined more significantly if the subjects wore 500-gram weights on their wrists.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44875045_4.jpg" alt="img44875045_4.jpg" style="width:293px;height:252px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The figure above illustrates RWS in four quadrants. The optimized RWS, as evaluated in Phase 2 ReDUX4 and the primary endpoint in Phase 3 REACH, includes an additional domain (Q5) for the lower back, as illustrated in the figure below. This posterior-facing quadrant (Q5) is associated with functional hygiene/toileting activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44875045_5.jpg" alt="img44875045_5.jpg" style="width:314px;height:215px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prior Clinical Development of Losmapimod by GSK</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK conducted multiple Phase 1 and Phase 2 clinical trials and one Phase 3 clinical trial of losmapimod, including in patients with chronic obstructive pulmonary disease, or COPD, acute coronary syndrome and other cardiovascular diseases, neuropathic pain, major depression disorder, focal segmental glomerulosclerosis, and rheumatoid arthritis. Nearly 3,500 subjects in 24 trials were given losmapimod with single doses as high as 60 mg and repeated oral doses as high as 15 mg twice per day for up to 52 weeks. We are using a dose of 15 mg twice per day in our clinical trials of losmapimod in FSHD. GSK did not conduct a clinical trial of losmapimod in patients with FSHD or any other muscle disorder.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In clinical trials of losmapimod conducted by GSK, no significant differences were observed in the frequency of adverse events, or AEs, in subjects given losmapimod and subjects given placebo. GSK generally observed a similar frequency of SAEs and deaths between patients given losmapimod and patients given placebo. These trials included extensive evaluation of the cardiovascular risk profile of losmapimod, including completion of an evaluation of the potential to prolong corrected QT. GSK reported that there was no clinically relevant difference with regard to the occurrence of electrocardiogram abnormalities post-baseline or vital signs with losmapimod as compared to placebo. GSK did not identify a safety signal attributed to losmapimod in any of these trials. There were no SAEs reported in 14 of these 24 clinical trials of losmapimod.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The largest placebo-controlled clinical trial of losmapimod conducted by GSK was a Phase 3 clinical trial for the treatment of acute coronary syndrome following a heart attack, in which over 1,700 patients were given 7.5 mg of losmapimod or placebo twice per day for 12 weeks and were followed for an additional 12 weeks. In this trial, GSK observed a similar proportion of AEs and SAEs in the placebo group as compared to the losmapimod group.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were also ten SAEs of fatality in the placebo group and 13 SAEs of fatality in the losmapimod group. In the placebo group, the SAEs of fatality were infections and infestations (two), general disorders and administrative site conditions (two), respiratory, thoracic and mediastinal disorders (three), cardiac disorder (one), gastrointestinal disorder (one) and neoplasm (one). In the losmapimod group, the SAEs of fatality were infections and infestations (four), general disorders and administrative site conditions (three), respiratory, thoracic and mediastinal disorders (two), cardiac disorder (one), injury poisoning and procedural complications (one), gastrointestinal disorder (one) and neoplasm (one).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Among the total of 14 Phase 1 and Phase 2 placebo-controlled clinical trials of losmapimod (N=1327 on losmapimod; N=735 on placebo), the distribution of SAEs was similar among losmapimod-treated and placebo-treated subjects. The most common SAEs were cardiac disorders (2% placebo; 3% losmapimod) and respiratory, thoracic and mediastinal disorders (1% placebo; 2% losmapimod). SAEs were reported in 11 of these 14 trials; 3 trials reported no SAEs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the 24 trials conducted by GSK, another sponsor conducted a placebo-controlled Phase 2 clinical trial of losmapimod in which 73 subjects with COPD with cardiovascular manifestations were given 7.5 mg of losmapimod or placebo for 16 weeks. There were 36 subjects in the losmapimod group and 37 in the placebo group. In this trial, there were a total of six (17%) SAEs in the losmapimod group, consisting of exacerbations of COPD and pneumonia, and there was one (3%) SAE in the placebo group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pociredir</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD. We also believe that people with some types of &#223;-thalassemia may benefit from treatment with pociredir.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of Sickle Cell Disease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sickle cell disease is a genetic disorder of RBCs. The root cause of SCD is a mutant hemoglobin that polymerizes in low oxygen conditions. This polymerization creates the abnormal, elongated, or sickle, shape of the RBC and results in, ultimately, hemolysis and vascular injury that causes major morbidities and significantly limits lifespan in people with SCD. People with SCD typically suffer from serious clinical consequences, which may include vaso-occlusive crises, anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease and reduced life expectancy. According to a study published by the American Medical Association, approximately 32.5% of adults with SCD were hospitalized three or more times per year due to pain crises. SCD is reported to shorten life expectancy by approximately 20 to 30 years. People with SCD are primarily treated by hematologists.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, where newborn screening for SCD is mandatory, the estimated prevalence is approximately 100,000 individuals. In Europe, the estimated prevalence is approximately 50,000 individuals. According to the World Health Organization, the global incidence is estimated to be approximately 300,000 births annually. SCD is most prevalent in Africa and the Middle East.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several approved drug treatments for SCD focus primarily on the management and reduction of painful vaso-occlusive crises, and improvement of hemolytic anemia, as well as gene therapies for the treatment of severe SCD. Despite ongoing efforts to develop and commercialize treatments for SCD, we believe there is still a high unmet need that could be better addressed by a small molecule, oral therapy capable of increasing HbF production. See &#8220;Competition&#8221; for a more comprehensive description of the competitive landscape in SCD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SCD Biology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SCD is caused by a mutation in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HBB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. Hemoglobin in adults is a complex of four proteins, two hemoglobin &#223;-subunits and two hemoglobin &#945;-subunits. In people with SCD, hemoglobin is composed of two mutant &#223;-subunits and two &#945;-subunits and the result is the formation of HbS. The result of the mutation is less efficient oxygen transport and the formation of RBCs that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels (vaso-occlusion) or rupture (lysis), leading to pain, anemia, irreversible organ damage or even death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During fetal development, the major form of hemoglobin is HbF. Similar to hemoglobin in adults, HbF is also a complex of four proteins, two &#945;-subunits and two &#947;-subunits. Shortly after birth, the genes encoding the &#947;-subunits, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HBG1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HBG2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> genes, are silenced and the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HBB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene is activated. As described above, SCD is caused by a mutation in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HBB </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gene that gives rise to mutated &#223;-subunits.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A small subset of individuals with the sickle cell mutation continue to produce high levels of HbF due to inheritance of additional genetic mutations, which is called Hereditary Persistence of HbF, or HPFH. Individuals with elevated HbF exhibit minimal clinical manifestations of SCD. HbF levels as low as 3% over baseline in individuals without HPFH, due to either therapeutic intervention or the inheritance of other genetic traits, can result in reduced clinical manifestations of the disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44875045_6.jpg" alt="img44875045_6.jpg" style="width:672px;height:283px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Approach to Address the Root Cause of SCD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategy to address the root cause of SCD was to identify a drug mechanism that induces expression of HbF. We believe that FTX-6058 may address the root cause of SCD through this mechanism of action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Identification of the Drug Target for SCD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted target identification and validation activities using human umbilical cord blood-derived erythroid progenitor 2, or HUDEP2, cells as a model to study HbF reactivation. HUDEP2 cells are immature RBCs. By screening our small molecule probe library and a CRISPR library, we identified several potential drug targets that activated the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HBG1/2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> genes and resulted in HbF elevation. Each screening approach identified the same protein complex, PRC2, which we believe plays an important role in the expression of genes responsible for the production of HbF. We conducted additional validation experiments in which we observed that inhibition of several components of this complex resulted in the desired elevation of HbF. We also observed that inhibition of these components did not adversely affect important cell health markers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We selected a component of this protein complex, EED, for drug discovery activities following an assessment of its tractability as a drug target,. The normal physiological role of EED is to facilitate a post-translational protein modification, and the goal of our medicinal chemistry program was to optimize inhibitors of EED. We developed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> target engagement assays, as well as enabled X-ray crystallography, to discover and develop pociredir, a novel small molecule inhibitor of the EED subunit of PRC2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pociredir</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pociredir is an oral HbF inducer that is in development for SCD. Pociredir is designed to bind to EED and inhibit the transcriptional silencing activity of PRC2. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in HbF. EED is a member of the PRC2 complex, which also includes EZH2. There are approved products in the EZH2 class of medications and their approved labeling outlines safety risks, including an increased risk of hematologic malignancies. We initiated our Phase 1b clinical trial of pociredir in SCD in the fourth quarter of 2021. In February 2022, the FDA granted orphan drug designation to pociredir for the treatment of SCD. In December 2022, the FDA granted fast track designation to pociredir for SCD. In February 2023, the FDA placed the IND for pociredir for the potential treatment of SCD on full clinical hold. Accordingly, we suspended enrollment and dosing in the Phase 1b trial of pociredir and withdrew our separate IND for pociredir in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#223;-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">thalassemia. The FDA&#8217;s clinical hold referenced the data from toxicology studies in rats and dogs that we submitted to the IND in April, October, and December 2022, as well as a response to an early February 2023 information request from the FDA about these toxicology studies that we submitted in mid-February 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our pociredir development program, we have conducted numerous non-clinical toxicology studies, including studies conducted under good laboratory practice, or GLP. These toxicology studies have included repeat-dose maximum tolerated dose and dose range finding studies; 28-day, 13-week, 17-week, and 26-week studies in rats; and 28-day, 13-week, and 39-week studies in dogs. In connection with the clinical hold, the FDA noted that the profile of hematological malignancies observed in the toxicology studies of pociredir is similar to that observed with other inhibitors of PRC2 and that hematological malignancies have been reported clinically with other inhibitors of PRC2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, the FDA lifted the full clinical hold on the IND for pociredir for the potential treatment of SCD of full clinical hold. The Phase 1b clinical trial is being re-initiated at the 12 mg once daily dose level, with that cohort expected to enroll approximately 10 patients, followed by an additional cohort of 10 patients at the 20 mg once daily dose level. The protocol was amended to revise the inclusion and exclusion criteria to target patients with higher disease severity. Key inclusion criteria includes patients with certain frequencies of vaso-occlusive crises and/or other specified measures of severity, previous experience with hydroxyurea, and previous experience with a stable dose of voxelotor, crizanlizumab, or L-glutamine (or lack of access to these advanced therapies). Key exclusion criteria excludes subjects currently on or having received hydroxyurea and voxelotor, crizanlizumab or L-glutamine within 60 days prior to initiating pociredir.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial: Phase 1b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we announced Phase 1b data from subjects in the 6 mg dose cohort, as well as completion of enrollment in the 6 mg and 2 mg dose cohorts and commencement of enrollment in the 12 mg dose cohort. Until being placed on clinical hold in February 2023, the Phase 1b trial was evaluating subjects both on and off background hydroxyurea therapy.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1b data from subjects in the 6 mg dose cohort (n=10) showed up to 9.5% absolute HbF increases from baseline. These data suggested no difference in response in subjects on (n=3) and off (n=7) background hydroxyurea. We also observed improved biomarkers of hemolysis in evaluable subjects dosed at 6 mg. The figures below illustrate percentage HbF increase by HPLC and absolute percentage HbF change from baseline for evaluable subjects (n=7) in the 6 mg dose cohort. Subjects with asterisks were on background hydroxyurea.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img44875045_7.jpg" alt="img44875045_7.jpg" style="width:395px;height:454px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed enrollment and dosing in the 6 mg and 2 mg dose cohorts, and we do not plan to enroll or dose additional subjects in these cohorts if we are able to resolve the clinical hold. Data from subjects in the 2 mg dose cohort (n=2), showed up to 4.6% absolute HbF increases from baseline.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img44875045_8.jpg" alt="img44875045_8.jpg" style="width:389px;height:473px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data from subjects in the 12 mg dose cohort (n=3), prior to the suspension of the trial in February 2023, showed up to 10.0% absolute HbF increases from baseline, or total HbF of ~25.0%, after 42 days of treatment (the full three months of treatment was interrupted by the clinical hold). Subjects with asterisks were on background hydroxyurea.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img44875045_9.jpg" alt="img44875045_9.jpg" style="width:409px;height:477px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increases in HbF have been shown to reduce the frequency or severity of a broad range of SCD symptoms, including VOC, anemia, pain, infection, stroke and others. Based on a large body of genetic, clinical, and observational evidence showing the effects of higher levels of HbF in people with SCD, for a given patient, even small increases in total HbF are expected to be associated with clinical benefit, with levels in the upper 20% to lower 30%-range being associated with significant reductions in the manifestations of SCD. We believe these initial data showing that pociredir increases HbF levels by up to ~10.0% from baseline after as few as six weeks of therapy support its potential to become a transformative therapy for people living with SCD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pociredir was generally well-tolerated as of the March 3, 2023 data cutoff date. There have been 23 TEAEs reported as of the data cutoff date, eight of which were reported as possibly related to study drug (headache, lip numbness, diarrhea, fatigue, somnolence, nausea or tinnitus), none of which were severe and were deemed non-serious. There have been no discontinuations due to TEAEs as of the data cutoff date. Four of the 23 TEAEs were characterized as VOCs, and were deemed unrelated to pociredir; one of these was reported as a serious adverse event, or SAE, with acute chest syndrome in a subject who was non-adherent to study drug administration.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, the FDA lifted the full clinical hold on the IND for pociredir for the potential treatment of SCD of full clinical hold. The Phase 1b clinical trial is being re-initiated at the 12 mg once daily dose level, with that cohort expected to enroll approximately 10 patients, followed by an additional cohort of 10 patients at the 20 mg once daily dose level. The protocol was amended to revise the inclusion and exclusion criteria to target patients with higher disease severity.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial: Phase 1 Healthy Volunteers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the fourth quarter of 2020, we initiated a Phase 1 clinical trial of pociredir in healthy adult volunteers. The Phase 1 randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, and PK of ascending doses of pociredir. In the single ascending dose, or SAD, cohorts, healthy volunteers received one dose of either placebo or 2, 4, 10, 20, 30, 40 or 60 mg of pociredir. In the multiple ascending dose, or MAD cohorts, healthy volunteers received a once-daily dose of placebo or 2, 6, 10, 20 or 30 mg of pociredir for 14 consecutive days. Each MAD cohort had six subjects on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">drug and two on placebo. Food effect was also studied in a separate 20 mg dose cohort. Exploratory measures were included in the MAD cohorts to assess target engagement, changes in human hemoglobin messenger RNA, or HBG mRNA, and HbF-containing reticulocytes, or F-reticulocytes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We reported data from the 2, 4, 10, 20, 30 and 40 mg SAD cohorts and the 2, 6 and 10 mg MAD cohorts in healthy volunteers in August 2021, and we reported data from the 60 mg SAD cohort and the 20 and 30 mg MAD cohorts in healthy volunteers, as well as data from the 20 mg cohort assessing food effect in December 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pociredir was generally well-tolerated in healthy adult volunteers with no SAEs reported and no discontinuations due to TEAEs across all SAD and MAD cohorts. Data continued to show dose-proportional PK, with a mean half-life of approximately 6-7 hours in the MAD cohorts, supporting once-daily dosing, and no food effect was observed with pociredir. Data from the MAD cohorts continued to show robust target engagement, as evidenced by an approximately 75-95% reduction from baseline in H3K27me3 after 14 days of treatment. Based on our preclinical studies, this level of target engagement is predicted to result in robust induction of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HBG1/2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and subsequently increase HbF production.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data from the MAD cohorts also showed time- and dose-dependent HBG mRNA induction, as shown in the chart below, demonstrating proof-of-biology. Persistent HBG mRNA induction was observed for 7-10 days after treatment. In preclinical studies of pociredir, increases in HBG mRNA have consistently translated to the same fold increases in HbF protein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HBG mRNA Mean Fold Induction for pociredir versus Placebo</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.867%;"/>
    <td style="width:8.335%;"/>
    <td style="width:6.236%;"/>
    <td style="width:8.335%;"/>
    <td style="width:7.296%;"/>
    <td style="width:9.374%;"/>
    <td style="width:7.296%;"/>
    <td style="width:8.335%;"/>
    <td style="width:7.296%;"/>
    <td style="width:8.335%;"/>
    <td style="width:7.296%;"/>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:1.5pt solid #000000;padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:1.5pt solid #000000;border-right:1.5pt solid #000000;padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2 mg*</span></p></td>
    <td colspan="2" style="border-top:1.5pt solid #000000;border-right:1.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6 mg*</span></p></td>
    <td colspan="2" style="border-top:1.5pt solid #000000;border-right:1.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10 mg*</span></p></td>
    <td colspan="2" style="border-top:1.5pt solid #000000;border-right:1.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20 mg</span></p></td>
    <td colspan="2" style="border-top:1.5pt solid #000000;border-right:1.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30 mg</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mean Fold Induction</span></p></td>
    <td style="border-top:1.5pt solid #000000;border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">P-value</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mean Fold Induction</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">P-value</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mean Fold Induction</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">P-value</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mean Fold Induction</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">P-value</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mean Fold Induction</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">P-value</span></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Day 7</span></p></td>
    <td style="border-right:0.5pt solid #000000;border-left:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.28</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3494</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.94</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0135</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.08</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0063</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.06</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0072</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.29</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0025</span></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Day 14</span></p></td>
    <td style="border-right:0.5pt solid #000000;border-left:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.20</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5122</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.45</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0025</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.54</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;0.0001</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.63</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;0.0001</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.15</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;0.0001</span></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.05in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Safety Follow-up (Day 21-24)</span></p></td>
    <td style="border-right:0.5pt solid #000000;border-left:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.21</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3736</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.75</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;0.0001</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.22</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;0.0001</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.45</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;0.0001</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.13</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.05in;vertical-align:top;border-bottom:1pt solid #000000;padding-right:0.05in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;0.0001</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pociredir Activity in Preclinical Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have observed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">activation of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HBG1/2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> genes in preclinical studies with pociredir. We observed that pociredir elevated levels of HbF with minimal adverse effects on important cellular health markers. As depicted in the graphic below, we also observed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upregulation of HbF in primary human CD34+ cells differentiated into RBCs from 14 donors, including nine different healthy human donors, four SCD donors and one sickle cell trait donor, after seven days of drug treatment. Pociredir showed a significant elevation of HbF over baseline in each of these 14 donor cell lines. We have conducted additional preclinical profiling in CD34+ derived cells and observed that treatment with pociredir increased HbF levels to approximately 30% of total hemoglobin, as measured by mass spectrometry, high performance liquid chromatography, and fast protein liquid chromatography techniques. Notably, based on a review of data from other mechanisms, HbF fold induction in CD34+ cells has translated reliably into the clinic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effect of pociredir treatment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in differentiated primary human CD34+ cells</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44875045_10.jpg" alt="img44875045_10.jpg" style="width:315px;height:230px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we compared the effect of pociredir in CD34+ derived cells relative to that of hydroxyurea. We observed that hydroxyurea had a minimal impact on HbF elevation, whereas we observed that pociredir significantly elevated HbF. In cells treated with the combination of pociredir and hydroxyurea, we observed an increased effect relative to either compound alone.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we studied pociredir in a mouse model of SCD, known as the Townes mouse model. In this model, mouse globin genes have been replaced with human globin genes, thereby allowing investigations of mechanisms that may regulate human hemoglobin gene expression. The Townes mouse model has been widely used to study potential treatments for SCD. As shown in the figures below, we observed that pociredir resulted in a significant increase in HbF-expressing cells, or F-cells, and HbF protein levels after 13 days of dosing at 5 mg/kg once per day whereas hydroxyurea resulted in modest increases in F-cells and HbF.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.52%;"/>
    <td style="width:47.48%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percentage of F-cells in Townes mice</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">treated with pociredir</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">HbF protein levels in Townes mice</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">treated with pociredir</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><img src="img44875045_11.jpg" alt="img44875045_11.jpg" style="width:348px;height:181px;"/></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44875045_12.jpg" alt="img44875045_12.jpg" style="width:296px;height:196px;"/>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the graphic on the left, we quantified the percentage of F-cells as a percentage of total cells (%F-cells) for the three treatment conditions from mouse blood, shown as a percentage of vehicle-alone-treated SCD mice. In the graphic on the right, we determined the level of human HbF protein for the three treatment conditions, quantifying HbF protein as a percentage of total hemoglobin. Each value represents the mean value from eight mice per treatment after 13 days of treatment. In these studies, we used a conventional method of assessing statistical significance known as a one-way analysis of variance, or ANOVA. The p-value for pociredir was less than 0.001 for both studies and the p-value for hydroxyurea in the study depicted on the right was less than 0.01.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Discovery Screening Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have leveraged our discovery approach to discover targets that we are pursuing with small molecules for FSHD and SCD. We are leveraging our discovery approach to discover drug targets for other rare, genetically defined diseases within hematology and muscle diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span><img src="img44875045_13.jpg" alt="img44875045_13.jpg" style="width:672px;height:123px;"/></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License Agreements and Collaborations</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Right of Reference and License Agreement with GlaxoSmithKline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, we entered into a right of reference and license agreement with affiliates of GSK, as amended in September 2020, pursuant to which GSK granted us a right of reference to certain INDs filed with the FDA and controlled by GSK or its affiliates relating to losmapimod and an exclusive worldwide license under certain patent rights related to losmapimod. The agreement also provides us with an exclusive worldwide license to certain of GSK&#8217;s preclinical and clinical data with respect to losmapimod. As partial consideration for the right of reference and licenses granted under the agreement, we issued 12,500,000 shares of our Series B preferred stock to GSK at the time we entered into the reference and license agreement. The agreement obligates us to use commercially reasonable efforts to develop and commercialize a licensed product for the treatment of FSHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The agreement grants us an exclusive, sublicensable license under the licensed patent rights and data rights to research, develop and commercialize losmapimod or any product containing losmapimod as an API, which we refer to as a licensed product, to treat disease in humans. GSK retained the right, without the right to grant sublicenses, to conduct nonclinical research under the licensed patents and data rights and, with our consent, GSK may engage in certain developmental activities relating to the use of a licensed product in connection with a specified prophylactic use. GSK also agreed to and has since transferred to us its existing manufactured supply of losmapimod.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the agreement, we will be obligated to make milestone payments to GSK aggregating up to $37.5 million upon the achievement of specified development and regulatory milestones with respect to the first licensed product to first achieve such milestones, including a $5.0 million milestone payment that we made to GSK during the year ended December 31, 2022 upon the initiation of the REACH Phase 3 clinical trial and a $2.5 million milestone payment we made to GSK during the year ended December 31, 2019 upon the initiation of ReDUX4, and up to $60.0 million upon the first achievement of one-time aggregate annual worldwide net sales milestones for a licensed product. We will also be obligated to pay royalties ranging from a mid single-digit percentage to a low double-digit, but less than teens, percentage to GSK based on our, and any of our affiliates&#8217; and sublicensees&#8217;, annual net sales of licensed products. The royalties are payable on a licensed product-by-licensed product and country-by-country basis, and may be reduced in specified circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our obligation to make royalty payments extends with respect to a licensed product in a country until the earlier of the approval of a generic version of such licensed product by the applicable regulatory agency in such country or the tenth anniversary of the first commercial sale of such licensed product in such country, which we refer to as the royalty term. Following the expiration of any exclusive marketing rights or data exclusivity rights granted by a regulatory authority, other than patent rights, for any licensed product on a country-by-country basis, the applicable royalty rate will be reduced in such country. Additionally, if we or our affiliates or sublicensees determine that it is necessary to obtain a license from a third party under any patent rights to exploit a licensed product in a country, then we may deduct a certain percentage of the license fees under such third party license payable by us to the third party from the royalty payment that would otherwise be due to GSK in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless earlier terminated in accordance with its terms, the agreement continues on a country-by-country and licensed product-by-licensed product basis until the expiration of the royalty term in each country, at which time the agreement expires with respect to such licensed product in such country and we shall have a fully-paid up, royalty-free and perpetual license to the licensed patent rights and data rights with respect to such licensed product in such country. Either party has the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">right to terminate the agreement if the other party has materially breached in the performance of its obligations under the agreement and such breach has not been cured within the applicable cure period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration and License Agreement with MyoKardia, a wholly-owned subsidiary of Bristol-Myers Squibb Company</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2020, we entered into a collaboration and license agreement with MyoKardia to identify biological targets that are capable of modulating genes of interest with relevance to certain genetically defined cardiomyopathies. Under the terms of the agreement, we granted MyoKardia an exclusive worldwide license under certain intellectual property rights to research, develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export, have exported, distribute, have distributed, market, have marketed, promote, have promoted, or otherwise exploit products directed against certain biological targets identified by us that are capable of modulating certain genes of interest with relevance to certain genetically defined cardiomyopathies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to a mutually agreed research plan, we will perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets, or the Identified Targets, for further research, development, manufacture and commercialization by MyoKardia. We and MyoKardia will work together to determine how best to advance at each stage of the research activities under the research plan and to identify which of the Identified Targets, if any, meet the criteria set forth in the research plan, or the Cardiomyopathy Target Candidates. Upon completion of the research plan, the parties will work together to prepare a final data package and MyoKardia may designate certain Cardiomyopathy Target Candidates for MyoKardia&#8217;s further exploitation under the agreement, or the Cardiomyopathy Targets. If MyoKardia does not designate any Cardiomyopathy Targets during the designated period, then the agreement will automatically terminate. If MyoKardia designates one or more Cardiomyopathy Targets, then MyoKardia will be obligated to use commercially reasonable efforts to seek regulatory approval for and to commercialize one product directed against an Identified Target in certain specified countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the period in which we are performing the research activities pursuant to the research plan, or the Research Term and for a specified period beyond the Research Term if MyoKardia designates a Cardiomyopathy Target, we may only use the data generated from such research activities for MyoKardia in accordance with the agreement. During the Research Term and for a specified period thereafter, we may not research, develop, manufacture, commercialize, use, or otherwise exploit any compound or product (a) that is a compound or product under the agreement that is directed against the Cardiomyopathy Target Candidates for the treatment, prophylaxis, or diagnosis of any indication or (b) for the treatment of any genetically defined cardiomyopathies shown to be related to certain specified genes of interest that are modulated by the Cardiomyopathy Targets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the agreement, MyoKardia made a $10.0 million upfront payment and a $2.5 million payment as prepaid research funding to us in July 2020. MyoKardia will also reimburse us for the costs of the research activities not covered by the prepaid research funding, up to a maximum amount of total research funding (including the prepaid research funding). Upon the achievement of specified preclinical, development and sales-based milestones, we will be entitled to preclinical milestone payments, development milestone payments and sales-based milestone payments of up to $298.5 million in the aggregate per target for certain Identified Targets, and of up to $150.0 million in the aggregate per target for certain other Identified Targets. To date, we have achieved a $2.5 million specified preclinical milestone. MyoKardia will also pay us tiered royalties ranging from a mid single-digit percentage to a low double-digit percentage based on MyoKardia&#8217;s, and any of its affiliates&#8217; and sublicensees&#8217;, annual worldwide net sales of products under the agreement directed against any Identified Target. The royalties are payable on a product-by-product basis during a specified royalty term, and may be reduced in specified circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The agreement continues on a country-by-country and product-by-product basis until the expiration of the last to expire royalty term for a product, at which time the agreement expires with respect to such product in such country, unless the agreement is terminated earlier in accordance with its terms. Either party has the right to terminate the agreement if the other party has materially breached in the performance of its obligations and such breach has not been cured within the applicable cure period. MyoKardia also has the right to terminate the agreement for convenience in its entirety or on a target-by-target, product-by-product or molecule-by-molecule basis, upon prior written notice to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with CAMP4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, we entered into a license agreement with CAMP4 pursuant to which we received a worldwide exclusive license (including the right to sublicense) from CAMP4 to rights under its Diamond Blackfan Anemia, or DBA program, which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how for us to research, develop, manufacture, use, commercialize or otherwise exploit therapeutic products in any indication, including the grant of a sublicense under certain intellectual property rights that CAMP4 has licensed under an agreement with Children&#8217;s Medical Center Corporation, or CMCC.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We made an undisclosed upfront non-refundable, non-creditable payment to CAMP4. If we succeed in developing and commercializing licensed products, CAMP4 will be eligible to receive (i) up to $35.0 million in development and regulatory milestone payments, and (ii) up to $35.0 million in sales milestone payments. CAMP4 is also eligible to receive royalties on worldwide net sales of licensed products ranging from mid-single digit to low-double digit, subject to potential reduction following loss of patent coverage, the launch of certain generic products or royalty stacking for licenses of third party intellectual property. The royalties will expire on a product-by-product and country-by-country basis upon the latest to occur of (i) the expiration of all valid patent claims covering the compounds in such country, (ii) the expiration of all regulatory exclusivities in such country, and (iii) 10 years following the first commercial sale of in such country. We are responsible for the costs associated with the development and regulatory approvals of licensed products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless earlier terminated in accordance with its terms, the license agreement continues on a country-by-country and licensed product-by-licensed product basis until the expiration of the royalty term in each country, at which time the license agreement expires with respect to such licensed product in such country and we will have a fully-paid up, royalty-free and perpetual license to the licensed patent rights and know-how with respect to such licensed product in such country. CAMP4 has the right to terminate the license agreement in the event of our non-payment (subject to cure periods and tolling for bona fide disputes). CAMP4 may also terminate the license agreement if we challenge certain patents sublicensed to us by CAMP4. Either party may terminate the license agreement in its entirety for the other party&#8217;s material breach if such other party fails to cure the breach. Either party may also terminate the agreement in its entirety upon certain insolvency events involving the other party. We have the right to terminate the license agreement with CAMP4 for any or no reason upon prior written notice to CAMP4.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to protect and enhance our discovery approach, inventions and improvements that are commercially important to the development of our business, including by seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in our field.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future commercial success depends, in part, on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce in our intellectual property rights, in particular our patents rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent positions of biotechnology and pharmaceutical companies like ours are generally uncertain and can involve complex legal, scientific and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our product candidates and methods of manufacturing the same. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our products will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented or invalidated by third parties. See &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We generally file patent applications directed to our key programs in an effort to secure our intellectual property positions vis-a-vis these programs. As of February 20, 2024, we owned or in-licensed eight U.S. patents, nine U.S. pending non-provisional patent applications and related pending foreign patent applications, and one pending U.S. provisional patent application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The intellectual property portfolio for our most advanced programs as of February 20, 2024, is summarized below. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications referred to below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Losmapimod</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to losmapimod, we own one U.S. patent covering the method of use of losmapimod for the treatment of patients with FSHD and two U.S. patents covering the use of other clinical-stage p38 inhibitors for the treatment of patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with FSHD, each of which are expected to expire in 2038, and related patents and pending patent applications in Canada and Mexico, Europe, Africa, Australia and New Zealand, South America, and Asia with expiration dates in 2038. We also own  two pending U.S. non-provisional applications and related patent applications pending in Europe, China, and other countries directed to methods of using losmapimod for FSHD, and one pending U.S. provisional application relating to formulations of losmapimod that, if resulting in issued patents, are expected to expire between 2038 and 2044. The patents to losmapimod licensed from GSK as a composition of matter and pharmaceutical composition have expired.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pociredir</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, our patent portfolio related to pociredir includes two issued U.S. patents directed to composition of matter that is expected to expire in 2040, one U.S. non-provisional application and related pending patent applications in Canada and Mexico, Europe, Africa, Australia and New Zealand, South America, and Asia that, if issued, are expected to expire between 2039 and 2040. We also own three U.S. non-provisional applications and related patent applications pending in Europe directed to solid forms and methods of using pociredir and one pending PCT application directed to pociredir methods of use and formulations, that, if resulting in issued patents, would be expected to expire between 2042 and 2043.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering the use of losmapimod and products from our intellectual property may be entitled to patent term extensions. If our use of drug candidates or the drug candidate itself receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or drug candidate. We also intend to seek patent term extensions in any jurisdictions where available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any collaborators, scientific advisors, employees and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. See &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any manufacturing facilities. We have obtained sufficient quantities of losmapimod from a contract manufacturing organization to complete our ongoing Phase 3 clinical trial in FSHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have obtained sufficient quantities of pociredir from a contract manufacturing organization to complete our Phase 1b clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to rely on third parties for the manufacture of pociredir for any future clinical trials and for the manufacture of any future product candidates for preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. Our lead product candidates are small molecules and can be manufactured in reliable and reproducible synthetic processes from readily available starting materials. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval or emergency use authorizations for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our lead product candidates are approved for the indications for which we are currently undertaking clinical trials, they will compete with the therapies and currently marketed drugs discussed below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FSHD</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no approved therapies for the treatment of FSHD. Current treatment is limited to symptomatic management including physical/ occupational therapy, low-intensity aerobic exercise tailored to the patient&#8217;s distribution of weakness, and general pain management, which may provide limited beneficial effect. Limited range of motion in the shoulder girdle can stem from periscapular muscle weakness leading to scapular winging and in such cases, surgical scapular fixation can result in some functional improvement for certain patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Losmapimod could face competition from other therapeutic approaches in development for patients with FSHD. Roche is evaluating RO7204239, a myostatin inhibitor, in a Phase 2 study in adults with FSHD. Avidity is evaluating AOC 1020, an siRNA antibody-oligonucleotide complex, in a Phase 1/2 clinical trial in adults with FSHD. Arrowhead Pharmaceutical is  evaluating ARO-DUX4, an antibody-oligonucleotide conjugate, in adults with FSHD in a Phase 1/2a trial.  We are not aware of any product candidate currently in clinical development for FSHD with the same mechanism of action as losmapimod.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SCD</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several approved drug treatments for SCD focus primarily on the management and reduction of painful vaso-occlusive crises, and improvement of hemolytic anemia. The six drug treatments approved in the United States are hydroxyurea, voxelotor, crizanlizumab, L-glutamine, lovo-cel, and exa-cel. Hydroxyurea is approved for the treatment of SCD, to reduce the frequency of painful crises and to reduce the need for blood transfusions. Hydroxyurea is available in both generic and brand name formulations including DROXIA manufactured by Bristol Myers Squibb, and SIKLOS manufactured by Addmedica. Voxelotor, brand name OXBRYTA, marketed by Pfizer Inc., is approved under accelerated approval as a hemoglobin polymerization inhibitor to increase hemoglobin. Crizanlizumab, a fully-human monoclonal antibody p-selectin inhibitor marketed by Novartis, is approved for the reduction in the frequency of VOCs. L-glutamine, brand name ENDARI, marketed by Emmaus Life Sciences, Inc., is approved to reduce acute complications of the disorder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lovo-cel and exa-cel are gene therapies approved for the treatment of severe SCD. Lovo-cel, brand name LYFGENIA, is a gene therapy designed to add functional copies of a modified form of the &#946;-globin gene into patient&#8217;s hematopoietic stem cells (HSCs), to make normally functioning RBCs. Exa-cel, brand name CASGEVY, is a gene therapy consisting of autologous CD34+ cells edited by CRISPR/Cas9-technology to decrease BCL11A expression, resulting in increased HbF production. Gene therapies need to be administered in an in-patient procedure known as HSCT. As part of the transplant process, the patient receives myeloablative chemotherapy to remove the original unedited stem cells in the bone marrow in order to enable the genetically modified stem cells to engraft.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An additional potentially curative treatment currently approved for severe SCD populations is allo-HSCT. However, allo-HSCT is more commonly offered to pediatric individuals with an available HLA-matched sibling donor. The 5-year survival rates in this young population is quite high but for older individuals (&gt;16 years), the survival rates can be considerably lower. There are also significant risks associated with allo-HSCT including infertility and graft-versus-host disease.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A supportive care option for management of SCD is red blood cell transfusion but this can potentially be complicated by alloimmunization, transfusion reactions, and iron overload.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pociredir could face competition from a number of different therapeutic approaches in development for people with SCD. Novo Nordisk A/S, or Novo, is evaluating nDec (decitabine-tetrahydrouridine), a small molecule designed to increase production of HbF, in a Phase 2 clinical trial that began enrolling in the summer of 2022. Novo is also evaluating etavopivat, a PKR agonist, in a Phase 2/3 clinical trial. Agios Pharmaceuticals, Inc., is evaluating mitapivat, a PKR agonist, in a Phase 2/3 clinical trial in subjects with SCD. Pfizer, Inc. is evaluating GBT-601, an HbS polymerization inhibitor, that is anticipated to initiate a Phase 3 clinical trial in 2023, inclacumab, a P-selectin inhibitor that is being evaluated in two Phase 3 clinical trials, and PF-07209326, an anti-E-selectin inhibitor, in a Phase 1 clinical trial. Takeda Pharmaceutical Company Limited, is evaluating TAK-755, recombinant ADAMTS13 protein, in a Phase 1 clinical trial in participants with baseline health SCD and SCD with acute VOCs. Sangamo Therapeutics Inc., or Sangamo, is developing SAR445136, a gene editing cell therapy that modifies cells to produce functional RBCs using HbF, in a Phase 1/2 clinical trial. There are also several other gene editing approaches being evaluated by Intellia Therapeutics, Inc. (in collaboration with Novartis), Editas Medicine, Inc., Graphite Bio, and Beam Therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation and Product Approvals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of biopharmaceutical products. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Approval and Regulation of Drugs in the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, drug products are regulated under the Federal Food, Drug and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. The failure of an applicant to comply with the applicable regulatory requirements at any time during the product development process, including non-clinical testing, clinical testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval and/or administrative or judicial sanctions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An applicant seeking approval to market and distribute a new drug in the United States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preclinical testing including laboratory tests, animal studies and formulation studies, which must be performed in accordance with the FDA&#8217;s GLP regulations and standards; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety and effectiveness of the product candidate for each proposed indication, in accordance with current good clinical practices, or GCP; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation and submission to the FDA of a new drug application, or NDA, for a drug product which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labelling for one or more proposed indication(s); </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product candidate or components thereof are manufactured to assess compliance with current good manufacturing practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the NDA; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of user fees and securing FDA approval of the NDA to allow marketing of the new drug product; and </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct any post-approval studies required by the FDA. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before an applicant begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity and long-term toxicity studies may continue after the IND is submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The IND and IRB Processes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research subjects provide their voluntary informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved NDA. In support of a request for an IND, applicants must submit a protocol for each clinical trial, and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine, among other things, whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In these cases, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, nonclinical, and/or chemistry, manufacturing, and controls areas. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol may not be allowed to proceed, while other protocols may be allowed. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, a clinical trial may only resume after the FDA has notified the sponsor. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the clinical trial can proceed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements, including GCP requirements, of the FDA in order to use the study as support for an IND or application for marketing approval. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements, the protocol, or other requirements or if the product candidate has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suspension or termination of development during any phase of clinical trials can occur for many reasons, including if the FDA, an IRB, a data safety monitoring board, or we determine that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on factors such as evolving business objectives and/or the competitive environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. Similar requirements for posting clinical trial information are present in the European Union and other countries, as well.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expanded Access to an Investigational Drug for Treatment Use</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new drug products outside of registrational clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to improve access to investigational drugs for patients who may benefit from investigational therapies that do not conflict with registrational trials. FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the drug under a treatment protocol or Treatment IND Application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When considering an IND application for expanded access to an investigational product, the FDA will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no obligation for a sponsor to make its drug products available for expanded access; however, sponsor must make its expanded access policy publicly available upon the earlier of initiation of a Phase 2 or Phase 3 clinical trial; or 15 days after the drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Human Clinical Trials in Support of an NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required after approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational drug product&#8217;s PK and pharmacological effects may be obtained to permit the design of scientifically valid Phase 2 clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are well controlled, closely monitored and conducted in a limited patient population.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial that is designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a drug, is referred to as &#8220;pivotal.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IND annual reports detailing, among other things, the results of the clinical trials must be submitted to the FDA and IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with clinical trials, companies often complete additional animal studies. They must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Pediatric Research Equity Act of 2003, or PREA, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans that contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or grant full or partial waivers from the pediatric data requirements. The FDA maintains a list of diseases that are exempt from the requirements of PREA, due to low prevalence of disease in the pediatric population, and product candidates that have received orphan drug designation are generally exempt from PREA requirements, although orphan-designated drugs intended for treatment of certain molecularly targeted cancer indications are not eligible for the exemption.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Review and Approval of an NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to obtain approval to market a drug product in the United States, a marketing application must be submitted to the FDA that provides sufficient data establishing the safety and effectiveness of the proposed drug product for its intended indication. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by independent investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the drug product to the satisfaction of the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NDA is a vehicle through which applicants formally propose that the FDA approve a new drug product for marketing and sale in the United States for one or more indications. Every new non-biologic drug product candidate must be the subject of an approved NDA before it may be commercialized in the United States. BLAs are submitted for approval of biologic products. Under federal law, the submission of most NDAs is subject to an application user fee, which for federal fiscal year 2023 is $3,242,026 for an application requiring clinical data. The sponsor of an approved NDA is also subject to an annual program fee, which for fiscal year 2023 is $393,933. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation, an exception from the program fee when the program does not engage in manufacturing the drug during a particular fiscal year and a waiver for certain small businesses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA conducts a preliminary review of the application, generally within 60 calendar days of its receipt, and strives to inform the sponsor within 74 days whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Under certain circumstances, the FDA may determine the application is not sufficiently complete to permit a substantive review and will issue a refuse to file letter. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA accepts the application for filing, and 90% of applications for NMEs that have been designated for Priority Review are meant to be reviewed within six months of the filing date. The review process and the Prescription Drug User Fee Act, or PDUFA, goal date may be extended by the FDA to consider new information or clarification provided by the applicant, to address a deficiency identified by the FDA in the original submission, or for other reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an application, the FDA typically will inspect the facility or facilities where the product is being or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">component manufacturing, finished product manufacturing and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that review, evaluate and provide a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but the FDA considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fast Track, Breakthrough Therapy, Priority Review</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has certain programs designed to expedite the development and review of product candidates intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review designation and Regenerative Medicine Advanced Therapy designation. Sponsors must request these designations at appropriate points in the development process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interaction with the FDA, and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete, in a process called rolling review. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information, and the sponsor must pay applicable user fees. However, the FDA&#8217;s PDUFA goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process or for the other reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A product that receives Breakthrough Therapy Designation is eligible for all of the features of Fast Track Designation, and additionally is eligible for intensive guidance throughout the development process and a commitment to involve senior staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may designate a product for Priority Review if it treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A Priority Review designation is intended to direct overall attention and resources to the evaluation of such applications and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accelerated Approval Pathway</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, efficacy biomarker or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. The benefit of accelerated approval derives from the potential to receive approval based on surrogate endpoints sooner than possible for trials with clinical or survival endpoints, rather than deriving from any explicit shortening of the FDA approval timeline, as is the case with Priority Review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date accelerated approval is granted. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of the product if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the agency, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA&#8217;s Decision on an NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA approves a new product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, or require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including Risk Evaluation and Mitigation Strategies (REMS), to help ensure that the benefits of the product outweigh the potential risks. REMS programs can include medication guides, communication plans for health care professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. The FDA may require a REMS before or after approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. After approval, many types of changes to the approved product, such as adding new indications, changing manufacturing processes and adding labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor that obtains regulatory approval for marketing of a new product or a new indication for an existing product, will be subject to numerous post-approval regulatory requirements. The sponsor will be required to report, among other things, certain adverse reactions and manufacturing problems to the FDA, provide updated safety and efficacy information, comply with requirements concerning advertising and promotional labeling requirements, and submit NDA annual reports. Manufacturers and certain of their subcontractors, including those supplying products, ingredients and components, are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort to maintain compliance with cGMP regulations and other regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, may result in revisions to the approved</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">labeling to add new safety information, requirements for post-market studies or clinical trials to assess safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, health care professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses. It may be permissible, under very specific conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a company is found to have promoted off-label uses, it may become subject to administrative and judicial enforcement by the FDA, the Department of Justice, or the DOJ, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, manufacturers and other parties involved in the drug supply chain for prescription drug products must comply with product tracking and tracing requirements and for notify the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 505(b)(2) NDAs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of the proposed new product for the proposed use. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This type of application allows the applicant to rely, in part, on the FDA&#8217;s previous findings of safety and efficacy or literature for a previously approved drug product, also known as a listed drug. Specifically, Section 505(b)(2) applies to NDAs for which certain investigations made to show whether or not the drug is safe and effective &#8220;were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NDAs filed under Section 505(b)(2) provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous approval is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the listed drug has been approved, subject to any regulatory exclusivities or patents for the listed drug (as further described below), as well as for any new indication or use sought by the Section 505(b)(2) applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Abbreviated New Drug Applications for Generic Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs, known as the reference listed drugs, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RLDs. Abbreviated new drug applications, or ANDAs, generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, the applicant must provide information and data showing that its proposed generic version is identical to the RLD with respect to the active ingredients, route of administration, dosage form, strength and conditions of use of the drug. The FDA must also determine whether the generic drug is bioequivalent to the RLD. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221; Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Depending on state laws, generic drugs that are found to be therapeutically equivalent may be automatically substituted for prescriptions for the RLD by the dispensing pharmacist, without the intervention of the prescriber.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hatch-Waxman Patent Certification and the 30-Month Stay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. To the extent that the Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any relevant patents listed for the approved product in the Orange Book in the same manner as an ANDA applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, the applicant must certify with respect to each patent that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the required patent information has not been filed; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent has expired; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent is invalid, unenforceable or will not be infringed by the new product. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents, the application will not be approved until all the listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the applicant is not seeking approval).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the ANDA or Section 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV notice. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) application until the earlier of 30 months after the receipt of the Paragraph IV notice, the expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, approval of a Section 505(b)(2) NDA or ANDA may be delayed until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, or, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of an existing regulatory exclusivity or certain patents. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a product available in the United States for treatment of the disease or condition will be recovered from sales of the product. A company must seek orphan drug designation before submitting an NDA for the candidate product. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not shorten the PDUFA goal dates for the regulatory review and approval process, although it does convey certain advantages such as tax benefits and exemption from the PDUFA application fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for an indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same drug for the same condition for seven years, except in certain limited circumstances. Orphan exclusivity does not block the approval of a different product for the same rare disease or condition, nor does it block the approval of the same product for different conditions. If a drug designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug exclusivity also may not bar approval of another product under certain specified circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term Restoration and Extension</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during the FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of an IND and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Health Care Law and Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other health care laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state health care laws and regulations, include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or making false statements relating to health care matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there&#8239; may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items or services; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians, certain other licensed healthcare practitioners and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to health care items or services that are reimbursed by non-government third-party payors, including private insurers. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State laws also govern the privacy and security of personal information, including health information. Many state laws differ from each other in various ways, thus complicating compliance efforts. For example, the California Consumer Protection Act, or CCPA, establishes data privacy rights for individuals located in California and imposes certain requirements on how businesses can collect and use personal information about such individuals. The California Privacy Rights Act, or CPRA, which became effective on January 1, 2023, imposes additional obligations on companies covered by the legislation and significantly modifies the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information, and establishes a state agency vested with the authority to enforce the CCPA. The CCPA catalyzed the enactment of similar, comprehensive privacy and data protection legislation in several other U.S. states, which became effective in 2023, including in Virginia, Colorado, Utah, and Connecticut. More than a dozen U.S. states have either passed or have proposed similar privacy and data protection legislation. Washington state&#8217;s My Health My Data Act, which comes into force on March 31, 2024, expands the definition of consumer health data, affords consumers with privacy rights and creates a private right of action, which could generate litigation. Although many of the existing state privacy laws exempt clinical trial information and health information governed by HIPAA, future privacy and data protection laws may be broader in scope and apply to our business. Further, data privacy and security laws and regulations in foreign jurisdictions, such as the EU&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom&#8217;s implementation of the same, may impose additional obligations on the collection, use and other processing of personal information, which may be more stringent or different than those in the United States.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pharmaceutical Insurance Coverage and Health Care Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The containment of health care costs also has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and biologics and other medical products, government control and other changes to the health care system in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2010, the United States Congress enacted the ACA, which, among other things, included changes to the coverage and payment for drug products under government health care programs. Among the provisions of the ACA of importance to our potential product candidates are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanded the types of entities eligible for the 340B drug discount program; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 70% point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D; and </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year. Subsequent legislation extended the 2% which remains in effect through 2031. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act of 2022, or IRA, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation, and delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general are not yet known.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In February 2023, HHS also issued a proposal in response to an October 2022 executive</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">order from President Biden that includes a proposed prescription drug pricing model that will test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#8217;s accelerated approval pathway. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Review and Approval of Medicinal Products in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Specifically, however, the process governing approval of medicinal products in the European Union, or EU, generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2014, the EU adopted the new Clinical Trials Regulation, (EU) No 536/2014, which replaced the Clinical Trials Directive 2001/20/EC on January 31, 2022. The Clinical Trials Regulation is directly applicable in all EU Member States meaning no national implementing legislation in each EU Member State is required. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial is required to submit a single application for approval of a clinical trial to a reporting EU Member State through an EU Portal. The submission procedure is the same irrespective of whether the clinical trial is to be conducted in a single EU Member State or in more than one EU Member State.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PRIME Designation in the EU</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation where the marketing authorization application will be made through the centralized procedure. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need. Products from small- and medium-sized enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the Committee for Medicinal Products for Human Use, or CHMP, or Committee for Advanced Therapies, are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketing Authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain a marketing authorization for a product under EU regulatory systems, an applicant must submit an MAA either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the EU, and in the additional Member States of the European Economic Area Iceland, Liechtenstein and Norway. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines), and products with a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions, and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. We anticipate that the centralized procedure will be mandatory for the product candidates we are developing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days, excluding clock stops, but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The European Commission may grant a so-called &#8220;marketing authorization under exceptional circumstances&#8221;. Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, a marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#8220;normal&#8221; marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates intended for treating, preventing or diagnosing seriously debilitating or life-threatening diseases (including medicines designated as orphan medicinal products), if (i) the risk-benefit balance of the product candidate is positive, (ii) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data post-authorization, (iii) the product fulfills an unmet medical need and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. A conditional marketing authorization can be converted into a standard centralized marketing authorization (no longer subject to specific obligations) once the marketing authorization holder fulfils the obligations imposed and the complete data confirm that the medicine&#8217;s benefits continue to outweigh its risks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted an EU marketing authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data and Market Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, innovative medicinal products approved on the basis of a complete and independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance the centralized authorization procedure. Data exclusivity prevents applicants for authorization of generics or biosimilars of these innovative products from referencing the innovator&#8217;s pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU, during a period of eight years from the date on which the reference product was first authorized in the EU. During an additional two-year period of market exclusivity, a generic or biosimilar MAA can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic or biosimilar medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Periods of Authorization and Renewals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State for a nationally authorized product. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period, unless the European Commission or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (in the case of the centralized procedure) or on the market of the authorizing EU Member State for a nationally authorized product within three years after authorization ceases to be valid (the so-called sunset clause).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Paediatric Studies and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining a marketing authorization in the EU, applicants must demonstrate compliance with all measures included in an EMA-approved pediatric investigation plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Paediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP. If an applicant obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate or SPC, provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a two year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products receiving orphan designation in the EU can receive ten years of market exclusivity, during which time no &#8220;similar medicinal product&#8221; may be placed on the market. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a product can be designated as an orphan product by the European Commission if its sponsor can establish: (1) that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five (5) in ten thousand (10,000) persons in the EU when the application is made, or (b) it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient return in the EU to justify the necessary investment in its development; and (3)there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such method exists, the product will be of significant benefit to those affected by that condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, a marketing authorization may be granted to a similar medicinal product with the same orphan indication during the ten-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory Requirements After a Marketing Authorization has been Obtained</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In case an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations. </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive (EU) 2017/1572, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.4961660705107365%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU. Direct-to-consumer advertising of prescription medicines is prohibited across the EU. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the EU Member States, plus Norway, Liechtenstein and Iceland.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reform of the Regulatory Framework in the European Union</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the EU for all medicines (including those for rare diseases and for children). The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval. In October 2023, the European Parliament published draft reports proposing amendments to the legislative proposals, which will be debated by the European Parliament. Once the European Commission&#8217;s legislative proposals are approved (with or without amendment), they will be adopted into EU law.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General Data Protection Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the EU GDPR, which became effective on May 25, 2018. Following the United Kingdom&#8217;s, or UK&#8217;s, withdrawal from the EU, or Brexit, the EU GDPR has been incorporated into UK laws, or UK GDPR (together with the EU GDPR, GDPR). The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, ensuring certain accountability measures are in place and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU and the UK, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United Kingdom formally left the EU on January 31, 2020, and the EU and the United Kingdom have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework currently continues to apply in Northern Ireland). Except in respect of the new EU Clinical Trials Regulation, the regulatory regime in Great Britain therefore currently largely aligns with EU regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of EU pharmaceutical legislation under the TCA, under a new international recognition procedure that was put in place by the Medicines and Healthcare products Regulatory Agency, or MHRA, on January 1, 2024, the MHRA may take into account decisions on the approval of a marketing authorization from the EMA (and certain other regulators) when considering an application for a Great Britain marketing authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 27, 2023, the UK government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single UK-wide marketing authorization will be granted by the MHRA for all medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. The Windsor Framework was approved by the EU-UK Joint Committee on March 24, 2023, so the UK government and the EU will enact legislative measures to bring it into law. On June 9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January 1, 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite Brexit, the EU and UK GDPR remain largely aligned. Currently, the most impactful point of divergence relates to transfer mechanisms (i.e., the ability for EU/UK companies to transfer personal information to third countries, including the United States), because it requires us to implement a variety of different contractual clauses approved by EU or UK regulators. There may be further divergence in the future, including with regard to administrative burdens. The UK has announced plans to reform the country&#8217;s data protection legal framework in its Data Reform Bill, which will introduce significant changes from the EU GDPR.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pricing Decisions for Approved Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, arbitrage between low-priced and high-priced EU Member States, can further reduce prices. Special pricing and reimbursement rules may apply to orphan products. Inclusion of orphan products in reimbursement systems tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any drug. Acceptance of any medicinal product for reimbursement may come with cost, use and often volume restrictions, which again can vary by country. In addition, results-based rules of reimbursement may apply. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU Member States have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital Management</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Mission &amp; Our Employees</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We launched with a bold vision to change the course of genetically defined diseases by developing small molecules to treat them at their root cause. Our approach to drug discovery generates significant insights into disease biology and allows us to think creatively about the best way to modulate and balance gene expression. Our patient-focused product discovery approach is designed to systematically identify and validate cellular drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. We take great pride in being purposeful patient partners who do this work, not just for patients, but with patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We view our employees as one of our most valuable assets in serving our mission. We believe that our future success is dependent on attracting, motivating and retaining talented employees. We value the health and wellness of our employees and their families. We aim to create an equitable, inclusive and empowering work environment in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to support our current pipeline and future business goals. Our success also depends on our ability to attract, engage and retain a diverse group of employees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Behaviors Support Our Mission</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe success comes when we and our employees align with our mission to improve the lives of patients with genetically-defined rare diseases in areas of high unmet medical need. We are the FULcrew united around these Pillars:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We take great pride in being Purposeful Patient Partners</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a culture of Trust and Transparency</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are Invested in our People</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a Playful spirit and have fun together at work</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We launched Fulcrum with a Bold Scientific Vision and remain committed to this journey</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Management of Human Capital</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To effectively leverage and manage our peoples, we ensure our hiring needs are directly aligned with our strategy, we invest in our people focused on their development and journey while at Fulcrum and most importantly we identify our key talent to ensure we are focused on their retention. We track and report internally on key talent metrics including a focus on overall headcount and by function, hiring metrics, career development (promotions, etc.), turnover trends, and employee demographics (including race, gender, ethnicity). Our senior executives use these metrics to make thoughtful decisions around our people including resource planning, recruitment and retention initiatives and design of compensation and benefits programs. We share these metrics quarterly with the senior executives and board of directors to assist it in fulfilling its duties to (a) establish our enterprise compensation philosophy, (b) administer our compensation plans, (c) evaluate the performance of our executive officers and key employees and (d) review and monitor management development and succession plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 20, 2024, we had 76 full-time employees, including a total of 26 employees with M.D. or Ph.D. degrees. Of these full-time employees, 47 employees are engaged in research and development. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Commitment to Diversity, Equity &amp; Inclusion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strongly believe in a diverse workplace where all our employees can thrive in an inclusive environment free from discrimination, harassment, bias and prejudice. We aim to treat all individuals with respect and dignity and to provide all our employees with equal opportunity and fair treatment based on merit. By embracing diversity and inclusion, we create an organization committed to working together to develop innovative solutions in support of our mission consistent with our values. We cultivate a culture and environment where different backgrounds and perspectives are not only respected and heard, but embraced and celebrated. Not only is a diverse, equitable and inclusive mindset and culture critical to an engaged and committed workplace, but it is also imperative to understanding and meeting the needs of the patients we seek to help with our medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we grow and mature, we look forward to establishing programs/metrics that support diversity, equity, inclusion, and belonging. We will focus on continuing to bring more diversity talent to Fulcrum, creating an inclusive environment by creating awareness (speakers, etc.) and ensuring our underrepresent employees are provided the right career opportunities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 20, 2024, women accounted for approximately 55% of our full-time employees. As of March 2, 2023, our employee records indicate that approximately 29% of our full-time U.S. employees identify as non-white.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Compensation &amp; Benefits</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the highly competitive nature of our industry and the importance of recruitment and retention to our success, we strive to furnish our employees with what we believe is a very competitive and comprehensive total rewards package of compensation, benefits and services. This package includes competitive compensation, including equity compensation,</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and comprehensive benefits program that provides resources to help employees manage their health and well-being, finances, and life outside of work (promoting flexibility), including health insurance and dental care, vision insurance, disability insurance, paid sick leave, paid family leave, matching contributions to a 401(k) plan, employee stock purchase plan, paid time off (inclusive of vacation, holidays, focus days) and employee assistance services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal executive office is located at 26 Landsdowne Street, Cambridge, MA 02139, and our telephone number is 617-651-8851. Our internet website address is www.fulcrumtx.com. The information contained on, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future operating results could differ materially from the results described in this Annual Report on Form 10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; on page i of this Annual Report on Form 10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Financial Position and Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have incurred significant operating losses. Our net loss was $97.3 million for the year ended December 31, 2023 and $109.9 million for the year ended December 31, 2022. As of December 31, 2023, we had an accumulated deficit of $509.7 million. To date, we have funded our operations primarily from the sale of shares of our capital stock and from upfront payments received under our collaboration and license agreements. We have devoted substantially all of our financial resources and efforts to research and development, including clinical trials and preclinical studies. We are still in the early stages of development of our product candidates, and we have not completed development of any product candidates. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our clinical development of losmapimod and pociredir; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our ongoing preclinical studies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance clinical-stage product candidates through later stage trials, such as REACH, the Phase 3 clinical trial of losmapimod for the treatment of FSHD; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pursue the discovery of drug targets for other genetically-defined rare diseases and the subsequent development of any resulting product candidates, including for Diamond Blackfan Anemia under our recent license agreement with CAMP4; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scale up our manufacturing processes and capabilities, or arrange for a third party to do so on our behalf, to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire or in-license products, product candidates, technologies and/or data referencing rights, such as our recent agreement with CAMP4; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make any milestone payments to affiliates of GlaxoSmithKline plc, or GSK, under our right of reference and license agreement with GSK upon the achievement of specified clinical or regulatory milestones, or to CAMP4 under our license agreement with CAMP4; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, enforce, defend and protect our intellectual property; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional clinical, quality control and scientific personnel; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts and our operations as a public company. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must succeed in developing, and eventually commercializing, a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses will increase if, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we are required by the FDA, the EMA, or other regulatory authorities to perform trials or studies in addition to, or different than, those expected; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there are any delays in completing our clinical trials or the development of any of our product candidates, such as the clinical hold imposed by the FDA on the Investigational New Drug, or IND, application for pociredir in SCD, which was lifted in August 2023; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we continue our ongoing and planned clinical trials of losmapimod and pociredir, continue research and development and initiate additional clinical trials of, and seek regulatory approval for, these and other product candidates. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our preclinical activities and clinical trials. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Given current uncertainty in the capital markets and other factors, such funding may not be available on terms favorable to us or at all. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, costs and results of our ongoing clinical trials of losmapimod, including REACH, the Phase 3 clinical trial of losmapimod for the treatment of FSHD, which completed enrollment in September 2023, and our Phase 1b clinical trial of pociredir in SCD;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional planned clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, costs and results of discovery research, preclinical development, laboratory testing and clinical trials for our current product candidates in additional indications or for any future product candidates that we may pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of and development requirements for other product candidates that we pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical ingredient, or API, and manufacture of our product candidates and the terms of such arrangements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of our collaboration with MyoKardia or under our recent license agreement with CAMP4;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain additional strategic collaborations, licensing or other arrangements and the financial terms of such arrangements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the payment or receipt of milestones, royalties and other collaboration-based revenues, if any; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents, and marketable securities of approximately $236.2 million. We believe that our cash, cash equivalents, and marketable securities as of December 31, 2023 will enable us to fund our operating expenses and capital expenditure requirements into 2026. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Commercial revenues, if any, will not be derived unless and until we can achieve sales of products, which we do not anticipate for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all, and may become even more difficult to obtain due to rising interest rates and the current downturn in the U.S. capital markets and the biotechnology sector in general. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our product candidates or discovery stage programs or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates. We may also choose to further realign our operations to achieve additional operational efficiencies beyond the strategic realignment commenced in August 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures or declaring dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have in the past relied, and in the future anticipate we will rely, in part on sales of our common stock through at-the-market, or ATM, offering programs. Increased volatility and decreases in market prices of equity securities generally and of our common stock in particular may have an adverse impact on our willingness and/or ability to continue to sell our common stock through an ATM offering program. Decreases in these sales could affect the cost or availability of equity capital, which could in turn have an adverse effect on our business, including current operations, future growth, revenues, net income and the market prices of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2022, we established an ATM offering program to sell shares of our common stock having an aggregate offering price of up to $50.0 million from time to time. We suspended this program in January 2023 immediately prior to commencing our underwritten public offering of common stock, and then terminated this ATM offering program in February 2024 in anticipation of entering into a new ATM offering program to sell shares of our common stock having an aggregate offering price of up to $100.0 million from time to time promptly after filing this annual report on Form 10-K. We may not make any sales of securities pursuant to any ATM offering program unless and until a registration statement with respect to the shares being offered thereunder becomes effective. However, given the overall volatility in the capital markets, even if a new ATM offering program becomes available to us, we may not be willing or able to raise equity capital through an ATM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">offering program. We may, therefore, need to turn to other sources of funding that may have terms that are not favorable to us, or reduce our business operations given capital constraints.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alternative financing arrangements could involve issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue debt securities, the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make-whole has been paid. In addition, if we borrow funds and/or issue debt securities through a subsidiary, the lenders and/or holders of those debt securities would have a right to payment that would be effectively senior to our equity ownership in the subsidiary, which would adversely affect the rights of holders of both our equity securities and, if any, our debt and debt securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest on any newly-issued debt securities and/or newly-incurred borrowings would increase our operating costs and reduce our net income, and these impacts may be material. If the issuance of new securities results in diminished rights to holders of our common stock, the market price of our common stock could be materially and adversely affected.  Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could result in a material adverse effect on our business, operating results, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our limited operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We commenced activities in 2015 and are a clinical-stage biotechnology company. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property, building our discovery platform, identifying drug targets and potential product candidates, in-licensing assets, producing drug substance and drug product material for use in clinical trials and conducting preclinical studies and clinical trials. We have not yet demonstrated our ability to successfully develop any product candidate, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as our business grows, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our financial condition and operating results to fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business was negatively impacted by the COVID-19 pandemic and may in the future be impacted by any future pandemics. In addition, the effects of any future pandemics may, adversely impact economies worldwide, which could result in adverse effects on our business and operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We experienced enrollment delays in our ReDUX4 clinical trial due to the COVID-19 pandemic as the clinical trial sites for our ReDUX4 clinical trial temporarily postponed trial-related activities. We also saw temporary disruptions in other business activities due to a temporary reduction in workforce presence at our Cambridge research facility, and COVID-19 had a significant impact on economies worldwide. Future pandemics may arise, and they, like COVID-19, could impact our company, our CMOs and contract research organizations, or CROs, creating disruptions that affect our ability to initiate and complete preclinical studies or clinical trials, disrupt our supply chain for our research and development activities, and disrupt any then planned or ongoing clinical trials for any number of reasons. Any future pandemics could similarly impact patient recruitment or retention for clinical trials, or result in resources being redirected in a way that adversely impacts our ability to progress regulatory approvals and protect our intellectual property. In addition, as with COVID-19 pandemic, we may face impediments to regulatory meetings and approvals due to recommended safety measures intended to limit in-person interactions in any future pandemic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic caused significant disruptions in the financial markets and any future pandemic could similarly cause such disruptions, which could impact our ability to raise additional funds through public offerings and may also impact the volatility of our stock price and trading in our stock. We cannot be certain what the overall impact of any future pandemic will be on our business. The extent of any future pandemic on our business, financial condition, results of operations and prospects will depend on future developments that are uncertain.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application), including with respect to net operating losses and research and development tax credits, could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, under Section 174 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the United States will be capitalized and amortized, which may have an adverse effect on our cash flow. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal and state net operating loss carryforwards of $312.3 million and $317.1 million, respectively, which begin to expire in 2036. Approximately $288.7 million of the federal net operating losses can be carried forward indefinitely. As of December 31, 2023, we also had federal orphan drug credits of $23.8 million, which begin to expire in 2040. As of December 31, 2023, we also had federal and state research and development tax credit carryforwards of $7.6 million and $4.9 million, respectively, which begin to expire in 2035 and 2030, respectively. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, under Section 382 of the Code, and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses and research and development tax credit carryforwards to offset future taxable income. We conducted an analysis under Section 382 of the Code to determine if historical changes in ownership through December 31, 2021 would limit or otherwise restrict our ability to utilize our pre-change net operating losses and research and development tax credit carryforwards to offset future taxable income. As a result of the analysis, we do not believe that there are any significant limitations on our ability to utilize our net operating losses and research and development tax credit carryforwards to offset future taxable income. However, we may experience such ownership changes in the future (which may be outside our control). As a result, if, and to the extent that, we earn net taxable income, our ability to use our pre-change net operating losses and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. Our net operating losses or credits may also be impaired under state law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future; thus, we do not know whether or when we will generate taxable income necessary to utilize our net operating losses or research and development tax credit carryforwards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. In March 2023, a number of banks (e.g., Silicon Valley Bank, Signature Bank and Silvergate Capital Corp.) were placed into receivership, followed by First Republic Bank in May 2023. Although the Federal Deposit Insurance Corporation, or FDIC, and others have taken steps to reduce risk to uninsured depositors, borrowers under credit agreements, letters of credit and certain other financial instruments with such banks or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder.  Even though we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors affecting the financial services industry or economy in general, such as these recent bank failures. These factors could also include, among others, liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry and the supervision thereof. In addition, investor concerns regarding the United States or international</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, which could have material adverse effect on our liquidity and on our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Discovery and Development of our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are early in our development efforts, and we only have two clinical-stage product candidates. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are early in our development efforts, and we have advanced only two product candidates into clinical trials, losmapimod for the treatment of FSHD, and pociredir for the treatment of SCD (which was on clinical hold between February and August 2023). We have invested substantially all of our efforts and financial resources in identifying and validating and conducting clinical trials on cellular drug targets that can potentially modulate gene expression to address the root cause of genetically-defined rare diseases. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development, regulatory approval and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully completing preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allowance by the FDA or other regulatory agencies of the INDs, clinical trial applications, or CTAs, or other regulatory filings for losmapimod, pociredir and future product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanding and maintaining a workforce of experienced scientists and others to continue to develop our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">applying for and receiving marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining intellectual property protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing sales, marketing and distribution capabilities and successfully launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of the products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effectively competing with other therapies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining a continued acceptable safety profile of the products following receipt of any regulatory approvals. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to build a pipeline of product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current strategy is focused on developing small molecules to improve the lives of patients with genetically defined rare diseases. Even if we are successful in identifying drug targets and potential product candidates, such candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance. Identifying, developing, obtaining regulatory approval for and commercializing additional product candidates will require substantial additional funding and is prone to the risks of failure inherent in product development. We cannot provide stockholders any assurance that we will be able to successfully identify additional product candidates, including as a result of our collaboration with MyoKardia, advance any additional product candidates through the development process or successfully commercialize any such additional product candidates. Regulatory authorities have substantial discretion in the approval process and may cause delays in the approval or rejection of an application. As a result of these factors, it is difficult for us to predict the time and cost of product candidate development. There can be no assurance that any development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">problems we experience in the future related to our discovery technologies or any of our research or development programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. If we do not successfully identify, develop, obtain regulatory approval for and commercialize product candidates, we will not be able to generate product revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. The results of preclinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have two product candidates in clinical development. The risk of failure for each of our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. We have not yet completed a pivotal clinical trial of any product candidate. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. For example, pociredir, our clinical trial stage candidate to treat SCD, is an embryonic ectoderm development, or EED, inhibitor. EED is a member of the PRC2 complex, which also includes EZH2. There are approved products in the EZH2 class of medications and their approved labeling outlines safety risks, including an increased risk of malignancies. In the event that pociredir has similar safety risks as other PRC2 medications, this could impact its acceptance. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned INDs and other regulatory filings in the United States and abroad. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or other regulatory agencies will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our current or future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin or continue. For example, in February 2023, the FDA imposed a clinical hold on our IND for pociredir in SCD. We worked diligently to resolve the hold as soon as possible, and in August 2023, the FDA lifted the clinical hold. Product candidates are subject to continued preclinical safety studies, which may be conducted concurrent with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. For example, we revised the inclusion and exclusion criteria of our clinical trial of pociredir in SCD to address the clinical hold imposed by the FDA, and there can be no certainty as to whether we will be successful in completing the clinical trial with its revised design. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. For example, our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials. A lack of clinical benefit may be due to insufficient dosing or for other reasons. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials, and we cannot be certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates and/or cause the FDA or other regulatory authorities to require additional testing before approving any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Item 1 &#8220;Business&#8212;Licenses and Collaboration--Right of Reference and License Agreement with GlaxoSmithKline&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2023, or this Annual Report on Form 10-K, we have entered into a right of reference and license agreement, as amended, with affiliates of GSK. Although losmapimod was originally evaluated by GSK in nearly 3,600 subjects, GSK did not evaluate losmapimod in FSHD or in any other muscular dystrophy, and most of the subjects in these trials were given a dose that was lower than our planned dosage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of 15 mg of losmapimod twice per day. Accordingly, the safety data generated from GSK&#8217;s clinical trials of losmapimod may not be predictive or indicative of the results of our clinical trials. Similarly, while we believe the safety data from GSK&#8217;s clinical trials may, in part, support the safety database for losmapimod, GSK evaluated a limited number of subjects at a dose of 15 mg twice daily.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators may decide the design of our clinical trials is flawed, for example if our trial protocol does not evaluate treatment effects in trial subjects for a sufficient length of time; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities would consider likely to predict clinical benefit; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preclinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional preclinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may decide, or regulators or IRBs may require us, to suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators or IRBs may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate the trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unforeseen global instability, including political instability, such as the Russian invasion of Ukraine or recent hostilities in Israel and Gaza Strip, or instability from an outbreak of pandemic or contagious disease in or around the countries in which we conduct our clinical trials, could delay the commencement or rate of completion of our clinical trials; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and mitigation strategy, or REMS. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in response to the COVID-19 pandemic, the clinical trial sites for our ReDUX4 trial temporarily postponed trial-related activities, impacting our clinical trial execution plans, and we cannot be certain that we will not face other postponements or similar difficulties in the future. Further, in February 2023, the FDA imposed a clinical hold on our IND for pociredir in SCD, which halted our clinical trial until the FDA lifted the clinical hold in August 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not obtain marketing approval at all; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval with labeling or a REMS that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development costs will also increase if we experience delays in testing or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses and/or delays. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we are developing some of our product candidates for the treatment of diseases in which there is limited clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to predict or provide clinically meaningful results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently no therapies approved to treat FSHD, and there may be no therapies approved to treat the underlying causes of diseases that we attempt to address or may address in the future. As a result, the design and conduct of a clinical trial or trials of the product candidates for the treatment of these diseases may take longer, be more costly or be less effective as part of the novelty of development in these diseases. In some cases, we may use new or novel endpoints or methodologies, such as RWS, which has not been proven for registration to our knowledge. The FDA and other regulatory authorities have indicated support for RWS as a primary endpoint with additional and appropriate supportive data from secondary endpoints. However, such regulatory authorities may not consider the endpoints of our clinical trial(s) to provide clinically meaningful results, even where we believe such results are clinically meaningful. For example, while we have met with regulators to discuss the REACH trial design and registration strategy for losmapimod for FSHD, including our proposed endpoints for REACH, regulators may require additional data to support the RWS functional primary endpoint for approval of losmapimod for FSHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the FDA does find our primary endpoint to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a magnitude, duration or degree of statistical significance in any pivotal or other clinical trials we may conduct for our product candidates. Even if we do meet the primary endpoint, our trials may produce results that are unpredictable or inconsistent with the results of the other, more traditional efficacy endpoints in the trials. The FDA also could ascribe substantial weight to other efficacy endpoints when interpreting the clinical trial data, such that even if we achieve statistically significant results on our primary endpoint, the FDA may regard the failure to show a statistically significant effect on our secondary efficacy endpoints as raising questions about the efficacy of the drug. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of approval. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying and qualifying patients to participate in and complete clinical trials for our product candidates is critical to our success. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in the trial until its conclusion. For example, in our Phase 1b trial of pociredir, although we enrolled six subjects in the initial cohort, only three subjects remained evaluable as of the initial data cutoff date. Subsequently, we modified the study protocol to monitor subject adherence. However, if such protocols do not improve adherence and improve compliance, we may not be able to generate meaningful data. Furthermore, we may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. We revised the design of our clinical trial of pociredir in SCD to address the clinical hold imposed by the FDA, and there can be no certainty as to whether we will be successful in completing the clinical trial with its revised design, which include updated inclusion and exclusion criteria and thus a narrower set of eligible patients. Because of our primary focus on genetically-defined rare diseases, we may have difficulty enrolling a sufficient number of eligible patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment is affected by a variety of other factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of the disease under investigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility criteria for the trial in question; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate under trial; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the requirements of the trial protocols, including invasive procedures such as muscle biopsies or medical resonance imaging (MRI), which requires the use of specialized equipment; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of existing treatments for the indications for which we are conducting clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the conduct of clinical trials by competitors for product candidates that treat the same indications as our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to identify specific patient populations for biomarker-defined trial cohort(s); and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost to, or lack of adequate compensation for, prospective patients. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are associated with serious adverse events or undesirable side effects in clinical trials or have characteristics that are unexpected in clinical trials or preclinical testing, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in February 2023, the FDA placed our IND for pociredir on clinical hold based on hematological malignancies observed in nonclinical toxicology studies. We addressed the FDA&#8217;s concern as diligently as possible, including FDA&#8217;s request for information about an SCD patient population with an appropriate benefit-risk profile for further clinical development of pociredir, and FDA's request for information to define the potential risk in any further studies that may be conducted in healthy volunteers. Although the FDA lifted the clinical hold in August 2023, we cannot make</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assurances that patients treated with pociredir will not develop hematological malignancies or other adverse events in the future. We also cannot make assurances that additional observations in preclinical studies of hematological malignancies or other adverse events will not occur. If such additional adverse events were to emerge, further advancement of our clinical studies could be halted or delayed and we may not receive regulatory approval for pociredir. Even if we receive regulatory approval for pociredir, our labeling may be restricted and/or market acceptance for our product may be diminished, and the commercial potential of our pociredir program may be materially and negatively impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In pharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that delay or prevent further development of the compound.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if results of our clinical trials reveal unacceptable side effects, we, the FDA or the IRBs at the institutions in which our studies are conducted could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials. If we elect or are forced to suspend or terminate any clinical trial of our product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenue from such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives regulatory approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal or limitation by regulatory authorities of approvals of such product; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seizure of the product by regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of the product; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing of the product or the manufacturing process for any component thereof; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirement by regulatory authorities of additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirement that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product may become less competitive; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of regulatory investigations and government enforcement actions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of legal action against us to hold us liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">harm to our reputation and resulting harm to physician or patient acceptance of our products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we are focusing our research and development efforts on rare neuromuscular, muscular, hematologic and central nervous system disorders. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are conducting clinical trials of losmapimod in patients with FSHD in Europe, the United Kingdom, and Canada and currently plan to conduct additional clinical trials for our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently conducting a Phase 3 clinical trial, an open label extension of our Phase 2b clinical trial, and an open label extension of our Phase 2 open label clinical trial of losmapimod in patients with FSHD in Europe, the United Kingdom, and Canada. We may also conduct additional clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations, including good clinical practices, and FDA&#8217;s ability to validate the data. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Commercialization of our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of our product candidates, if approved, may be smaller than we estimate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and potential advantages of our product candidates compared to the advantages and relative risks of alternative treatments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of sales and marketing efforts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments, including any similar generic treatments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to offer our products, if approved, for sale at competitive prices; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product is approved; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any restrictions on the use of our products, if approved, together with other medications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assessment of the potential market opportunity for our product candidates is based on industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties, one of which we commissioned. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Our estimates of the potential market opportunities for our product candidates include</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">several key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of our product candidates may be smaller than we expect, and as a result our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we expect to build a focused, specialty sales and marketing infrastructure to market some of our product candidates in the United States, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our products on our own include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">currently market and sell products or are pursuing the development of products for the treatment of many of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, we are aware of several product candidates in clinical development that could be competitive with product candidates that we may successfully develop and commercialize. See Item 1 &#8220;Business&#8212;Competition&#8221; in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. For example, on December 8, 2023, the FDA approved CASGEVY (exagamglogene autotemcel) and LYFGENIA (lovotibeglogene autotemcel), the first ex vivo cell-based gene therapies for the treatment of SCD. CASGEVY has also been FDA-approved for the treatment of transfusion-dependent beta-thalassemia. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because certain of the target patient populations of our product candidates are small, and the addressable patient population even smaller, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We primarily focus our research and product development on treatments for genetically-defined rare diseases. Given the small number of patients who have the rare diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these rare diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research that we conducted, and may prove to be incorrect or contain errors. New studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because the potential target populations for many of the indications we are evaluating are very small, we may never achieve profitability despite obtaining such significant market share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The target patient populations for some of the indications we are evaluating are relatively small, and there is currently no standard of care treatment directed at some of our target indications, such as FSHD. As a result, the pricing and reimbursement of our product candidates, if approved, is uncertain, but must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on CMOs to manufacture our product candidates. If we are unable to enter into such arrangements as expected or if such organizations do not meet our supply requirements, development and/or commercialization of our product candidates may be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any manufacturing facilities and rely, and expect to continue to rely, on third parties to manufacture clinical supplies of our product candidates and we expect to rely on third parties to manufacture commercial supplies of our products, if and when approved for marketing by applicable regulatory authorities, as well as for packaging, sterilization, storage, distribution and other production logistics. If we are unable to enter into such arrangements on the terms or timeline we expect, development and/or commercialization of our product candidates may be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities to support commercialization of any of our product candidates for which we obtain marketing approval, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements, or we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different manufacturer, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trial supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a manufacturer may possess technology related to the manufacture of our product candidate that such manufacturer owns independently. This would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another manufacturer manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. These facilities may also be affected by natural disasters, such as floods or fire, as well as public health issues (for example, an outbreak of a contagious disease such as COVID-19), or such facilities could face manufacturing issues, such as contamination or regulatory concerns following a regulatory inspection of such facility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our third-party manufacturers will be subject to inspection and approval by the FDA before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to FDA inspection from time to time. Failure by our third-party manufacturers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidates may result in regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters or injunctions or the loss of operating licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our third-party manufacturers may also encounter shortages in the raw materials or API necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API, including shortages caused by the purchase of such raw materials or API by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities of our product candidates, may have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any manufacturing facilities. Although we believe we have obtained sufficient losmapimod tablets from GSK to complete our ongoing clinical trials of losmapimod for the treatment of FSHD, we cannot be sure we have correctly estimated our drug product and API requirements or that such drug product or API will not expire before we want to use it. We have also engaged CMOs to prepare our own API and to manufacture losmapimod tablets. Although we believe we have produced sufficient losmapimod tablets to complete our planned Phase 3 registrational trial, we cannot be sure we have correctly estimated our drug product and API requirements or that such drug product or API will not expire before we want to use it. In addition, although we believe we have obtained sufficient quantities of pociredir from a CMO for the completion of our Phase 1b clinical trial for SCD, we cannot be sure we have correctly estimated our drug product requirements, which could delay, prevent or impair our development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to rely on third parties for the manufacture of pociredir for any future clinical trials and for the manufacture of any future product candidates for preclinical and clinical testing. We also expect to rely on third-party manufacturers or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party collaborators for the manufacture of commercial supply of any other product candidates for which we or our collaborators obtain marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a source for bulk drug substance. If any of our future contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. See Item 1 &#8220;Business &#8212; Government Regulation and Product Approval&#8212;Pharmaceutical Insurance Coverage and Health Care Reform&#8221; in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that our product candidates, even if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future profitability will depend, in part, on our ability to commercialize our product candidates in markets outside of the United States and the European Union. If we commercialize our product candidates in foreign markets, we will be subject to additional risks and uncertainties, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular economies and markets, which could include localized disputes that have a broader regional or global impact (such as the Russian invasion of Ukraine or recent hostilities in Israel and Gaza Strip); </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, many of which vary between countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tariffs and trade barriers, as well as other governmental controls and trade restrictions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or foreign governments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">longer accounts receivable collection times; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">longer lead times for shipping; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">language barriers for technical training; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to therapeutics; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency exchange rate fluctuations and currency controls; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing foreign reimbursement landscapes; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uncertain and potentially inadequate reimbursement of our products; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If risks related to any of these uncertainties materializes, it could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in human clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products that have been approved for commercial sale, the current and future use of product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for any product candidates or products that we may develop; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant costs to defend any related litigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced resources of our management to pursue our business strategy; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any products that we may develop. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently hold $10 million in clinical trial liability insurance coverage in the aggregate, with a per incident limit of $10 million, which may not be adequate to cover all liabilities that we may incur.  We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely on third-party contract CROs to conduct our clinical trials. We plan to rely on third-party CROs or third-party research collaboratives to conduct any future clinical trials. We do not plan to independently conduct clinical trials of our other product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. These agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities might be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely, and expect to continue to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have entered into, and may in the future enter into, collaborations with third parties for the discovery, development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a collaboration and license agreement with MyoKardia (for certain genetically defined cardiomyopathies).  See Item 1 &#8220;Business&#8212;License Agreements and Collaborations&#8221; in this Annual Report on Form 10-K. While we have retained all rights to and are developing on our own our current product candidates, we may in the future enter into development, distribution or marketing arrangements with third parties with respect to our other existing or future product candidates. Our likely collaborators for any such sales, marketing, distribution, development, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">companies and biotechnology companies. If we enter into any such arrangements with any third parties in the future, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations that we enter into, including our collaboration with MyoKardia, may not be successful, and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not perform their obligations as expected; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that may divert resources or create competing priorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator (e.g., termination of our collaboration with Acceleron Pharma, Inc., or Acceleron, following its acquisition by Merck &amp; Co., or Merck), and, if </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described herein also apply to the activities of our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. For example, in November 2020, subsequent to our entering into the MyoKardia collaboration agreement, MyoKardia was acquired by Bristol-Myers Squibb Company. Bristol-Myers Squibb Company could determine to reprioritize MyoKardia&#8217;s development programs such that it ceases to diligently pursue the development of our programs and/or cause the agreement between MyoKardia and us to terminate. If our collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are not able to establish or maintain collaborations, we may have to alter our development and commercialization plans and our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For some of our product candidates, we may decide to collaborate with pharmaceutical or biotechnology companies for the development and potential commercialization of those product candidates. For example, in July 2020, we entered into a collaboration and license agreement with MyoKardia to identify and validate potential biological targets for the potential treatment of certain genetically defined cardiomyopathies. We face significant competition in seeking appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be restricted under existing or future license agreements from entering into agreements on certain terms with potential collaborators. For example, we are restricted by GSK&#8217;s right of first negotiation under our current license agreement with them, and we had restrictions under our collaboration with Acceleron. Under our collaboration with MyoKardia, we are restricted from researching, developing, manufacturing, commercializing, using, or otherwise exploiting any compound or product (a) that is a compound or product under the agreement that is directed against certain targets identified by us in the performance of the research activities for the treatment, prophylaxis, or diagnosis of any indication or (b) for the treatment of any genetically defined cardiomyopathies shown to be related to certain specified genes of interest that are modulated by the targets chosen by MyoKardia under our collaboration, in each case , while we are performing the research activities pursuant to the research plan and for a specified period thereafter.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical and biotechnology companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain, maintain, enforce and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business and by in-licensing intellectual property related to our technologies and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and in-licensed patent rights are highly uncertain. Moreover, our owned and in-licensed pending and future patent applications may not result in patents being issued which protect our technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights. For information relating to our patent portfolio, see Item 1 &#8220;Business&#8212;Intellectual Property&#8221; in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. For example, while we believe that the specific and generic claims contained in our U.S. patent provide protection for the method of using losmapimod for the treatment of FSHD and while we also believe that the specific and generic claims contained in our issued and pending U.S. non-provisional and provisional applications provide protection for the pharmaceutical compositions and methods of use for pociredir, third parties may nevertheless challenge such claims. If</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any such claims are invalidated or rendered unenforceable for any reason, we will lose valuable intellectual property rights and our ability to prevent others from competing with us would be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. For example, the composition of matter patents covering losmapimod, licensed from GSK have expired and are no longer a barrier to entry for any new uses not covered by our other patents and patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under our current license agreements, we may not have the final or sole decision on whether we are able to opt out certain of our in-licensed European patents and patent applications from the recently created Unified Patent Court, or the UPC, for the European Union. While our licensors have decided to opt out of the UPC, we cannot guarantee that our in-licensed European patents and patent applications will be challenged for non-compliance during the opt-out procedure and if successful, brought under the jurisdiction of the UPC nor can we guarantee that our licensors will decide to opt back into the UPC at a later time. Thus, we cannot be certain that our in-licensed European patents and patent applications will not fall under the jurisdiction of the UPC. Under the UPC, a single European patent would be valid and enforceable in numerous European countries. A challenge to the validity of a European patent under the UPC, if successful, could result in a loss of patent protection in numerous European countries which could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to, among other factors, the length of time the drug is under regulatory review, but such patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one eligible patent may be extended. Similar provisions are available in Europe and certain other jurisdictions outside the United States. If and when our product candidates receive FDA approval, we expect to apply for patent term extensions where applicable, but there is no guarantee that the applicable governmental authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO a petition for patent term extension thus if one of our licensed patents is eligible for patent term extension, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, an ANDA applicant would not have to provide notice to us with respect to that patent.  See Item 1 &#8220;Business&#8212;Intellectual Property&#8221; in this Annual Report on Form 10-K for additional information regarding patent laws and patent protection.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our issued European patents could be subject to the jurisdiction of the UPC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our European patents and patent applications could be challenged in the UPC. We decided to remove, i.e., opt out, our European patents and patent applications from the jurisdiction of the UPC. However, if certain formalities and requirements are not met, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC. Under the UPC, a granted European patent would be valid and enforceable in numerous European countries. Although such patent rights would apply to numerous European countries, a successful challenge to a European patent under the UPC could result in loss of patent protection in numerous European countries. Accordingly, a single proceeding under the UPC addressing the validity and infringement of the European patent could result in loss of patent protection in numerous European countries rather than in each validated country separately as such patents always have been adjudicated. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Although we or our licensors are not currently involved in any litigation to protect or enforce our patent or other intellectual property rights, we may become involved in such lawsuits, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensor&#8217;s issued patents or other intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly, and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right and could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are party to license and funding agreements, such as our agreement with GSK and our recent license agreement with CAMP4, and we may enter into additional licensing and funding arrangements with third parties that impose or may impose diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Under our existing licensing and funding agreements, we are obligated to pay royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects. We also have licenses and agreements to certain technologies that we use in our discovery efforts, all of which are non-exclusive. While we still face all of the risks described herein with respect to those agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities. For example, under our license with GSK, GSK has certain rights of first negotiation if we wish to sublicense any of the patent or data rights licensed by GSK to us to a third party for use outside the United States. This may prevent or delay certain transactions, which could have an adverse effect on the development and commercialization of losmapimod and on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation related issues; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries and in Russia, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for our product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, to maintain our competitive position, including certain aspects of our discovery technology. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our owned and in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">portions of our discovery technology are protected by trade secrets, but much is not protected by intellectual property, including patents, trade secrets and know-how, and we may not be able to develop, acquire or in-license </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any patentable technologies or other intellectual property related to the unprotected portions of our discovery portfolio;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may harm our business; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Approval of our Product Candidates and Other Legal Compliance Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and we may not obtain approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketing approval of drugs in the United States requires the submission of a new drug application, or NDA, to the FDA and we are not permitted to market any drug candidate in the United States until we obtain approval of the NDA. An NDA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies may prolong the time necessary for regulatory submissions to be reviewed and/or new drugs to be approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown were to occur, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and European Union, may designate drugs for relatively small patient populations as orphan drugs. The FDA and EMA have granted orphan drug designation to losmapimod for the treatment of FSHD. We may seek orphan drug designation for our other current and future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity, which precludes the FDA or the EMA from approving another marketing authorization application for the same drug for a certain time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years at the end of the fifth year if it is determined that a drug no longer meets the criteria for orphan drug designation, including if the drug is sufficiently profitable so that market exclusivity is no longer justified. Proposed amendments to European Union regulations regarding orphan medicines are under consideration that could reduce the ten-year marketing exclusivity period to eight to nine years (or even as little as three to five years for well-established medicines). The European Union&#8217;s April 2023 draft legislative proposal is under review, including by the European Parliament and European Council but, if implemented in due course, may mean that orphan medicines have reduced marketing exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because competing drugs containing a different active ingredient can be approved for the same condition. In addition, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior to the first drug to obtain orphan drug exclusivity because it is shown to be safer, more effective or makes a major contribution to patient care. Moreover, if we pursue and obtain approval for the same product for another indication for which we are not entitled to or do not have orphan drug exclusivity, our period of orphan exclusivity will not prevent third parties from obtaining approval for a competing drug containing the same active ingredient for use in this other, non-orphan indication.  If that were to occur, the protection we derive from orphan exclusivity may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Designation by the FDA, such as fast track or breakthrough therapy, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA granted fast track designation to losmapimod for the treatment of FSHD and to pociredir for the treatment of SCD, and we may seek fast track designation for some of our other product candidates as well as breakthrough therapy designation, including for losmapimod. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure stockholders that the FDA would decide to grant it. Even with fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive breakthrough therapy designation, the receipt of such designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if the FDA agrees that we may pursue an accelerated approval NDA submission, approval of the NDA is not assured, nor does submission of an accelerated approval NDA ensure that the product candidate will have a faster development or regulatory review process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek approval, as applicable, of our product candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, an intermediate clinical endpoint).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that, after feedback from FDA, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted or that any expedited review or approval will be granted on a timely basis, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, as a condition of accelerated approval, the FDA likely would require that we perform adequate and well-controlled post-marketing clinical trials to confirm the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence. Under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also requires sponsors to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. In addition, the FDA generally requires pre-approval of promotional materials for products under consideration for accelerated approval, which could adversely impact the timing of the commercial launch of the product. Thus, even if we seek to utilize the accelerated approval pathway for a product candidate, we may not experience a faster development or regulatory review or approval process for that product. In addition, receiving accelerated approval does not assure that the product&#8217;s accelerated approval will ultimately be converted to a traditional approval.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market and sell our products in the European Union and many other foreign jurisdictions, we or our potential third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or our potential third-party collaborators may not obtain approvals, including conditional authorization, from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. We may not be able to file for marketing approvals and may not receive the necessary approvals to commercialize our products in any market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, now that the United Kingdom is no longer part of the European Union, separate applications and procedures will be required to obtain regulatory approval for our products in the United Kingdom and the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals could prevent us from commercializing any product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product, including the adoption and implementation of REMS. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. Violations of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may have various consequences, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of or restrictions on such products, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions and warnings on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning letters or untitled letters; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of the products from the market; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">damage to relationships with any potential collaborators; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable press coverage and damage to our reputation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation involving patients using our products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s or United Kingdom&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs applicable to drug manufacturers. Additionally, under FDORA, sponsors of approved drugs and biologics must provide six months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed. We will also be subject to other regulatory requirements, including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements regarding the distribution of samples to clinicians, and recordkeeping.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations, which, in the event of a violation, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we obtain regulatory approval and commercialize any products, healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with healthcare providers, physicians and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by U.S. federal and state governments and by governments in foreign jurisdictions in which we conduct our business. See Item 1 &#8220;Business&#8212;Government Regulation and Product Approvals&#8212;Health Care Law and Regulation&#8221; in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities that would be conducted by our sales team, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government funded healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The legislative and regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic Area, or EEA, including personal health data, is subject to the European Union&#8217;s General Data Protection Regulation, or EU GDPR. Following the withdrawal of the United Kingdom from the European Union, or Brexit, the EU GDPR has been incorporated into United Kingdom&#8217;s laws, or UK GDPR, alongside the UK Data Protection Act 2018, and together with the EU GDPR, is referred to as GDPR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite Brexit, the EU and UK GDPR remain largely aligned. Currently, the most impactful point of divergence relates to transfer mechanisms (i.e., the ability for companies in the European Union or the United Kingdom to transfer personal information to third countries, including the United States), because it requires us to implement a variety of different contractual clauses approved by European Union&#8217;s or United Kingdom&#8217;s regulators, and carry out transfer impact assessments to establish whether the third country can ensure essential equivalency. This complexity and the additional contractual burden increases our overall risk exposure, and may result in us needing to make strategic considerations around where EEA and UK personal data is stored and which service providers we can utilize for the processing of EEA and UK personal data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> There may be further divergence in the future, including with regard to administrative burdens. The UK Government has also now introduced a Data Protection and Digital Information Bill, or the UK Bill, into the UK legislative process. The aim of the UK Bill is to reform the UK's data protection regime following Brexit. If passed, the final version of the UK Bill may have the effect of further altering the similarities between the UK and EEA data protection regime. This may lead to additional compliance costs and could increase our overall risk exposure as we may no longer be able to take a unified approach across the European Union and the United Kingdom, and we will need to amend our processes and procedures to align with the new framework.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar data protection laws are either in place or under way in the United States. There are a broad variety of privacy and data security laws and regulations that may be applicable to our activities governing the collection, use, disclosure, and protection of health-related and other personal information (including, state data breach notification laws, health information and/or genetic privacy laws and federal and state consumer protection laws including Section 5 of the FTC Act, HIPAA, and the California Consumer Privacy Act, or CCPA). For example, the CCPA as amended by the California Privacy Rights Act, has created certain requirements for data use, sharing and transparency, and provides California residents certain rights concerning their personal information, such as access, correction, deletion and opt out of or selling or sharing such data. Several other states have implemented privacy legislation similar to the CCPA or are preparing to implement their own regulatory frameworks. A wide range of enforcement agencies at both the state and federal levels, such as the Federal Trade Commission and state Attorneys General have been increasingly aggressive in reviewing and enforcing privacy and data security-related consumer protection laws. See Item 1 &#8220;Business &#8211;Government Regulation and Product Approvals&#8221; in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the breadth and depth of changes in privacy, data protection and consumer protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and ongoing review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that store, process or transfer personal data on our behalf. Compliance with the GDPR and other similar laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business. Any failure or perceived failure by us to comply with such laws and regulations could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. There is also the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain for any products that are approved in the United States or foreign jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any FDA approved product. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed. See Item 1 &#8220;Business&#8212;Government Regulation and Product Approval&#8212;Pharmaceutical Insurance Coverage and Health Care Reform&#8221; in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022 the Inflation Reduction Act of 2022 was passed, which among other things, allows for Centers for Medicare &amp; Medicaid Services to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with select high-cost drugs in 2026. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for offering a price that is not equal to or less than the price negotiated under the law or for taking price increases that exceed inflation.  The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. Further, the legislation caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses at $2,000. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA's Medicare drug price negotiation program. The effect of Inflation Reduction Act of 2022 on our business and the healthcare industry in general is not yet known.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In countries outside of the United States, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or any third-party manufacturers we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and third-party manufacturers we engage now are, and any third-party manufacturers we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Liability under certain environmental laws governing the release and cleanup of hazardous materials is joint and several and could be imposed without regard to fault. We also could incur significant costs associated with civil or criminal fines and penalties or become subject to injunctions limiting or prohibiting our activities for failure to comply with such laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain general liability insurance as well as workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from developing manufacturing and selling certain products outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we expand our operations outside of the United States, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the EU GDPR. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer and information technology systems and infrastructure, or those of our collaborators or other contractors or consultants, may fail or suffer security compromises or breaches, which could result in a material disruption of our product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal computer and information technology systems and infrastructure and those of our CROs, collaborators, and other contractors or consultants upon which our business relies, are vulnerable to breakdown or damage or interruption or otherwise may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, system malfunction, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. Such systems and infrastructure are also vulnerable to service interruptions or to security compromises or breaches from inadvertent or intentional actions by our employees, CROs or other third-party vendors, contractors, consultants and/or business partners or other third parties, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include wrongful conduct by insider employees or vendors, hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud or cyber-attacks, including the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, phishing attacks and social engineering, business email compromise, and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. We have experienced cyber incidents in the past, and we cannot guarantee that the measures we take to prevent, detect, and respond to cyber-attacks will be effective to prevent or remediate future incidents. If our cybersecurity measures or those of our service providers fail to protect against unauthorized access, attacks, compromise or the mishandling of data by our employees or contractors, then our reputation, customer trust, business, results of operations and financial condition could be adversely affected. Because the techniques used by threat actors who may attempt to penetrate and sabotage our computer systems or those of our collaborators or other contractors or consultants change frequently and may not be recognized until launched against a target, we may be unable to anticipate these techniques.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have not experienced any material system failure, accident, cyber-attack or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security compromise or breach were to result in a loss of, damage to, unauthorized access, or misuse of our data, systems, infrastructure or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability (including in connection with or resulting from litigation or governmental investigations and enforcement actions), our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed and our business could be otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Employee Matters and Managing Growth</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive officers, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment offer letters with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. Recruiting and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have had recent executive transitions, including of our chief executive officer, chief financial officer, president of research and development, chief scientific officer, and chief medical officer. We cannot predict the likelihood, timing or effect of future transitions among our executive leadership. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. For example, our employees have taken on increased responsibilities in light of this turnover, which could divert attention from key business areas. Additionally, the number of recent departures has created some uncertainty. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Even if we are successful in our efforts to replace our executive leadership, we cannot guarantee that we will not face similar turnover in the future. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. In August 2022, we announced a workforce reduction in our research and development function, which may make us a less attractive employer to future candidates. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success as a public company also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 20, 2023, our executive officers and directors and our stockholders who owned more than 5% of our outstanding common stock in the aggregate beneficially owned shares representing approximately 48.6% of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This concentration of ownership control may:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay, defer or prevent a change in control; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entrench our management and board of directors; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or prevent a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a classified board of directors such that only one of three classes of directors is elected each year; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the manner in which stockholders can remove directors from our board of directors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit who may call stockholder meetings; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation or bylaws. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analyst will provide favorable coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock has been, and is likely to continue to be volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of or developments in preclinical studies and clinical trials of our product candidates or those of our competitors or potential collaborators; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our success in commercializing our product candidates, if and when approved; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license products, product candidates, technologies or data referencing rights, the costs of commercializing any such products and the costs of development of any such product candidates or technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or the financial results of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry and market conditions; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#8217;s attention and resources. Furthermore, negative public announcements of the results of hearings, motions or other interim proceedings or developments could have a negative effect on the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A significant portion of our total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Persons who were our stockholders prior to our initial public offering continue to hold a substantial number of shares of our common stock. If such persons sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have filed or intend to file universal shelf registration statements (which allows us to offer and sell securities from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale) subject to an aggregate offering amount stated therein, as well as registration statements registering all shares of common stock that we may issue under our equity compensation plans or pursuant to equity awards made to newly hired employees outside of equity compensation plans. Such registered shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an EGC until December 31, 2024, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.235 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may choose to take advantage of some or all of the available exemptions. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an EGC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company we have incurred, and particularly after we are no longer an EGC, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements, and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an EGC or a smaller reporting company with less than $100 million in revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we conduct a process each year to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders&#8217; sole source of gain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our certificate of incorporation designates the state courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. This exclusive forum provision will not apply to actions arising under the Securities Act or the Securities Exchange Act of 1934, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition and operating results.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cyber Risk Management and Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At Fulcrum Therapeutics, we recognize the importance of assessing, identifying, and managing risks from cybersecurity threats. We have implemented a cybersecurity risk management process in accordance with our risk profile and business that is informed by industry standards and is integrated into our enterprise risk management process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We leverage the support of third-party information technology and security providers, including for periodic security testing and risk assessments, as part of our risk management process, designed to identify, assess, and manage cybersecurity risks. We conduct employee cybersecurity training and maintain an incident response and notification plan designed to assist us in identifying, responding to, and recovering from cybersecurity incidents. Further, we intend to evaluate and update our existing cybersecurity policies and procedures as appropriate to continue to align them to our risk profile.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a process to assess the security practices of certain third-party vendors, including through the use of vendor security questionnaires, as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although risks from cybersecurity threats have to date not materially affected us, our business strategy, results of operations or financial condition, we have, from time to time, experienced threats to and breaches of our and our third party vendors&#8217; data and systems. For more information about these risks, please refer to the section entitled &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Executive Director, IT &amp; Operations, or Executive Director, who reports to the Chief Financial Officer, is responsible for the strategic leadership and direction of  our cybersecurity program. With over 15 years of experience in information technology, the Executive Director works alongside individuals across other functions, such as legal and engineering, to establish and implement our cybersecurity strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Executive Director and our Chief Legal Officer participate in periodic discussions with other members of our management, including executive leadership, regarding implementation of our cybersecurity program, program enhancements, and relevant cyber risks or threats.  Our Chief Legal Officer has received the National Association of Corporate Directors CERT Certificate in Cyber-Risk Oversight.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit committee has oversight over cybersecurity risks. With the input of the executive team, the Executive Director provides annual presentations to the audit committee on our cyber program, including updates on security testing and assessments, cyber risks, and related cyber strategy as applicable. The management team will also update the full board of directors on matters related to cybersecurity as needed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we have implemented an enterprise risk management process, which addresses cyber risks. This process is led by our Chief Legal Officer and includes participation by the board of directors, as appropriate. Our Chief Legal Officer reports regularly on the enterprise risk management process to executive leadership and the audit committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal facilities consist of office and laboratory space. We occupy approximately 28,731 square feet of office space in Cambridge, Massachusetts under a lease that currently expires in June 2028.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2023, a class action complaint was filed in the United States District Court for the District of New Jersey against our company and current and former officers, or the Securities Action. On May 19, 2023, the Securities Action was transferred to the United States District Court for the District of Massachusetts, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Celano v. Fulcrum Therapeutics, Inc., et al</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., Case No. 1:23-cv-11125-IT. On July 31, 2023, the court appointed a lead plaintiff, who filed an amended complaint on September 29, 2023. The Securities Action alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder against all defendants and control person violations of Section 20(a) against the individuals, related to our February 2023 announcement</span><span style="color:#00b0f0;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that the FDA issued a clinical hold regarding the IND application for pociredir for the potential treatment of SCD. The Securities Action alleges that the defendants made misleading statements and omitted to disclose material information related to the clinical hold and seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between March 3, 2022, and March 8, 2023, as well as attorneys&#8217; fees and costs. On November 28, 2023, all defendants filed a motion to dismiss the Securities Action, which motion is currently pending. We intend to defend vigorously against this litigation.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock trades under the symbol &#8220;FULC&#8221; on the Nasdaq Global Market and has been publicly traded since July 18, 2019. Prior to this time, there was no public market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Our Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 20, 2024, there were approximately 14 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unregistered Sales of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">served.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Our most advanced clinical-stage product candidate, losmapimod, is being developed for the potential treatment of FSHD. Our other clinical product candidate is pociredir, which is being developed for the potential treatment of SCD. We initiated REACH, a randomized, double-blind, placebo-controlled, multi-national Phase 3 clinical trial of losmapimod in the second quarter of 2022 and we completed enrollment during September 2023. The trial enrolled 260 patients. We expect to report topline data from REACH in the fourth quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we announced interim data from our Phase 1b clinical trial of pociredir in SCD. We completed enrollment in the 6 mg and 2 mg dose cohorts, and we do not plan to enroll additional subjects in these cohorts. Although we commenced enrollment in the 12 mg dose cohort, in February 2023 the FDA placed a full clinical hold on the IND application for pociredir for SCD, which was lifted in August 2023. The Phase 1b clinical trial is being re-initiated at the 12 mg once daily dose level, with that cohort expected to enroll approximately 10 patients, and will be followed by an additional cohort of approximately 10 patients at the 20 mg once daily dose level. Following the clinical hold, we amended the protocol to revise the inclusion and exclusion criteria for the Phase 1b clinical trial to target patients with higher disease severity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to product candidate development, we have developed discovery approach that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. Our discovery approach led to the identification of both losmapimod for FSHD and pociredir for SCD, as well as a robust discovery pipeline. With our priorities focused on the development and potential commercialization of our two clinical-stage assets, losmapimod and pociredir, and ongoing work on our preclinical programs in hematology and muscle diseases, we are realigning our strategy and resources accordingly and will be winding down certain exploratory activities from our discovery efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, our operations have focused on organizing and staffing our company, business planning, raising capital, establishing our intellectual property, building our discovery platform, including our proprietary compound library and technologies, identifying drug targets and potential product candidates, in-licensing assets, producing drug substance and drug product material for use in clinical trials and conducting preclinical studies and clinical trials. To date, we have funded our operations primarily from the sale of shares of our capital stock and from upfront payments received under our collaboration and license agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we issued and sold 9,615,384 shares of our common stock in a public offering at a public offering price of $13.00 per share, less underwriting discounts and commissions. The net proceeds of the offering were $117.3 million, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since our inception and we expect to continue to incur significant operating losses for the foreseeable future. Our ability to generate product revenue sufficient to achieve profitability, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $97.3 million and $109.9 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $509.7 million. We expect our expenses and operating losses will increase substantially over the next several years in connection with our ongoing activities, as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our clinical development of losmapimod and pociredir;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our ongoing preclinical studies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance clinical-stage product candidates into later stage trials such as REACH, the Phase 3 clinical trial of losmapimod for the treatment of FSHD;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pursue the discovery of drug targets for other genetically-defined rare diseases and the subsequent development of any resulting product candidates, including for Diamond Blackfan Anemia under our recent license agreement with CAMP4;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scale up our manufacturing processes and capabilities, or arrange for a third party to do so on our behalf, to support our clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire or in-license products, product candidates, technologies and/or data referencing rights, such as our recent agreement with CAMP4;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make any milestone payments to affiliates of GSK under our right of reference and license agreement with GSK upon the achievement of specified clinical or regulatory milestones, or to CAMP4 under our license agreement with CAMP4;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, enforce, defend and protect our intellectual property;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional clinical, quality control and scientific personnel; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts and our operations as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates, or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of increased expenses or the timing of when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $236.2 million in cash, cash equivalents, and marketable securities. We believe that our existing cash, cash equivalents, and marketable securities as of December 31, 2023 will enable us to fund our operating expenses and capital expenditure requirements into 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and Capital Resources.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not generated any revenue from product sales and do not expect to generate revenue from the sale of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval, we may generate revenue in the future from product sales. We cannot predict if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, we entered into a collaboration and license agreement with Acceleron to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The agreement terminated effective October 1, 2022, following notification from Acceleron in June 2022 of its decision to terminate the agreement for convenience. For the years ended December 31, 2023 and 2022, we recognized zero and $1.0 million, respectively of collaboration revenue under the Acceleron collaboration agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2020, we entered into a collaboration and license agreement with MyoKardia, which we amended in April 2023, pursuant to which we granted to MyoKardia an exclusive worldwide license under certain intellectual property rights to research, develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export, have exported, distribute, have distributed, market, have marketed, promote, have promoted, or otherwise exploit products directed against certain biological targets identified by us that are capable of modulating up to a certain number of genes of interest with relevance to certain genetically defined cardiomyopathies. MyoKardia was subsequently acquired by Bristol-Myers Squibb Company in November 2020. The primary goal of the collaboration is to identify and validate potential biological targets for further research, in order to support the development, manufacture and commercialization of product candidates by MyoKardia for the potential treatment of certain genetically defined cardiomyopathies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the MyoKardia collaboration agreement, we received a $10.0 million upfront payment and a $2.5 million payment as prepaid research funding in July 2020. MyoKardia will also reimburse us for the costs of the research activities not covered by the prepaid research funding, up to a maximum amount of total research funding (including the prepaid research funding). Upon the achievement of specified preclinical, development and sales milestones, we will be entitled to preclinical milestone payments, development milestone payments and sales milestone payments of up to $298.5 million in the aggregate per target for certain potential cardiomyopathy gene targets, and of up to $150.0 million in the aggregate per target for certain other potential cardiomyopathy gene targets. To date, we have achieved a $2.5 million specified preclinical milestone. MyoKardia will also pay us tiered royalties ranging from a mid single-digit percentage to a low double-digit percentage based on MyoKardia&#8217;s, and any of its affiliates&#8217; and sublicensees&#8217;, annual worldwide net sales of products under the MyoKardia collaboration agreement directed against any identified target. The royalties are payable on a product-by-product basis during a specified royalty term, and may be reduced in specified circumstances.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022 we recognized $2.8 million and $5.3 million, respectively, of collaboration revenue under the MyoKardia collaboration agreement. As of December 31, 2023, we have recorded no deferred revenue associated with the MyoKardia collaboration agreement. As of December 31, 2022 we have recorded $0.9 million of deferred revenue associated with the MyoKardia collaboration agreement, which is classified as either current or noncurrent, net of current portion in our consolidated balance sheets based on the period over which the revenue is expected to be recognized. As of December 31, 2023, we had received $7.2 million of cost reimbursement payments and $2.5 million of milestone payments under the MyoKardia collaboration agreement. As of December 31, 2023, we recorded unbilled accounts receivable of $0.5 million related to reimbursable research and development costs under the MyoKardia collaboration agreement for activities performed during the three months ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may generate revenue from milestones and royalty payments under the MyoKardia collaboration agreement. We expect that our revenue may fluctuate from quarter-to-quarter and year-to-year as a result of the timing, amount, and achievement of milestones under the MyoKardia collaboration agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also in the future enter into additional license or collaboration agreements for our product candidates or intellectual property, and we may generate revenue in the future from payments as a result of such license or collaboration agreements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses represent costs incurred by us for the discovery, development, and manufacture of our product candidates and include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">external research and development expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and consultants; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">salaries, payroll taxes, employee benefits and stock-based compensation expenses for individuals involved in research and development efforts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory supplies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to compliance with regulatory requirements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, insurance and other operating costs; and  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">milestone expenses associated with our right of reference and license agreement with GSK.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expense research and development costs as incurred. We recognize expenses for certain development activities, such as clinical trials and manufacturing, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment or other information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of expenses incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. These amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">External costs represent a significant portion of our research and development expenses, which we track on a program-by-program basis following the nomination of a development candidate. Our internal research and development expenses consist primarily of personnel-related expenses, including stock-based compensation expense. We do not track our internal research and development expenses on a program-by-program basis as the resources are deployed across multiple projects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our external research and development expenses by program following nomination as a development candidate for the years ended December 31, 2023 and 2022. Pre-development candidate expenses, unallocated expenses and internal research and development expenses are classified separately. Losmapimod external expenses during the year ended December 31, 2022 includes a $5.0 million milestone achieved under our right of reference and license agreement with GSK upon initiation of the REACH trial during the second quarter of 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Losmapimod external expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,069</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,260</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pociredir external expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,442</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,133</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-development candidate expenses and unallocated expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,536</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,964</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Internal research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,754</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,425</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,801</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,782</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the remainder of the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from our product candidates, if approved. This is due to the numerous risks and uncertainties associated with developing our product candidates, including the uncertainty related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and progress of preclinical and clinical development activities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to raise additional funds necessary to complete clinical development of and commercialize our product candidates;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain our current research and development programs and to establish new ones;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish new licensing or collaboration arrangements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress of the development efforts of parties with whom we may enter into collaboration arrangements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the receipt and related terms of regulatory approvals from applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of raw materials and active pharmaceutical ingredient, or API, for use in production of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and operate a manufacturing facility, or secure manufacturing supply through relationships with third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to consistently manufacture our product candidates in quantities sufficient for use in clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain intellectual property protection and regulatory exclusivity, both in the United States and internationally; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain, enforce, defend and protect our rights in our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the commercialization of our product candidates, if and when approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain third-party coverage and adequate reimbursement for our product candidates, if approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the acceptance of our product candidates, if approved, by patients, the medical community and third-party payors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competition with other products; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a continued acceptable safety profile of our products following receipt of any regulatory approvals. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate, and potentially other candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development activities account for a significant portion of our operating expenses. We expect our research and development expenses to increase significantly in future periods as we continue to implement our business strategy, which includes advancing losmapimod for the treatment of FSHD, advancing pociredir for the treatment of SCD, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist of personnel-related costs, including salaries, benefits and stock-based compensation expense, for our personnel in executive, finance and accounting, human resources, business operations and other administrative functions, legal fees related to patent, intellectual property and corporate matters, fees paid for accounting and tax services, consulting fees and facility-related costs not otherwise included in research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that our general and administrative expenses will increase in the future to support continued research and development activities and planned commercialization activities, including establishing a sales, marketing and distribution infrastructure to commercialize any medicines for which we may obtain marketing approval. These increases will likely include increased costs related to the hiring of additional personnel, legal, audit, filing fees, and general compliance and consulting expenses, among other expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net consists primarily of interest income related to our investments in cash equivalents and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes our results of operations for the years ended December 31, 2023 and 2022, along with the changes in those items in dollars:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,805</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,342</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,537</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,801</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,782</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,981</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,668</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,694</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(427</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,469</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,903</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,434</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(110,664</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(112,561</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,897</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,329</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,690</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,639</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(97,335</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(109,871</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,536</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue decreased by $3.5 million from $6.3 million for the year ended December 31, 2022 to $2.8 million for the year ended December 31, 2023. We recognize revenue under collaboration agreements based on our pattern of performance related to the respective identified performance obligation, which is the period over which we will perform research services under the respective agreement. For the years ended December 31, 2023 and 2022, we recognized zero and $1.0 million, respectively, of collaboration revenue under the Acceleron collaboration agreement, which terminated in October 2022, and $2.8 million and $5.3 million of collaboration revenue, respectively, under the MyoKardia collaboration agreement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2023 and 2022:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.351%;"/>
    <td style="width:1.24%;"/>
    <td style="width:1%;"/>
    <td style="width:10.962%;"/>
    <td style="width:1%;"/>
    <td style="width:1.24%;"/>
    <td style="width:1%;"/>
    <td style="width:10.962%;"/>
    <td style="width:1%;"/>
    <td style="width:1.24%;"/>
    <td style="width:1%;"/>
    <td style="width:11.001999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,179</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,944</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,765</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,754</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,425</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">329</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory supplies</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,501</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,242</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(741</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facility costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,834</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,593</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(759</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,578</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(45</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,801</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,782</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,981</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expense decreased by $5.0 million from $76.8 million for the year ended December 31, 2022 to $71.8 million for the year ended December 31, 2023. The decrease in research and development expense was primarily attributable to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$3.8 million of decreased external research and development costs, primarily associated with decreased costs for pociredir as a result of the clinical hold from February 2023 to August 2023, and achievement of a $5.0 million </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">milestone due to GSK upon initiation of REACH in the second quarter of 2022, partially offset by increased costs associated with the advancement of REACH as we completed enrollment in September 2023;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.8 million of decreased facilities costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.7 million of decreased laboratory costs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">partially offset by $0.3 million of increased employee compensation costs.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our general and administrative expenses for the years ended December 31, 2023 and 2022:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,809</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,488</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,321</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,278</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,255</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facility costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,516</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,206</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">310</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,320</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,722</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">598</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,668</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,694</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses decreased by less than $0.1 million from $41.7 million for the year ended December 31, 2022 to $41.7 million for the year ended December 31, 2023. The decrease in general and administrative expenses was primarily attributable to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$2.3 million in decreased professional services costs, primarily due to decreased consulting and insurance costs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">partially offset by $1.3 million of increased employee compensation costs, including a $1.4 million increase in stock-based compensation expense; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.3 million in increased facility-related costs, including increased costs associated with our leases as well as depreciation and other utility and maintenance costs; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.6 million in increased other costs.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net increased by $10.6 million from $2.7 million for the year ended December 31, 2022 to $13.3 million for the year ended December 31, 2023. The increase in other income, net was primarily attributable to an increased rate of return on our cash, cash equivalents, and marketable securities and an increase in our average cash, cash equivalents, and marketable securities balance.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since our inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. As of December 31, 2023, we have funded our operations primarily with aggregate gross proceeds of $712.5 million from the sale of shares of our capital stock and from upfront payments received under our collaboration and license agreements. As of December 31, 2023, we had cash, cash equivalents, and marketable securities of $236.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we completed a public offering of our common stock and issued and sold 9,615,384 shares of common stock at a public offering price of $13.00 per share, resulting in net proceeds of $117.3 million after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides information regarding our cash flows for the years ended December 31, 2023 and 2022:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.693%;"/>
    <td style="width:1.28%;"/>
    <td style="width:1%;"/>
    <td style="width:13.363%;"/>
    <td style="width:1%;"/>
    <td style="width:1.3%;"/>
    <td style="width:1%;"/>
    <td style="width:13.363%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(90,965</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(97,050</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(36,692</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,413</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118,122</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,323</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,535</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(314</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Used in Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities was $91.0 million during the year ended December 31, 2023 compared to net cash used in operating activities of $97.1 million during the year ended December 31, 2022. The decrease in net cash used in operating activities of $6.1 million was primarily due to a decrease in net loss, including as a result of decreased external research and development costs as a result of the clinical hold for pociredir, which was lifted in August 2023, and increased interest income.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash (Used in) Provided by Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities was $36.7 million during the year ended December 31, 2023 compared to net cash provided by investing activities of $12.4 million during the year ended December 31, 2022. The increase in net cash used in investing activities of $49.1 million was primarily due to net purchases of marketable securities during the year ended December 31, 2023, as compared to net maturities of marketable securities during the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities was $118.1 million during the year ended December 31, 2023 compared to net cash provided by financing activities of $84.3 million during the year ended December 31, 2022. Net cash provided by financing activities during the year ended December 31, 2023 primarily consisted of net proceeds of $117.3 million from the January 2023 public offering of our common stock. Net cash provided by financing activities during the year ended December 31, 2022 primarily consisted of net proceeds of $80.8 million from the August 2022 completion of the public offering of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we continue the research and development of, initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, we expect to incur additional costs to support the growth of our organization. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities as of December 31, 2023 will enable us to fund our operating expenses and capital expenditure requirements into 2026. However, we have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our funding requirements and timing and amount of our operating expenditures will depend largely on:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, costs and results of our clinical trials of losmapimod and pociredir;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, costs and results of discovery research, preclinical development, laboratory testing and clinical trials for our current product candidates in additional indications or for any future product candidates that we may pursue, including under our recent license agreement with CAMP4;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of and development requirements for other product candidates that we pursue;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into contract manufacturing arrangements for supply of API and manufacture of our product candidates and the terms of such arrangements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of our collaboration with MyoKardia;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain additional strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the payment or receipt of milestones, royalties and other collaboration-based revenues, if any;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.559494254318427%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We will need to continue to rely on additional financing to achieve our business objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the variables described above, if and when any of our product candidates successfully complete development, we will incur substantial additional costs associated with regulatory filings, marketing approval, post-marketing requirements, maintaining our intellectual property rights, and regulatory protection, in addition to other commercial costs. We cannot reasonably estimate these costs at this time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaboration arrangements, strategic alliances and marketing, distribution or licensing arrangements. We currently have no credit facility or committed sources of capital. To the extent that we raise additional capital through the future sale of equity securities, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated amounts, and additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements, strategic alliances or marketing, distribution or licensing arrangements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Our estimates are based on our historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and amount of expense recognized that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We evaluate our estimates and assumptions on an ongoing basis. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the most significant areas involving management&#8217;s judgments and estimates. See Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for a description of our other significant accounting policies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for revenue recognition under the Financial Accounting Standards Board Accounting Standards Codification, or ASC, 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We recognize revenue pursuant to ASC 606 when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for those goods or services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within the contract and determine those that are performance obligations. We then determine the transaction price and allocate it to the identified performance obligations. As part of the accounting for these arrangements, we must use significant judgment to determine the number of performance obligations and the transaction price, including the determination of whether milestones or other variable consideration should be included in the transaction price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use judgment to determine whether milestones or other variable consideration should be included in the transaction price. As part of management&#8217;s evaluation of the transaction price, we consider numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to the risks of success. If we conclude it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are based on the occurrence of events not within our control, such as regulatory approvals, are generally not considered probable of being achieved until the underlying events occur or the associated approvals are received. At the end of each reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Changes to the constraint of variable consideration can have a material effect on the amount of revenue recognized in the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis, except for any variable consideration that meets the criteria to be allocated entirely to a single performance obligation or to a distinct service that forms part of a single performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, we recognize revenue based on the use of either an output or input method. The estimation of measure of progress is complex, involves significant judgment, and is affected by our estimates of the total costs required to complete the performance obligations, including the total internal personnel costs and external costs to be incurred. Changes in these estimates can have a material effect on our revenue recognition. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For further description of our revenue recognition policy, see Note 2 &#8220;Summary of Significant Accounting Policies&#8212;Revenue Recognition&#8221; to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. See also Note 10, &#8220;Collaboration and License Agreements&#8221; to our audited consolidated financial statements included</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">elsewhere in this Annual Report on Form 10-K for further information on the application of ASC 606 to the Acceleron and MyoKardia collaboration agreements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure stock-based compensation expense related to all restricted stock awards, restricted stock units, and stock options based on the fair value of the award on the date of grant. We recognize compensation expense for these awards over the requisite service period, which is generally the vesting period of the respective award. Generally, we issue awards with only service-based vesting conditions and record the expense for these awards using the straight-line method. We have also granted certain stock-based awards with performance-based vesting conditions.We recognize compensation expense for awards with performance-based vesting conditions over the remaining service period using an accelerated attribution method when management determines that achievement of the performance condition is probable. At each reporting date, we evaluate if the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine the fair value of restricted stock awards and restricted stock units based on the estimated fair value of our common stock on the date of grant, less any applicable purchase price. We estimate the fair value of stock options granted using the Black-Scholes option-pricing model. The determination of the grant date fair value of stock options using an option pricing model is affected principally by our estimated fair value of our common stock and requires management to make a number of other assumptions, including the expected term of the option, the estimated volatility of the underlying shares, the risk-free interest rate, and expected dividends. The assumptions used in the determination of the grant date fair value of stock options represent management&#8217;s best estimates at the time of measurement. Given the lack of public market for our common stock prior to the closing of our IPO and a lack of company-specific historical and implied volatility data, we based the estimate of expected volatility on the historical volatility of a representative group of publicly traded companies for which historical information is available. The historical volatility is calculated based on a period of time commensurate with the assumption used for the expected term. We use the simplified method to calculate the expected term for all stock options. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is based on a U.S. treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid dividends and do not have current plans to pay any dividends on common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In future periods, we expect stock-based compensation expense to increase, due in part to our existing unrecognized stock-based compensation expense and as we grant additional stock-based awards to continue to attract and retain our employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in our tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. As of each balance sheet date, we did not have any uncertain tax positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Jumpstart Our Business Startups Act of 2012 permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ive Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our cash equivalents are in the form of money market funds that are invested in U.S. Treasury securities and our investments are in short-term marketable securities, such as corporate bonds and commercial paper. As of December 31, 2023, we had cash, cash equivalents, and marketable securities of $236.2 million. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also exposed to market risk related to changes in foreign currency exchange rates. We contract with vendors that are located outside of the United States and certain invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. We do not currently hedge our foreign currency exchange rate risk. As of December 31, 2023, we had minimal or no liabilities denominated in foreign currencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the years ended December 31, 2023 and 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements, together with the independent registered public accounting firm report thereon, are presented beginning on page F-1 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9(b). Director and Officer Trading Plans and Arrangements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive officer and principal financial officer, or persons performing similar functions, and effected by a company&#8217;s board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></p>
  <div style="margin-left:7.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of a company&#8217;s assets;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that a company&#8217;s receipts and expenditures are being made only in accordance with authorizations of a company&#8217;s management and directors; and</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.617714099641811%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company&#8217;s assets that could have a material effect on the financial statements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework (2013 framework). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies&#8221;.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 1.02.  Termination of a Material Definitive Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As previously disclosed, on May 9, 2022, we entered into an equity distribution agreement, or the 2022 Sales Agreement, with Piper Sandler &amp; Co., as sales agent, with respect to an at-the-market offering program to sell shares of our common stock having an aggregate offering price of up to $50.0 million, or the 2022 Shares, from time to time through the sales agent. Effective as of the date of this Annual Report on Form 10-K, we terminated the 2022 Sales Agreement pursuant to Section 7 thereof. We are not subject to any termination penalties related to the termination of the 2022 Sales Agreement. Prior to termination, all of the 2022 Shares remained available for sale pursuant to the 2022 Sales Agreement. As a result of the termination of the 2022 Sales Agreement, we will not offer or sell any shares under the 2022 Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A copy of the 2022 Sales Agreement was filed as Exhibit 1.1 to the Current Report on Form 8-K filed by us on May 10, 2022. The description of the 2022 Sales Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the copy of the 2022 Sales Agreement filed as Exhibit 1.1 to the Current Report on Form 8-K filed by us on May 10, 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_foreign_jurisdiction"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except to the extent provided below, the information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the SEC, with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We post our Code of Business Conduct and Ethics, which applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, in the &#8220;Corporate Governance&#8221; sub-section of the &#8220;Investor Relations&#8221; section (ir.fulcrumtx.com) of our corporate website at www.fulcrumtx.com. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tant Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ibits and Financial Statement Schedules.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Consolidated Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following documents are included on pages F-1 through F-31 attached hereto and are filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.111%;"/>
    <td style="width:6.889%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#0563c1;white-space:pre-wrap;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(PCAOB ID: 42)</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) Financial Statement Schedules</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(3) Exhibits</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are incorporated by reference herein.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.56%;"/>
    <td style="width:6.44%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(PCAOB ID: </span><span><ix:nonNumeric id="F_0b40b602-da45-4b82-9ed0-f06b07b12972" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Fulcrum Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Fulcrum Therapeutics, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20e2bec9-76ab-4122-b3dc-b8be86e3511e" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2017.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70e1fc64-39fd-47b7-a2aa-14d05f4cef62" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 27, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fulcrum Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">alance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7b55bf0-355c-46ab-8720-dd38ce6ebae8" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e62898e-a63e-43c7-bfea-1535709f0c29" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba1b5e26-ec88-44ee-a911-c7ac2eb7840a" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4677c03-a312-4d1f-9419-b12bf7e235f8" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unbilled accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0f09afd-2cdb-4a48-bf62-5aa9a9e8f6d6" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:UnbilledReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">537</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1d72ea1-e0b6-4e4f-ba33-a6a907ca9de3" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:UnbilledReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a717cb9-d1bb-4a7b-87d8-eb0d2e87c9aa" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcd6dc27-1047-4a70-9bc2-56c6d2322f8e" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,369</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6800d0f-3af5-4c5f-88ac-bce954859070" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">242,199</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28760d49-6bd8-4717-8f0a-b004ec22a2d4" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1fc2bf4-1612-4169-a7a6-0fdb872de439" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb660212-aad8-48cb-a265-3aa8cb94dde5" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,906</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0c835df-faca-48aa-9307-eff837ac5682" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,176</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0c0fafe-8649-4c24-ac10-52de3345a633" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,063</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2db271dd-5337-4bf9-9545-6c95612d4f3c" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,092</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_962a9d38-98e5-4bf8-95de-f17edb2686da" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,092</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0145b8f-29cf-48ea-b65b-c02f5699eda6" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,011</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef27ae72-a4a0-4929-bf00-594576273838" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,105</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52cf794e-4e82-4ee0-bcd0-a99a2e923fd4" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_284e3667-0efd-4928-8929-09acf754932b" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abafc4fd-3a67-4580-8816-c58a5b16d128" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,757</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee624c53-fab6-4fe0-9a52-a10397b789c2" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,638</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2470f77-a580-4ae2-a3f3-9cb18dd99927" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:AccruedLiabilitiesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,726</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c01ba62-91ae-4a48-993a-bc6775229729" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:AccruedLiabilitiesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,551</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue, current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8761609e-0050-45eb-b6d0-bf4b68791580" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c28ae14-f86c-4a0a-8e1c-a00289347031" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">934</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e610820-cfb6-4dd2-a840-a3363ac175c0" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88a0c25e-04f0-42b5-bd6a-b02f9b007643" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,602</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f820ee3-c70f-4016-b604-96fe39515ea7" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a48620d-a0db-4321-b1ba-c3c126ac7433" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, excluding current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc3d5799-a26e-43f6-8674-910a3af89033" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbdc0167-0788-4fdd-a8b9-a1fabf247278" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,821</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities, excluding current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a42372db-d046-4ccc-bf87-a79c76e89d83" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cac8c9d5-3392-4be2-b089-104df94acc5c" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33b5326a-8680-4b0c-8a3b-23f7879bd20c" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,501</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef0f0647-ed4f-492e-912e-4809b547e73a" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f5f1606d-dc3f-4973-a9fa-9933609a1b1d;"><span style="-sec-ix-hidden:F_766f3400-711f-4ffa-babd-fbc7095320eb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 13)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3f4b0de-4467-4c6a-8ec2-d3b0df5390b2" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_64a58510-e458-4609-9334-ca0317543db1" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e0d3bed-6c8f-4250-a5a6-1f26187151b0" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cdc91ff9-e431-4bf6-a1eb-b104a2acac25" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1e7fd3a-27f5-4f82-a97b-9b826faf4e96" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_531d3a13-2060-4109-b6f1-fad153f0a719" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7e24add3-83b3-4c84-bfed-d7102b0b0cb8" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_429a7793-ebb3-4b2a-a72c-115325f584a4" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued or outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eac7f2df-addd-4463-9cad-d306d73659ab" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ed92e28-5e3b-4663-8046-192ef0c4482f" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a3dc5ce-88ea-4dbd-a7a2-296f7fb73d0c" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_394a5a36-8883-46f4-ab7f-ad0aed7651b7" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3555aa0d-2daf-4a54-a6a2-8996c3a482c7" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_82aa2157-0a6a-40fe-b488-4c37398a586e" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cda6ce50-9b23-4468-a454-bf57aa6ba2c0" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c50b5d29-5289-4c7e-a1e2-a4b331c8220c" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,915,367</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23b0feb6-8755-48b7-9eb9-5ca7ab008e3b" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7bab9097-5c29-422d-8a70-ed14eeffbc1b" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">52,099,211</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54203ff8-a84d-414d-9e49-1995449f0923" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67429593-08ef-42cc-828c-b0acbb6a8623" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d8d02b1-7823-449f-b43d-2d4ceab31b5e" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">744,940</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2280f138-9ee0-4f4e-8eac-1ac0c03f3e3c" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">612,025</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b660fcb-6ba0-4c1d-9109-56f48249f579" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7db86fa1-bb06-4723-987e-2ce81b725b9a" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bbe546c-9c85-492d-84f6-080058e538f9" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">509,673</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8616c886-d926-4fbe-9673-8793df10df76" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">412,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a18940f9-148d-4c48-a3be-1b7c283631a6" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6999ac6c-9293-4a32-889a-361209901bd6" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198,942</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b81fb3f-f2a6-44d8-ab0a-f7a721bd1464" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69db5a5c-55df-4c86-b2da-01564fd5ddbe" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fulcrum Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Oper</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ations and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a2db02c-b0dd-4168-9fcd-255b3a031baf" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,805</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07098fde-a401-465f-8273-a180fed410d1" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,342</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a879eb8-1677-40ae-867a-e245ca344289" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e2f3b29-ca8b-40cf-94a9-404b8eec57a1" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,782</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ddb9beb-bdfc-4e81-81cc-6ff77ed6ffdd" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,668</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4650f3d-2df1-4dc5-8cea-85ceaae13ced" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c82e7ae8-827d-48f8-8984-67d30f5d8a26" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:RestructuringAndRelatedCostIncurredCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1e3d223-2ed4-4734-84f9-b29636824c7d" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:RestructuringAndRelatedCostIncurredCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92a3c45c-0c45-4a3b-8167-e6ed088816ed" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fe39b14-7b08-475f-9ac7-9891dd5edcdb" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd63ce32-88b9-4080-a689-b8bdfc4a6f4a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">110,664</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2587692-e41f-47f3-a2c2-25a925a7a784" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112,561</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91a410a8-55eb-4fd6-87b6-7e37df0e6d63" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dac4da0b-57f4-41c4-ae3c-ac0fcadb1e7f" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,690</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4510d6b-dcbd-447b-96d0-bf5a105c3afe" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ef21e64-4f47-46de-959f-a6e40487e689" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,871</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b40dcc3d-2204-4084-9327-7c417fd7920d" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cce06d28-151b-4f4d-9654-fe26f3f3068a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.59</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8be8302-c9d0-4399-ae9b-5e95dacbad05" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e3bf18fb-9c59-4060-8250-bf791f85a165" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.44</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c201371c-64f1-42ee-a24d-58f99385063a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c3a2f877-c6a7-4152-ba0a-505fac16a41a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,310</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05db2d71-ebfb-41dd-8cdc-38c5df06b2dc" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d10c649a-48df-48ec-ad35-1513d386dc22" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,991</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e61051c-9f4c-41a9-893a-22cad5595d56" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_591f7824-88f1-499b-a45b-e3cce91a99db" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,871</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive gain (loss):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a27ac672-1234-4ee4-849d-2ed18b9b0fbd" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14d1a153-5e13-47f3-a975-fc344a548125" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive gain (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_963d4ed7-9ea7-4b26-a15e-2a4fab7f62e7" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32b5a071-7f96-4702-bcf9-5c3469fc9c80" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfa9fbea-e9f3-45bd-a258-32da009ddaae" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">96,674</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5127829-fc05-4f29-b20c-9b170e3260c2" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">110,271</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fulcrum Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_convertible_pref"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.854%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.678%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.278%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.278%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.278%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.278%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.358%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8930882-56a6-40d5-8e54-fcf4c0a84a5a" contextRef="C_ae3bba65-b6cd-4d0b-9844-04bfbfe465a7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,626,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e7dc88d-2a72-4db7-9cd3-c3b8dde501c5" contextRef="C_ae3bba65-b6cd-4d0b-9844-04bfbfe465a7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42fa9de4-9855-4f82-8d83-9b48ff3e2a24" contextRef="C_e83c356b-9ff3-413e-a403-598979417ee5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">514,362</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bae38940-2cdb-4b5e-91a2-3d9bf77b2a1e" contextRef="C_cf9e5807-85a6-4487-b3cc-e06892d1b91c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">397</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f03324c0-7e9b-4a07-899d-274a99fd8857" contextRef="C_1e35e38c-6f43-4880-aab5-7ba1d31d8d24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">302,467</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3881198-ebc2-41d1-816d-bded0e4d4cdb" contextRef="C_57f214bc-60d6-4c5d-b206-28aa46d3644a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in connection with public offering, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce92a678-fcbb-4e3f-818a-ac2383da58f0" contextRef="C_e3bf28ad-b304-4305-a570-1122422d798b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,029,410</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fb24fa2-226b-4b25-b02a-a27805390dd2" contextRef="C_e3bf28ad-b304-4305-a570-1122422d798b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ab31b0a-2b4f-440a-8092-4775713c3fa0" contextRef="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26e5acfa-c936-4c78-b9dd-d807aae29c7c" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,804</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under employee benefit plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3c12b2f-66cc-4496-b6c1-a40599c3045a" contextRef="C_e3bf28ad-b304-4305-a570-1122422d798b" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">433,403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07b4137c-fa48-415a-a50c-5823fd11d3c2" contextRef="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f870157-85dc-411e-9a54-4abc9ac8eb76" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock awards</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a41ce53-d0c9-4760-9bb9-1783705f99bf" contextRef="C_e3bf28ad-b304-4305-a570-1122422d798b" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,174</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29f211d0-f17a-4ed1-b2ca-11db5ff3b07b" contextRef="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07f92cb3-2912-4990-9b27-e16f38b14291" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4422a81-aafb-4129-ac3c-5073491bf0b6" contextRef="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,350</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04f9b722-f61f-45e3-a167-6e46b9172fe4" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,350</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15235345-8d3e-4efb-afb5-27fb429f1857" contextRef="C_bca61fa2-7113-472f-975c-b0f57452da67" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc584789-a70f-447d-b419-ef4490e4f35f" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f865581-46b4-41a8-bdf2-c77c6d924b5a" contextRef="C_71bc03af-5035-47a1-a103-ae996647c88e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,871</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a95c9b9-1f43-46be-b34c-9f66025e02ee" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,871</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aadee3d3-f65b-4a7d-86a3-b5de77de8772" contextRef="C_a87177cb-5bc3-41bf-971c-4854bb97a946" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">52,099,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e845932-6b89-432d-bfc1-6dae07a9fe73" contextRef="C_a87177cb-5bc3-41bf-971c-4854bb97a946" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31435457-c386-4dc1-aee8-94963895c712" contextRef="C_fae73cbe-4594-47e0-a56a-d04732d2b464" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">612,025</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df6c9fec-5b3b-477d-b45e-418ae2694d7b" contextRef="C_bbc1c709-9a9f-4ee8-ae35-e6e93fd2f8f1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2c1bb9e-226b-4cb3-bc1f-c65532a47986" contextRef="C_edc3b5c0-37a2-4a67-b22d-a8f24b1a6030" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">412,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9586bffd-9503-492e-bba7-853a6e577fa2" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198,942</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in connection with public offering, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_415bcc82-89e2-43d8-97bc-c5f01a155469" contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,615,384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5a7a68b-670a-4c00-8119-b4b8af157530" contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67d529eb-048c-4c6a-913d-662b760d7db1" contextRef="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,336</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59b09fa6-6ced-466a-bec7-f38b6d819aab" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under employee benefit plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d71914b-3e8a-4b41-9f11-df3b52e7d0ff" contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">182,628</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1d81b05-4600-4da6-bdce-14b11c71df1c" contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7f0385d-dcb0-4dbd-8264-1191788603f6" contextRef="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6a8ef44-87e4-4485-be07-3c3b4dd12914" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock awards</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_680622f7-38b6-419e-ae4d-2a3574eaf43b" contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,144</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f720489-30b8-4cc0-896f-c05ff56f65e7" contextRef="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebba9278-4ad1-4c9e-bffc-15aeef1340ab" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e223d5-e659-4cce-a1d6-212829694f7b" contextRef="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,802</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7ebd902-04ad-4bd0-a0a6-78f94db73844" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,802</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba745d5e-2ba4-45b2-919c-5ac2a45971ed" contextRef="C_ea348ed2-fdcc-4579-91c5-808f2dfce003" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5190daf6-01d9-4325-9683-8f44eaeb15c5" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_781b28ef-e937-40f1-9088-568b902d5959" contextRef="C_465c59ff-4b61-4b2d-8eaa-5ac890630a2c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62d84c27-24c2-4347-9b59-450df47c377d" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25d0d1b5-ae16-4581-b4b3-5f690d4036bc" contextRef="C_fbda6a93-4094-47c4-ac19-6cebaec8a93d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,915,367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61c838bc-753b-4917-aca6-125b77c62da2" contextRef="C_fbda6a93-4094-47c4-ac19-6cebaec8a93d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d956c4a-f79a-4c6f-9653-8e40661fe0dc" contextRef="C_8919af49-dcdf-4a7e-89e1-427cdf1d9a7e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">744,940</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0beb74a-ca7e-49b3-aff4-058bc3a5e049" contextRef="C_45f470b7-37af-4351-8f8c-c8ecfdfc36bf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2c8d7ee-9cd1-42c4-ab98-3672f2a6e080" contextRef="C_aa92b40b-ab4d-458f-9b44-218ef3a76113" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">509,673</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e09e67a7-d01b-449e-89a5-6b1b5c268938" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fulcrum Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nts of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.533%;"/>
    <td style="width:1.559%;"/>
    <td style="width:1%;"/>
    <td style="width:12.675%;"/>
    <td style="width:1%;"/>
    <td style="width:1.559%;"/>
    <td style="width:1%;"/>
    <td style="width:12.675%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1684dfb9-077f-4778-aafe-e48c696111c0" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ebd2d47-c576-481e-929e-6a2a0298a098" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,872</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c34c300f-3738-4026-8608-75876dfc8b34" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffbf6e18-d516-4cdb-9365-d86b1b3dd51e" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,414</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cac9a478-84bc-4e0f-9d1c-c597486f3c9a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,802</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f75e940-5dc6-44b5-b6cc-3fe1bcaa529b" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,350</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (accretion of discounts) amortization of premiums on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0158e48-0ee4-4710-8743-f8b8b597a9ed" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,991</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cf1aa88-b2b8-47d6-af04-7e36ffe6632d" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">152</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2f8d36e-d20a-4675-b0de-e35b791ca68f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f782b3e-a215-4814-9ca7-ed1052b0b36c" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unbilled accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3d0f75a-7eb2-4517-adf3-948ecc0033d4" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2914351b-962b-4335-ab8a-5f92e2e5caac" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">908</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62f18481-08ab-4b2e-a0b2-e11a38a4da0c" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69fabd89-2887-466e-9457-97c5deaa383c" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease assets and liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b175f863-9ad4-43c3-828b-05e20e742eb2" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">715</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef42bca5-421f-4c16-b6df-b0df33861649" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="fulc:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">372</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1de0ead9-c097-45a5-ae94-ae641b334f7f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c87e6f1c-2b73-4d5d-b9c1-e3eb2ff37e29" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,562</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c27cd942-668a-464a-85e2-67bcd2dd95c4" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">853</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b97d928-2eee-4e76-b988-9ea1a3ae0dfb" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,176</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e88e61d0-4e47-4b3c-88fb-1ebbda0ac553" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">825</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ec3943b-2b04-4a8f-b058-0d91840935f2" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c57b7cf-4461-4fc1-9186-5d260ef490cf" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">934</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7ee3c5d-7b0d-4eb6-9227-3530ad0ef00e" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9729c94b-5a71-4ca4-b259-5f3aa4ea6853" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45dfc76c-24fe-47b9-8191-ef31a3214fb5" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,050</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34f0d9d3-e47b-4ac5-b656-d28bb9ca55e8" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,892</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eadef223-8c64-4d82-a8f4-9e0ffa683ba8" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0679ac34-00a7-4a54-82da-2839b6f7a82c" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:ProceedsFromMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,708</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_730a6405-d024-4e68-a112-7025505b5ef5" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="fulc:ProceedsFromMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,529</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b37ada8-d152-45e3-a025-1c6738c495b1" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">508</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fde9db4a-8f78-4ea4-8d6d-ab597a2d63db" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,963</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31e4a361-7d2e-477f-beca-df7c8cfcfe16" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,692</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a340afe-8ceb-4db7-a1d4-6293a32f5a92" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,413</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock in connection with public offerings, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04d86b98-c472-4b49-b1e0-1d4eb5793011" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,345</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04038a93-8cac-421c-9a6c-4ba63bbcf7a5" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="fulc:ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,804</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock under benefit plans, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46f52518-b2c4-4ea2-b549-8fa8263ea771" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b20ec3e-77b4-471a-bdae-5b0941f548e9" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0732bd3-42d0-4262-b4a7-5d955ae35727" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,122</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efb66392-3dc7-4748-b6cb-f3219c61a824" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,323</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5173a367-482b-48f7-900e-406b8d1cf61a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,535</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_845f2e06-0a21-433e-ab1a-2c864372dd14" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">314</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash, beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_609e0bed-bb46-4e7f-b5bb-51ec3dbca19d" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,190</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7d01b95-d9b9-4f71-9f32-fdbabb637b09" contextRef="C_57f214bc-60d6-4c5d-b206-28aa46d3644a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,504</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash, end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc464f91-ebc3-46a9-9d15-5bf46b2d4900" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,655</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af236a14-fc15-4318-ae09-efc32ea7aff8" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,190</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental cash flow information</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aa651ae-a3e7-4c6d-aee0-d6824c93a194" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:CashPaidForOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,333</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c03f6bc8-28f6-4b31-be70-3ed042ade783" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="fulc:CashPaidForOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,219</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment purchases unpaid at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f93096e-3da2-428b-a403-f692416e67a6" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of each of the periods shown above:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.88%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.88%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_605d4372-e65a-426d-9ee8-125d28caafa9" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2efd1c25-5cd4-4a68-a326-bf52f8c50763" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c308d85-78c0-412f-8d6b-413a00236198" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,092</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09a347d5-54d3-461c-9d54-8eb625631261" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,092</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0c67889-d17d-4bd4-aea5-7dd0580ad338" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,655</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc919db5-4fcd-4592-b348-1cb02388989f" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,190</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fulcrum Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2caf29d-9de8-4dd2-90b7-423ebd0f89f6" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of the Business and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fulcrum Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Fulcrum&#8221;) was incorporated in Delaware on August 18, 2015. The Company is focused on developing small molecules to improve the lives of patients with genetically-defined rare diseases in areas of high unmet medical need.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks similar to other companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, the Company completed a public offering of its common stock and issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edd9cda2-f069-4b58-ac2a-f186e564c289" contextRef="C_c9395349-8914-4a65-9d57-bc8e29bb62e9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,029,410</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71391dca-4767-48cb-8ef6-eaaee611f1af" contextRef="C_cf990f8e-d292-4776-92bd-5fa5305cf788" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb6d3d2d-1ed1-40e5-a4c8-528dbdb22c89" contextRef="C_c9395349-8914-4a65-9d57-bc8e29bb62e9" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company completed a public offering of its common stock and issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca54a7aa-c16f-4c49-92e6-6453ee4aa232" contextRef="C_1b2a8270-a42f-4a33-8218-0bc08d831c80" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,615,384</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_914d376f-537c-47b8-80fc-5ed254758ba3" contextRef="C_3ce307f7-639d-48f2-8416-d63934e3040e" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ae57e45-46ca-4583-8bcb-d2c2497959e1" contextRef="C_1b2a8270-a42f-4a33-8218-0bc08d831c80" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">117.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the sale of shares of its capital stock and from upfront payments received from the collaboration and license agreements with Acceleron Pharma Inc. (&#8220;Acceleron&#8221;), a wholly-owned subsidiary of Merck &amp; Co., Inc., (&#8220;Merck&#8221;) and MyoKardia, Inc. (&#8220;MyoKardia&#8221;), a wholly-owned subsidiary of Bristol Myers Squibb Company. As of December 31, 2023, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59c70a7d-2ce6-4801-b7a6-ee8eeb3f6927" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">509.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to expand its research and development efforts. The Company expects to finance its future cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these financial statements. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate development or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_3d7e110b-5607-4529-b4a4-bb24d39478ed" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd4972b6-4d23-4106-9d4d-00d9f978b642" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ConsolidationPolicyTextBlock" escape="true" continuedAt="F_cd4972b6-4d23-4106-9d4d-00d9f978b642_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_cd4972b6-4d23-4106-9d4d-00d9f978b642_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Fulcrum Therapeutics Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities. All intercompany transactions and balances have been eliminated.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_459da1f4-1172-4ca1-9b63-a2f36acf640d" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_459da1f4-1172-4ca1-9b63-a2f36acf640d_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_459da1f4-1172-4ca1-9b63-a2f36acf640d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date of the financial statements, and the reported amount of expenses during the reported periods. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ from those estimates or assumptions.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eeb71113-3d39-477f-a066-10fbe2c5d2b0" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. Cash equivalents include investments in money market funds that invest in U.S. Treasury obligations, and commercial paper. The Company maintains its bank accounts at major financial institutions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e512b5e7-9f15-49cb-81fe-865a076f0e43" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true" continuedAt="F_e512b5e7-9f15-49cb-81fe-865a076f0e43_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_e512b5e7-9f15-49cb-81fe-865a076f0e43_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash represents cash held to secure a letter of credit associated with the Company&#8217;s facility lease for its corporate headquarters.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78f11fa5-ec62-401b-a90e-6a309c359ee9" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value and are classified according to the fair value hierarchy described above (Note 3). The cash equivalents and marketable securities are initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, to determine fair value.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d70a3f5-26b7-45ab-8a93-5d5a062b3b68" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies securities with a remaining maturity when purchased of greater than three months as marketable securities. As of December 31, 2023, the Company&#8217;s marketable securities consisted of investments in U.S. Treasury securities, government agency securities, corporate bonds, and commercial paper. Marketable securities are classified as current assets on the consolidated balance sheets if the marketable securities are available to be converted into cash to fund current operations.</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities classified as available-for-sale are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, which is a component of stockholders&#8217; equity, until such gains and losses are realized. Any premium arising at purchase is amortized to interest expense (a component of other income, net) over the period of the earliest call date, and any discount arising at purchase is accreted to interest income (a component of other income, net) over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income, net.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other-than-temporary&#8221; and, if so, marks the investment to market through a charge to the Company&#8217;s statement of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90182429-a4a3-4f17-ba75-1b55825f4bcb" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_90182429-a4a3-4f17-ba75-1b55825f4bcb_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost, net of accumulated depreciation. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c3652f8-1652-4935-9f74-d181487b7929" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:EstimatedUsefulLifeOfAssetTableTextBlock" escape="true" continuedAt="F_6c3652f8-1652-4935-9f74-d181487b7929_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_6c3652f8-1652-4935-9f74-d181487b7929_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:34.84%;"/>
          <td style="width:65.16%;"/>
         </tr>
         <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-left:0.1in;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (in years)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2b4046c4-dcb6-4e85-a7d4-fbb4612e0718" contextRef="C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6be48353-a9fe-458b-851f-e288d6d74361" contextRef="C_5c4254ea-de8b-4774-8083-9eb5cd87bb6d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e956b45e-430c-4502-885a-37577fb02698" contextRef="C_375efc5e-e60e-4b9b-bf98-fb370dc4734f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4ea8d928-19ed-4a97-a188-163496a10e69" contextRef="C_990c5530-0921-4d0d-abca-bc365950858b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ef1253b7-df46-4f90-81ff-89e9d9b8e1ad" contextRef="C_e04dd368-3fa8-45c2-825d-2725b8979f16" name="fulc:Propertyplantandequipmentusefullives"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_90182429-a4a3-4f17-ba75-1b55825f4bcb_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63ffe8a0-ebff-4a05-ba84-b121c4d9a9f4" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" continuedAt="F_63ffe8a0-ebff-4a05-ba84-b121c4d9a9f4_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_63ffe8a0-ebff-4a05-ba84-b121c4d9a9f4_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist of property and equipment. The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use or disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95b2e08e-b11b-47ae-b7ac-85a84ed4750f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1853967c-c336-407a-a4fa-035b6f05cb37" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any impairment losses on long-lived assets during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5fabc73-3496-47cb-abde-f798941a08c4" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, the Company adopted ASU No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2016-02&#8221;). For contracts entered into on or after the effective date, at the inception of a contract, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than twelve months are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. The Company does not recognize leases with terms of twelve months or less on the balance sheet. Options to renew a lease are not included in the Company&#8217;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset or (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all operating leases, a lease liability and corresponding right-of-use asset are recognized. The lease liability represents the present value of the lease payments over the expected remaining lease term, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate the Company&#8217;s incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating and yield curve analysis, since the Company does not have a rating agency-based credit rating. The right-of-use asset represents the right to use the leased asset for the lease term. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred if any, less any lease incentives received.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease payments included in the measurement of the lease liability comprise (i) the fixed noncancelable lease payments, (ii) payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and (iii) payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease expense for operating leases consists of the lease payments plus any initial direct costs, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. The Company accounts for lease and non-lease components together as a single lease component.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03b2f503-6e0d-48fb-a3c5-e5a49155a1af" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1) Identify the contract with the customer</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2) Identify the promises and performance obligations in the contract</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other readily available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are capable of being distinct and distinct in the context of the contract. In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">3) Determine the transaction price</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Changes to the constraint of variable consideration can have a material effect on the amount of revenue recognized in the period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an arrangement includes research and development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are based on the occurrence of events not within the Company&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until the underlying events occur or the associated approvals are received.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company assesses its revenue generating arrangements in order to determine whether a significant financing component exists.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">4) Allocate the transaction price to the performance obligations in the contract</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis, except for any variable consideration that meets the criteria to be allocated entirely to a single performance obligation or to a distinct service that forms part of a single performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">5) Recognize revenue when or as the Company satisfies a performance obligation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may satisfy performance obligations over time or at a point in time, depending on the nature of the performance obligation. Revenue is recognized over time if the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For revenue that the Company recognizes over time, the Company assesses whether an input or an output method is the appropriate measure of progress associated with the satisfaction of the performance obligation. In determining the appropriate method for measuring progress, the Company considers the nature of the good or service that it has promised to transfer to the customer. Output methods recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract. Input methods recognize revenue on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation. Estimates inherent to the measurement of progress associated with the satisfaction of performance obligations based on an input method include the total estimated costs to satisfy the associated performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 10, &#8220;Collaboration and License Agreements&#8221;, for further information on the application of ASC 606 to the collaboration and license agreement with Acceleron (the &#8220;Acceleron Collaboration Agreement&#8221;) and the collaboration and license agreement with MyoKardia (the &#8220;MyoKardia Collaboration Agreement&#8221;).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48c821f8-9605-4655-9c82-8314d9bdcc4d" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_48c821f8-9605-4655-9c82-8314d9bdcc4d_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and development expenses include costs directly attributable to the conduct of research and development programs, including personnel-related expenses such as salaries, payroll taxes, benefits, and stock-based compensation expense, manufacturing and external costs related to outside vendors engaged to conduct both preclinical studies and clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_48c821f8-9605-4655-9c82-8314d9bdcc4d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trials, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory supplies, depreciation on and maintenance of research equipment, and the allocable portions of facility costs, such as rent, utilities, repairs and maintenance, depreciation, and general support services. Expenditures relating to research and development are expensed in the period incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a31469b1-1b02-4526-a444-332bed0536ce" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:ResearchContractCostsAndAccrualsPolicyTextBlock" escape="true" continuedAt="F_a31469b1-1b02-4526-a444-332bed0536ce_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research Contract Costs and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a31469b1-1b02-4526-a444-332bed0536ce_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions and other companies. The Company records accruals for estimated ongoing research costs that have not yet been invoiced</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials or the extent of services provided during the reporting periods, including invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at each reporting period. Actual results could differ from the Company&#8217;s estimates.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e55053dd-2269-4bfd-b7c8-1bc086d6d951" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:PatentCostPolicyTextBlock" escape="true" continuedAt="F_e55053dd-2269-4bfd-b7c8-1bc086d6d951_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent-Related Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_e55053dd-2269-4bfd-b7c8-1bc086d6d951_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statements of operations.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65eb842b-3ec4-4fca-83ee-01a33c6e3368" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures stock-based awards based on the fair value on the date of grant. Compensation expense associated with those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each restricted stock award is based on the fair value of the Company&#8217;s common stock on the grant date, less any applicable purchase price. The fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The historical volatility is calculated based on a period of time commensurate with the assumption used for the expected term. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its stock-based awards. The expected dividend yield is assumed to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3209ba7c-608d-4ba2-9f24-16096ffc9596" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient&#8217;s payroll or service costs are classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97a9f808-9e01-41d8-b7b3-52aaf6fd6628" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_97a9f808-9e01-41d8-b7b3-52aaf6fd6628_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_97a9f808-9e01-41d8-b7b3-52aaf6fd6628_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52dbf44e-92de-4a6a-81fa-bd9e81656f44" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records costs and liabilities associated with exit and disposal activities in accordance with Accounting Standards Codification 420, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exit or Disposal Cost Obligations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4369700a-7e92-406b-ba93-7a1ccc771abb" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. For the years ended December 31, 2023 and 2022, comprehensive loss </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consists of net loss and unrealized losses on investments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73ad1174-5a17-41df-9f41-4a34c783cfa4" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_73ad1174-5a17-41df-9f41-4a34c783cfa4_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Income (Loss) Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_73ad1174-5a17-41df-9f41-4a34c783cfa4_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock and unvested restricted stock awards are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b43e7914-9fae-45ca-ba05-c65bf27f623a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities, U.S. Treasury securities, and commercial paper. The Company&#8217;s marketable securities consist of U.S. Treasury securities, corporate bonds, and commercial paper, and potentially subject the Company to concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7cde6e7-88a7-4d95-a343-ab47ce8e0cc6" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_e7cde6e7-88a7-4d95-a343-ab47ce8e0cc6_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_e7cde6e7-88a7-4d95-a343-ab47ce8e0cc6_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s interim chief executive officer, view the Company&#8217;s operations and manage its business as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1a68b880-8a0c-4fb5-9af0-f610de17e8b2;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12ab5095-d304-4c92-894a-ae3745bdf5d9" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:EmergingGrowthCompanyPolicyPolicyTextBlock" escape="true" continuedAt="F_12ab5095-d304-4c92-894a-ae3745bdf5d9_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_12ab5095-d304-4c92-894a-ae3745bdf5d9_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates for ASUs. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its initial public offering or such earlier time that it is no longer an EGC.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fee7dc74-39f0-47d5-85c2-8494e1ff8c01" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements&#8212;Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e1e106e-2186-4393-abc7-159e26f33c11" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10321103-d038-4ee3-aaec-9693e0e94bb5" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the fair value hierarchy classification of such fair values as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb17082c-87c6-4d96-b66b-d13f2646ed5e" contextRef="C_bc43a13b-90f8-4ef8-89c3-5e47e6633f21" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b03733c7-3335-401a-8a9d-60db062d70f1" contextRef="C_1f634eef-7981-4392-81a6-c6c15de65892" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec37346f-8bcc-419a-b104-bea288c6842c" contextRef="C_51307bed-9fb2-4853-8cce-0c34673cf5f7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,215</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_593e8cdb-2d3b-443d-a84f-5f34dafc0837" contextRef="C_d6c403c7-c450-4827-9fce-058e2ee7e5b5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,215</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_beff8da9-a2ec-4cdb-b1c5-75bf884eb21f" contextRef="C_3e7c4269-98eb-4914-9616-c8e3cd7260bd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,107</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be7e279e-8528-44a3-ba92-88b3986234dd" contextRef="C_16f0f75c-5dfd-4809-a32b-10469163a156" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,107</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6c9c506-c571-4c41-9725-35668873af0b" contextRef="C_5854b7db-5036-4f5d-b484-aa8238657b18" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,889</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_caf5fef9-c7b8-4abf-9f32-3d8a10925d33" contextRef="C_7354e229-40c7-40da-a524-c89e5cf4d63b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,889</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be8f8638-2718-4c9c-9e51-bb20b5581a3b" contextRef="C_d3376273-a29c-48cf-8511-32060db0b560" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,447</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e5d3521-7416-4c7e-9309-ae6127a4cec5" contextRef="C_78fb4e2e-0240-4074-b54f-749132177dc0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,447</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5074a177-8663-42bd-ab69-01f54a0a8829" contextRef="C_542d5873-acb9-4a0a-8e2d-dac0c67b8056" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,221</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfb2af73-852b-40ab-aa16-4fb2854b33ed" contextRef="C_87e20816-2f34-485e-b3e4-7088d4e8e968" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea4fe32c-ca59-4e64-9829-e5874ca9166c" contextRef="C_fa1479d0-71e2-465d-899e-3a286e2d39c4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e118d0c2-bdd8-4444-a306-0f83af997b18" contextRef="C_5186a5a2-f3b1-4be3-90f3-23ff2a2bd44a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,174</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fce42646-1573-46e7-b75e-aeb5a38c429e" contextRef="C_cca8e9eb-dd24-4750-983a-2de55f115638" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,174</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2a4cf71-8a2e-4824-b6e6-53cf6a4d1697" contextRef="C_62175780-5393-425b-aa05-cee4f721a128" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ee2c43-0acc-4824-af90-9eed5deebc11" contextRef="C_8a1f01be-46f9-44b7-9528-8152dca6e10e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0988a8a5-d927-46cb-a908-c5fe437547ac" contextRef="C_da574656-31f4-41eb-8cfa-bc58b33e0fa1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,231</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_119f77fc-144d-40ab-8e6e-f43ccdacac0b" contextRef="C_944dfc71-acfe-4731-851c-eec85eb1064c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,231</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd040bf8-b74a-439a-866a-d601f1b2ad50" contextRef="C_c3e57f9c-5c4a-427a-ae13-ff85b90fbe11" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,444</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7966bd63-93f9-4dfd-909e-0ca937a45544" contextRef="C_ddb6c423-a9fc-4d5d-b7bc-80dc1e5b3113" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,444</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44ccdce4-ded3-4ad2-993a-e5cf170847d9" contextRef="C_62175780-5393-425b-aa05-cee4f721a128" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,476</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30c59fbc-a62b-463f-82dd-b114858415b8" contextRef="C_8a1f01be-46f9-44b7-9528-8152dca6e10e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,476</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af79de19-084d-40cd-ab69-f270d4af6306" contextRef="C_c4f28692-ee59-4c99-998d-16b6c76ed96d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,672</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8081aa36-1570-4340-b71f-d209233ae64e" contextRef="C_2b05eccd-bd38-4e74-aadd-9cd13b5c1a5f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,672</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b98ff466-d53f-443a-8358-b677dd882a31" contextRef="C_85e16b30-1163-467d-8e7c-c5891589de08" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_440fccbe-fac8-4d57-8ac1-3ffb3560d85b" contextRef="C_43ee8347-1c34-42ba-9abd-dcdc1b5cbd11" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,174</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e84cfd8-6f92-4c0a-823c-7092a2fb9b8f" contextRef="C_37fbfbef-7505-46ab-bce6-acf025a24bb3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177,747</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a50d38b6-93c1-4371-8c4f-f4bda3ae5719" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:FairValueTransfersBetweenLevels" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_deaf1f96-3560-438c-b287-4cfb511ff826" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:FairValueTransfersBetweenLevels" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers between fair value levels during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b44b7277-9f86-49ae-b866-cd3fe4834124" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Cash Equivalents and Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_508873a5-f24a-4bde-ba94-3c8669676c34" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents and marketable securities consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66d415a4-ac2e-45b6-85fd-fa0957d323d9" contextRef="C_a2846897-76a3-4206-9f4d-846065573bee" name="fulc:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c471c1c8-8301-40c7-b753-017a4b4bda02" contextRef="C_a2846897-76a3-4206-9f4d-846065573bee" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eb1d12c-1763-4cc3-bbb4-891f54337f10" contextRef="C_a2846897-76a3-4206-9f4d-846065573bee" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbade28f-3f49-4d85-a119-c170ee03e41d" contextRef="C_a2846897-76a3-4206-9f4d-846065573bee" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5515494b-e8de-4306-8b06-c99dcedec12b" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_184fcd76-3232-4562-bb67-309f0a077f01" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d21fea8-a942-4993-9af6-f9daa3ab696e" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03c56b8a-df1c-4183-8518-f3ab35bbce71" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_576cef89-8d5b-4961-ba03-9a7226c48a43" contextRef="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,229</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6948d46c-1ef5-4596-ac73-471832a89369" contextRef="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0731310-6e81-4993-aec2-2e8a0133c24b" contextRef="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a53a1c5-ee49-47ca-8899-b7124d01fa7f" contextRef="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,215</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbcacd44-ac6a-40bb-8694-89052c163b6f" contextRef="C_f1a6601c-64be-4399-85ae-db7867216139" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,182</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c70653f-6518-42b3-bbb7-2469c30cc4ef" contextRef="C_f1a6601c-64be-4399-85ae-db7867216139" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e0207fd-5b0e-4b95-8f67-8c4812de2f87" contextRef="C_f1a6601c-64be-4399-85ae-db7867216139" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5e19ece-8db7-4709-a15a-ff2534d84ca3" contextRef="C_f1a6601c-64be-4399-85ae-db7867216139" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,107</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18120e83-6b98-4ce2-bb80-777712eea1bb" contextRef="C_874dc0df-15d5-4f39-8253-51d6179f2225" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,891</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7d60395-606e-406e-b24b-0b7e1da34315" contextRef="C_874dc0df-15d5-4f39-8253-51d6179f2225" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_115df96d-77ce-4226-b713-4903c8608832" contextRef="C_874dc0df-15d5-4f39-8253-51d6179f2225" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_becbf605-83b3-440d-a97e-1166a67fd7cf" contextRef="C_874dc0df-15d5-4f39-8253-51d6179f2225" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,889</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08ad4836-00b2-40c9-95dd-1d77af2d4d8e" contextRef="C_b18d8319-eea3-4201-bf6f-cdbb16015369" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,492</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7770e584-481c-4efa-8894-688f9e845e8f" contextRef="C_b18d8319-eea3-4201-bf6f-cdbb16015369" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f08ff81f-2a20-4a36-a020-925693bb2a9d" contextRef="C_b18d8319-eea3-4201-bf6f-cdbb16015369" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_518bc0a3-7b14-4599-bf23-954185bbf2da" contextRef="C_b18d8319-eea3-4201-bf6f-cdbb16015369" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,447</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12d7056f-dcbc-47c8-805a-f62374f6e141" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,794</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0dffa0d-bcd1-40e8-80e2-cbbfcac98d3a" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6c6f968-2391-4dcb-b5dd-638ef58b531f" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ca738b1-aa95-4d0c-af81-af409a4c4d64" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a386aa33-d8b5-4eea-aefb-bbaf25195732" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,357</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5daba9f0-df3e-4dde-a434-3de2f1c4b619" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19c50895-4d4f-44bd-aa50-5c2ecc54a74c" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2eecdc5f-c4c2-4845-954c-5535d0fb194f" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,221</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24e0e221-3ced-4fb3-9b3f-cc8237acd674" contextRef="C_5418e51c-11bd-4ab1-86e5-58e2085729af" name="fulc:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,174</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb656689-9e14-47c4-8b40-ef73f68e44f4" contextRef="C_5418e51c-11bd-4ab1-86e5-58e2085729af" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ca1623c-0b83-4739-a6aa-f4e45b763019" contextRef="C_5418e51c-11bd-4ab1-86e5-58e2085729af" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d1ea54e-8dfd-4a3b-91ea-f4f6f4e65257" contextRef="C_5418e51c-11bd-4ab1-86e5-58e2085729af" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,174</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cbae5ec-b0c0-43e3-a0b8-2da96b3b321e" contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10" name="fulc:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,928</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d874e870-6b4c-45fc-b2bd-5fdbe79bb6e0" contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0b04575-abaf-4383-b58e-15864cf7426a" contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ab366e3-f00f-4aee-a201-31ea6b801f43" contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17e5f826-63c0-49bf-93c1-59723f259f44" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,102</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe2728b5-5d03-4be1-ad0a-a7108543bfe3" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92bb087b-589a-4d0e-b08d-9a660afb5b04" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a7b4be4-eae7-428e-b741-ea391a143dbd" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,098</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aabdb1c-0d12-4674-9602-14dc727b5cd0" contextRef="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,267</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6ab8a06-5c77-4ed2-bade-bd164a9bc856" contextRef="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_458e495d-e72a-465b-81b9-f10e6f54fa55" contextRef="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afa499c4-2f6c-4d84-9cbb-809b0a768378" contextRef="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,231</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dc7595b-277d-4980-bd39-4dbffd10ba23" contextRef="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,493</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c168132-833e-49e2-a2fb-25c785885bb8" contextRef="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a61d5be-e215-409d-9b9a-1db558bc7cbb" contextRef="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5634255c-394c-4c9e-aa5a-f82530bdfa9d" contextRef="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,444</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eb00453-8c63-459c-98ce-d532a93762d8" contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,661</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daa8d89c-08da-4127-91ad-1a3623fd14cc" contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13c0c223-98f9-4630-b3c3-238a64d47db7" contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_752e58b5-2105-4444-844f-a41d959b9f76" contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,476</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_900e5638-5f1b-4445-96b6-7f797c8a7066" contextRef="C_f435b74c-2ffc-441d-adc0-12a5eda8264a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,195</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_713acf75-dcd4-4ba7-a2d4-f8709ea75641" contextRef="C_f435b74c-2ffc-441d-adc0-12a5eda8264a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c532fb3f-e6af-47c5-a326-c8577f00314c" contextRef="C_f435b74c-2ffc-441d-adc0-12a5eda8264a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">526</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2945ae3b-f1a6-4a70-bcf1-a25c99808e27" contextRef="C_f435b74c-2ffc-441d-adc0-12a5eda8264a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,672</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdbe9396-bfd1-469f-af06-1921b1fa207e" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,616</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce56c8b9-2acb-42a1-a021-bd63d753f2f3" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bb98a21-1643-4f80-bc46-7b95353d880a" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">796</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8259c56e-02aa-40cb-8707-07655404f0ab" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,823</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ab19816-bfcb-4022-b5b6-5074c3890074" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203,718</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e948fb0-d92d-4c9c-b3ea-f01ec9c6b89a" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39c870bc-3b52-4505-8bff-c9c6fe1c43bb" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">800</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdfb3b59-efb2-43fb-b69e-ec69b73c55d9" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_809657ba-5c72-4d4d-8833-4e50dfa92daa" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sales of marketable securities during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the held 46 debt securities that were in an unrealized loss position for less than 12 months with an aggregate fair value of  $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d627204e-3e8d-485a-b696-263b4c52ecd4" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">130.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held 18 debt securities that were in an unrealized loss position for greater than 12 months with an aggregate fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_977fd516-8a7a-4cf8-a358-42cc946f0f95" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the aggregate fair value of marketable securities with a remaining contractual maturity of greater than one year was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f50402-1dc1-4744-9b6f-ca152fc74573" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has the intent and ability to hold its debt securities until recovery. As a result, the Company did not record any charges for credit-related impairments for its marketable securities for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0bf5816-4f51-4022-bc09-19694ce8baec" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1f46239-1c14-432c-b4f1-786e2d04a032" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.693%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1%;"/>
        <td style="width:13.363%;"/>
        <td style="width:1%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1%;"/>
        <td style="width:13.383%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b199ab34-1baf-40b5-a7f7-890802f135de" contextRef="C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,682</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be71b71c-8efc-4d0d-8531-1e605aa3c0af" contextRef="C_e4c94a63-164c-46e2-af94-f4aa5ed3dad5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,057</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01eaba7e-67bf-472a-b10e-4b386bd10e35" contextRef="C_5c4254ea-de8b-4774-8083-9eb5cd87bb6d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9786f354-26de-46e5-9f36-b4e5f9329a9e" contextRef="C_f46423a4-6cae-4566-b0b3-c4344e7e0ddc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">786</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f2adf6e-50e2-4bd6-9d3b-297dcc238540" contextRef="C_375efc5e-e60e-4b9b-bf98-fb370dc4734f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fd639b0-d6c2-4445-a939-f992119fb136" contextRef="C_749e2b12-a6eb-4d72-8bf1-bab5c1af0594" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7619cdf9-541b-41f2-815f-9fa6a2e5d791" contextRef="C_990c5530-0921-4d0d-abca-bc365950858b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8fef92e-acd9-4496-a621-fae68e44ea7c" contextRef="C_98a6da6d-074f-41ab-bfc4-6a2ea10c4c2a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_453b657e-71c1-45d1-9eb8-4511da07b3ff" contextRef="C_508a96d8-65ca-4e37-92e2-530cc3c9b8b6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,102</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25f8f59e-cb6f-4329-b3dd-130af53c7a1d" contextRef="C_a79a27de-8391-4e03-935a-a5b39db9ffc9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,102</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03a39c9b-8393-439b-8cd4-9561db61fad1" contextRef="C_343e6c36-f77a-4689-8990-03e75af7256f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24e461b1-9dc8-4ebf-875f-96e1e09214ce" contextRef="C_0663cabf-5a8c-4583-a6b8-7af5d48c1798" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b38ee409-5a5e-4993-a13d-13168ffded03" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ddfe214-3b7a-4bb5-84bd-382f49b4a27a" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,568</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16d494e0-301c-428c-b5d4-d3b8ffaabe45" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,760</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6970bf2-7277-45e9-b0ae-88418002d70a" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,662</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f17ca9d1-4f59-4bf5-af09-a747457fd27b" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,216</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f81df70-8067-4caf-b9d7-d73456fd5e2f" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,906</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27229485-6600-4ae5-8aa7-00390b705ecc" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aab076bb-ed8e-4923-b893-edc04e15e338" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bce4e763-9adc-4492-b146-08343b1af37b" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Additional Balance Sheet Detail</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f50dcf6a-5dcf-4a8b-8111-e9559ebc17c5" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e11e247a-cd94-4134-bc9e-68a83e2f6a0c" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:PrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_664749e3-db8f-4f54-a457-bbcf833c1d4f" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:PrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,425</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid sign-on bonuses subject to vesting provisions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fef4ed3-6e2d-4e32-b3aa-0556eccde726" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:PrepaidSignOnBonusesSubjectToVestingProvisions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6418612c-4d2e-42ab-9fb5-08f7f2915f4e" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:PrepaidSignOnBonusesSubjectToVestingProvisions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0a83954-7643-4525-98c7-b92f41941055" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,712</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc716983-d86b-4944-b280-1ca2ee1a9736" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c11df06-6db0-4721-afe3-faf9077b54cf" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5623e738-545f-4648-af59-e8eca3cb464a" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,369</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d71ce0a-afe5-4ac2-8b09-075966449c3b" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bc36e01-4109-46da-9c91-aa27b508648e" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,164</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7e87b66-f3a1-44d6-9a25-b1da2f272ecb" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d87d2602-5421-4b31-a6d3-94ed51d38c80" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,712</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a1c8b64-e8d9-4c90-9728-dac975132d9b" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1dd3bb8-d4f9-48d6-a9a9-2dd09e7b6496" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0e0f81b-2efb-422f-95fb-7c59738534b0" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">535</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a10876e-1dab-417b-9b72-b183603f6308" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74598710-d802-4b20-bb49-4dc7a715fa94" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a33d1d4-1d00-4a9b-b16e-979b12ffb349" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:AccruedLiabilitiesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,726</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09d381a3-65f6-4f77-ba21-c20032946a8e" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:AccruedLiabilitiesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,551</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36b1aec6-794c-4e49-b362-5b0e7a627c03" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:PreferredStockTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30664edb-b9bd-419f-a452-85ca5a50e57c" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dec6b98c-aa19-49b6-a8a6-d4e55321ca14" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of undesignated preferred stock were authorized. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abfebb00-bc98-4d09-a34f-53461f7aff51" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a468b614-5bc9-48f1-95af-e62dd24d9e77" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_86535969-6674-422f-952b-8cbffddade70" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ded0ee53-15cc-45b3-b912-59428194d3b7" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock were issued or outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d98784f-9513-4655-b974-d83bb8330325" contextRef="C_000f7fb2-957c-4f01-b3cf-38256d89b74f" name="fulc:TemporaryEquityDividendsDeclared" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7ac21e01-d2c2-4cad-adb9-30ad78d21376" contextRef="C_f3a948e1-3f74-4748-b84d-2b0696114a7f" name="fulc:TemporaryEquityDividendsDeclared" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared since inception.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6e52853-6727-40a1-9fda-65b76dc2cf02" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d87a370-dbcc-4ec9-b50c-3aa2596345d6" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1e2ecca1-ffb1-4011-9ba1-eb3fe28916c9" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cad333d-84aa-49d1-a657-9671f8a9bfee" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c03f0bd0-c464-4408-8254-f65fcda4d0c8" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share, were authorized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af6320d3-c1bb-4876-8b01-d4bfca2d9f8f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of common stock entitles the holder to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99b4c042-e6fd-4cc3-b0a8-ace2cbd96c13" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:NumberOfCommonStockVotingRights" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote on all matters submitted to a vote of the Company&#8217;s stockholders</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Common stockholders are not entitled to receive dividends, unless declared by the Company&#8217;s board of directors, subject to the preferential dividend rights of any preferred stock then outstanding. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f46b5a9-e573-4003-998c-ab929ab8061f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:Dividends" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared or paid by the Company since its inception.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd5cc117-757d-4f1c-ae17-e16631e53d64" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ScheduleOfStockByClassTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the Company has reserved for future issuance the following number of shares of common stock:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for exercises of outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c25a4a27-eb39-4af2-bbc2-0530cb26f99a" contextRef="C_1553121b-ab45-495e-b5a0-c6324fbe71f5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,972,217</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f16c318d-af7f-4a36-8217-a7011abb5be6" contextRef="C_c4c8c6c6-98f6-489e-a40d-a5ff2e15f073" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,504,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for vesting of restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_336829b8-4b40-4cea-8a99-1d975d479e5c" contextRef="C_909e565e-556f-4785-a3a2-94aa703eda4a" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">75,017</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ce26678-5c3c-4807-bde9-72711e03c549" contextRef="C_ddc92748-af69-48e3-ad4c-c0752140c842" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">76,718</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2019 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a26ea78-463a-46e6-b938-702ac46f9369" contextRef="C_ef714543-18c5-47fb-aabb-747b27cc8411" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,157,537</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26489ba9-bef1-4262-af47-8e548084ac31" contextRef="C_98e7f3b2-a03a-4688-bc57-f63c93ac0609" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,941,054</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8867b819-7d02-475c-b29e-7f18ace55c67" contextRef="C_1c1be40a-0714-4b4f-8656-46ec78f32fc0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,346,125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cbe6295-6518-4219-838b-9d1bc68b101f" contextRef="C_69b9c54c-e52c-4afc-b0d8-7b44074f2ffe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,061,279</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2022 Inducement Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d0cc0ae-d15c-4303-aa00-9e67facc1a8c" contextRef="C_cb406b69-1f55-4cbb-aacf-ebebc94b8c0b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">837,877</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_530a29bf-fc44-41d5-8579-c5464bafc541" contextRef="C_3d0c7846-78b1-4df1-8b8d-1b707923fa89" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">329,880</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1e972ba-20b1-4e57-b257-60d9a681af78" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,388,773</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1edbfe61-728c-4231-a6ef-e27df6e9fee2" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,913,011</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_a1034a58-34bb-438c-bcd2-11f5d704b23a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2016 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2016, the Company adopted the 2016 Stock Incentive Plan (the &#8220;2016 Plan&#8221;), which provided for the grant of restricted stock awards, restricted stock units, incentive stock options, non-statutory stock options, and other stock-based awards to the Company&#8217;s eligible employees, officers, directors, consultants, and advisors. As of the effective date of the 2019 Stock Incentive Plan (the &#8220;2019 Plan&#8221;), and as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fdfb2ba-e7d1-445e-949d-a77386cac4cb" contextRef="C_11995c32-99cc-441f-9c07-7fd5a7ad4859" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f3927417-66d4-4f29-82b5-d356f97712a5" contextRef="C_94104f8d-cdd1-47a0-bd4b-ab3238e5307d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remained available for future issuance under the 2016 Plan. Any options or other awards outstanding under the 2016 Plan remain outstanding and effective.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 2, 2019, the Company&#8217;s stockholders approved the 2019 Plan, which became effective on July 17, 2019. The 2019 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards to the Company&#8217;s officers, employees, directors, consultants and advisors. The number of shares initially reserved for issuance under the 2019 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59fc1b2a-bc41-4956-9257-cf7148d2d131" contextRef="C_4ba02dc0-884d-416e-855c-afa71a9532cf" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,017,142</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, plus the shares of common stock remaining available for issuance under the 2016 Plan as of July 17, 2019. The number of shares reserved was annually increased on January 1, 2020 and will be increased each January 1 thereafter through January 1, 2029 by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ada5bcbd-3faa-425e-a63b-7c98037a9959" contextRef="C_79eda3da-f82b-42a7-9282-e10d0fdfbdf1" name="fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f505e5-b8fb-4fe7-84ce-8f6677f02fd3" contextRef="C_79eda3da-f82b-42a7-9282-e10d0fdfbdf1" name="fulc:IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the first day of each such year or (iii) an amount determined by the Company&#8217;s board of directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_7bc925d2-7e4c-4c4d-913c-ffeb1eedbdb3" contextRef="C_4fb06a81-59b1-410a-943c-d31a633e10ff" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,157,537</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future issuance under the 2019 Plan. On January 1, 2024, the number of shares reserved for issuance under the 2019 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc9f268d-fdf9-48db-823e-915df95734e1" contextRef="C_0e910a3d-1e4f-4b7c-85cc-e29372e692ec" name="fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The shares of common stock underlying any awards that expire, terminate, or are otherwise surrendered, cancelled, forfeited or repurchased by the Company under the 2016 Plan or the 2019 Plan will be added back to the shares of common stock available for issuance under the 2019 Plan. As of July 17, 2019, no further awards will be made under the 2016 Plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Inducement Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, the Company's board of directors adopted the 2022 Inducement Stock Incentive Plan (the "Inducement Plan"), pursuant to which the Company may grant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to the terms of the Inducement Plan and Nasdaq rules, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The Company initially reserved a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ed2a4af-05ed-4ead-a450-5bf85357f24f" contextRef="C_b517f554-4042-404a-9af4-f3387f4737b9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for the issuance of awards under the Inducement Plan. The number of shares reserved and available for issuance under the Inducement Plan can be increased at any time with the approval of the Company&#8217;s board of directors. The Inducement Plan permits the board of directors, a delegated committee of the board of directors, or a delegated officer of the Company to grant the stock-based awards available under the Inducement Plan to attract key employees for the growth of the Company. Effective March 8, 2023, the Company&#8217;s board of directors amended the Inducement Plan to increase the number of shares reserved for issuance by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_520d1a31-f9b5-4243-b6cd-cbe50acaf60e" contextRef="C_e1084719-244f-4e97-8f34-58c058846345" name="fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. Effective May 18, 2023, the Company&#8217;s board of directors amended the Inducement Plan to increase the number of shares reserved for issuance by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5f0ea02-d3fc-4471-9c22-29af6e4caf7e" contextRef="C_5298f167-d10a-434d-ac4b-5d0e08769dd7" name="fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,400,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be1b1c1b-9ad0-4a43-a36f-ba415364bbbb" contextRef="C_18e2c630-6ac6-421f-9bc1-23e2b22a1afb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">837,877</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future issuance under the Inducement Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options granted by the Company typically vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52bfc8d1-b1a0-4544-a222-ec7a0742c468" contextRef="C_6b2cb0ed-bc13-4280-b556-83c472d55900" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period and have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4563870-4368-4b6b-8494-c53b99aa1883" contextRef="C_6b2cb0ed-bc13-4280-b556-83c472d55900" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contractual term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares issued upon the exercise of stock options are issued from the Company&#8217;s pool of authorized but unissued common stock. In addition to stock options granted under the 2019 Plan and 2016 Plan, the Company has granted stock options as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4), which were granted outside of the 2019 Plan and 2016 Plan. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f4c877b-61ad-4b2b-8997-8ab75f929ab3" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_9f4c877b-61ad-4b2b-8997-8ab75f929ab3_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_9f4c877b-61ad-4b2b-8997-8ab75f929ab3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.272%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1%;"/>
        <td style="width:11.581000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1%;"/>
        <td style="width:11.926%;"/>
        <td style="width:1%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1%;"/>
        <td style="width:10.346%;"/>
        <td style="width:1%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1%;"/>
        <td style="width:14.939%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae2088b6-c8e7-407c-99af-b69b1e68bdd0" contextRef="C_84b31042-326d-4a8d-bb3a-1fab245f12f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,504,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e86a276-740a-4e22-b8ab-fa256667068b" contextRef="C_84b31042-326d-4a8d-bb3a-1fab245f12f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.99</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_39b59d17-bef0-4798-a0f1-f59012896033" contextRef="C_2704081c-8b8e-46dd-97fd-b538434d0d04" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.55</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0e62dd4-f4f6-4b9f-afa7-3aa1494c2556" contextRef="C_84b31042-326d-4a8d-bb3a-1fab245f12f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,885,160</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_feb9d404-3739-47d6-941f-84a00e8f9fd5" contextRef="C_830548a4-6251-494e-acc6-0972515e7069" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,089,933</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9bf619b-32de-4594-b217-3f4d3244a455" contextRef="C_830548a4-6251-494e-acc6-0972515e7069" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.87</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4544fa51-e065-4b75-99f0-de04838f688a" contextRef="C_830548a4-6251-494e-acc6-0972515e7069" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,903</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3643a9e2-20bd-4151-8795-91ab71b85e68" contextRef="C_830548a4-6251-494e-acc6-0972515e7069" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.96</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23c5ae36-30dd-48be-8475-d143834e1383" contextRef="C_830548a4-6251-494e-acc6-0972515e7069" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,582,893</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03aad399-fe5d-4dc0-94e7-07383cee9a64" contextRef="C_830548a4-6251-494e-acc6-0972515e7069" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b0df4b7-d127-46b8-a819-6e42e5b80a13" contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,972,217</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d82f0a58-4282-44ac-8d46-116515a0309a" contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8dd40fba-1b02-479c-94c3-88d3b69e5371" contextRef="C_830548a4-6251-494e-acc6-0972515e7069" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.49</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13df0298-91aa-4621-82fe-ffd333537c31" contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,114,074</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_481a0c29-e815-4fdf-821b-8e703dc884d0" contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,225,146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9a8395e-bcfb-4886-9965-2b4005e591e3" contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6762641a-e633-4c0d-9f89-8b0c0c09cdd0" contextRef="C_830548a4-6251-494e-acc6-0972515e7069" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.17</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75ec2d17-c876-44c5-a3ec-a1d2290fbb44" contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">407,817</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock as of the balance sheet date for those options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value of stock options granted in the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d3a11c1-3a71-4171-a124-269231b7f5db" contextRef="C_67ea3264-4f09-49a3-8fab-3cdfe1108e54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_706b2744-de33-4a22-8c17-c7d9aa8714a3" contextRef="C_55fd13cf-5a49-4af6-b31e-8f8a1b4bf952" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.62</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The total intrinsic value of stock options exercised in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f626d3e-9437-4ed2-b239-37fa54bcfcbc" contextRef="C_67ea3264-4f09-49a3-8fab-3cdfe1108e54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4daab2b5-b305-4cea-bc5a-c28487dbcc09" contextRef="C_55fd13cf-5a49-4af6-b31e-8f8a1b4bf952" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d6ebefd-b4b3-4e28-acf9-ac563ab7de6c" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022 has been calculated on the date of grant using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.788%;"/>
        <td style="width:1.555%;"/>
        <td style="width:1%;"/>
        <td style="width:14.663%;"/>
        <td style="width:1%;"/>
        <td style="width:1.389%;"/>
        <td style="width:1%;"/>
        <td style="width:14.607%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year<br/>Ended<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year<br/>Ended<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d47260b-cfc9-4a57-bad8-a03552bb5104" contextRef="C_fb5c742b-1082-4c9f-adea-cdf8661b486d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5a0d9b0-a71d-4916-ad79-2e015c53ca65" contextRef="C_9a3bad76-7c81-4609-ae81-f7496ee21338" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_477f22c3-2612-4015-9481-a1a6c489deb2" contextRef="C_fb5c742b-1082-4c9f-adea-cdf8661b486d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42a2557a-c4dc-4106-9ff2-de78c6d676e0" contextRef="C_9a3bad76-7c81-4609-ae81-f7496ee21338" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b0ba673e-00de-49f7-9e77-9a1331b7920e" contextRef="C_fb5c742b-1082-4c9f-adea-cdf8661b486d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6bc83985-0940-4850-ac56-58c2fc19aacf" contextRef="C_9a3bad76-7c81-4609-ae81-f7496ee21338" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_394dff0d-593b-4ae0-b1b4-bdeb1483fdef" contextRef="C_fb5c742b-1082-4c9f-adea-cdf8661b486d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">98.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61be77dd-9964-4dea-8eac-2d0bc7f9f95d" contextRef="C_9a3bad76-7c81-4609-ae81-f7496ee21338" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">90.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has also granted restricted stock units. The shares of common stock underlying restricted stock units typically vest over a four-year period. The shares of common stock are recorded in stockholders&#8217; equity as they vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_377a7387-32ae-4f0c-ab6f-d72f17f44113" contextRef="C_96906aae-d485-4fa9-8d8d-c0baeaee0dc8" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock unit activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.656%;"/>
        <td style="width:1.698%;"/>
        <td style="width:1%;"/>
        <td style="width:20.914%;"/>
        <td style="width:1%;"/>
        <td style="width:2.235%;"/>
        <td style="width:1%;"/>
        <td style="width:20.497%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec43b9b9-4ea7-40bb-b0ac-18ec01a97d54" contextRef="C_04824925-8561-4f56-bff5-d30316c83058" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,718</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eab8562-501b-4791-b973-6920d252826f" contextRef="C_04824925-8561-4f56-bff5-d30316c83058" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.73</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c93a4f9c-f020-4175-a8d6-c0847faa9fdf" contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,045</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc5134ad-5958-4248-b859-2fe69c5a2858" contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ceb4d597-61ba-4489-955f-a7f59c88a03a" contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59dbeffa-57e2-4a71-b51c-00c8b8f1c5c9" contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.79</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da7aff0b-e982-4c81-93fc-cd70afce42f3" contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,602</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be0433a4-2a66-466e-a72b-6e81c6f0e060" contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.03</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b00f2f7-80b5-4486-920d-c621ba5e4bd6" contextRef="C_5df36d60-952e-4b70-a43a-be90787573aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,017</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c09e4c4-fccd-451c-bbd9-4dd79dfb1143" contextRef="C_5df36d60-952e-4b70-a43a-be90787573aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.77</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of all restricted stock units and restricted stock awards that vested during the years ended December 31, 2023 and 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_365c7841-2b4e-4a20-bf94-5f6b480992de" contextRef="C_96906aae-d485-4fa9-8d8d-c0baeaee0dc8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e77f4363-ba72-4196-8624-9768d5e2714c" contextRef="C_36c5b7d8-3257-4975-88e1-ef21c0684b9e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bb8d83c-0a35-40ee-84e5-652ed6c3b59a" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total compensation cost recognized in the statements of operations </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and comprehensive loss associated with all stock-based compensation awards granted by the Company is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2aead14-8319-4b2d-b80e-05038c9c1539" contextRef="C_3f962abd-0c59-46b0-942a-62bedb1c8907" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,026</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c55ec37f-6447-48f2-983b-bcc2e6c32463" contextRef="C_f8a31241-faea-4738-8c70-9704d5b4aa96" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,652</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c538ff1-638e-427b-9561-43056a30568e" contextRef="C_b63474af-44cc-4faf-b216-6548e22c9832" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,776</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87535653-2f66-4b79-ab7c-b094036fad9c" contextRef="C_40257969-ac48-44c3-9ca7-ffe11592ae76" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,698</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c9342cc-0b9f-4924-9ef1-e4b3eb9af494" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,802</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_021e3b9e-4029-4002-89d7-19b4a05c2611" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,350</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff1ef594-87ce-4bd0-ab51-60ad81995171" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f98a150-4501-4d70-a794-677ef7714827" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.91</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 2, 2019, the Company&#8217;s stockholders approved the 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on July 17, 2019. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c9f7592-555e-4168-97b1-b696dba5753f" contextRef="C_9a8da089-33c9-42b0-ba2e-0a03c031f084" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">252,142</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock reserved under the ESPP was increased on January 1, 2020, and will be increased annually on each January 1 thereafter through January 1, 2029, by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1abed8a0-1b57-4f8d-a7e6-5414e06b30df" contextRef="C_34147407-27d4-48db-9e5a-99ff76257ddc" name="fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">428,571</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5afab60f-b21d-4410-9221-d5080c3ba99d" contextRef="C_34147407-27d4-48db-9e5a-99ff76257ddc" name="fulc:IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the first day of each such year or (iii) an amount determined by the Company&#8217;s board of directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cec7b221-727d-4d33-b8f9-5287c6d68399" contextRef="C_98d7485a-ca98-4800-86e5-94959550472d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,346,125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future issuance under the ESPP. On January 1, 2024, the number of shares reserved for issuance under the 2019 ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_284ca7ba-22d9-40c9-80af-2e130aa8afb5" contextRef="C_331bbcc1-90e8-4bf6-9dcd-ca73f84cc749" name="fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">428,571</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46edbb76-07e8-4a88-9b7a-a21b3f933eff" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Collaboration and License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acceleron Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 20, 2019, the Company entered into the Acceleron Collaboration Agreement to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space (the &#8220;Indication&#8221;). Under the terms of the Acceleron Collaboration Agreement, the Company granted Acceleron an exclusive worldwide license under certain intellectual property rights to make, have made, use, sell, have sold, import, export, distribute and have distributed, market, have marketed, promote, have promoted, or otherwise exploit molecules and products directed against or expressing certain biological targets identified by the Company for the treatment, prophylaxis, or diagnosis of the Indication.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 3, 2022, Acceleron notified the Company of its termination of the Acceleron Collaboration Agreement for convenience, which became effective 120 days after the Company's receipt of the notice, or October 1, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, the Company recognized no collaboration revenue associated with the Acceleron Collaboration Agreement. During the year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c032797b-00f7-43c2-8a10-3e5cda328196" contextRef="C_e9320667-4317-4880-b542-adec903ee354" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of collaboration revenue associated with the Acceleron Collaboration Agreement, which includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5306dc97-8b1d-45ea-8622-fbc2c0514ef9" contextRef="C_eb41ec6a-6f90-42d8-a1d9-14d1685b4dbb" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue recognized that was included in deferred revenue as of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021. As of December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7088611c-3048-4d8e-99c4-02d49175c88b" contextRef="C_6d813c32-3ade-4f1e-a7d9-3519e68f4cac" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> deferred revenue, unbilled accounts receivable, or accounts receivable associated with the Acceleron Collaboration Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8084776-1119-4f79-94c3-9d0d8d5a5792" contextRef="C_884143a7-2e26-4a93-ac13-566cb4dd0eaa" name="fulc:ReimbursementPaymentRecieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cost reimbursement payments under the Acceleron Collaboration Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fefac233-4a26-4799-a72e-ee3432d6096d" contextRef="C_7022a87d-e56e-48d8-8868-7ed1b8f6cd32" name="fulc:ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the achievement of specified research milestones</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MyoKardia Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 20, 2020, the Company entered into the MyoKardia Collaboration Agreement, pursuant to which the Company granted to MyoKardia an exclusive worldwide license under certain intellectual property rights to research, develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export, have exported, distribute, have distributed, market, have marketed, promote, have promoted, or otherwise exploit products directed against certain biological targets identified by the Company that are capable of modulating up to a certain number of genes of interest with relevance to certain genetically defined cardiomyopathies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to a mutually agreed research plan, the Company will perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets (&#8220;Identified Targets&#8221;) for further research, development, manufacture and commercialization by MyoKardia. The Company and MyoKardia will work together to determine how best to advance at each stage of the research activities under the research plan and to identify which of the Identified Targets, if any, meet the criteria set forth in the research plan (the &#8220;Cardiomyopathy Target Candidates&#8221;). Upon completion of the research plan, the parties will work together to prepare a final data package and MyoKardia may designate certain Cardiomyopathy Target Candidates for MyoKardia&#8217;s further exploitation under the MyoKardia Collaboration Agreement (the &#8220;Cardiomyopathy Targets&#8221;). If MyoKardia does not designate any Cardiomyopathy Targets during the designated period, then the MyoKardia Collaboration Agreement will automatically terminate. If MyoKardia designates one or more Cardiomyopathy Targets, then MyoKardia will be obligated to use commercially reasonable efforts to seek regulatory approval for and to commercialize one product directed against an Identified Target in certain specified countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the period in which the Company is performing the research activities pursuant to the research plan (the &#8220;Research Term&#8221;) and for a specified period beyond the Research Term if MyoKardia designates a Cardiomyopathy Target, the Company may only use the data generated from such research activities for MyoKardia in accordance with the MyoKardia Collaboration Agreement. During the Research Term and for a specified period thereafter, the Company may not research, develop, manufacture, commercialize, use, or otherwise exploit any compound or product (a) that is a Compound or Product under the MyoKardia Collaboration Agreement that is directed against the Cardiomyopathy Target Candidates for the treatment, prophylaxis, or diagnosis of any indication or (b) for the treatment of any genetically defined cardiomyopathies shown to be related to certain specified genes of interest that are modulated by the Cardiomyopathy Targets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the MyoKardia Collaboration Agreement, MyoKardia made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a664ed6-bd1d-4dc8-a647-06247736b5bc" contextRef="C_1db948c7-31b2-4309-a481-9cda796e4d8a" name="fulc:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront payment and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a530ef9-b949-481a-b256-42d55d5db100" contextRef="C_1db948c7-31b2-4309-a481-9cda796e4d8a" name="fulc:PaymentForPrepaidResearchFunding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment as prepaid research funding to the Company in July 2020. MyoKardia will also reimburse the Company for the costs of the research activities not covered by the prepaid research funding, up to a maximum amount of total research funding (including the prepaid research funding). Upon the achievement of specified preclinical, development and sales milestones, the Company will be entitled to preclinical milestone payments, development milestone payments and sales milestone</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ff95216-8a04-4415-85dc-b16471316963" contextRef="C_a18d155f-7a8d-4b6c-9a25-f1314028d766" name="fulc:MilestonePaymentForCertainIdentifiedTargets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">298.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate per target for certain Identified Targets, and of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24d4f1d1-9c31-4e96-8370-37ddfe8f1ceb" contextRef="C_a18d155f-7a8d-4b6c-9a25-f1314028d766" name="fulc:MilestonePaymentForCertainOtherIdentifiedTargets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate per target for certain other Identified Targets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company has achieved a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8898f3f8-c10d-4afb-8044-b20a1de13f47" contextRef="C_ea0f142c-6216-4014-90e1-aa57c23c6c6b" name="fulc:ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million specified preclinical milestone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MyoKardia will also pay the Company tiered royalties ranging from a mid single-digit percentage to a low double-digit percentage based on MyoKardia&#8217;s, and any of its affiliates&#8217; and sublicensees&#8217;, annual worldwide net sales of products under the MyoKardia Collaboration Agreement directed against any Identified Target. The royalties are payable on a product-by-product basis during a specified royalty term, and may be reduced in specified circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MyoKardia Collaboration Agreement continues on a country-by-country and product-by-product basis until the last to expire royalty term for a product, at which time the MyoKardia Collaboration Agreement expires with respect to such product in such country. Either party has the right to terminate the MyoKardia Collaboration Agreement if the other party has materially breached in the performance of its obligations under the MyoKardia Collaboration Agreement and such breach has not been cured within the applicable cure period. MyoKardia also has the right to terminate the MyoKardia Collaboration Agreement for convenience in its entirety or on a target-by-target, product-by-product or molecule-by-molecule basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Analysis</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Identification of the Contract</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the MyoKardia Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Identification of the Promises and Performance Obligations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the MyoKardia Collaboration Agreement contains the following promises: (i) an exclusive worldwide license under certain intellectual property rights, including rights to a specified number of potential cardiomyopathy gene targets identified by the Company for further research, development, manufacture and commercialization for the treatment, prophylaxis, or diagnosis of certain genetically defined cardiomyopathies that was conveyed at the inception of the arrangement (the &#8220;MyoKardia License&#8221;), (ii) research services to identify and validate potential biological targets (the &#8220;MyoKardia Research Services&#8221;), and (iii) participation in the joint steering committee (the &#8220;MyoKardia JSC&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the above promises and concluded that the MyoKardia License is not capable of being distinct from the MyoKardia Research Services given that the MyoKardia License has limited value without the performance of the MyoKardia Research Services and the MyoKardia Research Services can only be performed by the Company due to their specialized nature. Therefore, the Company has concluded that the MyoKardia License and the MyoKardia Research Services represent a single combined performance obligation.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also assessed the participation on the MyoKardia JSC and concluded that the promise is quantitatively and qualitatively immaterial in the context of the MyoKardia Collaboration Agreement. Accordingly, the Company has disregarded its participation on the MyoKardia JSC as a performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of the Transaction Price</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company received a non-refundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e71a7b4-87a2-4585-9b27-79c3e2979a2d" contextRef="C_a2062e16-6f62-4e3b-89f8-c083e9ea8bfa" name="fulc:NonRefundableUpfrontPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company included in the transaction price. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company achieved a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcf11d46-2a1f-4f53-94a8-dec39a2e4bcd" contextRef="C_7baf9985-59a2-4afb-b460-9750260fe38c" name="fulc:ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million specified preclinical milestone associated with the MyoKardia Collaboration Agreement, which was previously constrained due to the significant uncertainty regarding whether such preclinical milestone would be achieved. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company included this amount in the transaction price as of December 31, 2021. Based on the continued uncertainty associated with the achievement of any of the remaining preclinical and development milestone payments that the Company is eligible to receive, the Company has constrained the variable consideration associated with those milestone payments and excluded them from the transaction price. As part of its evaluation of constraining the preclinical and development milestones, the Company considered numerous factors, including the fact that the achievement of the preclinical and development milestones are contingent upon the results of the underlying preclinical and development activities and are thus outside of the control of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also included in the transaction price the expected amount of costs to be reimbursed for the MyoKardia Research Services, which includes the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0d1dfd9-7f0b-4bd4-95aa-e96962604794" contextRef="C_a247c0da-5748-4ee1-809e-b40ff34a7c07" name="fulc:PrepaidResearchFundingPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million prepaid research funding payment that the Company received in the third quarter of 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reassesses the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the transaction price. There was no change in the amount of variable consideration constrained during the year ended December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any consideration related to sales milestone payments (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to MyoKardia and therefore are recognized at the later of when the related sales occur or the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Allocation of the Transaction Price to Performance Obligations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As noted above, the Company has identified a single performance obligation associated with the MyoKardia Collaboration Agreement. Therefore, the Company will allocate the entire amount of the transaction price to the identified single performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recognition of Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue related to the MyoKardia Collaboration Agreement over time as the MyoKardia Research Services are rendered. The Company has concluded that an input method is a representative depiction of the transfer of services under the MyoKardia Collaboration Agreement. The method of measuring progress towards the delivery of the services incorporates actual cumulative internal and external costs incurred relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs are estimated reflects the Company&#8217;s estimate of the period over which it will perform the MyoKardia Research Services. Changes in estimates of total internal and external costs expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8944ce3b-95a2-454f-876c-9a060cedc3b5" contextRef="C_a2062e16-6f62-4e3b-89f8-c083e9ea8bfa" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of collaboration revenue associated with the MyoKardia Collaboration Agreement, which includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d0d5a7f-9534-4197-8146-d1dd6cb951e6" contextRef="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue recognized that was included in deferred revenue as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022. During the year ended December 31, 2022, the Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85f1df7b-f9d6-4b06-8606-e942cfd6df1a" contextRef="C_1e7d6101-2b2e-4757-966e-e38a693e1fe6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of collaboration revenue associated with the MyoKardia Collaboration Agreement, which includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4213087d-a3f4-47ad-a88f-8ad50cf1447d" contextRef="C_d0796c66-5faa-42cb-bb2a-9806d8b59cc7" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue recognized that was included in deferred revenue as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021. As of December 31, 2023, the Company recorded no deferred revenue associated with the MyoKardia Collaboration Agreement. As of December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded deferred revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfd14e2a-e784-478f-af32-2e5dbe389730" contextRef="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391" name="fulc:DeferredRevenueCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the MyoKardia Collaboration Agreement, which is classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue is expected to be recognized. The aggregate deferred revenue balance represents the aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. As of December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company had received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b1cab70-9247-4275-aa82-bf8c650b9a6b" contextRef="C_a2062e16-6f62-4e3b-89f8-c083e9ea8bfa" name="fulc:ReimbursementPaymentRecieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cost reimbursement payments under the MyoKardia Collaboration Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88dcb756-d67f-454b-a928-e865767ca209" contextRef="C_19b2e307-2653-4c2d-ac68-2e2064f71c76" name="fulc:PaymentForPrepaidResearchFunding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the achievement of a preclinical milestone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company had received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c24740d6-20f0-48e8-bb67-8ebe6ba40ab1" contextRef="C_3a2cdb21-6525-45f5-bf28-66b9a5ce67b6" name="fulc:ReimbursementPaymentRecieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cost reimbursement payments under the MyoKardia Collaboration Agreement and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83e1c9cb-3114-46a2-ae6e-4b586676fb47" contextRef="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391" name="fulc:PaymentForPrepaidResearchFunding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the achievement of a preclinical milestone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded unbilled accounts receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_054128a8-ba91-45f3-bb94-da03125816ca" contextRef="C_19b2e307-2653-4c2d-ac68-2e2064f71c76" name="fulc:UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to reimbursable research and development costs under the MyoKardia Collaboration Agreement for activities performed during the three months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. As of December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded unbilled accounts receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ee53e8e-488c-4b95-b125-04ead424551f" contextRef="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391" name="fulc:UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to reimbursable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and development costs under the MyoKardia Collaboration Agreement for activities performed during the three months ended December 31, 2022. As of December 31, 2023 and 2022, the Company recorded no accounts receivable under the MyoKardia Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d615888-3a42-4e62-8e53-5477733a209b" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:AssetAcquisitionDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GSK Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, the Company entered into the right of reference and license agreement, as amended (the &#8220;GSK Agreement&#8221;), with subsidiaries of GlaxoSmithKline plc (collectively referred to as &#8220;GSK&#8221;), pursuant to which the Company has been granted an exclusive worldwide license to develop and commercialize losmapimod. Under the GSK Agreement, the Company also acquired reference rights to relevant regulatory and manufacturing documents and GSK&#8217;s existing supply of losmapimod drug substance and product. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize losmapimod at its sole cost. The Company is also responsible for costs related to the filing and maintenance of the licensed patent rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the GSK Agreement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c6ab2af-961c-4c2a-af11-85ab0442cbaf" contextRef="C_dc2dcbed-a530-47fe-b591-af8023e6e6ca" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series B Preferred Stock to GSK. In addition, the Company may owe GSK up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16af583f-765b-4cf6-a78e-3e4be19c6bd7" contextRef="C_b9eb8757-a555-4809-8e7b-95ed236c0f69" name="fulc:ClinicalAndRegulatoryMilestonePayables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain specified clinical and regulatory milestones, including a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c0b44f6-0b3e-47e1-aa7a-df102623b4ed" contextRef="C_91aa4910-0766-4281-855f-db89fadd437e" name="fulc:ClinicalAndRegulatoryMilestonePayables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone that was achieved during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb990585-553d-4ff3-9ed1-3c1f4b394c64" contextRef="C_91aa4910-0766-4281-855f-db89fadd437e" name="fulc:ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone previously achieved and paid during 2019, and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d52ab741-65e7-4459-9063-c829e7ba7e3e" contextRef="C_b9eb8757-a555-4809-8e7b-95ed236c0f69" name="fulc:SalesMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain specified sales milestones. The Company agreed to pay tiered royalties on annual net sales of losmapimod that range from mid single-digit percentages to a low double-digit, but less than teens, percentage. The royalties are payable on a product-by-product and country-by-country basis, and may be reduced in specified circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK Agreement may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the GSK Agreement will continue in effect until the expiration of the Company&#8217;s royalty obligations, which expire on a country-by-country basis on the later of (i) ten years after the first commercial sale in the country or (ii) approval of a generic version of losmapimod by the applicable regulatory agency.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes clinical and regulatory milestone payments when the underlying contingency is resolved and the consideration is paid or becomes payable. The milestone payments are capitalized or expensed depending on the nature of the associated asset as of the date of recognition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CAMP4 Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company entered into a license agreement (the &#8220;CAMP4 Agreement&#8221;) with CAMP4 Therapeutics Corporation (&#8220;CAMP4&#8221;) pursuant to which the Company received a worldwide exclusive license (including the right to sublicense) from CAMP4 to rights under its Diamond Blackfan Anemia (&#8220;DBA&#8221;) program, which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how for the Company to research, develop, manufacture, use, commercialize or otherwise exploit therapeutic products in any indication, including the grant of a sublicense under certain intellectual property rights that CAMP4 has licensed under an agreement with Children&#8217;s Medical Center Corporation (&#8220;CMCC&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company made an undisclosed upfront non-refundable, non-creditable payment to CAMP4. If the Company succeeds in developing and commercializing licensed products, CAMP4 will be eligible to receive (i) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51de192b-a99e-43f0-acc8-48c7fb740be5" contextRef="C_fd317054-d5af-4b47-89c2-049b6bdcf482" name="fulc:ClinicalAndRegulatoryMilestonePayables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in development and regulatory milestone payments, and (ii) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e0986c5-5ccd-493d-9a23-b0ea09ce7d7b" contextRef="C_e5fa44bd-3098-4335-bd36-e6a28c5c81f2" name="fulc:ClinicalAndRegulatoryMilestonePayables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in sales milestone payments. CAMP4 is also eligible to receive royalties on worldwide net sales of licensed products ranging from mid-single digit to low-double digit, subject to potential reduction following loss of patent coverage, the launch of certain generic products or royalty stacking for licenses of third party intellectual property. The royalties will expire on a product-by-product and country-by-country basis upon the latest to occur of (i) the expiration of all valid patent claims covering the compounds in such country, (ii) the expiration of all regulatory exclusivities in such country, and (iii) 10 years following the first commercial sale in such country. The Company is responsible for the costs associated with the development and regulatory approvals of licensed products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless earlier terminated in accordance with its terms, the license agreement continues on a country-by-country and licensed product-by-licensed product basis until the expiration of the royalty term in each country, at which time the license agreement expires with respect to such licensed product in such country and the Company will have a fully-paid up, royalty-free and perpetual license to the licensed patent rights and know-how with respect to such licensed product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAMP4 has the right to terminate the license agreement in the event of the Company&#8217;s non-payment (subject to cure periods and tolling for bona fide disputes). CAMP4 may also terminate the license agreement if the Company challenges certain patents sublicensed to the Company by CAMP4. Either party may terminate the license agreement in its entirety for the other party&#8217;s material breach if such other party fails to cure the breach. Either party may also terminate the agreement in its entirety upon certain insolvency events involving the other party. The Company has the right to terminate the license agreement with CAMP4 for any or no reason upon prior written notice to CAMP4.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes development and regulatory milestone payments when the underlying contingency is resolved and the consideration is paid or becomes payable. The milestone payments are capitalized or expensed depending on the nature of the associated asset as of the date of recognition.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_3949344b-2193-40b4-bf14-6c2bb1b3345c" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">26 Landsdowne Street</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2017, the Company entered into a lease agreement for its current corporate headquarters comprising approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_413e5cf2-0845-4372-8eff-b00f3e6abf1a" contextRef="C_7c3c4af6-ca10-4044-9408-a2cfdd8766f8" name="fulc:OfficeAndLaboratorySpace" unitRef="U_SquareFeet" decimals="0" format="ixt:num-dot-decimal">28,731</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space at 26 Landsdowne Street  in Cambridge, Massachusetts, commencing December 2017. The Company began to occupy and use the leased space for its intended purpose in June 2018. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease ends on June 30, 2028. The Company has the option to extend the term of the lease for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1b806f6-04cc-44b0-a600-f55da1e5cc5d" contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901" name="us-gaap:LessorOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five-year</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period, at the market rate, by giving the landlord written notice of its election to exercise the extensio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n at least nine months prior to the original expiration of the lease term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease has a total commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e05764b8-7731-478a-a46d-03f7bd4e50c8" contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901" name="us-gaap:OtherCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1e0924d-d1a0-4fa0-8ed4-16d27345586e" contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term, and includes escalating rent payments. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease provides the Company with an allowance for normal leasehold improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2a89bb7-8f6c-435e-94d2-9529bdf77fb1" contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease agreement requires the Company to either pay a security deposit or maintain a letter of credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc626c98-e273-444b-bd72-ed40537e6fd0" contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company maintains a letter of credit for this lease and has recorded the cash held to secure the letter of credit as restricted cash on the consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022. Operating lease and variable lease expense associated with this lease for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c74682e5-3595-40a7-8fa9-cc2aa7ee54eb" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a38d27a-6440-4064-87a0-0ed92825d8b9" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:VariableLeasePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Operating lease expense and variable lease expense associated with this lease for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aed25f7-399f-4952-8763-6b3111aa7447" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f00c2d30-ef85-42b2-8ba7-60c359e0b530" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:VariableLeasePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ae5e658-5e80-49a5-bcfa-600dfeface66" contextRef="C_307f7d91-6fab-4f2c-b389-665c233bce30" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future minimum lease payments associated with the 26 Landsdowne Street lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01b6ddf8-bf28-418a-bc0f-9fcf2fca69aa" contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,572</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eaf70c2-9260-4b12-9e02-0385a3c29013" contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,649</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fd88fe2-8774-4130-9bd7-b3d20ba25a7c" contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,729</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_380a3bed-bf5e-4fb4-b0f6-49c6f5cd1175" contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82a45766-5637-4935-9c0c-7daeb2c171f7" contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1" name="fulc:Thereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,426</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b43e7edf-0e20-4670-a230-7b39bf9c3f2d" contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,187</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fdca038-6eed-41b5-a987-841834ddeeb9" contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1" name="fulc:LessImputedInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,575</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd97193a-f6c8-4bce-9af2-d87c875cab1d" contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,612</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">125 Sidney Street</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into a lease agreement comprising approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f9712d4-47e8-4472-8552-36f8b30225df" contextRef="C_63c6c909-d955-4771-8848-2cdb7bda457f" name="fulc:OfficeAndLaboratorySpace" unitRef="U_SquareFeet" decimals="0" format="ixt:num-dot-decimal">12,196</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space at 125 Sidney Street in Cambridge, Massachusetts, commencing November 2021. The Company began recognizing rent expense associated with this lease during November 2021. The lease ends on March 31, 2024. The Company has the option to extend the term of the lease for two successive one-year periods, at the market rate, by giving the landlord written notice of its election to exercise the extension at least nine months prior to the original expiration of the lease term. The lease has a total commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5af8acfb-7764-4a38-a5b8-f796d68f3fe2" contextRef="C_6a8b9b58-5d94-486d-a1c0-5e1919ae1ab3" name="us-gaap:OtherCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the initial term, and includes escalating rent payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b92c66e9-2552-4d68-b1b4-25e1d4d77a5e" contextRef="C_3ccff940-b46f-49f2-a0ba-1cf5bf8580ae" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_b92c66e9-2552-4d68-b1b4-25e1d4d77a5e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense associated with this lease for each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa4777a3-beea-4cd1-b3e6-8e36b4c7459b" contextRef="C_3ccff940-b46f-49f2-a0ba-1cf5bf8580ae" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_57a6accf-c0f6-4517-ab4b-4e8626d7423d" contextRef="C_3bf64331-d750-4ee0-8b5b-6d241408072d" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9182ebcf-b7ad-4050-8e04-07c22ba12cd7" contextRef="C_3ccff940-b46f-49f2-a0ba-1cf5bf8580ae" name="us-gaap:VariableLeasePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> variable lease expense was recorded associated with this lease for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022. The future minimum lease payments associated with this lease as of December 31, 2023, are as follows (in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b92c66e9-2552-4d68-b1b4-25e1d4d77a5e_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11c2465f-db8b-426a-a12c-623023658cbc" contextRef="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5b9ec8a-8c8f-46d1-a9e3-2526c7cf46d5" contextRef="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_823a9c1d-6131-41ec-a9b0-441fc7dd2384" contextRef="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241" name="fulc:LessImputedInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_103a26da-edad-4217-b77a-1f7d1e97bc61" contextRef="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a36b5ad-90bd-478c-8281-1c076e362265" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c380771-8a46-4e1b-9557-6c5e0164433c" contextRef="C_f027d984-8450-4048-9d00-1f28f5700faa" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d32887a9-c1c1-4754-9dc3-6b0223f0cf50" contextRef="C_30e3fda8-1f2a-42d1-bbf1-8d7c093ac7d6" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t accrued any liabilities related to such obligations as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2023, a class action complaint was filed in the United States District Court for the District of New Jersey against the Company and current and former officers (the &#8220;Securities Action&#8221;). On May 19, 2023, the Securities Action was transferred to the United States District Court for the District of Massachusetts, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Celano v. Fulcrum Therapeutics, Inc., et al</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., Case No. 1:23-cv-11125-IT. On July 31, 2023, the court appointed a lead plaintiff, who filed an amended complaint on September 29, 2023. The Securities Action alleges violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder against all defendants and control person violations of Section 20(a) against the individuals, related to the Company&#8217;s February 2023 announcement that the U.S. Food and Drug Administration issued a clinical hold regarding the investigational new drug application for pociredir (formerly known as FTX-6058) for the potential treatment of sickle cell disease. The Securities Action alleges that the defendants made misleading statements and omitted to disclose material information related to the clinical hold and seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between March 3, 2022, and March 8, 2023, as well as attorneys&#8217; fees and costs. On November 28, 2023, all defendants filed a motion to dismiss the Securities Action, which motion is currently pending. The Company intends to defend vigorously against this litigation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At each reporting date, the Company eva</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">luates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as they are incurred. Other than attorneys&#8217; fees and costs related to the defense of the Securities Action, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df0a93e7-bfb4-4908-8c59-a9de478dad0c" contextRef="C_22c69f38-8bae-4283-a815-fd207b1f78a2" name="us-gaap:LossContingencyLossInPeriod" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such costs have been incurred during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fd76c55-2be7-49c6-bb4c-44de9335cc75" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Income Taxes</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d31d1de1-9c9d-407b-866b-98f777c63e04" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.545%;"/>
        <td style="width:1.321%;"/>
        <td style="width:1%;"/>
        <td style="width:14.907%;"/>
        <td style="width:1%;"/>
        <td style="width:1.321%;"/>
        <td style="width:1%;"/>
        <td style="width:14.907%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c3d3c91-d7fa-4366-9b07-5180b9a46074" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db1e67a3-0306-4407-972f-696f9e385d9d" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8b532aa-1716-46f6-a0b5-6eac3ce7e045" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:num-dot-decimal">0.71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_181f5258-ebe1-4807-b632-5a4cf2024ed2" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:num-dot-decimal">0.46</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c40b210-055b-4fbe-90ab-86576924522e" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1.47</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f431da3-b4e6-4746-bc59-f2790a9daa42" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1.44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal orphan drug credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72f8c3b0-053e-4679-84c3-09cf6fe60cd5" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">9.41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4f859c4-b824-4e53-99d7-932ff25d3cd4" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="fulc:EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">7.23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9828961a-6d43-464e-acc1-dd4b15b58141" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5.92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d661e0c8-d283-43b4-a7bb-3713977b8d41" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5.78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Officers' compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34084f92-a398-4c00-bfc4-20e19aa465e7" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:num-dot-decimal">1.06</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b759c243-5902-4468-8896-683a860dc2db" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="fulc:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:num-dot-decimal">0.23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact of ownership change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1b05a15-e143-4ee2-b700-fecc1b30a44c" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12d4786a-ed85-44e4-a22e-30df807ad2cc" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="fulc:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">2.92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a27c445f-9c52-4bc2-a5ff-d79cee3e40c2" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:num-dot-decimal">0.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5683da60-5306-41b9-97b9-6564082f5508" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:num-dot-decimal">0.13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01d35edb-5634-4a57-8e73-e3fa66ae5e2b" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:num-dot-decimal">35.93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f11b1152-5ae7-4104-a053-46e42b82f9f6" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="INF" sign="-" format="ixt:num-dot-decimal">31.71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51ad5fcb-3d0f-43ec-a298-77c5bf132a68" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_755c010e-1598-480a-ac8b-13e1c05d59f2" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company incurred book and tax losses and, because it maintains a full valuation allowance on its net deferred tax assets, did not recognize federal or state income tax expense or benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7836b155-312c-45d9-9429-1454938ebbd6" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s deferred tax assets and liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.52%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:14.440000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:14.440000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5c5993f-2bb2-49b6-b557-6a8dbe57d4ac" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,622</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dae9f351-6e3d-4e25-a65e-6f69f2d4788a" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,005</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2261d01-a7e5-44a6-93e6-ad72e8a94a28" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,019</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d445e18d-1123-4da7-9ac9-988d308d15a1" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,911</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Orphan drug credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b16458cc-2933-41a6-a924-7fe1d3b95bd9" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,790</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ab99df4-a2df-485d-8358-018adf5065d5" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,628</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c096bd95-9f1a-4847-afd7-d7beb16183ec" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,569</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8602eb32-9102-4e45-9ed6-013d6ba399b5" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,140</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73535e15-b1a8-4d0a-bd10-cdb5557dd2ae" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,291</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0188bb73-de8b-4898-bcbf-598d69ffdb39" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,918</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdffd483-1dcd-40cd-a464-e64dfba24553" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,740</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b7e2ced-4964-4bd1-85f6-6aa7ec7bd6ff" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,232</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_701d2047-3c96-4d24-9d4a-f85c4c01babf" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="fulc:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,911</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd601f7a-ece4-4689-a3f8-8f4e8a694f31" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="fulc:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8ad2c53-a7d5-487d-b0f8-b745aab1b081" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9aa9e91-cc45-4bf6-8919-33142beb73d7" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e32c7e0-98fd-4d68-9fdb-81347a51a9a5" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,942</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d2c072b-b0ff-4fa7-be96-51077e7af93e" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,698</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35985c09-b5c3-46d0-a7aa-30881bc74116" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,483</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_406c0d8e-ac3f-4cb9-82f1-045f5648be60" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,512</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_392345be-d202-4bfc-ba5f-a9fc87576d1b" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,459</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2326433-68ae-40fd-84d8-2ab30e33cc1d" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,186</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec7d7a4a-a7d7-4c9d-8e85-e32ed86fe4a8" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,459</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_274908d0-ffdb-4828-8467-1c06ef1e83eb" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,186</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca58174c-b40f-406f-a204-a53391306274" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a28ac2e1-17de-4fdc-aee2-08b95f6d666b" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the net deferred tax assets. The Company considered its history of cumulative net losses incurred since inception and its lack of commercialization of any products since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f1ce589-70eb-47e8-85d0-de344ad2e5d9" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, which is primarily attributable to increases in net operating loss carryforwards as a result of current year net losses, increases in capitalized research and development costs, and the generation of research and development and orphan drug tax credit carryforwards. The Company reevaluates the positive and negative evidence at each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18bc6b47-a267-4c4a-87ca-d0c78544d388" contextRef="C_e3d54fc7-6a3d-43de-9e32-8e241187c233" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">312.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a portion of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c93bdc6f-c3ef-4d54-bcb7-5b9fe720e44b" contextRef="C_477d49f1-72c7-42b4-91d0-1ea14d3bf239" name="fulc:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9de034f-a0ce-44c9-9500-41de6779712e" contextRef="C_477d49f1-72c7-42b4-91d0-1ea14d3bf239" name="fulc:OperatingLossCarryforwardsIndefinitely" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">288.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the federal net operating losses can be carried forward indefinitely. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_887d90c2-6779-425d-83df-c5d46a165c13" contextRef="C_848b9802-2af7-4a3a-b897-56f5907cf9a6" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">317.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e048132-786c-49b6-a0e6-d957700959f2" contextRef="C_8ddbacbc-0594-4cc9-a6ac-745a13b49459" name="fulc:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal orphan drug credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73b65394-4688-482e-80f0-0d650a4c7cee" contextRef="C_e3d54fc7-6a3d-43de-9e32-8e241187c233" name="fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5931b6de-6971-40a6-a559-cb46fccc1baf" contextRef="C_477d49f1-72c7-42b4-91d0-1ea14d3bf239" name="fulc:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal research and development tax credit carryforwards of approximately $7.</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32b106cb-5f82-471a-93af-1681facdefbf" contextRef="C_1ba2348b-df57-42f0-b766-38e72c616f8c" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c4ddd80-67a2-4772-b49d-7c1e3944a831" contextRef="C_630894ba-94c3-4b2d-a63f-cbe1dd1d4533" name="fulc:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e545f98-4255-4583-9887-68dcf528a4fd" contextRef="C_3409faec-0230-4835-b5e3-04aae93d50b9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a7f06b0-a16b-4150-9baa-00d098f083b2" contextRef="C_4ce2bbff-4474-45cb-9d57-0f72591eb0e3" name="fulc:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Internal Revenue Code&#8221;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2021 would limit or otherwise restrict the Company's ability to utilize its pre-change net operating losses and research and development tax credit carryforwards to offset future taxable income. As a result of the analysis, the Company does not believe that there are any significant limitations on its ability to utilize its net operating losses and research and development tax credit carryforwards to offset future taxable income. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since December 31, 2021. If the Company has experienced a change of control, as defined by Section 382, subsequent to December 31, 2021, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s tax years are still open under statute from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_34f687fe-c7b7-4d4d-a574-1aceb3c54fb6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2016</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the present.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as a component of the provision for income taxes. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4343bf1-0618-4250-a1a4-6799705cbed5" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a3610ea2-62e0-46e6-9752-012909c1517b" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e584d35e-def5-4198-88ac-3f26f0a3e2c7" contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d7dcc4f9-2713-424d-a654-5fd4fd02a4f8" contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest or penalties related to uncertain tax positions and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ed2afa5-3e4c-46d2-8e47-5ed02e4c26fc" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9c0f7c5e-3628-4702-9cea-70b939c964fc" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts have been recognized in the Company&#8217;s statements of operations. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company generated research and development tax credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#8217;s research and development tax credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development tax credit carryforwards and, if an adjustment is required, this adjustment would result in an adjustment to the deferred tax asset established for the research and development tax credit carryforwards and the valuation allowance.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32c0c5a5-bafd-4765-9fd5-e4a30248c1e9" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. Defined Contribution Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a defined contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fad43420-5693-4e54-817d-88c615c81818" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="fulc:DefinedContributionPlanName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">401(k)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants the option to elect to defer a portion of their annual compensation on a pretax basis. As currently established, the Company is not required to make contributions to the 401(k) Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he Company made $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_765f9dec-b171-4be3-99bf-fe59bd4ba22d" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47784b2a-6409-41b4-8068-414c41267837" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in contributions to the 401(k) Plan for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c510f09c-536c-4839-b2a9-47ec7c0a243f" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Net Loss per Share</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d97977cb-ac7f-4ac4-b840-4e11102853c2" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.969%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:19.836%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:19.836%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3e8a1b8-ea57-4c75-8191-0bf1e7c6c25e" contextRef="C_b7d85ad2-5aaa-4c27-af4c-3ddc57509e92" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,972,217</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f18b0349-707e-48ee-a8e4-3fb0d3d60cc9" contextRef="C_dbd2599a-812b-4ac3-94fe-e6eac2633ccd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,504,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf3ee3f1-724d-4801-ad4c-74ff38b65e94" contextRef="C_94054f0d-7eb4-4308-b9a8-6595c31dccc1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,017</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19fd4a7b-bf14-4e82-92e2-197c5a4dfcb3" contextRef="C_cfcc2344-b6f1-4e48-98ac-862abef9fa95" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,718</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2666cbc-9d73-42b9-ae51-9f29691b7be4" contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,047,234</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce5d1630-c979-4e68-9569-36a3acf46d76" contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,580,798</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT INDEX</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.44%;"/>
    <td style="width:1%;"/>
    <td style="width:90.56%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001680581/000104746919004324/a2239321zex-3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;3.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000119312523164435/d463131dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;3.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001680581/000104746919004324/a2239321zex-3_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/a2239080zex-4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen Stock Certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on June 21, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/fulc-ex42_198.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of the Registrant&#8217;s Securities Registered under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.1#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/a2239080zex-10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2016 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on June 21, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.2#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/a2239080zex-10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Incentive Stock Option Agreement under the 2016 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on June 21, 2019)</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.3#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/a2239080zex-10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Statutory Stock Option Agreement under the 2016 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on June 21, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.4#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/a2239080zex-10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Agreement under the 2016 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on June 21, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.5#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001680581/000104746919004014/a2239182zex-10_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on July 8, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.6#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001680581/000104746919004014/a2239182zex-10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement under the 2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to Amendment No. 1 to Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on July 8, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.7#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000156459021054234/fulc-ex101_13.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Statutory Stock Option Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.8#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017022002727/fulc-ex10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Agreement under the 2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.9#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001680581/000104746919004014/a2239182zex-10_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on July 8, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.10#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017022002727/fulc-ex10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.11#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023006841/fulc-ex10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to 2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 9, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.12*#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fulc-ex10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to 2022 Inducement Stock Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.13#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017022002727/fulc-ex10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Statutory Stock Option Agreement under 2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.14#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017022002727/fulc-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.15#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023006841/fulc-ex10_16.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Summary of Non-Employee Director Compensation Program (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 9, 2023).</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.44%;"/>
    <td style="width:1%;"/>
    <td style="width:90.56%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.16#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001680581/000104746919004014/a2239182zex-10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Employment Agreement for Executive Officers (incorporated by reference to Exhibit 10.12 to Amendment No. 1 to Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on July 8, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.17#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023006841/fulc-ex10_18.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter Agreement, dated January 3, 2023, by and between Registrant and Robert J. Gould (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 9, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.18#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023006841/fulc-ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Separation Agreement, dated January 2, 2023, by and between Registrant and Bryan Stuart (incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 9, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.19#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023037579/fulc-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated May 12, 2023, by and between Registrant and Alex C. Sapir (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.20#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023059755/fulc-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated August 7, 2023, by and between the Registrant and Alan A. Musso (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.21#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000156459021010715/fulc-ex1016_279.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated October 29, 2020, by and between the Registrant and Curtis Oltmans (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.22#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001680581/000104746919003793/a2239080zex-10_15.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors (incorporated by reference to Exhibit 10.15 to Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on June 21, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.23#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023021960/fulc-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consulting Agreement, dated April 22, 2023, by and between the Registrant and Esther Rajavelu (incorporated</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023021960/fulc-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023021960/fulc-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exchange Commission on May 15, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.24</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/a2239080zex-10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Right of Reference and License Agreement, dated as of February 8, 2019, by and among the Registrant, GlaxoSmithKline Intellectual Property (No. 2) Limited, GlaxoSmithKline LLC and Glaxo Group Limited (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on June 21, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.25</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000156459020052732/fulc-ex102_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to the Right of Reference and License Agreement, dated as of September 23, 2020, by and among the Registrant, GlaxoSmithKline Intellectual Property (No. 2) Limited, GlaxoSmithKline LLC and Glaxo Group Limited (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38978) filed with the Securities and Exchange Commission on November 10, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.26</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000156459020052732/fulc-ex101_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Collaboration and License Agreement, dated as of July 20, 2020, by and between the Registrant and MyoKardia, Inc, a wholly-owned subsidiary of Bristol Myers Squibb Company (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38978) filed with the Securities and Exchange Commission on November 10, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.27</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023037579/fulc-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Collaboration and License Agreement, effective as of April 20, 2023, by and between the Registrant and MyoKardia, Inc, a wholly-owned subsidiary of Bristol Myers Squibb Company (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.28</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000095017023059755/fulc-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement, effective as of July 5, 2023, by and between the Registrant and CAMP4 Therapeutics Corporation (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.29</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/a2239080zex-10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease for 26 Landsdowne Street, dated November 22, 2017, by and between the UP 26 Landsdowne, LLC and the Registrant (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232260) filed with the Securities and Exchange Commission on June 21, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;21.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fulc-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiary of the Registrant.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;23.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fulc-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;31.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fulc-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;31.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fulc-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;32.1+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fulc-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;32.2+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fulc-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;97.1*#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fulc-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Compensation Recovery Policy of Registrant.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Instance Document</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.44%;"/>
    <td style="width:1%;"/>
    <td style="width:90.56%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># Indicates a management contract or any compensatory plan, contract or arrangement.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; Certain portions of this exhibit have been omitted because the registrant has determined that they are both not material and is the type of information that the registrant treats as private or confidential.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Furnished herewith.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.44%;"/>
    <td style="width:5.06%;"/>
    <td style="width:3.04%;"/>
    <td style="width:46.46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fulcrum Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alex C. Sapir</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alex C. Sapir</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39%;"/>
    <td style="width:1%;"/>
    <td style="width:43%;"/>
    <td style="width:1%;"/>
    <td style="width:16%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alex C. Sapir</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alex C. Sapir</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alan Musso</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer (Principal Financial Officer)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alan Musso</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Gregory Tourangeau</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vice President, Finance (Principal Accounting Officer)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gregory Tourangeau</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Kate Haviland</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Kate Haviland</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sonja Banks</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sonja Banks</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James J. Collins</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James J. Collins Ph.D.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Katina Dorton</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Katina Dorton</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alan Ezekowitz</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alan Ezekowitz, MBChB, D. Phil</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James Geraghty</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James Geraghty</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert J. Gould</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert J. Gould, Ph.D.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>fulc-ex10_12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<html>
 <head>
  <title>EX-10.12</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SECOND AMENDMENT<br>TO<br>FULCRUM THERAPEUTICS, INC.<br>2022 INDUCEMENT STOCK INCENTIVE PLAN</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan (as amended by the First Amendment to the Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan and as amended from time to time, the &#x201c;Plan&#x201d;) is hereby amended by deleting the first sentence of Section 4(a) and substituting therefore the following:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Subject to adjustment under Section 9, Awards may be made under the Plan for up to 5,150,000 shares of common stock, $0.001 par value per share, of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).&#x201d;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The effective date of this Second Amendment shall be May 18, 2023.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as amended herein, the Plan is confirmed in all other respects.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>fulc-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">List of Subsidiaries</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"></td>
    <td style="width:2%;"></td>
    <td style="width:49%;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:1pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #ffffff03;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jurisdiction of Incorporation</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fulcrum Therapeutics Securities Corp.</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Massachusetts</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>fulc-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="exhibit_23_1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-233452) pertaining to the 2016 Stock Incentive Plan, as amended, 2019 Stock Incentive Plan, and 2019 Employee Stock Purchase Plan of Fulcrum Therapeutics, Inc.;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-236910) pertaining to the 2019 Stock Incentive Plan and 2019 Employee Stock Purchase Plan of Fulcrum Therapeutics, Inc.;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-1 No. 333-239353) and related Prospectus of Fulcrum Therapeutics, Inc. (as amended by Form S-3/A No. 333-239353); </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-253862) pertaining to the 2019 Stock Incentive Plan and 2019 Employee Stock Purchase Plan of Fulcrum Therapeutics, Inc.,</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-262356) pertaining to the 2019 Stock Incentive Plan, 2019 Employee Stock Purchase Plan, and Inducement Stock Option Awards (September 2021 &#x2013; January 2022) of Fulcrum Therapeutics, Inc.; </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263249) pertaining to 2022 Inducement Stock Incentive Plan, and Inducement Stock Option Award, as amended (February 2022) of Fulcrum Therapeutics, Inc.; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-270385) pertaining to the 2019 Stock Incentive Plan, 2019 Employee Stock Purchase Plan, and Inducement Stock Incentive Plan, as amended, of Fulcrum Therapeutics, Inc. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of our report dated February 27, 2024, with respect to the consolidated financial statements of Fulcrum Therapeutics, Inc. included in this Annual Report (Form 10-K) of Fulcrum Therapeutics, Inc. for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">February 27, 2024</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>fulc-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES <br>EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-<br>OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Alex C. Sapir, certify that:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K, of Fulcrum Therapeutics, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:56%;"></td>
    <td style="width:4%;"></td>
    <td style="width:40%;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alex C. Sapir</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alex C. Sapir</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>fulc-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES <br>EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-<br>OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Alan Musso, certify that:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Fulcrum Therapeutics, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:59%;"></td>
    <td style="width:4.2%;"></td>
    <td style="width:36.8%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alan Musso</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alan Musso</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>fulc-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Fulcrum Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned, Alex C. Sapir, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44%;"></td>
    <td style="width:5.38%;"></td>
    <td style="width:3.86%;"></td>
    <td style="width:46.76%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td rowspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alex C. Sapir</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alex C. Sapir</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>fulc-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Fulcrum Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned, Alan Musso, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44%;"></td>
    <td style="width:5.38%;"></td>
    <td style="width:3.86%;"></td>
    <td style="width:46.76%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td rowspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alan Musso</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alan Musso</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>fulc-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FULCRUM THERAPEUTICS, INC.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COMPENSATION RECOVERY POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adopted as of November 16, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fulcrum Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has adopted a Compensation Recovery Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as described below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.	Overview</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) of the Company in accordance with rules issued by the United States Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) under the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and the Nasdaq Stock Market.  Capitalized terms used and not otherwise defined herein shall have the meanings given in Section 3 below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.	Compensation Recovery Requirement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event the Company is required to prepare a Financial Restatement, the Company shall recover reasonably promptly all Erroneously Awarded Compensation with respect to such Financial Restatement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3.	Definitions</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Applicable Recovery Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Applicable Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Executive Officer. A person&#x2019;s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the person&#x2019;s current role or status with the Company (e.g., if a person began service as an </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive Officer after the beginning of an Applicable Recovery Period, that person would not be considered a Covered Person with respect to Erroneously Awarded Compensation received before the person began service as an Executive Officer, but would be considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means November 16, 2023.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Erroneously Awarded Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the amount of any Incentive-Based Compensation received by a Covered Person on or after the Effective Date and during the Applicable Recovery Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in a Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules.  Incentive-Based Compensation is deemed received, earned, or vested when the Financial Reporting Measure is attained, not when the actual payment, grant, or vesting occurs.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">h.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market LLC.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">An &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person who served the Company in any of the following roles at any time during the performance period applicable to Incentive-Based Compensation such person received during service in such role: the president, principal financial officer, principal accounting officer (or if there is no such accounting officer the controller), any vice president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy making function, or any other person who performs similar policy making functions for the Company. Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">j.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, any measures that are derived wholly or in part from such measures </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(including, for example, a non-GAAP financial measure), and stock price and total shareholder return.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">k.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">l.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned, or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure and any equity-based compensation provided by the Company or any of its subsidiaries, including, without limitation, stock options, restricted stock awards, restricted stock units and stock appreciation rights.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">m.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board or the Audit Committee of the Board concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare the Financial Restatement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4.	Exception to Compensation Recovery Requirement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5.	Tax Considerations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6.	Recovery Where Intentional Misconduct</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition to (and without limiting) the provisions of paragraph 2 above, in the event the Company is required to prepare a Financial Restatement after the Effective Date and the Board (or a duly established committee thereof), in its sole discretion, determines that a Covered Person&#x2019;s act or omission contributed to the circumstances requiring the Financial Restatement and such act or omission involved any of the following: (i) willful, knowing or intentional misconduct or a willful, knowing or intentional violation of any of the Company&#x2019;s rules or any applicable legal or regulatory requirements in the course of the Covered Person&#x2019;s employment by the Company or (ii) fraud in the course of the Covered Person&#x2019;s employment by the Company, the Company will use reasonable efforts to recover from such Covered Person up to 100% (as determined by the Board or a duly established committee thereof in its sole discretion) of the Incentive-Based Compensation received by such Covered Person from the Company during the three fiscal years preceding the date on which the Company determined that it is required to prepare a Financial Restatement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7.	Method of Compensation Recovery</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash Incentive-Based Compensation previously paid;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or rescinding some or all outstanding vested or unvested equity-based awards; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">adjusting or withholding from unpaid compensation or other set-off;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or offsetting against planned future grants of equity-based awards; and/or </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any other method permitted by applicable law or contract.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person&#x2019;s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8. 	Policy Interpretation</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9.	Policy Administration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered by the Committee. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of this Policy. The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this policy shall be final, binding and conclusive.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10.	Compensation Recovery Repayments not Subject to Indemnification</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img44875045_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *>!@@# 2(  A$! Q$!_\0
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M@I_Y+R__ !-'_"P?"_\ T%/_ "7E_P#B:\,HHL%SW/\ X6#X7_Z"G_DO+_\
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M?_"P?"__ $%/_)>7_P")H_X6#X7_ .@I_P"2\O\ \37AE%%@N>Y_\+!\+_\
M04_\EY?_ (FC_A8/A?\ Z"G_ )+R_P#Q->&446"Y[G_PL'PO_P!!3_R7E_\
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MH_X6#X7_ .@I_P"2\O\ \37AE%%@N>Y_\+!\+_\ 04_\EY?_ (FC_A8/A?\
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M>Y_\+!\+_P#04_\ )>7_ .)H_P"%@^%_^@I_Y+R__$UX9118+GN?_"P?"_\
MT%/_ "7E_P#B:/\ A8/A?_H*?^2\O_Q->&446"Y[G_PL'PO_ -!3_P EY?\
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M_B:/^%@^%_\ H*?^2\O_ ,37AE%%@N>Y_P#"P?"__04_\EY?_B:/^%@^%_\
MH*?^2\O_ ,37AE%%@N>Y_P#"P?"__04_\EY?_B:/^%@^%_\ H*?^2\O_ ,37
MAE%%@N>Y_P#"P?"__04_\EY?_B:/^%@^%_\ H*?^2\O_ ,37AE%%@N>Y_P#"
MP?"__04_\EY?_B:/^%@^%_\ H*?^2\O_ ,37AE%%@N>Y_P#"P?"__04_\EY?
M_B:/^%@^%_\ H*?^2\O_ ,37AE%%@N>Y_P#"P?"__04_\EY?_B:/^%@^%_\
MH*?^2\O_ ,37AE%%@N>Y_P#"P?"__04_\EY?_B:/^%@^%_\ H*?^2\O_ ,37
MAE%%@N>Y_P#"P?"__04_\EY?_B:/^%@^%_\ H*?^2\O_ ,37AE%%@N?1NFZI
M9ZQ9K=V$WG0,2H?:5Y'7@@&BN;^&@;_A#X]Q!'G2;<#&!GOZ\YHJ1F'\7/\
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M*8!1110 5M^%O#W_  DNJM8_:OLVV(R;_+W]"!C&1ZUB5VWPM_Y&J3_KU?\
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M!@[&SGG/'Y5ZM11<+'E(^$U]O(.IV^W P=C9SSGC\J$^$U\44OJ=N&QR C$
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M7U.W#8Y 1B ?K0GPFOBBE]3MPV.0$8@'ZUZM11<+'E*?":^**7U.W#8Y 1B
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MU\!\NIVY.1U1AQGG]*]6HHN%CRO_ (5->?\ 05@_[]'_ !IH^$U]O(.IV^W
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M+G_GO)_WT:@HHY5V#F9/]LN?^>\G_?1H^V7/_/>3_OHU!11RKL',R?[9<_\
M/>3_ +Z-'VRY_P">\G_?1J"BCE78.9D_VRY_Y[R?]]&C[9<_\]Y/^^C4%%'*
MNP<S)_MES_SWD_[Z-'VRY_Y[R?\ ?1J"BCE78.9D_P!LN?\ GO)_WT:/MES_
M ,]Y/^^C4%%'*NP<S)_MES_SWD_[Z-'VRY_Y[R?]]&H**.5=@YF3_;+G_GO)
M_P!]&C[9<_\ />3_ +Z-044<J[!S,G^V7/\ SWD_[Z-'VRY_Y[R?]]&H**.5
M=@YF3_;+G_GO)_WT:/MES_SWD_[Z-044<J[!S,G^V7/_ #WD_P"^C1]LN?\
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M.9D_VRY_Y[R?]]&C[9<_\]Y/^^C4%%'*NP<S)_MES_SWD_[Z-'VRY_Y[R?\
M?1J"BCE78.9D_P!LN?\ GO)_WT:/MES_ ,]Y/^^C4%%'*NP<S)_MES_SWD_[
MZ-'VRY_Y[R?]]&H**.5=@YF3_;+G_GO)_P!]&C[9<_\ />3_ +Z-044<J[!S
M,G^V7/\ SWD_[Z-'VRY_Y[R?]]&H**.5=@YF3_;+G_GO)_WT:/MES_SWD_[Z
M-044<J[!S,G^V7/_ #WD_P"^C1]LN?\ GO)_WT:@HHY5V#F9/]LN?^>\G_?1
MH^V7/_/>3_OHU!11RKL',R?[9<_\]Y/^^C1]LN?^>\G_ 'T:@HHY5V#F9/\
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MB*Q0_P )(SBI:X6K.QUIW5PHHHH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M S\Q/H*JVO@SP]9W*W$.F1B53D%W9P#]&)%;U%5[2?=BY([6"BBBH*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** -C1/NS_4?UHHT3[L_U']:*YI_$S>.Q<N?]?%_NM_,4RGW/^OB_W6_F
M*94E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %,3[\G^]_04^F)]^3_>_H* 'T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ,B^X?]YOYFGTR+[A_P!YOYFGT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,B^X?]YOYFGTR+[A_W
MF_F:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%'U2C_*@^LUOYCO_ /A;_B/<6\G3\D ?ZIO_ (KWI?\ A<'B3_GCIW_?EO\
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M9UBREN?L'B/[/%/.\QC^Q(^"Q]2:O:=X>-O?C4=0OY=0OE4JDDBA%C!Z[5'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^&MGJ=SXRM9=.<QK
M!\]PY!V^7T*GUST'OSVKE(();JXCMX(VDED8(B*.6)X KZ-\%^%XO"VA1VQ"
MM>2X>YD'.7] ?0=!^)[UQXVNJ=.W5G7@Z+J5.;HCHZ***^?/<"BBB@ HHHH
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M+_[97K5%'U[$?S?@O\@^I4/Y?Q9Y+_PI+_J8?_)+_P"V4?\ "DO^IA_\DO\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!]M_KY?]U?YFBBV_U\O^ZO\
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MWFBO!O\ A;GB?ULO^_/_ ->C_A;GB?ULO^_/_P!>C^SJWD'U^CYGO-%>#?\
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M45SFX4444 %%%% !1110 4444 %%%% #$^_)_O?T%/IB??D_WOZ"GT %%%%
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MO))T$,[,ODL!G+MUR#0OB^0/X?N)].B;PSX_@TK3[V2>TFP)(V;.,@]<<9&
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MA169X=LKO3?#UC9W\_GW4,(61_?TSWQTSWQ6G7R\E9V1]$G=7"BBBD,****
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M>N<]?>M&B@"O/8VUQ8-8RQ[K9D\LIN(ROIGK4<^DV%UIR6$]LDEJBA5C;)P
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M_P *9T/_ *"&H_\ ?2?_ !-']H4.X?4:QXE17MO_  IG0_\ H(:C_P!])_\
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M1110 4444 %%%% !1110 Q/OR?[W]!3Z8GWY/][^@I] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #!_KV_W1_,T^
MF#_7M_NC^9I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #[;_7R_[J_S-%%M_KY?]U?YFB@ N?\ 7Q?[K?S%,J::
M&22565U4!2.5SUQ[^U,^S2_\]4_[X/\ C0 RBG_9I?\ GJG_ 'P?\:/LTO\
MSU3_ +X/^- #**?]FE_YZI_WP?\ &C[-+_SU3_O@_P"- #**?]FE_P">J?\
M?!_QH^S2_P#/5/\ O@_XT ,HI_V:7_GJG_?!_P :/LTO_/5/^^#_ (T ,HI_
MV:7_ )ZI_P!\'_&C[-+_ ,]4_P"^#_C0 RBG_9I?^>J?]\'_ !H^S2_\]4_[
MX/\ C0 RBG_9I?\ GJG_ 'P?\:/LTO\ SU3_ +X/^- #**?]FE_YZI_WP?\
M&C[-+_SU3_O@_P"- #**?]FE_P">J?\ ?!_QH^S2_P#/5/\ O@_XT ,HI_V:
M7_GJG_?!_P :/LTO_/5/^^#_ (T ,HI_V:7_ )ZI_P!\'_&C[-+_ ,]4_P"^
M#_C0 RBG_9I?^>J?]\'_ !H^S2_\]4_[X/\ C0 RBG_9I?\ GJG_ 'P?\:/L
MTO\ SU3_ +X/^- #**?]FE_YZI_WP?\ &C[-+_SU3_O@_P"- #**?]FE_P">
MJ?\ ?!_QH^S2_P#/5/\ O@_XT ,HI_V:7_GJG_?!_P :/LTO_/5/^^#_ (T
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M#_C1]FE_YZI_WP?\: &44_[-+_SU3_O@_P"-'V:7_GJG_?!_QH 913_LTO\
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M/^- #**?]FE_YZI_WP?\:/LTO_/5/^^#_C0 RBG_ &:7_GJG_?!_QH^S2_\
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MV:7_ )ZI_P!\'_&@!E%/^S2_\]4_[X/^-'V:7_GJG_?!_P : &44_P"S2_\
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M#_C1]FE_YZI_WP?\: &44_[-+_SU3_O@_P"-'V:7_GJG_?!_QH 913_LTO\
MSU3_ +X/^-'V:7_GJG_?!_QH 913_LTO_/5/^^#_ (T?9I?^>J?]\'_&@!E%
M/^S2_P#/5/\ O@_XT?9I?^>J?]\'_&@ MO\ 7R_[J_S-%/AA>*1V9E;< !@8
MZ9_QHH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.9=RS15;[8O_ #RD_3_&C[8O_/*3]/\ &BS#F7<LT56^V+_SRD_3_&C[8O\
MSRD_3_&BS#F7<LT56^V+_P \I/T_QH^V+_SRD_3_ !HLPYEW+-%5OMB_\\I/
MT_QH^V+_ ,\I/T_QHLPYEW+-%5OMB_\ /*3]/\:/MB_\\I/T_P :+,.9=RS1
M5;[8O_/*3]/\:/MB_P#/*3]/\:+,.9=RS15;[8O_ #RD_3_&C[8O_/*3]/\
M&BS#F7<LT56^V+_SRD_3_&C[8O\ SRD_3_&BS#F7<LT56^V+_P \I/T_QH^V
M+_SRD_3_ !HLPYEW+-%5OMB_\\I/T_QH^V+_ ,\I/T_QHLPYEW+-%5OMB_\
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M.9=RS15;[8O_ #RD_3_&C[8O_/*3]/\ &BS#F7<LT56^V+_SRD_3_&C[8O\
MSRD_3_&BS#F7<LT5%#.)BP"LI7!^;'?Z?2BD,AN_]=%_NM_2H:FN_P#71?[K
M?TJ&M([&%3<****H@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** )K3_72_P"ZO]:*+3_72_[J
M_P!:*REN=$=@N_\ 71?[K?TJ&IKO_71?[K?TJ&KCL95-SR[Q6=6U'XFVNB66
MN7NG13VX.897VJ0'.=H89SBHM9M/%?@.&/5H_$4^JVHD59XKG=CGIPS-P?4$
M'I5S4O\ DN6E_P#7L?\ T"2M+XJWUO;^#9K5Y%$]Q(@C3/)PP)./3BO14FO9
MP2T>^GF<3BFYR?3_ ")/$6NZ=)8Z!>S7>KVR7LBM"-/D";B0#B3/4<_SK8UO
MQ5I^AW,-I)'=75[,-T=K:1>9(P]<?G^1KS[Q+:RV?ACP1;S*5D25-RGJ"=IQ
M^M=#XL\-ZE/XFM]9T#58+;5!%Y?D2L 749Y (.>.H([5#IPT3>EY?AL4IS:;
M6]D;FA^,-,UV]EL8TNK6^B&7M;N+RY /IDU2U[XC:#H%ZUG,T]Q<(<2);(&V
M'T)) S65X<\4ZLGBP:'X@TBWM]0N$+B>  %@%R-V"<\*>0>PXJG\+S$=6\1"
M["?VCY_SE_O;<MNZ]L]?PH=&,6Y-:)7WWUMOV#VC:23UO;;;2YW&C^)=*UW3
M'U"RN08(\^;Y@VF/ R=V>G'?I7.R_%?PS%??9@UVZ X-PD.8Q^N[]*I>(/[!
M7P-KL?A@VHD&W[4(/O8W\Y[X^][=<5=T#^Q/^%5Q[_L_V7[*WVC=C_68.[/^
MUGI^%3R4TG-IVO:WR_JQ7--M035^YL:QXRTO1M.LM0D$UQ9W;!8YK=591D9R
M<D>_Y5:U_P 16/AS2O[1O/,>(LJJL0!9B?3) Z<]:\[\,:-<:Y\(KZTD0L1,
M\EGGU4 \?5MP_$UG6>H2>-KKPIHC99;-2]X#WV''/U51_P!]5I]6CS-7V>OI
M:_\ P#/VTN52[K3UO;]3TK5_&FDZ'IEK>WYFC:YC$D5L%!E((SR,X'YXH\-^
M,]'\4%TL9)$G0;F@F7:X7.,\$@CZ'O7#^)?MP^+UH+860F$"_9?M^[RL[3_=
MYSG./>M6P\/:]+\0(-;O;O0TFA79<PV,C[F4J1DJPZ\CJ>PJ?8T^2[W:O_P"
MG4GS672Q>N_BEH%E-=PRQ7OG6TQA,8C4ER"02OS8P,=\=16OI'BVPUC6;K28
MX+J"[MT#LLZ*NY>.1@GU'7'6N1^'<$;>-O%4[(#)'.55O0%WS_(5+XN*^&?'
M^C^(\E;:YS;W1'3IC)_ @_\  :'2I\W(EJU^-KASSLY=$_PN=:WBBR'BI?#J
M17$EX8_,9T5?+08S\QSGT[=Q5CQ%+)!X;U.6*1HY$M9&5T."I"G!![5R'PZ@
M?5-3UKQ3.GS7<QB@)ZA >?\ V4?\!KK?$_\ R*NK?]>DO_H)K&K!0DHK?2_J
M;4I.3OTOH><>%_#GB+Q+H$>IKXTU.W+LRB(O(W0XZ^8/Y5J^!?%.HJNMV&LS
MM>'2E9Q,.695R&&3C/3@GUK#\&^#]6UGPS%=6OBN]T^!V=?LT0<J,$@]' Y^
ME=C:^$;'PIX2UE+9Y)IY[60RSR=6PAP .PY/YUUXB<%S1;OV5MOF<N'A*7*T
MO5W$L/B;H6I7MC:6T5\T]V^P)Y2_NSG'S?-^/&>*L:_\0]!\/79M+AYKBY7[
M\=L@8I]22!^&<UG_  FMXXO!GFHH$DMPY=NYQ@#^59GPP^S_ -L^(/MFS^UO
MM!W;_O;<MNQ^/7\*SE2IJ4M':/XEQJ3<$[[G<:#XDTSQ):-<:=/O"$"2-AM=
M#[C^O2L2Z^)WANUU?^SWFG;#;'N$CS$I]SG/X@$5R^G8_P"%A^*/[%V_9OL,
MF?*^YYFU>F/]K/ZUI?"S^S/^$,O/-\G=YK_:_,Q]W QG/;&?UI.C"*<VG:R=
MO4?M)-J'6[5_0Z2Q\:Z9J-AJUY!'<F'3,^:2J_/C/*8;GIWQ5+3?B3HFK:C9
M6%I%>M/=Y !C7$9Y^]\WH,\9KBO!WE?\(7XS\G_5;&V?[NUL?I77_#".&V\
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MXSD'!&3TXQD_2I5"#32U>O6VW8IU9*TGHM#TNBBBN,Z HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS1'C<AR/I18">BJ.GZQ8:I)<1V<_FO;MLE&QEVGGU ST/2KU !1110 4444
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MH_F:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&#_7M_NC^9I],'^O;_='\S3Z "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** 'VW^OE_W5_F:*+;_7R_[J_S-% !<_Z^
M+_=;^8IE/N?]?%_NM_,4R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F)]^3_
M 'OZ"GTQ/OR?[W]!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"G<V45_9O!*."S%6'53D\UR%[HU[9
M.=T32)V=!D?_ %J[B+[A_P!YOYFGUO1Q$J6BV.3$X.%?5Z/N>:D$'!&#[TE>
MET5T_7O[OX_\ XO[)_O_ (?\$\THKTNBCZ__ '?Q_P" ']D_W_P_X)YI17I=
M%'U_^[^/_ #^R?[_ .'_  3S2BO2Z*/K_P#=_'_@!_9/]_\ #_@GFE%>ET4?
M7_[OX_\  #^R?[_X?\$\THKTNBCZ_P#W?Q_X ?V3_?\ P_X)YI17I=%'U_\
MN_C_ , /[)_O_A_P3S2@ D@ 9)KTNBCZ]_=_'_@!_9/]_P##_@F9HFF#3[3+
MC]_)R_M[5IT45PSDYR<F>K3IQIQ4([(****DL**** "BBB@!D7W#_O-_,T^F
M1?</^\W\S3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** &)]^3_>_H*?3$^_)_O?T%/H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8/\ 7M_NC^9I],'^
MO;_='\S3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** 'VW^OE_P!U?YFBBV_U\O\ NK_,T4 %S_KXO]UOYBF4^Y_U
M\7^ZW\Q3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8GWY/][^@I],3[\G^]
M_04 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 9%]P_[S?S-/ID7W#_O-_,T^@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!D7W#_ +S?S-/I
MD7W#_O-_,T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!B??D_WOZ"GTQ/OR?[W]!3Z "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &#_7M_NC^9I],'^O
M;_='\S3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** 'VW^OE_W5_F:*+;_7R_[J_S-% !<_Z^+_=;^8IE/N?]?%_N
MM_,4R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "F)]^3_ 'OZ"GTQ/OR?[W]!
M0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!D7W#_O-_,T^F1D!"2<#<W\S6+>^)[>!REO&9R.K9PO\
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MHH **** "BBB@ HHHH **** "BBB@!@_U[?[H_F:?3!_KV_W1_,T^@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!]
MM_KY?]U?YFBBV_U\O^ZO\S10 7/^OB_W6_F*93[G_7Q?[K?S%,H \Y\7^)];
MTSQ(]I876R%8E?9Y2-VR>2,]JZ37]>>U\)IJ%B^)[D1BW. ?F;'8^V:YS5K5
M;WXHQVSC*26Q4_0QL*S]&NI-4NM"T&4-FPN)'FST^4Y7\N10M8V_KS!NSN=#
MX&\0:AJEOJ4NJW/FBWVD'RU7:,-G[H&>E=/IVKV.K6;7=E/YL"L5+;&7! R>
M" >]<)X%4+I_B-1T Q^CUH_#QU'A"[)8 +-(3[?**<NK[),$M4O-G36&NZ;J
M=G+>6MTKV\)(DD92@7 SSN [52C\:>'9+@0+J<>\G&61@O\ WT1C]:Y#PIID
MNL> ]4L8) DLEQ\I;H2 IP?KBB34[_2].M]/\2>&UGLK<@)*@P!C@'(RI/XC
M--I)V]!+:YZ-=WMK8VQN;J>.&$=7=L"L_3O%&BZM/Y%E?I)+V1E9"?IN S^%
M<AXLN+?4K[PS"@QIEP58+C:,$J,>V!Q^-=-/X8T!=3L[CR8K:>+F*.)A&'((
MYP,$D?UYI)=POV*MEK%_+\0K[2WGS910[DCV+P<+WQGN>]:=_P"*-%TRZ^RW
M=_''-W0*S;?K@''XUS-JS)\3]7=!EEM"1]=J5A>%H)[VRO9?^$;CU=Y9"'GE
MN41D)&< ,,@\YR/Z4EJEZ#>[_KH>K03Q7,"302)+$XRKH<@CZUR_CS6=0T;3
M[273[CR9))MK'8K9&/<&G>!=,U32=-N+74H#"OF[X09%?@CGH3Z?K6?\3O\
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M?R+.N^+R]YH_]B:BC03S%)@$!)Y7@AAD=3Z5U6IZWINC(KZA=I"&^Z""6/T
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M6YR!1110 4444 %%%% !1110 4444 %%%% !1110!L^']4^QW/D2M^XE/?\
MA;UKLJ\TKT#3%N$TV!;DYE"\^H';/OBO-QM-)J:ZGMY96E).F]D6Z***X3U@
MHHHH **** &1?</^\W\S3Z9%]P_[S?S-/H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8GWY/][^@I],3[\G^]_04
M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!@_P!>W^Z/YFGTP?Z]O]T?S-/H **** "BBB@ HHHH **** "BBB@
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MB@ HHHH **** "F)]^3_ 'OZ"GTQ/OR?[W]!0 ^BBB@ HHHH **** "BBB@
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M]_Y"_P#LJ/\ A$O^G[_R%_\ 94?6J/?\P_L_$?R_BO\ ,YFBNF_X1+_I^_\
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M>3/_ '8_^^S_ (4>3/\ W8_^^S_A0 VBG>3/_=C_ .^S_A1Y,_\ =C_[[/\
MA0 VBG>3/_=C_P"^S_A1Y,_]V/\ [[/^% #:*=Y,_P#=C_[[/^%'DS_W8_\
MOL_X4 -HIWDS_P!V/_OL_P"%'DS_ -V/_OL_X4 -HIWDS_W8_P#OL_X4>3/_
M '8_^^S_ (4 -HIWDS_W8_\ OL_X4>3/_=C_ .^S_A0 VBG>3/\ W8_^^S_A
M1Y,_]V/_ +[/^% #:*=Y,_\ =C_[[/\ A1Y,_P#=C_[[/^% #:8GWY/][^@J
M7R9_[L?_ 'V?\*:L$X9SMCY.?OGT'M0 44[R9_[L?_?9_P */)G_ +L?_?9_
MPH ;13O)G_NQ_P#?9_PH\F?^['_WV?\ "@!M%.\F?^['_P!]G_"CR9_[L?\
MWV?\* &T4[R9_P"['_WV?\*/)G_NQ_\ ?9_PH ;13O)G_NQ_]]G_  H\F?\
MNQ_]]G_"@!M%.\F?^['_ -]G_"CR9_[L?_?9_P * &T4[R9_[L?_ 'V?\*/)
MG_NQ_P#?9_PH ;13O)G_ +L?_?9_PH\F?^['_P!]G_"@!M%.\F?^['_WV?\
M"CR9_P"['_WV?\* &T4[R9_[L?\ WV?\*/)G_NQ_]]G_  H ;13O)G_NQ_\
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MZJ1MCZD\N?7Z4[R9_P"['_WV?\* &T4[R9_[L?\ WV?\*/)G_NQ_]]G_  H
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MT4[R9_[L?_?9_P */)G_ +L?_?9_PH ;13O)G_NQ_P#?9_PH\F?^['_WV?\
M"@!;;_7R_P"ZO\S13K>.1)7+A1D #!SZT4 6**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BJ6H:B-/",T6]7X&&P<U0_X22/_GV?_OH4 ;E%8?\ PDD?
M_/L__?0H_P"$DC_Y]G_[Z% &Y16'_P ))'_S[/\ ]]"C_A)(_P#GV?\ [Z%
M&Y16'_PDD?\ S[/_ -]"C_A)(_\ GV?_ +Z% &Y16'_PDD?_ #[/_P!]"C_A
M)(_^?9_^^A0!N45A_P#"21_\^S_]]"C_ (22/_GV?_OH4 ;E%8?_  DD?_/L
M_P#WT*/^$DC_ .?9_P#OH4 ;E%8?_"21_P#/L_\ WT*/^$DC_P"?9_\ OH4
M;E%8?_"21_\ /L__ 'T*/^$DC_Y]G_[Z% &Y16'_ ,))'_S[/_WT*/\ A)(_
M^?9_^^A0!N45A_\ "21_\^S_ /?0H_X22/\ Y]G_ .^A0!N45A_\))'_ ,^S
M_P#?0H_X22/_ )]G_P"^A0!N45A_\))'_P ^S_\ ?0H_X22/_GV?_OH4 ;E%
M8?\ PDD?_/L__?0H_P"$DC_Y]G_[Z% &Y16'_P ))'_S[/\ ]]"C_A)(_P#G
MV?\ [Z% &Y16'_PDD?\ S[/_ -]"C_A)(_\ GV?_ +Z% &Y16'_PDD?_ #[/
M_P!]"C_A)(_^?9_^^A0!N45A_P#"21_\^S_]]"C_ (22/_GV?_OH4 ;E%8?_
M  DD?_/L_P#WT*/^$DC_ .?9_P#OH4 ;E%8?_"21_P#/L_\ WT*/^$DC_P"?
M9_\ OH4 ;E%8?_"21_\ /L__ 'T*/^$DC_Y]G_[Z% &Y16'_ ,))'_S[/_WT
M*/\ A)(_^?9_^^A0!N45A_\ "21_\^S_ /?0H_X22/\ Y]G_ .^A0!N45A_\
M))'_ ,^S_P#?0H_X22/_ )]G_P"^A0!N45A_\))'_P ^S_\ ?0H_X22/_GV?
M_OH4 ;E%8?\ PDD?_/L__?0H_P"$DC_Y]G_[Z% &Y16'_P ))'_S[/\ ]]"C
M_A)(_P#GV?\ [Z% &Y16'_PDD?\ S[/_ -]"C_A)(_\ GV?_ +Z% &Y16'_P
MDD?_ #[/_P!]"C_A)(_^?9_^^A0!N45A_P#"21_\^S_]]"C_ (22/_GV?_OH
M4 ;E%8?_  DD?_/L_P#WT*/^$DC_ .?9_P#OH4 ;E%8?_"21_P#/L_\ WT*/
M^$DC_P"?9_\ OH4 ;E%8?_"21_\ /L__ 'T*/^$DC_Y]G_[Z% &Y16'_ ,))
M'_S[/_WT*/\ A)(_^?9_^^A0!N45A_\ "21_\^S_ /?0H_X22/\ Y]G_ .^A
M0!N45A_\))'_ ,^S_P#?0H_X22/_ )]G_P"^A0!N45A_\))'_P ^S_\ ?0H_
MX22/_GV?_OH4 ;E%8?\ PDD?_/L__?0H_P"$DC_Y]G_[Z% &Y16'_P ))'_S
M[/\ ]]"C_A)(_P#GV?\ [Z% &Y16'_PDD?\ S[/_ -]"C_A)(_\ GV?_ +Z%
M &Y16'_PDD?_ #[/_P!]"C_A)(_^?9_^^A0!N45A_P#"21_\^S_]]"C_ (22
M/_GV?_OH4 ;E%8?_  DD?_/L_P#WT*/^$DC_ .?9_P#OH4 ;E%8?_"21_P#/
ML_\ WT*/^$DC_P"?9_\ OH4 ;E%8?_"21_\ /L__ 'T*/^$DC_Y]G_[Z% &Y
M16'_ ,))'_S[/_WT*/\ A)(_^?9_^^A0!N45A_\ "21_\^S_ /?0H_X22/\
MY]G_ .^A0!N45A_\))'_ ,^S_P#?0H_X22/_ )]G_P"^A0!N45A_\))'_P ^
MS_\ ?0H_X22/_GV?_OH4 ;E%8?\ PDD?_/L__?0H_P"$DC_Y]G_[Z% &Y16'
M_P ))'_S[/\ ]]"C_A)(_P#GV?\ [Z% &Y16'_PDD?\ S[/_ -]"C_A)(_\
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MDC_Y]G_[Z% &Y16'_P ))'_S[/\ ]]"C_A)(_P#GV?\ [Z% &Y16'_PDD?\
MS[/_ -]"C_A)(_\ GV?_ +Z% &Y16'_PDD?_ #[/_P!]"C_A)(_^?9_^^A0!
MN45A_P#"21_\^S_]]"C_ (22/_GV?_OH4 ;E%8?_  DD?_/L_P#WT*/^$DC_
M .?9_P#OH4 ;E%8?_"21_P#/L_\ WT*/^$DC_P"?9_\ OH4 ;E%8?_"21_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ 9ZX)]^N.F,4U>_=W_ -+:Z*WXFQXGD67XL>$9$(9'C9E([@YIT7_)>)O\
ML'_T%1>(8%M?BCX-MU)*Q0E 3W R*EB_Y+Q-_P!@_P#H*(VTMWE^HG?6_:/Y
MHT]1_P"$ROM2OF34;?P[IEOQ;RR113FXZ\MECM''MUK#TCQ9>>*/AMXE&H>4
MUU:6\D9EB&!("AP<>O!Z5B6$VGKXNUC_ (3FUN[S45D/V"W>)Y5=<MPB 8Z
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M''!(S@<#.>>G%3#=>NO]>A4MOEIZ_P##FAK'BCQ2GQ+N?#^CR02H\*^3'<(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Z'PW_J9
M_P#>%%'AO_4S_P"\**0P\2?ZF#_>-<]70^)/]3!_O&N>IB"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6** *_V&T_Y]8/\ OV*/L-I_SZP?]^Q5BB@"O]AM/^?6#_OV*/L-I_SZP?\
M?L58HH K_8;3_GU@_P"_8H^PVG_/K!_W[%6** *_V&T_Y]8/^_8H^PVG_/K!
M_P!^Q5BB@"O]AM/^?6#_ +]BC[#:?\^L'_?L58HH K_8;3_GU@_[]BC[#:?\
M^L'_ '[%6** *_V&T_Y]8/\ OV*/L-I_SZP?]^Q5BB@"I'9VI>4&VA(#X&8Q
MP-HI_P!AM/\ GU@_[]BGQ?ZR?_?'_H(J6@"O]AM/^?6#_OV*/L-I_P ^L'_?
ML58HH K_ &&T_P"?6#_OV*/L-I_SZP?]^Q5BB@"O]AM/^?6#_OV*/L-I_P ^
ML'_?L58HH K_ &&T_P"?6#_OV*/L-I_SZP?]^Q5BB@"O]AM/^?6#_OV*/L-I
M_P ^L'_?L58HH K_ &&T_P"?6#_OV*/L-I_SZP?]^Q5BB@"O]AM/^?6#_OV*
M/L-I_P ^L'_?L58HH K_ &&T_P"?6#_OV*/L-I_SZP?]^Q5BB@"O]AM/^?6#
M_OV*/L-I_P ^L'_?L58HH K_ &&T_P"?6#_OV*/L-I_SZP?]^Q5BB@"O]AM/
M^?6#_OV*/L-I_P ^L'_?L58HH K_ &&T_P"?6#_OV*/L-I_SZP?]^Q5BB@"H
M+.U^T.OV:':$4@>6,9R?\*?]AM/^?6#_ +]BGK_Q]2?[B_S:I: *_P!AM/\
MGU@_[]BC[#:?\^L'_?L58HH K_8;3_GU@_[]BC[#:?\ /K!_W[%6** *_P!A
MM/\ GU@_[]BC[#:?\^L'_?L58HH K_8;3_GU@_[]BC[#:?\ /K!_W[%6** *
M_P!AM/\ GU@_[]BC[#:?\^L'_?L58HH K_8;3_GU@_[]BC[#:?\ /K!_W[%6
M** *_P!AM/\ GU@_[]BC[#:?\^L'_?L58HH K_8;3_GU@_[]BC[#:?\ /K!_
MW[%6** *_P!AM/\ GU@_[]BC[#:?\^L'_?L58HH K_8;3_GU@_[]BC[#:?\
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M'K\S=CUX^G2NHH:&%%%%( HHHH **** "HHO]9/_ +X_]!%2U%%_K)_]\?\
MH(H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH B@_P!6?]]__0C4M10?ZL_[[_\ H1ID]]! =K/EO[J\
MF@"Q16?_ &O#_P \Y/TI/[7A_P">;_I0!HT5G?VQ%_SR?]*/[8C_ .>3_F*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW,=S!<F*%.&=BJX!SP,'.2>F#5^&_3Q'=SZ5>VDVFZC:KO:-BKY1AC<K#@T
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M%% $2_\ 'U)_N+_-JEJ)?^/J3_<7^;5+0 4444 %%%% !1110 4444 %%%%
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MD_\ OC_T$5+447^LG_WQ_P"@BI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (E_X^I/]Q?YM4M1+_P ?4G^XO\VJ
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@")?^/J3_<7^;44+_Q]2?[B_P VHH &_P"/J/\ W&_FM2TQHE=@QW9
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M_?QO\:/)7U?_ +^-_C0 D'^K/^^__H1J6HQ @&!O'?AV_P :/)7U?_OXW^-
M$E%1^2OJ_P#W\;_&CR5]7_[^-_C0!)14?DKZO_W\;_&CR5]7_P"_C?XT 245
M'Y*^K_\ ?QO\:/)7U?\ [^-_C0!)14?DKZO_ -_&_P :/)7U?_OXW^- $E%1
M^2OJ_P#W\;_&CR5]7_[^-_C0!)14?DKZO_W\;_&CR5]7_P"_C?XT 245'Y*^
MK_\ ?QO\:/)7U?\ [^-_C0!)14?DKZO_ -_&_P :/)7U?_OXW^- $E%1^2OJ
M_P#W\;_&CR5]7_[^-_C0!)14?DKZO_W\;_&CR5]7_P"_C?XT 245'Y*^K_\
M?QO\:/)7U?\ [^-_C0!)14?DKZO_ -_&_P :/)7U?_OXW^- "0?ZL_[[_P#H
M1J6HQ @&!O'?AV_QH\E?5_\ OXW^- $E%1^2OJ__ '\;_&CR5]7_ ._C?XT
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J_P!_&_QH\E?5_P#OXW^- "+_ ,?4G^XO\VHIR1JA)&<G@DDG^=% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img44875045_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #/!),# 2(  A$! Q$!_\0
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MB^&?^?Y_^_#_ .%'_"Q?#/\ S_/_ -^'_P *\0HHL%SV_P#X6+X9_P"?Y_\
MOP_^%'_"Q?#/_/\ /_WX?_"O$**+!<]O_P"%B^&?^?Y_^_#_ .%'_"Q?#/\
MS_/_ -^'_P *\0HHL%SV_P#X6+X9_P"?Y_\ OP_^%'_"Q?#/_/\ /_WX?_"O
M$**+!<]O_P"%B^&?^?Y_^_#_ .%'_"Q?#/\ S_/_ -^'_P *\0HHL%SV_P#X
M6+X9_P"?Y_\ OP_^%'_"Q?#/_/\ /_WX?_"O$**+!<]P/Q#\-J%)O7PPR/W#
M].GI[4G_  L7PS_S_/\ ]^'_ ,*\5F_U<'_7/_V9JBHL%SV__A8OAG_G^?\
M[\/_ (4?\+%\,_\ /\__ 'X?_"O$**+!<]O_ .%B^&?^?Y_^_#_X4?\ "Q?#
M/_/\_P#WX?\ PKQ"BBP7/;_^%B^&?^?Y_P#OP_\ A1_PL7PS_P _S_\ ?A_\
M*\0HHL%SV_\ X6+X9_Y_G_[\/_A1_P +%\,_\_S_ /?A_P#"O$**+!<]O_X6
M+X9_Y_G_ ._#_P"%'_"Q?#/_ #_/_P!^'_PKQ"BBP7/;_P#A8OAG_G^?_OP_
M^%'_  L7PS_S_/\ ]^'_ ,*\0HHL%SV__A8OAG_G^?\ [\/_ (4?\+%\,_\
M/\__ 'X?_"O$**+!<]O_ .%B^&?^?Y_^_#_X4?\ "Q?#/_/\_P#WX?\ PKQ"
MBBP7/;_^%B^&?^?Y_P#OP_\ A1_PL7PS_P _S_\ ?A_\*\0HHL%SW!OB'X;1
MBC7KA@<$>0_^%)_PL7PS_P _S_\ ?A_\*\5NO^/N;_?/\ZBHL%SV_P#X6+X9
M_P"?Y_\ OP_^%'_"Q?#/_/\ /_WX?_"O$**+!<]O_P"%B^&?^?Y_^_#_ .%'
M_"Q?#/\ S_/_ -^'_P *\0HHL%SV_P#X6+X9_P"?Y_\ OP_^%'_"Q?#/_/\
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M;_\ A8OAG_G^?_OP_P#A1_PL7PS_ ,_S_P#?A_\ "O$**+!<]O\ ^%B^&?\
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MC+R"W&" >XH Y>BBBF(**** "BBB@ J6U_X^X?\ ?'\ZBJ6U_P"/N'_?'\Z
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M>Q BD%NKD3H  /N]#@#D].>#0!1M_ RP:QJL6J73KI^FQB626%</(""5V@Y
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M9;IV$>[ML1N0>O6LG2)X[76K&XF;;%%<1N[8)PH8$GB@#9\?_P#([ZE]8_\
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MJ1GSGK'_ "&[_P#Z^9/_ $(U2KZ&?PYHLCL[Z59L[')8PJ23ZTW_ (1G0_\
MH$67_?A?\*=Q6/GNBOH3_A&=#_Z!%E_WX7_"C_A&=#_Z!%E_WX7_  HN%CY[
MHKZ$_P"$9T/_ *!%E_WX7_"C_A&=#_Z!%E_WX7_"BX6/GNBOH3_A&=#_ .@1
M9?\ ?A?\*/\ A&=#_P"@19?]^%_PHN%CY[HKZ$_X1G0_^@19?]^%_P */^$9
MT/\ Z!%E_P!^%_PHN%CY[HKZ$_X1G0_^@19?]^%_PH_X1G0_^@19?]^%_P *
M+A8^>Z*^A/\ A&=#_P"@19?]^%_PH_X1G0_^@19?]^%_PHN%CY[HKZ$_X1G0
M_P#H$67_ 'X7_"C_ (1G0_\ H$67_?A?\*+A8^>Z*^A/^$9T/_H$67_?A?\
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M *!%E_WX7_"C_A&=#_Z!%E_WX7_"BX6/GNBOH3_A&=#_ .@19?\ ?A?\*/\
MA&=#_P"@19?]^%_PHN%CY[HKZ$_X1G0_^@19?]^%_P */^$9T/\ Z!%E_P!^
M%_PHN%CY[HKZ$_X1G0_^@19?]^%_PH_X1G0_^@19?]^%_P *+A8^>Z*^A/\
MA&=#_P"@19?]^%_PH_X1G0_^@19?]^%_PHN%CY[HKZ$_X1G0_P#H$67_ 'X7
M_"C_ (1G0_\ H$67_?A?\*+A8^>Z*^A/^$9T/_H$67_?A?\ "C_A&=#_ .@1
M9?\ ?A?\*+A8^>Z*^A/^$9T/_H$67_?A?\*/^$9T/_H$67_?A?\ "BX6/GNB
MOH3_ (1G0_\ H$67_?A?\*/^$9T/_H$67_?A?\*+A8^>Z*^A/^$9T/\ Z!%E
M_P!^%_PH_P"$9T/_ *!%E_WX7_"BX6/GNBOH3_A&=#_Z!%E_WX7_  H_X1G0
M_P#H$67_ 'X7_"BX6/GNBOH3_A&=#_Z!%E_WX7_"C_A&=#_Z!%E_WX7_  HN
M%CY[HKZ$_P"$9T/_ *!%E_WX7_"C_A&=#_Z!%E_WX7_"BX6/GNBOH3_A&=#_
M .@19?\ ?A?\*/\ A&=#_P"@19?]^%_PHN%CY[HKZ$_X1G0_^@19?]^%_P *
M/^$9T/\ Z!%E_P!^%_PHN%CY[HKZ$_X1G0_^@19?]^%_PH_X1G0_^@19?]^%
M_P *+A8\!'_'FW_70?R-0U]"_P#"-:'C']DV>/3R5Q2?\(SH?_0(LO\ OPO^
M%%PL?/=%?0G_  C.A_\ 0(LO^_"_X4?\(SH?_0(LO^_"_P"%%PL?/=%?0G_"
M,Z'_ - BR_[\+_A1_P (SH?_ $"++_OPO^%%PL?/=%?0G_",Z'_T"++_ +\+
M_A1_PC.A_P#0(LO^_"_X47"Q\]T5]"?\(SH?_0(LO^_"_P"%'_",Z'_T"++_
M +\+_A1<+'SW17T)_P (SH?_ $"++_OPO^%'_",Z'_T"++_OPO\ A1<+'SW1
M7T)_PC.A_P#0(LO^_"_X4?\ ",Z'_P! BR_[\+_A1<+'SW17T)_PC.A_] BR
M_P"_"_X4?\(SH?\ T"++_OPO^%%PL?/=%?0G_",Z'_T"++_OPO\ A1_PC.A_
M] BR_P"_"_X47"Q\]T5]"?\ ",Z'_P! BR_[\+_A1_PC.A_] BR_[\+_ (47
M"QX!-_JX/^N?_LS5%7T+_P (UH?'_$IL^.G[E>*3_A&=#_Z!%E_WX7_"BX6/
MGNBOH3_A&=#_ .@19?\ ?A?\*/\ A&=#_P"@19?]^%_PHN%CY[HKZ$_X1G0_
M^@19?]^%_P */^$9T/\ Z!%E_P!^%_PHN%CY[HKZ$_X1G0_^@19?]^%_PH_X
M1G0_^@19?]^%_P *+A8^>Z*^A/\ A&=#_P"@19?]^%_PH_X1G0_^@19?]^%_
MPHN%CY[HKZ$_X1G0_P#H$67_ 'X7_"C_ (1G0_\ H$67_?A?\*+A8^>Z*^A/
M^$9T/_H$67_?A?\ "C_A&=#_ .@19?\ ?A?\*+A8^>Z*^A/^$9T/_H$67_?A
M?\*/^$9T/_H$67_?A?\ "BX6/GNBOH3_ (1G0_\ H$67_?A?\*/^$9T/_H$6
M7_?A?\*+A8^>Z*^A/^$9T/\ Z!%E_P!^%_PH_P"$9T/_ *!%E_WX7_"BX6/
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M*K_;K7_GNGYT?;K7_GNGYT687+%%5_MUK_SW3\Z/MUK_ ,]T_.BS"Y8HJO\
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M_P#/=/SH^W6O_/=/SHLPN6**K_;K7_GNGYT?;K7_ )[I^=%F%RQ15?[=:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "K6G?\?\7U_I56K6G?\?\
M%]?Z5,MF..YTE%%%<QT'+7/_ !\R_P"^?YUQ'C*"[LM7TOQ#:VSW,=EN$\:#
MD+CK],$\]N*[>Y_X^9?]\_SJ*NVE/D:9R5(<RL<79^.Y-;UBTL]%TR:6(M_I
M+SC;L7URI('X]>@'-8LW_'QX[_W5_F:].HK55HQ?NQ_J]S)TI2^*7]6L>9J
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MW6II?:=K]S8D+M:(IYL9]PA( /YU/H&@KH<%QNN7NKJYE,L\[J%WL?0#H/\
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M*/[-A_O2?F/\*N44<\NX<J*?]FP_WI/S'^%']FP_WI/S'^%7**.>7<.5%/\
MLV'^])^8_P */[-A_O2?F/\ "KE%'/+N'*BG_9L/]Z3\Q_A1_9L/]Z3\Q_A5
MRBCGEW#E13_LV'^])^8_PH_LV'^])^8_PJY11SR[ARHI_P!FP_WI/S'^%']F
MP_WI/S'^%7**.>7<.5%/^S8?[TGYC_"C^S8?[TGYC_"KE%'/+N'*BG_9L/\
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M_"KE%'/+N'*BG_9L/]Z3\Q_A1_9L/]Z3\Q_A5RBCGEW#E13_ +-A_O2?F/\
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MSH,@YJ/3]1D%OJ_BR40B3RO)%K'G*,O9R0.<X_"F([>F2R)#$\LAPB*68XZ
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MZ7$H_P#9J3_A67@__H$?^3,W_P 77H?VG2[/\/\ ,X?[/J]U_7R/GBBOH?\
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M;_XNC^TZ79_A_F']GU>Z_KY'SQ17T/\ \*R\'_\ 0(_\F9O_ (NC_A67@_\
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M'_DS-_\ %T?VG2[/\/\ ,/[/J]U_7R/GBBOH?_A67@__ *!'_DS-_P#%T?\
M"LO!_P#T"/\ R9F_^+H_M.EV?X?YA_9]7NOZ^1\\45]#_P#"LO!__0(_\F9O
M_BZ/^%9>#_\ H$?^3,W_ ,71_:=+L_P_S#^SZO=?U\CYXHKZ'_X5EX/_ .@1
M_P"3,W_Q='_"LO!__0(_\F9O_BZ/[3I=G^'^8?V?5[K^OD?/%%?0_P#PK+P?
M_P! C_R9F_\ BZ/^%9>#_P#H$?\ DS-_\71_:=+L_P /\P_L^KW7]?(^>**^
MA_\ A67@_P#Z!'_DS-_\72-\,_" 4G^R.W_/S+_\71_:=+L_P_S#^SZO=?U\
MCYYHKZ''PR\(8'_$H_\ )F7_ .+H_P"%9>#_ /H$?^3,W_Q=']ITNS_#_,/[
M/J]U_7R/GBBOH?\ X5EX/_Z!'_DS-_\ %T?\*R\'_P#0(_\ )F;_ .+H_M.E
MV?X?YA_9]7NOZ^1\\45]#_\ "LO!_P#T"/\ R9F_^+H_X5EX/_Z!'_DS-_\
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M4%G=17UE#=P',4R!U)ZX(SS[U/2 **** "BBB@ HHHH **** "BBB@ HHHH
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MTO\ \#(_\:/^$J\._P#0>TO_ ,#(_P#&OF&BC^S(?S,/[1E_*?3W_"5>'?\
MH/:7_P"!D?\ C1_PE7AW_H/:7_X&1_XU\PT4?V9#^9A_:,OY3Z>_X2KP[_T'
MM+_\#(_\:/\ A*O#O_0>TO\ \#(_\:^8:*/[,A_,P_M&7\I]/?\ "5>'?^@]
MI?\ X&1_XT?\)5X=_P"@]I?_ (&1_P"-?,-%']F0_F8?VC+^4^GO^$J\._\
M0>TO_P #(_\ &C_A*O#O_0>TO_P,C_QKYAHH_LR'\S#^T9?RGTX/%/A[S"?[
M>TOH/^7R/W]Z=_PE7AW_ *#VE_\ @9'_ (U\PT4?V9#^9A_:,OY3Z>_X2KP[
M_P!![2__  ,C_P :/^$J\._]![2__ R/_&OF&BC^S(?S,/[1E_*?3W_"5>'?
M^@]I?_@9'_C1_P )5X=_Z#VE_P#@9'_C7S#11_9D/YF']HR_E/I[_A*O#O\
MT'M+_P# R/\ QH_X2KP[_P!![2__  ,C_P :^8:*/[,A_,P_M&7\I]/?\)5X
M=_Z#VE_^!D?^-'_"5>'?^@]I?_@9'_C7S#11_9D/YF']HR_E/K*.1)8UDC=7
M1AE64Y!'J#3J\H^%'B_>@\/7TGS+DVC,>H[I_45ZO7F5Z+HS<&>C1JJK!204
M445B:A1110 4444 %%%% #4Z'ZG^=.IJ=#]3_.G4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4C?</TI:1ON'Z4  Z"EI!T%+0 4444 %%%%
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MFV$EV+M[*V:Y!!$S1*7!'3YL9IW X*W$FE^(_#DVM-Y42V&Q'FX$;@'@D]"
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M =/KTKULNK1BG3>C/,Q]*3:FCC:*5E*DA@01U!I*]8\L**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +ND07MS
MJ]I#IV[[8T@\HJ>0WK7U%;+,MK$MPZO.$ D91@,V.2!V&:\]^%OA#^S+'^V[
MV/%W<K^Y5AS'&>_U/\J]'KPL?752?+'H>U@J+A#F?4****X#M"BBB@ HHHH
M**** &IT/U/\Z=34Z'ZG^=.H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I&^X?I2TC?</TH !T%+2#H*6@ HHHH **** "BBB@ HHHH ****
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M['YF@".BI/(D_P!C\S1Y$G^Q^9H A'^L;Z#^M.IWV>7<3E.1ZFG>1)_L?F:
M(Z*D\B3_ &/S-'D2?['YF@".BI/(D_V/S-'D2?['YF@".BI/(D_V/S-'D2?[
M'YF@".BI/(D_V/S-'D2?['YF@".BI/(D_P!C\S1Y$G^Q^9H CHJ3R)/]C\S1
MY$G^Q^9H CHJ3R)/]C\S1Y$G^Q^9H CHJ3R)/]C\S1Y$G^Q^9H CHJ3R)/\
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L4GD2?['YFCR)/]C\S0!'2K_K$_WJ?Y$G^Q^9H6"0.I)7 .>#0!9HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img44875045_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=R96<@5&]U
M<F%N9V5A=0  !9 #  (    4   0J) $  (    4   0O)*1  (    #,C4
M )*2  (    #,C4  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 'V S8# 2(  A$! Q$!_\0
M'  !  $% 0$               <! @,%!@0(_\0 51   0,# @,$!P4$!0D%
M!0D! 0 " P0%$08'$B$Q$T%1D106(C)287$50E-5@1<C-W((,Y*AL20T-D-4
M8H+!T24F-41S=(.R\/$G*#A6=9.5HM+A_\0 &P$!  ,! 0$!
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M1.DF<_HUC02XG/=@%!JK7JVUWO1GK/;:CM;>:=\_$?9+0P$N:X=Q!!!^BP:
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MFJB]LM/P?>EP[Z<+EZ"<<T%41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MUS8:J,PPAWM.(ZA?03@2,#JJ@85%]%AM;?B]#%^H];CQSCF=_P"Y1LW9NU<
MXW9=CG@*[]CMJ^-22!X<E1S>\*STN+;;BQ?O6O[SDES&E]#T.FG/?3'+W=2N
MI:,!4;DJY7TI6D;5>=FS9,]^>2=Y:V\WF@L%IGNMWJ6TM%2MXIIG-)#1G'0
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MD%;3O@JXFRQ/&',<,AP^86@U'!INQZ4+;Q34T5JIQGLW,'"/H$$4BKV2^['
M>F#@K;Z:J=IW:CI6V)L7V@7XBP#R=@K4NW VR<[,.DFR,[G-HVX/SZ+;:8UG
MH2NU)24UJTP:6KD=^[F]&#>$_7""96^Z/HJH.8"HXX_ZH*HM-?-46K3D;7W>
MMBIP>@<>9_18[%K"R:EXA9KA%4.;U:#S'Z(-ZBU=YU#;=/TPJ+O5QT\?0<1Y
ME8+'JVRZE:\V6OCJ2SWFM/,?H@W:A&U_Q]KOYE-H/C_]5"5K_C]6_5!-R(B
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M[EPNR=K;9]2:OMT<KIA3UP9VCC[3O8:<GS4QEI Z]W-13M6 -?:YQT^T0/\
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M<6M,3WMRYA/3HNFO]EI]06.JME5RBJHRPD=V5\^ZTVGU;8M-PT=!>I*^WLF
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M@"]*(*<(Y?)0E;.>_M;R^\IN4(VO^/M=_,@FY$1 1$0$1$!$1 1$0$1$!$1
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MJ'1VX6BY(9)9JVK!DJJB20N=(\_,]RZ#4-'-H;>JSW"W5DOH]]>Z.JIBXD9
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M9I.AGCBJ+S$U\@!Y#( /BB77HM5-J&UT]D^UY*Z/T #B-0#EN%I/VIZ+X?\
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MZ*_6T=:OHEO()D+Q6NM97V^.H800]H/(KV8ZKU(F)C=\E:LTF:SWA>J8541
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M)GJT=PUC:+94F"IJ&MD'49Z+S'<"Q?[6WS7+ZGVK-\O$E9%4N:']V5I_V+2
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MZ@;C_GP3U W'_/@IN5"<((2]0-Q_SX)Z@;C_ )\%,-5=*&B<&UE7!"X\P))
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M\^">H&X_Y\%-4<C96!\;@YAYAP.05D00CZ@;C_GP3U W'_/@IN1!"/J!N/\
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MIU;[K?HH2WV/I&J=(TM(?\K-9EH'7'+*"1-;ZHJ].VV$6JW37"MJCPP,C;D
M^)^2BS;G[>&^E;ZT2@UDM.7NC:?99RZ!3M"S_)X>,9<UC>?SPHDM0_\ O,7
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/$1$!$1 1$0$1$!$1!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img44875045_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %[ ;X# 2(  A$! Q$!_\0
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M)_XC_P"_!_\ B:]8HH \G_X71>?]$_\ $?\ WX/_ ,31_P +HO/^B?\ B/\
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MQN_Z%GPY_P!_#_\ 'J/[9^-W_0L^'/\ OX?_ (]7K%% 'DYUKXW#KX9\.?\
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M/[//_)-I?^PA+_Z"E>L5Y/\ L\_\DVE_["$O_H*5ZQ0 4444 %%%% !1110
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MS1!M,#1!-Q!9FY^\0,9Z'&" =*?'>B?V5#?(;N1YIVM4LTM7-R9EY9#%C<"
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M!Y/VB.8N9<;0552NTG.0!CO706FG'5M7UZXU.WD\E_\ B76Z2*5S;[ 79?\
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ML<T22Q.KQNH974Y# ]"#Z5Y3HW_)S7B'_L")_."@#UBB@D 9/ JK-J>GV_\
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MB*I8Y; QD^IH>-),;T5MIR,C.#ZT >2V/P\\7:CX?T.2#QWJ.B"/3;>)K&.
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M!@ *]$/^L'T/]*=0!PGBCP?-J%],VD6B6\C02W#W+29$MR #"FTDX'F!9&.
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M*[WJ_<E_P0^L8=?#17S;?Y6.2%WXRG^YIEG I/623)Z_[W]*7[!XRF^_J=G
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M"C>>O0=_K2[1ZG\S0!Y3^SS_ ,DVE_["$O\ Z"E>L5Y/^SS_ ,DVE_["$O\
MZ"E>L4 %%%% !1110 4444 %%-=UC1G<X5023Z"N&T#XHZ9X@U#7A;VTT>FZ
M3:K=?;9,J9T()+!" 0,*<'//H* .[HKA?"/Q%D\2:O#I]]H4VE->67V^P=[A
M91<0;L9. -K=#CGC]7^+_B#+X;U8Z;I^ARZM<06+:C>!+A8A!;J<%N0=QX/R
MB@#MZ\GT;_DYKQ#_ -@1/YP5WMOXNT";3[.\?5K*V2[@2XB2XN$C?8XR,@GW
MKSSPW>6M_P#M)>(+BSN8;F!M%4"2&0.IP8,\CB@#UZBBB@ HHHH 0_?'T/\
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M+T5@.WITQ7,>"= TOPU^T)KNEZ3:_9[*+1@R1;V?!+0$\L2>I]:]JKR?1O\
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M=S1:M+"CR Y5 D9"]>F2?SKT?_A5?@;_ *%FQ_[Y/^- %C_A9'@K_H:-*_\
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MYT"#39KB\BCNTB+2*7V,P<[BG EVC.20.U 'O6G:A:ZMIUOJ%C,)K6X0212
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M !1110 4CHKJ5=0RGJ",@TM% #61&0HRJ4(QM(XQ2@!0   !P *6B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ I&4,I5@"",$'O2T4 ?/?AKX=ZQ=S^+-+U.QN4L].T^XT[
M2&FB95DWS/(KH3][D#D=F%-L/"GBG4OA-XAO;S3KQ=9OKVW,MK) RRS6\ 0
M;&P3_$<=\<5]#44 > W'AO5O$.E>++O24U,W$^F16P6325L([@K*CD*N[+,$
M5TZ8^;&>F;FBZ1=:C=:K?P6^JJ\7AZ:SV-H@LHW+*=L.-V7<''12/?I7N5%
M'@'A#PGJV@:=<VNKZ-J.I1>(-#,?F10%)[1D4@VQ+<1@J1C=@%@!BK_PYL]7
MM/&NEQ0VEW=Z9%:/'--J>C"UGT\!?EC67'[PEL#KTSQ7N%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7&?%>:6#X;ZG+!+)%(LEMM>-BK#_2(^A'(KLZXGXN?\DRU3_KI;
M?^E$=73UFO4BI\#/G_\ MC5O^@OJ7_@9)_\ %4?VQJW_ $%]2_\  R3_ .*J
MG17TOL:?\J^X^?\ :U/YG]Y<_MC5O^@OJ7_@9)_\51_;&K?]!?4O_ R3_P"*
MJG7;?#?3+;4KS5_/L+6\DAL&D@CNCA-X88R<C J*D*4(N3BON15.52<E%29R
MO]L:M_T%]2_\#)/_ (JC^V-6_P"@OJ7_ (&2?_%5Z'XB\-6+VFD6EYIUAI&N
M7NH1PI%93%PT#\;V&2!\QXK.U;5_#6FZOJ.@R^&+<V-L7MTN(V/VKS%XWER<
M'D=,?X5E&5*7PPO]QK*-2/Q3_,XW^V-6_P"@OJ7_ (&2?_%4?VQJW_07U+_P
M,D_^*KM_#%[I=SX3UBXN/#>ERS:5;Q%'=&S*6;:2_/\ +%<GI]H/$GBNVM8X
M8[1+VY5?+A'RQ*3SMSZ#-7%4VY7@E;T(;J)*TKW]2I_;&K?]!?4O_ R3_P"*
MH_MC5O\ H+ZE_P"!DG_Q5=MI/AW2]5\<7EQ<P+;Z#;WZV<42Y'G2%@B(._/W
MF]L^M:.A^'-+EU?Q0D>EVMQ+::D((([QV2".(R%2 V<;L= 3GTSS42G1C]GM
MT74N,*S^U^+/./[8U;_H+ZE_X&2?_%4?VQJW_07U+_P,D_\ BJV=7M],TCXA
MS01VS?V9;WRAH9U/W 1N!SSCKC/;%>@V/@O1;75M>M=0M(L7M^;+3MP_U),+
M2@K^#*/J!1.=&"3<=U?9!"-63:4MG;<\E_MC5O\ H+ZE_P"!DG_Q5']L:M_T
M%]2_\#)/_BJ[H>"8[W1="L0B6EW]EN-0U"Y,9=Q$'P@"CECZ"J'_  KFY?6;
M:VAOMUC/:->?:WMV5DC7ALQ]=P) QGN*:GA^J7W"<*_1O[SE/[8U;_H+ZE_X
M&2?_ !5']L:M_P!!?4O_  ,D_P#BJ[[0_ L-KXCM4FQJ5C?6$\ML98&B;>@Q
M@H>002._>LF#X>R2^)H= ?4T6^%L;B[582WD< A%Y^=L$=,#W-"GA[O1=]@Y
M*]MW]YR_]L:M_P!!?4O_  ,D_P#BJ/[8U;_H+ZE_X&2?_%5U=KX:T_2_&VEZ
M7=S&]M;\>2Z2VS02Q%\J,JW0@D$')Z5R.H6;Z=J5U8R$&2VF>%B.Y4D'^5:1
MC1D[**^XB3JQ5W)_>/\ [8U;_H+ZE_X&2?\ Q5']L:M_T%]2_P# R3_XJJ=%
M7[&G_*ON(]K4_F?WDM[K&J_8Y,ZMJ)Z<&[D/<?[53_VQJW_07U+_ ,#)/_BJ
MR[W_ (])/P_F*L5*I4^9^ZNG3U*=6?*O>?\ 5BY_;&K?]!?4O_ R3_XJC^V-
M6_Z"^I?^!DG_ ,55.BJ]C3_E7W$^UJ?S/[RY_;&K?]!?4O\ P,D_^*H_MC5O
M^@OJ7_@9)_\ %53KN8O[-\+>#](U&31[34M0U5I7+7@+)%&C;=H4$<GKFHG"
MG&WNIM^2*A*I*_O-6]3DO[8U;_H+ZE_X&2?_ !5']L:M_P!!?4O_  ,D_P#B
MJ]&A\.:+/JHOX+!$L[_0)KU+5R6$$PP#M)[9Z5R'@.RMM1\;Z9:7D*36\CL'
MC<9#?(Q_I4)T7%RY=O)%M55)1YM_-F1_;&K?]!?4O_ R3_XJC^V-6_Z"^I?^
M!DG_ ,57;^+;9+71[H+I/AB%2X19+&XWSK\W8;O;!^M8/A[3+9_#WB'6;J)9
M190)%"C=/-E;:&_X",G\J(^R<>;E7X!+VBER\S_$QO[8U;_H+ZE_X&2?_%4?
MVQJW_07U+_P,D_\ BJ]1U'P;IDGAV]%II$2V=MI0O;;5TF)>>4+N92,]",]N
M/RJOJOA&TTWPI)'%H,5TZ:<ERUZET!<+(1DOLS_JQTZ=OQK-5:#^ROP-'2K+
M[7YGFW]L:M_T%]2_\#)/_BJ/[8U;_H+ZE_X&2?\ Q5;OA'3[35=-\16DUNDE
MVFGFZMI"/F1HSDA?J#^E=K?^"]*FL]&T^TM$74+*\M(-391RRRH&8G\:N<Z,
M)<KC^"(A&K./,I?B>6_VQJW_ $%]2_\  R3_ .*H_MC5O^@OJ7_@9)_\57>7
M'@*WUG4KB\@NDT^UN[Z6VTZ&*U:16"-LRQ!^121U.:S=*^'4]Y;^9J%\;)WO
M'LH42V:;=(IVDL1]Q=W&30IX>UVE]P.%>]DW]YRO]L:M_P!!?4O_  ,D_P#B
MJ/[8U;_H+ZE_X&2?_%5WFE^ Y-1\(W-J8H(=0M-;>"YO&Y\J%(LM]1GH.^16
M=HW@"'5]+DU-=7E6S^TM!$\=BTI('\;A3\B_G1SX?6Z6GD')7TLWKYG*?VQJ
MW_07U+_P,D_^*H_MC5O^@OJ7_@9)_P#%5NVVCVUWX,UN1!&UYI%U&_GIG][$
MY*$?0%0P^IKEJUC"E*]HK3R,Y3J1M[SU\RY_;&K?]!?4O_ R3_XJC^V-6_Z"
M^I?^!DG_ ,55.BJ]C3_E7W$^UJ?S/[RY_;&K?]!?4O\ P,D_^*KZ,^&KO)\.
MM$>1WD=H,LSL6).X]2:^9Z^EOAE_R3;0O^O?_P!F->9F4(Q4>56W/0R^<I.5
MW<ZRBBBO*/3"BBB@ HHHH **** "BBB@ KB?BY_R3+5/^NEM_P"E$==M7$_%
MS_DF6J?]=+;_ -*(ZNE\<?4BI\#]#YSHHHKZD^;"MG0M>_L2WU:+[-YW]H63
MVF?,V^7NQ\W0YZ=.*QJ*4HJ2LQQDXNZ.B;Q9-+X:LM,G@+W>GSB6QO1)AH5X
M.S&#D9''(Q@>E:S_ ! M/-N=1B\-6D>N7$1CDO?.9DR1AF$1& 3]?ZUSGAFP
M@U3Q/IEA<@F"XN$CD"G!()YYJ/4[!8?$EYIUJIVI=O!$">P<J.?RK%TZ;ERM
M>9JJE11YK^18TG7O[+T76=.^S>;_ &E%''YGF;?+VMG.,'.?PJ#P_J8T;Q#I
M^I$%EMYTD8#J5!Y'Y9KLYM'\'6'B.+PI<6E]+=,R02ZFL^W;*P'2/&-H) Y_
M6G^'_ ]G]FUK[182ZUJ&GWQM390W(@(C'_+7U.3T'M4.M3Y6VM_QZ?UL6J52
MZ2>WX=2@WC74O"_B6[M]+OHKG2!J#70B18V$J,P;&\J2"5P#CH?>D?X@1ZE)
MJD>MZ6;NSO+I;F..*81/"5X5=P7YAMP,X![]:Y_Q18V>G:_<6UA'=Q6ZX(BN
MXRDD9(Y4CO['TQ5MO!6J+?26QDMML=A_:)GWGRS#C.0<9]NG6G[.C92>[7HP
MYZMW%;?>4/$>MR^(]?N]6FB6)[A@=BG(4 !0,]^ .:Z'6?B+=:M+H$JV@@DT
MEUD8B7=Y\@V_,>!C[OOUJCJ/@74=+TY[JYN]/$L<2S/:"?\ ?*C=#@@ _@37
M,5<8TII6UL0Y5(-WTN=[/\3);CQ7+JQTXQVLUE]A>UCN"&6/.<JX P<\CBH(
M?'XM/$$=[;65Q]C%HUI)%-?2222*V-S>8?NMD*?E Z5MV7A'0WM?#T4F@ZM=
M/J=M')->6LIV0LW!)&" !UZ]*9I_@O2X])U28Z5?:W/:ZO)8H+6;8?+500Q
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M5=>9/?-;Q13B'&/+7'!/.<G'(%<?9W5I8^(K>[A$QLX+M94#X\PQJ^1G'&[
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M=#>7-OLUC;/$WF3Q,FUP=PSDD>M37KVXEUBX%W;LMS"OE*L@);@=J .9^RW
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M5MFU1#)SAU/]VMO_ (3?P[_T$/\ R#)_\37044 <_P#\)OX=_P"@A_Y!D_\
MB:/^$W\._P#00_\ (,G_ ,37044 <_\ \)OX=_Z"'_D&3_XFC_A-_#O_ $$/
M_(,G_P 37044 <__ ,)OX=_Z"'_D&3_XFC_A-_#O_00_\@R?_$UT%% '/_\
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*>8W8UT5% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img44875045_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #\ 24# 2(  A$! Q$!_\0
M'0   00# 0$               0%!@<!" D# O_$ %P0  $# P($ @4%"@@+
M! @'  $" P0 !1$&$@<3(3$4(@@5,D%1%F&1DM$7&"-24U1Q@932"20T0G2A
ML=,S-U565W*"D\'"X26#A+,F)S4V8G.BQ"A#14=UA?#_Q  = 0 !!0$! 0$
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MMLFWIT[!TK(B+:1AR;ZP##SRD8P5!E*U9(ICUQZ/5CL]RTSPMFN.1XUM:O\
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M4'[4?LH^^DXO?Z1]0?M1^RK T_Z.FG;UJ+0,9URYEB_Z&DZGG*;>2"B4VE9
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MXK.VRVLD=2!%;S_92"YVK2%I;87)M-L >?1'04PVU>=9PD=$_&F'Q-2-;G"
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MA'KC2,%B>U=6M3VUQR0RN;IBZ*N#4=QA&]YMTHZH*$9421C:"02!4<^2VN_
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M!W) )'3W]< 4[$<5PAU/"3FP'W*>^BCI>/IV;J!$-I+;(Y2"$@G"BXXO;D_
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MO;*QXZ($YZ#GHZ#Z:U#]*+3,6T<4H&I(+K+D2^,<J1RW4JQ):  . ?YS9_\
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ME/-CO-J:=;7DA:% @I/Z036BX BRGSX+G]Z&7%1C0^O46:YR>3:M10T1F7%
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M;0EL@J2"GJ-E"%=%TT]9[A/C7"=!C/RXN.4^\@;D#.1U/N!ZC/8]1UIX20H
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MA%-CG%Z\Q9MW9>@VJ:FSL2I4EV ^M8>0TS&6$M].BB9&#DD (]^:LM[3=K5
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A"$5C:/A6:*$+&T?"C:/A6:*$+&T?"LT44(11110A?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img44875045_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=R96<@5&]U
M<F%N9V5A=0  !9 #  (    4   0J) $  (    4   0O)*1  (    #,#(
M )*2  (    #,#(  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" $2 9 # 2(  A$! Q$!_\0
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M?S5>E272^^WZD,[N18V0O&.SQM<=[F@_)>KXV7)H'9_0N22=G]"Y)* "$(0
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MF,;%)&)1+J YH=OZ[WOHM&N;4.)MQ)]77].;FXCY7E)+3M:W5V9NEVD%PZ(
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M/'$YU1BD;FD,(LUMO6'Z'KNNL+D^W-#18;BKJ+ J5S\0G'.JJ4F_(Q;A<\.
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M_P#9=&V^3DY-[MCJ$E],X=[4/NW_ +(^F<.]J'W;_P!E '4)+Z9P[VH?=O\
MV1],X=[4/NW_ +(!U>.:'-+7 %I%B"+@A)_3.'>U#[M_[(^F<.]J'W;_ -DH
M6,P4\%+ V&EAC@B9YL<3 QK>X#0*1)?3.'>U#[M_[+Y&-X:7%K:MI<VUP&.T
MONZE)!>3^A<DD[/_ +.[N22@D$(0@!"$( 0A" %FMN'1T^SLT@9&Q]1)'#))
ME&8MN2 3O.HW+2K/[<0<MLC5$"YC+7[K_6M^JK/TL'",<FOBLC8C=C  !Q-M
MZ4BJ&R- <;.X)W%8<N)9[:.8".]4TS,DI W;PLBX+#8F:U^X]JCDJ T]%OS7
M5O)7@6$8ULC++BV%TM7+%5OC;)+'=V7*TVO\5M6[%;,-<'-P"@!:;@\B-"NJ
MQWN19^<87S54PBI8G2R'<R-I<? *R&!XX=^$UFF[^PY?I"DP^BH!_H:2"FWZ
MQ1AIUWZA,YCQ/BK^6+/S'] XY<GZ(K+?\ERTFSODIQO%:B*3%HCAM&3=YD(Y
M4C@&]7Q7>,QXGQ7BE8T+%,,PNBP;#XZ'#(&P4\8T:WK/63Q)XIM"%T(!"$(
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M-I<)K,!K*>"><R21$-#J*=H)[RRP^*U>=WK'Q59CQEJ<-=0PN=RE4US38ZY
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MQ_DX>-C\5LLI1\_1L_VM6^+?V1]&S_:U;XM_9/H2Q0A]&S_:U;XM_9'T;/\
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M_-&3$_:*/[A_\UL*CB$GDQ/VBC^X?_-&3$_:*/[A_P#- .(2>3$_:*/[A_\
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M/%_@$<TIO9XO\ ID(!V?T#NY)*>M:]]*]L4O)/(%GAH=;7@56<UKOM1WX9B
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MB=U/2E\8O(1DC'%Q-A^=_@HZ2ECHJ2.GA%F1MMWG>3WDW*9JJ'G=53R/DLR
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8$( 0A" $(0@!"$( 0A" $(0@!"$(#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img44875045_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=R96<@5&]U
M<F%N9V5A=0  !9 #  (    4   0J) $  (    4   0O)*1  (    #.#,
M )*2  (    #.#,  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" '(!#L# 2(  A$! Q$!_\0
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M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/BCZ^\TE
M[9*XOD_$9R1\O@MY[]K"[P&5R?4FHJ>Q6^6OKG;WN)V1@^E*\]W_ !65-$UU
M133S8U513&M5R7*;5<I_Y/3,:/%[B?JPO#-5U0/WR"%P_P G(_>OS7?-7W:_
M3$U%0Z*#/HP0DM:/[_G6A07>X6NH$U!5RP/!_!=P?E'0_.NM3[)KFG,U<7,G
MVE1%6(IX/UM0ZBI:QXCD!AD/3<<M/JRIA<+T;K:+4;/-:MK8;A&W):/>RCQ;
MZ_$?^1U[3U:^KMVV4ESXG;=Q[QW+EW;5=JK5KCBZ-NY3<IUJ9X)=$15K!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M3><;Z&W/^]=))6GWWJ'J^OZVIM3><;Z&W/\ O7224'WWJ'J^OZZJNIHNB_\
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MSMG>W@2-!!(]?K]:WAT"97G+EZNY[SV5G1;=GC1P>D1%2VQ$1 1$0$1$!$1
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MX;%.TO/^3G#OU$J_2;%-RU-../13H]ZJW<B<\.K] HB+R+U K[:F]G::5O\
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MQTYC/&?1YQUPKPBPVTXQCG_C/94YRB-+T=1;])6BBKF=G4T]%#%,S<';7MC
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M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0:ES_FFK_J7_P!DKDRZS<_YIJ_ZE_\
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M26>1QY<YV!GZ!X]229Y.Y1-RN8Q,\$Q;IIG,0^HB+!8(B("(B B(@(B("(B
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M"D=-T%PI+C6.='5TEK+8V4U)65(G>QP'I$$.=M;T&-Q[^ K.B B(@(B("(B
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M537MII2,M+7-!;(UW.' CH>JVM=Z)J=17"V7:U"WRUE#O:::YQ&2GF8[J'
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M]68GLIV%&)CNJ^EK=<O:W4TE^-0SMIIA#'43B::*!Q(:US\NR[J??.P"!GC
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M5I6UU5RH:J>YW&25L-- V,.F#227-R\-:QHXR\@\=^03E_UF,S/Y.?\ 6/\
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M[D_BQ./U#]ZZGM&]1<U-6>G\N9H-JJC7SW_A<41%RG3$1$!$1 1$0$1$!$1
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MI _>@I:L&E&9K*A_A&!])_X*OJRZ29B.J?XEH^O^]!9$1$!$1 1$0$1$!$1
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MVC^T@@D4[[2[_P# /VT?VD]I=_\ @'[:/[2""13OM+O_ , _;1_:3VEW_P"
M?MH_M(()%.^TN_\ P#]M']I/:7?_ (!^VC^T@@D4[[2[_P# /VT?VD]I=_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img44875045_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_7.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1"B17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=R96<@5&]U
M<F%N9V5A=0   >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MD;GR%\#"2<@D] <$_P#T5@H@KN>^T=XO<%XL<)=;['1U#Y*TQ&-CG&/#8FY
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M6VFLU;4Z;HJD3W&CIQ45#(^K807!H:X^3NN=O?'S"#>HB("(B B(@(B("(B
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MH:UM.V*5KR7!QWR/<!CZ#KZ;S4/"K1VJ+S)=+Q:.95R@-FDAJ)(3,!T >&.
M=T&,GKCH@@E*+EKJY:.T]K6OJ(()+)-65;**K#!<*ADC8PUTD9PX!I+\-/<K
M'USP[T_2/TO:1<*ZOA&I8:?PT]>Y[J.&6)[C&"#N:"8VN!/49.#U*L^^Z TQ
MJ2ST=KNMIB=2T&WPC8BZ)U/@  ,<P@M& .@..@]%A?J4Z-.EOQ>;: *#Q0JS
MB>3FF<?WPR;M^[!(SGL<=D$MBIHX:-E,P'ELC$8!<<[0,=^ZKBPV.V:?XZS6
M^RT,-%2,TK$1%"W )-7)DGS)/F3U*LB&)L$+(H\[8VAK=Q). ,=SU*P18J!N
MIW7\1'V@^C;1&7><<H/+PW;V^TXG/=!M$1$!$1 1$0$1$!$1!@W6YT=EMM1<
MKG4-IJ2FC,DLS^S&CS_^@ZE1S2W%+3&K[I[.M%7.VK=#SXHJFF?"9HOSV;@-
MP^2V^K!8W:4N#M6,@DL\<7,JFU#=S"UI#AT\SD#&.N<8ZJL-%3R\0-;QZX>V
M"UV^BH9*+3]L,C!42 @[IG@'W1C( ].O89<$RI.+6CJ[5#;#37,OJ7U#J2*7
MD/$$DP[QMEQM+OKUR,9R,S=>7;55T$O ;0]F@E8;S'JB-KJ5KASF2B>0G+>[
M<,<WJ<=QZJQN*GZL/XTT_P"IC_T3X-O._P"9_M^]^[]N][[.SMT^N4$)XQ_]
M:30?_=W^VR+T@"#V.5YAIK9JJ?5[Z[BBUDFH::EB\('" F*'?(6O')]W.\/Z
M_:&/3"M+0MSNKJN6D@(FB$>[$SW88<@=,9]>RMUTMIP^EW:E?#;6TOK'%'P6
M<N,K6BFNK_VROAC'I%3G(^KG'^A<>RI7C]D7*KE^ >(__(&JMPQW9W#$=9AL
MBX#S6%->+?3OVS5D+'?FF09_1W7P+%;C^VTPG^,[C+_YB5F0TT,#-L$+(AZ,
M:!_0GLO?\<=Y_;^V%[;ICTA94S'^!3O(_P!(C'\Z>T*Z0?D+5*/C-*QH_F+C
M_,MCM'I_,N?HF\>4'%6.D?7\AK,WF4=J*F/S=-_^Q/ W&3]MNDC#Z00L:/\
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MWCSY;_D>];#M14DGNV]LMQ>>PI6[F_5YPP?5RY_Y:KCUY%NC^'Y:0_T-:?\
M2670T,5!004T/5L$;8P7=\-&!_0L6IU#;J2H-.^H,U2.]/3,,T@^;6 D?,X"
MT:X[WZ_2&K3'>\>U/RAQ'IZD=A]>9:^0==U4_>,^H9T8/HT+:-:&,PT!H'0
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MRFJ&23UL\+H1 UK@2YKG#!=Y@#.>A[=4'MI%'J73-53U44SM47N=K'AQAE?
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MD9R&D!I[8+AE5W0MM5LK- R\1*B"LL3+%+#15E=3N\/XKF,+"X2-]TF%O0O
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M=VEXQK='GSQ?14BL;<^76?AT:>#3-L@F;/+3NJZAIRV:J>9GM/P+R=OTP%N
M WL %RN%:B(A@VO:\^U.YY_!#@=455\0M9W.@OKK;;)S2QQ,:Y\@ RXD9[GR
M QV^*KZC45P4XI4M5J::;'QW^'):@'18E9<:6WL;XN9K-QPQO=SSZ-:.KC\
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M5FWWL$.C<'=\=1GMW6SNW$>II[Y6VW3FE+IJ$6QP97U%*6,9"\C=RV[B.8\
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M[<RC;.X.F?N<]\A';+G$G Z].PR>G5!\^T]8R#\EIJUL\_R]Z>WI_F4[NO\
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MJ\GUC'98]514U=#RJRGBJ(\YV3,#VY]<%9"+L@ZXXV0QMCC:UC&C#6M& !Z
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MEC:Z6T0&/<>KV":?(;\CU/\ ]%N]#V^HJ:V:1_.CH]FUY9(Y@>[/09!!]?\
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M^*_X0W[^]/\ \0S^RI^*_P"$-^_O3_\ $,_LJ"[47EOAWJSC1Q,]H^P=86^
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M/D/+D_)$1N:<'[6<X]T?!4'#/I^GJ:BH@XYWV*:J(-1*RUU8=,0, O(FR[H
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MVM5WHKW;HZVV3MGIY&Y:]O\ 00>H/P*HWB'I#4D^IY[J+5/-'7$.8VGS,Z/
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M%&XW^"7A[J2V6JVMIFMEAJXVN>Z;<XEPS"_IM+!W\CT]0B_''^ZGPF_RT?\
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M-:/)H[ ?[R2L\A5ITN/+[6>L6GW^2>+-DQ[S29C?RB?Y<-8UC0U@#6M&  ,
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M0MEE(C#@#[YQC/DO/VH[=:]-P\0[!I"0-L8T['55%+%4NFCI:LRO&!DG87,
M)'R\@%VZQI:O4?%&>V5VGJ;4=-06RF?0T5;>#11QA[7<R5K?[X21M)^[@?#
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MU#P6D;7[F>\<X =@#&3Z,5!W[6%&[B9=:W2'"J74E?;9'TE9=HPYOY5HV/:
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M?NV*A]F4A_[?=(B'.'K'3Y#OK(68_-<LB@TK14M8VOK9)KK<F_9K*YP>Z/\
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M7Z9I#@*YP,#3Y;8&@1]/(EI=\5(F1MC8UD;0UK1AK6C  ]%2OZZK1'[EW_\
MD\']<GZZK1'[EW_^3P?URRDEVHJ2_75:(_<N_P#\G@_KD_75:(_<N_\ \G@_
MKD%VHJ2_75:(_<N__P G@_KD_75:(_<N_P#\G@_KD%VHJ2_75:(_<N__ ,G@
M_KD_75:(_<N__P G@_KD%VHJ2_75:(_<N_\ \G@_KD_75:(_<N__ ,G@_KD%
MVHJ2_75:(_<N_P#\G@_KD_75:(_<N_\ \G@_KD%VHJ2_75:(_<N__P G@_KD
M_75:(_<N_P#\G@_KD%VHJ2_75:(_<N__ ,G@_KD_75:(_<N__P G@_KD%VHJ
M2_75:(_<N_\ \G@_KD_75:(_<N__ ,G@_KD%VHJ2_75:(_<N_P#\G@_KD_75
M:(_<N_\ \G@_KD%VHJ2_75:(_<N__P G@_KD_75:(_<N_P#\G@_KD%VHJ2_7
M5:(_<N__ ,G@_KD_75:(_<N__P G@_KD%VHJ2_75:(_<N_\ \G@_KD_75:(_
M<N__ ,G@_KD%@6S27L;76I=2>-YWM_PO['Y6WD<B(Q_:W'=NSGL,?%;Y>=+)
M^$%I^WZ^U7=ZJFO;[;>'TDE'3-CC)B=' (Y'.:9-K2[:SJ"<AHSV"DGZZ+17
M[EW[^3P_UJ"YT5,?KHM%?N7?OY/#_6I^NBT5^Y=^_D\/]:@N=%3'ZZ+17[EW
M[^3P_P!:GZZ+17[EW[^3P_UJ"YT5,?KHM%?N7?OY/#_6I^NBT5^Y=^_D\/\
M6H+G14Q^NBT5^Y=^_D\/]:GZZ+17[EW[^3P_UJ"YUD4WWOHJ0_71:*_<N_?R
M>'^M6RL'X1VD;W?Z&T4MOO3)Z^JBI8G200AC7/<&@N(E)QDC. 4%R(B("(B
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MJ#;(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(J4MU3K+6/%?65GH=:U-FHK--$((HJ.&7
M(>#TRX9Z;?CW076BJC2VN;QI[5=_TEQ"N$=PEM-#[2@ND-.(W3T_3<#&S[P+
M@  ,G![]SFV[C-;*Z^VVV5FG[_:W7C)MLU?2MCCJB!T .XXSEOP]X9QE!92*
M"6_BO8Z[AM<-9.BJ::EM[I(ZBEG#6S,E:0!&1G <XN;@$_>"E-BN@O=AH;H*
M>:E;60,F;!. )&!PR X#L<'L@V2(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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&$!$1!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img44875045_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_8.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=R96<@5&]U
M<F%N9V5A=0  !9 #  (    4   0J) $  (    4   0O)*1  (    #,#@
M )*2  (    #,#@  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" +) DH# 2(  A$! Q$!_\0
M'  !  (# 0$!              8' P0%" (!_\0 61   0,# @0"! <+"00(
M! <! 0 " P0%$082!Q,A,4%1%!4B80@8,D)Q@=,6%R,S-U56E*2TTE)7=821
ME:&ELR0XA;$E-#5#8G+!T8*RX? V1E-4=':2HO_$ !H! 0 # 0$!
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ME9ONKFMU[X=ZDX@D6I]3:JR*IFE86,9,[E%H< /8+FMS@X\1X()[J?7-+9:
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MVN!!P<'![K>S*.L_I=92T\[>*=UM^NWL8Z2TWN404G/Z;H?1G,&6YRT.9GS
M\%;<6IGOX@.TM+1M:]EH9<C4B7(RZ5T98&[?#;G=GQ[*"WR/B1J?3M3I6^:'
MM$SJJG-.^]FYL= QQ;CG-A+-X(/M >!PMZ[V75VG-=6V^Z8M46HXS9([/4LG
MK6TSXW,D+Q.7.SN!W=0 2@Y^K.(%=4V.PW6W4M; Z#6!MTE)0S%SZMD0G;L^
M:"'EH.T]!TR>F5NW+B'65.F-3V[4=@N.F[Q0VB6N9!!7L+Y8.K=\,[ 0UP.
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M?^(_OL:#TDB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M@9)#D?+:X@@$=\D(*&U/PXUK:#!JS4W%"*%]H:\05CZ1Q=#S!L<&AO4EV<8
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M[%=VK:L;F%=,M+S,5G>GVB(N%@B(@(B((/K;A_)J*O;<+;410U):&2LFR&O
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M$CV%K9 YNX%I\1@JOX.#=+'=&RRW-\E$U^[D\K#W#^279_QQ_8K,8QL; Q@
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MX<!T\1D>*CNDN'UWM^K_ +IM77YEYN,% VW4G*IN2R*('+G$9.7N/T8R>_3
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M;0?:=U ^<?-6_P#>YT1^ANG_ .ZX/X4%;_&JT1^:[_\ J\'VR?&JT1^:[_\
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MW.=(]N&[G N:"/!W7Q)E#K4^KKB+E11W33L]!1U\_)IZB6I89"X@ENZ(=6Y
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MHB'.YSN8UKW\PD'.0 SIT[+XDI*^_5>HZV6_U]NH:.=T4+::<L#711@.<?\
MPYR2!C))Z] H%@HN1IBLJ;CI6VUE=_UB>G:]YVXW$CY6/?W^M== 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%H7>\6^PVR6XWFMAHZ.+&^:9VUK
M<G Z^\D!!OHN9=[_ &JQ6LW&\W"GHJ+H.=/(&M)/8#/<GR62U7:@OEOBK[36
M05M),#LG@D#VNP<'J/$$$$>!0;Z(B B(@(B("(B B(@(B("(B B(@(B("(B
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MRU+G3UE$)W1QSN,A<.8SOG&T>'8*;>DO\FIZ2_R:@RLC;%&UD;0QC0 UK1@
M#P 618(YW/D#2!@K.@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*E
M/A(Z9@K-!UFH*FLK'OH6P14U'SL4['NFPZ78.[RU^W)[ *ZUQM5:6MFL=/3V
M6]QR244[FN>V-Y826N#AU'O 05]K^)E7Q&X6T-=&V:@EGJI)8I6AT;I&0L,9
M(/3().%K</*JKLUBXFG35**AEMO->^W4K8RYKIFQYY36-P2W<&@-;C.>A5AZ
MDT99=6VF"WWNF=+'32-EIWQR.CDA>WLYKVX(*RZ:TO:](V:.TV*F]'I6/<\A
MSR]SWN.7.<YQ))/_ -.P04)4<:>,M'235-9H".GIX6&2666S5C61M R7.)DP
M  ,DE7/POU57:VX;VO4%UCIXJNL,W,93M<V,;)GL& XD]FCQ[K:XC_DLU7_0
MU9_H/4;^#Y^0K3W]9_>94%DHB("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M'2:%TO;KC!<:#3MNAKZ:)L<%0V!H>P-;M: [&>C0&Y[XZ=D%-:SGJX[3JR"
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M7HNR7:&_6&WW:DCD93W"FCJ8FR@!X:]H< X D9P>N"50?KWBRS1HUX=<Z?\
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M[71U4<\SWM+<'((&,@^84W1!#.+-JKK[PKOEMM%,^JK*B%K8H68R\[VGIGW
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M@(B("(B B(@_,K]7RYP8TN<0UH&22>RTIJR5U/3S6V%E='-(P.>R8-:V,]Y
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M'M-ZCP[KI_!\_(5I[^L_O,JDG$?\EFJ_Z&K/]!ZC?P?/R%:>_K/[S*@LE$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$6H*^F=<GT#90:ED0E='@Y#"< _VA1N('
M)U!K*SZ;FCAN4YYT@R(XF;G!OF?(+9H=0V^XLHG4#WU$=87B-\<9+6EHR0\_
M-/T]U5NN](ZAK=05%T;0>D,J'8#:8F0L#1M;D=^H:#V\5-^&^GZW3^GI&7,<
MN:HFYG)SGEC  S[SC_DL./-EOEFDUU#3?'CKCBT3RDT5/4^E59JIV34TI;R8
M>5CEC;AP)S[63U6>"GBIH&PTT3(8HQM:R-H:UH\@!V69,+=$1#/L1$4H$1$!
M$1!\DX&5YUXCU#X-92?= TN=)7!E(9&!P:#N,1'ET&,CL3U\2KX?B\4-3 ]E
M;1ALQCW@\I[MK@=S2#\D^?B,KE:PT?2:M=975K^6RU7..X8:P.,VQK@(R3V:
M7.:3T.0W'3.1?BR>*9G6V'JNF_51%=ZB.6#0AJSHZB-?NW8/+W]^7GV?\.WN
MPI"M>&6H-9-"^E$=/&UO*F$@/,R.HV^&/\5]U53%1T<U34.VQ0L,CSC. !DJ
MNTS:\S]K\-8Q8HKOU&MS^&5%74'%=C[F&3V_91N=C>'Y>T>>,8/T*?0UM+41
MR205$<C(G%LCF/!#".I!\BNLF')C_FA7T_5X<^_';>F=%J276ACM?K)]3&*/
M:'<X'+<$X_YK)45U/2RT\<\FU]2_EQ#:3N=C..G;H/%5ZGZ:.^/O_9],Z^)8
M8YX]DT;)&?R7M!"Q^F1"XBB]OG&+F_(.W;G'RNV<^"KG7FL;G1WQUMMDKZ2.
M #>\-PZ1Q&>Y\.O_ #5F/#;+;MAGZKK*=+C\EN>=<?:S0   !@#L BB/#[45
M9?;94,N!WS4KVMYN,;P0<9]XQ_R4N7.2DX[36?A;@S5SXXRU]2R0?C6K;6I!
M^-:MM<+A$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!03B3PPL/$>.@DU'6UU)';!
M*6/I98XQA^S<7%['=M@\O%3M5MQ>X9UG$BVT$=%=A1OH7O?Z+.'F"IW;<!^T
M@C&WH0"1N*"D;_HO@Y:JYMMLMWU1J6ZR$MCI+1)#-N/7YXAP>Q^3N/N7IK1M
M*:/0EAIC33T9AMM/&:>H<'20[8FC8\@-RX8P3@=1V'94%(;MP]U[I2[ZHT+#
M9K58Q5-J*^PQ&6"?FQ%@>[Q:02/ENR1G Z87HVUW&GO%IH[E02&2EK(&5$+R
MTMW,>T.:<'J.A'0H*ZX[UTE)I&V1>OY;%1U-UAAKJJ%Q$G((=NV@=78."0/
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M_P EFJ_Z&K/]!ZC?P?/R%:>_K/[S*N9QJN?$&EM5TI-,V.WUFFI;+-ZPK)Y
M)8<MD$NT&5I.(]I'LNZGQ[+I_!\_(5I[^L_O,J"R41$!$1 1$0$1$!?B_?!<
MN\W^VV*F$UUJV4S''#<@DN^AH!)_L7,VBL;DB)F=0Z:_2N9;K];+M3QS6ZMB
MF;*2&8=AQ(&2-IZY ZXPL\-3++6U-.^EEB9!LV3.(VS9&3MZYZ=CE(M$\PG4
MQ[9*BJ@I(^;4S1PLR!OD<&C). ,GS*^)*BH;<8864CGP/8YSYP\ 1D8P,=SG
M)_L6*"W_ /1;*2Z2BXD=7R3Q-]L@Y!+0,=.G]BWTYG\'$-2"EDAEJ72U,E0R
M=^YL<@&V(8 VC [>/59XHF0Q-CA8UC&C#6M& !Y +*OS"F(B$;V_41%((B(/
MGL.AP@_M7)O.I;18BQMTK&PND&6M <YQ'GAH)Q[UO45;3W"D94T<[)H)!EDC
M#D%==MHC>N%<9*3::Q,;CX^6TBU9:VFIZNGII9F,GJ=W*C/=^T9./H"^8JSF
M7":EY$[>4QKN<YF(WYST:?$C'51J77=&]-K.!U[A<^\W>GL=KFN%87<J(#HT
M9+B>@ ^M?L?I]11U+)Q'23%SV0O8>9AO9KR#CKXX6A?M.F_Z:%LJZESIPUI%
M0&[=TC1\HM'3!Z]/>NJQ7NCNGA5DMD\<SCCG7&_M'[#Q/IKQ=HZ&IH741F<&
M0R<S>"X]@>@QG_U4TH(9Z:D;%5U3JJ7+B97,#2<DD# Z=!T^I5SIKAA74-\I
MZVZ5$!AIGB1K(7%Q>X'([@8&>JM =!T5V>,46UB],?03U-J3;J??Q_1](B+,
M],4?U37:?H66K[IF4[C47*&"W\^F,V*QV>66X:=CNCL/Z8\PI HOK;2?W616
M/_;?1/5%YI[I^*W\[E;OP?<;<[OE=<8[%!V41$!$1 1$0$1$!$1!D@_&M6VM
M2#\:U;: B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(*5IJFBJ_A-W:?5=Z
M-#-98(6V.DFF;'%,R6$\TC=\H]?#KU_\/3#J.2@MWPAM-W32VH)*NYWJ;T>Y
MVZ*<2QBG;& '$-^2  3@]R-P['-BZPX;Z6UV(W:DM;9YH06Q3QO='(P>6YI&
M1[CD+#H_A=I/0LTE3IZV".JD;M=42R.DDV_R07'V1]&,^*"8HB("*O\ B!J:
M^4NI--Z4TK/34=QOLDY-;4Q<UL$<,>]V&Y&7'PSY>_(R\.M:55[TM=)=4R4L
M%=8:^HH+C4-/+A/)ZF7J?9;M/4G R">@0=;B/^2W57]#5G^@]1KX/WY"M/\
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M'[V#'4EPP>N1D]U*41 4:U[9[E?=#W*W6-U(*^:,<D5L#)H7D.!VN8\%ISC
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@(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img44875045_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_9.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=R96<@5&]U
M<F%N9V5A=0  !9 #  (    4   0J) $  (    4   0O)*1  (    #-C
M )*2  (    #-C   .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" +/ F@# 2(  A$! Q$!_\0
M'  !  (# 0$!              8' P0%" (!_\0 5A   0,# @0"!0@$"P0&
M"@,! 0 " P0%$082!Q,A,4%1%!4B88$(%C(W0G%ULR-2D907&"0S559BDZ'3
MU"53@K$T0W)SP?$V1%1C=(.BLN'P)C5%6/_$ !D! 0 # 0$
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M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*
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M]J<Q_P"L[]J#=6G76ZFN+865D7-;#,V=@W$8>TY:>G?[CT7YS'_K._:G,?\
MK._:@W46ES'_ *SOVIS'_K._:@W46ES'_K._:G,?^L[]J#=18('%V[<2>W<K
M.@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@I+Y57U66
MW\9B_(G5D<./JLTI^#4?Y#%2/RC]?:8OVE6:<M%T](NUOO(])I^1*SE\MDT;
M_:<T-.'$#H3[NBN[AQ]5FE/P:C_(8@DJ(B B(@(B("(B#X/<#"T[K=(+10.J
MJC<6MP UHR7$]@%NNQCJH)Q&O]);=*/N4A)BI)F.C>.TLF<-8S]8G/W#!Z]%
MCJ1JVKV:,9O.T1ZRUT:UF\=^T>9=0:GKJ4LENUH?2TDC@T2B4.V9[;AW'^"D
MW<JC[KQ#O]+:Z>GUCI2ILEJKZB-KKA+4<YS,X.2P $=LX &,8QE68RMO=WC:
MVSTOJJBP,5=='NE>/-D.1M^]Y!'ZA6U.@ZSI[?WYB:S$8G,3OYC-><;>];5M
MI6K$TC$[YC?C;$[^N[LW"Z45JIC4W&JBIH<AH=([&XGL!YD^ '4KD^LKU>3B
MS4?JVE/_ *Y<8SO</[$&0[XO+<?JE;5OTW0T%3Z;+S*ZX8(-;5NYDN#W#?!@
M_LL#1[EV5KFE?TQF?6?M_/@P<.ATU14=4VMJG2W&X,[5E:0][?/8,!L8]S T
M>:[3XV2,+'M#FD8((R"OK*_52;6F<S*,,4$$5-$V*"-D4;1AK&-#0/N 65 B
MKG.\I$1$!$1 1$0$1$!$1 1$0$1$!5?P7US=^(.B*JZW_P!'])AN4T#/1X]C
M=FUDC1C)^CS"T'OAHSDY)M!1+1^K-/ZQL,MPTF?Y%'6SPR#D&',N[>Y^,#._
M>),]SOZX=D .\B(@(B("(B B(@(B(-BF^U\%G6"F^U\%G0?BXNJ-2T.DM.U5
MYN9=R(&CV&#+GN)PUH'F20%TZREAKJ22FJ6<R*5NU[<D9'WA0/7'"VVW_255
M1V:%M+</9DIY'RO<W>TYP<D]#U&<=,Y75TE-"VK6->TQ&8SB/'U5MG&SF2\3
MM56:FBO&J=%/H+#*YN^>*J;)+3-<<-<]G?Q'@,=N_16A#/'4PLEA>'LD:',<
M.Q!&051-PT[JC5%J;IX:%;9:F4M95W66X&2%C007.8S/7..W7&<>\6M;]!V"
MWT]-'%1%SJ=K U[IGY):!@D;L>"]'K]'I*TK,8BV9VKB8QMB9]J<>?/R4I-I
ME)U%^(E\N6F^']VN]E@$];2PAT8<"YK,N#7/('4AC27X\=JE"X&LI[]2:8J*
MK25/%5W*!S)&TLO05# X;V ^#BW.#YX7B-4&M%!JB:*EN^EN)L.JY&2L=5T<
MD< @J(R0'AI9DQ$ DCOU !5B45_H:_4%SLU.]YK+6V%]2"P@ 2AQ9@^/1I5,
M:CK+%JF-@T7H.[VW6<DK'4U6+8:%U%+GK)-*, M R"#NSG'W26HO=1HCBUJ"
MKN=FNM?!?:2C]#FMM&Z9KY(6O:Z,X^BXEX(STQW*#9U;Q#HX*33-ZH;G)1VJ
M2]R4M;(]NW>R-DP<TCN?;8,8ZGICNNE#Q&TYJ33-_?;KE5T,UMH99:DOIG1U
M-,SED\UK'CVL8R._4#*KNC]84.A=&5M5IRLJYZ;5-753VZ./?(P;J@Y'8$MR
M"#V) QW"WM0UTFLIM5:FMUHKJ&UT.D*^@=55].8'U<CV[PUK3[1:T-/4^)QC
MQ03ZOX@6#2]DL[KG7U-5/7TS)*:.*G=+45#=H)D+& X[Y)Z#*VV<0M,/T=+J
MDW2-MHARV29S7!T;@<%A9C<'YP-N,]1YJI;W07.V7;3VHA6WZWVZHTU24?IM
MEHVU+XI&9<62-():TAP(([E9J;3]T?HUU_IZ+4-T;3ZF@N\]/<H&1U5?%$S8
MY[(1C^RX!W5W+'3L@F%TXSV Z5OM99GU7K2W4+JF*CJJ*5CCGV62%I )CWEH
M<0>@[X4HT-J,:KT;;KMMF;)+"T3<V$Q$R!HW$ ^&<X/8A1.[:K9KW2VHZ#3^
MF[NZ1UDJXQ5U=$8 9'1D-A9N]ISB3V'08&>X4GX>7*.Z</[/+%3U-.8::.GD
MBJH71/:]C0UPP?>._8H([K[5.J:#4MCH[70^@6AU\H:2IN$KVEU8)7M)CB8,
MD- R'.=CKT'B5U-?17V5].^DU$W3-@IHI)[E<6,:^8D$!D;=P(:WJ27>X!8^
M*%//4TNEQ!#)*8]3VZ1^QI=M:)>KCCL!YK;UAJV?2URI#7V*LK[%41N;+544
M)G?3S @M#XQUV$9]H=B /%!J\*KU<[YI6IGN=P];4\5=+#07-T(A=6T[<8D<
MP=CG<W.!D-!QUR9TJYX7TLTUWU1?8+3466SW>KB?14%3#R7ES&;99S']GF''
MW[<^*L9 1$0$1$!$1 1$0$1$!$1!YL^4?H'3%ATJS4=HM?H]VN%Y'I-1SY7\
MSF,FD?[+G%HRX ] /=T5W<./JLTI^#4?Y#%6_P JKZK+;^,Q?D3JR.''U6:4
M_!J/\AB"2HB("(B B(@^<+5JJR.EVAQ)D=T9&P9<X^X?^/8>*PNK):PEEN +
M#T-0[Z _[(^T?\/?X+-2T<=,7/\ :DE?].1_5Q^/E[AT"Q[IOM7Z_9?MB/U?
M1@]$FKCNK\-B\*9IR#_VS]K[NWWJ(\5[)-?=.4-OLY#KO%61U=#3XZ2.B[[N
MH 8 [J3TSM'<A2VZW)MNCCBAC-165!+:>F8<&0^))^RT=R[P]Y(!_+5;#1"2
MIK)?2*^HQSY\8&!V8P?98W)P/O)R22>SII_IKUUXYCC/GX^Y2\S:,>%-W*V:
MMUY0&QUFD);;75CV"Y7JND:]L4;7AQ9"/!N6MPUI\.N22Y7G3PM@IXX8_HQM
M#!]P&%EQA?BVZKK)ZBL4BL5K&9Q&>9QZS/I$*UKC=](B+C6$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0%"= \/J+AOIR6SVZLJ*N*:MEJS)4!H<-VUK6]!X,8T$
M^)R>@(:)LJKX(VC5%ET'5T^M65<=<Z[5,C&U<W,>6G;N<#D]'2B5V?M;BX9#
M@2%BHB("(B B(@(B("(B#8IOM?!9U@IOM?!9T!$1 1$0$1$!%K0UU+/.^"&I
MADE9]-C) 7-^\#LME 4=UGIAVKM/26876LMD,[MM2^CV[IHBTM=$2X' (=_A
MY97=DGBB<QLLC&&1VU@<X#<?(>97T^1L;'/D<&M:,N<XX 'F@Q4=+%04,%)3
M-V0P1MBC;Y-:, ?L"V%CCE9-&V2)[7L> YKFG(<#V(*R("(B B^))&1,+Y7M
M8T=W.. %]H"+%'-'+NY3VOV.+7;3G:1W!]Z_8Y&31A\3VO8<X<TY!\$&1$1
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M:AMT=76. 8XEIIFY#<@X.[];[NW7Q[KGPZ>O5M;)2VJKI&TKR?TLD9YK1Y9
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MP:C_ "&()*B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M\G"QW_0MON>JG:@MEUGYOI%)ED/+VRN:WV'Q%PRT-/4^.>RDW\571']*7_\
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M 1$0$1$!$1 1$0$1$!$1 1$0137^@+7Q&L$-HO=35P4\-4VJ:ZD>UKRX-<T
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M:""GM<5562G+!%,\_1R3@-P">N?O6Q:M:6"]/FCMEQ;,^%AD>PQO8[:.Y <
M3\,J'78>EPWFZU$;YZ WR&.LCC!=NIH!@Y [C=U^"ZU'<*/5.LK95V.!TENM
M<4S9:PPEC'%S T1-R 3C.<>_]H20ZEM/H]OG], CN4@CI#L=^E<>PQC(^.%L
MPW&FGN%30PR[ZBF#3,P-.&;AEO7&,D=<952TPF&E([S4M=R=/30T]."/M"H:
MZ1X!_P"!OP*FM!I^^^IH9:2\^J:^JD?5UW\D9/O>_!#?:QMV@8P@DLUQIJ:X
MT]!++MJ:H/=#'M)W!HRXY P._BM2?4MJIA4.GK0QM-4-II28W8;([&&YQU[C
MJ.@\5%9[S!8]>XOT\U14T]K9#3EE.=U6]Q+GN:UHVM)+<=P!Y]UR9:J V"PU
M%WB<^"Y7*:[5C1&7X8T^( ZM <S/3L$P+ LVI[/?W3-M%<RI=!_.-VN:1[\.
M R/>.B["AU@JV:AUC5W^WPN;;XZ,4<=0]A9Z2_?N+@",X;C'7_RF*A(B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B N>^]6V.^QV:2MA;
M<I83.REW>VZ,'!=CRRN@J,M&F8M,?*?H*9E=77&HJ-/OJ:FKKYN9+-(97M)\
M@,-: T   (+5N>L].66[0VJ[7NAHZZ<CET\T[6O.3@=/#)[9[KO+SQ<*&WW*
MW<:JR[P0SUT,Q:Q\[ 71L9&>3M)[=0,8[X"GS[KKFGX-Z5K-$VNFO%ZFHZ3T
MJ.O>&C8:?+WY,C/:W[?'Q/3R"R47G?57%CC/HJULN6IM*6"AI))A R3)DR\M
M<X##*@GLUW7&.BN[2=TJ+[HRRW>M;&RHN%!!52MB!#&N?&UQ#023C)Z9)0=I
M$1 1$0$1$!$1 1$0$1$!$1!^>*QRRQPQNDE>UC&C)<XX 'WK(J@XI2TMPXBZ
M>L6J*B:'3DE/+4211N<!5S-SMC.WJ3T;@#J2[ ZD+IZ3I_ZG5[,XC$S.(S.(
MC.T>J+6Q&5KTE;35L7-HZB*HCSC?$\.'[0MC*I06BWZ+XL:4ATA%);I;PR1M
MSM#9S(UL89D/<,G!'M=0<>ST\<W5E6ZOIJZ$UM2<UM&8S&)YF-]Y\QZHK;/+
MZ1$7(L(B("(B B(@(B("(B B(@+3H[E17'TCU?64]7Z-,ZGGY$K7\J5OTHW8
M/LN&1D'J,K<4.TCI2?2DFHA/41U#+K?*BYPO8TM+&RMC]AP/B'-<,@G( /3.
M $Q1:"(-]%H(@WURI+-S=40WA\N>32NIV0[.Q<X$OW9\AC&%F1!OHM!$&^BT
M$0;Z+!3?:^"SH"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(BQ331TT$D
MTS@R.-I>]Q\ !DE!E14_8.+FH]1:@HQ1Z1?2V6XP54ENGJ9?TU8Z*,N&&Y :
M"<>8Z]"IWH35C=:Z2IKSZ')0S/<^.HII?I0RL<6N;^T>X^8!Z()*N%+I.US:
MVAU6^.0W6&C-$QXD.WE;B[&WMG+CU7=1!"K_ ,*=):EOS[O=K<]]1-L%2(YW
MQQU(9]'FL:</Q@=_(>2F3(VQL:R-H:UHPUK1@ >2^T04E\JKZK+;^,Q?D3JR
M.''U6:4_!J/\ABK?Y57U66W\9B_(G5D<./JLTI^#4?Y#$$E1$0$1$!$1 1$0
M$1$!$1 1$08Y)&QL+WN#6M&7%QP %#;AIJW\1HN?J&D,UI:"*"(N<QS\]YR1
M@C/9H_5ZG.[#>E4%VIJ^2B9UL]*_;5N\*J0=X1YL:?I^9]CP>%(L=%O2]M#%
MJ3BWK',?]1^KX(GI7ASIK1U1)4V:@+:N1NU]3-(Z20CR!/8=/#&?%2WP1%GJ
MZVIK7[]29F?69(B(C$/U$142(B("(B B(@(B("(B B(@*O.&]XN-ZDUA)=*N
M2I-+JBLI( \](H8VQ-8QH'0  ?$DDY))-AJ+Z<U7#JI][%+320,M%VFMA=(X
M$RNB:S<_ [#<X@#)R #TS@!V41$!$1 1$0$1$!$1!L4WVO@LZP4WVO@LZ OS
M**)WCYZ^JJ[T'U3S>1)R=G-W[MIVX\,YPKZ>G^9;&8CXHF<-FNUYI6V73U;7
MZ@H(*P.VNBDG:"P^3O!I^_"D#'MD:',(<UPR"#D$+SCI'YM?P;2^M?FP)L/]
M/]9[O3>9DY_M9_5V_P#/*G7"3YX_P96O9Z!Z/A_H_IO,YO*W';G'3&.WNPO9
MZS\,IH4M:MIS6W;.=HGG>/IQO\6=;S,K87R2&M)<0 !DD^"Q4O/]&C],V<_:
M.9RL[=WCC/7"^:R:*EH:B>=KGQQQN>]K6[B6@9( \?N7A\3AJKYW%\3PR7"S
MZ.U#<[)&7?[3IJ=NV5K3@OC87!SV^_IV*G=HNM'?+/27.VS<^DJX6S0R8(W-
M<,CH>H/N/4*NM.66]TNDJ2MX9ZNIJJPR0\VAM]ZI>8R)AZ\OG,(>T-.1AP<1
MC'@M:UZL;J357#"XTK#;:>XTMT#Z)DGZ,OC:QI Q@. +7%IQVZH+%U3?XM+:
M6N%\J87SQ4,)F?'&0'. \!E=2&0301R@8#VAP!\,A4IK>M?4'C#3>DNDBI[7
M0!L?,RV-QCD+L#P)Z9^"W:ZPRZ&N>D[Y:M3W6XU5UNE-0UL=35\R"NCFSN>V
M/LW:/:;MZ #'O06E:J^HN%/+)4V^:@='/)$&3$$O:UV \8\'#J%T%Y^N5^O3
M-&0VVAENDWK/5E?2S^@3!E4^)DDCA%&]W1F=H'W @>2V+/==2Z09J1]%:KY;
M[9%8JBMAI[[5MJ3%51@;71D.+MA!<7 ],CN$%\KE66^T-^96NMSW2"AK9:&8
MN86XEC.'@9[@'IGQPH)ICA]!34-EU$[6-ZFK9V1S5<\U?OAK>8WJS8?9#3NP
MW'4=.I/58>"FFJ.T?.JII9:MSVWZLHP)JAT@V1R8:<'[7F[N?%!/-3:IM.D;
M'-=;[5,IZ>)I(!(W2N\&,'VG'R"Y]5KJVT/#ZCU;50U(@K::":"DB;OGD?,&
MED36CZ3R7 ?_ (7UKJT6^NTU<;A64<,]70VZK]%GDC#G0;XB'%I/8D- R%I:
M/KK9;^%.C'WB:G@9);J"*!T^,&9T+ P#/9V>R#[TQK]M^OLUDN5CN5ANC*?T
MJ."O8T">+=M+F.:2#@D9'AD=^N)DJMIJ&ITGQLMPJ;G+>SJ*DJ(FNJQF:@;$
M.;AA'00N/0C&=P;DGPM) 1$0$1$!8IVQ/IY&U :87-(D#OHEN.N?=A95IW0-
M-IJQ)$Z9A@?NB8<.>-I]D>\]D'D"YW32MMOK(M,<2-2TMLHG2"C9'2/D]&:\
M8>(W<UG0^>T?'NO2/!^;3\O#:B&DC5R6Z-\C!+6M EEDW$O>['FXE5/H?B/=
MM):3I;'+PINTXI-S6SQTKV&5I<2'/'*^E@C)SU/7IV5W:'U!+J?3$=RJ+)4V
M)[Y'L]"J6EKVX.,X('?[D$D1$0$1$'DKCQH[6UG]-O6H-1^G6&LO+_0J#TV>
M7D;^:^/]&]H8W:P%OLDXS@=%Z0X<?59I3\&H_P ABK?Y57U66W\9B_(G5D<.
M/JLTI^#4?Y#$$E1$0$1$!$1 1$0$1$!$1!^+A76JGKJP62URNCE<T.K*EG>F
MB/8-/^\=@AOD,N/8!V:\7.6E;%1V]@FN55EL$;OHM ^E(_'V&Y&?,D-'4A9[
M3;&6JC$+'NED>XR3SO\ I32'N]WO/EV   P  M*QV1W3SX.6S1T<%!1Q4M)&
MV*"%@9&QO9H'@MA$6<S,SF01$0$1$!$1 1$0$1$!$1 1$0$1$!1NQ:5H=+>M
M/0):B3UK<Y[G/SW-.V67;N#< 8;[(P#D^\J2* \/=/W2P?.KUM3>C^L=2UM?
M2_I&OYD$FS8_V2<9P>AP?,()>B(@(B("(B B(@(B(-BF^U\%G6"F^U\%G0$1
M$$;K=!Z5N=U]95VGZ">K+MSI7P-)>?-W@X_?E2%K QH:T - P !V7UA%:^I>
M\1%K3,1QF>/@8B.'ZB(JBOJO@IHFKJZB44%53153R^HI*2NEA@F)[YC:X ?<
M,+L7_A_IS4=EH+774!BIK<]KJ+T21T#J8@8&PM(P,>';MX@*4H@A=%PKTM;[
M7>+?244D-/>H(X*UHG<3(&;L'<>NX[W$N[DE8*?AQIG2E7-J*S66>LKZ.&1U
M'2B=SQ$2,ED+'NVL+NW3&,X&!T4[1!6VD]"QWKAQ/;=<VCDNK[G4W T;I?TE
M,7S.<PA[#T< <Y!\<'Q"[^F^'FG]+S54U!2RSU%7'R9JBMJ'U$CX_P!3+R<-
M]P[^*E2((':^$&CK1>(+A26^;-)-Z12T\M5(^GIY,D[V1D[0022/(]1CHNY9
M='6G3]]NMUM4<T,]VE,U5'SG&)TA.2\,)P'$]R%($0:U?10W*W5-%5 F"IB=
M#(&G!+7 @]?N*Y51I"R5>C(M*UU&VIM,=-'2M@E))V,: WVN^X;0<CKD97>1
M!$]+\.=/:1N$U?:Z::2MFC$+JNJJ7SR",'.P%Y.UN? =^F>REB(@(B("*N..
M]SK[/PANE;::VIH*J.2 ,GI971/;F5H.'-((R#A;E[U#=*7C/IFPT]5LME=0
MU4M1!RVG>]@]D[B-PQ[B$$[4#XG5\MNIK-.S6-/I>)M:'3/G'2J8!DQCRZ*>
M+B:FT]8+_;A\Y[;3U]-2;I@V=FX,P.I ^Y!Y_P#6][__ .@+;_=__A77PQGJ
M*C1,+ZS4T.J)>=(#<81AKQGZ/P[*E=/4$&H]0V^9O#&P4-BO%/5OM;9!NGJ'
M11ES=QWX:"<?9'CU[%7%PDN%#<N'M)-;K-#9=DLL510P?0CF:\M?M]Q(S\?'
MN@G"(B"F]5\5M4VZ^ZG]16JSNM6E3#Z>*^=[:BI$@!'* Z-\?I YZ8R>BMBV
M5S;G::2N9&Z-M5 R8,?])H<T'!]_5>>>(6E;E7ZSU1/>='WR\W6K=&W3ESMP
M)IZ5C1[/,+2 W!/7>#G!QCN;7U#P]9Q!X?66RZXJZF.KIFP5%5)0O8TNJ&Q%
MC^I:1MR]QZ >""&_*J^JRV_C,7Y$ZLCAQ]5FE/P:C_(8O.G&C@OISASHNEN]
MDK+I45$UP92N;62QN8&F.1Q(#8VG.6#Q\UZ+X<?59I3\&H_R&()*B(@(B("(
MB B(@(B(/Q:%TN45JH75,H=(YS@R**,9?-(>C6-'F3\!U)P 2L3]169O/:ZZ
MT>ZF87S-;.TNC:!DD@'(6K;*6>XU[;W<XG1.VEM%2R#!IXSW<X?[QP[_ *HP
MW]8G2-/MWO&(_P F?1FLUMFIW2UUP<V2XU>#,YO5L;1]&-F?LMR?O)+O'"["
M_45)F;3D$1% (B("(B B(@(B("(B B(@(B("(B H3HK55=JDZC]814\?JF_U
M=L@Y#7#=%%LVEV2<N]HY(P/<%-E&[%7Z>KO6@TPRG;Z/<YX+CR*<PYK&[>:7
M9:-[NK<OZY\R@ZJ(B B(@(B("(B B(@V*;[7P6=8*;[7P6=!^>"_"X-&2< +
M]7)J[.Z>FE8VMJLR,<T9D\Q]RRU+6K&:QE:E:VGVIPT)=94HE>:>CJZBF8<.
MJ8XLL'Q7=I:N"NI65%-()(GC+7#Q4&I*MUKMHMU73W%M5'E@BB^A+U[@^77J
MN[IZPS4=EA95U%1%(<N='')@,R<X7E=)U6OJ:F)WVS.V,3ML]'J.GT:4S&V^
M(\YCU25?$C^7&YY!(:"< 9)7Y&SEQ-9N<_:,;G')/WKXJG3LI)G4C&R5 8XQ
M,><!SL= 3X#*]J'F*LLE\XEZQL#-4Z=JM.4]'4;GTEKFCDD<Y@) ;)*",/Z>
M P.G;JI]:]0,GI;1%>8A:[O=(#*VW2/R\.8T&1H([[<CKY$*GA?.%==05%TN
MU34Z*U,&GUC#;YIZ2HAG^UAC?9D.>H.TYSUZY"VW:CKK54<+=3<03)1_H;A!
M65<T6P,?*QO),C1]%SVLR1X'/8!!86N=8-LNDM25%FJH7W:S4C9WPN&[E%X)
M87#R(!_8M^SZTT]>+BZV4-\H:FZ0LS-2Q3M+VD#VACW'OCMXJGKS?J'4=+QA
MN-J>^:C?:Z 13.C<P2@,E&YN0"6YS@]CW'3JNA57'1E[N>B+;P_I867F@ND$
MLD5/2F.:CI8\^D-F.T;>GLD.[N(^]!9]IOL,5NN]=>+Y;YJ6BKZB-T[/T3*5
MC78$4A)QO;V)\2MJP:JL6IX))M/W:EN+(B&R>CRAQ83VR.XS[U16H8:IVBKK
M41.B90TO$"LFKGU%.Z>&.,/> ^6-O5[ XMR.O@<=%T=(.J+SK>XU%DU'9[G7
MLL=1"XV2V.IXP78Y7,D^B7!S?9'4XSX(+:@UWI6IOWJ6GU!;I;D7F,4S:AI<
M7CNWOU</+OT7+T)Q)M>N*^]4M#4TQ?;ZU\<#(I"XS4[0S$W;L7.</A\5!M%Z
M@X8PZ*T[9:RBI'7RE=!%)0"@=Z8RN;@/=C;N#@\.)=GMX^"D7"V6V4VI=<6J
M,4\-Q9?YYO1VL#9!3N9$&N Q] D'W()1K'5,^F;1OH+5576XS,D-/30,]G+6
MY+I'GV8V#IDD^X9*SZ(N]3?M!V2[7#9Z36T,4\NQNUNYS03@> ZK?OW_ *.7
M+_X27_["JWI;?J"[?)XTW0:5$1J:FWTD<PEF,6ZGV#F-#QG:7#V<]P'''5!U
M=,\0*O4O$^OME) UMCCM@JJ*;'M59YQC,H/ZA+7!OF '=B%\:0XB7+4>M:ZR
MU=E=2LBRX/-3$YC&L&R38YKB9AS06DM V9 =@G"C.FYM6P<=Z>EKK!:J!K-/
M0P20TM47,@I6SOVN9T&7;NFWR&5=#(F-=EK&@]>H'F<G]IZH,B(B"/ZRTC0Z
MYTM46"[S5$-+4.8Y[J9S6O\ 9<'#!<TCN/)>5[_HK25-J.OM.C].ZTU2+=,8
M*NHI9XVQLD'1S1MIGDX.1DX['&1U/I[B)?;KIK1-7=+ VW/KHGQB,7*=D,&'
M/ .Y[GL Z$X]H=<=^R\^V#B+Q TW-='6MFB6Q7*L?6R4[[W2%D4K\;RS^5[@
M"1G!) \,#H@LSY/U%I:FT_=CI;UM#4&I;'<*.ZN89:>1@( &UC>AR>_7(/;"
MMR4,,3Q,&F,M.X.[8\<^Y5+P(JKM7C4]QU"^U35U=7,GDFMU;!49RT@-=RI'
MAH:&@-!P>_?NK6K:=M;05%*]Q:V>)T9<.X#AC/\ B@\KW^T\/+5:X-06366I
M*2T2UL\%';Z$!S\C E,6Y[=K,.'5W4@C.5Z#X91Z<BX=6ENBW/=:.6XQ.E_G
M'.W'>7_VMV[/AY=,*CK!IK4=JU/2#4-?IRG;HVWU$-FB=7PAE54D/,;GLW[F
MY<YI<7;/HMZ9R5<?""U1VCAY3TXN5'<9W3S2U4U"\.A$SWESF-+>A#<@=/$%
M!.T1$!$1!27RJOJLMOXS%^1.K(X<?59I3\&H_P ABI'Y1^OM,7[2K-.6BZ>D
M7:WWD>DT_(E9R^6R:-_M.:&G#B!T)]W17=PX^JS2GX-1_D,025$1 1$0$1$!
M$1!^*O\ C1<*^V\,ZR6W2OI^9+%%//%]**)S@'$?\OBK 7)U+4TE)IJX35],
MVK@$+@^F>T.$^1@1X/0[B0,>]='27C3ZBEYC.)C;UW5M&:S"B-8:9T;;=)3W
MC3$D="ZT&)EOK8IM\M?4G8\G)/M!H<.P[EW8-PO0%HFJ*BRT<U<SEU4D$;YF
M8QM>6@N'[<J$Z7X-Z3L1HJ^:TQS72%C'/D?(]\8EQ[3FL)VCKVZ=.F%8:[_Q
M'J]/6K73I:;=LSO;G?&W,[;9YYGB%:5F-Y?J(B\AH(B("(B B(@(B("(B B(
M@(B("(B B(@*':1TI/I2340GJ(ZAEUOE1<X7L:6EC96Q^PX'Q#FN&03D 'IG
M F*KCAC<JZX_/+UA65%7Z-JROIX!/*Y_*B;R]L;<GV6C)P!T&4$X1$0$1$!$
M1 1$0$1$&Q3?:^"SK!3?:^"SH"(B!@>01$0$1$&M)0TLU2RHEIH7S,^C(Z,%
MS?N/<+)/!#4Q&*HB9-&[NR1H<#\"LJ(-4T-(X2!U-">:T-D!C'M@=@?,!8JN
MDD%)6.M IZ:OFC<(YWQ9 DVX87@8+@#CIGLM]$$7T-I6HTM8*BEN-8ROKJZM
MGKJN=D7+8^65VYV&Y.!X*0T])3T<7+I8(H&9SMB8&C/W!9T0:XI*9M4:H4\0
MJ",&4,&\CRSW7ZVF@9.Z=L,;97@!T@8-SAY$]RLZ(/ES0YI:X M(P01W7S'$
MR")L<+&LC8,-:T8 'D LB(,/(B](Y_+;S=NSF8&[;G.,^6?!9D1 1$0<G4>G
M+7JNR2V>_P!,:N@F+3)#S'LW%K@X=6D'N!XJDJ_A!H:#CC:=/QV3;;*BT35,
MM/Z7.=TC7X#MV_<.G@#A7#K;2MNUII6>Q7JHGIJ2J?'E].]K'[FO#F@%P(ZD
M#P5+:N^3_H72EGCK#-J:X3U%3'24M+3U%/OFFD.&MR8L =R2>V$%T:2T'IS0
MT53%I:W>@LJG-=,.?)+N+00/IN..Y[+LU[9GVVI;1G;4.B>(CG&'X./\55?!
M"R6W2\U\LL%LO-JN;>145--=*B&?V';PQS'Q-:".CL@^*D'%36%YTK:[73:5
MI(:J]7FN914HJ/H,)!)<>HSX#J<#.3VP0H"#2FC++IG3>H]46>[5=#4-JJ&^
M=9&2TU:UP+#@EO\ ;;CMTZY<KWX&0MAX3T IZ6:GI73SOI>>QK998#*[EO>&
M]-Q;CJ.^,^.5!(KGQ;US?KAI=EQMNG*^P1M=7R0M#V5DDGM1=P[ VCP^([ 6
M7PGU3<-7\.Z*XWL-]8,DEIZES&AK7OC>6[L#H,C&<=,YQT039$1 1?#I&,+0
MYP:7'#03W7V@\_\ RFM.V.W:!I;G06:@I+A4WEG/JX*5C)9=T4SG;G@9=EP!
M.3U(RK;X<?59I3\&H_R&*M_E5?59;?QF+\B=61PX^JS2GX-1_D,025$1 1$0
M$1$!$1!^*.WK%TU):K.WK%"[UA5#PVQG$33]\A#A_P!T5(O!1W2P]/=<+\[K
MZRFQ3GRIH\MCQ[G'?(/^\6FG[,3?T_S/\R)&B(LP1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0%%].:KAU4^]BEII(&6B[36PND<"971-9N?@=AN<0!DY !Z9
MP)0HW8M*T.EO6GH$M1)ZUN<]SGY[FG;++MW!N ,-]D8!R?>4'51$0$1$!$1
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MT52*>>6/>YCA'(>C7@.R//!'BNCH_1M1=;U653[5JF@A=;)Z1M7J.Y"20.E
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M50VDHYJAS7.;#&Z0M;W( S@(*4H/DRVNGM\,57JN]F9K</\ 1I&QQY_LM()
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MT2. K=)TD6L"]]X9N;4RO-;B0[CAS>4 W;C&,@''?KE>A.&WS1^9D7\'?_\
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M+ \'MD@'O@KMH@\]?*1TIIRP\-Z"JLE@M=NG?=HXW2T=%'"]S3#,2TEH!QD
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M+#H_3]505.[E3;]F[:XL/LNJ01[32.H\%TOG1\H;^HFG_P"_9_JD%VHJ O\
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MRJ"%XYSP3U<1]EH&>I[XP%LZQU]2Z1KK9;66VMNUVNCGBDH*%H+WA@RYQ)(
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ME8',>,YP0>_4+\MMMH;10QT-JHX*.FB^A!3QAC&^)P!T0;B(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img44875045_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'M J0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDS17)?$AA<C/!]*@CAUZRM7L(&@\E7V"82 %"3P.N03D=L\BK&LZ?>7&D6T
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MN<.'<5&?-V_5&3IJ:IJLEW&FI2PQQOU+$DGG '/ XK2\,7ES<PW,5S*9#"X
M9CD]^_X5)X>T^ZL7O3<Q;!(X*?,#D<^A]Z/#VGW5B]Z;F+8)'!3Y@<CGT/O7
MGX2C5A*E-WN^;FO?Y>AV8BK"4:D5;2UMOF6M>_Y =W_N?U%8>E:S>VVF00Q:
M/<3HH.)%SAN3_LFN@U>"6ZTJXAA7=(ZX49 SS[TW1K>6TTBW@G39(@.Y<@XY
M/I756HU9XM2@W%<N]K]=M3"G4IQPUI*_O;7\M]#G_#]V;6QU:Z*?,A#;3Z\X
M'YU1_M.YD@:Z;6I$N<Y%N%;'7_OFMO2M'G6WU*"\C\M;@_*=P/KSP?I4%O;>
M([&#[%;K"8@?DF)!P,^Y_I7F>QKJE3BU*UGLG>]WT373:^AW>THNI-IJ]UNU
MM;NT_P#,MO?75]X>@N(KJ"U=SB65VVXP2#CCJ<5FPZ@8-<M(;/4Y[N"0A9!*
MQ;DG'&:T-:TJ^O+.SVNMS-"29 <*'SCZ#M5:73M1FU2RN_[/B@BB<9BB=<J
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M'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BL?Q3H]YKWAR[TRPU:?2;J;9LO8,[XL.K'&&4\@$=1
MUKR+1=)U_P )_''0-%U'Q=J6MQ7-G+.3<22!1\DH"[6=LX*YH ]UHHI&)"D@
M9(' ]: %J&>[MK4#[1/%%NZ>8X7/YU@_V]K'_0"E_,_X5Q^IW=Q>ZA-+<@K)
MN(V'^#';\*=@/4U974,C!E(R"#D$4M<%X>U;4;6"6"VLWNXP0=HS\F?P[_TK
MIM,U._O+HQW6F/;1A"P=B>3D<=*0&O5>]O;?3K.6[NY1%;Q#+N02 /PJQ7-?
M$#=_P@>L;" _D?*6&1G(ZT ;MU>V]DL1N91&)95A3(/S.QPH_$U8KB/$<>NJ
MVBF_NM-DM_[7M<K!;NC9W\<ER/TK#FUW7+RUU?5[6/6/M=IJ,T5NBR0I:".&
M788W#.,[@IRQ&06X( % 'J=4/[:TW[5<6QO(A-;S1V\J,<%9) &1>>I(8'CU
MKSOQ1K>KVZ:UJ>GRZG(+&^CCCN1*D5K" T:M%Y9):4Y+9)7JV 1BH=6LDO?%
MNNH\MQ&!XCTP9AF:,\V\0ZJ10!Z?9ZC:7[W26LRR-:S&WG !^20*&*G\&4_C
M5JO*%BNK*U\<:S::E>03V6M[HHTD_=DB*#.Y?XMP.#GTXP>:U+_5]0M]<O?"
MXOIOME[JMM):2;CO2TD4R2 'T'D7"C'3*]* /0Z*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR?7_\ DY7PK_V"
MI?Y3UZQ7D^O_ /)ROA7_ +!4O\IZ /6**** "L34_#%GJ5R;@L\4C?>*=&_"
MMNJ=WJEI9.$ED^?^ZHR1]:3:6Y482F[15PT[3;?2[;R+=3@G+,W)8^]7*B@N
M(KJ(2PN'0]Q4M,333LPJKJ.GVVJZ?-8W:%[>9=KJ&(R.O45:JKJ>HVVDZ9<Z
MA>,5M[>,R.54L<#T Y)]J!!>Z?;:BL"W*%A!.D\>&(PZ'*GCWK.G\):/<W[W
M<D$Q,DJSRP"YD$$DB]':(-L8\ \CD@$YP*;:^(Y'U"UL[_1K_3FN\BW><Q.K
M,%+%"8W;:V 3SP>Q)K5M[KS;-;B9/L^<Y5W4[><=02/UH P]0\"Z#JANQ=07
M)BNY/.FA2[E2(R8'S[ P4-P#G'49Z\U:NO"FDWCWSRPRB2]GBN99(YW1O-B5
M51E*D%2 J]*M)JT+Z_<:1L<306L5TSG&TJ[2*!]<QG\Q3+?6[>Y\07>CQHYE
MMK:*Y:3C8RR%P .>OR'\Q0!'_P (SI?V'4K,PN8=2F,]T#(Q+N55<YSD<(O3
MTJH-"FNO':Z]=P01QV=HUK:%)"SR;V!9F&T;<;<  G[S=.*Z!'61=R,&'J#F
MLG4?$"V>I)IEI8W.H7[1^<\-OL BCR0&=G90 2" ,DG!P, D &Q16;HVMP:S
M!.R136UQ;2F&YMK@ 20O@'#8)!R""""0000:36=<MM%T^*]E5YHI+B&W7RL'
MYI)%C!Z] 6&: -.BL[2-9AUC[?Y,<B?8[R2T??CYF3&2,=N:R)_%MW!K<&D-
MX;OS=3Q231 3P89$*ACG?QRZ_G0!U%%11SAD3?B.5@,QLP)4XSCBG>8IW[6#
M,G501D4 /HK+L]=MKO4SIA5HKU+6.ZDB9E;:KE@!D$@G*-T]O6M2@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBD=UC1G=@JJ,EB< #UH 6BO,=2^-NBI=R6OA_2]4\02QG#
M/90'RP?3=U/U QZ&HK7XX:;#(J^(O#VM:&C' FN+9FC'UX#?DIH ]3HJ"SO+
M;4+.&\LYXY[:9 \<L;95E/0@U/0 5Y3\1_BE<>'/%NC^'-&,+74TT9O6D7=Y
M:.P"J/\ :()/L,>M>BZ]JAT70+[4EMY+EK:%I%AB&6D('"@>YKY=U6_MDT_1
M[^_BOVU^\UL7^I2S6;H,9^6-"1R%'0#U..,4 >[>-O%^JV7BG1/"/AP68U?5
M \KS78+)!$H)W;1U)VOC_=]^)/ 7B[5-8U/7/#WB"*W36-&F57EMP1'/&V=K
M@$Y'3G_>%<M>:C%>?M >$-56*:.UO]'>.!IH]AW#SB00>0<$?]]"K7@A3<_'
M3Q[>0ON@B2&%\=-^ /S&QA^= 'K%>3Z__P G*^%?^P5+_*>EU'P+\2KC4[N>
MT\?^1;23.\46P_NT))"].PP*YG2-&\0:)\?_  Y;^(M;_M>Z>QF=)L$;4V3#
M;S[@G\: /?:0YVG'7'%+10!C>7KW_/:#\A_A7.7@F6\E%Q_K=QW?6N\JK<Z=
M:7C!IX0S#OD@_I64Z=UHSOH8Q4Y7E%6\D<YHZ:BR2FR=53(W;^A/M6[8IJ:S
MDWDD31;> O7/Y5=BAC@B$<2!$'0"GU4866YE6Q/M&VHK7RU"LGQ.VE+X;OAK
M>[^S'C\NX(#?*C$+G*\@#.2W8#/&*UJ" 1@C(-6<IP%H-3\.Z[HMK9>)9M<T
MS4)FA:VNRDLT*"-W\U95P2HV@'=G[PYR:P_",&GWD7A>VUJ."6R^P7KV\5T
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M=@S( "!*%.&*,1AP"1G:3C-<;'IFHI<>&+JXLI4EGU^ZOI8@N3;QR13[ Y'
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M%^(?'L5G=_V3H-O_ &IJ[DJ(X^4C/^T1UQZ#IW(J)SC!7D=&&PM7$SY*2O\
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M0K#%?P)^C_(UH?Q8^J_,T:***W,@HHHH **** "BBB@ HHHH **** "BBB@
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M?>%/J/3UK2UW5#I=CO0 S2':@/0>IK+\,FR:9I7N#/J,H+-E6^0=^2,9]_\
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MDL9D2').Y-DQW<^Y(_"@#WVBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_EFGS-^7;\:R_[1UO5^-/M1:6Y_Y;2]2/;_ .L#]: -ZZO;:RC\RYF2)?\
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MZ=/]ZNC\-?#N"PB#70VYY9 <NW^\W;Z"M_5?$>@>$K41W,\4) RMO$-TC?\
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M:V"/J.M"PROS3=V5/.)*/LL+!0B^BZ^KW?S9KW.O2,HC6:1D P%3Y$ ]@/\
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M GZ/\C6A_%CZK\S1HHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEWJ\J%A'#9Q_WY2!C\_\*R[N\TZ-2^HZV9@.2L/*C\>E3S/HBU02^*2^6K_
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MVW^HMXHO]Q *GHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_OH_X4?\+4\#?]#-8_\ ?1_PH ["BN/_ .%J>!O^AFL?^^C_ (4?\+4\#?\
M0S6/_?1_PH ["BN/_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\ "@#L**X_
M_A:G@;_H9K'_ +Z/^%'_  M3P-_T,UC_ -]'_"@#L**X_P#X6IX&_P"AFL?^
M^C_A1_PM3P-_T,UC_P!]'_"@#L**X_\ X6IX&_Z&:Q_[Z/\ A1_PM3P-_P!#
M-8_]]'_"@#L**X__ (6IX&_Z&:Q_[Z/^%'_"U/ W_0S6/_?1_P * .PHKC_^
M%J>!O^AFL?\ OH_X4?\ "U/ W_0S6/\ WT?\* .PHKC_ /A:G@;_ *&:Q_[Z
M/^%'_"U/ W_0S6/_ 'T?\* .PHKC_P#A:G@;_H9K'_OH_P"%'_"U/ W_ $,U
MC_WT?\* .PHKC_\ A:G@;_H9K'_OH_X4?\+4\#?]#-8_]]'_  H ["BN/_X6
MIX&_Z&:Q_P"^C_A1_P +4\#?]#-8_P#?1_PH ["BN/\ ^%J>!O\ H9K'_OH_
MX4?\+4\#?]#-8_\ ?1_PH ["BN/_ .%J>!O^AFL?^^C_ (4?\+4\#?\ 0S6/
M_?1_PH ["BN/_P"%J>!O^AFL?^^C_A1_PM3P-_T,UC_WT?\ "@#L**X__A:G
M@;_H9K'_ +Z/^%'_  M3P-_T,UC_ -]'_"@#L**X_P#X6IX&_P"AFL?^^C_A
M1_PM3P-_T,UC_P!]'_"@#L**X_\ X6IX&_Z&:Q_[Z/\ A1_PM3P-_P!#-8_]
M]'_"@#L**X__ (6IX&_Z&:Q_[Z/^%'_"U/ W_0S6/_?1_P * .PHKC_^%J>!
MO^AFL?\ OH_X5TVFZE9:QI\-_I]PEQ:3 F.5.C '''X@T 6J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ROQE!>^&_BSHWC
M,6-Y>:2UDUC>?9(3*\)^8ABHYVDLO_?)]0#/\+],OKGQ#XK\7WMC/91:O= 6
M<-Q'LD\E"WS%3R,Y7\CU&#7IM% '*7'PS\%W=S+<S^';*2:9S)(Y4Y9B<D]?
M6JY^$_@0RB3_ (1JSW 8P"V/RSBNSHH X_\ X57X&_Z%FQ_[Y/\ C1_PJOP-
M_P!"S8_]\G_&NPHH X__ (57X&_Z%FQ_[Y/^-'_"J_ W_0LV/_?)_P :["B@
M#C_^%5^!O^A9L?\ OD_XT?\ "J_ W_0LV/\ WR?\:["B@#C_ /A5?@;_ *%F
MQ_[Y/^-'_"J_ W_0LV/_ 'R?\:["B@#C_P#A5?@;_H6;'_OD_P"-'_"J_ W_
M $+-C_WR?\:["B@#C_\ A5?@;_H6;'_OD_XT?\*K\#?]"S8_]\G_ !KL** .
M/_X57X&_Z%FQ_P"^3_C1_P *K\#?]"S8_P#?)_QKL** /"/#?@CPS=_&OQ9I
M$^C6TFGVEM"T%N0=L9*QDD<^Y_.O1_\ A5?@;_H6;'_OD_XTFC>#+C3/B7K_
M (I>[B>#4X8XT@53N0J$&2>G\/ZUV- ''_\ "J_ W_0LV/\ WR?\:/\ A5?@
M;_H6;'_OD_XUV%% ''_\*K\#?]"S8_\ ?)_QH_X57X&_Z%FQ_P"^3_C7844
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M+ << #M7144 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img44875045_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1Y")T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 445\Y6/QP^(VKS7$>D^&;&_P#(.)/LMA<2E 2<;MLAQG!_*@#Z
M-HKY_P#^%I_%_P#Z$+_RCW?_ ,71_P +3^+_ /T(7_E'N_\ XN@#Z HKY_\
M^%I_%_\ Z$+_ ,H]W_\ %T?\+3^+_P#T(7_E'N__ (N@#Z HKY__ .%I_%__
M *$+_P H]W_\71_PM/XO_P#0A?\ E'N__BZ /H"BOG__ (6G\7_^A"_\H]W_
M /%T?\+3^+__ $(7_E'N_P#XN@#Z HKY_P#^%I_%_P#Z$+_RCW?_ ,71_P +
M3^+_ /T(7_E'N_\ XN@#Z HKYPU/XX?$C11$=5\+V-@)<^6;K3[B+?C&<;I!
MG&1^=?1D3EX4<XRR@G% #Z*** "BBB@ HHHH **\L^./BC6O"V@:;<:)?O9R
MRW#([*JMD;<XY!KPO_A<'C[_ *&.?_OU'_\ $T ?8]%?''_"X/'W_0QS_P#?
MJ/\ ^)JS!\;OB#"RYUT2JO\ #):0G/U(3/ZT ?7U%?/7A7]HRX%Q%;^*-.B:
M$G#7=F"&7W*'.?P(^E>]Z;J5GJ^GP7^GW$=Q:SKNCE0Y#"@"U1110 4444 %
M%%% !1110 4444 %%%% !1110 45X_\ $WXUQ^%KV31M!BAN]23B::0YC@/]
MW ^\WXX'O7E<?Q"^+&K@WUG<ZK-""3NM; &,=OX4Q^= 'UI17S-X6_: \0Z9
M?+;^)XDU"UW;9)%B$4\?X#"G'H0#[U]&Z5JEEK6F6^HZ?.L]K.@>.1>X_H?:
M@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5.^TC3-34K?Z=:7:D8(N(
M%D!_,5<HH R;:PT+PCI=W-:VMGI=BI-Q.8HQ&@P "Q ]@*\C^*_Q@\.WGA2]
MT'0;G[?=7B^5)*B$1Q)D%N2!N)' QD<YSQ@^D_$?3-3UKP#JNF:/ )[ZZ1(D
M0NJ#!==Q)) X7<:^8_$7PA\9>&M,?4KS3DFM(E+3/;2B3RAZL.N/< @8YQ0!
ME>!?"%[XT\46NF6T3&W#J]W*.D46?F)/KC@#N:^V0 JA5   P .U?+'PO^+_
M /PAPATC4=.M3I3O^\N;>(),A/\ &V/]9CCKS@=3TKZD@GBN;>.>"19(95#H
MZG(92,@@^F* /GC]I740^KZ#I@8YA@DN&7/]]@H./^V9_6N5^$'C+0? U]J^
MJZOY[SO;I!;101[F<%MS\D@ #:G4]^]/^.\EW<_$R\DEMIDMH8HK>&5D(5\(
M&.#C!^9F'X5G>!OA-XA\<V_VVV\JSTT,5%U<YPY'78H&6P>,\#J,Y!H ]=M_
MVD/#4EP$N-(U2&(G'F (V/<C</TS7IWAWQ1HWBO3OMVBWT=U"#APO#1GT93R
MI^M?,7C/X*>(_".F2:HLMOJ-A",S/;Y#Q#NQ4_PCU!..IP*Y3P=XLO\ P9XC
MM]6L';Y"%FAW86:/NI_IZ'!H ^N/B1?-IWPW\0W"L5;[#)&K X(+C8"/^^J^
M**^N?BUJ,6H?!'5-1LI=T%U!;21N.Z/-'_,&OD:@#[STBS33]%L;*)-D=O;Q
MQ*N,;0J@ 8_"O!_VF+0+<^'+P(=SI<1,V/0H0,_\";]:^A*\*_:6_P"05X>_
MZ[S?^@K0!PGP#O\ ['\4;>#./MEK-!]<#S/_ &G7UA7QW\&BR_%K02N<[Y1Q
MZ>2^?TK[$H **^8/VCO^2A:?_P!@J/\ ]&RUX_0!]_T5\ 44 ??]%? %>@?!
M+_DKVA?]O'_HB2@#Z_HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBOG]O^3NQ_G_EQH ^@****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ /5JC2>&1V2.5&9>H5@2*^1]/\ #/Q&^*"-?M)=WEJ6.)[RXV19SR$!./\
MOD8%6;_X$>.K" SQ6MK=E!NVVUP"WX!@,GZ4 ?6=%?'_ (6^)OBSP-JZV]U<
MW<]K%)LN-/O225 X(&[E"/;\17UKIU_;ZOI5M?VS;[:ZB65#ZJPR* +=%?'G
MC.37/!'Q#N[6/4KW;:W(GMP\[D,F0R9YYXQFOK+0=6AUW0;'5+<YBNH%E7VR
M,XH T:**\ _:&\77%M>:;H%A=2PLBFYN#$Y4Y/"@X]@3^(H ]_HKSGX*:3=V
M'@""]U">>:YU%C<9F<L50\(!GM@ _C7HU !7*?$?Q.?"7@?4-3C.+G;Y-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M: />**** "OCOXR;?^%J:UMZ;T_/8,U]B5\2>.-2_M_Q]J]Y;_.MQ>.(=O\
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M3 _V26_I0!]I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG]O^3NQ_G_EQKZ
MKY_;_D[L?Y_Y<: /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^8OVC_^
M1^T[_L%I_P"C9:^G:^8OVC_^1^T[_L%I_P"C9: /IN/_ %2?[HIU-C_U2?[H
MIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?,/P4\:^'O!U_XA;7M0^R
M"Z,0A_<R2;MIDS]Q3C[PZ^M?3U>0O^SGX0=V<ZCKF6.3B>+_ .-4 ;W_  NW
MX>?]##_Y)7'_ ,;H_P"%V_#S_H8?_)*X_P#C=<__ ,,X^#_^@EKG_?\ A_\
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MT19W5[X9TI;6VFG9;IB1%&6(&WVKPG2+CQGH"RKI']LV*RD&06Z2)N(Z9P*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *^?V_Y.['^?\ EQKZ KY_;_D[L?Y_Y<: /H"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^8OVC_ /D?M._[!:?^C9:^G:^8OVC_ /D?
MM._[!:?^C9: /IN/_5)_NBG4V/\ U2?[HIU !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!7DL+.:42RVD#R#D.T8)'XU.JJBA5 "@8
MX%+10 4444 %>.?'_P 7P:?X77P[;W"F]OG!FC5N4B'//IDXQ]#6+\;;/QC;
M^+K:_P##AUP6LMHJR/IYEVAPS#!V>V*X/PI\*?%OC'6DFU2TO;.S9PUQ>7RL
MKL.^T-RQ/KTH ]._9W\+FQT"\\0W$>);Y_+@)'_+->I_%L_D*]KJKINGVVDZ
M;;:?9QB*VMXUCC0=E P*M4 %%%% !1110 56FTZQN9 \]G;RN#D-)$K$'\15
MFB@!%544*H"J!@ # %+110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KY_;_ ).['^?^7&OH"OG]O^3NQ_G_ )<: /H"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *^8OVC_P#D?M._[!:?^C9:^G:^8OVC_P#D?M._
M[!:?^C9: /IN/_5)_NBG4V/_ %2?[HIU !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $1)7L'[1W_)/+#_ +"L?_HJ6O'_ ()?\E>T+_MX_P#1$E 'U_1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?/[?\G=C_/_ "XU] 5\_M_R=V/\_P#+C0!] 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7S%^T?\ \C]IW_8+3_T;+7T[7S%^T?\ \C]IW_8+
M3_T;+0!]-Q_ZI/\ =%.IL?\ JD_W13J "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_DGEA_V%8_\ T5+7C_P2_P"2O:%_V\?^B)* /K^BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W
M$$=U;2V\RAHI4*.I[J1@BI** /B#QIX5N_!OBF[T>Z5BL;;H)"/];$2=K?D.
M?<$=J[OPO\?_ !#H>G1V.I6<&K1Q*$CEDD,<N!_>;D-VYQGU)KZ!\8>"-$\;
MZ:+35[?+H#Y%Q'Q+"3U*G\!D'@XKP;6_V=?$EI.YT>^LM0M_X1(QAE_$'*_C
MN_ 4 ><>#O$?_")>++#7?LOVK[(S-Y/F;-V4*_>P<=<]*ZGQS\9-?\:V;:=Y
M<6G::^-\$!+-)CG#N>HSV 'OFF+\$/B$T@4Z$JC.-YO(,?7A\_I76^'?V<M5
MGG63Q%J<%K;@\Q6A\R1O;) 5?K\WTH Y?X+>$9O$OCNUO'C;[!I;K=3/C@N#
MF-?J6 ./137UQ67X?\.Z7X7TB+2](M5M[6/G .2S'JS$\DGUK4H **** "BB
MB@ I"0H))  Y)-+7AG[0OC6XT^UM?"MA,T37<?GWC+P3%DJJ9]"0Q/\ N@="
M: .M\0?&_P %Z!</;+=S:C.APRV"!U!_WR0I_ FLBR_:*\(W$XCN+/5;52?]
M8\*,H^NUB?R!KP#P=X(UOQSJ;V6CPQGR@&FGF;;'$#G&X\GG'  )]N#70>-/
M@YXC\%Z4=5GDM;VQ0@2R6S',63@%@P'&2!D9ZT ?5FC:YIGB'3DO])O8;RU?
MI)$V<'T(Z@^QYK0KXO\ AOXUNO!/BRVO$E86$[K%>Q9^5XR?O8]5R2#]1T)K
M[0H :[I'&SNP5%!+,QP !W->9ZY\>?!>CW#6\$MUJ<BG!:RC!0'_ 'F(!^HS
M7&_M!^.;F*XA\(V$QCC,8FOV0\OG[D9]L#<1WRM>3^"? >L^/-2EM-*6)$@4
M-//.Q"1@],X!))P< #L: /H32/V@/!FHW AN1?Z<6( DN804Y]T+$?B,5Z?;
M75O>VL5S:SQSV\JAXY8F#*ZGH01P17QMXZ^&NN> 9+=M2,$]K<$K%<V[$J6'
M.TY (./\\&NV^ 7CBXT_Q /"UY,SV%]N-L&/$,P!.!Z!AGCUQZF@#Z8JAK&M
MZ9X?TZ34-6O8K2UCZR2'J?0#J3[#FK]?''Q1\<7'C7Q;<2+,3I=J[1640;Y=
MH.-_U;&?I@=J /:KW]HKPC;SF.WL]5NE'_+5(D53]-S _F!70>%OC#X0\5W<
M=G;W<MG>2'"07J",N?0,"5)]!G)]*\!\'_!GQ+XQT7^UK>2TL[1\B!KIF!E(
MXR JG"YR,GTZ&N/\0^'M1\+:W<:1JL/E74!&<'*L#R&4]P1_]?!XH ^ZZ*\N
M^!_CB?Q7X6EL-0E:74=+*QO(Y):6)L[&)/4\$'Z GK7J- !1110 4444 >0?
MM'?\D\L/^PK'_P"BI:\?^"7_ "5[0O\ MX_]$25[!^T=_P D\L/^PK'_ .BI
M:\?^"7_)7M"_[>/_ $1)0!]?T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S^W_ "=V/\_\N-?0
M%?/[?\G=C_/_ "XT ?0%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M45TGB!1110 4444 <'\4O'UUX TBRO;6RANVN)C&5E8J  ,YXKRO_AI36/\
MH7['_O\ /72_M(_\BOI'_7VW_H-<I\"O!GA[Q59ZP^MZ9'>-!)&(R[LNT$'/
MW2* )O\ AI36/^A?L?\ O\]3V_[2]\I'VGPS;R#//EW;)Q^*FO4&^#O@!E(/
MAR'!&.)I1_[-5.Y^!GP_GB*1Z/+;L?XXKR4D?]],1^E %7PM\=?"OB&XBM+O
MSM)NY#A1<D&(GT$@_J!7IP(8 @@@]"*^3_B9\'[SP1'_ &G83O>Z.S[2[+^\
M@)Z!\<$?[0_(<5V7P(^(]Q/<)X0U67S%"$V,KGYACK'[C&2/3!'I0![_ $44
M4 %%%% !1110 4444 %%%% !1110 4444 %97B/Q!8^&-"NM6U&4)! I.,X+
MMV4>YJAXL\=:!X,LVFU:]19BN8[5#NED^B^GN<"OE?Q]\0]6^(&I>;.A@L+?
M)@M(R2L8Z;F/=NG- 'N?PN^*^I^/?$%[87FGVEM###YJ&'=N/S8P<G%>LU\S
M?LX_\CCJ7_7G_P"S"OIF@ KD?&WQ&T'P+;J=2E:6[D&8K2#!D8>ISP![G\,U
MNZ_J\.@:!?:M<<QVD+2$?WB!P/Q.!^-?(.DV.J_%+XAB.><FXOI3)/*>D<8Z
MX'L. /I0!Z)=_M*ZBTQ^Q^';6.+/ FN&=L?4 5M^'_VCM-NKA(=>TB6Q5B!]
MHMY/-4>[*0"!],UZ'HGPR\'Z%8I;0:#93L%PTUW"LTC^I)8'KZ# K@?BS\(M
M$?P[=Z[H-E%87EFGFR0P#;%*@Z_*. 0.>,=#0![%8:A9ZK8Q7MA<Q7-K*NZ.
M6)MRL/K5FOFK]GOQ9<VGB&;PW-*SV=TAEA0G(CD7KCZC^5?2M !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'F6H?'?P?INI75A<+J/G6T
MSPR;;<$;E)!Q\W3(JO\ \-">"?[NI_\ @,/_ (JO!?%7A7Q%/XPUN6+0-4DC
M>_G9'2SD(8&1B"#CD5D?\(AXF_Z%W5__  "D_P#B: /I'_AH3P3_ '=3_P#
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M25R>I>)=>UFW6WU36]2OH%<.L=U=/*H;!&0&)&<$C/N:ZSX)?\E>T+_MX_\
M1$E 'U_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?/[?\ )W8_S_RXU] 5\_M_R=V/\_\ +C0!
M] 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7S%^T?_ ,C]IW_8+3_T;+7T
M[7S%^T?_ ,C]IW_8+3_T;+0!]-Q_ZI/]T4ZFQ_ZI/]T4Z@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ]J](H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ<J?INQ^% 'R#XHMS:>+=:MB IAOIX\ 8 Q(PKZ>^ TPE^%=D@QF*XF0X/\
MMEO_ &:O$OC?X?DT3XDWMQL(MM2 NHFQP21AQGUW GZ,/6NB^!7Q$TKPU'?:
M#K=RMI;7$HN+>X<?(),!65CVR%7!Z<'GI0![%\6[@6OPK\02$@ VXCY_VG5?
MZU\;11O-*D4:EG=@J@=R>E>^_'#XEZ+JOAU/#FA7T5\T\JR74L)W1JB\A0W0
MDM@\9QCWKS/X4^'I/$?Q&TFV"%H+>47=P1T"1D-S[%MJ_P# J /I;XH6/F?"
M37+4*K>59AL;>/W95NG_  &OC:OO35=/BU;2+W3I_P#57<#P/_NLI4_SKX6U
M/3KG2-4NM.O(]ES:RM%(OHP.#^% 'W?;3"XM89AC$B!QCIR,UX/^TQ<8A\-6
MPQAFN)&]1CRP/YG\JZ3X:?%KPY=>#;&SUG5K>PU&QA6"5;EM@D51A65CPV0!
MD=<YXZ9\<^,7C>T\:^+DDTUV?3;*+R8)"I7S"3EGP>0"<#GLM #_ (&6C7/Q
M8TR0#*V\<\K<=O*9?YL*^N:^?/V;_#LGVG5?$DL9$806=NQ_B)(9\?3"#/N:
M^@Z .7\2?#OPKXNU&._US2_M=U'$(5?[1+'A 20,(P'5C^=8_P#PI+X>?]"]
M_P"3MQ_\<KT"B@#S_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\ '*]
MHH ^>/C7\._"OA'P;9W^AZ5]DNI-02%G^T2R90QR$C#L1U4?E7#_  2_Y*]H
M7_;Q_P"B)*]@_:._Y)Y8?]A6/_T5+7C_ ,$O^2O:%_V\?^B)* /K^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^?V_Y.['^?\ EQKZ KY_;_D[L?Y_Y<: /H"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^8OVC_ /D?M._[!:?^C9:^G:^8OVC_ /D?M._[
M!:?^C9: /IN/_5)_NBG4V/\ U2?[HIU !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>3?!G_C\U[_ME_-Z]9KR;X,_\?FO?]LOYO7+5_C4_G^1[F7_ /(M
MQ?\ VY_Z4>LT445U'AA1110 4444 %%%% !1110!Y3\:_P#4:+_O3?R2O4X?
M]1'_ +H_E7EGQK_U&B_[TW\DKU.'_41_[H_E7+2_CU/E^1[F._Y%>$_[?_\
M2D/HHHKJ/#"BBB@ HHHH \4_:1_Y%?2/^OMO_0:I?LU?\>&O?]=8OY&KO[2/
M_(KZ1_U]M_Z#5+]FK_CPU[_KK%_(T >\4444 %?%GQ,OTU+XD:[<1'*?:FC4
M^H7Y<_I7U)\1O&UIX)\+7%V\J_;YE,=G#GYF<C[V/0=3^7>OE_X<^')_&/C^
MQMG5I(5E^TW;'D;%.3GZG _&@#ZV\)6+Z9X/T:QE&)+>RBC8>X4"L?QO\2M
M\"1*NH2//>R+NCLX,%R/4]E'N?PS77DK#$2>$1<_@*^);ZZO/''C_?<S8GU.
M^6(,QR(PS!0![ 8_*@#TC4OVD==E=AIFBZ?;(>GVAGF8#\"H_2L8?%;XH^)&
M,6ER7#;N-NGV 8_GM)'YU]!>'?AQX5\-6D45GHUH\R ;KF>,22L>YW,,CZ#
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M_A'?AY9M(FVYO_\ 2I<CGYONC\%Q0!Z%1110 4444 %<+\9/^23:]_USB_\
M1J5W5<+\9/\ DDVO?]<XO_1J4 >0?LX_\CCJ7_7G_P"S"OIFOF;]G'_D<=2_
MZ\__ &85],T %%<I\1M?U7PQX*O-8TB*"2XMRI83H64(3@G (YY%>>?"+XLZ
MQXM\476EZ]-;YDAWVJQQ! &4_,/4Y!_2@#VZL/Q5X2TGQAI$FGZK;)("I\J7
M;\\+$?>4]OZ]ZW*"<#)Z4 ?$MO<7_P ._'Y:-\W.EW;1OM.!(H.&'T(S^=?:
MMK.MU:0W"?=D0./Q&:^+_'U_%K_Q&U>XL!YD<]V4A*_Q\X!'UK['T:U:RT6Q
MM7.6B@1"?< 4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *R/%6I/HWA'6-3B_UMK9331_[RH2/UQ6O6)XQT^75?!6N6$ S-<6$T<8]7
M*':/SQ0!\2Z=8W&KZM::?;X-S>3I!'O/!=V"C)^IK[#\"_#30_ 4)>P$TU_+
M$(Y[N5SEQG. H^51GVS[FOD'0]2.B^(--U58_,-E=17 3.-VQPV/TK[<T#Q%
MI7B?2HM1TB\CN() "=I^9#_=8=5/L: -2O)?B;\(O#VH^&K_ %32+"'3M3M(
M6G4VRA(Y0H+%60?+R,X(P<XSQQ7K5>>?%CQWI?AGPEJ%B;J-]5O;=X(+9&!=
M=ZE=[#L!DGGJ>* /EWPCJ4FC^,=&U"-RI@O(F)'==PW#Z$9'XU]RU\+^%=/D
MU;Q;I%A$K%I[R)/EZ@%AD_@,G\*^Z* "BBB@ HHHH *Y_P 8>#]+\;:&^EZI
M&<9W0S)]^%^S*?YCO7044 ?)GB#X%^,M&N7%E:)JMKD[9K5P&Q[HQ!!^F?K6
M+:?"CQU>RB./PW>(<XS,!$!^+$"OLVB@#QGX;? Z+P[?0ZUXCEAN]0B.Z"VC
M^:*%NS$G[S#MQ@'UX(]FHHH Y?QWX&TWQYH7]GWQ:*:,[[:Z09:%_P"H/<=_
M8@$?->N_!7QMHURZ1:8=1MP?EGLV#;A_N_>!_#\:^O** /CO2O@YXZU6X6,:
M)):(3AIKQA$J>Y!^8_@#7T?\.?AU8?#_ $AXHW%SJ-Q@W5T5QNQT51V4?KU]
MAVM% !7E?Q1^#T'C24ZOI,D5IK(7$F\?N[D 8&XCHPX ;GC@]L>J44 ?&=[\
M)_'5C.8I/#EW(02 T $JGWRI-=!X7^ _BO6+R,ZM"NDV(;]X\KJTA'HJ GG_
M 'L?CTKZLHH SM"T2P\.:-;:3ID AM+==J+W/<DGN2<DGWK1HHH **** "BB
MB@#R#]H[_DGEA_V%8_\ T5+7C_P2_P"2O:%_V\?^B)*]@_:._P"2>6'_ &%8
M_P#T5+7C_P $O^2O:%_V\?\ HB2@#Z_HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG]O\ D[L?
MY_Y<:^@*^?V_Y.['^?\ EQH ^@**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KYB_:/_ .1^T[_L%I_Z-EKZ=KYB_:/_ .1^T[_L%I_Z-EH ^FX_]4G^Z*=3
M8_\ 5)_NBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA(DM()!AI6[.1V4=1ZGGIU^C:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#Y;^,/PMO?#^L7.O:1:O-HMRQED$8)-JYY8,/[A
M/(/0=#CC/E5K=W-E,)K2XEMY0,!XG*-CZBOO@@,"" 0>"#7$ZU\(_!&N3M<7
M&AQ0SL<F2U=H<GN2%(4GWQF@#Y.D\5>(ID*2Z_JCH>JM>2$?SK*):1\G+.Q^
MI)KZJ3]G[P0KABNHL/[IN>#^2YKJ_#_PY\)>%YEGTK1;>.X7[L\F99 ?9F)(
M_#% 'FGP0^%UWH]P/%.NV[071C*V5M(,-&&&#(P[$C@#T)SVKW.BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R
M#]H[_DGEA_V%8_\ T5+7C_P2_P"2O:%_V\?^B)*]@_:._P"2>6'_ &%8_P#T
M5+7C_P $O^2O:%_V\?\ HB2@#Z_HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG]O\ D[L?Y_Y<
M:^@*^?V_Y.['^?\ EQH ^@**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYB
M_:/_ .1^T[_L%I_Z-EKZ=KYB_:/_ .1^T[_L%I_Z-EH ^FX_]4G^Z*=38_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %?/[?\G=C_/\ RXU] 5\_M_R=V/\ /_+C0!] 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8_\ 5)_NBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[>/_ $1)0!]?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7S^W_ "=V/\_\N-?0%?/[?\G=C_/_
M "XT ?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Q?M'_P#(_:=_V"T_
M]&RU].U\Q?M'_P#(_:=_V"T_]&RT ?3<?^J3_=%.IL?^J3_=%.H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#S+5_&7CJTUB]MK+PUYUK%.Z0R_89VWH"0#D-@
MY'<53_X3OXA_]"I_Y3KC_P"*KUFBN9T)M_&SVH9IAHQ2>&B_O/)O^$[^(?\
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M?M'?\D\L/^PK'_Z*EKQ_X)?\E>T+_MX_]$24 ?7]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\
M_M_R=V/\_P#+C7T!7S^W_)W8_P _\N- 'T!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?,7[1__(_:=_V"T_\ 1LM?3M?,7[1__(_:=_V"T_\ 1LM 'TW'
M_JD_W13J;'_JD_W13J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/C
M7_JM$_WIO_9*]7KRCXU_ZK1/]Z;_ -DKFQG\"7]=3V^'/^1G2^?_ *2SOO"7
M_(G:+_UY0_\ H K9K&\)?\B=HO\ UY0_^@"MFMJ?P(\S%_[Q/U?YA1115G.%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR*VZ^/O@]XIG\,_$&Q3S"+/476TN$R<'<<(V/4,1SZ%O6OL&@ HHHH ****
M"O*?&WP0M?&7B.[UM]>N;:XN HV>2)$3:@48&0<<9Z]S7JU% '"?#/X;Q_#N
MTU&+[>M_+>2(QF$'E$*HX7&YNY8]>]=Q,T202/,5$2J2Y?H%QSGVI]> _&GX
MLQ-!=>$M F$A?,5_=(<@#O$OJ>S'\/7 !X%<&(W,I@!$)<[ >RYX_2OLGX40
MR0?"WP^DBE6-MO ]F8L#^1%?+/@+P9=^./%%OID =;8$/=SJ/]5$#R?J>@'J
M?3-?:=M;0V=I#:V\:QP0HL<:+T50, #\!0!X)^TMJ1SH&EJPQ^]N)%[_ ,*J
M?_0ZYWX!3Z7I.O:QKFK7]M9P6UHL"O<2! 6D;/&>IQ&>!ZU2^/VI"^^)TMNK
M9%C:Q0$>A(,G_L]<+H7AG6_$URUOHNF7%ZZ_?,2?*G^\QX7\30!]=6_Q2\#7
M,_DQ^)K -G&9',:_]], /UKK(I8YHEEB=9(W&Y70Y##U!KXAU_P5XD\+HCZU
MH]S:1N<+*P#(3Z;E)&?;-='\,OB;J'@C5X+>XN))=!E?;<6S?,(P3_K$]".I
M Z\]\$ 'U!XVU-]'\#ZYJ$3;98+*5HSZ/M(4_F17P]7V#\8[D+\(-<FA*NKQ
MP@-U!5IHQD?@:^/J /NKPSIL>C^%]*TZ)0$MK2./CN0HR?Q.37@_[2FFQ0ZY
MH6IJH$MS;RPN1W$;*1_Z,-?1@ 50   . !7A7[2X']E^'C@9$TPS_P !2@#C
M_P!GK4WM/B'+9;SY=[9NA7L64A@?P ;\S7U-7QY\&)#'\6]!8 '+S+S[PN/Z
MU]AT %%?.GQ]\2Z]HWCJQM]+UO4K&!M,C=H[6Z>)2WFRC)"D#. !GV%>5_\
M"=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7
M/_!C-_\ %4 ?0'[1W_)/+#_L*Q_^BI:\?^"7_)7M"_[>/_1$E<GJ7B77M9MU
MM]4UO4KZ!7#K'=73RJ&P1D!B1G!(S[FNL^"7_)7M"_[>/_1$E 'U_1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\3]7^844459SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYB_:/
M_P"1^T[_ +!:?^C9:^G:^8OVC_\ D?M._P"P6G_HV6@#Z;C_ -4G^Z*=38_]
M4G^Z*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45Y1\:_]5HG^]/\ ^R5&OP4W*&_X2#J,
M_P#'E_\ ;*Y95Y\[A"-[>9[E'*\+]5IXC$5^3GO9<K>SMT9ZW17DW_"D_P#J
M8?\ R2_^V4?\*3_ZF'_R2_\ ME'M:_\ S[_%!]0RO_H+_P#*<O\ ,]9HKR;_
M (4G_P!3#_Y)?_;*/^%)_P#4P_\ DE_]LH]K7_Y]_B@^H97_ -!?_E.7^9ZS
M7E'QK_U6B?[TW_LE-_X4G_U,/_DE_P#;*/\ A2?_ %,/_DE_]LK.LZ]2#AR6
MOYH[LMAE>"Q4<1]:YN6^G));IKS[GH'A+_D3M%_Z\H?_ $ 5LUY-_P *3_ZF
M'_R2_P#ME'_"D_\ J8?_ "2_^V5<:E=)+V?XHY:N$RNI4E/ZWNV_X<CUFBO)
MO^%)_P#4P_\ DE_]LH_X4G_U,/\ Y)?_ &RG[6O_ ,^_Q1G]0RO_ *"__*<O
M\SUFBO)O^%)_]3#_ .27_P!LH_X4G_U,/_DE_P#;*/:U_P#GW^*#ZAE?_07_
M .4Y?YGK-%>"^,?AU_PB>C1ZA_:OVK?.L/E_9]F,ACG.X_W:]+^&'_)/]._W
MI?\ T8U.G7E*I[.4;.U]Q8W*J-'"+%T*W/%RY?A:Z-]7Y=CKZ***Z3Q HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@^K/@#\Z]\^%GP97PG=)K>NR17&K*#Y,,?,=OGOG^)L?@.<9ZUZ]10 5X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?V_Y.['^?^7&OH"OG]O\
MD[L?Y_Y<: /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^8OVC_\ D?M.
M_P"P6G_HV6OIVOF+]H__ )'[3O\ L%I_Z-EH ^FX_P#5)_NBG4V/_5)_NBG4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7S^W_)W8_S_ ,N-?0%?/[?\G=C_ #_RXT ?0%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\Q?M'_\C]IW_8+3_P!&RU].U\Q?M'_\C]IW_8+3_P!&RT ?
M3<?^J3_=%.IL?^J3_=%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \H^-?^JT3_ 'I__9*]
M5C_U2?[HKRKXU_ZK1/\ >G_]DKU6/_5)_NBN6E_'J?+\CW,=_P BO"?]Q/\
MTI#J***ZCPPHHHH **** "BBB@ HHHH **** //_ (P_\B=!_P!?J?\ H#UH
M_##_ ))_IW^]+_Z,:L[XP_\ (G0?]?J?^@/6C\,/^2?Z=_O2_P#HQJXU_O3]
M#Z.I_P B"'_7S]&=?11178?.!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !7S^W_)W8_P _\N-?0%?/[?\ )W8_S_RXT ?0%%%% !1110 4444
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M\D\L/^PK'_Z*EKQ_X)?\E>T+_MX_]$25[!^T=_R3RP_["L?_ **EKQ_X)?\
M)7M"_P"WC_T1)0!]?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7S^W_)W8_P _\N-?0%?/[?\
M)W8_S_RXT ?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Q?M'_\ (_:=
M_P!@M/\ T;+7T[7S%^T?_P C]IW_ &"T_P#1LM 'TW'_ *I/]T4ZFQ_ZI/\
M=%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \H^-?\ JM$_WI__ &2O58_]4G^Z*\J^-?\
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M $1)7L'[1W_)/+#_ +"L?_HJ6O'_ ()?\E>T+_MX_P#1$E 'U_1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?/[?\G=C_/_ "XU] 5\_M_R=V/\_P#+C0!] 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7S%^T?\ \C]IW_8+3_T;+7T[7S%^T?\ \C]IW_8+
M3_T;+0!]-Q_ZI/\ =%.IL?\ JD_W13J "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/C7_JM
M$_WI_P#V2O58_P#5)_NBO*OC7_JM$_WI_P#V2O58_P#5)_NBN6E_'J?+\CW,
M=_R*\)_W$_\ 2D.HHHKJ/#"BBB@ HHHH **** "BBB@ HHHH \_^,/\ R)T'
M_7ZG_H#UH_##_DG^G?[TO_HQJSOC#_R)T'_7ZG_H#UH_##_DG^G?[TO_ *,:
MN-?[T_0^CJ?\B"'_ %\_1G7T445V'S@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?]@M/_1LM 'TW'_JD_W13J;'_JD_W13J "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/C7_J
MM$_WI_\ V2O58_\ 5)_NBO*OC7_JM$_WI_\ V2O58_\ 5)_NBN6E_'J?+\CW
M,=_R*\)_W$_]*0ZBBBNH\,**** "BBB@ HHHH **** "BBB@#S_XP_\ (G0?
M]?J?^@/6C\,/^2?Z=_O2_P#HQJSOC#_R)T'_ %^I_P"@/6C\,/\ DG^G?[TO
M_HQJXU_O3]#Z.I_R((?]?/T9U]%%%=A\X%%%% !1110 4444 %%%% !1110
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M1E"E';(VHISE!W]:YOX)?\E>T+_MX_\ 1$E>P?M'?\D\L/\ L*Q_^BI:\?\
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M.!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!XS\7_ (03>)KAO$/AY4_M/;BY
MM20OVG  #*3P& &.>O'0CGYNO;&[TV[DM+ZUFMKF,X>*9"C+]0>:^]ZHZGHF
ME:U"(M4TVTO8QT6XA60#Z9'% 'P=6CHV@ZKXAOUL=(L)[RX;^")<X]R>BCW.
M!7V(GPT\$QR;U\+Z83Z- &'Y'BNALM/LM-MEMK"TM[6!>D4$811^ &* .%^%
M7PTB\!:7)/=LDVLW:@7$B\K&O41K[9Y)[GZ"O0Z** "BBB@ HHHH *^1/BFF
MN^(_B-J]V-+U"2WAF-M;D6SE?+C^7(('0D%O^!5]=T4 ?"7_  CNN?\ 0&U#
M_P !7_PH_P"$=US_ * VH?\ @*_^%?=M% 'PE_PCNN?] ;4/_ 5_\*^LO@U;
M3VGPHT2"YADAF7S]T<BE6&9Y",@^U=W10!YQ\6OAF/'>EQ75@8X]9LU(A9^!
M,G4QL>W/(/8D^I-?+&HZ5J_AO4O(U"TNM/O(FRHD4HV0>JGN/<<5]W5'-;PW
M,?ESPQRI_==0P_(T ?",%MJ>O:CY<$5WJ%[*>B*TLC=O<GM7TS\&_A=+X.MY
M-9UE5&L7,>Q800?L\9Y(ST+' SCIC'K7JD%K;VJE;>"*%3U$:!0?RJ6@ KY[
M^,'P?OY]4N/$OAJV^T)/F2\LHE^=7[N@_BSU('.>><\?0E% 'P5'<7^ESRQQ
M37-I+RDJJS1M]&''Y&M+PUX/UWQ=?+:Z-I\L^6"O-C$47NS]!Z^OH#7VW/86
M=TP:XM()F'0R1AB/SJ9$6- B*%4= HP!0!SG@3P=:>!O"\&D6[^;)DR7$^W!
MED/4_3@ >P%=+110 4444 %%%% 'D'[1W_)/+#_L*Q_^BI:\?^"7_)7M"_[>
M/_1$E>P?M'?\D\L/^PK'_P"BI:\?^"7_ "5[0O\ MX_]$24 ?7]%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5\_M_R=V/\ /_+C7T!7S^W_ "=V/\_\N- 'T!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?,7[1__ "/VG?\ 8+3_ -&RU].U\Q?M'_\ (_:=
M_P!@M/\ T;+0!]-Q_P"J3_=%.IL?^J3_ '13J "BBB@ HHHH **** "BBB@
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M3^W/^H:E_P" ?\$\F_XN_P#Y^R4?\7?_ ,_9*]9HH^K?WY?>']N?]0U+_P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8_D!F@#[5AFBN(5F@E26)AE71@P(]B*?7Q?X,\:ZY\//$2,AN$MQ*!>Z?*"
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MO_,3_P!N_J>Y_P R3_N+_P"V'74445U'AA1110 4444 %%%% !1110 4444
M%%%% !1110 5\Q?M'_\ (_:=_P!@M/\ T;+7T[7S%^T?_P C]IW_ &"T_P#1
MLM 'TW'_ *I/]T4ZFQ_ZI/\ =%.H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O OVF?]3X9_WKK_VE7OM>!?M,_P"I\,_[UU_[2H ]:\ ?\DZ\-?\
M8,M__1:UT=<YX _Y)UX:_P"P9;_^BUKHZ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O*/C7_JM$_P!Z;_V2O5Z\H^-?^JT3_>F_]DKF
MQG\"7]=3V^'/^1G2^?\ Z2SOO"7_ ")VB_\ 7E#_ .@"MFL;PE_R)VB_]>4/
M_H K9K:G\"/,Q?\ O$_5_F%%%%6<X4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !45R[1VLSJ<,J,0??%2TC*'4JPRI&"/44 >"^$?VBHG$=KXLL3&W
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MT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <G\2_P#DGVJ?
M2+_T:E-^&/\ R3[3/K+_ .C7IWQ+_P"2?:I](O\ T:E-^&/_ "3[3/K+_P"C
M7KE_YB?^W?U/<_YDG_<7_P!L.NHHHKJ/#"BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^?V_Y.['^?^7&OH"OG]O\ D[L?Y_Y<: /H"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH Y/XE_\D^U3Z1?^C4IOPQ_Y)]IGUE_]&O3
MOB7_ ,D^U3Z1?^C4IOPQ_P"2?:9]9?\ T:]<O_,3_P!N_J>Y_P R3_N+_P"V
M'74445U'AA1110 4444 %%%% !1110 4444 %%%% !1110 5\Q?M'_\ (_:=
M_P!@M/\ T;+7T[7S%^T?_P C]IW_ &"T_P#1LM 'TW'_ *I/]T4ZFQ_ZI/\
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MO^$I\/?]![2__ R/_&N2_P"%-^'O^?S5/^_L?_Q%'_"F_#W_ #^:I_W]C_\
MB*N+Q"27*OO.>K3RBI.4W5EJ[_"=;_PE/A[_ *#VE_\ @9'_ (U;LM5T[4RX
ML+^UNS'C?Y$RR;<],X/'0UP__"F_#W_/YJG_ ']C_P#B*Z'POX,T[PDUTUA-
M=2&Y"A_/93C;G&,*/[QK2$JSE[R5CDQ-'+8TFZ%23ET35D=%1116YY04444
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M'!P1[U;KSGX%_P#))M+_ .ND_P#Z-:O1J $9E12S,%4=23@"HOMEK_S\P_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 <G\2_P#DGVJ?2+_T:E-^&/\ R3[3/K+_ .C7IWQ+_P"2?:I](O\
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M]T4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\"_:9_U/AG_>NO\
MVE7OM>!?M,_ZGPS_ +UU_P"TJ /6O '_ "3KPU_V#+?_ -%K71USG@#_ ))U
MX:_[!EO_ .BUKHZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/[?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLKA_[TT"N?S(JU#!#;1"*"*.*,=$10H'X"@#F_ '@RV\"^%H=*A<2SDF6YG
MQYDAZD>PP /85U%%% !1110 4444 >0?M'?\D\L/^PK'_P"BI:\?^"7_ "5[
M0O\ MX_]$25[!^T=_P D\L/^PK'_ .BI:\?^"7_)7M"_[>/_ $1)0!]?T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^T?_ ,C[IO\ V"T_]&RU]-1?ZE/]T5\R_M'_ /(^Z;_V"T_]&RU]-1?ZE/\
M=% #Z*** "BBB@ HHHH **** "BBB@ HHHH \B_:+_Y)U:?]A./_ -%RUW7P
M_P#^2=>&O^P9;_\ HM:X7]HO_DG5I_V$X_\ T7+7=?#_ /Y)UX:_[!EO_P"B
MUH Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1Q;3(3QO/$;?7<0/HQKZVH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M77/_  1+_P#&:/\ A,OCG_SZZY_X(E_^,T ?3]%?,'_"9?'/_GUUS_P1+_\
M&:/^$R^.?_/KKG_@B7_XS0!]/T5\P?\ "9?'/_GUUS_P1+_\9JGJ7Q(^,.CV
MZW&J3:E8P,X19;K2(XE+$$XRT0&< \>QH ^JZ*X[X6:YJ/B/X<Z7JNK7'VB]
MG,WF2[%3=ME=1PH '  Z5V- !1110 4444 %>>_&/_D3[7_K^3_T"2O0J\]^
M,?\ R)]K_P!?R?\ H$E88G^#(]7)/^1C1]34^&/_ "3[3/K+_P"C7KKJY'X8
M_P#)/M,^LO\ Z->NNJJ'\*/HC#-/]^K?XI?FPHHHK4X0HHHH **** "BBB@
MHHHH *Y3XE?\D^U7Z1?^C4KJZY3XE?\ )/M5^D7_ *-2LJW\.7HSNRS_ 'ZC
M_BC^:,;X-_\ (IWG_7\W_HM*]$KSOX-_\BG>?]?S?^BTKT2IPO\ !B=&>?\
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M &#+?_T6M '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7S^W_)W8_S_ ,N-?0%?/[?\G=C_
M #_RXT ?0%%%% !1110 4444 %%%% !1110 5X#^TU]WPO\ 6Z_]HU[]7@/[
M37W?"_UNO_:- 'OJ_='TI:1?NCZ4M !1110 4444 %%%% !1110 4444 %>0
M_M&_\D[L?^PI'_Z*EKUZO(?VC?\ DG=C_P!A2/\ ]%2T ;OP1_Y)%HGUN/\
MT?)7H->??!'_ ))%HGUN/_1\E>@T %%%% !1110 5Y[\8_\ D3[7_K^3_P!
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M_"[/^I>_\G?_ +71]<H?S?@P_P!6\T_Y]?\ DT?\SUFBO)O^%V?]2]_Y._\
MVNC_ (79_P!2]_Y._P#VNCZY0_F_!A_JWFG_ #Z_\FC_ )GK-%>3?\+L_P"I
M>_\ )W_[71_PNS_J7O\ R=_^UT?7*'\WX,/]6\T_Y]?^31_S/6:Y3XE?\D^U
M7Z1?^C4KD?\ A=G_ %+W_D[_ /:ZR?$OQ2_X2+P_=:5_8WV?S]O[W[5OVX8-
MTV#/3UJ*N+HRA))]/,Z\#P_F-+%4JDZ=DI)O6.R:\SJ_@W_R*=Y_U_-_Z+2O
M1*\[^#?_ "*=Y_U_-_Z+2O1*VPO\&)YV>?\ (QJ^H4445N>2%%%% !1110 4
M444 %?,7[1__ "/VG?\ 8+3_ -&RU].U\Q?M'_\ (_:=_P!@M/\ T;+0!]-Q
M_P"J3_=%.IL?^J3_ '13J "BBB@ HHHH **** "BBB@#YB_:/_Y'W3?^P6G_
M *-EKZ:B_P!2G^Z*^9?VC_\ D?=-_P"P6G_HV6OIJ+_4I_NB@!]%%% !1110
M 4444 %%%% !1110 4444 >1?M%_\DZM/^PG'_Z+EKNOA_\ \DZ\-?\ 8,M_
M_1:UPO[1?_).K3_L)Q_^BY:[KX?_ /).O#7_ &#+?_T6M '1T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110!Y!^T=_R3RP_["L?_HJ6O'_@E_R5[0O^WC_T1)7L'[1W_)/+#_L*Q_\
MHJ6O'_@E_P E>T+_ +>/_1$E 'U_1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/[?\G=C_ #_R
MXU] 5\_M_P G=C_/_+C0!] 4444 %%%% !1110 4444 %%%% !7@/[37W?"_
MUNO_ &C7OU> _M-?=\+_ %NO_:- 'OJ_='TI:1?NCZ4M !1110 4444 %%%%
M !1110 4444 %>0_M&_\D[L?^PI'_P"BI:]>KR']HW_DG=C_ -A2/_T5+0!N
M_!'_ ))%HGUN/_1\E>@UY]\$?^21:)];C_T?)7H- !1110 4444 %>>_&/\
MY$^U_P"OY/\ T"2O0JY;Q]X:O/%.@PV-C+!'*ERLQ,[$+@*P[ \_,*QQ$7*E
M)(]'*:L*.-IU*CLD]697P[T#1KWP-I]Q=Z387$[F7=)+;(['$C 9)&>@KJ/^
M$6\/?] '2_\ P#C_ ,*\E_X4WXA_Y_-+_P"_LG_Q%'_"F_$/_/YI?_?V3_XB
MN6$ZD8J/LMOZ['T&)P^$K5IU5CK<S;M9Z7>WQ'K7_"+>'O\ H Z7_P" <?\
MA1_PBWA[_H Z7_X!Q_X5Y+_PIOQ#_P _FE_]_9/_ (BC_A3?B'_G\TO_ +^R
M?_$57M9_\^OZ^XP^I87_ *#_ ,'_ /)'K7_"+>'O^@#I?_@''_A1_P (MX>_
MZ .E_P#@''_A7DO_  IOQ#_S^:7_ -_9/_B*/^%-^(?^?S2_^_LG_P 11[6?
M_/K^ON#ZEA?^@_\ !_\ R1ZU_P (MX>_Z .E_P#@''_A1_PBWA[_ * .E_\
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M<<?\>%8?[1__ "/NF_\ 8+3_ -&RU]-1?ZE/]T4 >!?\9#_Y_L^C_C(?_/\
M9]?0%% 'S_\ \9#_ .?[/H_XR'_S_9]?0%% 'S__ ,9#_P"?[/H_XR'_ ,_V
M?7T!10!\_P#_ !D/_G^SZ/\ C(?_ #_9]?0%% 'S_P#\9#_Y_L^C_C(?_/\
M9]?0%% 'S_\ \9#_ .?[/H_XR'_S_9]?0%% 'RC\1O\ A:W_  CD/_";_P#(
M+^U+L_X]?];M;'^J^;IN]OTKZ+^'_P#R3KPU_P!@RW_]%K7"_M%_\DZM/^PG
M'_Z+EKNOA_\ \DZ\-?\ 8,M__1:T ='1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'D'[1W_ "3RP_["L?\ Z*EKQ_X)?\E>T+_MX_\ 1$E>P?M'?\D\L/\
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M=G_4O?\ D[_]KI1Q#:O*K9_X2J^3TX5'&G@>:*V?M;7^5P_X79_U+W_D[_\
M:ZUO#/Q1_P"$B\0VNE?V-]G\_?\ O?M6_;M0MTV#/3'6LG_A=G_4O?\ D[_]
MKH_X79_U+W_D[_\ :ZN.(2:;J_\ DIS5<HE*$HPP%FUH_:WL^]KZV/6:*\F_
MX79_U+W_ ).__:Z/^%V?]2]_Y.__ &NNCZY0_F_!GC?ZMYI_SZ_\FC_F>LT5
MY-_PNS_J7O\ R=_^UUV_@WQ3_P );I$U_P#8_LGESF'9YOF9PJG.<#^]^E73
MQ%*H^6+U.;%9-C<)3]K7A:/JG^3.BHHHK<\P**** "BBB@ HHHH *^?V_P"3
MNQ_G_EQKZ KY_;_D[L?Y_P"7&@#Z HHHH **** "BBB@ HHHH **** "O ?V
MFON^%_K=?^T:]^KP']IK[OA?ZW7_ +1H ]]7[H^E+7R^/V<?%Y&?[2T/_O\
MS?\ QJE_X9Q\8?\ 02T/_O\ S?\ QJ@#Z?HKY@_X9Q\8?]!+0_\ O_-_\:H_
MX9Q\8?\ 02T/_O\ S?\ QJ@#Z?HKY@_X9Q\8?]!+0_\ O_-_\:H_X9Q\8?\
M02T/_O\ S?\ QJ@#Z?HKY@_X9Q\8?]!+0_\ O_-_\:H_X9Q\8?\ 02T/_O\
MS?\ QJ@#Z?HKY@_X9Q\8?]!+0_\ O_-_\:H_X9Q\8?\ 02T/_O\ S?\ QJ@#
MZ?HKY@_X9Q\8?]!+0_\ O_-_\:H_X9Q\8?\ 02T/_O\ S?\ QJ@#Z?KR']HW
M_DG=C_V%(_\ T5+7GW_#./C#_H):'_W_ )O_ (U7-^-?A+KW@31HM4U2[TV:
M"6X6W5;61V;<59L_,BC&%/?TH ^@O@C_ ,DBT3ZW'_H^2O0:\^^"/_)(M$^M
MQ_Z/DKT&@ HHHH **** "BBB@ HHHH ***XCQEX;\4ZSJT-QH>M?8;98 CQ_
M:I8LON8DX0$=".?:HJ2<5=*YTX6A"M4Y)S4%W>QV]%>3?\()\0_^AK_\J-Q_
M\31_P@GQ#_Z&O_RHW'_Q-8>WG_(ST_[*PO\ T%0_$ZWXE_\ )/M4^D7_ *-2
MF_#'_DGVF?67_P!&O7'7/PZ\=WMN]O=>(XIX'QNCEOIV5L'(R"N#R*+7X=>.
MK*W6WM/$<5O F=L<5].BC)R< +CJ:RYZGM?:<CVM^)Z'U;"?4/JGUF-^?FOK
MVM8]?HKR;_A!/B'_ -#7_P"5&X_^)H_X03XA_P#0U_\ E1N/_B:U]O/^1GG_
M -E87_H*A^)ZS17#>#O#7BK1]8EN-<UO[=:M R+%]JEEPY92#AP!T!Y]Z[FM
MZ<G)7:L>9BJ$*-3DA-37=!1115G,%%%% !1110 4444 %%%% !1110 5\Q?M
M'_\ (_:=_P!@M/\ T;+7T[7S%^T?_P C]IW_ &"T_P#1LM 'TW'_ *I/]T4Z
MFQ_ZI/\ =%.H **** "BBB@ HHHH **** /F+]H__D?=-_[!:?\ HV6OIJ+_
M %*?[HKYE_:/_P"1]TW_ +!:?^C9:^FHO]2G^Z* 'T444 %%%% !1110 444
M4 %%%% !1110!Y%^T7_R3JT_["<?_HN6NZ^'_P#R3KPU_P!@RW_]%K7"_M%_
M\DZM/^PG'_Z+EKNOA_\ \DZ\-?\ 8,M__1:T ='1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=V/\_P#+C7T!7S^W_)W8_P _\N- 'T!1110 4444 %%%% !1110 4444 %>
M_M-?=\+_ %NO_:->_5S_ (F\$^'O&(M?[>T_[9]EW^3^^DCV[L;ON,,YVCKZ
M4 <^/C;\/ H_XJ'M_P ^5Q_\;H_X7;\//^AA_P#)*X_^-T?\*2^'G_0O?^3M
MQ_\ '*/^%)?#S_H7O_)VX_\ CE !_P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&
M'_R2N/\ XW1_PI+X>?\ 0O?^3MQ_\<KQ#7O@EXR_X2+4_P"Q_#W_ !*_M4OV
M3_38?]3N.S[TF[[N.O/K0![?_P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2
MN/\ XW7@'_"DOB'_ -"]_P"3MO\ _'*/^%)?$/\ Z%[_ ,G;?_XY0![_ /\
M"[?AY_T,/_DE<?\ QNC_ (7;\//^AA_\DKC_ .-UX!_PI+XA_P#0O?\ D[;_
M /QRC_A27Q#_ .A>_P#)VW_^.4 >_P#_  NWX>?]##_Y)7'_ ,;H_P"%V_#S
M_H8?_)*X_P#C=> ?\*2^(?\ T+W_ ).V_P#\<H_X4E\0_P#H7O\ R=M__CE
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5SVM>.O"WAZ1HM5UVRMYE^]#YFZ0?\ 7
M+?I7BGQA^+U])JMSX:\.73VUO;,8KN[B;#RN."BD<JH/!(Y)![=?#T22>4*B
MM)(QZ*,DT ?8^C?%CP;X@UNWTC2]4>>[N"1$OV:50Q +'EE&. >M==+>VMO<
MP6TUS#'/<;O)B=P&DQC.T'DXR,X]:^0/@Y_R5G0?^NDG_HIZ[3]I#5&?Q7HN
MGHS VEH9P0<89WQQ[_NQ^E 'TE17AGP2^*=WK%ROA;7KAI[K83974ART@49,
M;'N< D'O@Y[5[G0 4444 %%%% !7 ?%CQ]>^ =!M;JPM()[BZE,*M,3MCPN<
MX'7\Q7?UPWQ+^'\GQ!L],LEOTLX;:X,LKE"[$;<84<<_4T ?*^HZMXB\>^(8
MVNIKG4M1N&V0Q*,X_P!E%'"CZ?4^M9%]9S:??W-E<J%GMY6BD .0&4D'GZBO
ML[P;\//#W@>W*Z5:EKIQB2[G(:5QZ9[#CH,"OD/Q?_R.NO?]A&X_]&-0!]0?
M O\ Y)-I?_72?_T:U>C5YS\"_P#DDVE_]=)__1K5Z-0!\??&;6VUOXGZI\X:
M*R(LHL=@GWA_WV7KT?\ 9V\*64FFWWB:ZMTENOM'V:V:10?+"J"S+Z$EL9_V
M?<UX;XCN/M?BC5KG=N\Z]FDW>N7)KZC^!$0C^%-@P/\ K)IV/_?PC^E &)^T
M#X3LKSPC_P )'%!''?V$J"655PTD3L%VD]\,5(STY]:\+^'>N/X>\?Z+J"OM
M07*Q3<X!C<[6S^!)^H%?4_Q6B6;X7>(4;H+4M^*L"/Y5\9 D$$$@CH10!]WZ
MWJ::-H.H:I)@I9VTDY![[5)Q^E?"EU<S7MW-=7,ADGF=I)';JS$Y)/XFOK_X
MHWX3X.ZQ=[\":TC&[!Y\QE7]=U?'= 'V9\,_"5EX7\$:=#';1B[N;=)KN7:-
MSNX!()[@9P![5X1\>?"EIX>\8V][I\$<%MJ<)D,4:[5653AL < $%3]2:^IX
M8Q#!'$#D(H4?@*\(_:8A5K/PW/D[DDN$ ]B(S_[+0!D?LWZX\'B'5=#=SY5S
M;BY0$\!T(!Q[D-_X[7TC7R%\$;DV_P 6M'7=A91-&WN/*<@?F!7U[0 45Y?\
M1_C!_P *^\0V^E?V%]O\ZT6Y\W[7Y6,NZ[<;&_N9SGO7'_\ #37_ %*/_E2_
M^U4 ?0%%?/\ _P --?\ 4H_^5+_[51_PTU_U*/\ Y4O_ +50!T/[1W_)/+#_
M +"L?_HJ6O'_ ()?\E>T+_MX_P#1$E:'Q'^,'_"P/#UOI/\ 87V#R;M;GS?M
M?FYPCKMQL7^_G.>U9_P2_P"2O:%_V\?^B)* /K^BBB@ HHHH **** / /VFN
MGA?_ +>__:-6_#7P#\*ZSX5TC5+C4-96>]LH;B18YH@H9T#$#,9.,GU-5/VF
MNGA?_M[_ /:->O\ @3_DGGAK_L%6O_HI: //_P#AG'P?_P!!+7/^_P##_P#&
MJ/\ AG'P?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_
M -!+7/\ O_#_ /&J]@HH \?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02U
MS_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\
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M **** "BBB@ HHHH **** "BBB@ KYB_:/\ ^1^T[_L%I_Z-EKZ=KYB_:/\
M^1^T[_L%I_Z-EH ^FX_]4G^Z*=38_P#5)_NBG4 %%%% !1110 4444 %%%%
M'S%^T?\ \C[IO_8+3_T;+7>)^T;X05%4Z;KF0 /]1%_\=KNO$GP\\+>+K^.^
MUS2_M=S%$(4?[1+'A 2<81@.K'\ZQO\ A27P\_Z%[_R=N/\ XY0!S_\ PT=X
M/_Z!NN?]^(?_ ([1_P -'>#_ /H&ZY_WXA_^.UT'_"DOAY_T+W_D[<?_ !RC
M_A27P\_Z%[_R=N/_ (Y0!S__  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;KG_?
MB'_X[70?\*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE '/\ _#1W@_\
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M/'>).6N8XU7:$<$95V.?F':O=_A__P DZ\-?]@RW_P#1:UA?\*2^'G_0O?\
MD[<?_'*[?3["VTO3K;3[*/RK6VB6&&/<6VHHP!DY)X'>@"S1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !63XHU-]%\)ZOJ<>#):6<LR ]V5"0/S K6K&\7:=)J
M_@W6M.AR9KFQFBC'JQ0@?KB@#XKT+2I_$7B.PTM)=LU]<I#YK<[=S8+'GG&2
M?>OM/PUX4T;PEI<=AI%G'"BJ \FT>9*?[SMU)_R,"OBWP[J[:!XETS5U3?\
M8[F.<I_>"L"1^(R*^VM"U_2_$NEQ:CI-W'<VT@!RIY4_W6'53[&@#Y+^#G_)
M6=!_ZZ2?^BGKZ2\?_#C1O'&ESF:VCCU98B+:]08=6'*AC_$N>,'U.,'FOFWX
M.?\ )6=!_P"NDG_HIZ^F/B!XZT[P1X>N+B>XC.HO&PL[7=\\C] <?W0>2?ZX
MH ^1?"NH2:5XMTB_C8AH+R)^.X##(_$9%?=%?#'A33WU7Q?H]A&I8SWD2''8
M;AD_@,G\*^YZ "BBB@ HHHH **** "OAGQ?_ ,CKKW_81N/_ $8U?<U?#/B_
M_D==>_["-Q_Z,:@#Z@^!?_))M+_ZZ3_^C6KT:O.?@7_R2;2_^ND__HUJ]&H
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MW_\ $4?\*L^+_P#T/O\ Y6+O_P"(KH/^&CO!_P#T#=<_[\0__':/^&CO!_\
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M_P#/YI?_ ']D_P#B*/K%;_GW^/\ P _LC+O^@Q?^ _\ VQ[A17A__"F_$/\
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M10 4444 %%%% !1110 4444 %%%% !1110 5X%^TS_J?#/\ O77_ +2KWVO
MOVF?]3X9_P!ZZ_\ :5 'K7@#_DG7AK_L&6__ *+6NCKG/ '_ "3KPU_V#+?_
M -%K71T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^WC_P!$25[!^T=_R3RP_P"PK'_Z*EKQ_P""7_)7M"_[>/\ T1)0!]?T444
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M\N%%%% !1110 4444 %?/[?\G=C_ #_RXU] 5\_M_P G=C_/_+C0!] 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?,7[1__ "/V
MG?\ 8+3_ -&RU].U\Q?M'_\ (_:=_P!@M/\ T;+0!]-Q_P"J3_=%.IL?^J3_
M '13J "BBB@ HHHH **** "BBB@ HHHH **** /$?$'[/7]N^(]2U;_A*/(^
MVW4EQY7]G[MF]BV,^8,XSUP*S?\ AF7_ *F[_P IO_VVOH"B@#Y__P"&9?\
MJ;O_ "F__;:/^&9?^IN_\IO_ -MKZ HH ^?_ /AF7_J;O_*;_P#;:/\ AF7_
M *F[_P IO_VVOH"B@#Y__P"&9?\ J;O_ "F__;:[_P"&7PP_X5T^IM_;']H?
M;A$/^/;RMFS=_MMG.[VZ5Z#10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH \@_:._Y)Y8?]A6/_ -%2UX_\$O\ DKVA?]O'_HB2O8/VCO\
MDGEA_P!A6/\ ]%2UX_\ !+_DKVA?]O'_ *(DH ^OZ*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MY_;_ ).['^?^7&OH"OG]O^3NQ_G_ )<: /H"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *^8OVC_P#D?M._[!:?^C9:^G:^8OVC_P#D?M._[!:?^C9: /IN
M/_5)_NBG4V/_ %2?[HIU !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 CHLB,CJ&5A@J1D$>E><>*OA3\.I+>;5-3LX=)B7'FW$$_D1KDX&1]P9)
MZ=Z](KS_ .-O_)(==_[=_P#THCH \[C^''P:1PS>-Y) /X6U*#!_) :]2\-?
M#+P9X=>*]TO289)\!H[F=C,P]"I8D#Z@"OC*OO+1O^0'I_\ U[1_^@B@"[11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Y!^T=_P D\L/^PK'_ .BI:\?^"7_)7M"_[>/_ $1)7L'[1W_)/+#_
M +"L?_HJ6O'_ ()?\E>T+_MX_P#1$E 'U_1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/[?\G=
MC_/_ "XU] 5\_M_R=V/\_P#+C0!] 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7S%^T?\ \C]IW_8+3_T;+7T[7S%^T?\ \C]IW_8+3_T;+0!]-Q_ZI/\
M=%.IL?\ JD_W13J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOG]O^3NQ_G_EQKZ KY_;_D[L?Y_Y<: /H"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^8OVC_^1^T[_L%I_P"C9:^G:^8OVC_^1^T[_L%I_P"C9: /IN/_
M %2?[HIU-C_U2?[HIU !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RGXC
M^,7CVP\4:O9VVO>7;V][-%$GV. [55R ,E,G@=Z^A/ASJ]]KWP_T?5-2G\^\
MN(F:638J[CO8=%  X Z"OD'Q?_R.NO?]A&X_]&-7UA\(O^25:!_UP;_T-J .
MHUK58-"T2]U:Z21X+.%IY%B +%5&3@$@9_&O,8/VB?"-Q<1PIIVMAI'" F"+
M&2<?\]:[;XB_\DW\2?\ 8.F_] -?&&F?\A6S_P"NZ?\ H0H ^]:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BN"^,7B2[\,?#RYN]/NFM;Z6>*&"5<;@
M2VXXS_LJU?-__"V/'?\ T,MY_P"._P"% 'V;17QE_P +8\=_]#+>?^._X5J^
M&?B?XUO/%>CVMQXANY()KZ&.1#MPREP".GH: /KBBBO)/BW\7&\'M_8FB>7)
MK+H&EE<;EME/3CNQZ@'@#!.<T >MT5\.W_C7Q1J=PT]YX@U*5R<X^TN%'T4$
M ?@*U_#?Q6\7^&KN.2+5[B\MP?GM;V0RHP]/FY7_ ("10!]ET5SW@OQ?8>-O
M#<&KV&4W$I-"QRT,@ZJ?S!![@@UT- !1110 4444 >0?M'?\D\L/^PK'_P"B
MI:\?^"7_ "5[0O\ MX_]$25[!^T=_P D\L/^PK'_ .BI:\?^"7_)7M"_[>/_
M $1)0!]?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7S^W_ "=V/\_\N-?0%?/[?\G=C_/_ "XT
M ?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5\Q?M'_P#(_:=_V"T_]&RU
M].U\Q?M'_P#(_:=_V"T_]&RT ?3<?^J3_=%.IL?^J3_=%.H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ KY_;_D[L?Y_Y<:^@*^?V_Y.['^?^7&@#Z HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OG]O^3NQ_G_EQKZ KY_;_ ).['^?^7&@#
MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OF+]H__ )'[3O\ L%I_Z-EK
MZ=KYB_:/_P"1^T[_ +!:?^C9: /IN/\ U2?[HIU-C_U2?[HIU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M\Q?M'_\ (_:=_P!@M/\ T;+7T[7S%^T?_P C]IW_ &"T_P#1LM 'TW'_ *I/
M]T4ZFQ_ZI/\ =%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDT?FPR1YQO4
MKGTS3Z* /DKQ=\$?%7AHO/:0_P!KV"\^=:*?,4?[4?4=^FX<=:9X2^-/BOPL
MR6US.=5L4X-O>,2ZCT63[P_'('I7UQ7&^+?A?X6\9;YK^P$-ZP_X_+7]W)GU
M;LW_  (&@"IX1^+WA7Q<8[>.[-A?MQ]EO,(6/HK?=;\\^U;/CKPA:^-_"MSH
MUP_E.Q$EO/MSY4J]&Q^)!]B:^=_%_P "O$WA\R7&EK_;-BN3F!<3*/>/J?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7S^W_)W8_S_ ,N-?0%?/[?\G=C_
M #_RXT ?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Q?M'_\C]IW_8+3
M_P!&RU].U\Q?M'_\C]IW_8+3_P!&RT ?3<?^J3_=%.IL?^J3_=%.H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHILCB.-I&^ZH)/T% ')^,_B1X=\#*B:I</
M)>2+OCM+==TK+TR<D!1[DC.#C.*\SN/VF+=92+;PK+)'_>DO@A_(1G^=>3V5
MAK/Q4^($ZQ-&+W4)7F=Y6.R)!ZD#. ,*./2O3XOV9I3&#-XL1'[A-/+#\S(/
MY4 ='H7[0_AK4;A(-4LKO2R_'FMB6-?J1AO_ !VNQ\3?#_PIX[M5N;VSB>65
M 8K^U8+(01P0PX8<\9R*\"\<_!#5/!VA3:S#JD&HV=N1YP$1CD4$@!MN2",D
M9YXKT3]G/7KB_P##&IZ//(SKITR-"6_A20-\H]MR,?\ @5 '!>+_ (">(]$:
M2XT0C6+(9.V,;9T'/5/XNWW22?05SGACXF^+O TXLXKJ22VA;:^GWJEE7'50
M#\R?0$?2OLBN:\4^ O#?C&/&L:;').!A;F/Y)5]/F')'L<CVH Y/PC\=/#'B
M(QVVI,='O6P,7+ PL?:3H/\ @0'XUZ@K*ZAE(*D9!!X(KYD\7?L^ZYI1DN?#
MLPU6U'/DMA)U'T^ZWX8/M7T3X;BDA\+Z1%*C1R)90JZ.,%2$ (([&@#3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MR#]H[_DGEA_V%8__ $5+7C_P2_Y*]H7_ &\?^B)*]@_:._Y)Y8?]A6/_ -%2
MUX_\$O\ DKVA?]O'_HB2@#Z_HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG]O^3NQ_G_EQKZ K
MY_;_ ).['^?^7&@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF+]H__
M )'[3O\ L%I_Z-EKZ=KYB_:/_P"1^T[_ +!:?^C9: /IN/\ U2?[HIU-C_U2
M?[HIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7S^W_)W8_S_ ,N-?0%?/[?\G=C_ #_RXT ?0%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\Q?M'_\C]IW_8+3_P!&RU].U\Q?
MM'_\C]IW_8+3_P!&RT ?3<?^J3_=%.IL?^J3_=%.H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/VCO^2>6'_85C_]
M%2UX_P#!+_DKVA?]O'_HB2O8/VCO^2>6'_85C_\ 14M>/_!+_DKVA?\ ;Q_Z
M(DH ^OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KY_;_D[L?Y_Y<:^@*^?V_Y.['^?^7&@#Z H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OF+]H__D?M._[!:?\ HV6OIVOF
M+]H__D?M._[!:?\ HV6@#Z;C_P!4G^Z*=38_]4G^Z*=0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !117E7Q6^+J>"F&D:0D5QK3J&<R<I;*>A8#JQ'0?0
MGL" >JT5\57_ ,2_&VHS>;/XHU-&]+><P+_WS'M'Z5O>&?C;XPT&ZC-Y>MJU
MF/OP79RQ'M)C<#]<CVH ^MZ*R/#/B/3_ !9H%KK.FNS6\Z_=88:-AP58>H/^
M<5KT %%%% !1110!Y!^T=_R3RP_["L?_ **EKQ_X)?\ )7M"_P"WC_T1)7L'
M[1W_ "3RP_["L?\ Z*EKQ_X)?\E>T+_MX_\ 1$E 'U_1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?/[?\ )W8_S_RXU] 5\_M_R=V/\_\ +C0!] 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7S%^T?_ ,C]IW_8+3_T;+7T[7S%^T?_ ,C]IW_8+3_T;+0!
M]-Q_ZI/]T4ZFQ_ZI/]T4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM 'L%%>/_\
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MZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.T >P45X_\ \-'>#_\ H&ZY_P!^(?\
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M\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\
MOQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =
MH ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_
M .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\
M] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\
M0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH
M[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_]
M W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_
M /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@
MHKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&C
MO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7
M/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\
MQVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_
M - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/
M^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':
M /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ_
M_AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__
M $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$
M/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_
M (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W
M7/\ OQ#_ /': /8*^8OVC_\ D?M._P"P6G_HV6N]_P"&CO!__0-US_OQ#_\
M':\=^+/C?3?'GB>TU/2X+N&&&S6W9;I%5BP=VR-K,,88=Z /L"/_ %2?[HIU
M>/)^T;X05%!TW7.!C_41?_':7_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&C
MO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7
M/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\
MQVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_
M - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/
M^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':
M /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ_
M_AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__
M $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$
M/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_
M (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W
M7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/
M_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8*
M*\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[
MP?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=
M<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QV
MC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.
M\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\
MOQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =
MH ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_
M .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\
M] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\
M0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH
M[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVNO\#?$G1OB
M ]\FE6U_";((9/M4:+G?NQC:S?W3Z4 =C1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME\0_^A>_\G;?_P".4?\ "DOB'_T+W_D[;_\ QROK^B@#Y _X4E\0_P#H7O\
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M?^3MO_\ '*^OZ* /D#_A27Q#_P"A>_\ )VW_ /CE'_"DOB'_ -"]_P"3MO\
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M /QROK^B@#Y _P"%)?$/_H7O_)VW_P#CE'_"DOB'_P!"]_Y.V_\ \<KZ_HH
M^0/^%)?$/_H7O_)VW_\ CE'_  I+XA_]"]_Y.V__ ,<KZ_HH ^0/^%)?$/\
MZ%[_ ,G;?_XY1_PI+XA_]"]_Y.V__P <KZ_HH ^0/^%)?$/_ *%[_P G;?\
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MB'_T+W_D[;__ !ROK^B@#Y _X4E\0_\ H7O_ "=M_P#XY1_PI+XA_P#0O?\
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M?^3MO_\ '*^OZ* /D#_A27Q#_P"A>_\ )VW_ /CE'_"DOB'_ -"]_P"3MO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/@=X&N/"OAF74=2A:+4M3*N8G&&BB'W5([$Y)(]P#R*]3HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^8/VCO^2A:?_P!@J/\ ]&RUO_LR]?%'_;I_[6K _:._Y*%I_P#V
M"H__ $;+6_\ LR]?%'_;I_[6H ^@**** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#Y@_:._Y*%I__ &"H_P#T;+6_^S+U\4?]NG_M:OH"
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^8?VC_^2@:=_P!@N/\ ]&RU]/44
M ?/W[,OW_$_TM?\ VK7T#110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?$?Q _
MY*+XE_["=Q_Z,:OIGX'_ /)(]'_WI_\ T<]>AT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%Y>
M6^GV4UY=RK%;P(9)9&Z(H&23[ 4 3T5R7_"T/ __ $,^G_\ ?RNEL+^TU2QA
MOK&X2XM9EW1RQG*L/44 6**** "BN:O_ (@^$M+OIK&^\06,%U"VV2)Y.5/H
M:O:)XIT/Q(9QHVIV]]Y&WS?);.S=G&?K@_E0!KT444 %%%% !117)?\ "T/
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M **** "BBB@ HHHH **Y23XF>"HI&CD\2Z>KH2K*9.013?\ A:'@?_H9]/\
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M-I9<D *URJ9)[#.,T =-12*RNH92&4C((.0:6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6)#?@17OVG:C::MIUOJ%C,LUK<1B2*1>C*>E %JBBB@ HHHH **** "BBB@
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MN=#GO8V5RK[X'5GB*G.1UP>H^A- 'B?P-^)-[;ZQ#X4U6X::RN 5LWD8EH7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFC7 (^Z2S#)!R/R]:^J:* /._@]H7BCPSX7FTCQ)"D:0R[K,"99"J,,LOR]
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MUOH>AW=_* MO96[S,J_W44G _*OAS6-6N]=UB[U2^D,ES=2M)(V3U/89Z =
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MLV"/.V7E89$2#EF([X';N<#O7U+I?P9\#:;IPM7T9+QRN'GN79I'/KG("_\
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MS-_K/$_TM?\ VK6[^T?_ ,B1IO\ V$!_Z+>@#YGBBDGF2&)&>61@J(HR6)X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWA^ST;3U(@MDV[F^\[=69O<G)H UJ*** "BBB@ HHHH **** "BBB@ HHHH
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M^N*^\B 1@C(KYC^)WP7U32=3N=6\-V;7FE2L7-M I:6W)ZC:/O+Z$=.A'&2
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MD@ID=<#')QG->K_L[S7EC8:OHM]975LWFK=1&:%D#9 5L9';:OYT >WT444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4,
M]K;W2A;B"*91T$B!OYU-10!%!:V]JI6W@BA4]1&@4'\JEHHH **** "BBB@
MHHHH **** "BBB@"H=+T\R>8;&U,F<[O)7/YXJV  , 8 HHH **** "BBB@
MJI_9>G^9YGV&U\S.=WDKG\\5;HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,B?Q5X>MK$WLVN:<MJ!GS?M
M2%3]#GFOD;XF>+E\:>-[S4X"WV- (+4,,'RUZ''N26_&M77OA%XUBUV^^R^'
MYY;8W$AA>-T8,FX[3PW'&.M:7AKX!^+-5O(SK$4>DV6[]X\DBO(5_P!E5)Y_
MWB/QH [+]G'PT8;+4_$D\>#.1:VS$<[5Y<CV)VC_ (":]WJCHVD66@Z/:Z5I
M\7E6EK&(XU]O4GN2>2?4U>H **** *\MA9SRB6:T@DD'1WC!(_$U8Z444 %%
M%% !1110 4444 %5IM.LKB3S)K.WE?\ O/$K'\R*LT4 (JJBA54*HZ # %+1
M10 4444 %%%% !56XU.PM)Q!<WUM#,R[Q')*JL5Z9P3G%6J\7^.W@;7?%,^C
M7>AZ<]X8$ECG".H*C*E>"03GYNF>E %+X[?$33)= _X1C2+Z&ZN+F16NV@8.
ML<:G(4L.-Q8#CL <]17BW@;PZ_BOQGIFD!"T4TP,^,C$2\N<]N 1]2*VK/X-
M^/;V<1C0)(03@O/*B*OORV3^ ->^_"SX60^ ;:6[O)H[K6+E DDJ#Y(DZ[$)
MY//)/&<#CB@#T9$6-%10 JC  Z 4M%% !44]K;W2A;B"*91R!(@8#\ZEHH 9
M%#%!&(X8TC0=%10 /P%/HHH **** "BBB@ HHHH KSV-I=$&XM8)B.ADC#?S
MJ6*&*WC$<,21H.BHH _(4^B@ HHHH AGM;>Z4+<6\4P'02(&Q^=/BABMXQ'#
M$D:#HJ* /R%/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CF@AN(_+G
MB25/[KJ&'Y&FP6EM:@BWMXH0>HC0+G\JFHH **** "JTNGV4\OFS6=O)(/XW
MB4G\R*LT4 ( %    '0"EHHH **** *ITS3S+YIL;8R==WE+G\\5:HHH ***
M* &R1I*A21%=#U5AD&H8-/LK5]]O:6\3?WHXPI_058HH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img44875045_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1X!L # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;;V$CDXX!+*H_F: /J:OCSQIXT\56OCKQ#;V_B7688(M3N4CCCOY55%$K
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?$'CO_ )*'XE_["MU_Z-:OM^OB#QW_ ,E#\2_]A6Z_]&M0!]?^!/\ DGGA
MK_L%6O\ Z*6N@KG_  )_R3SPU_V"K7_T4M=!0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KX@\=_\E#\2_\ 85NO_1K5]OU\0>._^2A^
M)?\ L*W7_HUJ /K_ ,"?\D\\-?\ 8*M?_12UT%<_X$_Y)YX:_P"P5:_^BEKH
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\0>._^2A^)?\ L*W7_HUJ^WZ^(/'?_)0_$O\ V%;K_P!&M0!]?^!/
M^2>>&O\ L%6O_HI:Z"N?\"?\D\\-?]@JU_\ 12UT% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *^(/'?_)0_$O_ &%;K_T:U?;]?$'CO_DH?B7_ +"MU_Z-:@#Z_P# G_)/
M/#7_ &"K7_T4M=!7/^!/^2>>&O\ L%6O_HI:Z"@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHY]_D2>5_K-IV_7'%"
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M "4/Q+_V%;K_ -&M0!]?^!/^2>>&O^P5:_\ HI:Z"N?\"?\ )//#7_8*M?\
MT4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5X7\8_P#DI7AC_=B_]'&O=*\+^,?_ "4K
MPQ_NQ?\ HXU[O#O^_?\ ;LOR,JWPGN8^Z/I2T@^Z/I2UX1J%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\0>._^2A^)?\ L*W7
M_HUJ^WZ^(/'?_)0_$O\ V%;K_P!&M0!]?^!/^2>>&O\ L%6O_HI:Z"N?\"?\
MD\\-?]@JU_\ 12UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?QC_P"2E>&/]V+_ -'&
MO=*\+^,?_)2O#'^[%_Z.->[P[_OW_;LOR,JWPGN8^Z/I2T@^Z/I2UX1J%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\YZO1117YL=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\0>._\ DH?B7_L*W7_HUJ^WZ^(/'?\ R4/Q
M+_V%;K_T:U 'U_X$_P"2>>&O^P5:_P#HI:Z"N?\  G_)//#7_8*M?_12UT%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'?C?_D?/$/\ V$KC
M_P!&-6#6]XW_ .1\\0_]A*X_]&-6#7[3A?X$/1?D>=+=A111702%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7T7\ /^1)U#_L(O_P"BXZ^=*^B_@!_R).H?]A%__1<=?.<4_P#(N?JC:A\9
MZO1117YB=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\0>._^2A^)?\ L*W7_HUJ^WZ^(/'?_)0_$O\
MV%;K_P!&M0!]?^!/^2>>&O\ L%6O_HI:Z"N?\"?\D\\-?]@JU_\ 12UT% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'?C?\ Y'SQ#_V$KC_T
M8U8-;WC?_D?/$/\ V$KC_P!&-6#7[3A?X$/1?D>=+=A111702%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MT7\ /^1)U#_L(O\ ^BXZ^=*^B_@!_P B3J'_ &$7_P#1<=?.<4_\BY^J-J'Q
MGJ]%%%?F)VA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7Q!X[_P"2A^)?^PK=?^C6K[?KX@\=_P#)0_$O
M_85NO_1K4 ?7_@3_ ))YX:_[!5K_ .BEKH*Y_P "?\D\\-?]@JU_]%+704 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\=^-_^1\\0_P#82N/_
M $8U8-;WC?\ Y'SQ#_V$KC_T8U8-?M.%_@0]%^1YTMV%%%%=!(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?1?P _Y$G4/^PB__ *+CKYTKZ+^ '_(DZA_V$7_]%QU\YQ3_ ,BY^J-J'QGJ
M]%%%?F)VA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^!/^2>>&O^P5:_\ HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /COQO\ \CYXA_["5Q_Z,:L&M[QO_P CYXA_["5Q_P"C&K!K]IPO\"'H
MOR/.ENPHHHKH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KZ+^ '_(DZA_V$7_]%QU\Z5]%_ #_ )$G4/\
ML(O_ .BXZ^<XI_Y%S]4;4/C/5Z***_,3M"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KP+X^>+_$-GKMGX7TNYDAM+JS6:1;
M<$2S,SNNW(YVX0<#KDYS7OM0?8;3[=]N^RP_:_+$7G^6/,V DA=W7&6/'N:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?FCSU.,C!]&'4Y-=Y^S7J\@N-<T5GS&42[C3T(.QS^.4_*@#Z#HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(/'?_)0_$O_ &%;
MK_T:U?;]?$'CO_DH?B7_ +"MU_Z-:@#Z_P# G_)//#7_ &"K7_T4M=!7/^!/
M^2>>&O\ L%6O_HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /COQO_ ,CYXA_["5Q_Z,:L&M[QO_R/GB'_ +"5Q_Z,:L&OVG"_P(>B_(\Z
M6["BBBN@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OHOX ?\B3J'_81?\ ]%QU\Z5]%_ #_D2=0_["+_\
MHN.OG.*?^1<_5&U#XSU>BBBOS$[0HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M117YB=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M' -5-!\=>&?$]\]EHNK0WERD9E:-%8$(" 3R!W8?G0!T5%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444 %%%% !1110 4444 %?1?P _Y$G4/^PB__HN.OG2OHOX ?\B3J'_81?\
M]%QU\YQ3_P BY^J-J'QGJ]%%%?F)VA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445\S?M$WES;_ ! L$AN9HU.EQDA'(&?-
ME]* /IFBO@K^T[__ )_KG_OZW^-']IW_ /S_ %S_ -_6_P : /O6BO@K^T[_
M /Y_KG_OZW^-']IW_P#S_7/_ '];_&@#Z(_:3_Y%C1?^OQO_ $ UQO[./_)0
M]0_[!4G_ *-BKR6:ZN+@ 3W$LH'0.Y;'YUZU^SC_ ,E#U#_L%2?^C8J /I^B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX@\=_\
M)0_$O_85NO\ T:U?;]?$'CO_ )*'XE_["MU_Z-:@#Z_\"?\ )//#7_8*M?\
MT4M=!7/^!/\ DGGAK_L%6O\ Z*6N@H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***IWFJ66GNJW4ZQLPR 03G\J +E%97_"
M2:1_S^I_WRW^%'_"2:1_S^I_WRW^% &K165_PDFD?\_J?]\M_A1_PDFD?\_J
M?]\M_A0!JT5E?\))I'_/ZG_?+?X4?\))I'_/ZG_?+?X4 :M%97_"2:1_S^I_
MWRW^%'_"2:1_S^I_WRW^% &K165_PDFD?\_J?]\M_A1_PDFD?\_J?]\M_A0!
MJT5E?\))I'_/ZG_?+?X4?\))I'_/ZG_?+?X4 :M%97_"2:1_S^I_WRW^%'_"
M2:1_S^I_WRW^% &K16=#KVF7$R0Q7:M(YPJA3R?RK1H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X[\;_ /(^>(?^PE<?
M^C&K!K>\;_\ (^>(?^PE<?\ HQJP:_:<+_ AZ+\CSI;L****Z"0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH *^>_VE-6F^TZ'HZN1 $DNG3LS9VJ?P ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAO+E(S*T:*P(0$ GD#NP_.OB*O8/V<?^2AZA_P!@J3_T;%0!]/T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$'CO_DH?B7_ +"M
MU_Z-:OM^OB#QW_R4/Q+_ -A6Z_\ 1K4 ?7_@3_DGGAK_ +!5K_Z*6N@KG_ G
M_)//#7_8*M?_ $4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.>-?
M^0-%_P!?"_\ H+5T=<YXU_Y T7_7PO\ Z"U '!T4450!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :_
MA?\ Y&.T_P"!_P#H!KTBO-_"_P#R,=I_P/\ ] ->D4F 4444@"BBB@ HHHH
M**** "BBB@ HHHH **** /COQO\ \CYXA_["5Q_Z,:L&M[QO_P CYXA_["5Q
M_P"C&K!K]IPO\"'HOR/.ENPHHHKH)"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ+^ '_(DZA_V$7_]%QU\
MZ5]%_ #_ )$G4/\ L(O_ .BXZ^<XI_Y%S]4;4/C/5Z***_,3M"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.2"&5MTD4;G&
M,LH-25\X?M :[K&E^/+&#3]5OK2)M,C<QV]P\:EO-E&< CG 'Y4 ?1/V.U_Y
M]H?^^!1]CM?^?:'_ +X%?#__  E_B;_H8M7_ / V3_XJC_A+_$W_ $,6K_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_\ $U\W>$/^1UT'_L(V_P#Z,6ON:@#RK_AGOP3_ 'M3_P# D?\ Q-=!X/\
MA;X=\$:M+J6D&\-Q+ ;=O/E##:65CQ@<Y45VM% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5\0>._^2A^)?^PK=?\ HUJ^WZ^(
M/'?_ "4/Q+_V%;K_ -&M0!]?^!/^2>>&O^P5:_\ HI:Z"N?\"?\ )//#7_8*
MM?\ T4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.>-?^0-%_U\+_
M .@M71USGC7_ ) T7_7PO_H+4 <'1115 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MYW7O OAGQ/?)>ZUI,-Y<I&(ED=F!" D@<$=V/YUT5>%_&/Q[XI\$^/=/?2+I
MH[&;3U+0RQ;X9'$DF[KWP4S@@_=S0!WW_"HO 7_0MVW_ 'W)_P#%4?\ "HO
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M4 %%%% !1110 4444 %%%% !1110 5SGC7_D#1?]?"_^@M71USGC7_D#1?\
M7PO_ *"U '!T4450!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 :_A?_ )&.T_X'_P"@&O2*\W\+_P#(
MQVG_  /_ - ->D4F 4444@"BBB@ HHHH **** "BBB@ HHHH **** /COQO_
M ,CYXA_["5Q_Z,:L&M[QO_R/GB'_ +"5Q_Z,:L&OVG"_P(>B_(\Z6["BBBN@
MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OHOX ?\B3J'_81?\ ]%QU\Z5]%_ #_D2=0_["+_\ HN.OG.*?
M^1<_5&U#XSU>BBBOS$[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *S]:T+2_$6FR:=J]E%=VLG5)!T/J".5/N,&M"B@#YU\
M8_L[W<#27?A.[%S%U^Q73!9![*_0_P# L?4UXWJ^@:OH%R;?5M-NK*7) $\9
M4-CT/0CW%?=U1SV\%U"T-Q#'-$W5)%#*?P- 'P)17VC>_"[P/?@^=X9T]<C'
M[B/R?_0"*SX_@M\/8W#KX>4D?WKN=A^1?% 'Q]74>&_AWXJ\5,ATO2)S V/]
M)F'EQ8/?<W!_#)KZXTSP/X6T9UDT_P /Z=!*O246ZEQ_P(C/ZUOT >,^"_V?
M])TEHKWQ+.NJ7:_,+9 1;J??/+\^N!Z@U['%%'!$D44:QQHH5408"@= !V%/
MHH **** "L[6-!TKQ!!!!J]A#>PP3"=(IUW('"E02O0\,>#D<UHT4 -1$BC6
M.-%1%&%51@ >@%?"GB+_ )&?5O\ K\F_]#-?=M?"7B+_ )&?5O\ K\F_]#-
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -?PO_ ,C':?\  _\
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MT34;Z7S;JYLHI9I-H7<Q4$G   _"N G_ &=O"-Q<23/J.MAI'+D">+&2<_\
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M@2$GU*#)/T+$>H->M !0   !P * %HHHH **** "OB#QW_R4/Q+_ -A6Z_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -?PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** -?PO_ ,C':?\  _\ T UZ17F_A?\ Y&.T_P"!_P#H!KTBDP"BBBD
M4444 %%%% !1110 4444 %%%% !1110!\=^-_P#D?/$/_82N/_1C5@UO>-_^
M1\\0_P#82N/_ $8U8-?M.%_@0]%^1YTMV%%%%=!(4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?1?P _Y$G4
M/^PB_P#Z+CKYTKZ+^ '_ ").H?\ 81?_ -%QU\YQ3_R+GZHVH?&>KT445^8G
M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MS!^T=_R4/3_^P5'_ .C9:^GZ^8/VCO\ DH>G_P#8*C_]&RT =E^S9_R+&M?]
M?B_^@"O5_%'_ "*6M?\ 7A/_ .BVKY2\!?%34_ &GW=G8V%I<I<RB5FGW9!
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M6N@KG_ G_)//#7_8*M?_ $4M=!0 4444 %%%% !1110 4444 %%%% !1110
M5\0>._\ DH?B7_L*W7_HUJ^WZ^(/'?\ R4/Q+_V%;K_T:U '/T5V'PX\"_\
M"P/$-QI/]H_8/*M&N?-\CS<X=%VXW+_?SG/:O3_^&9?^IN_\IO\ ]MH \ HK
MW_\ X9E_ZF[_ ,IO_P!MH_X9E_ZF[_RF_P#VV@#P"BO?_P#AF7_J;O\ RF__
M &VC_AF7_J;O_*;_ /;: / **]__ .&9?^IN_P#*;_\ ;:/^&9?^IN_\IO\
M]MH \ HKW_\ X9E_ZF[_ ,IO_P!MH_X9E_ZF[_RF_P#VV@#P"BO?_P#AF7_J
M;O\ RF__ &VC_AF7_J;O_*;_ /;: / **]__ .&9?^IN_P#*;_\ ;:/^&9?^
MIN_\IO\ ]MH \ HKW_\ X9E_ZF[_ ,IO_P!MH_X9E_ZF[_RF_P#VV@#P"BO?
M_P#AF7_J;O\ RF__ &VC_AF7_J;O_*;_ /;: / **]__ .&9?^IN_P#*;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7T7\ /^1)U#_L(O_Z+CKYTKZ+^ '_(DZA_V$7_ /1<=?.<4_\ (N?J
MC:A\9ZO1117YB=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>+_ !=^%7B#QSXKM=3TF6Q6"*Q2W87$K*VX/(QX"GC#"O:*
M* /EG_AG?QI_S\:1_P"!#_\ Q%'_  SOXT_Y^-(_\"'_ /B*^IJIZIJMAHNG
MR7^IWD-I:Q_?EF8*H]!]?:@#YE_X9W\:?\_&D?\ @0__ ,11_P ,[^-/^?C2
M/_ A_P#XBO0]7_:+\-6<S1Z9IU]J 7I*<0HWTSEOS K%B_:9C,@$OA-TC[LF
MH;B/P\L?SH Y;_AG?QI_S\:1_P"!#_\ Q%=]\(OA5X@\#>*[K4]6EL6@EL7M
MU%O*S-N+QL."HXPIK<\.?'7P?KUPEM<2SZ5<.<+]M4"-C_O@D#_@6*]+!# $
M$$'D$4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5\0>._^2A^)?^PK=?\ HUJ^WZ^(/'?_ "4/Q+_V%;K_ -&M0!]?^!/^2>>&
MO^P5:_\ HI:Z"N?\"?\ )//#7_8*M?\ T4M=!0 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &OX7_Y&.T_X'_Z :](KS?PO_R,=I_P/_T UZ128!1112 ****
M"BBB@ HHHH **** "BBB@ HHHH ^._&__(^>(?\ L)7'_HQJP:WO&_\ R/GB
M'_L)7'_HQJP:_:<+_ AZ+\CSI;L****Z"0HHHH **** "BBB@ HHHH ****
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M4/Q+_P!A6Z_]&M0!W_[./_)0[_\ [!4G_HV*OJ"OE_\ 9Q_Y*'?_ /8*D_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !7Q!X[_Y*'XE_["MU_P"C6K[?KX@\=_\
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MXI_Y%S]4;4/C/5Z***_,3M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH **** "OB#QW_R4/Q+_P!A6Z_]&M7V_7Q!X[_Y*'XE_P"PK=?^C6H ^O\
MP)_R3SPU_P!@JU_]%+705S_@3_DGGAK_ +!5K_Z*6N@H **** "BBB@ HHHH
M **** "BBB@ HHHH *^(/'?_ "4/Q+_V%;K_ -&M7V_7Q!X[_P"2A^)?^PK=
M?^C6H [_ /9Q_P"2AW__ &"I/_1L5?4%?+_[./\ R4.__P"P5)_Z-BKZ@H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /(/VCO\ DGEA_P!A6/\ ]%2U\OU]0?M'?\D\L/\ L*Q_^BI:^7Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?1?P _Y$G4/^PB_P#Z+CKYTKZ+^ '_ ").H?\ 81?_ -%QU\YQ3_R+
MGZHVH?&>KT445^8G:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?$'CO_DH?B7_ +"MU_Z-:@#Z_P# G_)//#7_ &"K7_T4M=!7/^!/^2>>&O\
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MU^TX7^!#T7Y'G2W84445T$A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5]%_ #_D2=0_["+_ /HN.OG2OHOX
M ?\ (DZA_P!A%_\ T7'7SG%/_(N?JC:A\9ZO1117YB=H4444 %%%% !1110
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M%_U\+_Z"U='7.>-?^0-%_P!?"_\ H+4 <'1115 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!K^%_\
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M?\!YS7KWP<^$6J:9K<7B7Q'!]E-N";2T8@N7((WN/X0 3@=<\\8Y /?:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB#QW_R4/Q+
M_P!A6Z_]&M7V_7Q!X[_Y*'XE_P"PK=?^C6H ^O\ P)_R3SPU_P!@JU_]%+70
M5S_@3_DGGAK_ +!5K_Z*6N@H **** "BBB@ HHHH **** "BBB@ HHHH *^(
M/'?_ "4/Q+_V%;K_ -&M7V_7Q!X[_P"2A^)?^PK=?^C6H [_ /9Q_P"2AW__
M &"I/_1L5?4%?+_[./\ R4.__P"P5)_Z-BKZ@H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/VCO\ DGEA
M_P!A6/\ ]%2U\OU]0?M'?\D\L/\ L*Q_^BI:^7Z /K_X(_\ )(=#_P"WC_T?
M)7H%>?\ P1_Y)#H?_;Q_Z/DKT"@ HHHH **** "BBB@ HHHH **** "BBB@
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MN9$ABE@R\,LC$ #'WDR3CN/4T >QT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?$'CO_ )*'XE_["MU_Z-:OM^OB#QW_ ,E#\2_]
MA6Z_]&M0!]?^!/\ DGGAK_L%6O\ Z*6N@KG_  )_R3SPU_V"K7_T4M=!0 44
M44 %%%% !1110 4444 %%%% !1110 5\0>._^2A^)?\ L*W7_HUJ^WZ^(/'?
M_)0_$O\ V%;K_P!&M0!W_P"SC_R4._\ ^P5)_P"C8J^H*^7_ -G'_DH=_P#]
M@J3_ -&Q5]04 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'D'[1W_)/+#_L*Q_\ HJ6OE^OJ#]H[_DGEA_V%
M8_\ T5+7R_0!]?\ P1_Y)#H?_;Q_Z/DKT"O/_@C_ ,DAT/\ [>/_ $?)7H%
M!1110 4444 %%%% !1110 4444 %%%% !7.>-?\ D#1?]?"_^@M71USGC7_D
M#1?]?"_^@M0!P=%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &OX7_Y&.T_X'_Z :](KS?PO_P C
M':?\#_\ 0#7I%)@%%%%( HHHH **** "BBB@ HHHH **** "BBB@#X[\;_\
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M0>._^2A^)?\ L*W7_HUJ^WZ^(/'?_)0_$O\ V%;K_P!&M0!W_P"SC_R4._\
M^P5)_P"C8J^H*^7_ -G'_DH=_P#]@J3_ -&Q5]04 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'[1W_)/+
M#_L*Q_\ HJ6OE^OJ#]H[_DGEA_V%8_\ T5+7R_0!]?\ P1_Y)#H?_;Q_Z/DK
MT"O/_@C_ ,DAT/\ [>/_ $?)7H% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OHOX ?\ (DZA_P!A%_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'D'[1W_)/+#_L*Q_\ HJ6OE^OJ#]H[_DGEA_V%8_\ T5+7R_0!
M]?\ P1_Y)#H?_;Q_Z/DKT"O/_@C_ ,DAT/\ [>/_ $?)7H% !1110 4444 %
M%%% !1110 4444 %%%% !7.>-?\ D#1?]?"_^@M71USGC7_D#1?]?"_^@M0!
MP=%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &OX7_Y&.T_X'_Z :](KS?PO_P C':?\#_\ 0#7I
M%)@%%%%( HHHH **** "BBB@ HHHH **** "BBB@#X[\;_\ (^>(?^PE<?\
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MDGG-;E% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%%
M'/\ _"">#_\ H5-#_P#!=#_\37QYXT@AM?'7B&WMXHX8(M3N4CCC4*J*)6
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MTFU?4KO4]ISY2J((V^H!+?DPKU^TL[;3[2*TLX([>VA4)'%$H54 [ #I4U%
M!1110 4444 %?$'CO_DH?B7_ +"MU_Z-:OM^OB#QW_R4/Q+_ -A6Z_\ 1K4
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M,:L&M[QO_P CYXA_["5Q_P"C&K!K]IPO\"'HOR/.ENPHHHKH)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MZ+^ '_(DZA_V$7_]%QU\Z5]%_ #_ )$G4/\ L(O_ .BXZ^<XI_Y%S]4;4/C/
M5Z***_,3M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OB#QW_ ,E#\2_]A6Z_]&M7V_7Q!X[_ .2A^)?^
MPK=?^C6H ^O_  )_R3SPU_V"K7_T4M=!7/\ @3_DGGAK_L%6O_HI:Z"@ HHH
MH **** "BBB@ HHHH **** "BBB@ KX@\=_\E#\2_P#85NO_ $:U?;]?$'CO
M_DH?B7_L*W7_ *-:@#O_ -G'_DH=_P#]@J3_ -&Q5]05\O\ [./_ "4._P#^
MP5)_Z-BKZ@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M +>/_1\E>@4 %%%% !1110 4444 %%%% !1110 4444 %<YXU_Y T7_7PO\
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MHH **** "BBB@ HHHH *^B_@!_R).H?]A%__ $7'7SI7T7\ /^1)U#_L(O\
M^BXZ^<XI_P"1<_5&U#XSU>BBBOS$[0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#(QVG_  /_ - ->D5YOX7_ .1CM/\ @?\ Z :](I, HHHI %%%% !1110
M4444 %%%% !1110 4444 ?'?C?\ Y'SQ#_V$KC_T8U8-;WC?_D?/$/\ V$KC
M_P!&-6#7[3A?X$/1?D>=+=A111702%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7T7\ /^1)U#_L(O\ ^BXZ
M^=*^B_@!_P B3J'_ &$7_P#1<=?.<4_\BY^J-J'QGJ]%%%?F)VA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7Q!X[_P"2A^)?^PK=?^C6K[?KX@\=_P#)0_$O_85NO_1K4 ?7_@3_ ))Y
MX:_[!5K_ .BEKH*Y_P "?\D\\-?]@JU_]%+704 %%%% !1110 4444 %%%%
M!1110 4444 %?$'CO_DH?B7_ +"MU_Z-:OM^OB#QW_R4/Q+_ -A6Z_\ 1K4
M=_\ LX_\E#O_ /L%2?\ HV*OJ"OE_P#9Q_Y*'?\ _8*D_P#1L5?4% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y!^T=_R3RP_["L?_ **EKY?KZ@_:._Y)Y8?]A6/_ -%2U\OT ?7_ ,$?
M^20Z'_V\?^CY*] KS_X(_P#)(=#_ .WC_P!'R5Z!0 4444 %%%% !1110 44
M44 %%%% !1110 5SGC7_ ) T7_7PO_H+5T=<YXU_Y T7_7PO_H+4 <'1115
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MBBB@ HHHH **** "OB#QW_R4/Q+_ -A6Z_\ 1K5]OU\0>._^2A^)?^PK=?\
MHUJ /K_P)_R3SPU_V"K7_P!%+705S_@3_DGGAK_L%6O_ **6N@H **** "BB
MB@ HHHH **** "BBB@ HHHH *^(/'?\ R4/Q+_V%;K_T:U?;]?$'CO\ Y*'X
ME_["MU_Z-:@#O_V<?^2AW_\ V"I/_1L5?4%?+_[./_)0[_\ [!4G_HV*OJ"@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH \@_:._Y)Y8?]A6/_T5+7R_7U!^T=_R3RP_["L?_HJ6OE^@#Z_^
M"/\ R2'0_P#MX_\ 1\E>@5Y_\$?^20Z'_P!O'_H^2O0* "BBB@ HHHH ****
M "BBB@ HHHH **** "N<\:_\@:+_ *^%_P#06KHZYSQK_P @:+_KX7_T%J .
M#HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M117YB=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %\+_P"@M0!P=%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &OX7_P"1CM/^!_\ H!KTBO-_"_\
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M?_06KHZYSQK_ ,@:+_KX7_T%J .#HHHJ@"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH U_"__(QVG_ _
M_0#7I%>;^%_^1CM/^!_^@&O2*3 ****0!1110 4444 %%%% !1110 4444 %
M%%% 'QWXW_Y'SQ#_ -A*X_\ 1C5@UO>-_P#D?/$/_82N/_1C5@U^TX7^!#T7
MY'G2W84445T$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5]%_ #_D2=0_["+_\ HN.OG2OHOX ?\B3J'_81
M?_T7'7SG%/\ R+GZHVH?&>KT445^8G:%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$'CO_DH?B7_ +"M
MU_Z-:OM^OB#QW_R4/Q+_ -A6Z_\ 1K4 ?7_@3_DGGAK_ +!5K_Z*6N@KG_ G
M_)//#7_8*M?_ $4M=!0 4444 %%%% !1110 4444 %%%% !1110 5\0>._\
MDH?B7_L*W7_HUJ^WZ^(/'?\ R4/Q+_V%;K_T:U '?_LX_P#)0[__ +!4G_HV
M*OJ"OE_]G'_DH=__ -@J3_T;%7U!0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >0?M'?\D\L/\ L*Q_^BI:
M^7Z^H/VCO^2>6'_85C_]%2U\OT ?7_P1_P"20Z'_ -O'_H^2O0*\_P#@C_R2
M'0_^WC_T?)7H% !1110 4444 %%%% !1110 4444 %%%% !7.>-?^0-%_P!?
M"_\ H+5T=<YXU_Y T7_7PO\ Z"U '!T4450!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :_A?\ Y&.T
M_P"!_P#H!KTBO-_"_P#R,=I_P/\ ] ->D4F 4444@"BBB@ HHHH **** "BB
MB@ HHHH **** /COQO\ \CYXA_["5Q_Z,:L&M[QO_P CYXA_["5Q_P"C&K!K
M]IPO\"'HOR/.ENPHHHKH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KZ+^ '_(DZA_V$7_]%QU\Z5]%_ #_
M )$G4/\ L(O_ .BXZ^<XI_Y%S]4;4/C/5Z***_,3M"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB#QW_
M ,E#\2_]A6Z_]&M7V_7Q!X[_ .2A^)?^PK=?^C6H ^O_  )_R3SPU_V"K7_T
M4M=!7/\ @3_DGGAK_L%6O_HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@
M KX@\=_\E#\2_P#85NO_ $:U?;]?$'CO_DH?B7_L*W7_ *-:@#O_ -G'_DH=
M_P#]@J3_ -&Q5]05\O\ [./_ "4._P#^P5)_Z-BKZ@H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/VCO^
M2>6'_85C_P#14M?+]?4'[1W_ "3RP_["L?\ Z*EKY?H ^O\ X(_\DAT/_MX_
M]'R5Z!7G_P $?^20Z'_V\?\ H^2O0* "BBB@ HHHH **** "BBB@ HHHH **
M** "N<\:_P#(&B_Z^%_]!:NCKG/&O_(&B_Z^%_\ 06H X.BBBJ **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#7\+_\ (QVG_ __ $ UZ17F_A?_ )&.T_X'_P"@&O2*3 ****0!1110
M 4444 %%%% !1110 4444 %%%% 'QWXW_P"1\\0_]A*X_P#1C5@UO>-_^1\\
M0_\ 82N/_1C5@U^TX7^!#T7Y'G2W84445T$A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]%_ #_ )$G4/\
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M4 %%%% 'D'[1W_)/+#_L*Q_^BI:^7Z^H/VCO^2>6'_85C_\ 14M?+] 'U_\
M!'_DD.A_]O'_ */DKT"O/_@C_P DAT/_ +>/_1\E>@4 %%%% !1110 4444
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M[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@ HHHH *^(/'?\ R4/Q+_V%;K_T:U?;]?$'CO\ Y*'XE_["MU_Z-:@#Z_\
M G_)//#7_8*M?_12UT%<_P"!/^2>>&O^P5:_^BEKH* "BBB@ HHHH **** "
MBBB@ HHHH **** "OB#QW_R4/Q+_ -A6Z_\ 1K5]OU\0>._^2A^)?^PK=?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5]%_ #_D2=0_["+_ /HN.OG2OHOX ?\ (DZA_P!A%_\ T7'7SG%/_(N?JC:A
M\9ZO1117YB=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 45]_P!% 'P!17W_ $4 ? %%??\ 10!\ 45]_P!% 'P!17W_ $4 ? %%??\
M10!\ 45]_P!% 'P!170>//\ DH?B7_L*W7_HUJ^G_@E_R2'0_P#MX_\ 1\E
M'R!17W_10!\ 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]% 'P!1
M7W_10!\ 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]% 'P!17W_1
M0!\ 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]% 'P!17W_10!\
M45]_T4 ? %%??]% 'P!17W_10!\ 45]@?&O_ ))%KOT@_P#1\=?/WP4_Y*[H
M7UG_ /1$E ' 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]% 'P!1
M7W_10!\ 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]% 'P!17W_1
M0!\ 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]% 'P!17W_10!\
M45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]?(7QO_ .2N:S_NP?\
MHA* //:*^O?@A_R2/1O]Z?\ ]'O7H5 'P!17W_10!\ 45]_T4 ? %%??]% '
MP!17W_10!\ 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %%??]% 'P!17
MW_10!\ 45]_T4 ? %%??]% 'P!17W_10!\ 45]_T4 ? %?3G[-__ "(>I?\
M83?_ -%1U['10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+Z)+XG\5:;HZ%MUY<*CN.2JYRS?@H)_"@#ZA^"/A[^P?AO932)MN-2)O)/\
M=;A/_' I_$UW][>VNG6<MY>W,5M;1#=)+*X55'N34D,,=O!'#$@2.-0B*.@
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MEU#2;Q+JT9BHD3(&0<$<\UX9^T?X;V3Z7XEAC&'!L[@CU&60_EO'X"E_9O\
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M133[995/((!XYZC)%>NZWJ4OPC^"&G65N!%J\T8A0CG9,^7D?GKMRV/?;VH
M[/Q1\2O"OA";[/JNIJ+O&?LT*F20?4#[OXXK!L/COX%OKA87O;JTW' >XMR%
MS[E<X^IKY[\!>"-0^(WB:6V^U-'$H,]Y=R9=@"?_ !YB?4^IKOO'GP$C\/\
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M )#%[_UW?_T(U[AH_P"T39:9HEC8/X=N':VMXX2PNE 8JH&?N^U '>_\*+\
M?] B;_P,E_\ BJW/"_PZ\,^#KV:\T2R>WFFC\MV:=WRN<]&)[BO-/^&EK#_H
M6KG_ ,"E_P#B:]7\&>)X_&/A2SUV*U:V2Y+@1,^XKM=DZX']W- &3K_PI\(>
M)M9GU;5=.DFO9]OF.MS(@.U0HX!QT KA_B#\(_!F@^ ]7U33M-EBN[>(-$YN
M9& .X#H6P>M>V5Q?Q:_Y)9K_ /UP'_H:T ?*/@O3;76/&FCZ;>H9+6YNDCE0
M,5RI/(R.17TY_P *+\ ?] B;_P #)?\ XJOF[X<?\E(\/?\ 7]'_ #K[7H Q
M/#'A/1_!VG2V&B6S06\LIF96D9\N0!G+$GHHKYN^-O@'_A%O$?\ :UA#MTK4
MG+ *.(9>K)[ ]1^([5]65C>*O#=EXM\.7FC7P_=7"_*XZQN.58>X/Y].] 'A
M/P*^(\&DB?PUK5VD-EM:>TFE.%B(RSJ3V!Y8>^?45P/Q+\;R^.?%DUZI9;"#
M,-G$3TC!^\1ZMU/X#M7.ZYHUYX>UN[TF_0)<VLAC< Y!]"/8C!'UKL_A!X$'
MC3Q4)+R/=I5AMEN01Q(?X8_QP<^P/J* /6O@3X .A:,?$>HPE=0U!,0(XYBA
MZC\6X/T ]Z]BI  JA0, < "EH **** /E_\ : \53:GXO70(I6%EIJ@N@/#S
M,,DGUP" /3YO6K_PB^#VF^)M#_M_Q#YLEM,S):VT;E 0IP78CGJ" !CIWSQY
MGX]N9+OX@>()I"2QU"8#/8!R /P&*]1M/CC9^$O"&B:)H>FB^N+>RC%Q-,Y2
M-)"H+* .6P2<G(Z<9H QOB;\(+K0=?ME\*Z=J%_8W:%A%%$TQ@8'!!8#[O((
M)]_2O7_@O:^(=-\$_P!F>(+&XM7M9B+83]3$0"!Z\$L/RKB?#_[2*2WD</B#
M15@@8X:XLW+;.>I0\D>N#GV->ZV5[;:C90WEG.D]M,@>.6,Y5E/0@T ?+?Q[
M\1RZOX^;3%<_9=+C$2+VWL SM_(?\!KJ?A7\&=#UWPC%K?B&.>:6]W&"))3&
ML: X!XY).,]<8(XKR+QU,]QX^\02N26;49^_3YSQ7UU\/(UB^''AM5Z'38&_
M$H"?YT ?*'Q%\'_\(1XQN=(CDDEM=JRV\DF-S1L.,X[@Y&?:OISX2^))?$_P
M\T^ZN7+W<&;:=B<EF3@$^Y7:?QKR']I&)!XOTF8??:PVGZ"1L?S-=5^S;,Q\
M+:Q"?N+>AQ]2B@_R% $O[1^H"'PAI>GAL-<WADQG&0BD'ZC+C]*\I^''PJN?
MB%9WUTFII8QVLBQ@M#YF\D9/\0QCC\ZZG]I'4?.\4Z3IPY%O:&4^Q=B,?D@_
M.N+\*_%'7?!GA^32M$BM(O-G:>2XEC+N20!@9.  %'8T >A?\,SW7_0TP_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+\1Z-%XA\-ZCH\V EY;O
M%N/\)(X;\#@_A7Q##+>:!KD<R@PWVGW(8!OX)(VSS]"*^\J^2_CGX<_L+XBW
M%U%&%MM40728&!O/$@^NX;C_ +U '9_'CQE#JG@_PY:6,G[K5$&H. >0@4;
M1[EF_%*S_P!G+P[]JU[4?$,J?N[.(6\)(ZR/RQ'N%&/^!UXQ<WMS=QVT=Q,\
MBVT7DPACG8FXMM'MEF_.OL#X2>'/^$:^'&F02(%N;I?M<_&#NDY /N%VK^%
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MNC' ?87# >_S+QUP/:@#V[QS_P D_P#$G_8+NO\ T4U?&_A+_D<]"_["%O\
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M>VND&7A;^H/<=_8@$?.>L? GQOIMTR6EC#J4&?EFMYT7([95R"#^8]Z^M**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MP_$_@_0_&-G%:ZY9?:8H7+QXE="K8QG*D?K6%IGP?\":5=+<P:#%+*O*FYE>
M91_P%B5_2NYHH 0 *    . !2T44 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!R/B3X9^$_%FI?VCJ^F-->; AE2>1,J.@(5@/TJ;P]\.O"?A:
M<7&D:-!#<CI/(S2R#MPSDE?PQ7444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img44875045_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44875045_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #S!2\# 2(  A$! Q$!_\0
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M $#;7_OIJ/\ A;&H_P#0-M?^^FHL%SUBBO)_^%L:C_T#;7_OIJ/^%L:C_P!
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M&VO_ 'TU%@N>L45Y/_PMC4?^@;:_]]-1_P +8U'_ *!MK_WTU%@N>L45Y/\
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ML45Y/_PMC4?^@;:_]]-1_P +8U'_ *!MK_WTU%@N>L45Y/\ \+8U'_H&VO\
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MG@K2?$,D"1WKR^1(4&-P^?/X93(],F@#BK;3+^\@>:UL;F>)#AWBB9E7C/)
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MJ#25O^-6W^,-1;[,]N#(/D<8)^4#=^.,_C6!3 **** "BBB@#N?A9_R,T_\
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M]"T+3;&4NMK S3C:0!*YRPYZXYYZ<\5-X$U:QT;Q$;K4)_)@\ADW;&;DD8X
M)[5S%% 'I6F>-M/M="UJ*2Y NFN+B2R'E,=P?E><<<D]<5FZKXGL_P#A%_#T
M5C<A]0T]XW="C *57N< $9P.#7#T46&>C7NI>!O$TD>HZG+<V-Z0/.2-6._'
M&"0I!'OP<8JKJGB30]0OM(TBW!MM!LI1(\CH3OP#QMY..HR>3NK@Z*+ >C:M
M\4KR+5)H]*BLY;)2!')+&^YN!D_>'?/:LKQMK.E>(+;3=0MIE&H"()<PB-AM
MXSU(P<'(_&N.HHL 4444Q!1110 4444 %%%% !1110 4444 %319^SW'IA?7
MU^G^%0U-%CR)^F<#T]?K_+- $-%%% !1110!U^BZWIUIX U?3)[C9>7$A:*/
M8QW#"]P,#H>IKD***0'5^*]9L-2T'PY;6D_F36=KY<Z[&&QML8QDCGE3T]*W
MH?%6E:II6EK>:W?Z7/9@)/% ) MPH [ITSCKVR?K7FU%%AG=:;XTL[/QG<7A
M6Y.F31?9QYLKRR*H.0Q+$GKG@'H?6J%Y'X/T_2+I;2XEU6^E;$#,CQ" >IZ!
MB/ISQP*Y2BBPCT34?$^CSZOX6GBO-T=B,7+>4XV<+[<]#TS4]CXKT6'Q3XAO
M)+W%O=Q1K _E/\Y"8/&,CGUKS2BBPSL?#^N:=8^"-:TZYN-EW<[O*CV,=V5
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M:-U,QW*3@D'' P,^E7-(\2:-IQMGB\5:@+-%^>QN[8RL>.@<+@#Z>E>8T46
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M'_"JM'_Y^[S_ +Z7_#_/'X]W11<#A/\ A56C?\_=[_WTO^'T_7\#_A56C_\
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MHHN!PG_"JM'_ .?N\_[Z7_"C_A56C9_X^[W'^\O_ ,37=T47 X3_ (55H_\
MS]WF?]Y?\*/^%5:-G_C[O<?[R_\ Q-=W11<#A/\ A56C_P#/W>?]]+_A_GC\
M3_A56C?\_=[_ -]+_A]/U_#NZ*+@<)_PJK1_^?N]_P"^E_P^OZ?B?\*JT;_G
M[O/^^E_P^GZ_AW=%%P.$_P"%5:-_S]WO_?2_X?7]/Q/^%5:/_P _=Y_WTO\
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M]_[Z7_#Z?K^'=T47 X3_ (55H_\ S]WO_?2_X?7]/Q/^%5:-_P _=Y_WTO\
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M>_\ ST?\Z.1A[1&A16?O?_GH_P"=&]_^>C_G1R,/:(T**S][_P#/1_SHWO\
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M_P#/1_SHWO\ \]'_ #HY&'M$:%%9^]_^>C_G1O?_ )Z/^='(P]HC0HK/WO\
M\]'_ #HWO_ST?\Z.1A[1&A16?O?_ )Z/^=&]_P#GH_YT<C#VB-"BL_>__/1_
MSHWO_P ]'_.CD8>T1H45G[W_ .>C_G1O?_GH_P"='(P]HC0HK/WO_P ]'_.C
M>_\ ST?\Z.1A[1&A16?O?_GH_P"=&]_^>C_G1R,/:(T**S][_P#/1_SHWO\
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M_P#/1_SHWO\ \]'_ #HY&'M$:%%9^]_^>C_G1O?_ )Z/^='(P]HC0HK/WO\
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MZT:-XCTCQ LATN^2X\O[Z@%67\& -3R2MS6T*YHWM?4U****D84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXN+0U1:DG<LT445RFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%!15:[U"RL-GVR\M[??G;YTJINQUQD\]14<&LZ7<RB*WU*SED;HD<ZL3^ -
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M^YR;R?/LY'\JZJ>$G-7>AY];,:5.7*E<] HKSW^T;[_G]N/^_K?XT?VC??\
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MBBB@ HHHH **** "BBB@ HHHH :?]:/]T_TIU-/^M'^Z?Z4Z@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !]]/]X?SJ[5(??3_>
M'\ZNT ,E_P!2_P#NFJHZ5:E_U+_[IJJ.E ' ?$AK=+[07NT:2V620RHO5DS'
MD#D<XSWKE]3N/#=XUK%H-G<6-R9AF>XEPBC\6;OSGBNY\9Z7JU]?:/=Z5:K<
M264C2D,ZJ <H5SDC(^4]*RM5LO&?B.!+&^TRQMX2X)E5ERO_ (^Q_(4T(M:W
MD?$C0,MN/DC+>O+\U;7Q'K.KZC>PZ!:6;6]FVQI;IF_>-SPN"/0]:;>:!?#Q
M9H5S!$9;.RMUBDF+J,8W#H3GN.E16NEZ[X9U'4/[+L(;^TNW\Q-TPC,9YZYZ
MCG].U %B'QS ?#$^IS6Y6Y@D\E[<'K(>F#Z=?R-02^)]>TF&SO\ 6+"T&GW#
M '[.6\R+(R,Y.#QSQ4,7@:X?PG=6D\R#4+B87''W%8=%_4\^_M27NE^)/$-G
M9:5?V,%G;0LIFN1,KE]H(^51TX/_ .J@#2U#Q%J,OB,:+HEO:R2I$)99;@G8
MH(!_A]BO/O63X.>>3QKKCW42Q3E?WB*<@-N&<'TJ_>Z/JNE>+#K6D6B7D4T(
MAE@:4(5 "CJW^ZOZTGA?2-7M?$NJ:AJ=LD0NER"D@9<DYP.<_G0 SXG?\BU;
M?]?B_P#H#U#XE\%:-9Z%<WEC ]M/;IYBLLK-G'8Y)_2M/QWI-]K.B0V]A!YT
MJW*N5WJN%"L,\D=R*R+Z'QQKML=/NK*SL[>7B21''3/^\Q_(4 -N-?E.C>&)
MY[.SNY;ERC/<Q;V4A@NY3G@GKFK=[XNU%O$%WIEB--@^S\ WSLIE/HN"!GZT
MNN>&+OR/#UKIL)FBL)/WK%E7 RI)Y/?!/%&O:7J-YJ4YF\.6&I0,,0S1S>1(
MOIO)/./:@#3NO$5QI7ADZEJEB(;H'8($D#!V/0@@GCO^%9DOB?7M)AL[_6+"
MT&GW# '[.6\R+(R,Y.#QSQ4-OX.U&;P3)I=Y<*+GSO.@0MN6/ QMS[\].F:2
M]TOQ)XAL[+2K^Q@L[:%E,UR)E<OM!'RJ.G!__50!;O?$NL'Q;)HFFP6,@,:M
M')-NP,J&))!Y'7H/2GW?B+6?[7M=$LK:S;4C")+EY"WE(<9(&#G'O[TZVT2]
MA^(,VI"WVV!MQ&DF]3R%48QG/;TIFJZ1JMGXM37M*M4O!)'Y<T#2A#TQD$\=
MA^5 &-H-_):>,M?OM1B6&2&V9YD0[AP5Z?7''UJ4>/K]+>/4)(]+-H\FTVJ3
MYN57/4C/]*FT_P .:O=ZSK<^J6Z6\=_;-&KQR!@K';@=<\8].U5+;PUKD=G!
MI@T72XV23YM2=(I2R9/\+ DGGT[#I0!K:CXIU,>)K;2M+@M)5N85DC:8,,9!
M.20>@ STJ/4O%>K6&H6FE2)IL%X\>^::=F$())P!@YZ <FK!T.]C\?6FH1VX
M^P0VWE>8&48(5@!M'U'08J7Q+8ZA=W<>W1+'5;,+]UG\J9#[.3C'TH T]"O=
M3O+:1M3M(875OW<D$H>.5?48)(_'UK5KD_!NA:AI,M]-=1BU@G8>59K+Y@C]
M\_I[UUE(84444 %%%% !1110 4444 -7_6/^%.IJ_P"L?\*=0 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** &K_K'_"G4U?\ 6/\ A3J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)]T?[P_G3J;
M)]T?[P_G0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ H/2B@]* &Q_ZM?H*=38_]6OT%.H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** &I]Y_\ >_H*=34^\_\ O?T%.H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &G_6C_=/]*=33_K1
M_NG^E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M  ??3_>'\ZNU2'WT_P!X?SJ[0 R7_4O_ +IJJ.E6I?\ 4O\ [IJJ.E !17G'
MQ(MWN]9T>VC&9)@8U'N6 %0ZGJKZGX#T>Q1OW\[^5)["+KG_ ,=-.P'IM%>;
M^&-;_P"$?\!27WV?[1_II39OV=57G.#73ZMXH_LM-);['YO]H$#_ %NWR\[?
M8Y^][=*5@.AHKF+WQ9,FMSZ5INE-?3P+F3,ZQ=LG&1S5IO$T5OX>?5KZRNK0
MH=AMYD*N6[ 9QD'U^OI0!NT5RMIXPF-]90:EI$MC'??\>\K2APWID8&.H_,5
MEZ)=0V7C;Q-=3OLBB1G<^@!%%@.^HKCU\<R+##?7.BSPZ7,^Q+HR@GZE,9 _
M'\ZZ\$, 000>01WH 6BO*] \+67B/4M9:[EN(S!<$+Y3*,Y+=<@^E:FAM/X?
M\27_ (>FN'NK,V[2QACC'&<>W&13L(] HKAM'\2:9I/@Z34;;2WMH?M1C6W6
M8R;G(!SN;IQ_*MC3?$-_=7L,%YH5Q;1S+N2>.031^VXJ,"D,Z&BN9NO%<S:I
M<V&DZ3+J+VO^O=91&J'N!D')X_0XIC^-K<^&I=7AM6=X9!%+;.^UD8GUP?Y4
M =317-6WBN9M,FU2]TJ2UL$A$L<IE#&0D@ !<<9)XS7+>+]>O-6\,P-/H\UI
M;RS*\,QD#AQ@]1@$$YR/6G8#TZBN:N?$K6<]GI5A8/?W[0*[1K($"+CNQHA\
M7QRZ)J-Z;)X[G3SMGM7?!!SC[V/KV[4@.EHKE+/QC<7&GMJ<VC2PZ<L3.9_.
M#98'&T+@$\\9X[^E%CXNOKL6TY\/7/V*=L+/!*)BONRJ,C\:+ =71110 444
M4 %%%% !1110 U?]8_X4ZFK_ *Q_PIU !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %-D^Z/]X?SIU0W4@AMWE/1/F/X4;B;LKLJ:EK-OIN
M$8&28\A%/3Z^E8;>*KPGY(( /0@G^M8L\SW$[S2'+N<DU'7K4\+3BO>5V?/5
MLPJSE[KLC<_X2J^_YY6__?+?XT?\)5??\\K?_OEO\:PZ*T^KTOY3'ZY7_F9N
M?\)5??\ /*W_ .^6_P :/^$JOO\ GE;_ /?+?XUAT4?5Z7\H?7*_\S-S_A*K
M[_GE;_\ ?+?XT?\ "57W_/*W_P"^6_QK#HH^KTOY0^N5_P"9FY_PE5]_SRM_
M^^6_QH_X2J^_YY6__?+?XUAT4?5Z7\H?7*_\S-S_ (2J^_YY6_\ WRW^-'_"
M57W_ #RM_P#OEO\ &L.BCZO2_E#ZY7_F9N?\)5??\\K?_OEO\:/^$JOO^>5O
M_P!\M_C6'11]7I?RA]<K_P S-S_A*K[_ )Y6_P#WRW^-=-8WD=]:)/'W'(]#
MZ5Y[6IHFIFPN]KG]Q)PWM[UC7PT7&\%J=6$QTU4M5=TSMZ* 00"#D'O17EGO
M!1110 4'I10>E #8_P#5K]!3J;'_ *M?H*=0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 -3[S_[W]!3J:GWG_WOZ"G4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #3_K1_NG^E.II_
MUH_W3_2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%%  /OI_O#^=7:I#[Z?[P_G5V@!DO^I?_=-51TJU+_J7_P!TU5'2@#C?%5A=
M77BWP]-#;32113*TDB1EE3#J>2.G2L?3?#MY'XNU%9+:<6,"W#P,T9VL7& %
M..3@_I7I5%.X'F-MH>IS?#BXM!93K<K>>:(70J[+@#@'K_\ 6I^JOJ>K_P#"
M/HFAZA"EHZB1I(3U^4'@<@<=3BO2Z*+BL<#XDT^WN-:E>[\.ZD6QE+S37WF3
MCC*XPO\ GK4']A^(-4\#S6]YYK3QSB6VBG;]X4 Q@G\3C/I7HM%%QG)66N:Y
M=S:?9VNBS6JJ MW+>1,%4#'W#D9[_I64FAWU[KGBF(V\T2743"&5XR$<[@1@
MGCM7H5% 'E%IH+26MK8CPI-_:7F;9[FY:40[?[P*L!GZ>G?->J11K#"D2C"H
MH4#V%/HI >9Z/?:QX=U#52GAR^NUN9RP8(Z@ %O]DYSFM/1=,U74=7O_ !!J
MEH;9WMVB@@P=W3'3KT'?KFNYHIW \[T73KJ'P'/;W6A2W;&Z+-;2$POMP/F7
M(SG_ .O4>C6-];>(+(Z+9ZQ9V6[-VE\-J8SR%'?C//7->D447 X6Q34/"6MZ
MKG2KN^M;R3S89+5-Y!RQ ;TZ\GV[UER^']4C\'ZG-)9R_:[ZZ246T:EV50Q/
M('U->G447%8YC5-&N-3\ PV$2%;E+:(K&WR_,H'RG/3H1]:YG6Y]6U3PG9Z8
MF@:BDML4$KF$X.U2HVCJ<]<]J]-HH&><ZUH+IXB@U&\TFYU&PEMT62.WW;T8
M*!T!![?K4EMHEPGA+6I8]&^QR7*A8+>,R/*R!N-P9CS] .AKT*BBX6.:TBUF
MA\!06TFG>?*("&M)3Y9?).0<C@UQXTZ\BG@?P_I.M:=?&0>8LI_<*/\ >(^8
M?6O5:*+@(N=HW8W8YQTS2T44@"BBB@ HHHH **** &K_ *Q_PIU-7_6/^%.H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"\B\^TDB_OC
M;^?%3TV3[H_WA_.A.VHFKJS/.'1HY&1P0RG!![&FUV6K:"E^YFA81S]\CAOK
M6"WAW4U.! &'J'7^IKV*>)IS5V[,^;K8*M3E9*Z\C+HK3_X1_5/^?7_R(O\
MC1_PC^J?\^O_ )$7_&M/;4_YE]YC]7K?R/[F9E%:?_"/ZI_SZ_\ D1?\:/\
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MBBB@ HHHH **** "BBB@ HHHH :GWG_WOZ"G4U/O/_O?T%.H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &G_6C_ '3_ $IU-/\
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M9O[J_P#?7_UJ &T4[R9O[J_]]?\ UJ/)F_NK_P!]?_6H ;13O)F_NK_WU_\
M6H\F;^ZO_?7_ -:@!M%.\F;^ZO\ WU_]:CR9O[J_]]?_ %J &T4[R9O[J_\
M?7_UJ/)F_NK_ -]?_6H ;13O)F_NK_WU_P#6H\F;^ZO_ 'U_]:@!M%.\F;^Z
MO_?7_P!:CR9O[J_]]?\ UJ &T4[R9O[J_P#?7_UJ/)F_NK_WU_\ 6H ;13O)
MF_NK_P!]?_6H\F;^ZO\ WU_]:@!M%.\F;^ZO_?7_ -:CR9O[J_\ ?7_UJ &T
M4[R9O[J_]]?_ %J/)F_NK_WU_P#6H ;13O)F_NK_ -]?_6H\F;^ZO_?7_P!:
M@!M%.\F;^ZO_ 'U_]:CR9O[J_P#?7_UJ &T4[R9O[J_]]?\ UJ/)F_NK_P!]
M?_6H ;13O)F_NK_WU_\ 6H\F;^ZO_?7_ -:@!M%.\F;^ZO\ WU_]:CR9O[J_
M]]?_ %J &T4[R9O[J_\ ?7_UJ/)F_NK_ -]?_6H ;13O)F_NK_WU_P#6H\F;
M^ZO_ 'U_]:@!M%.\F;^ZO_?7_P!:CR9O[J_]]?\ UJ &T4[R9O[J_P#?7_UJ
M/)F_NK_WU_\ 6H ;39/NC_>'\ZD\F;^ZO_?7_P!:D:"9@/E7J#][_P"M0 E%
M.\F;^ZO_ 'U_]:CR9O[J_P#?7_UJ &T4[R9O[J_]]?\ UJ/)F_NK_P!]?_6H
M ;13O)F_NK_WU_\ 6H\F;^ZO_?7_ -:@!M%.\F;^ZO\ WU_]:CR9O[J_]]?_
M %J &T4[R9O[J_\ ?7_UJ/)F_NK_ -]?_6H ;13O)F_NK_WU_P#6H\F;^ZO_
M 'U_]:@!M%.\F;^ZO_?7_P!:CR9O[J_]]?\ UJ &T4[R9O[J_P#?7_UJ/)F_
MNK_WU_\ 6H ;13O)F_NK_P!]?_6H\F;^ZO\ WU_]:@!M%.\F;^ZO_?7_ -:C
MR9O[J_\ ?7_UJ &T'I3O)F_NK_WU_P#6H\F;^ZO_ 'U_]:@"./\ U:_04ZE6
M"95 VKP,?>_^M2^3-_=7_OK_ .M0 VBG>3-_=7_OK_ZU'DS?W5_[Z_\ K4 -
MHIWDS?W5_P"^O_K4>3-_=7_OK_ZU #:*=Y,W]U?^^O\ ZU'DS?W5_P"^O_K4
M -HIWDS?W5_[Z_\ K4>3-_=7_OK_ .M0 VBG>3-_=7_OK_ZU'DS?W5_[Z_\
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MM%.\F;^ZO_?7_P!:CR9O[J_]]?\ UJ &T4[R9O[J_P#?7_UJ/)F_NK_WU_\
M6H ;13O)F_NK_P!]?_6H\F;^ZO\ WU_]:@!M%.\F;^ZO_?7_ -:CR9O[J_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>fulc-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-26T12:50:12.0545+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.fulcrumtx.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:fulc="http://www.fulcrumtx.com/20231231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails2" id="DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Future minimum lease payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" id="DisclosureCashEquivalentsAndMarketableSecurities1">
        <link:definition>100100 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100110 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetail" id="Role_DisclosureAdditionalBalanceSheetDetail">
        <link:definition>100120 - Disclosure - Additional Balance Sheet Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStock" id="Role_DisclosurePreferredStock">
        <link:definition>100130 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100140 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" id="Role_DisclosureStockBasedCompensationExpense">
        <link:definition>100150 - Disclosure - Stock-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100160 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreements1" id="DisclosureLicenseAgreements1">
        <link:definition>100170 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeases1" id="DisclosureLeases1">
        <link:definition>100180 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100190 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100200 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100210 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivities" id="DisclosureRestructuringActivities">
        <link:definition>100220 - Disclosure - Restructuring Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100230 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100240 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100270 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" id="DisclosureCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>100280 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100290 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailTables" id="Role_DisclosureAdditionalBalanceSheetDetailTables">
        <link:definition>100300 - Disclosure - Additional Balance Sheet Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100310 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" id="Role_DisclosureStockBasedCompensationExpenseTables">
        <link:definition>100320 - Disclosure - Stock-based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>100330 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100340 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100350 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesTables" id="DisclosureRestructuringActivitiesTables">
        <link:definition>100360 - Disclosure - Restructuring Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100370 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of the Estimated Useful Life of Related Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails">
        <link:definition>100410 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" id="DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
        <link:definition>100430 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" id="DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100470 - Disclosure - Additional Balance Sheet Detail - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100480 - Disclosure - Additional Balance Sheet Detail - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails" id="Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Additional Balance Sheet Detail - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" id="Role_DisclosurePreferredStockAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails" id="Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails">
        <link:definition>100520 - Disclosure - Common Stock - Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Stock-based Compensation Expense - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails" id="Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails">
        <link:definition>100540 - Disclosure - Stock-based Compensation Expense - Summary of Restricted Stock Activity under 2019 Plan and 2016 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails">
        <link:definition>100550 - Disclosure - Stock-based Compensation Expense - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails" id="Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails">
        <link:definition>100560 - Disclosure - Stock-based Compensation Expense - Summary of Weighted Average Assumptions Used to Calculate Fair Value of Stock Option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails" id="Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails">
        <link:definition>100570 - Disclosure - Stock-based Compensation Expense - Summary of Restricted Stock Activity outside of 2019 and 2016 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails" id="Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails">
        <link:definition>100580 - Disclosure - Stock-based Compensation Expense - Summary of Stock-Based Compensation Expense Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails">
        <link:definition>100610 - Disclosure - Leases - Schedule of Future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" id="DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails">
        <link:definition>100620 - Disclosure - Leases - Schedule of Minimum rental commitments under non-cancelable leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Leases (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails">
        <link:definition>100650 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne">
        <link:definition>100660 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details One)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
        <link:definition>100670 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100680 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100690 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100700 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails" id="DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails">
        <link:definition>100710 - Disclosure - Restructuring Activities - Schedule of Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetails" id="DisclosureRestructuringActivitiesAdditionalInformationDetails">
        <link:definition>100720 - Disclosure - Restructuring Activities (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100730 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100740 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="fulc-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails2" xlink:href="fulc-20231231.xsd#DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="fulc-20231231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="fulc-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="fulc-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fulc-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="fulc-20231231.xsd#DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="fulc-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="fulc-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="fulc-20231231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="fulc-20231231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="fulc-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="fulc-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" xlink:href="fulc-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecurities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="fulc-20231231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetail" xlink:href="fulc-20231231.xsd#Role_DisclosureAdditionalBalanceSheetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStock" xlink:href="fulc-20231231.xsd#Role_DisclosurePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="fulc-20231231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" xlink:href="fulc-20231231.xsd#Role_DisclosureStockBasedCompensationExpense" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:href="fulc-20231231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreements1" xlink:href="fulc-20231231.xsd#DisclosureLicenseAgreements1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeases1" xlink:href="fulc-20231231.xsd#DisclosureLeases1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="fulc-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="fulc-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:href="fulc-20231231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivities" xlink:href="fulc-20231231.xsd#DisclosureRestructuringActivities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="fulc-20231231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="fulc-20231231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fulc-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="fulc-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="fulc-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:href="fulc-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="fulc-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailTables" xlink:href="fulc-20231231.xsd#Role_DisclosureAdditionalBalanceSheetDetailTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="fulc-20231231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" xlink:href="fulc-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:href="fulc-20231231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="fulc-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="fulc-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesTables" xlink:href="fulc-20231231.xsd#DisclosureRestructuringActivitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="fulc-20231231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosurePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:href="fulc-20231231.xsd#DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne" xlink:href="fulc-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails" xlink:href="fulc-20231231.xsd#DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#DisclosureRestructuringActivitiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="fulc-20231231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements" xlink:label="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" xlink:label="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredRevenueCurrentAndNoncurrent" xlink:label="fulc_DeferredRevenueCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalProgram" xlink:label="fulc_ClinicalProgram"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="us-gaap_AccountsAndNotesReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" xlink:label="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ChangeInVariableConsiderationConstrained" xlink:label="fulc_ChangeInVariableConsiderationConstrained"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ReimbursementPaymentRecieved" xlink:label="fulc_ReimbursementPaymentRecieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTable" xlink:label="us-gaap_PublicUtilitiesInventoryTable"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="fulc_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" xlink:label="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PaymentForPrepaidResearchFunding" xlink:label="fulc_PaymentForPrepaidResearchFunding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Propertyplantandequipmentusefullives" xlink:label="fulc_Propertyplantandequipmentusefullives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ConsultingServicesMember" xlink:label="fulc_ConsultingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" xlink:label="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember" xlink:label="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:label="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Camp4AgreementMember" xlink:label="fulc_Camp4AgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial" xlink:label="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CorporateBondsMember" xlink:label="fulc_CorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidResearchFundingPaymentReceived" xlink:label="fulc_PrepaidResearchFundingPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GovernmentAgencySecuritiesMember" xlink:label="fulc_GovernmentAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PatentCostPolicyTextBlock" xlink:label="fulc_PatentCostPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OfficeAndLaboratorySpace" xlink:label="fulc_OfficeAndLaboratorySpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LeaseIncentivePayableNoncurrent" xlink:label="fulc_LeaseIncentivePayableNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock" xlink:label="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromMaturityOfMarketableSecurities" xlink:label="fulc_ProceedsFromMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DefinedContributionPlanName" xlink:label="fulc_DefinedContributionPlanName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBStockPurchaseAgreementMember" xlink:label="fulc_SeriesBStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Thereafter" xlink:label="fulc_Thereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NumberOfDirectorsStockholdersAreEntitledToElect" xlink:label="fulc_NumberOfDirectorsStockholdersAreEntitledToElect"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months" xlink:label="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromSaleOfMarketableSecurities" xlink:label="fulc_ProceedsFromSaleOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForOperatingActivities" xlink:label="us-gaap_PaymentsForOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesTable" xlink:label="fulc_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MilestonePaymentForCertainOtherIdentifiedTargets" xlink:label="fulc_MilestonePaymentForCertainOtherIdentifiedTargets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AtTheMarketOfferingMember" xlink:label="fulc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityDividendsDeclared" xlink:label="fulc_TemporaryEquityDividendsDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="us-gaap_LeaseIncentivePayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MilestonePaymentForCertainIdentifiedTargets" xlink:label="fulc_MilestonePaymentForCertainIdentifiedTargets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryLineItems" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PercentageOfCommissionOnGrossSalesPricePerShare" xlink:label="fulc_PercentageOfCommissionOnGrossSalesPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EstimatedUsefulLifeOfAssetTableTextBlock" xlink:label="fulc_EstimatedUsefulLifeOfAssetTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm" xlink:label="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesLineItems" xlink:label="fulc_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NumberOfCommonStockVotingRights" xlink:label="fulc_NumberOfCommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidExpenses" xlink:label="fulc_PrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="us-gaap_LossContingencyLossInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion" xlink:label="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TaxCreditCarryforwardExpirationYear" xlink:label="fulc_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncomeTaxesDisclosureLineItems" xlink:label="fulc_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_RangeOfTieredRoyaltiesOnNetSales" xlink:label="fulc_RangeOfTieredRoyaltiesOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LabEquipmentMember" xlink:label="fulc_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ThirdRockVenturesLLCMember" xlink:label="fulc_ThirdRockVenturesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CumulativeCatchUpAdjustment" xlink:label="fulc_CumulativeCatchUpAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAmortizedCost" xlink:label="fulc_CashAndCashEquivalentsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncomeTaxesDisclosureTable" xlink:label="fulc_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GSKAgreementMember" xlink:label="fulc_GSKAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseAbstract" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AreaOfPropertiesHeldUnderOperatingLeases" xlink:label="fulc_AreaOfPropertiesHeldUnderOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedResearchAndDevelopmentExpenses" xlink:label="fulc_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwothousandtwentytwoinducementstockincentiveplanMember" xlink:label="fulc_TwothousandtwentytwoinducementstockincentiveplanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesAConvertiblePreferredStockMember" xlink:label="fulc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AssetAcquisitionDisclosureTextBlock" xlink:label="fulc_AssetAcquisitionDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NonRefundableUpfrontPaymentsReceived" xlink:label="fulc_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LessImputedInterest" xlink:label="fulc_LessImputedInterest"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LegalProceedingsMember" xlink:label="fulc_LegalProceedingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense" xlink:label="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AggregateRestructuringCharges" xlink:label="fulc_AggregateRestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid" xlink:label="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WorldwideNetSalesMilestonesMember" xlink:label="fulc_WorldwideNetSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference" xlink:label="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo" xlink:label="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:label="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashPaidForOperatingLeaseLiabilities" xlink:label="fulc_CashPaidForOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_UpfrontPayment" xlink:label="fulc_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OperatingLossCarryforwardsIndefinitely" xlink:label="fulc_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WorkforceReduction" xlink:label="fulc_WorkforceReduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:label="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PreferredStockConversionPricePerShare" xlink:label="fulc_PreferredStockConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBConvertiblePreferredStockMember" xlink:label="fulc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" xlink:label="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedRestructuringCharges" xlink:label="fulc_AccruedRestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" xlink:label="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedRestrictedStockLiabilityCurrent" xlink:label="fulc_AccruedRestrictedStockLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_FairValueTransfersBetweenLevels" xlink:label="fulc_FairValueTransfersBetweenLevels"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MyoKardiaCollaborationAgreementMember" xlink:label="fulc_MyoKardiaCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" xlink:label="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesMember" xlink:label="fulc_ClinicalAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonePayables" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayables"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Asc840Member" xlink:label="fulc_Asc840Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsLeaseIncentive" xlink:label="fulc_DeferredTaxAssetsLeaseIncentive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidSignOnBonusesSubjectToVestingProvisions" xlink:label="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember" xlink:label="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SalesMilestone" xlink:label="fulc_SalesMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OperatingLossCarryforwardsExpirationYear" xlink:label="fulc_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchMilestoneMember" xlink:label="fulc_ResearchMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear" xlink:label="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating leases, allowance for normal leasehold improvements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases Allowance For Normal Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating leases, allowance for normal leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in number of shares reserved for issuance, percent of common stock outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Number Of Shares Reserved For Issuance Percent Of Common Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares reserved for issuance, percent of common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredRevenueCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue current and noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredRevenueCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current And Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredRevenueCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue current and non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities, excluding current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical program | Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock in connection with private placement, net of placement agent fees and offering costs, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with private placement, net of placement agent fees and offering costs, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Assets Acquired Other Than Through Business Combination [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock in connection with asset acquisition, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Development And Sales Arrangement Amount Received Upon Achievement Of Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Development And Sales Arrangement Amount Received Upon Achievement Of Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options repurchased in period weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of securities, unrealized loss position for less than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued in exchange for services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, share issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsAndNotesReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts and Financing Receivable, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsAndNotesReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsAndNotesReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and Financing Receivable, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets orphan drug credit carryforwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Orphan Drug Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan drug credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen and two thousand sixteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Sixteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan and 2016 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ChangeInVariableConsiderationConstrained_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in variable consideration constrained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ChangeInVariableConsiderationConstrained_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Variable Consideration Constrained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ChangeInVariableConsiderationConstrained_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in variable consideration constrained.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ReimbursementPaymentRecieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement Payment Recieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ReimbursementPaymentRecieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Payment Recieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ReimbursementPaymentRecieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement Payment Recieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, excluding current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of unvested restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Utilities, Inventory [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Utilities Inventory [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities accumulated gross unrealized gains before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Gains Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents and marketable securities, Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares initial public offering net of underwriting discounts, commissions and offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Initial Public Offering Net Of Underwriting Discounts Commissions And Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering net of underwriting discounts, commissions and offering costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PaymentForPrepaidResearchFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for Prepaid Research Funding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PaymentForPrepaidResearchFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Prepaid Research Funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PaymentForPrepaidResearchFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for prepaid research funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Propertyplantandequipmentusefullives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment Estimated Useful Lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Propertyplantandequipmentusefullives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PropertyPlantAndEquipmentUsefulLives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Propertyplantandequipmentusefullives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PropertyPlantAndEquipmentUsefulLives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents accumulated gross unrealized gains before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Accumulated Gross Unrealized Gains Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents, Gross unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ConsultingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ConsultingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ConsultingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease end date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares reserved for future issuance under the 2022 Inducement Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Off-balance sheet risk and concentrations of credit risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Off Balance Sheet Risk And Concentrations Of Credit Risk Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-Balance Sheet Risk and Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents accumulated gross unrealized losses before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Accumulated Gross Unrealized Losses Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash equivalents, Gross unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities accumulated gross unrealized gains before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total cash equivalents and marketable securities, Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Dividend Rate, Per-Dollar-Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, dividend per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Operating Leased Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grants outside of two thousand sixteen stock incentive plan and two thousand nineteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Outside Of Two Thousand Sixteen Stock Incentive Plan And Two Thousand Nineteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants Outside of 2016 Stock Incentive Plan and 2019 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of securities, unrealized loss position for more than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Stock Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Two Inducement Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twenty Two Inducement Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, capitalized research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Research And Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research contract costs and accruals.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Contract Costs And Accruals Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Contract Costs and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income tax at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due, Next 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LandsdowneStreetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">26 Landsdowne Street [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LandsdowneStreetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">26 Landsdowne Street [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LandsdowneStreetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">26 Landsdowne Street [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease option to extend description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest related to uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of minimum rental commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessor, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Camp4AgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CAMP4 Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Camp4AgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CAMP4 Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued penalties related to uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestones payable upon initiation of phase two clinical trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestones Payable Upon Initiation Of Phase Two Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified clinical and regulatory milestones due upon phase two clinical trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate bonds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidResearchFundingPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research funding payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidResearchFundingPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research Funding Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidResearchFundingPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research funding payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GovernmentAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government Agency Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GovernmentAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Agency Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GovernmentAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government agency securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PatentCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PatentCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Cost Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PatentCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent-Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OfficeAndLaboratorySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and laboratory space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OfficeAndLaboratorySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OfficeAndLaboratorySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office and laboratory space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LeaseIncentivePayableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Incentive payable noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LeaseIncentivePayableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Incentive Payable Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LeaseIncentivePayableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred lease incentive, excluding current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds threshold of automatic conversion of preferred stock to common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds Threshold Of Automatic Conversion Of Preferred Stock To Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds threshold of automatic conversion of preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from maturity of marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturity Of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DefinedContributionPlanName_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined Contribution Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DefinedContributionPlanName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DefinedContributionPlanName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Lease Obligations, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital lease obligation, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under benefit plans, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock in connection with private placement, net of placement agent fees and offering costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with private placement, net of placement agent fees and offering costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 shares authorized; 61,915,367 and 52,099,211 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesBStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series b stock purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesBStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Stock Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesBStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grants under two thousand nineteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Under Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Thereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Thereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Thereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SidneyStreetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">125 Sidney Street [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SidneyStreetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">125 Sidney Street [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SidneyStreetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">125 Sidney Street [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NumberOfDirectorsStockholdersAreEntitledToElect_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of directors stockholders are entitled to elect.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NumberOfDirectorsStockholdersAreEntitledToElect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Directors Stockholders Are Entitled To Elect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NumberOfDirectorsStockholdersAreEntitledToElect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of directors stockholders are entitled to elect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Greater than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Greater than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments for Operating Activities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts paid during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Retired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Retirement of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock awards, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares reserved for vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MilestonePaymentForCertainOtherIdentifiedTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payment for certain Other Identified Targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MilestonePaymentForCertainOtherIdentifiedTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment For Certain Other Identified Targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MilestonePaymentForCertainOtherIdentifiedTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment for certain other identified targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due, Next 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-The-Market Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Assets Acquired Other than Through Business Combination [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Assets Acquired Other Than Through Business Combination [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityDividendsDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityDividendsDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Dividends Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityDividendsDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingency Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessor, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncentivePayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Incentive, Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncentivePayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred lease incentive, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MilestonePaymentForCertainIdentifiedTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payment For Certain Identified Targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MilestonePaymentForCertainIdentifiedTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment For Certain Identified Targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MilestonePaymentForCertainIdentifiedTargets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment for certain identified targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Utilities, Inventory [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Utilities Inventory [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents schedule of prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PercentageOfCommissionOnGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission on sales price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PercentageOfCommissionOnGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commission as percentage of sale price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PercentageOfCommissionOnGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission On Gross Sales Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated useful life of asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Useful Life Of Asset Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Life of Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease written notice period to extend additional lease term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Written Notice Period To Extend Additional Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to extend additional lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in common stock capital shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Common Stock Capital Shares Reserved For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares reserved for issuance (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounting Standards Update and Change in Accounting Principle</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penalties and interest expense related to income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock voting rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unbilled Receivables, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of restricted stock awards vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Costs, Period Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct expenses related to the transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Incurred Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareRepurchaseProgramAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareRepurchaseProgramAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Repurchase Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee benefit plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingency, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyLossInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Loss in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyLossInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred for legal proceedings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of shareholders vote or written consent required for automatic conversion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Shareholders Vote Or Written Consent Required For Automatic Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of shareholders vote or written consent required for automatic conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U S Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards, Expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_RangeOfTieredRoyaltiesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Range of tiered royalties on net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_RangeOfTieredRoyaltiesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range Of Tiered Royalties On Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_RangeOfTieredRoyaltiesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of tiered royalties on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee benefit plans, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ThirdRockVenturesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third Rock Ventures LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ThirdRockVenturesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Rock Ventures L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ThirdRockVenturesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TRV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unbilled accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CumulativeCatchUpAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative catch-up adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CumulativeCatchUpAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Catch Up Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CumulativeCatchUpAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Catch-Up Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officers' compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Officers Compensation Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation officers compensation percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts and Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Nonoperating, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense, weighted average period expect to recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents amortized cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash equivalents, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GSK agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G S K Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds of after deducting offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, Ending balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, Beginning balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, share outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividends declared or paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently adopted accounting pronouncements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Adopted Accounting Pronouncements Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Purchase of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AreaOfPropertiesHeldUnderOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of properties held under operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AreaOfPropertiesHeldUnderOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Properties Held Under Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AreaOfPropertiesHeldUnderOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Square feet of office and laboratory space leased under operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Capital Lease Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on capital lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwothousandtwentytwoinducementstockincentiveplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Inducement Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwothousandtwentytwoinducementstockincentiveplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TwoThousandTwentyTwoInducementStockIncentivePlan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwothousandtwentytwoinducementstockincentiveplanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TwoThousandTwentyTwoInducementStockIncentivePlan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Assumptions Used to Calculate Fair Value of Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related-Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from calculation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AssetAcquisitionDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AssetAcquisitionDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AssetAcquisitionDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net (accretion of discounts) amortization of premiums on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities for indemnification agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leased Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non refundable upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Treasury Stock, Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Treasury Stock, Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Treasury Stock, Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock, at cost; no shares as of December 31, 2020 and December 31, 2019</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, at cost; no shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareRepurchaseProgramDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareRepurchaseProgramDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Repurchase Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LessImputedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LessImputedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LessImputedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LegalProceedingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Member stands for legal proceedings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LegalProceedingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Proceedings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_LegalProceedingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Proceedings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock in connection with asset acquisition, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total cash equivalents and marketable securities, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements-Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options repurchased in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified clinical and regulatory milestones phase two clinical trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestone Payables Upon Phase Two Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestone payables upon phase two clinical trial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Purchase of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for asset acquisition, estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred stock converted into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable securities, Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeasePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Lease, Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeasePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestones due upon initiation of phase two clinical trial recorded as expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestones Due Upon Initiation Of Phase Two Clinical Trial Recorded As Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and regulatory milestones due upon phase two clinical trial recorded as expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, ownership change, percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Ownership Change, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of ownership change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AggregateRestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AggregateRestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AggregateRestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, terms of conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestone due upon initiation of phase two clinical trial achieved and paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestone Due Upon Initiation Of Phase Two Clinical Trial Achieved And Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and regulatory milestone due upon phase two clinical trial achieved and paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Unvested, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Unvested, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WorldwideNetSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Worldwide net sales milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WorldwideNetSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Worldwide Net Sales Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WorldwideNetSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Worldwide Net Sales Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of outstanding shares of preferred stock for liquidation preference.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Outstanding Shares Of Preferred Stock For Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of outstanding shares of preferred stock for liquidation preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acceleron Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of minimum lease payments for capital leases due after the second fiscal year, December 31, 2021.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Due After Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, after 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease In Operating Lease Assets And Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Assets And Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashPaidForOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashPaidForOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash paid for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashPaidForOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Balance Sheet Detail</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandSixteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandSixteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandSixteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2016 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards indefinitely.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Common Stock and Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grants under two thousand nineteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Under Two Thousand Nineteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WorkforceReduction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Workforce reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WorkforceReduction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workforce reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_WorkforceReduction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Workforce reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds and Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, excluding current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PreferredStockConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock conversion price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PreferredStockConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Conversion Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PreferredStockConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unbilled accounts receivable related to reimbursable research and development cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unbilled Accounts Receivable Related To Reimbursable Research And Development Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled Accounts Receivable Related To Reimbursable Research And Development Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedRestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedRestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedRestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accrued restructuring charges Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedRestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accrued restructuring charges Ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research, development and sales arrangement aggregate amount receivable upon achievement of milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Development And Sales Arrangement Aggregate Amount Receivable Upon Achievement Of Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount receivable on achievement of milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value Initial public offering net of underwriting discounts, commissions and offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Initial Public Offering Net Of Underwriting Discounts Commissions And Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of underwriting discounts, commissions and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Commitment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedRestrictedStockLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued restricted stock liability, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedRestrictedStockLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Restricted Stock Liability Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AccruedRestrictedStockLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock liability, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_FairValueTransfersBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value transfers between levels.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_FairValueTransfersBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Transfers Between Levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_FairValueTransfersBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value transfers between levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation federal orphan drug credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Federal Orphan Drug Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal orphan drug credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities amortized cost basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities Amortized Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash equivalents and marketable securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MyoKardiaCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MyoKardia Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MyoKardiaCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Myo Kardia Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_MyoKardiaCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MyoKardia Collaboration and License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity's secondary offering of stock to the public.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock in Connection with Follow-on Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with public offerings, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other than Temporary Impairment Losses, Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other than Temporary Impairment Losses, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities with other-than-temporary impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestone payables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestone Payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified clinical and regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Asc840Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 840 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Asc840Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ASC 840 member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_Asc840Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ASC 840 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsLeaseIncentive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease incentive.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsLeaseIncentive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Incentive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_DeferredTaxAssetsLeaseIncentive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred lease incentive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases unpaid at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid sign-on bonuses subject to vesting provisions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Sign On Bonuses Subject To Vesting Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid sign-on bonuses subject to vesting provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge, Massachusetts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering of common stock, net of underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Member stands for commitment for office and laboratory space lease of current corporate headquarters.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment For Office And Laboratory Space Lease Of Current Corporate Headquarters [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment for Office and Laboratory Space Lease of Current Corporate Headquarters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_SalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified sales milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration beginning year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_ResearchMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate fair value of securities, Remaining contractual maturity of greater than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate fair value of securities, Remaining contractual maturity of greater than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements" xlink:to="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" xlink:to="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_DeferredRevenueCurrentAndNoncurrent" xlink:to="fulc_DeferredRevenueCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ClinicalProgram" xlink:to="fulc_ClinicalProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount" xlink:to="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" xlink:to="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:to="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNotesReceivableNet" xlink:to="us-gaap_AccountsAndNotesReceivableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" xlink:to="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ChangeInVariableConsiderationConstrained" xlink:to="fulc_ChangeInVariableConsiderationConstrained_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ReimbursementPaymentRecieved" xlink:to="fulc_ReimbursementPaymentRecieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_PublicUtilitiesInventoryTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="fulc_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" xlink:to="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_PaymentForPrepaidResearchFunding" xlink:to="fulc_PaymentForPrepaidResearchFunding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_Propertyplantandequipmentusefullives" xlink:to="fulc_Propertyplantandequipmentusefullives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="fulc_NatureOfBusinessAndBasisOfPresentationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" xlink:to="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ConsultingServicesMember" xlink:to="fulc_ConsultingServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" xlink:to="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:to="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndemnificationGuaranteeMember" xlink:to="us-gaap_IndemnificationGuaranteeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" xlink:to="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember" xlink:to="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:to="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_LandsdowneStreetMember" xlink:to="fulc_LandsdowneStreetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseRenewalTerm" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_Camp4AgreementMember" xlink:to="fulc_Camp4AgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial" xlink:to="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CorporateBondsMember" xlink:to="fulc_CorporateBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_PrepaidResearchFundingPaymentReceived" xlink:to="fulc_PrepaidResearchFundingPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_GovernmentAgencySecuritiesMember" xlink:to="fulc_GovernmentAgencySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_PatentCostPolicyTextBlock" xlink:to="fulc_PatentCostPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_OfficeAndLaboratorySpace" xlink:to="fulc_OfficeAndLaboratorySpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_LeaseIncentivePayableNoncurrent" xlink:to="fulc_LeaseIncentivePayableNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock" xlink:to="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ProceedsFromMaturityOfMarketableSecurities" xlink:to="fulc_ProceedsFromMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_DefinedContributionPlanName" xlink:to="fulc_DefinedContributionPlanName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares" xlink:to="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_SeriesBStockPurchaseAgreementMember" xlink:to="fulc_SeriesBStockPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_Thereafter" xlink:to="fulc_Thereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_SidneyStreetMember" xlink:to="fulc_SidneyStreetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_NumberOfDirectorsStockholdersAreEntitledToElect" xlink:to="fulc_NumberOfDirectorsStockholdersAreEntitledToElect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months" xlink:to="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ProceedsFromSaleOfMarketableSecurities" xlink:to="fulc_ProceedsFromSaleOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOperatingActivities" xlink:to="us-gaap_PaymentsForOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="fulc_CommitmentsAndContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_MilestonePaymentForCertainOtherIdentifiedTargets" xlink:to="fulc_MilestonePaymentForCertainOtherIdentifiedTargets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AtTheMarketOfferingMember" xlink:to="fulc_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="fulc_NatureOfBusinessAndBasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TemporaryEquityDividendsDeclared" xlink:to="fulc_TemporaryEquityDividendsDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncentivePayableCurrent" xlink:to="us-gaap_LeaseIncentivePayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_MilestonePaymentForCertainIdentifiedTargets" xlink:to="fulc_MilestonePaymentForCertainIdentifiedTargets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PublicUtilitiesInventoryLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_PercentageOfCommissionOnGrossSalesPricePerShare" xlink:to="fulc_PercentageOfCommissionOnGrossSalesPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_EstimatedUsefulLifeOfAssetTableTextBlock" xlink:to="fulc_EstimatedUsefulLifeOfAssetTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm" xlink:to="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_CommitmentsAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_NumberOfCommonStockVotingRights" xlink:to="fulc_NumberOfCommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledReceivablesCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCosts" xlink:to="us-gaap_AcquisitionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_PrepaidExpenses" xlink:to="fulc_PrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyLossInPeriod" xlink:to="us-gaap_LossContingencyLossInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion" xlink:to="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TaxCreditCarryforwardExpirationYear" xlink:to="fulc_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_IncomeTaxesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_RangeOfTieredRoyaltiesOnNetSales" xlink:to="fulc_RangeOfTieredRoyaltiesOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_LabEquipmentMember" xlink:to="fulc_LabEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ThirdRockVenturesLLCMember" xlink:to="fulc_ThirdRockVenturesLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CumulativeCatchUpAdjustment" xlink:to="fulc_CumulativeCatchUpAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CashAndCashEquivalentsAmortizedCost" xlink:to="fulc_CashAndCashEquivalentsAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_IncomeTaxesDisclosureTable" xlink:to="fulc_IncomeTaxesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_GSKAgreementMember" xlink:to="fulc_GSKAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance" xlink:to="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AreaOfPropertiesHeldUnderOperatingLeases" xlink:to="fulc_AreaOfPropertiesHeldUnderOperatingLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AccruedResearchAndDevelopmentExpenses" xlink:to="fulc_AccruedResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TwothousandtwentytwoinducementstockincentiveplanMember" xlink:to="fulc_TwothousandtwentytwoinducementstockincentiveplanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_SeriesAConvertiblePreferredStockMember" xlink:to="fulc_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AssetAcquisitionDisclosureTextBlock" xlink:to="fulc_AssetAcquisitionDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_NonRefundableUpfrontPaymentsReceived" xlink:to="fulc_NonRefundableUpfrontPaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="us-gaap_ShareRepurchaseProgramDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_LessImputedInterest" xlink:to="fulc_LessImputedInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_LegalProceedingsMember" xlink:to="fulc_LegalProceedingsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xlink:to="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" xlink:to="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance" xlink:to="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeasePayment" xlink:to="us-gaap_VariableLeasePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense" xlink:to="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AggregateRestructuringCharges" xlink:to="fulc_AggregateRestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid" xlink:to="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_WorldwideNetSalesMilestonesMember" xlink:to="fulc_WorldwideNetSalesMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference" xlink:to="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo" xlink:to="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:to="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CashPaidForOperatingLeaseLiabilities" xlink:to="fulc_CashPaidForOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TwoThousandSixteenStockIncentivePlanMember" xlink:to="fulc_TwoThousandSixteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_UpfrontPayment" xlink:to="fulc_UpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_OperatingLossCarryforwardsIndefinitely" xlink:to="fulc_OperatingLossCarryforwardsIndefinitely_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember" xlink:to="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_WorkforceReduction" xlink:to="fulc_WorkforceReduction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:to="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_PreferredStockConversionPricePerShare" xlink:to="fulc_PreferredStockConversionPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_SeriesBConvertiblePreferredStockMember" xlink:to="fulc_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" xlink:to="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AccruedRestructuringCharges" xlink:to="fulc_AccruedRestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" xlink:to="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" xlink:to="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AccruedRestrictedStockLiabilityCurrent" xlink:to="fulc_AccruedRestrictedStockLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_FairValueTransfersBetweenLevels" xlink:to="fulc_FairValueTransfersBetweenLevels_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_MyoKardiaCollaborationAgreementMember" xlink:to="fulc_MyoKardiaCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" xlink:to="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ClinicalAndRegulatoryMilestonesMember" xlink:to="fulc_ClinicalAndRegulatoryMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ClinicalAndRegulatoryMilestonePayables" xlink:to="fulc_ClinicalAndRegulatoryMilestonePayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_Asc840Member" xlink:to="fulc_Asc840Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_TwoThousandNineteenStockIncentivePlanMember" xlink:to="fulc_TwoThousandNineteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_DeferredTaxAssetsLeaseIncentive" xlink:to="fulc_DeferredTaxAssetsLeaseIncentive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions" xlink:to="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember" xlink:to="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_SalesMilestone" xlink:to="fulc_SalesMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_OperatingLossCarryforwardsExpirationYear" xlink:to="fulc_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_ResearchMilestoneMember" xlink:to="fulc_ResearchMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear" xlink:to="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="us-gaap_LeaseIncentivePayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LeaseIncentivePayableNoncurrent" xlink:label="fulc_LeaseIncentivePayableNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LeaseIncentivePayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_UnbilledReceivablesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="fulc_LeaseIncentivePayableNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesAConvertiblePreferredStockMember" xlink:label="fulc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBConvertiblePreferredStockMember" xlink:label="fulc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AtTheMarketOfferingMember" xlink:label="fulc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" xlink:label="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" xlink:label="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_28"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fulc_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBConvertiblePreferredStockMember" xlink:label="fulc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashPaidForOperatingLeaseLiabilities" xlink:label="fulc_CashPaidForOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" xlink:label="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AtTheMarketOfferingMember" xlink:label="fulc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromMaturityOfMarketableSecurities" xlink:label="fulc_ProceedsFromMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:label="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="fulc_CashPaidForOperatingLeaseLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fulc_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="fulc_ProceedsFromMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreements1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AssetAcquisitionDisclosureTextBlock" xlink:label="fulc_AssetAcquisitionDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="fulc_AssetAcquisitionDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeases1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:label="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PatentCostPolicyTextBlock" xlink:label="fulc_PatentCostPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" xlink:label="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:label="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fulc_PatentCostPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EstimatedUsefulLifeOfAssetTableTextBlock" xlink:label="fulc_EstimatedUsefulLifeOfAssetTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fulc_EstimatedUsefulLifeOfAssetTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_LandsdowneStreetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_SidneyStreetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesTable" xlink:label="fulc_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesLineItems" xlink:label="fulc_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fulc_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="fulc_SidneyStreetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="fulc_CommitmentsAndContingenciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PercentageOfCommissionOnGrossSalesPricePerShare" xlink:label="fulc_PercentageOfCommissionOnGrossSalesPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fulc_NatureOfBusinessAndBasisOfPresentationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="fulc_PercentageOfCommissionOnGrossSalesPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LabEquipmentMember" xlink:label="fulc_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Propertyplantandequipmentusefullives" xlink:label="fulc_Propertyplantandequipmentusefullives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fulc_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="fulc_Propertyplantandequipmentusefullives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GovernmentAgencySecuritiesMember" xlink:label="fulc_GovernmentAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CorporateBondsMember" xlink:label="fulc_CorporateBondsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="fulc_GovernmentAgencySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="fulc_CorporateBondsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_FairValueTransfersBetweenLevels" xlink:label="fulc_FairValueTransfersBetweenLevels"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="fulc_FairValueTransfersBetweenLevels" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAmortizedCost" xlink:label="fulc_CashAndCashEquivalentsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GovernmentAgencySecuritiesMember" xlink:label="fulc_GovernmentAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashAndCashEquivalentsAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="fulc_GovernmentAgencySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear" xlink:label="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromSaleOfMarketableSecurities" xlink:label="fulc_ProceedsFromSaleOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months" xlink:label="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="fulc_ProceedsFromSaleOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ImpairmentOfInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LabEquipmentMember" xlink:label="fulc_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fulc_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidExpenses" xlink:label="fulc_PrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidSignOnBonusesSubjectToVestingProvisions" xlink:label="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="fulc_PrepaidExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_InterestReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedResearchAndDevelopmentExpenses" xlink:label="fulc_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedRestrictedStockLiabilityCurrent" xlink:label="fulc_AccruedRestrictedStockLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="fulc_AccruedResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="fulc_AccruedRestrictedStockLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTable" xlink:label="us-gaap_PublicUtilitiesInventoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryLineItems" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo" xlink:label="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PublicUtilitiesInventoryTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="us-gaap_PublicUtilitiesInventoryLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesAConvertiblePreferredStockMember" xlink:label="fulc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBStockPurchaseAgreementMember" xlink:label="fulc_SeriesBStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock" xlink:label="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NumberOfDirectorsStockholdersAreEntitledToElect" xlink:label="fulc_NumberOfDirectorsStockholdersAreEntitledToElect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PreferredStockConversionPricePerShare" xlink:label="fulc_PreferredStockConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion" xlink:label="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference" xlink:label="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityDividendsDeclared" xlink:label="fulc_TemporaryEquityDividendsDeclared"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="fulc_SeriesBStockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_NumberOfDirectorsStockholdersAreEntitledToElect" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_PreferredStockConversionPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DividendsCommonStock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_TemporaryEquityDividendsDeclared" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NumberOfCommonStockVotingRights" xlink:label="fulc_NumberOfCommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="fulc_NumberOfCommonStockVotingRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_Dividends" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember" xlink:label="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" xlink:label="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwothousandtwentytwoinducementstockincentiveplanMember" xlink:label="fulc_TwothousandtwentytwoinducementstockincentiveplanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandSixteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwothousandtwentytwoinducementstockincentiveplanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchMilestoneMember" xlink:label="fulc_ResearchMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NonRefundableUpfrontPaymentsReceived" xlink:label="fulc_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchMilestoneMember" xlink:label="fulc_ResearchMilestoneMember_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesMember" xlink:label="fulc_ClinicalAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MyoKardiaCollaborationAgreementMember" xlink:label="fulc_MyoKardiaCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WorldwideNetSalesMilestonesMember" xlink:label="fulc_WorldwideNetSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_RangeOfTieredRoyaltiesOnNetSales" xlink:label="fulc_RangeOfTieredRoyaltiesOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CumulativeCatchUpAdjustment" xlink:label="fulc_CumulativeCatchUpAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone_6"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredRevenueCurrentAndNoncurrent" xlink:label="fulc_DeferredRevenueCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ReimbursementPaymentRecieved" xlink:label="fulc_ReimbursementPaymentRecieved"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" xlink:label="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="us-gaap_AccountsAndNotesReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ChangeInVariableConsiderationConstrained" xlink:label="fulc_ChangeInVariableConsiderationConstrained"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_UpfrontPayment" xlink:label="fulc_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PaymentForPrepaidResearchFunding" xlink:label="fulc_PaymentForPrepaidResearchFunding"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MilestonePaymentForCertainIdentifiedTargets" xlink:label="fulc_MilestonePaymentForCertainIdentifiedTargets"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MilestonePaymentForCertainOtherIdentifiedTargets" xlink:label="fulc_MilestonePaymentForCertainOtherIdentifiedTargets"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidResearchFundingPaymentReceived" xlink:label="fulc_PrepaidResearchFundingPaymentReceived"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fulc_ResearchMilestoneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_NonRefundableUpfrontPaymentsReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fulc_ResearchMilestoneMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fulc_ClinicalAndRegulatoryMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fulc_MyoKardiaCollaborationAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fulc_WorldwideNetSalesMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_RangeOfTieredRoyaltiesOnNetSales" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_CumulativeCatchUpAdjustment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_DeferredRevenueCurrentAndNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ReimbursementPaymentRecieved" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsAndNotesReceivableNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ChangeInVariableConsiderationConstrained" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_UpfrontPayment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_PaymentForPrepaidResearchFunding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_MilestonePaymentForCertainIdentifiedTargets" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_MilestonePaymentForCertainOtherIdentifiedTargets" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_PrepaidResearchFundingPaymentReceived" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GSKAgreementMember" xlink:label="fulc_GSKAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBConvertiblePreferredStockMember" xlink:label="fulc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Camp4AgreementMember" xlink:label="fulc_Camp4AgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonePayables" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayables"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial" xlink:label="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SalesMilestone" xlink:label="fulc_SalesMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid" xlink:label="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense" xlink:label="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="fulc_GSKAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_TransactionTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="fulc_Camp4AgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestonePayables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_SalesMilestone" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_AcquisitionCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Thereafter" xlink:label="fulc_Thereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LessImputedInterest" xlink:label="fulc_LessImputedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_LandsdowneStreetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_SidneyStreetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fulc_Thereafter" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fulc_LessImputedInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseAbstract" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Asc840Member" xlink:label="fulc_Asc840Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_LandsdowneStreetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="fulc_Asc840Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OfficeAndLaboratorySpace" xlink:label="fulc_OfficeAndLaboratorySpace"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_LandsdowneStreetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="fulc_OfficeAndLaboratorySpace" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_SidneyStreetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_VariableLeasePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_SecurityDeposit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OtherCommitment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesTable" xlink:label="fulc_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesLineItems" xlink:label="fulc_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AreaOfPropertiesHeldUnderOperatingLeases" xlink:label="fulc_AreaOfPropertiesHeldUnderOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember" xlink:label="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LegalProceedingsMember" xlink:label="fulc_LegalProceedingsMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm" xlink:label="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements" xlink:label="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="us-gaap_LossContingencyLossInPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fulc_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_AreaOfPropertiesHeldUnderOperatingLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="fulc_LegalProceedingsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="fulc_SidneyStreetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="fulc_CommitmentsAndContingenciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyLossInPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="fulc_SidneyStreetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" xlink:label="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="fulc_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsLeaseIncentive" xlink:label="fulc_DeferredTaxAssetsLeaseIncentive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="fulc_DeferredTaxAssetsOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="fulc_DeferredTaxAssetsLeaseIncentive" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncomeTaxesDisclosureLineItems" xlink:label="fulc_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncomeTaxesDisclosureTable" xlink:label="fulc_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OperatingLossCarryforwardsExpirationYear" xlink:label="fulc_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OperatingLossCarryforwardsIndefinitely" xlink:label="fulc_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TaxCreditCarryforwardExpirationYear" xlink:label="fulc_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" xlink:label="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fulc_IncomeTaxesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_OperatingLossCarryforwardsExpirationYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureTable" xlink:to="fulc_IncomeTaxesDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_OperatingLossCarryforwardsIndefinitely" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_TaxCreditCarryforwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DefinedContributionPlanName" xlink:label="fulc_DefinedContributionPlanName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="fulc_DefinedContributionPlanName" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedRestructuringCharges" xlink:label="fulc_AccruedRestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForOperatingActivities" xlink:label="us-gaap_PaymentsForOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedRestructuringCharges" xlink:label="fulc_AccruedRestructuringCharges_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="fulc_AccruedRestructuringCharges" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_PaymentsForOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="fulc_AccruedRestructuringCharges_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalProgram" xlink:label="fulc_ClinicalProgram"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WorkforceReduction" xlink:label="fulc_WorkforceReduction"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AggregateRestructuringCharges" xlink:label="fulc_AggregateRestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="fulc_ClinicalProgram" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="fulc_WorkforceReduction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="fulc_AggregateRestructuringCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringCharges" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ThirdRockVenturesLLCMember" xlink:label="fulc_ThirdRockVenturesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ConsultingServicesMember" xlink:label="fulc_ConsultingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_ThirdRockVenturesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fulc_ConsultingServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesAConvertiblePreferredStockMember" xlink:label="fulc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBConvertiblePreferredStockMember" xlink:label="fulc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AtTheMarketOfferingMember" xlink:label="fulc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount" xlink:label="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" xlink:label="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" xlink:label="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fulc_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBConvertiblePreferredStockMember" xlink:label="fulc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashPaidForOperatingLeaseLiabilities" xlink:label="fulc_CashPaidForOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" xlink:label="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AtTheMarketOfferingMember" xlink:label="fulc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromMaturityOfMarketableSecurities" xlink:label="fulc_ProceedsFromMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:label="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="fulc_CashPaidForOperatingLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fulc_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="fulc_ProceedsFromMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_LandsdowneStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_SidneyStreetMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables">
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesLineItems" xlink:label="fulc_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesTable" xlink:label="fulc_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="fulc_SidneyStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="fulc_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PercentageOfCommissionOnGrossSalesPricePerShare" xlink:label="fulc_PercentageOfCommissionOnGrossSalesPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="fulc_NatureOfBusinessAndBasisOfPresentationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="fulc_PercentageOfCommissionOnGrossSalesPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LabEquipmentMember" xlink:label="fulc_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Propertyplantandequipmentusefullives" xlink:label="fulc_Propertyplantandequipmentusefullives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fulc_LabEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="fulc_Propertyplantandequipmentusefullives" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GovernmentAgencySecuritiesMember" xlink:label="fulc_GovernmentAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CorporateBondsMember" xlink:label="fulc_CorporateBondsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="fulc_GovernmentAgencySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="fulc_CorporateBondsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAmortizedCost" xlink:label="fulc_CashAndCashEquivalentsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GovernmentAgencySecuritiesMember" xlink:label="fulc_GovernmentAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashAndCashEquivalentsAmortizedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="fulc_GovernmentAgencySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LabEquipmentMember" xlink:label="fulc_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fulc_LabEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryLineItems" xlink:label="us-gaap_PublicUtilitiesInventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTable" xlink:label="us-gaap_PublicUtilitiesInventoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo" xlink:label="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_PublicUtilitiesInventoryTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_PublicUtilitiesInventoryTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryLineItems" xlink:to="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesAConvertiblePreferredStockMember" xlink:label="fulc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBStockPurchaseAgreementMember" xlink:label="fulc_SeriesBStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock" xlink:label="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NumberOfDirectorsStockholdersAreEntitledToElect" xlink:label="fulc_NumberOfDirectorsStockholdersAreEntitledToElect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PreferredStockConversionPricePerShare" xlink:label="fulc_PreferredStockConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion" xlink:label="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference" xlink:label="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TemporaryEquityDividendsDeclared" xlink:label="fulc_TemporaryEquityDividendsDeclared"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="fulc_SeriesBStockPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_NumberOfDirectorsStockholdersAreEntitledToElect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_PreferredStockConversionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fulc_TemporaryEquityDividendsDeclared" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember" xlink:label="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" xlink:label="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwothousandtwentytwoinducementstockincentiveplanMember" xlink:label="fulc_TwothousandtwentytwoinducementstockincentiveplanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandSixteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwothousandtwentytwoinducementstockincentiveplanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance" xlink:label="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" xlink:label="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" xlink:label="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchMilestoneMember" xlink:label="fulc_ResearchMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_NonRefundableUpfrontPaymentsReceived" xlink:label="fulc_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesMember" xlink:label="fulc_ClinicalAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MyoKardiaCollaborationAgreementMember" xlink:label="fulc_MyoKardiaCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_WorldwideNetSalesMilestonesMember" xlink:label="fulc_WorldwideNetSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_RangeOfTieredRoyaltiesOnNetSales" xlink:label="fulc_RangeOfTieredRoyaltiesOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CumulativeCatchUpAdjustment" xlink:label="fulc_CumulativeCatchUpAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredRevenueCurrentAndNoncurrent" xlink:label="fulc_DeferredRevenueCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ReimbursementPaymentRecieved" xlink:label="fulc_ReimbursementPaymentRecieved"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" xlink:label="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" xlink:label="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="us-gaap_AccountsAndNotesReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ChangeInVariableConsiderationConstrained" xlink:label="fulc_ChangeInVariableConsiderationConstrained"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_UpfrontPayment" xlink:label="fulc_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PaymentForPrepaidResearchFunding" xlink:label="fulc_PaymentForPrepaidResearchFunding"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MilestonePaymentForCertainIdentifiedTargets" xlink:label="fulc_MilestonePaymentForCertainIdentifiedTargets"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_MilestonePaymentForCertainOtherIdentifiedTargets" xlink:label="fulc_MilestonePaymentForCertainOtherIdentifiedTargets"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidResearchFundingPaymentReceived" xlink:label="fulc_PrepaidResearchFundingPaymentReceived"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fulc_ResearchMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_NonRefundableUpfrontPaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fulc_ClinicalAndRegulatoryMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fulc_MyoKardiaCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fulc_WorldwideNetSalesMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_RangeOfTieredRoyaltiesOnNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_CumulativeCatchUpAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_DeferredRevenueCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ReimbursementPaymentRecieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsAndNotesReceivableNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_ChangeInVariableConsiderationConstrained" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_PaymentForPrepaidResearchFunding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_MilestonePaymentForCertainIdentifiedTargets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_MilestonePaymentForCertainOtherIdentifiedTargets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fulc_PrepaidResearchFundingPaymentReceived" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_GSKAgreementMember" xlink:label="fulc_GSKAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SeriesBConvertiblePreferredStockMember" xlink:label="fulc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Camp4AgreementMember" xlink:label="fulc_Camp4AgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonePayables" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayables"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" xlink:label="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial" xlink:label="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SalesMilestone" xlink:label="fulc_SalesMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid" xlink:label="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense" xlink:label="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="fulc_GSKAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fulc_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="fulc_Camp4AgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestonePayables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_SalesMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_AcquisitionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Thereafter" xlink:label="fulc_Thereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LessImputedInterest" xlink:label="fulc_LessImputedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_LandsdowneStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_SidneyStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fulc_Thereafter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fulc_LessImputedInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Asc840Member" xlink:label="fulc_Asc840Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_LandsdowneStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="fulc_Asc840Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LandsdowneStreetMember" xlink:label="fulc_LandsdowneStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OfficeAndLaboratorySpace" xlink:label="fulc_OfficeAndLaboratorySpace"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_LandsdowneStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="fulc_OfficeAndLaboratorySpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_SidneyStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_VariableLeasePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OtherCommitment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesLineItems" xlink:label="fulc_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentsAndContingenciesTable" xlink:label="fulc_CommitmentsAndContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AreaOfPropertiesHeldUnderOperatingLeases" xlink:label="fulc_AreaOfPropertiesHeldUnderOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember" xlink:label="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LegalProceedingsMember" xlink:label="fulc_LegalProceedingsMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm" xlink:label="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements" xlink:label="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="us-gaap_LossContingencyLossInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_AreaOfPropertiesHeldUnderOperatingLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="fulc_LegalProceedingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="fulc_SidneyStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fulc_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyLossInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_SidneyStreetMember" xlink:label="fulc_SidneyStreetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="fulc_SidneyStreetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncomeTaxesDisclosureLineItems" xlink:label="fulc_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncomeTaxesDisclosureTable" xlink:label="fulc_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OperatingLossCarryforwardsExpirationYear" xlink:label="fulc_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_OperatingLossCarryforwardsIndefinitely" xlink:label="fulc_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_TaxCreditCarryforwardExpirationYear" xlink:label="fulc_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" xlink:label="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_IncomeTaxesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fulc_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fulc_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_OperatingLossCarryforwardsIndefinitely" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fulc_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ThirdRockVenturesLLCMember" xlink:label="fulc_ThirdRockVenturesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ConsultingServicesMember" xlink:label="fulc_ConsultingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fulc_ThirdRockVenturesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fulc_ConsultingServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="fulc_LeaseIncentivePayableNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LeaseIncentivePayableCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LeaseIncentivePayableNoncurrent" xlink:label="fulc_LeaseIncentivePayableNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="us-gaap_LeaseIncentivePayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="fulc_LessImputedInterest" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_LessImputedInterest" xlink:label="fulc_LessImputedInterest"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="fulc_ProceedsFromMaturityOfMarketableSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" xlink:label="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_ProceedsFromMaturityOfMarketableSecurities" xlink:label="fulc_ProceedsFromMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:label="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_CashAndCashEquivalentsAmortizedCost" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" xlink:to="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashAndCashEquivalentsAmortizedCost" xlink:label="fulc_CashAndCashEquivalentsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:label="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="fulc_PrepaidExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivable" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidExpenses" xlink:label="fulc_PrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_PrepaidSignOnBonusesSubjectToVestingProvisions" xlink:label="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="fulc_AccruedResearchAndDevelopmentExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="fulc_AccruedRestrictedStockLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedResearchAndDevelopmentExpenses" xlink:label="fulc_AccruedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_AccruedRestrictedStockLiabilityCurrent" xlink:label="fulc_AccruedRestrictedStockLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="fulc_Thereafter" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_Thereafter" xlink:label="fulc_Thereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:label="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fulc_DeferredTaxAssetsLeaseIncentive" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsLeaseIncentive" xlink:label="fulc_DeferredTaxAssetsLeaseIncentive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" xlink:label="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="fulc-20231231.xsd#fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fulc_NumberOfCommonStockVotingRights" name="NumberOfCommonStockVotingRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion" name="MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" name="UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_OfficeAndLaboratorySpace" name="OfficeAndLaboratorySpace" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_IncomeTaxesDisclosureLineItems" name="IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_DefinedContributionPlanName" name="DefinedContributionPlanName" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" name="IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_PatentCostPolicyTextBlock" name="PatentCostPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_CashAndCashEquivalentsAmortizedCost" name="CashAndCashEquivalentsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" name="EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_LegalProceedingsMember" name="LegalProceedingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_Thereafter" name="Thereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_ThirdRockVenturesLLCMember" name="ThirdRockVenturesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_ClinicalProgram" name="ClinicalProgram" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear" name="AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_NonRefundableUpfrontPaymentsReceived" name="NonRefundableUpfrontPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_ClinicalAndRegulatoryMilestonePayables" name="ClinicalAndRegulatoryMilestonePayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" name="ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" name="GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_AreaOfPropertiesHeldUnderOperatingLeases" name="AreaOfPropertiesHeldUnderOperatingLeases" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fulc_WorldwideNetSalesMilestonesMember" name="WorldwideNetSalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_GovernmentAgencySecuritiesMember" name="GovernmentAgencySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember" name="GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_LandsdowneStreetMember" name="LandsdowneStreetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense" name="ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_PaymentForPrepaidResearchFunding" name="PaymentForPrepaidResearchFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember" name="CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo" name="CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" name="EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_CumulativeCatchUpAdjustment" name="CumulativeCatchUpAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_WorkforceReduction" name="WorkforceReduction" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_NatureOfBusinessAndBasisOfPresentationLineItems" name="NatureOfBusinessAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember" name="GrantsUnderTwoThousandNineteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_GSKAgreementMember" name="GSKAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance" name="WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_RangeOfTieredRoyaltiesOnNetSales" name="RangeOfTieredRoyaltiesOnNetSales" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_OperatingLossCarryforwardsIndefinitely" name="OperatingLossCarryforwardsIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_TwothousandtwentytwoinducementstockincentiveplanMember" name="TwothousandtwentytwoinducementstockincentiveplanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference" name="MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" name="IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_AggregateRestructuringCharges" name="AggregateRestructuringCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" name="CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_NatureOfBusinessAndBasisOfPresentationTable" name="NatureOfBusinessAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" name="ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" name="TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_ReimbursementPaymentRecieved" name="ReimbursementPaymentRecieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" name="CashEquivalentsAndMarketableSecuritiesFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" name="StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_ClinicalAndRegulatoryMilestonesMember" name="ClinicalAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_AccruedRestrictedStockLiabilityCurrent" name="AccruedRestrictedStockLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_EmergingGrowthCompanyPolicyPolicyTextBlock" name="EmergingGrowthCompanyPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_PrepaidSignOnBonusesSubjectToVestingProvisions" name="PrepaidSignOnBonusesSubjectToVestingProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_FairValueTransfersBetweenLevels" name="FairValueTransfersBetweenLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_Propertyplantandequipmentusefullives" name="Propertyplantandequipmentusefullives" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_DeferredTaxAssetsLeaseIncentive" name="DeferredTaxAssetsLeaseIncentive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_NumberOfDirectorsStockholdersAreEntitledToElect" name="NumberOfDirectorsStockholdersAreEntitledToElect" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" name="OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_AccruedRestructuringCharges" name="AccruedRestructuringCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember" name="TwoThousandAndTwentyTwoInducementStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" name="ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_ChangeInVariableConsiderationConstrained" name="ChangeInVariableConsiderationConstrained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_CorporateBondsMember" name="CorporateBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_Camp4AgreementMember" name="Camp4AgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_MyoKardiaCollaborationAgreementMember" name="MyoKardiaCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_PreferredStockConversionPricePerShare" name="PreferredStockConversionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fulc_DeferredRevenueCurrentAndNoncurrent" name="DeferredRevenueCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_LessImputedInterest" name="LessImputedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_ResearchContractCostsAndAccrualsPolicyTextBlock" name="ResearchContractCostsAndAccrualsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_SeriesBStockPurchaseAgreementMember" name="SeriesBStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares" name="IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_ResearchMilestoneMember" name="ResearchMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_TwoThousandSixteenStockIncentivePlanMember" name="TwoThousandSixteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_SalesMilestone" name="SalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_IncomeTaxesDisclosureTable" name="IncomeTaxesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_PercentageOfCommissionOnGrossSalesPricePerShare" name="PercentageOfCommissionOnGrossSalesPricePerShare" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" name="EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_Asc840Member" name="Asc840Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" name="StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_LeaseIncentivePayableNoncurrent" name="LeaseIncentivePayableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance" name="WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_ProceedsFromMaturityOfMarketableSecurities" name="ProceedsFromMaturityOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_MilestonePaymentForCertainOtherIdentifiedTargets" name="MilestonePaymentForCertainOtherIdentifiedTargets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm" name="LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_TwoThousandNineteenStockIncentivePlanMember" name="TwoThousandNineteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_ConsultingServicesMember" name="ConsultingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards" name="DeferredTaxAssetsOrphanDrugCreditCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial" name="ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" name="CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_EstimatedUsefulLifeOfAssetTableTextBlock" name="EstimatedUsefulLifeOfAssetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_ProceedsFromSaleOfMarketableSecurities" name="ProceedsFromSaleOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_CashPaidForOperatingLeaseLiabilities" name="CashPaidForOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock" name="GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_PrepaidResearchFundingPaymentReceived" name="PrepaidResearchFundingPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid" name="ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" name="ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_SidneyStreetMember" name="SidneyStreetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_PrepaidExpenses" name="PrepaidExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_AssetAcquisitionDisclosureTextBlock" name="AssetAcquisitionDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_AccruedLiabilitiesAndOtherCurrentLiabilities" name="AccruedLiabilitiesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_MilestonePaymentForCertainIdentifiedTargets" name="MilestonePaymentForCertainIdentifiedTargets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements" name="LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_TemporaryEquityDividendsDeclared" name="TemporaryEquityDividendsDeclared" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" name="CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount" name="IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" name="IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fulc_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127559691584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 20, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FULC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FULCRUM THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001680581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,935,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4839948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Landsdowne Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-8851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,559,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2024 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127561846880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,563<span></span>
</td>
<td class="nump">$ 35,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">210,658<span></span>
</td>
<td class="nump">167,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled accounts receivable</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,441<span></span>
</td>
<td class="nump">4,369<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">242,199<span></span>
</td>
<td class="nump">207,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,216<span></span>
</td>
<td class="nump">6,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">7,176<span></span>
</td>
<td class="nump">9,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">257,694<span></span>
</td>
<td class="nump">226,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,757<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,726<span></span>
</td>
<td class="nump">9,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">2,602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,675<span></span>
</td>
<td class="nump">16,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, excluding current portion</a></td>
<td class="nump">8,629<span></span>
</td>
<td class="nump">10,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, excluding current portion</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,501<span></span>
</td>
<td class="nump">27,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized; 61,915,367 and 52,099,211 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">744,940<span></span>
</td>
<td class="nump">612,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(509,673)<span></span>
</td>
<td class="num">(412,338)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">235,193<span></span>
</td>
<td class="nump">198,942<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 257,694<span></span>
</td>
<td class="nump">$ 226,685<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560229568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">61,915,367<span></span>
</td>
<td class="nump">52,099,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">61,915,367<span></span>
</td>
<td class="nump">52,099,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127557017984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 2,805<span></span>
</td>
<td class="nump">$ 6,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">71,801<span></span>
</td>
<td class="nump">76,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">41,668<span></span>
</td>
<td class="nump">41,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">113,469<span></span>
</td>
<td class="nump">118,903<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(110,664)<span></span>
</td>
<td class="num">(112,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Other income, net</a></td>
<td class="nump">13,329<span></span>
</td>
<td class="nump">2,690<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,335)<span></span>
</td>
<td class="num">$ (109,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">61,310<span></span>
</td>
<td class="nump">44,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">61,310<span></span>
</td>
<td class="nump">44,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,335)<span></span>
</td>
<td class="num">$ (109,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">661<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="nump">661<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (96,674)<span></span>
</td>
<td class="num">$ (110,271)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127557080560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 211,539<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 514,362<span></span>
</td>
<td class="num">$ (397)<span></span>
</td>
<td class="num">$ (302,467)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,626,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">80,804<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">80,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,029,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under employee benefit plans</a></td>
<td class="nump">3,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under employee benefit plans, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock awards</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock awards, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(109,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,871)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">198,942<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">612,025<span></span>
</td>
<td class="num">(797)<span></span>
</td>
<td class="num">(412,338)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,099,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">117,346<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">117,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,615,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under employee benefit plans</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under employee benefit plans, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock awards, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">14,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(97,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,335)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 235,193<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 744,940<span></span>
</td>
<td class="num">$ (136)<span></span>
</td>
<td class="num">$ (509,673)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,915,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560170448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (97,335)<span></span>
</td>
<td class="num">$ (109,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,172<span></span>
</td>
<td class="nump">2,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,802<span></span>
</td>
<td class="nump">13,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net (accretion of discounts) amortization of premiums on marketable securities</a></td>
<td class="num">(5,991)<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Unbilled accounts receivable</a></td>
<td class="num">(308)<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,072)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities', window );">Operating lease assets and liabilities</a></td>
<td class="num">(715)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">94<span></span>
</td>
<td class="num">(1,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(853)<span></span>
</td>
<td class="num">(1,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(825)<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(934)<span></span>
</td>
<td class="num">(3,777)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(90,965)<span></span>
</td>
<td class="num">(97,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(194,892)<span></span>
</td>
<td class="num">(151,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ProceedsFromMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">158,708<span></span>
</td>
<td class="nump">165,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(508)<span></span>
</td>
<td class="num">(1,963)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(36,692)<span></span>
</td>
<td class="nump">12,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering', window );">Proceeds from issuance of common stock in connection with public offerings, net of issuance costs</a></td>
<td class="nump">117,345<span></span>
</td>
<td class="nump">80,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under benefit plans, net</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">3,519<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">118,122<span></span>
</td>
<td class="nump">84,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(9,535)<span></span>
</td>
<td class="num">(314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">36,190<span></span>
</td>
<td class="nump">36,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">26,655<span></span>
</td>
<td class="nump">36,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashPaidForOperatingLeaseLiabilities', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases unpaid at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="nump">35,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CashPaidForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CashPaidForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Operating Lease Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's secondary offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ProceedsFromMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturity of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ProceedsFromMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562581696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of the Business and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fulcrum Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Fulcrum&#8221;) was incorporated in Delaware on August 18, 2015. The Company is focused on developing small molecules to improve the lives of patients with genetically-defined rare diseases in areas of high unmet medical need.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks similar to other companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, the Company completed a public offering of its common stock and issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,029,410</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company completed a public offering of its common stock and issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,615,384</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">117.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the sale of shares of its capital stock and from upfront payments received from the collaboration and license agreements with Acceleron Pharma Inc. (&#8220;Acceleron&#8221;), a wholly-owned subsidiary of Merck &amp; Co., Inc., (&#8220;Merck&#8221;) and MyoKardia, Inc. (&#8220;MyoKardia&#8221;), a wholly-owned subsidiary of Bristol Myers Squibb Company. As of December 31, 2023, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">509.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to expand its research and development efforts. The Company expects to finance its future cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these financial statements. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate development or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127563010976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Fulcrum Therapeutics Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities. All intercompany transactions and balances have been eliminated.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date of the financial statements, and the reported amount of expenses during the reported periods. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ from those estimates or assumptions.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. Cash equivalents include investments in money market funds that invest in U.S. Treasury obligations, and commercial paper. The Company maintains its bank accounts at major financial institutions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash represents cash held to secure a letter of credit associated with the Company&#8217;s facility lease for its corporate headquarters.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value and are classified according to the fair value hierarchy described above (Note 3). The cash equivalents and marketable securities are initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, to determine fair value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies securities with a remaining maturity when purchased of greater than three months as marketable securities. As of December 31, 2023, the Company&#8217;s marketable securities consisted of investments in U.S. Treasury securities, government agency securities, corporate bonds, and commercial paper. Marketable securities are classified as current assets on the consolidated balance sheets if the marketable securities are available to be converted into cash to fund current operations.</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities classified as available-for-sale are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, which is a component of stockholders&#8217; equity, until such gains and losses are realized. Any premium arising at purchase is amortized to interest expense (a component of other income, net) over the period of the earliest call date, and any discount arising at purchase is accreted to interest income (a component of other income, net) over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income, net.</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other-than-temporary&#8221; and, if so, marks the investment to market through a charge to the Company&#8217;s statement of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost, net of accumulated depreciation. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:34.84%;"></td>
          <td style="width:65.16%;"></td>
         </tr>
         <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-left:0.1in;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (in years)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist of property and equipment. The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use or disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any impairment losses on long-lived assets during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, the Company adopted ASU No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2016-02&#8221;). For contracts entered into on or after the effective date, at the inception of a contract, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than twelve months are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. The Company does not recognize leases with terms of twelve months or less on the balance sheet. Options to renew a lease are not included in the Company&#8217;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset or (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all operating leases, a lease liability and corresponding right-of-use asset are recognized. The lease liability represents the present value of the lease payments over the expected remaining lease term, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate the Company&#8217;s incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating and yield curve analysis, since the Company does not have a rating agency-based credit rating. The right-of-use asset represents the right to use the leased asset for the lease term. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred if any, less any lease incentives received.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease payments included in the measurement of the lease liability comprise (i) the fixed noncancelable lease payments, (ii) payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and (iii) payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease expense for operating leases consists of the lease payments plus any initial direct costs, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. The Company accounts for lease and non-lease components together as a single lease component.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1) Identify the contract with the customer</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2) Identify the promises and performance obligations in the contract</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other readily available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are capable of being distinct and distinct in the context of the contract. In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">3) Determine the transaction price</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Changes to the constraint of variable consideration can have a material effect on the amount of revenue recognized in the period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an arrangement includes research and development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are based on the occurrence of events not within the Company&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until the underlying events occur or the associated approvals are received.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company assesses its revenue generating arrangements in order to determine whether a significant financing component exists.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">4) Allocate the transaction price to the performance obligations in the contract</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis, except for any variable consideration that meets the criteria to be allocated entirely to a single performance obligation or to a distinct service that forms part of a single performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">5) Recognize revenue when or as the Company satisfies a performance obligation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may satisfy performance obligations over time or at a point in time, depending on the nature of the performance obligation. Revenue is recognized over time if the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For revenue that the Company recognizes over time, the Company assesses whether an input or an output method is the appropriate measure of progress associated with the satisfaction of the performance obligation. In determining the appropriate method for measuring progress, the Company considers the nature of the good or service that it has promised to transfer to the customer. Output methods recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract. Input methods recognize revenue on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation. Estimates inherent to the measurement of progress associated with the satisfaction of performance obligations based on an input method include the total estimated costs to satisfy the associated performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 10, &#8220;Collaboration and License Agreements&#8221;, for further information on the application of ASC 606 to the collaboration and license agreement with Acceleron (the &#8220;Acceleron Collaboration Agreement&#8221;) and the collaboration and license agreement with MyoKardia (the &#8220;MyoKardia Collaboration Agreement&#8221;).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and development expenses include costs directly attributable to the conduct of research and development programs, including personnel-related expenses such as salaries, payroll taxes, benefits, and stock-based compensation expense, manufacturing and external costs related to outside vendors engaged to conduct both preclinical studies and clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trials, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory supplies, depreciation on and maintenance of research equipment, and the allocable portions of facility costs, such as rent, utilities, repairs and maintenance, depreciation, and general support services. Expenditures relating to research and development are expensed in the period incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research Contract Costs and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions and other companies. The Company records accruals for estimated ongoing research costs that have not yet been invoiced</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials or the extent of services provided during the reporting periods, including invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at each reporting period. Actual results could differ from the Company&#8217;s estimates.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent-Related Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statements of operations.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures stock-based awards based on the fair value on the date of grant. Compensation expense associated with those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each restricted stock award is based on the fair value of the Company&#8217;s common stock on the grant date, less any applicable purchase price. The fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The historical volatility is calculated based on a period of time commensurate with the assumption used for the expected term. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its stock-based awards. The expected dividend yield is assumed to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient&#8217;s payroll or service costs are classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records costs and liabilities associated with exit and disposal activities in accordance with Accounting Standards Codification 420, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exit or Disposal Cost Obligations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. For the years ended December 31, 2023 and 2022, comprehensive loss </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consists of net loss and unrealized losses on investments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Income (Loss) Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock and unvested restricted stock awards are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities, U.S. Treasury securities, and commercial paper. The Company&#8217;s marketable securities consist of U.S. Treasury securities, corporate bonds, and commercial paper, and potentially subject the Company to concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s interim chief executive officer, view the Company&#8217;s operations and manage its business as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1a68b880-8a0c-4fb5-9af0-f610de17e8b2;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates for ASUs. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its initial public offering or such earlier time that it is no longer an EGC.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements&#8212;Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127563003632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the fair value hierarchy classification of such fair values as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236,221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,476</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,476</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers between fair value levels during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560767184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Cash Equivalents and Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents and marketable securities consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,182</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,891</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,492</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,794</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236,221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,476</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,195</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">526</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168,616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sales of marketable securities during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the held 46 debt securities that were in an unrealized loss position for less than 12 months with an aggregate fair value of  $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held 18 debt securities that were in an unrealized loss position for greater than 12 months with an aggregate fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the aggregate fair value of marketable securities with a remaining contractual maturity of greater than one year was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has the intent and ability to hold its debt securities until recovery. As a result, the Company did not record any charges for credit-related impairments for its marketable securities for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127565750336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.693%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.363%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.383%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,057</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">786</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,662</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127565746816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Balance Sheet Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Additional Balance Sheet Detail</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Additional Balance Sheet Detail</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,425</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid sign-on bonuses subject to vesting provisions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">535</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,726</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,551</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127563929616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of undesignated preferred stock were authorized. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock were issued or outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared since inception.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127565750336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share, were authorized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of common stock entitles the holder to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote on all matters submitted to a vote of the Company&#8217;s stockholders</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Common stockholders are not entitled to receive dividends, unless declared by the Company&#8217;s board of directors, subject to the preferential dividend rights of any preferred stock then outstanding. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends have been declared or paid by the Company since its inception.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the Company has reserved for future issuance the following number of shares of common stock:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for exercises of outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,972,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for vesting of restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2019 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,157,537</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,941,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,346,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,061,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2022 Inducement Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">837,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">329,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,388,773</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,913,011</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562644592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2016 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2016, the Company adopted the 2016 Stock Incentive Plan (the &#8220;2016 Plan&#8221;), which provided for the grant of restricted stock awards, restricted stock units, incentive stock options, non-statutory stock options, and other stock-based awards to the Company&#8217;s eligible employees, officers, directors, consultants, and advisors. As of the effective date of the 2019 Stock Incentive Plan (the &#8220;2019 Plan&#8221;), and as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remained available for future issuance under the 2016 Plan. Any options or other awards outstanding under the 2016 Plan remain outstanding and effective.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 2, 2019, the Company&#8217;s stockholders approved the 2019 Plan, which became effective on July 17, 2019. The 2019 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards to the Company&#8217;s officers, employees, directors, consultants and advisors. The number of shares initially reserved for issuance under the 2019 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017,142</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, plus the shares of common stock remaining available for issuance under the 2016 Plan as of July 17, 2019. The number of shares reserved was annually increased on January 1, 2020 and will be increased each January 1 thereafter through January 1, 2029 by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the first day of each such year or (iii) an amount determined by the Company&#8217;s board of directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">3,157,537</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future issuance under the 2019 Plan. On January 1, 2024, the number of shares reserved for issuance under the 2019 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The shares of common stock underlying any awards that expire, terminate, or are otherwise surrendered, cancelled, forfeited or repurchased by the Company under the 2016 Plan or the 2019 Plan will be added back to the shares of common stock available for issuance under the 2019 Plan. As of July 17, 2019, no further awards will be made under the 2016 Plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Inducement Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, the Company's board of directors adopted the 2022 Inducement Stock Incentive Plan (the "Inducement Plan"), pursuant to which the Company may grant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to the terms of the Inducement Plan and Nasdaq rules, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The Company initially reserved a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for the issuance of awards under the Inducement Plan. The number of shares reserved and available for issuance under the Inducement Plan can be increased at any time with the approval of the Company&#8217;s board of directors. The Inducement Plan permits the board of directors, a delegated committee of the board of directors, or a delegated officer of the Company to grant the stock-based awards available under the Inducement Plan to attract key employees for the growth of the Company. Effective March 8, 2023, the Company&#8217;s board of directors amended the Inducement Plan to increase the number of shares reserved for issuance by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. Effective May 18, 2023, the Company&#8217;s board of directors amended the Inducement Plan to increase the number of shares reserved for issuance by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">837,877</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future issuance under the Inducement Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options granted by the Company typically vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period and have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contractual term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares issued upon the exercise of stock options are issued from the Company&#8217;s pool of authorized but unissued common stock. In addition to stock options granted under the 2019 Plan and 2016 Plan, the Company has granted stock options as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4), which were granted outside of the 2019 Plan and 2016 Plan. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.272%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.581000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.926%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.346%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.939%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.55</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,885,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,089,933</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.96</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,582,893</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,972,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.49</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,114,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,225,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.17</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407,817</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock as of the balance sheet date for those options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value of stock options granted in the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.64</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.62</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The total intrinsic value of stock options exercised in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022 has been calculated on the date of grant using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.788%;"></td>
        <td style="width:1.555%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.663%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.389%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.607%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year<br/>Ended<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year<br/>Ended<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has also granted restricted stock units. The shares of common stock underlying restricted stock units typically vest over a four-year period. The shares of common stock are recorded in stockholders&#8217; equity as they vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock unit activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.656%;"></td>
        <td style="width:1.698%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.914%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.497%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of all restricted stock units and restricted stock awards that vested during the years ended December 31, 2023 and 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total compensation cost recognized in the statements of operations </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and comprehensive loss associated with all stock-based compensation awards granted by the Company is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,026</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,652</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,776</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.91</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 2, 2019, the Company&#8217;s stockholders approved the 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on July 17, 2019. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">252,142</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock reserved under the ESPP was increased on January 1, 2020, and will be increased annually on each January 1 thereafter through January 1, 2029, by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">428,571</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the first day of each such year or (iii) an amount determined by the Company&#8217;s board of directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,346,125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future issuance under the ESPP. On January 1, 2024, the number of shares reserved for issuance under the 2019 ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">428,571</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127563929616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Collaboration and License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acceleron Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 20, 2019, the Company entered into the Acceleron Collaboration Agreement to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space (the &#8220;Indication&#8221;). Under the terms of the Acceleron Collaboration Agreement, the Company granted Acceleron an exclusive worldwide license under certain intellectual property rights to make, have made, use, sell, have sold, import, export, distribute and have distributed, market, have marketed, promote, have promoted, or otherwise exploit molecules and products directed against or expressing certain biological targets identified by the Company for the treatment, prophylaxis, or diagnosis of the Indication.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 3, 2022, Acceleron notified the Company of its termination of the Acceleron Collaboration Agreement for convenience, which became effective 120 days after the Company's receipt of the notice, or October 1, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, the Company recognized no collaboration revenue associated with the Acceleron Collaboration Agreement. During the year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of collaboration revenue associated with the Acceleron Collaboration Agreement, which includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue recognized that was included in deferred revenue as of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021. As of December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> deferred revenue, unbilled accounts receivable, or accounts receivable associated with the Acceleron Collaboration Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cost reimbursement payments under the Acceleron Collaboration Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the achievement of specified research milestones</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MyoKardia Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 20, 2020, the Company entered into the MyoKardia Collaboration Agreement, pursuant to which the Company granted to MyoKardia an exclusive worldwide license under certain intellectual property rights to research, develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export, have exported, distribute, have distributed, market, have marketed, promote, have promoted, or otherwise exploit products directed against certain biological targets identified by the Company that are capable of modulating up to a certain number of genes of interest with relevance to certain genetically defined cardiomyopathies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to a mutually agreed research plan, the Company will perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets (&#8220;Identified Targets&#8221;) for further research, development, manufacture and commercialization by MyoKardia. The Company and MyoKardia will work together to determine how best to advance at each stage of the research activities under the research plan and to identify which of the Identified Targets, if any, meet the criteria set forth in the research plan (the &#8220;Cardiomyopathy Target Candidates&#8221;). Upon completion of the research plan, the parties will work together to prepare a final data package and MyoKardia may designate certain Cardiomyopathy Target Candidates for MyoKardia&#8217;s further exploitation under the MyoKardia Collaboration Agreement (the &#8220;Cardiomyopathy Targets&#8221;). If MyoKardia does not designate any Cardiomyopathy Targets during the designated period, then the MyoKardia Collaboration Agreement will automatically terminate. If MyoKardia designates one or more Cardiomyopathy Targets, then MyoKardia will be obligated to use commercially reasonable efforts to seek regulatory approval for and to commercialize one product directed against an Identified Target in certain specified countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the period in which the Company is performing the research activities pursuant to the research plan (the &#8220;Research Term&#8221;) and for a specified period beyond the Research Term if MyoKardia designates a Cardiomyopathy Target, the Company may only use the data generated from such research activities for MyoKardia in accordance with the MyoKardia Collaboration Agreement. During the Research Term and for a specified period thereafter, the Company may not research, develop, manufacture, commercialize, use, or otherwise exploit any compound or product (a) that is a Compound or Product under the MyoKardia Collaboration Agreement that is directed against the Cardiomyopathy Target Candidates for the treatment, prophylaxis, or diagnosis of any indication or (b) for the treatment of any genetically defined cardiomyopathies shown to be related to certain specified genes of interest that are modulated by the Cardiomyopathy Targets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the MyoKardia Collaboration Agreement, MyoKardia made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront payment and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment as prepaid research funding to the Company in July 2020. MyoKardia will also reimburse the Company for the costs of the research activities not covered by the prepaid research funding, up to a maximum amount of total research funding (including the prepaid research funding). Upon the achievement of specified preclinical, development and sales milestones, the Company will be entitled to preclinical milestone payments, development milestone payments and sales milestone</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">298.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate per target for certain Identified Targets, and of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate per target for certain other Identified Targets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company has achieved a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million specified preclinical milestone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MyoKardia will also pay the Company tiered royalties ranging from a mid single-digit percentage to a low double-digit percentage based on MyoKardia&#8217;s, and any of its affiliates&#8217; and sublicensees&#8217;, annual worldwide net sales of products under the MyoKardia Collaboration Agreement directed against any Identified Target. The royalties are payable on a product-by-product basis during a specified royalty term, and may be reduced in specified circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MyoKardia Collaboration Agreement continues on a country-by-country and product-by-product basis until the last to expire royalty term for a product, at which time the MyoKardia Collaboration Agreement expires with respect to such product in such country. Either party has the right to terminate the MyoKardia Collaboration Agreement if the other party has materially breached in the performance of its obligations under the MyoKardia Collaboration Agreement and such breach has not been cured within the applicable cure period. MyoKardia also has the right to terminate the MyoKardia Collaboration Agreement for convenience in its entirety or on a target-by-target, product-by-product or molecule-by-molecule basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Analysis</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Identification of the Contract</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the MyoKardia Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Identification of the Promises and Performance Obligations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the MyoKardia Collaboration Agreement contains the following promises: (i) an exclusive worldwide license under certain intellectual property rights, including rights to a specified number of potential cardiomyopathy gene targets identified by the Company for further research, development, manufacture and commercialization for the treatment, prophylaxis, or diagnosis of certain genetically defined cardiomyopathies that was conveyed at the inception of the arrangement (the &#8220;MyoKardia License&#8221;), (ii) research services to identify and validate potential biological targets (the &#8220;MyoKardia Research Services&#8221;), and (iii) participation in the joint steering committee (the &#8220;MyoKardia JSC&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the above promises and concluded that the MyoKardia License is not capable of being distinct from the MyoKardia Research Services given that the MyoKardia License has limited value without the performance of the MyoKardia Research Services and the MyoKardia Research Services can only be performed by the Company due to their specialized nature. Therefore, the Company has concluded that the MyoKardia License and the MyoKardia Research Services represent a single combined performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also assessed the participation on the MyoKardia JSC and concluded that the promise is quantitatively and qualitatively immaterial in the context of the MyoKardia Collaboration Agreement. Accordingly, the Company has disregarded its participation on the MyoKardia JSC as a performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of the Transaction Price</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company received a non-refundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company included in the transaction price. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company achieved a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million specified preclinical milestone associated with the MyoKardia Collaboration Agreement, which was previously constrained due to the significant uncertainty regarding whether such preclinical milestone would be achieved. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company included this amount in the transaction price as of December 31, 2021. Based on the continued uncertainty associated with the achievement of any of the remaining preclinical and development milestone payments that the Company is eligible to receive, the Company has constrained the variable consideration associated with those milestone payments and excluded them from the transaction price. As part of its evaluation of constraining the preclinical and development milestones, the Company considered numerous factors, including the fact that the achievement of the preclinical and development milestones are contingent upon the results of the underlying preclinical and development activities and are thus outside of the control of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also included in the transaction price the expected amount of costs to be reimbursed for the MyoKardia Research Services, which includes the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million prepaid research funding payment that the Company received in the third quarter of 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reassesses the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the transaction price. There was no change in the amount of variable consideration constrained during the year ended December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any consideration related to sales milestone payments (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to MyoKardia and therefore are recognized at the later of when the related sales occur or the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Allocation of the Transaction Price to Performance Obligations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As noted above, the Company has identified a single performance obligation associated with the MyoKardia Collaboration Agreement. Therefore, the Company will allocate the entire amount of the transaction price to the identified single performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recognition of Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue related to the MyoKardia Collaboration Agreement over time as the MyoKardia Research Services are rendered. The Company has concluded that an input method is a representative depiction of the transfer of services under the MyoKardia Collaboration Agreement. The method of measuring progress towards the delivery of the services incorporates actual cumulative internal and external costs incurred relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs are estimated reflects the Company&#8217;s estimate of the period over which it will perform the MyoKardia Research Services. Changes in estimates of total internal and external costs expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of collaboration revenue associated with the MyoKardia Collaboration Agreement, which includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue recognized that was included in deferred revenue as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022. During the year ended December 31, 2022, the Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of collaboration revenue associated with the MyoKardia Collaboration Agreement, which includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue recognized that was included in deferred revenue as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021. As of December 31, 2023, the Company recorded no deferred revenue associated with the MyoKardia Collaboration Agreement. As of December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded deferred revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the MyoKardia Collaboration Agreement, which is classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue is expected to be recognized. The aggregate deferred revenue balance represents the aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. As of December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company had received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cost reimbursement payments under the MyoKardia Collaboration Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the achievement of a preclinical milestone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company had received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cost reimbursement payments under the MyoKardia Collaboration Agreement and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million associated with the achievement of a preclinical milestone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded unbilled accounts receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to reimbursable research and development costs under the MyoKardia Collaboration Agreement for activities performed during the three months ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. As of December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded unbilled accounts receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to reimbursable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and development costs under the MyoKardia Collaboration Agreement for activities performed during the three months ended December 31, 2022. As of December 31, 2023 and 2022, the Company recorded no accounts receivable under the MyoKardia Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562644592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_AssetAcquisitionDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GSK Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, the Company entered into the right of reference and license agreement, as amended (the &#8220;GSK Agreement&#8221;), with subsidiaries of GlaxoSmithKline plc (collectively referred to as &#8220;GSK&#8221;), pursuant to which the Company has been granted an exclusive worldwide license to develop and commercialize losmapimod. Under the GSK Agreement, the Company also acquired reference rights to relevant regulatory and manufacturing documents and GSK&#8217;s existing supply of losmapimod drug substance and product. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize losmapimod at its sole cost. The Company is also responsible for costs related to the filing and maintenance of the licensed patent rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the GSK Agreement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series B Preferred Stock to GSK. In addition, the Company may owe GSK up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain specified clinical and regulatory milestones, including a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone that was achieved during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone previously achieved and paid during 2019, and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain specified sales milestones. The Company agreed to pay tiered royalties on annual net sales of losmapimod that range from mid single-digit percentages to a low double-digit, but less than teens, percentage. The royalties are payable on a product-by-product and country-by-country basis, and may be reduced in specified circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK Agreement may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the GSK Agreement will continue in effect until the expiration of the Company&#8217;s royalty obligations, which expire on a country-by-country basis on the later of (i) ten years after the first commercial sale in the country or (ii) approval of a generic version of losmapimod by the applicable regulatory agency.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes clinical and regulatory milestone payments when the underlying contingency is resolved and the consideration is paid or becomes payable. The milestone payments are capitalized or expensed depending on the nature of the associated asset as of the date of recognition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CAMP4 Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company entered into a license agreement (the &#8220;CAMP4 Agreement&#8221;) with CAMP4 Therapeutics Corporation (&#8220;CAMP4&#8221;) pursuant to which the Company received a worldwide exclusive license (including the right to sublicense) from CAMP4 to rights under its Diamond Blackfan Anemia (&#8220;DBA&#8221;) program, which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how for the Company to research, develop, manufacture, use, commercialize or otherwise exploit therapeutic products in any indication, including the grant of a sublicense under certain intellectual property rights that CAMP4 has licensed under an agreement with Children&#8217;s Medical Center Corporation (&#8220;CMCC&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company made an undisclosed upfront non-refundable, non-creditable payment to CAMP4. If the Company succeeds in developing and commercializing licensed products, CAMP4 will be eligible to receive (i) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in development and regulatory milestone payments, and (ii) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in sales milestone payments. CAMP4 is also eligible to receive royalties on worldwide net sales of licensed products ranging from mid-single digit to low-double digit, subject to potential reduction following loss of patent coverage, the launch of certain generic products or royalty stacking for licenses of third party intellectual property. The royalties will expire on a product-by-product and country-by-country basis upon the latest to occur of (i) the expiration of all valid patent claims covering the compounds in such country, (ii) the expiration of all regulatory exclusivities in such country, and (iii) 10 years following the first commercial sale in such country. The Company is responsible for the costs associated with the development and regulatory approvals of licensed products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless earlier terminated in accordance with its terms, the license agreement continues on a country-by-country and licensed product-by-licensed product basis until the expiration of the royalty term in each country, at which time the license agreement expires with respect to such licensed product in such country and the Company will have a fully-paid up, royalty-free and perpetual license to the licensed patent rights and know-how with respect to such licensed product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAMP4 has the right to terminate the license agreement in the event of the Company&#8217;s non-payment (subject to cure periods and tolling for bona fide disputes). CAMP4 may also terminate the license agreement if the Company challenges certain patents sublicensed to the Company by CAMP4. Either party may terminate the license agreement in its entirety for the other party&#8217;s material breach if such other party fails to cure the breach. Either party may also terminate the agreement in its entirety upon certain insolvency events involving the other party. The Company has the right to terminate the license agreement with CAMP4 for any or no reason upon prior written notice to CAMP4.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes development and regulatory milestone payments when the underlying contingency is resolved and the consideration is paid or becomes payable. The milestone payments are capitalized or expensed depending on the nature of the associated asset as of the date of recognition.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_AssetAcquisitionDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_AssetAcquisitionDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127654182704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">26 Landsdowne Street</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2017, the Company entered into a lease agreement for its current corporate headquarters comprising approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,731</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space at 26 Landsdowne Street  in Cambridge, Massachusetts, commencing December 2017. The Company began to occupy and use the leased space for its intended purpose in June 2018. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease ends on June 30, 2028. The Company has the option to extend the term of the lease for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five-year</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period, at the market rate, by giving the landlord written notice of its election to exercise the extensio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n at least nine months prior to the original expiration of the lease term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease has a total commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term, and includes escalating rent payments. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease provides the Company with an allowance for normal leasehold improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease agreement requires the Company to either pay a security deposit or maintain a letter of credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company maintains a letter of credit for this lease and has recorded the cash held to secure the letter of credit as restricted cash on the consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022. Operating lease and variable lease expense associated with this lease for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Operating lease expense and variable lease expense associated with this lease for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future minimum lease payments associated with the 26 Landsdowne Street lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,575</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">125 Sidney Street</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into a lease agreement comprising approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,196</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space at 125 Sidney Street in Cambridge, Massachusetts, commencing November 2021. The Company began recognizing rent expense associated with this lease during November 2021. The lease ends on March 31, 2024. The Company has the option to extend the term of the lease for two successive one-year periods, at the market rate, by giving the landlord written notice of its election to exercise the extension at least nine months prior to the original expiration of the lease term. The lease has a total commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the initial term, and includes escalating rent payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense associated with this lease for each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> variable lease expense was recorded associated with this lease for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022. The future minimum lease payments associated with this lease as of December 31, 2023, are as follows (in thousands): </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560258656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t accrued any liabilities related to such obligations as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2023, a class action complaint was filed in the United States District Court for the District of New Jersey against the Company and current and former officers (the &#8220;Securities Action&#8221;). On May 19, 2023, the Securities Action was transferred to the United States District Court for the District of Massachusetts, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Celano v. Fulcrum Therapeutics, Inc., et al</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., Case No. 1:23-cv-11125-IT. On July 31, 2023, the court appointed a lead plaintiff, who filed an amended complaint on September 29, 2023. The Securities Action alleges violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder against all defendants and control person violations of Section 20(a) against the individuals, related to the Company&#8217;s February 2023 announcement that the U.S. Food and Drug Administration issued a clinical hold regarding the investigational new drug application for pociredir (formerly known as FTX-6058) for the potential treatment of sickle cell disease. The Securities Action alleges that the defendants made misleading statements and omitted to disclose material information related to the clinical hold and seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between March 3, 2022, and March 8, 2023, as well as attorneys&#8217; fees and costs. On November 28, 2023, all defendants filed a motion to dismiss the Securities Action, which motion is currently pending. The Company intends to defend vigorously against this litigation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At each reporting date, the Company eva</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">luates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as they are incurred. Other than attorneys&#8217; fees and costs related to the defense of the Securities Action, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such costs have been incurred during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564665904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Income Taxes</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.545%;"></td>
        <td style="width:1.321%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.907%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.321%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.907%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal orphan drug credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Officers' compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.06</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact of ownership change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, the Company incurred book and tax losses and, because it maintains a full valuation allowance on its net deferred tax assets, did not recognize federal or state income tax expense or benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s deferred tax assets and liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.52%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.440000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.440000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,005</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,019</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Orphan drug credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,140</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,291</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166,942</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">132,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,483</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,512</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,459</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,459</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the net deferred tax assets. The Company considered its history of cumulative net losses incurred since inception and its lack of commercialization of any products since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, which is primarily attributable to increases in net operating loss carryforwards as a result of current year net losses, increases in capitalized research and development costs, and the generation of research and development and orphan drug tax credit carryforwards. The Company reevaluates the positive and negative evidence at each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">312.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a portion of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">288.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the federal net operating losses can be carried forward indefinitely. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">317.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal orphan drug credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2040</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal research and development tax credit carryforwards of approximately $7.</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2035</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Internal Revenue Code&#8221;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2021 would limit or otherwise restrict the Company's ability to utilize its pre-change net operating losses and research and development tax credit carryforwards to offset future taxable income. As a result of the analysis, the Company does not believe that there are any significant limitations on its ability to utilize its net operating losses and research and development tax credit carryforwards to offset future taxable income. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since December 31, 2021. If the Company has experienced a change of control, as defined by Section 382, subsequent to December 31, 2021, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s tax years are still open under statute from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_34f687fe-c7b7-4d4d-a574-1aceb3c54fb6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2016</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the present.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is the Company&#8217;s policy to include penalties and interest expense related to income taxes as a component of the provision for income taxes. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest or penalties related to uncertain tax positions and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts have been recognized in the Company&#8217;s statements of operations. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company generated research and development tax credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#8217;s research and development tax credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development tax credit carryforwards and, if an adjustment is required, this adjustment would result in an adjustment to the deferred tax asset established for the research and development tax credit carryforwards and the valuation allowance.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562517664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. Defined Contribution Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a defined contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">401(k)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants the option to elect to defer a portion of their annual compensation on a pretax basis. As currently established, the Company is not required to make contributions to the 401(k) Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he Company made $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in contributions to the 401(k) Plan for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564769712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Net Loss per Share</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.969%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.836%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.836%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,972,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,047,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,580,798</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560961568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Fulcrum Therapeutics Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities. All intercompany transactions and balances have been eliminated.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date of the financial statements, and the reported amount of expenses during the reported periods. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ from those estimates or assumptions.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. Cash equivalents include investments in money market funds that invest in U.S. Treasury obligations, and commercial paper. The Company maintains its bank accounts at major financial institutions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash represents cash held to secure a letter of credit associated with the Company&#8217;s facility lease for its corporate headquarters.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value and are classified according to the fair value hierarchy described above (Note 3). The cash equivalents and marketable securities are initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, to determine fair value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies securities with a remaining maturity when purchased of greater than three months as marketable securities. As of December 31, 2023, the Company&#8217;s marketable securities consisted of investments in U.S. Treasury securities, government agency securities, corporate bonds, and commercial paper. Marketable securities are classified as current assets on the consolidated balance sheets if the marketable securities are available to be converted into cash to fund current operations.</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities classified as available-for-sale are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, which is a component of stockholders&#8217; equity, until such gains and losses are realized. Any premium arising at purchase is amortized to interest expense (a component of other income, net) over the period of the earliest call date, and any discount arising at purchase is accreted to interest income (a component of other income, net) over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income, net.</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other-than-temporary&#8221; and, if so, marks the investment to market through a charge to the Company&#8217;s statement of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost, net of accumulated depreciation. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:34.84%;"></td>
          <td style="width:65.16%;"></td>
         </tr>
         <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-left:0.1in;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (in years)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist of property and equipment. The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use or disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any impairment losses on long-lived assets during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, the Company adopted ASU No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2016-02&#8221;). For contracts entered into on or after the effective date, at the inception of a contract, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than twelve months are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. The Company does not recognize leases with terms of twelve months or less on the balance sheet. Options to renew a lease are not included in the Company&#8217;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset or (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all operating leases, a lease liability and corresponding right-of-use asset are recognized. The lease liability represents the present value of the lease payments over the expected remaining lease term, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate the Company&#8217;s incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating and yield curve analysis, since the Company does not have a rating agency-based credit rating. The right-of-use asset represents the right to use the leased asset for the lease term. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred if any, less any lease incentives received.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease payments included in the measurement of the lease liability comprise (i) the fixed noncancelable lease payments, (ii) payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and (iii) payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease expense for operating leases consists of the lease payments plus any initial direct costs, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. The Company accounts for lease and non-lease components together as a single lease component.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1) Identify the contract with the customer</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2) Identify the promises and performance obligations in the contract</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other readily available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are capable of being distinct and distinct in the context of the contract. In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">3) Determine the transaction price</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Changes to the constraint of variable consideration can have a material effect on the amount of revenue recognized in the period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an arrangement includes research and development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are based on the occurrence of events not within the Company&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until the underlying events occur or the associated approvals are received.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company assesses its revenue generating arrangements in order to determine whether a significant financing component exists.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">4) Allocate the transaction price to the performance obligations in the contract</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis, except for any variable consideration that meets the criteria to be allocated entirely to a single performance obligation or to a distinct service that forms part of a single performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">5) Recognize revenue when or as the Company satisfies a performance obligation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may satisfy performance obligations over time or at a point in time, depending on the nature of the performance obligation. Revenue is recognized over time if the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For revenue that the Company recognizes over time, the Company assesses whether an input or an output method is the appropriate measure of progress associated with the satisfaction of the performance obligation. In determining the appropriate method for measuring progress, the Company considers the nature of the good or service that it has promised to transfer to the customer. Output methods recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract. Input methods recognize revenue on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation. Estimates inherent to the measurement of progress associated with the satisfaction of performance obligations based on an input method include the total estimated costs to satisfy the associated performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 10, &#8220;Collaboration and License Agreements&#8221;, for further information on the application of ASC 606 to the collaboration and license agreement with Acceleron (the &#8220;Acceleron Collaboration Agreement&#8221;) and the collaboration and license agreement with MyoKardia (the &#8220;MyoKardia Collaboration Agreement&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and development expenses include costs directly attributable to the conduct of research and development programs, including personnel-related expenses such as salaries, payroll taxes, benefits, and stock-based compensation expense, manufacturing and external costs related to outside vendors engaged to conduct both preclinical studies and clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trials, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory supplies, depreciation on and maintenance of research equipment, and the allocable portions of facility costs, such as rent, utilities, repairs and maintenance, depreciation, and general support services. Expenditures relating to research and development are expensed in the period incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ResearchContractCostsAndAccrualsPolicyTextBlock', window );">Research Contract Costs and Accruals</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research Contract Costs and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various research and development contracts with research institutions and other companies. The Company records accruals for estimated ongoing research costs that have not yet been invoiced</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials or the extent of services provided during the reporting periods, including invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at each reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_PatentCostPolicyTextBlock', window );">Patent-Related Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent-Related Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statements of operations.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures stock-based awards based on the fair value on the date of grant. Compensation expense associated with those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each restricted stock award is based on the fair value of the Company&#8217;s common stock on the grant date, less any applicable purchase price. The fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The historical volatility is calculated based on a period of time commensurate with the assumption used for the expected term. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its stock-based awards. The expected dividend yield is assumed to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient&#8217;s payroll or service costs are classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records costs and liabilities associated with exit and disposal activities in accordance with Accounting Standards Codification 420, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exit or Disposal Cost Obligations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. For the years ended December 31, 2023 and 2022, comprehensive loss </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consists of net loss and unrealized losses on investments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Income (Loss) Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock and unvested restricted stock awards are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock', window );">Off-Balance Sheet Risk and Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities, U.S. Treasury securities, and commercial paper. The Company&#8217;s marketable securities consist of U.S. Treasury securities, corporate bonds, and commercial paper, and potentially subject the Company to concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s interim chief executive officer, view the Company&#8217;s operations and manage its business as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1a68b880-8a0c-4fb5-9af0-f610de17e8b2;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_EmergingGrowthCompanyPolicyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates for ASUs. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its initial public offering or such earlier time that it is no longer an EGC.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements-Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements&#8212;Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_EmergingGrowthCompanyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_EmergingGrowthCompanyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off-balance sheet risk and concentrations of credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_PatentCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_PatentCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ResearchContractCostsAndAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research contract costs and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ResearchContractCostsAndAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564788080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_EstimatedUsefulLifeOfAssetTableTextBlock', window );">Schedule of Estimated Useful Life of Asset</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:34.84%;"></td>
          <td style="width:65.16%;"></td>
         </tr>
         <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-left:0.1in;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful Life (in years)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
          <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_EstimatedUsefulLifeOfAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated useful life of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_EstimatedUsefulLifeOfAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564760128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the fair value hierarchy classification of such fair values as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236,221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,476</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,476</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562515184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents and marketable securities consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and December 31, 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,182</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,891</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,889</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,492</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,794</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236,221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,476</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,195</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">526</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168,616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564707536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.693%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.363%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.383%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,057</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">786</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,662</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564754864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Balance Sheet Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,425</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid sign-on bonuses subject to vesting provisions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">535</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,726</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,551</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents schedule of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562515184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the Company has reserved for future issuance the following number of shares of common stock:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for exercises of outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,972,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for vesting of restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2019 Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,157,537</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,941,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2019 Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,346,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,061,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares reserved for future issuance under the 2022 Inducement Stock Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">837,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">329,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,388,773</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,913,011</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127668695344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:81.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.272%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.581000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.926%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.346%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.939%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.55</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,885,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,089,933</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.96</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,582,893</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,972,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.49</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,114,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,225,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.17</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407,817</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions Used to Calculate Fair Value of Stock Option</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022 has been calculated on the date of grant using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.788%;"></td>
        <td style="width:1.555%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.663%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.389%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.607%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year<br/>Ended<br/>December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year<br/>Ended<br/>December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total compensation cost recognized in the statements of operations </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and comprehensive loss associated with all stock-based compensation awards granted by the Company is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,026</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,652</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,776</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember', window );">Grants Outside of 2016 Stock Incentive Plan and 2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s restricted stock unit activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.656%;"></td>
        <td style="width:1.698%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.914%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.235%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.497%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.79</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,602</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562955024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember', window );">26 Landsdowne Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future minimum lease payments associated with the 26 Landsdowne Street lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,575</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember', window );">125 Sidney Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense associated with this lease for each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> variable lease expense was recorded associated with this lease for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years ended December 31, 2023 and 2022. The future minimum lease payments associated with this lease as of December 31, 2023, are as follows (in thousands): </span><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564744624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.545%;"></td>
        <td style="width:1.321%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.907%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.321%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.907%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal orphan drug credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Officers' compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.06</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact of ownership change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s deferred tax assets and liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.52%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.440000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.440000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,005</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,019</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Orphan drug credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,140</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,291</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166,942</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">132,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,483</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,512</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,459</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,459</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564734400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.969%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.836%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.836%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,972,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,047,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,580,798</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127555853456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="nump">9,615,384<span></span>
</td>
<td class="nump">11,029,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 7.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds of common stock</a></td>
<td class="nump">$ 117,300<span></span>
</td>
<td class="nump">$ 80,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under benefit plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 3,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 509,673<span></span>
</td>
<td class="nump">$ 412,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_NatureOfBusinessAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of business and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_NatureOfBusinessAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560796848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of the Estimated Useful Life of Related Asset (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fulc_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_Propertyplantandequipmentusefullives', window );">Property Plant And Equipment Estimated Useful Lives</a></td>
<td class="text">Shorter of useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_Propertyplantandequipmentusefullives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PropertyPlantAndEquipmentUsefulLives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_Propertyplantandequipmentusefullives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fulc_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fulc_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127557021248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127561663664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 25,563<span></span>
</td>
<td class="nump">$ 35,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">210,658<span></span>
</td>
<td class="nump">167,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="nump">25,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U S Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">10,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fulc_GovernmentAgencySecuritiesMember', window );">Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">65,107<span></span>
</td>
<td class="nump">12,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">17,889<span></span>
</td>
<td class="nump">48,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">236,221<span></span>
</td>
<td class="nump">202,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="nump">25,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">210,658<span></span>
</td>
<td class="nump">177,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="nump">25,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="nump">25,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U S Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">10,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U S Treasury Securities [Member] | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">10,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">65,107<span></span>
</td>
<td class="nump">12,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Government agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">65,107<span></span>
</td>
<td class="nump">12,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">17,889<span></span>
</td>
<td class="nump">9,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial Paper [Member] | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">17,889<span></span>
</td>
<td class="nump">9,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">113,447<span></span>
</td>
<td class="nump">96,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate Bonds [Member] | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 113,447<span></span>
</td>
<td class="nump">$ 96,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fulc_GovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fulc_GovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fulc_CorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fulc_CorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127563047904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_FairValueTransfersBetweenLevels', window );">Fair value transfers between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_FairValueTransfersBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value transfers between levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_FairValueTransfersBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127555764208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Summary of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 25,563<span></span>
</td>
<td class="nump">$ 35,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax', window );">Cash equivalents, Gross unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax', window );">Cash equivalents, Gross unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="nump">35,098<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized Cost</a></td>
<td class="nump">210,794<span></span>
</td>
<td class="nump">168,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="nump">210,658<span></span>
</td>
<td class="nump">167,823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">236,357<span></span>
</td>
<td class="nump">203,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">236,221<span></span>
</td>
<td class="nump">202,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="nump">25,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax', window );">Cash equivalents, Gross unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax', window );">Cash equivalents, Gross unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="nump">25,563<span></span>
</td>
<td class="nump">25,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U S Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized Cost</a></td>
<td class="nump">14,229<span></span>
</td>
<td class="nump">10,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">10,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fulc_GovernmentAgencySecuritiesMember', window );">Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized Cost</a></td>
<td class="nump">65,182<span></span>
</td>
<td class="nump">12,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="nump">65,107<span></span>
</td>
<td class="nump">12,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax', window );">Cash equivalents, Gross unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax', window );">Cash equivalents, Gross unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized Cost</a></td>
<td class="nump">17,891<span></span>
</td>
<td class="nump">48,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="nump">17,889<span></span>
</td>
<td class="nump">48,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized Cost</a></td>
<td class="nump">113,492<span></span>
</td>
<td class="nump">97,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="nump">$ 113,447<span></span>
</td>
<td class="nump">$ 96,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized gains before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized losses before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CashAndCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CashAndCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities accumulated gross unrealized gains before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities accumulated gross unrealized gains before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fulc_GovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fulc_GovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562991600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear', window );">Aggregate fair value of securities</a></td>
<td class="nump">$ 25,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ProceedsFromSaleOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Aggregate fair value of securities, unrealized loss position for less than 12 months</a></td>
<td class="nump">130,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months', window );">Debt Securities, Available-for-Sale</a></td>
<td class="nump">$ 33,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of securities, Remaining contractual maturity of greater than one year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Greater than 12 Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560210176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 17,976<span></span>
</td>
<td class="nump">$ 17,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(12,760)<span></span>
</td>
<td class="num">(10,662)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,216<span></span>
</td>
<td class="nump">6,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fulc_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">9,682<span></span>
</td>
<td class="nump">9,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,102<span></span>
</td>
<td class="nump">7,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fulc_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fulc_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560903184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 2,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">17,976<span></span>
</td>
<td class="nump">17,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 12,760<span></span>
</td>
<td class="nump">$ 10,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560988080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Additional Balance Sheet Detail - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_PrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">$ 3,658<span></span>
</td>
<td class="nump">$ 3,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_PrepaidSignOnBonusesSubjectToVestingProvisions', window );">Prepaid sign-on bonuses subject to vesting provisions</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest income receivable</a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 5,441<span></span>
</td>
<td class="nump">$ 4,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_PrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_PrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_PrepaidSignOnBonusesSubjectToVestingProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid sign-on bonuses subject to vesting provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_PrepaidSignOnBonusesSubjectToVestingProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127561790432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Additional Balance Sheet Detail - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_AccruedResearchAndDevelopmentExpenses', window );">External research and development</a></td>
<td class="nump">$ 3,164<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and benefits</a></td>
<td class="nump">4,712<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 8,726<span></span>
</td>
<td class="nump">$ 9,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560760992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_TemporaryEquityDividendsDeclared', window );">Temporary equity, dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_TemporaryEquityDividendsDeclared', window );">Temporary equity, dividends declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_TemporaryEquityDividendsDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity dividends declared</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_TemporaryEquityDividendsDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127561616752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_NumberOfCommonStockVotingRights', window );">Number of common stock voting rights | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared or paid | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_NumberOfCommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_NumberOfCommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127555264528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">15,388,773<span></span>
</td>
<td class="nump">9,913,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">9,972,217<span></span>
</td>
<td class="nump">6,504,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares reserved for vesting of restricted stock units</a></td>
<td class="nump">75,017<span></span>
</td>
<td class="nump">76,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember', window );">2022 Stock Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">837,877<span></span>
</td>
<td class="nump">329,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">1,346,125<span></span>
</td>
<td class="nump">1,061,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember', window );">2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">3,157,537<span></span>
</td>
<td class="nump">1,941,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127556075472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 18, 2023</div></th>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jul. 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,388,773<span></span>
</td>
<td class="nump">9,913,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted average period expect to recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,142<span></span>
</td>
<td class="nump">1,346,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in number of shares reserved for issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,571<span></span>
</td>
<td class="nump">428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding', window );">Increase in number of shares reserved for issuance, percent of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,972,217<span></span>
</td>
<td class="nump">6,504,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_TwoThousandSixteenStockIncentivePlanMember', window );">2016 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_TwoThousandNineteenStockIncentivePlanMember', window );">2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017,142<span></span>
</td>
<td class="nump">3,157,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in number of shares reserved for issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding', window );">Increase in number of shares reserved for issuance, percent of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="nump">$ 7.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_TwoThousandNineteenStockIncentivePlanMember', window );">2019 Stock Incentive Plan | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember', window );">2019 Plan and 2016 Plan | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 5 months 26 days<span></span>
</td>
<td class="text">8 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember', window );">Grants Outside of 2016 Stock Incentive Plan and 2019 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value of restricted stock awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fulc_TwothousandtwentytwoinducementstockincentiveplanMember', window );">2022 Inducement Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in number of shares reserved for issuance (shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in number of shares reserved for issuance, percent of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_TwoThousandSixteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_TwoThousandSixteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_TwothousandtwentytwoinducementstockincentiveplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_TwothousandtwentytwoinducementstockincentiveplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127736007728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense - Summary of Stock Option Activity (Details) - 2019 Plan and 2016 Plan - Stock Option - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding, Beginning balance</a></td>
<td class="nump">6,504,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">6,089,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(38,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares, Cancelled</a></td>
<td class="num">(2,582,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding, Ending balance</a></td>
<td class="nump">9,972,217<span></span>
</td>
<td class="nump">6,504,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable</a></td>
<td class="nump">3,225,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning balance</a></td>
<td class="nump">$ 11.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">5.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">8.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">11.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending balance</a></td>
<td class="nump">8.44<span></span>
</td>
<td class="nump">$ 11.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 12.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
<td class="text">8 years 5 months 26 days<span></span>
</td>
<td class="text">8 years 6 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 15,114,074<span></span>
</td>
<td class="nump">$ 1,885,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 407,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127563193968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense - Summary of Weighted Average Assumptions Used to Calculate Fair Value of Stock Option (Details) - 2019 Plan and 2016 Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">98.60%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127561622704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense - Summary of Restricted Stock Activity outside of 2019 and 2016 Plan (Details) - Grants Outside of 2016 Stock Incentive Plan and 2019 Stock Incentive Plan - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning balance | shares</a></td>
<td class="nump">76,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">37,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(18,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Cancelled | shares</a></td>
<td class="num">(20,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending balance | shares</a></td>
<td class="nump">75,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested, Beginning balance | $ / shares</a></td>
<td class="nump">$ 9.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">12.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">9.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled | $ / shares</a></td>
<td class="nump">11.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested, Ending balance | $ / shares</a></td>
<td class="nump">$ 10.77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127736005856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense - Summary of Stock-Based Compensation Expense Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 14,802<span></span>
</td>
<td class="nump">$ 13,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">11,026<span></span>
</td>
<td class="nump">9,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,776<span></span>
</td>
<td class="nump">$ 3,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127556245312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Acceleron Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ReimbursementPaymentRecieved', window );">Reimbursement Payment Recieved</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Acceleron Collaboration Agreement | Research Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone', window );">Research Development And Sales Arrangement Amount Received Upon Achievement Of Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fulc_MyoKardiaCollaborationAgreementMember', window );">MyoKardia Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_NonRefundableUpfrontPaymentsReceived', window );">Non refundable upfront payment received</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_DeferredRevenueCurrentAndNoncurrent', window );">Deferred revenue current and non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ReimbursementPaymentRecieved', window );">Reimbursement Payment Recieved</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost', window );">Unbilled Accounts Receivable Related To Reimbursable Research And Development Cost</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_PaymentForPrepaidResearchFunding', window );">Payment for prepaid research funding</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_PrepaidResearchFundingPaymentReceived', window );">Prepaid research funding payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fulc_MyoKardiaCollaborationAgreementMember', window );">MyoKardia Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_MilestonePaymentForCertainIdentifiedTargets', window );">Milestone payment for certain identified targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_MilestonePaymentForCertainOtherIdentifiedTargets', window );">Milestone payment for certain other identified targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fulc_MyoKardiaCollaborationAgreementMember', window );">MyoKardia Collaboration and License Agreement | Clinical and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone', window );">Aggregate amount receivable on achievement of milestone</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone', window );">Research Development And Sales Arrangement Aggregate Amount Receivable Upon Achievement Of Milestone</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_DeferredRevenueCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_DeferredRevenueCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_MilestonePaymentForCertainIdentifiedTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment For Certain Identified Targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_MilestonePaymentForCertainIdentifiedTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_MilestonePaymentForCertainOtherIdentifiedTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment for certain Other Identified Targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_MilestonePaymentForCertainOtherIdentifiedTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_NonRefundableUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_NonRefundableUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_PaymentForPrepaidResearchFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for Prepaid Research Funding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_PaymentForPrepaidResearchFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_PrepaidResearchFundingPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research funding payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_PrepaidResearchFundingPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ReimbursementPaymentRecieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Payment Recieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ReimbursementPaymentRecieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research, development and sales arrangement aggregate amount receivable upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Development And Sales Arrangement Amount Received Upon Achievement Of Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled accounts receivable related to reimbursable research and development cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fulc_ResearchMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fulc_ResearchMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fulc_MyoKardiaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fulc_MyoKardiaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fulc_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fulc_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560212848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research And Development Assets Acquired Other Than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 7.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=fulc_GSKAgreementMember', window );">GSK Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research And Development Assets Acquired Other Than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ClinicalAndRegulatoryMilestonePayables', window );">Specified clinical and regulatory milestones</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial', window );">Specified clinical and regulatory milestones phase two clinical trial</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=fulc_GSKAgreementMember', window );">GSK Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research And Development Assets Acquired Other Than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ClinicalAndRegulatoryMilestonePayables', window );">Specified clinical and regulatory milestones</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_SalesMilestone', window );">Specified sales milestone</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=fulc_Camp4AgreementMember', window );">CAMP4 Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research And Development Assets Acquired Other Than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ClinicalAndRegulatoryMilestonePayables', window );">Specified clinical and regulatory milestones</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=fulc_Camp4AgreementMember', window );">CAMP4 Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research And Development Assets Acquired Other Than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_ClinicalAndRegulatoryMilestonePayables', window );">Specified clinical and regulatory milestones</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fulc_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | GSK Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research And Development Assets Acquired Other Than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued for asset acquisition</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ClinicalAndRegulatoryMilestonePayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and regulatory milestone payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ClinicalAndRegulatoryMilestonePayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and regulatory milestone payables upon phase two clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_SalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_SalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=fulc_GSKAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=fulc_GSKAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=fulc_Camp4AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=fulc_Camp4AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fulc_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fulc_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560667104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future minimum lease payments (Details) - Accounting Standards Update 2016-02 [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember', window );">26 Landsdowne Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2024</a></td>
<td class="nump">$ 2,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2025</a></td>
<td class="nump">2,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2026</a></td>
<td class="nump">2,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2027</a></td>
<td class="nump">2,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_Thereafter', window );">Thereafter</a></td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">12,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_LessImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(1,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">10,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember', window );">125 Sidney Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2024</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_LessImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_LessImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Less: imputed interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_LessImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_Thereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_Thereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127557208256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Additional Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>SquareFeet</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>SquareFeet</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable Lease, Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember', window );">26 Landsdowne Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_OfficeAndLaboratorySpace', window );">Office and laboratory space | SquareFeet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold Improvements, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lessor, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Lessor, Operating Lease, Renewal Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember', window );">125 Sidney Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_OfficeAndLaboratorySpace', window );">Office and laboratory space | SquareFeet</a></td>
<td class="nump">12,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable Lease, Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_OfficeAndLaboratorySpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office and laboratory space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_OfficeAndLaboratorySpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_LandsdowneStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fulc_SidneyStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127560229328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued liabilities for indemnification agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=fulc_LegalProceedingsMember', window );">Legal Proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Expenses incurred for legal proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Cambridge, Massachusetts | Commitment for Office and Laboratory Space Lease of Current Corporate Headquarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=fulc_LegalProceedingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=fulc_LegalProceedingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127736012960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.71%)<span></span>
</td>
<td class="num">(0.46%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development credits</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="nump">1.44%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits', window );">Federal orphan drug credits</a></td>
<td class="nump">9.41%<span></span>
</td>
<td class="nump">7.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">5.92%<span></span>
</td>
<td class="nump">5.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent', window );">Officers' compensation</a></td>
<td class="num">(1.06%)<span></span>
</td>
<td class="num">(0.23%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent', window );">Impact of ownership change</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">2.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.13%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(35.93%)<span></span>
</td>
<td class="num">(31.71%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation federal orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation officers compensation percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, ownership change, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127555627312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 75,005<span></span>
</td>
<td class="nump">$ 85,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">16,911<span></span>
</td>
<td class="nump">30,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards', window );">Orphan drug credit carryforwards</a></td>
<td class="nump">14,628<span></span>
</td>
<td class="nump">23,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">10,140<span></span>
</td>
<td class="nump">11,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">6,918<span></span>
</td>
<td class="nump">6,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">5,232<span></span>
</td>
<td class="nump">6,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">3,613<span></span>
</td>
<td class="nump">2,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">132,698<span></span>
</td>
<td class="nump">166,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(129,512)<span></span>
</td>
<td class="num">(164,483)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">3,186<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(3,186)<span></span>
</td>
<td class="num">(2,459)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets orphan drug credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127556076784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards', window );">Orphan drug credit carryforwards</a></td>
<td class="nump">$ 14,628,000<span></span>
</td>
<td class="nump">$ 23,790,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2016 2017 2018 2019 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued', window );">Accrued penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Penalties and interest expense related to income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 312,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_OperatingLossCarryforwardsIndefinitely', window );">Net operating loss carryforwards indefinitely</a></td>
<td class="nump">$ 288,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, Expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards', window );">Orphan drug credit carryforwards</a></td>
<td class="nump">$ 23,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 317,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, Expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets orphan drug credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_OperatingLossCarryforwardsIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards indefinitely.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_OperatingLossCarryforwardsIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127564685280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fulc_DefinedContributionPlanName', window );">Defined contribution plan name</a></td>
<td class="text">401(k)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fulc_DefinedContributionPlanName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fulc_DefinedContributionPlanName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fulc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127562993680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activities - Schedule of Restructuring Charges (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140127556271152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">10,047,234<span></span>
</td>
<td class="nump">6,580,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">9,972,217<span></span>
</td>
<td class="nump">6,504,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">75,017<span></span>
</td>
<td class="nump">76,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MHE]_ZMO6U7<.M4PF/3_EI">1J[;1B+A$IK7YNFMT"0Z*R:HEFCQVM[JKPHP
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MW5>F?E]+JEQK$8>6CBOE&T(+A0ZT!&),1HU,@L6&P'K\>0?^O%?Q![8%?R$
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M&_#?5Y2RYYOZ1.3A4.[L?U!+ P04    "  [@%M8B#(BDNT&  #;'@  &
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MWYUY[SR>>W^N12EIGLC+B0(,6M,DWGWOIOX>'O@>PMYGD:NU]'[/$Y;L*Y@
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MK(6(3AV^V>F=,@(9XZWPZ=1*]]AK'!P.N,1.M%<ZSPW?8(T3V-CM#/7S1.F
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MC"']F,V<X0KLA@;X4K#RN;A]1"<@-+A N'(,&0S9(0>O2[A27QC%2PC:!O^
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M@=2[8MNU>UBZA5M/D-6E1UT7%\;O:%7ZQVO@,@"3Z( ^L,D'"-\.[('Z".0
MG^,] 8IZ)AOFL8YP53D8 Y1V#9SI$&D@3-JBQ 6)I>&JKH#T:D!/KY*,*+2S
MMMBS=@5 01*C: 39<A@ZP(Q'T3(!2^5L"@R@#Y:Q1[WX+=R:@,C#<,3']240
M%U[M@ IB4[LKHD7A2B#!/4A Y(X#B-XN)T0T#5'J\&UN3/,I"GG896]^AP-$
M_H*!O>L'0?JO  %0*[(.'2?YFY $C(N*%M>BOW>V)B8C&0V$ ICI03J3-.IL
MY8A\6]@(5R ,)TKFSW_Z]NST+]]YI""44'![<&201P"@(YKI0*:@H-K!S?TQ
M&) O'0#YQKBN^ ?0+$FP-^$H;^$HH)((.L3(%L==Z[C9C</<!8$)-BL:M'YV
MMM(N"6F1UWR3/1C'2.^D@T#P6#"%*V*=MFG$0 [8\$ N"J"  0@X&+<X@Y3>
MEM&,?Z<0.V;V#F1!G:E'D!;]#:I#H3R0P*"S'9R("0,7VA/)L51 0;P&G$X@
MX$$J]W,DX[7-HW*5F1?>VD^>]>0M"/#/;(P,K)S;#9IRAMGS,,!:CP5F@,G
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MMK_!XS__ZAVZ_!3G%4RQ/KO<8321/-P,\"Y1SQPM0/ZDF#AP-)D^)ZXY@95
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MT %N.BX9 &?#H1)@0F<--4</@?U6Q:$>/!MU,CYS-0%I[ ^P8EBQ3L7A(ET
MJ0T:0SYDD$5CI327J](T?SL/53A)T##,'V!#E*BL.$Z4D[8HD+#KEA0AZ@TC
M2A6CQ%SV@\87*N9%O4&B/YW"NCE7)DAKK%"R33&,>"Q8.D@R3HP-L0KNW)8/
M1;N)Q-&5L! (EU;\JN.^G='XZC'Z!3%PYZ5+$9$?67YF%,1AB1,CEPDYOTUN
MO,Z I4!Y@RDAT#C32TSHK4DCM%EV;TQ/N2F6JZB'+<_IW&-F5J+[)@N3E0"(
M/#T;&9>YG1HB#%OZFJQ),7S5I)$H,-J=5VS^DPV&0JV.AH^,PJ@O5X7]&JO"
MBH]40'5^>5%\\^R;51A";NI%\&#H"!=4*HP&&5XI>C6L<.56?:@Z(R>9G%69
M(>4+GMV8MI;(PQX)O[AJD84PI2LYM)74<XBD8;69:C>-]#([Q& " \1:7&QQ
MDB&X'EA'5,PE\A++L"8;4^4':@[RBP-.4B$/-XQ9<3^R9;>XB^_MP;\L3I\4
M;SE$?E1H"8LQ@1+0<C[ZTL2O["WQ&Z%2I98"0?ZD9W>2+@) *BV[ TOK<7C6
M;LE9I,0GI36#<B5U@5=X922QNYO!D)C :IIW$I33E("H"@VJ"9^P2Y58Y '(
M':;.8M)-+%<),D?C>L;=I>.@S6)#9')J]^9T@A?/!Z+\<#B1RH+T4 Z]WG9#
M*,U<9<5G8I3TZI*JH$"_PAS%_!0BST!9%V<C&I%Q#)K0&"$BJ8-3(1.P]V%A
M7-C4-4GD@+,S>E%5?JPEO*B:2G$C]E1.6;@X);%+<R"LP85L+-(16,V@24JR
M+T!+BM,69H,"AH$-$&82&T-P$K)3U[1EJ0+N((7Z5.9Q$6//!:1L3L?L#QA2
M7"RU"BDJA2A%J+T-QD,,M:0 C\O/QB!BS)T+?"WLKW@F$.A8#%^XY]%=DO&;
MY*22:PLQ^SV&EP^U'4O.]-9R8;4')+,\*WX?JBO-2,4" @T:W;&B)(07+E4+
MLA^"3Y:N%-3 )71OD^\^PFFDGOE4'\:LVLYS+MBH^/$6"U"HWG? $1PXS%/\
M[C.+!3J;5@ IR$J=6@\N]"1E5<%YUB)/J@'N'=?I]"&M?ZA-.0H^@:_>)N"K
M!TF!3&6#$=Z(C;\0;?\6*;X=N_+!5-I;N8C["$9L%RNVD"3W-Q0MGA=OZ^+Y
MD^*G0)F!Y=+*'L+D]%,DDYE@](RET,ZXPL$21^NA9JF9&PLJ^RBW,R,H<WFH
M^!OMO2"4 W>;:,.RW9-3?"P9SWWRA0.Z_@O/-7.I([5ODA-FX=14*:>@A?/D
M,((\C=&3$''A^(PF<MD%V(/W /;W)Z1B698'Y  $%'(HF[.,7"R;O-X(+O\"
M6,(%$^KBO62AL:LP2XLI $(;,AVQ'NXG-3%8A8+='I]$H2W=>4.FLJ0F'=55
M9P\[*"6ESATEV];%^;3&+1;#S92[I636V9.8X:-5[L?;?2B)"5*V"@-^>O$,
MMT5C,3-%3ZRX,B3?7"4B.H=HU\U<$M;YL X(E24^KW;@*%?$9&GZ<G<R',3Q
MS#TXS+F$A=;%A;P#458/)[B#SM&PD4@0GJ%# Y=S/2J<(G7.W&H&C]3-Y(D=
M)7M5=ZR+L42UY9*#O0.GLL?8>PQJ9#)EDLLEKM-9FGWG0U$EK9!K, ,ZI"[Q
M 68E%+L+]]-(E AW,/W;[0/YAE$I_,.YT, ?H0) =7?$$LL@-XTPS=#;+Q/<
M)G9P5I9>2ER4T";)<H0&K=;E>@#TDE?!J@&O#,FV[8Y<# J0HCT+>UV!S="1
MPX-KWGE9<%7XB*I*RBWH]11[NYK&IY+Q6%*N6 K;*E-);(YB_)$J)5)0 X[H
MK1P5;((9@FX:OHP*Y092#\#UWEAXZ"5"VK5'4W,.+Y;'3BDY1W)-A=GH ^)*
M\1F?P,$6 @!8J?_*F8&JQ4@8\E)O][EU$, 0L346DS'F00./@>[(-$C.D[(3
M"V8*LR.PZ-:3?Y_ZS#1729620>FH>=MI#O0C.=?T%!3(HRUI\? 1/O/SZ :2
M4:XJ7'EPIJ0Z/;V*Z*E[34*;9%PPI4$HV)A]X6=@+GR%.V(L* 02^0U"]O1(
M0QDIER>FLCQGTG!Z )(L9GG>IY?#W,)A^91HT\<@4^\HWSKLEU1A<K!F7;QX
M@H]UVU(S&%-!)QKDH2[^VY$KD.3Q)<@WO](J!,2Z!2LE$H56?-VUWCJ)!4KH
MA0!)G-*%$\E38=)>O&522#:+'PY.S1,Z*7%B%0ZX86E]C7(!GT^344.KR'-/
MS(@>^A".75#4_/K"6@TNJM/#HB+BB;%9']D8OA-=')[ &E9UC=4WH\TX@JB)
MX7O66A=?/]&([6>;QUC9MTIY11D;*60!MI1+L R*IQP7;Y!#\LC&N!WJVT/K
MI!S$[:D2"-^@$2LS^3:FE]?9R[0>H]&CS$#8S8U\<>^0V$QCV\'3FP[205H7
MU_AA+W)#A$.0)E6L%,  <5"S"6"K>[Z7Y_J<9V]V7!>3E[[F42W6X/J<..;?
M]-E_7*=:J;J]8_N06^3Y<6O-+8#$MUW#;$%IPC8-B:L^E#]WG-I/X\8AQZ@Q
M6V2:# &A"A-E)#^3W*:+!A"5GA8),%SQ*H\6SX_&:(9JJQGRH[L=>[))FN&.
M.,G(J7U#=;9,DY-:FD3CC\"?*)R@-AI^&E;PX[YVZ/$/<7$UN8YF%<@LO%/)
M8TINA"MCYQX2,S9,5I&[Q&,SRCW?DH#!NXX/7'7SI9#;E,,GB)7WP$AG ?M(
MD1I#G81,WJ?(2>1!N)!0=D5)PJTF&)/<;[ XY#7G*$J=@#H*;>2A;>H1$32,
MK!+K0:;SPP&35@1)Q//+CC4C!L"> H>=]I27AJJP1W2PQ&^S32EDC5'N_(OH
M;DE?!,L\,(#2?-*"I6^QBB-&%[@\ !_5B_08^1]+1[NTMJ!7A:?/5OIBXP)+
M63:MJ'>4?>_$#SB'TS&Q2*DFUZILAZ[GERK9BU?AEMI%HT5R@C$0,-Y)/0ZC
M.S'^SLO2UK:#0?3*6DM'PZ<YR %,+2@- OS!&_YR;/\3$WDFVS!^>L^&U!0A
M1A5^2J(*K[4/RJ]+<8?0*44OG"^761;=^IGW!L RU5!*,&1A7:).L\\\0Z +
MCT_UZQ-5(V%W=9[!HP+##]U"T&V@%6KN9+(*=H(\&+VW%\HTFX#9F@X+0OB$
M20,6D/8H+@M@\ZJE4N4K(T]>]*B4+L.7!F"XTJ-DW\.9U*#1#WL,' &(<EL8
M O #$B6>('NI( 2Q3][JI-@,Q?W1/6;;%F^!8H)D[&UC8PJIWHA!")Q+[UO9
M/]=70*-=<[!X-PE3$.BP59)Q)W*J'+^<8;G+KXH7R8!>9/"=C LOM!YC#3*A
M 8K QY$<4J^N"2%99<U]24_M$R!U_<L 8?EV?+@98 M>NPQ(7'(19VP(AG$,
M4.SA%)IHP,6']_0Q%B"6FL/7#)5-6%9]-?B'E]+I<^S]@^&;U/I'<++:=/20
MP+I>/FJ95X2$<6E#E:31#S>L<N.V01R3Y5>.!!35.05=H&T&PNJB'/!N"#EH
M91ZQ !B1Y)KK%NZN*N0UD$0U@[E3885L&;-VT@1IL4L'E?A]9L7.RE!F*GM2
MZL1)T2TG,7I]LYH8!>QY3)I%Q<A[)L?D%+'L3=T:0K<JR'76-4USNGX4?Z5Z
M:D,]>*;6GQP_= P#G,X^@W]0,Z/E]C#X,M$@6DY^%:'(M"@?QEQ 7A4X;;QR
M,)P0CWIXQ&4FF5]%PV]H8F4\-R[A.RC1? _48*/T@0-+.YNPW+1&7N48Y30J
MQ"LF LA43+2>8CKVIUMZU 472FKG%:F=BU3M9&XZFVD^4U+FQB 398'0M,2;
M/]&>9U?X5&J=;Q&JZ";6'I9'R?IS[CEA$O2)=[T-5K_FD\*#[AB;)K,<22.0
M5ZR(QW?%A$#:;UW\K+-RMG3>#TBN#!27?#3U47<7G.@FJ&-=E$8J<,*5>ZT#
ML_&@=[\N7<]T5Q+&"=VBZ'9X.3S_XLW,]V7"T@08S(MH70X]<..'0:%4-JEM
M#N\7DESE#(RRYD$=ZE36CO9)T/"J-D!LE^6NI9 TS3[1AA?4PR+6GDL_P'$O
M%"U%]</F=[WFV/@D%8!Z-0DB.99WW:)-P,7%V2 MHR1F0YQ+.,'Y3R=;[$V1
ME>:O0K,VFEPY>A5>B07".>BP$T5J3%W*@]!PG-#O+QE*[9FXXCW4;;-$D,=S
MX"D-X+&4W)FJ$O.2U&*2$4YZYJ5NB$N:-/#U)@/O!]BD[(;1$JI_:4"8X%4'
MUR[>"1L](9:?XEK+RF?1.Z'WO#%'6D./=0B<!]4.+A1;%!&U &%^ZQ'>W+ 8
MM%C=TT,,DMK,OBMQSV.:)%_1\3.W(<\1[5W%P29M(Y8*LHH#<1I9"R)-E?8@
MI;XC$+D_#(*)AAM[QHG>0I[#E;(>BEPCSJ2F.QYJ9*P8B,& YU0]\.83LI<+
M<=+@*QSZ,WBCXY R6HD-9E.Y/5O@'(*$OFS#RSP BE_!80$D/_?4T?0 /$JX
M.VJ=X7];*QX!PW+4VH9T3MK/YA[?#6F.\;/PMCI]QP)N7D/!@(186*:C4W-P
MXB9SC%8\RB3X)6_J,].!2MBQ=\=OZ'DNGSSMM)D(8GG]E#0E.P:R'@E@-7*T
MO!M#95:C6^9VJ9/:A.'%Y\$I&/GCCF&<T)5,<33'U5<9E2[<W]N43CRK"W'?
MS@((:")]E,!:X)?5@\XTZF22/%)&$Y:/D_+U#(CCU]8^<!_NR]U/\R:&8R"2
M4J>&#7DZF@3C5! *%OA5<T9X*;!J]L87Y5CB@(9KTEL*??H;KJ&FWB[]+*[2
MKAINN\I%]PVU&0\'FS1264D9QK[%U^E<JD&N*?IE1!:^E6Q1?'PX!T7Z+"6V
M[/G0HL6/]["EB'RTV!=.HG4LE.?1.#4WY:*"(2T23<T-L8!"0\= [FQ6=2TE
MD!3;JW1\" =P@0GSQ*UCI: KA%8QZ0VN,NC&FZ'S@^2V00T07$3-;NFL0S=4
M6G"^!>U*#5T1'RAZ&_8UD+RN)EYW)FF">\1SI0.!#P_B\&Y/^&ZY]PW?+8@8
M:ENB-X,<K\$PK+2NK^EQZ_SBHHLBK5(CRGDX4G-":WS#[7$SY'$CY*19+RO2
MF]5<C#O?IS>?.(^:,A9J?_I<P!)))/9G>*^//;WKL"Y0![W*$%.7LDL +;77
MN>%_AD"07&L$F)_>3WIH) %%DP$N36L'#4:&H.Q<F*4,4:"\+7;N] $)AW)N
MV :=W!C7FFD$GO1LOY06=]@ O8J=H5Z</5L!9(XR8#_IJA@'*-XG^0+L"A^"
M/%G]5-(G>9NZ-7G0;RSS8Q P148L=F/?/509^J"R?98;0Q)?ZO],8ROV,$<&
M^\:B"L^L]HNL:<L[;-"1?Z2-8OAY3J4&F-3JHIJ@OF><Y-D@BZ(K2)$[?M8H
M4:9@[7-X9MPEGF-RHKZG;1YH$KXNH^?VVF.6\Z)1.]W7<V,UTZ,F>SZ(S:;H
M0V[/&EK)Q<X?28N_=?%W&"[&TV-$W1-\]E)<[O"F7X'X*VE!;8U6TX@#@D\C
MJ!R7>C&1<B!K5&7^=)Z4";#^PWM ]0$WT QT5@SPX:J>"Z]3;QV<7N0!4@]M
MV@QN#81?T_;_"IC_)R!FZ92@>RL$F^ID915:EJGA,'384(E5>^)Y4K@_W:B-
M;3%"I"*#BFD K]M6"Y&4:1GJO3".8]Q2]H7HBN3GR%8*3WC%<]>'N,@J=HL&
MCN9G2Q&.\39IF7B)1@:3$V'T;0=@UJ>)>@4>W_PK^&D[3NW<@P_93G3$NGB_
MW9Z\DIXCE]0GY5=PQ FDBY8>3:LK QM=\"MS&C'&!3AK:35;"^OF_5?0P0\Y
M'\0 C(X/!T("8*7AI/03[>.OTW:VNAH7VZV3YN4N:5Y.AF.*'M#(K<^?V'/V
M;'1:?5./<&MGJ_B('0<8OUM-VLVNYGMOKM2625O +S?7G5MW9@%Q1DA]6VV.
M&=K3U]00<*D]?7J#X8<0V )'$XC1Q WIDXM-L9*$%U(G!XS2*PRCJH%.T&&"
M,<OF9.[(_)$73XR=\N]JU#]9Z%_XI8#TZI:_N?<G!![6@Q:1M;S)@YK*\J<I
MH0>+\0LH?2KDM'>5214H[%.[4LJMR5A.R_/S. _6 D8D:]N>_GC@\%)8<[JU
MD*'\# :_]A!8M:LHBDXM$!,B%AI.Z)<*&!=HF'U3C-L/%+6]M/R>\6UB>[T/
M;0N\U<P8\5TPJY(G\]QL+3&B.$O$M*[OYZCG"W9BS;AS/CS+6<SHW>A+UYVS
MVZ2C0F5+ZE9W@K^60P$0^$?Z1?H(6U^OIK6S9+^&]X!)8<S(W9-(Q41JW0G/
M4O<9+(G=RUQ["S1/BJO%IO(XZ=I)DZGQS%'_0OX!%OZ1#K5CTY8%[?@&U\5K
MX!Y2(C]W[0UV(9#S@=/1#[G#X[BL42=<\01)PX6&;:]_OM R%^H3IN0A7L7?
MAOT!#)@.G)2A*UXIE)?XT7#PF!;-:FK^]O[5)7Z8K$D'/9(/R94'/1X:&5A_
M&^G6:N]WLKICWEV3L!+0&[TLR;O:R#M.2BXD.86LN04<=I1FP2\;_)Q>*$UA
M#!EMM//)A^!(HK@6!LO1DII:/7XP*C'RSEUZU,='_Y=K*ZE.SD3'47NCS]AL
MM@[NN+:]N0,J<M:P0I6"=>2?/F!7>1+N*75#W1G5HM5?]%O);[+<%\G$ZY9
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M1AI2P/6YUNY^0AML_XRF_P%02P,$%     @ .X!;6'!QNU\B P  ] 8  !D
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M:WJ6T'@%DE=:N^/".S@]=.M_ 5!+ P04    "  [@%M8H7O.]"H#  !:!P
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M-H9PRMDYD^Y+;O/87&296"-E;7!D)X%@.W7X<.:4LN,[KC<D+:6A !N,OVW
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M9>L#Y$+R0TZR;TG>,JW=]&Q&&+12A#^*0PP@[,\(MK"!.V3 BN;%632V(X*
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MSZ$W*"[E;'0PCA%'^GF#N"<:I--[II+M75A]V)V6!@4@@=M"A6Z]/(,1_&J
M$N$ZI3C$D=QUAV\'-OKAW>W09#EHPH!WZ \GN]FQU[%)Q -W'1+JH<.[4$05
M]::AB<YG->.Y>ZR+%6RC.;8-N=9*@T_%4N]]I6SZ;BHPW+>;;';=UOZ8 F;+
M)?XB+;]O)66O0OFBK3=#KHMAB)+,@L5M%>9.))DG2?<42I,3)5? >2-!8L%6
M,Q),<GT[,*#0-<+"&'5FMWD&0!W"1\ /H>)?U-'AGB%\AC<7/*J&)[J.H3X"
MF]RI^M#MJ_#PN1QW3HCI[;Z$ 4$J#?@$D<+H*6Q1(#HDM&_5Q)'XS_ M3OK;
M76\M%#*2;3KWD["2Y@FP '?/AK);/6.Y<7U]/M5.RXY@O6,=-F]I<\3#T9V6
M^=58+!];V4P>)I[00_ L;'SY?Z=-[RIJ"S5T8XD!.EB0H!8<!_*&>D A%E#P
M8QV23]FL?4<\9*E3=&Y,7U'7+W$ZQKH>$$O])U_,'Q+FX4/MU['*BJBEG+\<
M47W"Z6NHQ7R?@NXN^MQA8(MLYIZB/%E>UG%5@*PFC/%I)@-PTOTD)="[.PE+
MY 07+Q#DXMVJ/38,S/M =X#3'"]=50^.?P*E-]X:8Q:OR*4GLTJD94V4^V6R
MTP");/BL2%E 3U"V8NPHC^+$C9+.),@=)9V^OS_I9#"LZ$T?^SOPSGTU]*0X
MX:NV]RD[ZUAQX6ZIB  3B'G$6%R-LV93#;DZLS_AX>_U'?P4A6$HRU.CRS?4
M8H<RM-[*E-P="4U[]TUH_$Z#\%!7,/K%/8 GEQKY6&O+H<5V/O7UC<.Q%P[A
MS1TR=+^%\OTF+@A!E[%<'87..2O!#38NZ!Y*Y[4.ZDU%-,56N"C6E'(Z/D?)
M&PG"%*@@.<7CT\@&W#@G+<*7+'_M2=)L$$B>*#I&M4Z8$*<6[%KI#A-OEWIB
M27<'K'KL@4^Z006;S:PJ7D9*_>J#C<&L'YK:.(]3>S*[9[2)IW1QU=!?(GD)
M7UB[R)KSMQFX6,\K-Q,F$ZQ*0Z&ZZ>@(SP>86'$=N$,2#D<H6PM*3;0%?-#2
M#+&CM :[F,XBR#\[?'(4:R%3E(S%/?D$R#Q4P=YP\DT$4O:^[^2S^B[EA@?H
M^J@ ?S#!#=U/9BXX%NYAY/WS:1_D5941?I3L&9P.:RF*\*=P'VTG"?.*=-G]
MMH3<TRI].B_P#;;0XSE:7S!Z&HX^8T\TD?A+JNM:%#(UDALZ1Z44-.7TG"P#
MXZTN<I2PX)8>C*DZ?4#_RU,5=J1;.?"0W@\@@U_1;56(9H,E/+,E4@H((*4K
M:4L8M[$M+4]L^ZX%G!W?\*$K3714U83@ALS>?_$!!5/[<*$OC"9E\*'*L6DI
M0/F E%9A'T1VM3UB?9[MX-!9I2''YFW]!J2\Z'Z)N"5U8UR.[G0]8M=+[R^L
MN_$%HGN0,Q.W0]R(J[OAM.EC!+/CRH96JO:J#Z&#*Y],=3#<8OVD;T-8>LCM
MUNMCMUOGLR\_[G;KR=7&Z';K5__%VZTG7S^>'Y''L]GU_TX>U[/Y_^6V[^G7
M>C\V#DUO?/!"\=ZV7'[G</DTD</+5U@AA%X8IS\Y89-LN#5/)VBD[_"$D\WL
M5+,H/,F^P1=_&$0=*%FQ4^-?6[GAO&_:__@<Q;.H]WS$H'?O&(>SU#WYQ&VS
MCGTWFG%?8(_)0(JYTQXZ5+3DM/HF)4H' .?O7WM+/ EY.U>QOQB;PVE7L4\[
MZQA7.:<T PX=*1] ]E'&GHUO]?^>&)L*'FRRQZ[[1_,=",L2O,@X#QPNA.R4
MVSZ(/D0:? R;76)+3>*LHNK6&"UJ_S/$PY75PYS7*9*8_PXE<=B*DYT?#B13
MLG@(#[.I'SQ>9+]IK95=\2]WG3\0]S]O34_3CX-O_&]BA^'^E\4_2KNBD\)*
M+3'U<O;%LS-_B!>_=*;E7\@N3->9FC^NE00#- #OEP:57OA"&Z2?3+_Z#U!+
M P04    "  [@%M8== XS;<)  !P&P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6S=65MSV[@5_BL8;6?'F9%U<YRDB>T9V]G-;K>>\:R;]J'3!PB$
M1-0DP05 *^JO[W<.0(J4)2?I8U]L7H!S/]_Y(%YLK'OTN=9!?"F+RE^.\A#J
M]].I5[DNI9_86E=XL[*NE &W;CWUM=,RXTUE,5W,9F^FI335Z.J"G]V[JPO;
MA,)4^MX)WY2E=-L;7=C-Y6@^:A_\;M9YH ?3JXM:KO6##I_K>X>[:2<E,Z6N
MO+&5<'IU.;J>O[]Y3>MYP=^-WOC>M2!/EM8^TLVOV>5H1@;I0JM $B3^/>E;
M710D"&;\D62..I6TL7_=2O^9?8<O2^GUK2W^8;*07X[>C42F5[(IPN]V\XM.
M_IR3/&4+SW_%)JX]/QL)U?A@R[09%I2FBO_EEQ2'WH9WLR,;%FG#@NV.BMC*
MCS+(JPMG-\+1:DBC"W:5=\,X4U%2'H+#6X-]X>JO1B'"6EROG=8(=O 7TP"Y
M]':JDHR;*&-Q1,9\(>YL%7(O?JHRG0T%3&%09]6BM>IF\:+$CUI-Q-E\+!:S
MQ=D+\LXZ+\]8WMD1>9^LS3:F*(2L,O%K%62U-LL"7GNO@Q<?C5>%]8W3XI_7
M2Q\<:N5?A^(0M;P^K(7ZY[VOI=*7(S2(U^Y)CZY^_&'^9O;A!1]>=SZ\?DGZ
M-V;J11F'+9S/)^*Y</'IX;?=+8(F?M9+UZ!QD93YG\<BY%K<VK*6U59@A78Z
M$Z8*EE\X:@9A5]2W>%,IS:$ODAK9RAT+Z87$%>I&G-#.'W]XMUC,/@RT\[/Y
MAU=C-$?( 2!+;S(CG=&>='PJY!?[4.+5;^2PJ LE3M 8W/E/NMA&*\A F >%
M.QT[R77C?"/A*99L<J/R@8,Y=BVUKL3:80T$R4KH+ZIH/!00\!2HKTQW#D)(
MIJ':UNRWLF6IG3*R,/_!(NM+69O29A/Q&9X[5C7P>!A>67C8K?YH#/FP"RE'
MV9,R!YA[(NN=7C>%#!9I(L6EK)H5JKEQIEJ+S*HF)I?>)??G;S]X^&)\H"6^
MJ6L$#%'=62DRUZPYZFB<E,G:V:Q182+^MF\GA6I7 K -&]NP&*A.1C>=XP>*
M EO^C>31;J5=P&Q!"*O,$)#[H4Z#$H#\M0PQO0TD[<+-N9?>5I+:7:\PQ6+
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M;>7H%O 8JV,"L(+[&TXN84*I?5O9T;X#2JGZ%?P,/!-X*Y(2,3K3N&#\2BE
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MRUR#G3I:@/<K"TJ3;DA!]Y'MZK]02P,$%     @ .X!;6-\M*H6W!0  EQ
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MXQWH?*6U:S8^0?OAF_P!4$L#!!0    ( #N 6UC:6+ZHU0(   D&   9
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M66$WIB^[C_7U/ZQLB #,Z[*E_\^N^=WOOK^7Y7W;U3L9#!#L7,7_-3>"B&C
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M+U'4PB$WEU8U^% $^E A':WG9Y5/ _8YIH!.'X4,T:-;T@.X4,>6*<:%]@C
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MB/N3Q0+M38O6%&2E3KUI(O0DE8#>C==R:;I=T#DN+>M\ <B^-/D@#&;*MH[
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M$NE6Y#F<*6G_R]<AF-1TQ7V)C!4B?1A1'ZL'7GQ$]G(@3IH>^DW_:9MZF+-
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M'J?$:R%=O:-_XB=^;8,OP.^;&OQN^0,7N*Z;SP3>\_\!4$L#!!0    ( #N
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MY22ZBB#'@M7"/>K-#]S5,_1\F18V?&'3Q Z3"++:.BUW8%(@N6K^;+L[AP/
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M8)I!TQA.5Z&YE]K1J C+DF8S&A] _D)KMS=\@G;:I_\!4$L#!!0    ( #N
M6UBJZ$4!OP,  &8)   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;+U6
MVX[;-A!]]U<02A D@&!)M'Q9KVU@O=M-"G2!Q5[2AZ(/M#RRB)5(A:3LN%_?
M(76QG>RZ[4M?1 XY<WC.#"^:[:1ZT1F (=^+7.BYEQE33H- )QD43/=E"0)G
M4JD*9M!4FT"7"MC:!15Y0,-P%!2,"V\Q<V/W:C&3E<FY@'M%=%443.V7D,O=
MW(N\=N"!;S)C!X+%K&0;> 3S7-XKM((.9<T+$)I+012D<^\JFBYCZ^\<OG+8
MZ:,^L4I64KY8X]?UW LM(<@A,1:!8;.%:\AS"X0TOC687K>D#3SNM^BW3CMJ
M63$-US+_G:]--O<F'EE#RJK</,C=%VCT#"U>(G/MOF37^(8>22IM9-$$(X."
MB[IEWYL\_)L V@10Q[M>R+&\888M9DKNB++>B&8[3JJ+1G)<V*(\&H6S'./,
MXI9Q1;ZRO )R!TQ7"C#C1I./3VR5@_XT"PRN8GV#I$%<UHCT#<2(DCLI3*;)
M+V(-ZU.  .EU'&G+<4G/(MY TB>#R"<TI(,S>(-.\\#A#?Y9\PW722ZM;$W^
MN%IIHW";_/F:Z!HR?AW2'IVI+ED"<P_/A@:U!6_QX5TT"B_/$(X[PO$Y],5C
M?6*(3,DM%TPDG.7D2FO 0C556Q-FR)$PW/ /D%1*<;$A2Z:Y)DRLR6^PA=SA
M'%R_<%!,)=F>/!N>\[]^K%FM_RS#U_4_94!2F>.YMR2,VU#$30M#N*AO%'<T
M5WA=$(/NU[(HF=A_>#>AT?A2D[23RVJYQ9'<U&K8MG(9WA&MX%4GF(LU3Y@!
MAWX4D'6BDQRA>6J]+!?,C:Z2[,@7@;0=QFT(Q0I4MQ7= MBAY",7N("L-([H
M3]/>6Z>*F=Z3-*BFKD/4M+1I![UKIC,"WRJ.*]N(:0_/$NSQQ*L7O*'3"O')
M>T*'_G T:!N7+7K9MKT[YVS33;1-"3<<$.FY_]@G3\KQV1_-D"CV:33L8$[-
MWF>Y!24L?X*WM$A.0D=#/PK'7>BIV<-J%J!<^4I68N:BL3^97!Q6.C'17952
MV6*MI-4910,_C@_H/]A-*C$;@Y%/:73("W:BT!\-)]AKG?^'DD3C^+C3TG[_
M=CXN_ L:=XXGUG^O8NC3071(UHEYOHH1Q;P>>)R:/[..)WX\'G7NI^9/5;P8
M^:,Q/8@\,0\U#"FJCX[S%XW'_AC+?<CD:U=I</3V(<V->^$U260E3/T,=J/=
M3\15_78>W.L_$,SXA@M-<D@Q-.R/AQY1]:M>&T:6[B5=28/OLNMF^",$RCK@
M?"JE:0V[0/=KM?@;4$L#!!0    ( #N 6UAJ^$.RX@,  -()   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;+U636_;.!"]^U<,U*)( "$2J6_7-I"/
MMMM#@*!)NX?%'FAY; N11)>DXF9__0XE67%2V\!>]B*1PWDS;QZ'$B=;J1[U
M&M' KZJL]=19&[,9>Y[.UU@)?2$W6-/*4JI*&)JJE:<W"L6B!56EQWT_]BI1
MU,YLTMKNU&PB&U,6-=XIT$U5"?5\A:7<3AWF[ S?BM7:6(,WFVS$"N_1?-_<
M*9IY0Y1%46&M"UF#PN74N63CJ]#ZMPX_"MSJO3'82N92/MK)U\74\2TA+#$W
M-H*@UQ->8UG:0$3C9Q_3&5):X/YX%_US6SO5,A<:KV7Y9[$PZZF3.K# I6A*
M\TUN_\"^GLC&RV6IVR=L.]^(.Y WVLBJ!Q.#JJB[M_C5Z[ '2/TC -X#>,N[
M2]2RO!%&S"9*;D%9;XIF!VVI+9K(%;7=E'NC:+4@G)E="[V&3S^;XDF46!L-
MHE[ K5"/:,2\1+C'O%&%*5##V8.UZ/.)9RBQA7MYG^2J2\*/)&$<;F5MUAH^
MU0M<O [@$>.!-M_1ON(G(]Y@?@$!<X'[/#@1+QAD"-IXP9%X7^LGU*:R"KAP
M@W/3ZF!U,<_[&OQU.==&42O]?4B%+D=X.(<]7F.]$3E.'3H_&M43.K,/[UCL
M?SQ103A4$)Z*/KOO3A7(Y>'M.\3W9,3#?-M^P3?]4KTDU"]:Y9*.KC:XL)S,
M&F$I2_H&%/4*A+8VVD2LYJB&C6R#O;5R."MJPLM&T[(^'X\^BT+!#U$V"+<H
M=*.PZJB8T64EE2G^H9Q?E-2Z?[X 1F_YCT?4F?C<EP#+AE+ >^"1&\4!#3Z\
M2SGC'U^-NL71@S2BA/RM(#UTY[Y[]Z#;0U*-1]\O[B_@0;75/.^+R$*7\PR8
M#V? 0SAO#2P:?9%/J&I;-]"WL\Y?@>+(92D'$O0,LI1 UN GHVM95:CR@FAO
MQ(8D9HF;9@Q2\J,,Y^T\S<A/;:02!F$NK1Z,!6Z8<<@L"Q9$UM.:PJ07X7 #
M<.:[2182@EGV<4(X:XNC])AXQ[N)9 ]B-X@2&MF [X>0W0KG[']J#):$QQN#
M%G^7.7,SG@Y^9V#WT=K"8S($=K_X&P09_2S][QWDNU:GEUA!;/>/K $[W4:,
MTZX'^RPRBR1K>*#(,'7CF.UYL]0V"IG#)/ZMI;+$95D$MD,C;@EEL1LG_&0_
ML9A2L+@%)5E;14P-RX\>Q9/=Y =NPE(:!6TOI;[?]9+/:6<8'/HD>WO_62I^
MU=XF[(>NJ4WWRQVLPX7ELOM/O[AWMQW:Q551:RAQ25#_(HD<4-T-HIL8N6G_
MVG-IZ [0#M=TZ4)E'6A]*:7936R"X1HW^Q=02P,$%     @ .X!;6*"QIIWU
M @  <P8  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULA57;;MLP#'W/
M5Q#>4+2 45^2.)<F =INQ0:T0]#N\C#L0;'I6)@L>9+<M'\_2D[3%,BR!UNB
M1!X>BB(UVRC]VU2(%IYJ(<T\J*QMIE%D\@IK9LY5@Y)V2J5K9DG4Z\@T&EGA
MC6H1I7&<137C,EC,_-I2+V:JM8)+7&HP;5TS_7R%0FWF01*\+-SS=67=0K28
M-6R-#VB_-4M-4K1#*7B-TG E06,Y#RZ3Z=7 Z7N%[QPW9F\.+I*54K^=\+F8
M![$CA )SZQ 8#8]XC4(X(*+Q9XL9[%PZP_WY"_J-CYUB63&#UTK\X(6MYL$X
M@ )+U@I[KS:?<!O/T.'E2AC_ATVG.R"/>6NLJK?&)-=<=B-[VI[#GL$X_H=!
MNC5(/>_.D6?Y@5FVF&FU >VT"<U-?*C>FLAQZ9+R8#7M<K*SBZ6F_&K[#$P6
M\/%/RQLZ<1O"%[H/IU_92J YFT66/#G]*-^B7G6HZ3]0DQ3NE+25@8^RP.(M
M0$04=SS3%YY7Z5'$#YB?0S\)(8W3_A&\_B[NOL?K_R?N$):"2?LV?/AYN3)6
MTXWY=2CV#GEP&-E5T=0T+,=Y0&5B4#]BL#AYEV3QQ1'>@QWOP3'TQ0-59=$*
M!%7"D=P=HGT4^##M-Q[PU8.DVY$KJDQCL7!4;(50*D$ESN4:3KFD%=4:,C-G
MTQXE#^L5:I_ ?:%WRU:ON/ >)F$V3OT8#T>]FU9+;EN-WG_)G]S<0!;',!IG
MO6M5-ZTEI%>$_J3OOMZ#*NV&D6$RF;BO=XM4NI42!?"ZT>H1G;J!49C$:?<G
M.$E);[MN01&06H[&P,F[<9JD%\2W]U59)MS&@5.!9!1.1ID;AMF8'!HSI::3
MMW4KF#NF NE@<\X\_BDD:3C*8CASTSC,LA3.>L?.^ST,PS3):,S"29S!H<L4
M[36"&O7:MSM#J6JE[7K";G7742^[1O*JWK7C.Z;77!H06))I?#X:!J"[%M<)
M5C6^K:R4I2;EIQ6]"JB= NV72MD7P3G8O3.+OU!+ P04    "  [@%M8'*6T
M7%D#   :"   &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RM5MN.VS80
M??=7#-1%D0#NZN[+UC9@[V[1  UJ[*;M0]$'2AK;;"A2(2E[\_<=4K;BH%XC
M!?IB7C1SS@P/9^C90>F/9H=HX:46TLR#G;7-71B:<H<U,[>J04E?-DK7S-)2
M;T/3:&25=ZI%F$31**P9E\%BYO?6>C%3K15<XEJ#:>N:Z<\K%.HP#^+@M/'$
MMSOK-L+%K&%;?$;[6[/6M I[E(K7* U7$C1NYL$ROEOESMX;_,[Q8,[FX#(I
ME/KH%N^J>1"Y@%!@:1T"HV&/]RB$ Z(P/ATQ@Y[2.9[/3^@_^=PIEX(9O%?B
M#U[9W3R8!%#AAK7"/JG#SWC,QP=8*F'\+QPZVWP:0-D:J^JC,T50<]F-[.5X
M#F<.D^@5A^3HD/BX.R(?Y0.S;#'3Z@#:61.:F_A4O3<%QZ43Y=EJ^LK)SRZ6
M5<7=\3 !*R:8+!&>_65X0,NX@#<?6"'0O)V%EMB<3U@>D5<=<O(*<IS >R7M
MSL"CK+#Z&B"D,/M8DU.LJ^0JX@.6MY#&0TBB)+V"E_:YIQXO?07OZX2?4#"+
M%3QP4PIE6HT&_EP6QFJZ.7]=RK]#SRZCNVJZ,PTK<1Y0N1C4>PP6WW\7CZ(?
MK\2>];%GU] 7SU2=52L0U ;6&AO&*WA\H5(U%#:3%?QJ=ZCAOM4:I86E,6C-
MI22NTEQ.XL2'YWS*\Y5'/N;YH%14O<:=*H5)!K!1@MH EUMXPR7MJ-:0LWE[
M-R!QL2X(P@E\OAC\B^X&TN$HG_@Q2_+>P/"M_($JO5"R=7:F+?ZFX@>K8(_&
M.M9&JSUW#<7 .(9I,G@G+5)B%K@L58W49TKD>W?G(1Z.Z0Y/\F3P05FJC^:;
MT[Z!?)AE,8W9,!U-X8K>>:]W_LUZ+\M2MWA5[U\X*[B@RL:+HE_ENBSZB?1*
M]N(+Z?^C_.,+B>-:DXN"Z7+G22O<TUO2U([278%XE/F3'D?18,T^:R+R=@5*
MW'"2(_-"9L,DCNFNJ T:TW4\EQHO*=HLSR!/\T%WB.ET!'&4'V5G_RWQ&Y@,
MQ\F(QNDPS^.+VH=G_;I&O?6ODCNS5MJN=?>[_<.W[/K]%_/NU7S/]);3;1:X
M(=?H=DS2ZNXEZA96-;[[%\K26^*G.WJ\43L#^KY1RIX6CJ#_.[#X!U!+ P04
M    "  [@%M8'I^O\3 #  !%!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6R=E=]OVS80Q]_[5QQ48-@ (I(HR[(SVT"2IE@>"AAUUST,>Z"ELT5$
M(E62BI/_?D=*<9W!-;:]V/QQ][GO\<3CXJ#-HZT1'3RWC;++J':NNXYC6];8
M"GNE.U2TL].F%8ZF9A_;SJ"H@E/;Q#Q)IG$KI(I6B["V-JN%[ETC%:X-V+YM
MA7FYQ48?EE$:O2Y\EOO:^85XM>C$'C?H?N_6AF;QD5+)%I656H'!W3*Z2:]O
M)]X^&'R5>+ G8_"9;+5^]).':ADE7A V6#I/$/3WA'?8-!Y$,KZ-S.@8TCN>
MCE_I'T/NE,M66+S3S1^R<O4RFD50X4[TC?NL#[_AF$_N>:5N;/B%PVB;1%#V
MUNEV="8%K53#OW@>S^'?./#1@0?=0Z"@\H-P8K4P^@#&6Q/-#T*JP9O$2>6+
MLG&&=B7YN=6=;ELZG(W3Y2/\_$5L&[2_+&)':&\0ER/F=L#P'V!2#I^T<K6%
M>U5A]180DZ:C,/XJ[)9?)'[ \@JRE %/>':!EQT3S0(O^P'O_ELOW0O\>;.U
MSM"W\->Y) ?$Y#S"WX]KVXD2EQ%= (OF":/53^_3:?+K!8&3H\#))?IJ0_>M
MZAL$O8.U=JB<% W<:?6$)EP!OTZ?+!J#U5@PH2KXV+O>(#Q8VPM5!O?3HIY+
M\Z*0\VG>6 ^FHF"[17,L3%!  \[ U>@#=T*]0"TLC*X54.> W2!2OHKTQCO=
M4$N0:@^J#U *8&M!?GY4#CE8G\/UNS>!3R?O-H/'FVCXC*:4=@!1)[*.9/I
M@0:Z\PW!PIS-"\YX6L"4Y<F$);/D+.X)K?/>!*-U9V3I:&=@]4HZ"T7.$L(4
M4U:DL[.,?QY 3]?$A&/@23H?R_E .\IW*5@W0D'&TKQ@>59 RN:3E"7YY/^P
M[]NNT2^(8Y!U;TJJSQ@C9=EDRE*>TRB9IHP7\_\<@W-27O54%%)_/I595K!9
M44#&YVQ&QYSF+)O-6%%DO@II1L>7PKE+%)^TMA;-/C1P2U]'K]S0Y8ZKQS?B
M9FB-W\V'!^:3,'M)96]P1Z[)59%'8(:F/4R<[D*CW&I';3<,:WKGT'@#VM]I
MNI;CQ <XOIRKOP%02P,$%     @ .X!;6'ZN0W,$!0  N0P  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S N>&ULK5?;<MLV$'WG5^PH;<:>82C>+XZM&=MQ
MTCRD\3BWZ2-$0A+')*$"H&3WZ[L+4I222FP[DP?3(($]>W9QL M=;H5\5"O.
M-3S55:.N)BNMUQ?3J<I7O&;*$6O>X,Q"R)II?)7+J5I+S@IC5%=3WW7C:<W*
M9C*[--_NY>Q2M+HJ&WXO0;5US>3S#:_$]FKB378?'LKE2M.'Z>QRS9;\$]=?
MUO<2WZ8#2E'6O%&E:$#RQ=7DVKNX26B]6?"UY%MU, :*9"[$([V\+ZXF+A'B
M%<\U(3#\M^&WO*H("&G\V6-.!I=D>#C>H;\UL6,L<Z;XK:B^E85>74W2"11\
MP=I*/XCM;[R/)R*\7%3*/&';K4W"">2MTJ+NC9%!73;=?_;4Y^' ('5/&/B]
M@6]X=XX,RS=,L]FE%%N0M!K1:&!"-=9(KFQH4SYIB;,EVNG9)RWRQU<45P&W
MHL:]5LRDZ^Z)QAS./K-YQ=7YY52C.S*:YCWT30?MGX#V?/@@&KU2<-<4O/@>
M8(H\![+^CNR-/XKXAN<.!)X-ONL'(WC!$'Q@\,)3P7=*!+$ DP?XN#:Q7Y-4
M2OU\+.911#I"%VK-<GXUP3.BN-SPR>SSBL-"5*C_LEF"IGSVAZ#\BRO0.$VI
M9\WSRQ>I[R6O%2A#1ZSWRD4Z4+32(*#!,V<2..45,"N\GG,Y9.;"^KTU'S"N
M;T:6N&H87"^7DB^9YM;'5BO-FH(PF?X'C@^Q';FA[:8N_ *>YV09I$X4T8N=
MII'MQ:[U3K*&4&-<EME9$$#DI(EU]\1E7I*HSB!([<P-X!R-L]BZ94V.9]#,
M^':4^G::T23B!\&_40H ?22^C4E"%JD3AO3(B!'2\9!K$NY\FS0?Q0ALW\?E
M84QVOA-ED#@&,'03.\71B+3"05KAJ+3VZ=YPB=4-KA5NN=E/!5\H,5K +:OR
MML*M@+>LE/"552W_48S'-#CNVLB-\#8[O$,U*5CV6_:#FM0I.0'N1Z>'%5,P
MY[R!?$>\ -0G(104!;HRX-"J'?)>]]M=1EB?$;;/R(7U!^F9'M9#J1Y?+23G
M4")-/$0:)($'3@*_@D]/BXI3;F+ @U$@;W@N>56 Z[BXQCSW:Q"DAC,3XCG$
MCD=_^]DN-VM9YAPV F,J*SIJ6>K$")49K!$]1(,>HO]5:E[=G"ZY#SP7RP9K
M0W%L\T?]G"Y 6FA607[H+Q>4V\$9YMML&1Y S;'O:D5LL?U+U@F'=$  DJ^H
M*V\X5$(IVD>1ET8,VU*O@%55E]6^K7SGDVV9+/8:G#\?EC\H":W7C((S0TBT
M"AVK\UXCII=81I>D2>L=;Y!@9<BQ CMDJ3011G94M&S7IV.>V7'D6P^8$";S
ME5E<\ U>2=84*%:$)(GQ&6>I]=DDZF0 O-\D! _MU/5I$-A!Y(Y5C7A023RJ
M$E--%5 51%E3^GW7B_MZ\!X+9V,"NZ]8TY]*+SLZ>TPXHZZ/"^?E"ZSQKT<"
M2X; DO\J?]P$C:>-=K]C/M9M1U%_6K>5>TI=.6B;4O^4MFM]:38(3E7O6(--
M8COQ4M*GDP1#+PT2VPVCKC597SOS,_!2;%DA=DI<FWW?1ET[1B&:'NH&HRX#
M2"+;-<W.<YWD>*N;'EPG:RZ7YM*L\!BTC>YNEL/7X5Y^W5U']\N[2_T')I<E
MEHZ*+] 4/6+UDMU%N7O18FTNIW.A\:IKABO\;<$E+<#YA1!Z]T(.AE\KL[\!
M4$L#!!0    ( #N 6UA0'FE,?0,  ($*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;+56;6_;-A#^GE]QT(JB 0SKQ:_U; --NZ(%DBU(LNY#L0^T
M=+*(4J1&4E'\[W>D%"WK;+7HD"_V4;Q[[CGQ'NK6C=)?3(%HX:$4TFR"PMIJ
M%88F+;!D9JPJE+23*UTR2TN]#TVED64^J!1A$D7SL&1<!MNU?W:MMVM56\$E
M7FLP=5DR?;A H9I-$ >/#V[XOK#N0;A=5VR/MVA_KZXUK<(>)>,E2L.5!(WY
M)G@3KRZ6SM\[?.+8F"<VN$IV2GUQBX_9)H@<(1286H? Z.\>WZ(0#HAH_-5A
M!GU*%_C4?D1_[VNG6G;,X%LE_N"9+3;!,H ,<U8+>Z.:#]C5,W-XJ1+&_T+3
M^DZ3 -+:6%5VP<2@Y++]9P_=>W@2L(Q.!"1=0.)YMXD\RW?,LNU:JP:T\R8T
M9_A2?321X](=RJW5M,LISFXOD4HR\.J.[02:\W5H"=1MA6D'<-$")"< X@2N
ME+2%@5]DAMF_ 4)BTU-*'BE=)(.([S =PR0>01(EDP&\25_BQ.--3^ E<[AD
M,C.9:B0"[;A>_WR%Y0[UG\<*'H1S*EF9BJ6X"4@&!O4]!MN7/\7SZ.<!LM.>
M[-2C3TZ0O4'!+&9PS;0]P)UFTK"V?S]?DBM\M%B:HZRGS\!ZUK.>#;[B6[HK
MLEH@J!S>U[;6"%=<\K(NP3<8E7,@)5MSC/@@]''B=P5"WN8INSS"YZFZ/,",
M42GWK[+AM@!+$4<;H8UCQE&GSO-=T7??")CVF[D2='V13K@D*%4;AW.^.B.G
M*22CV2)QYHS,^?2U,^=D+A)O+LA<QO$9D:9K,[>$'X^FR?SL3EDF3A40)Z-X
MN3B[1&-6P,NJ=J5P2=%H++PBB-EB!N<=2!LL.-MQP:EQ7D <C>:DS8'#G?>'
M.Q\\W)CJNN69Q,/WB&<0ZP?;<-$S73R3>!;/P'K9LUX^GW@&H8\3_ZU"S2R7
M^ZYK\(&^\%X#7TN&F\Z%/OZ +"T<1:>D S)M -V%_U_1 &G#&0DTI!Q655H]
M</I^HG!]&8T7U/)"T*F,X5<%]TQS]^WYBHP+U9@J[5)\@]GW,QK#C]P<?;+_
M=TO$T;#BG<-IN0](/8E>']5Y^&0L*%'O_?!C(%6UM.V$T#_MYZLW[5CQCWL[
MG%TQO>?2O8><0ND,Z=+6[<#3+JRJ_)"Q4Y9&%F\6-".B=@ZTGRME'Q<N03]U
M;O\&4$L#!!0    ( #N 6UB<$@F0B00  )4*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;(U6VV[C-A!]UU<0WDL30+!%2I;M7 SDLML&Z#9!G-VB
M*/I 2R.;6(E422I.^O4=4K;L31RW+Q(ES9QSYD;Q;*7T=[,$L.2I*J4Y[RVM
MK4\& Y,MH>*FKVJ0^*50NN(6'_5B8&H-//=.53E@490.*BYD;WKFW]WIZ9EJ
M;"DDW&EBFJKB^OD22K4Z[]'>YL6]6"RM>S&8GM5\ 3.P7^L[C4^##B47%4@C
ME"0:BO/>!3VY'#I[;_!-P,KLK(F+9*[4=_=PDY_W(B<(2LBL0^!X>X0K*$L'
MA#+^7F/V.DKGN+O>H'_VL6,L<V[@2I6_B]PNSWOC'LFAX$UI[]7J%UC'XP5F
MJC3^2E:M;3KID:PQ5E5K9U10"=G>^=,Z#SL.X^@-![9V8%YW2^157G/+IV=:
MK8AVUHCF%CY4[XWBA'1%F5F-7P7ZV>F-S%0%Y($_@2%'#WQ>@CD^&UB$=@:#
M; USV<*P-V H(U^4M$M#/LD<\A\!!JBI$\8VPB[90<1KR/HDIB%A$8L/X,5=
MH+''B_\S4'(M3%8JTV@@?U[,C=78&G_MB[E%3/8CNG$Y,37/X+R'\V! /T)O
M^O$=3:/3 WJ33F]R"'TZP_'+FQ*(*L@]9$IFHA3<=S*^^=J?]<EGR$'SDLPL
MMXU5^IGL!'G/+>R+Z3#K!0[:2RZ[A):O6/.9CD^T?!;Y-/(1J[SUE:IJ+I\_
MOALS.CHU!(H"_/2]<A"&<$,*5>+F8$Z"/X#KMH/(=AELXMQQYG9'A4=BM!]%
MY,/F'MP!SJP$:4DND%Z#S%R'DZ@_HN38+Y*4''?@7.8>$HBK)=?9TK_*X1$W
MKKIR0)F&7%A#:#\9N4O2.2M=+[DDN6X6G=6DGU RZK,XF'G8K?J02-QM,;.;
MA,Y!0B$L&?8G#"^C<7!;%"(#;7XBZ(0;L&FK<82T4;J6SV*4?X.9SCR86DET
M6(J:9*AE <2GGYVB+7.XQ\$MUD9[5QJM,:C#N&KMA22/O&Q:)NXJPC%G:!:C
MKM@[Q-1G+_CT9D$WI!^VJP/#,.R&8?B_A^$:L)J88]_E%\8 YMI5ZE?!Y]BV
M5H#9U_<'"?;/\L.>5LXW[+X+M^SEEAU+AO\L8S>STW:WD MRA"FV2]48]##'
M)P'N<5#-L29NG]M]"*Y?TYP$O[FNJ;%CK /#'0RIN-;/^&M><9T;\IZ,AV'*
M&"Y&PS"*AL$5KX7EI?@'H=[N:V4PBC@*(SHA- TGE :WKSKZ!1>+P]$D(C1!
MPG%P?WAF7OA2&@Y3I(I"FD3!C;38?P+_/)N$IB&;4.*$C(.++-,-JH<G-P;0
M9EOY3D[#41*18<AB%MQN\P+XD^[J\4R8BX?$84KC;5HU2I3-MEW9D 8_:Y?1
M?06F*6I)&*$Q"]/)./BV=TQHFH3)N!T4RB;AD+JA<T7;A\G"9#A!672<_ECM
MK?*CM9&?/&=X .Y]%\IVM6_P!CM'A0KTPA^(7,LVTK:GANYM=^:Z:(\:6_/V
MP/:%ZX60!A->H"ONJSABNCT$M0]6U?[@,5<6CS%^N<1S(VAG@-\+I>SFP1%T
M)]'IOU!+ P04    "  [@%M8&8F\"@X#  !H!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6R-55UOVS@0?/>O6.B PQV@1K+LQ$[.-N D+5K@T@9Q
MVJ(XW ,MK2PB%*F2*SOW[[ND;%T"N$9?;'[L#&>6R]5L9^R3JQ )GFNEW3RJ
MB)JK)'%YA;5P9Z9!S3NEL;4@GMI-XAJ+H@B@6B59FEXDM9 Z6LS"VKU=S$Q+
M2FJ\M^#:NA;VOVM49C>/AM%AX4%N*O(+R6+6B VND#XW]Y9G2<]2R!JUDT:#
MQ7(>+8=7UV,?'P*^2-RY%V/P3M;&//G)AV(>I5X0*LS),PC^V^(-*N6)6,;W
M/6?4'^F!+\<']G?!.WM9"X<W1GV5!57S:!I!@:5H%3V8W7O<^SGW?+E1+OS"
M;A^;1I"WCDR]![."6NKN7SSO\_ K@&P/R(+N[J"@\E:06,RLV8'UT<SF!\%J
M0+,XJ?VEK,CRKF0<+3[RO?]MG(,&+:PJ81'^>!1KA>[/64)\@ ]+\CW9=4>6
M_81LF,&=T50Y>*L++%X3)*RLEY<=Y%UG)QEO,3^#T3"&+,U&)_A&O=U1X!O]
MA.^ML%KJC8/[WNX_R[4CR]7Q[S'#'=WX.)U_,5>N$3G.(WX2#NT6H\7OOPTO
MTK].B!WW8L>GV!<K?H%%JQ!,"4M-LI"J]34,*\Q;*TDB)_HY5RWG&DIK:K@1
M*F^5"/7.H%L/X+TCE[PDLG+=DK]J( ,WIJX9M"*3/U5&%6C=L72<%'P\'8\5
M0FD4OWY./.3=.<Z? _B]E5NA4).#';(J?.6&&)F_=E3L'6EVI Z.7'#$#2H@
M>$6:PH'4A<R%#UYC+EJ'O.+9O0J.J[E=M*J 2G!"*U& X!;!27[39QG+DEO'
MU> ;"ML5],!7H2_%;/"I)4="![;.C&F\2 >7\>4DB[/A!"[B\W0<I]-T\%EO
MT7DIG!7.>^Z'':K5DLU/SN.4 9.+>#*<#AX-"07#-$['DS@;C3W1-(TGEU,X
M5E7)B]=?H]V$'N<XTZVFKA'TJWT;77;=X__PK@??";N1[$%AR=#T;'(>@>WZ
M6C<ATX1>LC;$G2D,*_X4H/4!O%\:0X>)/Z#_N"Q^ %!+ P04    "  [@%M8
M1P3.D)8#  !*#0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6RM5]MN
MXS80_15"712[0#:Z6E)2VX =N6B*O1B;IGTH^L!(8XN(1*HD%6__OB0E:VU9
M$6+ +Q(O<PYG#D?4<+IC_%GD !)]+PLJ9E8N975KVR+-H<3BFE5 U<R&\1)+
MU>5;6U0<<&9 96%[CA/:)2;4FD_-V)K/IZR6!:&PYDC498GY?TLHV&YFN=9^
MX!O9YE(/V/-IA;?P /*Q6G/5LSN6C)1 !6$4<=C,K(5[NXJUO3'XD\!.'+21
MCN2)L6?=N<]FEJ,=@@)2J1FP>KW '12%)E)N_-MR6MV2&GC8WK/_:F)7L3QA
M 7>L^(MD,I]9L84RV."ZD-_8[C=HXYEHOI05PCS1KK5U+)360K*R!2L/2D*;
M-_[>ZG  <(-7 %X+\-X*\%N WP>$KP""%A"\=85)"S"AVTWL1K@$2SR?<K9#
M7%LK-MTPZANTTHM0G2</DJM9HG!R_@7+F@-B&R1S0,M:J'DA$*896F)!A)Y9
M<Q! )38[^Q$MLHSH)B[0/6TR54^\3T!B4H@/RN3Q(4'OWWU [Y"-1(X5'A&*
M'BF1XDH-JO8?.:N%6D5,;:G"T,[8:>MRTKCLO>*RZZ'/C,I<H!7-(#LFL%7\
MG0C>7H2E-\KX.Z;7R'>OD.=X_H!#=^/P1;WMX-Y0/./P!-+1U5=OAWLC8OA=
M1OB&SQ_/B*^;']FPZ++A:R\;_OZD+-"]A%+\,^#ZLEDJ&%Y*GX&WHL(IS*Q*
ML_(7L.8__^2&SB]#NW!)LN229*L+D1WM5]#M5S#&/K\7HL8T-=]PRLI2[8HZ
M-=+G*_1@OKRA;6D8)X91_TE>YC>A._'C8&J_'"I^:N>ZCG<3N,ZQ83+JXKEJ
M7HCL2,U)I^9D5$VC&:HX26%(N 8<'@KB]S1K3.(#D^@Z]GIZC3IQKEX7(CO2
M*^ST"D?U^J)*F8JS%" 3_0P<$C \%="-?*>73W>G9K$3]ZV24=?.5?%"9$<J
M1IV*T:B*Z[V"&\Y*1%[YHE&M_G>J+@(*&Z)D+S!5OU,*<DCHT07//7DO299$
M)WL;1='QSJY.;?R)>],9'8D<=R+'HR(OTK0NZP)+R'0I25(R*-PHR;G"79(L
MB4]$F3@W8=0[@%:G9H'K^7[<4\\^*!I+X%M3K0N5<#653>G4C787@H6I@WOC
MB;HH-'7]#YKFEO$9\RVA A6P493.=:1.*MY4[DU'LLJ4ID],JD+7-'-UV0&N
M#=3\AC&Y[^@%NNO3_']02P,$%     @ .X!;6!&ND==# P  S@T  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&ULM5=;:]LP%/XKPH.QP59?<FN[)- K
M*[00&KH]C#VH]G$L*DNN)"?MOY\D.W8*CCI"_9+H=CY]YR*?<Z8;+IYD!J#0
M2TZ9G'F94L6I[\LX@QS+(UX TSLI%SE6>BI6OBP$X,0*Y=2/@F#LYY@P;SZU
M:PLQG_)24<)@(9 L\QR+UW.@?#/S0F^[<$]6F3(+_GQ:X!4L03T4"Z%G?H.2
MD!R8))PA >G,.PM/S\.)$; G?A'8R)TQ,JH\<OYD)C?)S L,(Z 0*P.!]=\:
M+H!2@Z1Y/->@7G.G$=P=;]&OK?):F4<LX8+3WR11V<P[]E "*2ZINN>;GU K
M-#)X,:?2_J)-?3;P4%Q*Q?-:6#/(":O^\4MMB!V!X62/0%0+1)9W=9%E>8D5
MGD\%WR!A3FLT,["J6FE-CC#CE:42>I=H.35?5MY /$5+LF(D)3%F"IW%,2^9
M(FR%%IR2F(!$W]%2QT124C"G50;H2BJB#0,)>I"0EA3=DM1NW@.URV=2ZL#Z
M<@D*$RJ_3GVE*9N+_;BF=U[1B_;0"R-TQYG*)+IB"21O 7RM:Z-PM%7X/'(B
M7D)\A ;A-Q0%T<"!-V@,.+!XPSUXM_@173V7I-"AJKH4=(J;1W<J"QS#S-.O
M2H)8@S?__"D<!S\<Y(8-N:%%'^PAMQ#Z^0KUBA;4>I4E+5?TYU:?1C<*<OFW
MB_BP!^*CAOC(:=4VLLHJLF@=6=A$5!=;-]X(O0(6TL%LW# ;.Y&N2\&(*@4@
MK*UY35[,6'8Q<N(<:+])PW+2G^,G/1 _;H@??[#CW7C#=QU_TC [<2)=\+PH
M%0CW:W=B'&B[,&@_YD%_;J^Q/YC[3B(*/]CS[P .WG5]&+7D(B?6DJ=J@P5T
MTG"*'FJW-O^$@QY]WD=V"MOT%#J3R"$^=P/^A\_;%!2Z<\8MZ&HOXS1!-WDA
M^!J,13N_]&Z@0ZW89J1PW&,$])&FPC9/A<YLXN;>45^NNW/M.[<L,R[,IUM'
MUIM $[JQ,*V+J7.I<3?2I_(NQ?R=$CL'L;*-A$2V2JZJ[6:U:5;.JA*]/5YU
M.G=8K B3^L)4BP9'$QT]HFH>JHGBA2W8'[G2Y;\=9KKA F$.Z/V4<[6=F N:
M%F[^#U!+ P04    "  [@%M8SVD8(Y<"  "$!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6R556UOFS 0_BL6FZ966@LA23MU!"DOG=8/G:)&W3X[
M<(!58S/;>:FT'[^S35A:-6S[ O;Y[KGG.<Y'LI/J25< ANQK+O0DJ(QI;L)0
M9Q745%_*!@2>%%+5U.!6E:%N%-#<!=4\C*/H*JPI$T&:.-M2I8G<&,X$+!71
MF[JFZGD&7.XFP2 X&!Y861EK"-.DH26LP#PV2X6[L$/)60U",RF(@F(23 <W
M\['U=P[?&>STT9I8)6LIG^SF+I\$D24$'#)C$2B^MC 'SBT0TOC98@9=2AMX
MO#Z@?W':4<N::IA+_H/EIIH$GP*20T$WW#S(W5=H]3B"F>3:/<G.^UZC<[;1
M1M9M,#*HF?!ONF_K<!0PC$X$Q&U _"H@CD\$#-N H1/JF3E9"VIHFBBY(\IZ
M(YI=N-JX:%3#A/V**Z/PE&&<25?^ZQ%9D!4K!2M81H4ATRR3&V&8*,E2<I8Q
MT.2"3/.<V>)33NZ$[R#[*<X68"CC^CP)#5*RP&'6II_Y]/&)](.8W$MA*DUN
M10[Y2X 0M72"XH.@6=R+N(#LD@P''TD<Q4/RN%J0L_?G9 4EMIYY@^#\W^'B
M UP/S6%7]Z'#'9W O:L;RI3E1+C4&LN+A>12E!<<VSHG%&U&OU50CWOE<.T=
MW:91$FZ/%?5YO" [ZLB.>LG>[AN\=<@J9UN6@\C),P.>O\5N]%=VO:GLT+K1
M#<U@$N!4TJ"V$*0?W@VNHL\]51]W0L:]0KYMZC4HV^PX!A5U_:U]:Y!?/4TR
M\[#C(UF#5[)Z$_^OK/#H0M>@2C?G-'%WTE^%SMJ-TJF;(*_L,QRQ?B+^@?'S
M^9ZJD@E-.!0(&5U>HP#E9Y[?&-FXL;&6!H>06U;XFP!E'?"\D-(<-C9!]^-)
M?P-02P,$%     @ .X!;6 H12)# !@  N3D  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&ULS9M=;]LV%(;_"N$50PMLM4F1DMTE!AH'60NT6] TW46Q
M"\9F8J&2Z%*RTPS[\:-D510MBI96&M!-XH_#U^>+\N,CZ>R1BR_IFK$,?(NC
M)#T?K;-L\VH\3I=K%M/T)=^P1+YSST5,,_E4/(S3C6!T52R*HS&:3/QQ3,-D
M-#\K7KL6\S.^S:(P8=<"I-LXIN+I@D7\\7P$1]]?^! ^K+/\A?'\;$,?V W+
M;C?70CX;5RJK,&9)&O($"'9_/GH-7RW(-%]06'P*V6-:>PSR4.XX_Y(_>;LZ
M'TURCUC$EEDN0>6_'5NP*,J5I!]?2]%1]9GYPOKC[^I71? RF#N:L@6/_@I7
MV?I\-!V!%;NGVRC[P!_?L#(@DNLM>906?\%C:3L9@>4VS7A<+I8>Q&&R_T^_
ME8FH+8"X90$J%Z"N"[QR@5<$NO>L".N29G1^)O@C$+FU5,L?%+DI5LMHPB0O
MXTTFY+NA7)?-KV@HP"<:;1EXSVBZ%4S6*$O!K^!F7UC [\%5F-!D&=((O$Y3
M)M\M35> 9J"F(,OR@2VW0H3) [B@:9@"FJS .[9C4:&C3-^$3%"Q7#^!VRR,
MPG^DUO-+EM$P2E_(#[^]N03/G[T ST"8@(]KODVE4'HVSF3(N>/C91G>Q3X\
MU!+>)5N^!![\!: )\@S+%]V7(WWY6":ZRC:JLHT*/>]XMLM,OL[S$]([F8,L
M9+7,_EG/96[U!T_$07(_OY/ZX&W&XO1O4V[VSF"S,_D!XE6ZH4MV/I)'@)2)
M'1O-?_X)^I/?3)ER)*;ES:ORYMG4YPN:K@'[N@UW-,K;TQ3L7L$O%/*#UVZ.
M"/%ET7?U*)I6'IG,II65YAZNW,-6]]Y3\47V[EW$0)J7J"BER<>]#*G[""<^
MF1XXV32#?C!%GME+4GE)[%[RA#V!O:_@:MNRGZP:?7O&D9@6KE^%ZP]IK_DN
M\^9(3,M;4.4M^.&]%C3[V+#73%8PP.8NGE;N3:WNW8(;\%$4E7L"-]5N Y_?
ML_B."6-MK(I]:^-(3 M^5@4_&U)/SUSFS9&8EC<X49@S<7.(+G6T@R]&D!ST
MMLE,(@8T-S>LX1BT^OD[WS&1Y P&)$4GRZ=C[EKE^M;(E9H>O*(C."@\@D[Y
MR)6:GCM%2-".2-T;W&MTKD_@)#AL\*891!BW'+VA0B5H9Z4%CV,FBA\3UW3#
MA/7 ;=?J72%':GKD"K\@&51W.R4Y5VIZ[A3+02OR=((2NT3O@/U&_\]FJ*W]
M%5Q!.UUUWZ9->H+!=#H[W*9-,SS%@=_BIZ(L:,>LJOV,OCD%*E=J>J0*J>"@
MF HZA2I7:OHT0U$5LE/51Y[1R#AY:.(1\GR$X$'[FNPF:(9:. HICD)VCE)U
M^K></T&CGT[QR96:'G-MN#0H?$)NQTNGP">D\ G9\:F]DYL<9/JM:S1K_;&+
M%"XA.RXU^Q@9O70*2J[4])@5**%!@1)R"DJNU/3<*5!"=E!J[^,FSQAGCP8[
M& 0!#EHZ69$/LI-/O9.[C2+M@KT+XTA-#U\!%9H.JJF=(IHK-3UW"M&0%6,Z
MT7\I<?0X;3)K/4Y[BH0\.PG9N]L.(7;IOK5RI:8G0H&7!X?4YYY3@'.EIN=.
M 9QGA9QNI[E0ISXWFK7W>>U$G)V3ZGW^?T;Q=OG>]7*DIB=#P9F'!]7K3B'/
ME9J>.P5YWI&SD5T'(:7.L8&\R:Q](.\IH/+L0-6GX>V,;O^@WN4[Q3E"3]&<
M%PRJ]9VBH"LU/7<*!3W[;*U[ZT^[M;[!S-+Z"KL\.W;56[_O>2F[=.^"G6+,
MA17<X<F0FAT[Y4%7:GKN% ]B^R"N^[4QL--Y*8.9Y;P45NR%[>S5M=GMQWC[
MA_0NW2EF8EBQ'O8&U?9.T="5FIZ[VA5AKBX):U[L96Q[PS5AEK97&(;M&%9O
M^UZG9NVZO:MUBJD95I"'!W6M&'9*@J[4]-PI$L0_?KT8[G8RTV#6?LX5*]["
MCGC+KM.[+DTLLYR:Q0K+<'<L:]VR1[ZFG-*9*S7]JE9%9V10=$:<TIDK-3UW
MBLZ(G<ZZ;%YB("[#YC68M6]>HKB,V+FL\^:UZ_2N2W-^9MF\1#$5Z3X_6W"Q
MX8)F#%SP?$AL^[JUR_:.[A1P1!0<D4'-S8C3N9DK-3UWM8OX'<W-B&$@!CV,
M#\G28#?S_0"U=+IB*M)]<-;6Z?9O*?L']*[;*3")*$PB@QJ8$:<#,U=J>NX4
MP!%' %?J^$=[OFEGZOEQ[;ZZ_*9&Z<=#F*0@8O=RW>1E(#>-V-\GN'^2\4UQ
MJ]T=SS(>%P_7C*Z8R WD^_><9]^?Y'?O57=KSO\#4$L#!!0    ( #N 6U@Z
MIWA\,P(  "@%   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;*U4T4[;
M,!3]%<M#$TA;G2;035T:J;1"XP&IHH,]3'MPDYO&PK$S7Z>!OY_MA*I(A?&P
ME\37ON?XGF-?IYTV#U@!6/)82X4S6EG;3!G#O(*:XT@WH-Q*J4W-K0O-EF%C
M@!<!5$L61]&$U5PHFJ5A;F6R5+=6"@4K0["M:VZ>+D'J;D;']'GB5FPKZR=8
MEC9\"VNP=\W*N(CM60I1@T*A%3%0SNA\/%TD/C\DW OH\&!,O)*-U@\^N"YF
M-/(%@83<>@;N?CM8@)2>R)7Q9^"D^RT]\'#\S'X5M#LM&XZPT/*G*&PUHU\I
M*:#DK;2WNOL.@YX+SY=KB>%+NB$WHB1OT>IZ +L*:J'Z/W\<?#@ C,]? <0#
M('XO(!D P3G65Q9D+;GE66IT1XS/=FQ^$+P):*=&*'^*:VO<JG XFUUQ8<@]
MERV0&^#8&G!'9)%\)O.B$-YI+LFUZJ^+]_UT"98+B6<NY6Z])*<G9^2$"$5^
M5+I%K@I,F76%>7J6#T5<]D7$KQ2QA'Q$DO$G$D=Q<@2^>#\\?@EGSHZ])_'>
MDSCP)?_V9"DPE]K;@N37?(/6N'OW^YC"GO+\.*7OQ2DV/(<9=<V&8'9 LX\?
MQI/HVS&]_XGLA?IDKSYYB[U7OPOJG5J%)1@D&[ =@"(2=B"/GG!/.@FD_NG8
M95'*=H>BWLKH*V4']]B_(3?<;(5"MVOI,-'HRP4EIN_+/K"Z"5=[HZUKE#"L
MW%,&QB>X]5)K^QSX;MD_CME?4$L#!!0    ( #N 6UAVG$6/>P8  *$I   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+U:;6_;-A#^*X17#!W0U.*+
MWKK$0)NL78$6"^JF^S#L@V+3L5!)="7::??K1\FN*(DOMA0E7Q)+/IZ>.QWO
MGCOS_)[E7XLUI1Q\3Y.LN)BL.=^\FDZ+Q9JF4?&2;6@FOEFQ/(VXN,SOIL4F
MI]&R6I0F4^0XWC2-XFPR.Z_N7>>S<[;E29S1ZQP4VS2-\A]O:,+N+R9P\O/&
MI_ANS<L;T]GY)KJC<\IO-M>YN)K66I9Q2K,B9AG(Z>IB\AJ^NB1!N:"2^!+3
M^Z+Q&92FW#+VM;QXO[R8."4BFM %+U5$XM^.7M(D*34)'-\.2B?U,\N%S<\_
MM;^MC!?&W$8%O63)W_&2KR\FP00LZ2K:)OP3N_^3'@QR2WT+EA357W!_D'4F
M8+$M.$L/BP6"-,[V_Z/O!T<T%D!B6( ."]"I"_!A :X,W2.KS+J*>#0[S]D]
MR$MIH:W\4/FF6BVLB;/R-<YY+KZ-Q3H^NXR*-?CCVS;>10G-> &B; D^1OE7
MRJ/;A((Y76SSF,>T &=@OG_7@*T,(L^OQ+TX*7X3PC?S*_#\V6_@&8@S\'G-
MMH5079Q/N4!=/GNZ."!\LT>(# BOZ.(EP/ %0 ["FN67IR]'[>53X:O:8:AV
M&*KT88.^N=A(RZTP^Z\5>+T3QE8^$"$%YE';&?]\$$O!>T[3XE^=V?OG$/US
MRNW[JMA$"WHQ$?NSH/F.3F:__@(]YW>=$T92UG()KEV";=KW,41E#+T KU.6
M\_@_N@27K. ZX_<:O4ICF6IV,^2ZGGB_NZ95JA1VH8-JJ19<4L,E/>&^RUE1
M@&TF\F!2H7XG\I\V5/>:W08@IP/9)M&"Z]9PW8?"_2"NJ1:O>Q2O*D'T>+T:
MK]<3[]LHSL&7*-E2'41/ :"+!%4*NTX8Z*'Z-53?"K61Q(IZWYX2O;Z*&3I^
M2#J@53'H!1[T]*B#&G4P!/4^*FY.".) A85A![HJ@_6HPQIU. IJ<RR'"J0S
MY/D=W!HA/S0X'#JR2#I#P-L#^Z"S$R6>&W0@:^2@YP?(X'#8*.W0BOHSXU$"
M%IW]6%7X=&CD'Q[9,@I[V.V^!YV<@WUHV+%0EE]H+64#C#I]8QP>;=\9&B'3
MFY(%%-HKZ A&F??-X=E'-HY.*G ,M0O*6@OMQ;:_94<VE5I?1?PAI+PEC9R#
MPH9<VR!9C:&]'']D&?UQH+_@[=9$::U*^I*[L;2U398%'7I/1'FAE3KT=LM(
MVMIND>0!VMG#$-H+-<Q!PW:T8M W,#,HF0.T4X>'4%^H4H(NE[2*M"%+V@#M
MO.%!]!>J=$#!;!-I=XB2+B [7>A+@9&&*6BB0BMFC HD>0*R\X0;, >?A3>+
MK>CMF[OY(TUO::YO7JTJ>W>O(VEK.Z#1TC]93S]N4_\873V2K 396<G@]@BI
M7 (2A,)N/&O$G"8S:>.6G /9.<>#&R2DD@?8S1L:&5/>D-P"'>$6#^9Z2&WG
MSU"W+=4)84./A"1+0/:^?U"/A-2^7D0*=+N(-6(.P@8RAV0)1_82_H[M:)ZE
M(D>#Z(YFBQ\-Z%JX5G6]M_=(VMK&2S* @J?*>E;6T=LM(VEKNT42#C1H4'%"
MUE.9A.?" '5C616#B(2&'A)+TH$'S2A.SWI80R^4@:PJ8\AZ6-(/;*<?#\]Z
M6!TVG(7=,8M.B(0&\)(Z8/LX8E#6P^H(042*TVW)-6(B4HB![^'&N/[(O)ZE
M*<T7L6C,KZ,-S;40K2KZ;NFQM+4-EH0 DR?*=-C*/'J[921M;;=(NH'[_K)P
MPN\VHPXVL,I$PA 99H184A'<]R>(T]M<N^K>!JK$Q90O)6G!?><./3IBN^[>
MYJES"E-VDK0$]YU1'$FFHY(/K(XP1$2:C)*D C\2J< :MN '87?<J1$C@><9
M"#*1I((\,JD@*F'H%F:-B&&/$,DIR&-S"J*A"TH3J!4*7 -Z22K((Y *HF$+
M?A!TFVZ-& F(;VC_B"05Y!BIR#<LCS@%;YAA*&[7T'>GCJ6M;6_C$,%3<0HR
M*J<82UO;+9)3D$$CC..)CJA4 $),PF[[I)$+?1B:]ISD#&30^*)'IE-+?:CD
M"\TQ!@-P20?(H$,,?5*=6L7/(.[.8'12+C+E#5GNR:#3#$=RW5ZGUPD6TNV@
M-'*AY_G= T33QOFY\O"BP'0GWC)(Z$JL<U[ZPNA\?QYP?\'9ICI2=\LX9VGU
M<4VC)<U+ ?']BC'^\Z(\I5>?RIS]#U!+ P04    "  [@%M8#]C^^LT"  #'
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6REE5%/VS 0Q[_**4,3
M2$#2A+:(M9$*91H/2(B.[6':@YM<$PO'#K;3PC[]SDX;.M'V92^M[?C^_MT_
MY\MHI?2S*1$MO%9"FG%06EM?A:')2JR8.5<U2GJR4+IBEJ:Z"$VMD>4^J!)A
M'$6#L&)<!NG(KSWH=*0:*[C$!PVFJ2JFWZY1J-4XZ 6;A4=>E-8MA.FH9@7.
MT#[5#YIF8:>2\PJEX4J"QL4XF/2NKH=NO]_P@^/*;(W!93)7ZME-[O)Q$#D@
M%)A9I\#H;XDW*(03(HR7M6;0'>D"M\<;]:\^=\IES@S>*/&3Y[8<!Y<!Y+A@
MC;"/:O4-U_GTG5ZFA/&_L%KOC0+(&F-5M0XF@HK+]I^]KGW8"HCC/0'Q.B#V
MW.U!GG+*+$M'6JU N]VDY@8^51]-<%RZES*SFIYRBK/I#3,EW+XT?,D$2FN
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MR:HP5QTM"EO;'H3&2FF;*;YE($T SB^%T+N.6:!Y':/?4$L#!!0    ( #N
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MY%HOKUU7I3D45%V()92X,A>RH!JG<N&JI02:65#!W<#S8K>@K'22@?TVD<E
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M8,I 7E]3*HXGZ@;M=&W^+U!+ P04    "  [@%M8"!3]:@L)  "]7P  &0
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MK6>R1%;J0VD!BJ;+DK:RI.9&LA+4+YNR$]>K)6/X8"TA:2Z4QJ T#TKSH;0
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M:1;@_$H(_=HQ!NK:.OX74$L#!!0    ( #N 6UAI<7$#( ,  ,H+   9
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MI@+D_HI2L9^H TK[[O\%4$L#!!0    ( #N 6UAV-HW7U@8  !(W   9
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;,V;77.C-A2&_XK&W>EL9[JVP1^)
MT\0SCD'3;3?;3+)I+SJ]4$"VF07D"CG9S.R/KP0*6$16S/1<Y"8Q6.>1X#T<
MI-=P_LCXUV)#J4#?LC0O+GH;(;9G@T$1;6A&BC[;TEQ^LV(\(T)N\O6@V')*
MXC(H2P?^<#@=9"3)>_/S<M\UGY^SG4B3G%YS5.RRC/"G2YJRQXN>UWO><9.L
M-T+M&,S/MV1-;ZFXVUYSN36H*7&2T;Q(6(XX75WT%MX9]F<JH&SQ9T(?B[W/
M2!W*/6-?U<;'^*(W5".B*8V$0A#Y[X$N:9HJDAS'OQK:J_M4@?N?G^FX/'AY
M,/>DH$N6_I7$8G/1.^VAF*[(+A4W[/%7J@]HHG@12XOR+WK4;8<]%.T*P3(=
M+$>0)7GUGWS3)V(OP)L>"/!U@-\.&!\(&.F T;$!8QTP/C9@H@,FQP9,=<"T
M//?5R2K/=$ $F9]S]HBX:BUIZD,I5QDM3W"2J\RZ%5Q^F\@X,9>*I.2><5+I
MG,?H4Q+)Q*%HL>:4RAP2!?J %G&<J!8D11_S*I]5^_<!%21)BY]DD[O; +U_
M]Q-ZAY(<725I*AL4YP,A!ZFZ&D1Z0)?5@/P# _)\=,5RL2E0F,<T-@$#>73U
M(?K/AWCI.XD!C?IHY/V,_*$_L@QH>7RX;PD/C@_W+.'A\>%#2SAVA_^V2P^%
M&^=R5*?+J.2-#_ 6422+ I?2FXE3)XM-<"=2E<ZS8DLB>M&3M;&@_('VYC_^
MX$V'O]C$@H0%D+ 0$H:!8(;(XUKD<4D?O5X3'F0=X)SD:UT)%K) ?&9Y=*@%
M^B(_%J2\:Q3H[T^2C#X*FA7_V!)C#)D8D+  $A9"PC 0S$B,29T8$^?5?T,?
M:+ZCUJKNC.RJ906;EC U-WJ8R]+YL"\09'<A) P#P0R!IK5 4Z=  5U1SFF,
MM%(VH:8OSNW0/+?+JH4WVF_2G[8$< ZDJP"0, P$,P0XJ04X>>4*2;+['2^J
M8GA-GLK_-S1*I""Q38Z3ER=[W)^U%'%VVK6V0<)"2!@&@AG*G=;*G?Z_F0WZ
M+G4L*.'11DUOJ9R:Y_92Z.RH:RF$A 60L! 2AH%@AO2S6OK9VYCOS" 3 Q(6
M0,)"2!@&@AF)X0V;U?'PE7JNK_A UN^4;4O-55+<$ED!C$Q89&Q7U7HJDR1&
M=UM5/:*-JOQE@S]63=VPKHN=0^F:'IHVV;NO^*U;.&B'(2@-0]%,W?=<$<^I
M^]43^YWP."'H"(/$*J:3WUE,2%H 2@M!:1B*9NKN-[K[;^-6H,<!E1^0M "4
M%H+2,!3-S(_&_O+<_M?GRD_?Y3&Y3RG:;5=RQBC05D_TN2[^5L5'+PJRUUYY
MN7OOK".HO05*PU T4\?&X?*</HG3R="AQI+,[Y^VI;*TFO1'[5LLJ)$$2L-0
M-%."QDORW&;2,5Z%&]&Y2DYLQL:L+5G5:K;7:-1O39U"T(%A*)JI1&,:>4>Z
M1KQ2 D4[N2G+F9KMY"S_H+>M"D%:-TO/:CV]4 C4>P*E82B:*65C/WG0_I-G
M,:!.VOF^='?;^<9DZ7/2=AA#T#XQ%,T4IG&7/+>]=)??)VDJK[%%%*EU8J$7
MBN4TXH:F1,COOC#T+*#>KU>?:NZYOP)=LL)^-9[:KI])6TQKJQ>K0U"S")2&
MH6BFF(U?Y#E=A_F=.>VS*@'J]8#2 E!:"$K#FF;\]-/,DLW?_QL7QW>[.,]U
M<,4XDH/8DD3=Z_2UI2;S2;ZVB:BQK9E@^W+2K6:N1H%[A%W/.2@-OW:8YEEO
M/!3?[:%<'SC31ZV6W.RNUP\H+0"EA9KF3!\,U:4I96.+^,YE=3<[#'U'5^1;
MDNTRJ["@Q@<H+0"EA: T#$4S,Z Q/OS1VS#&?-"GA4!I 2@M!*5A*)J9'XVA
MXKL-E?J7C;JZJYMM1+D@28Z26.Y)5HF<XPK"UU18C1=W%YVE!WT@")06@M*P
M;S.L9J<'[^"-1>.[+1JWJ$QL*#]66E C!Y06@-)"4!KV+4]"30[-AQO#QW<;
M/EUOYTL)2"*2E@UNZ'HGEZN,/[WR&(1[$)TUAZ0%H+00E(:A:&9R-!:2?_)&
M[O20_LX2E!: TD)0&H:BF?G1.%G^*P]*K65E6!-!$:F>>."-D56^*M(\\<!6
M*',]\>!;C"C+^AKT$:BC^@Q!^\10-%.QQJ[RW795EX=8:G&-QUE*<3L_T**'
MY5S9+MUC[ZSN$5V&H%UB*%HE[F#O59Z,ROF4>NFJ0*5G7+WR4N^M7^Q:E*\S
MM?9?>F=!]7I6@ZG>%KN2T[1$UN>4KB1RV#^1<PQ>O8!5;0BV+5\8NF="L*S\
MN*$DIEPUD-^O&!//&ZJ#^C6X^7]02P,$%     @ .X!;6&P+5>6]!   B!T
M !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULS5G;;N,V$/T50ET4NT :
M77S=U#;@6-TV[1H-XJ9]6/2!EL86L9*H)2D["_3C2TJ*+K'"C5$6B!]LB>(<
MSIPA1SSF[$C99QX!"/20Q"F?6Y$0V95M\R""!/-+FD$JG^PH2["0MVQO\XP!
M#@NC)+8]QQG;"2:IM9@5;;=L,:.YB$D*MPSQ/$DP^WH-,3W.+==Z;+@C^TBH
M!GLQR_ >-B#NLULF[^P:)20)I)S0%#'8S:VE>^5[A4'1XT\"1]ZZ1BJ4+:6?
MU<U-.+<<Y1'$$ @%@>7/ 580QPI)^O&E K7J,95A^_H1_4,1O QFBSFL:/P7
M"44TMZ86"F&'\UC<T>,O4 4T4G@!C7GQC8Y57\="0<X%32ICZ4%"TO(7/U1$
MM S<\3,&7F7@/348/F,PJ P&+S485@;#@IDRE((''PN\F#%Z1$SUEFCJHB"S
ML);ADU3E?2.8?$JDG5A\)(%,(J#EG@'(? J.?D#+,"0J*SA&-VDYMU2.WOH@
M,(GY.]GE?N.CMV_>H3?(1CS"##@B*;I/B> 7LE%>KTD<2RL^LX7T4XUF!Y5/
MUZ5/WC,^N1Y:TU1$'/V4AA!V 6P98!VE]QCEM:=%]"&X1 /W GF.-^AQ:*4W
M_Q6G6G-?;[[,][6YIXEF4.=L4. -GL&[ PZ8!1%:IB'RX2 7;Z92AY:<@TS@
M,OB2$P8A^EU$P- ?$4[E%Z/Y/D+7.9=HG*,53;8D+1/[Z:-L0S<"$OYW7[I*
M=X;][JC*=,4S',#<DJ6' SN M?C^.W?L_-A'M4DPWQ!8)PW#.@U#'?IB4TU[
MSG,(+U#&Y%)"F22\6 ]]/&KQSN6Q!!L78*JZ'Q:NG)N'-CMEEVFKR^1RZM6=
M.E&/ZJA'VJA_WOS6%(N^(+7FYP9I$LPW!-:A;5S3-GY=:W9L,@TFP7Q#8)TT
M3.HT3/1K-H. [(CD.9"/2"#?<%@FA,$^C[&@[*M\Q\8@W[J2[SY6)R>+;M1=
M<ROM^.=290BL0]6TIFIJC"J417+OA<21-IT%(SCNX[ <UAVT2/0NG]*H]>U<
M&@V!=6A\7]/X_N7U$OV#UOB!)'G21XP6Z-PE:Q+,-P36(=!UFBVJ\[IJ9^6/
MH4P81?--H75ST9(+[O]:0"OXSNH?3$Z6O]Z+LSDSA-;ES&LX\U[(&<>2FX:A
M7H)*K%&+G['SE!WM>&>S8PBMRTXC9ESM)GVQ6JYOAZT2^6D-R198_\(TJD2,
MHOFFT+HT-F+$';ZR(FE4S1A%\TVA=7/12"17KY'^<Y$<G=2 P4F%-"J-3*%U
M"6O$D:O=]#]; _3[)3WHV3/0J,@QA=8EM)$Y[N2550.3NF=E%,TWA=;-1:.C
M7'-"JI?:Z8GH/*T&1O62*;0N88UB<O62:0.,R&W2M9R Z0&8(-L8T"V#'3 U
M93>"!I]E9?CF/U'Z8<Z>DT85E2FT[M_AC:3R7IFD\HQ**J-HOBFT;BX:2>5]
M0U*U_T=&.\H05DE 6.6 %P<QO8RZ)YL$UQLYZO.D..C'/YLMHV+*;AU=)<#V
MQ1$@1P'-4U&>8M6M]3'CLCA<LYONY1GE&K,]23F*82=-G<N)I(:5QW[EC:!9
M<1"VI4+0I+B, (? 5 ?Y?$>I>+Q1 ]2'KXM_ 5!+ P04    "  [@%M8"$F9
MU5(#  "E"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6RU5F%OVC 0
M_2M6-DV=M#:Q(0GM *E=-6U2)Z'2;A^J?3#) =8<.[,=*/]^=@*!C21M)_4+
MV(G?O7=G[G'#M52_]!+ H,>,"SWREL;D%[ZODR5D5)_)'(1],Y<JH\9NU<+7
MN0*:EJ",^R0((C^C3'CC8?ELHL9#61C.!$P4TD664;6Y B[7(P][NP>W;+$T
M[H$_'N9T 5,P]_E$V9U?1TE9!D(S*9""^<B[Q!=7.': \L1W!FM]L$8NE9F4
MO]SF:SKR J<(."3&A:#V:P6?@',7R>KXO0WJU9P.>+C>1?]<)F^3F5$-GR3_
MP5*S''D##Z4PIP4WMW+]!;8)A2Y>(KDN/]%Z>S;P4%)H([,MV"K(F*B^Z>.V
M$ < 0EH 9 L@I>Z*J%1Y30T=#Y5<(^5.VVAN4:9:HJTX)MRM3(VR;YG%F?$-
MV)0T.D53>]]IP0').?I<F$*!HV-9D2'NSJ"<;NQM&(U.KL%0QO5[B[I,$ED(
MP\0"30T5*56I1O=Y2@T@$N#H-"#HX1MD,U _T5O$!+I;RD+;DWKH&ZO?J?"3
MK=:K2BMIT7H-R1GJX0\V,NFA^^DU.GG[_N\PODV_K@&I:T#*N/V6N"1"-TY1
M*M<";![*=<-.=9/,SG"NCRYT3A,8>;91-*@5>.-W;W 4?.P0VZO%]LKHO1:Q
MM\!M<5,TH<ILT)VB0M/J!_YP8X^BKP8RW:BZ]PJJ^[7J?G>) ])OTE2AHA+E
M#&0U)F%,AOZJ@2NLN<*GN,(FK@H5'G)%_?-FKJCFBI[BBIJXHF.NF+1PQ357
M_!17W,05'W,-,&[F&M1<@TZNNR58CY\;4$V,@R-&W'=U:&(\KQG/NQFEH;S%
M<IHTG!]K('@0-XO P=X.@TX9-Z#U!6)97K@F8\)6 +1I]*K@2,$I#N.P1<&!
M(>-G%*(J &=TQC@SFT8!^+@$081;N@?OW1!WVR$F(9JR5,#F.5[8'>P_;07O
MW1"_EAWBU_!#O#=$_'^.N(7]U<XX:+G3O27B;D]\:7?A!K-L5;$W2]SMEB]H
MKF,#/6VQ-+SW3]QMH,_OK/CX;RGXU[W]@Z'+#;#?J%HPH6W\N44%9[$5KZJ9
ML-H8F9=SV$P:.]65RZ6=HT&Y _;]7$JSV[C1KI[,QW\ 4$L#!!0    ( #N
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M,_.EW,R"B;_9!^:J<4!AU%(8.2E<089[ZHT4"4"*(=4Y2*?%L8/LTRSNR>P
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M%$_STSFCH.?U /A]RKEZOM 35%MSXQ]02P,$%     @ .X!;6""*S6*1 @
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MM"O _852=A>X%W0?K/PW4$L#!!0    ( #N 6UB)D'F\9P(  -P%   9
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M"^S[5E]:6>Z^6MQ]<7GR'U!+ P04    "  [@%M8)V75I0P"  "$)0  &@
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M#?]VFKT!4$L! A0#%     @ .X!;6 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  [@%M8G<*'1>X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ .X!;6!#:L<3A @
MWPD  !@              ("!8Q<  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( #N 6UAI:@&[O 0  +H2   8              " @7H:
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  [@%M8HH8D
MJF8&  "@*P  &               @(%L'P  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ .X!;6(@R(I+M!@  VQX  !@
M ("!""8  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #N
M6UB=I*0M\P@  /05   8              " @2LM  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  [@%M8EZ0_5"<E  #F>   &
M        @(%4-@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
M  @ .X!;6!XFW4+# P  A0D  !@              ("!L5L  'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #N 6UB;Q;,JZ00  "4-   9
M              " @:I?  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L!
M A0#%     @ .X!;6'!QNU\B P  ] 8  !D              ("!RF0  'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  [@%M8H7O.]"H#
M  !:!P  &0              @($C:   >&PO=V]R:W-H965T<R]S:&5E=#$R
M+GAM;%!+ 0(4 Q0    ( #N 6UBJ<IEU> (  )4%   9              "
M@81K  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ .X!;
M6/1X+3G@ P  $0D  !D              ("!,VX  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  [@%M8!Q1SS=0*  "A(P  &0
M        @(%*<@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( #N 6U@BB8"W>A   #X]   9              " @55]  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ .X!;6'70.,VW"0  <!L
M !D              ("!!HX  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  [@%M8WRTJA;<%  "7$   &0              @('TEP
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #N 6U@N>=O^
M2P<   81   9              " @>*=  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ .X!;6$*T=J'M"@  @"   !D
M ("!9*4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  [
M@%M8A'C)O2,#   $!P  &0              @(&(L   >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #N 6UC:6+ZHU0(   D&   9
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M970R-BYX;6Q02P$"% ,4    "  [@%M8H+&FG?4"  !S!@  &0
M    @('6Z   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M #N 6U@<I;1<60,  !H(   9              " @0+L  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ .X!;6!Z?K_$P P  10<  !D
M             ("!DN\  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    "  [@%M8?JY#<P0%  "Y#   &0              @('Y\@  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #N 6UA0'FE,?0,
M ($*   9              " @33X  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ .X!;6)P2"9")!   E0H  !D              ("!
MZ/L  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  [@%M8
M&8F\"@X#  !H!@  &0              @(&H  $ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( #N 6UA'!,Z0E@,  $H-   9
M      " @>T# 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ .X!;6!&ND==# P  S@T  !D              ("!N@<! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  [@%M8SVD8(Y<"  "$!@
M&0              @($T"P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( #N 6U@*$4B0P 8  +DY   9              " @0(. 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ .X!;6#JG>'PS
M @  * 4  !D              ("!^10! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    "  [@%M8=IQ%CWL&  "A*0  &0
M@(%C%P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( #N
M6U@/V/[ZS0(  ,<&   9              " @14> 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ .X!;6)C-L5@.!   ?18  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( #N 6UA\^$MV,P,  (0)   9
M  " @?XQ 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M.X!;6/SCQQ@)!   :1,  !D              ("!:#4! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    "  [@%M8"!3]:@L)  "]7P  &0
M            @(&H.0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( #N 6UBVH-)XBP0  +03   9              " @>I" 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ .X!;6-<RE=<8 P
M=@@  !D              ("!K$<! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    "  [@%M861$)KHT#  !G"P  &0              @('[
M2@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( #N 6UAI
M<7$#( ,  ,H+   9              " @;]. 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ .X!;6'8VC=?6!@  $C<  !D
M     ("!%E(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #N 6UBL%S6YR0,  *$,   9              "
M@8AJ 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ .X!;
M6/$/P='. P  )@T  !D              ("!B&X! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    "  [@%M8-;Z'F?@$  "F&P  &0
M        @(&-<@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( #N 6U@@BLUBD0(  +P&   9              " @;QW 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ .X!;6(F0>;QG @  W 4
M !D              ("!A'H! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    "  [@%M8WSJ?E%D#  "G#   &0              @($B?0$
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( #N 6U@:G7\[
M2 ,  ,H4   -              "  ;*  0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ .X!;6)>*NQS     $P(   L              ( !)80! %]R96QS
M+RYR96QS4$L! A0#%     @ .X!;6/1[LZGO!   ]2D   \
M ( !#H4! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #N 6U@G9=6E# (
M (0E   :              "  2J* 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( #N 6UCNU>T8Y@$  /4D   3              "
M 6Z, 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< :!,  (6. 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>170</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Additional Balance Sheet Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetail</Role>
      <ShortName>Additional Balance Sheet Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense</Role>
      <ShortName>Stock-based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreements1</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeases1</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Additional Balance Sheet Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailTables</Role>
      <ShortName>Additional Balance Sheet Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetail</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables</Role>
      <ShortName>Stock-based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeases1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of the Estimated Useful Life of Related Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of the Estimated Useful Life of Related Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Additional Balance Sheet Detail - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Additional Balance Sheet Detail - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Additional Balance Sheet Detail - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Additional Balance Sheet Detail - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Common Stock - Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails</Role>
      <ShortName>Common Stock - Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stock-based Compensation Expense - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation Expense - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stock-based Compensation Expense - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation Expense - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-based Compensation Expense - Summary of Weighted Average Assumptions Used to Calculate Fair Value of Stock Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails</Role>
      <ShortName>Stock-based Compensation Expense - Summary of Weighted Average Assumptions Used to Calculate Fair Value of Stock Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-based Compensation Expense - Summary of Restricted Stock Activity outside of 2019 and 2016 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails</Role>
      <ShortName>Stock-based Compensation Expense - Summary of Restricted Stock Activity outside of 2019 and 2016 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-based Compensation Expense - Summary of Stock-Based Compensation Expense Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails</Role>
      <ShortName>Stock-based Compensation Expense - Summary of Stock-Based Compensation Expense Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100600 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Leases - Schedule of Future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Leases (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Restructuring Activities - Schedule of Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails</Role>
      <ShortName>Restructuring Activities - Schedule of Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="fulc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="fulc-20231231.htm">fulc-20231231.htm</File>
    <File>fulc-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img44875045_0.jpg</File>
    <File>img44875045_1.jpg</File>
    <File>img44875045_10.jpg</File>
    <File>img44875045_11.jpg</File>
    <File>img44875045_12.jpg</File>
    <File>img44875045_13.jpg</File>
    <File>img44875045_2.jpg</File>
    <File>img44875045_3.jpg</File>
    <File>img44875045_4.jpg</File>
    <File>img44875045_5.jpg</File>
    <File>img44875045_6.jpg</File>
    <File>img44875045_7.jpg</File>
    <File>img44875045_8.jpg</File>
    <File>img44875045_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="535">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fulc-20231231.htm": {
   "nsprefix": "fulc",
   "nsuri": "http://www.fulcrumtx.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "fulc-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "fulc-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 259,
   "keyCustom": 59,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 21,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2023": 7,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 170,
   "entityCount": 1,
   "segmentCount": 54,
   "elementCount": 604,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 535,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_57f214bc-60d6-4c5d-b206-28aa46d3644a",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57f214bc-60d6-4c5d-b206-28aa46d3644a",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation",
     "longName": "100070 - Disclosure - Nature of the Business and Basis of Presentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100090 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1",
     "longName": "100100 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "100110 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetail",
     "longName": "100120 - Disclosure - Additional Balance Sheet Detail",
     "shortName": "Additional Balance Sheet Detail",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStock",
     "longName": "100130 - Disclosure - Preferred Stock",
     "shortName": "Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "100140 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense",
     "longName": "100150 - Disclosure - Stock-based Compensation Expense",
     "shortName": "Stock-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements",
     "longName": "100160 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreements1",
     "longName": "100170 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "fulc:AssetAcquisitionDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "fulc:AssetAcquisitionDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeases1",
     "longName": "100180 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100190 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100200 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan",
     "longName": "100210 - Disclosure - Defined Contribution Plan",
     "shortName": "Defined Contribution Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "100230 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "fulc:EstimatedUsefulLifeOfAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "fulc:EstimatedUsefulLifeOfAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "100270 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables",
     "longName": "100280 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "100290 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailTables",
     "longName": "100300 - Disclosure - Additional Balance Sheet Detail (Tables)",
     "shortName": "Additional Balance Sheet Detail (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "fulc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "fulc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables",
     "longName": "100310 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables",
     "longName": "100320 - Disclosure - Stock-based Compensation Expense (Tables)",
     "shortName": "Stock-based Compensation Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables",
     "longName": "100330 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_307f7d91-6fab-4f2c-b389-665c233bce30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_307f7d91-6fab-4f2c-b389-665c233bce30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "100350 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "100370 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "100380 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_1b2a8270-a42f-4a33-8218-0bc08d831c80",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b2a8270-a42f-4a33-8218-0bc08d831c80",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails",
     "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of the Estimated Useful Life of Related Asset (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of the Estimated Useful Life of Related Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails",
     "longName": "100410 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_542d5873-acb9-4a0a-8e2d-dac0c67b8056",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "100420 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:FairValueTransfersBetweenLevels",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:FairValueTransfersBetweenLevels",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
     "longName": "100430 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Marketable Securities (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Summary of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:CashAndCashEquivalentsAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:CashAndCashEquivalentsAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
     "longName": "100440 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "100460 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "100470 - Disclosure - Additional Balance Sheet Detail - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Additional Balance Sheet Detail - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:PrepaidExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fulc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:PrepaidExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fulc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "100480 - Disclosure - Additional Balance Sheet Detail - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Additional Balance Sheet Detail - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fulc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "fulc:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fulc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
     "longName": "100500 - Disclosure - Preferred Stock - Additional Information (Details)",
     "shortName": "Preferred Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f3a948e1-3f74-4748-b84d-2b0696114a7f",
      "name": "fulc:TemporaryEquityDividendsDeclared",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "fulc:TemporaryEquityDividendsDeclared",
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "longName": "100510 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
     "longName": "100520 - Disclosure - Common Stock - Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock (Details)",
     "shortName": "Common Stock - Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_909e565e-556f-4785-a3a2-94aa703eda4a",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
     "longName": "100530 - Disclosure - Stock-based Compensation Expense - Additional Information (Details)",
     "shortName": "Stock-based Compensation Expense - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails",
     "longName": "100550 - Disclosure - Stock-based Compensation Expense - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation Expense - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_84b31042-326d-4a8d-bb3a-1fab245f12f7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_830548a4-6251-494e-acc6-0972515e7069",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails",
     "longName": "100560 - Disclosure - Stock-based Compensation Expense - Summary of Weighted Average Assumptions Used to Calculate Fair Value of Stock Option (Details)",
     "shortName": "Stock-based Compensation Expense - Summary of Weighted Average Assumptions Used to Calculate Fair Value of Stock Option (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_fb5c742b-1082-4c9f-adea-cdf8661b486d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fb5c742b-1082-4c9f-adea-cdf8661b486d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
     "longName": "100570 - Disclosure - Stock-based Compensation Expense - Summary of Restricted Stock Activity outside of 2019 and 2016 Plan (Details)",
     "shortName": "Stock-based Compensation Expense - Summary of Restricted Stock Activity outside of 2019 and 2016 Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_04824925-8561-4f56-bff5-d30316c83058",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04824925-8561-4f56-bff5-d30316c83058",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails",
     "longName": "100580 - Disclosure - Stock-based Compensation Expense - Summary of Stock-Based Compensation Expense Recognized (Details)",
     "shortName": "Stock-based Compensation Expense - Summary of Stock-Based Compensation Expense Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f962abd-0c59-46b0-942a-62bedb1c8907",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "longName": "100590 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_e9320667-4317-4880-b542-adec903ee354",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9320667-4317-4880-b542-adec903ee354",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "longName": "100600 - Disclosure - License Agreements - Additional Information (Details)",
     "shortName": "License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_3ce307f7-639d-48f2-8416-d63934e3040e",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_91aa4910-0766-4281-855f-db89fadd437e",
      "name": "fulc:ClinicalAndRegulatoryMilestonePayables",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "fulc:AssetAcquisitionDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
     "longName": "100610 - Disclosure - Leases - Schedule of Future minimum lease payments (Details)",
     "shortName": "Leases - Schedule of Future minimum lease payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_e746306c-e757-4570-81a1-01d41ff4c7c1",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e746306c-e757-4570-81a1-01d41ff4c7c1",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "100630 - Disclosure - Leases (Additional Information) (Details)",
     "shortName": "Leases (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:VariableLeasePayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:VariableLeasePayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "100640 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_22c69f38-8bae-4283-a815-fd207b1f78a2",
      "name": "us-gaap:LossContingencyLossInPeriod",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_22c69f38-8bae-4283-a815-fd207b1f78a2",
      "name": "us-gaap:LossContingencyLossInPeriod",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails",
     "longName": "100670 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "100680 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "100690 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "longName": "100700 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "fulc:DefinedContributionPlanName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "fulc:DefinedContributionPlanName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails",
     "longName": "100710 - Disclosure - Restructuring Activities - Schedule of Restructuring Charges (Details)",
     "shortName": "Restructuring Activities - Schedule of Restructuring Charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "100730 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fulc-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update 2016-02 [Member]",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_AccountsAndNotesReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsAndNotesReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts and Financing Receivable, after Allowance for Credit Loss, Total",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts and Financing Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r903"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r775"
     ]
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r252",
      "r253",
      "r753"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net (accretion of discounts) amortization of premiums on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "fulc_AccruedLiabilitiesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities and other current liabilities.",
        "label": "Accrued Liabilities And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "fulc_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "fulc_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "fulc_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "External research and development"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_AccruedRestrictedStockLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AccruedRestrictedStockLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "fulc_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued restricted stock liability, current.",
        "label": "Accrued Restricted Stock Liability Current",
        "terseLabel": "Restricted stock liability, current portion"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_AccruedRestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AccruedRestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Restructuring Charges",
        "label": "Accrued Restructuring Charges",
        "periodStartLabel": "Accrued restructuring charges Beginning",
        "periodEndLabel": "Accrued restructuring charges Ending"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r167",
      "r608"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r95",
      "r174",
      "r604",
      "r624",
      "r628"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r31",
      "r477",
      "r480",
      "r537",
      "r619",
      "r620",
      "r820",
      "r821",
      "r822",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_AcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquisitionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Costs, Period Cost",
        "terseLabel": "Direct expenses related to the transaction",
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r644",
      "r827",
      "r828",
      "r829",
      "r884",
      "r906"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r202",
      "r203",
      "r204",
      "r205",
      "r214",
      "r254",
      "r255",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r309",
      "r427",
      "r428",
      "r429",
      "r452",
      "r453",
      "r454",
      "r455",
      "r461",
      "r462",
      "r463",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r577",
      "r578",
      "r579",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r391"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate fair value of securities, Remaining contractual maturity of greater than one year",
        "documentation": "Aggregate fair value of securities, Remaining contractual maturity of greater than one year",
        "terseLabel": "Aggregate fair value of securities"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_AggregateRestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AggregateRestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Restructuring Charges",
        "label": "Aggregate Restructuring Charges",
        "terseLabel": "Aggregate Restructuring Charges"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from calculation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "fulc_AreaOfPropertiesHeldUnderOperatingLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AreaOfPropertiesHeldUnderOperatingLeases",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of properties held under operating leases.",
        "label": "Area Of Properties Held Under Operating Leases",
        "terseLabel": "Square feet of office and laboratory space leased under operating lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "fulc_Asc840Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "Asc840Member",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASC 840 [Member]",
        "documentation": "ASC 840 member.",
        "label": "ASC 840 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_AssetAcquisitionDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AssetAcquisitionDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreements1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreements",
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Asset Impairment Charges, Total",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment losses on long-lived assets",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r50"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r169",
      "r196",
      "r231",
      "r242",
      "r246",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r466",
      "r470",
      "r506",
      "r599",
      "r681",
      "r775",
      "r787",
      "r847",
      "r848",
      "r893"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r176",
      "r196",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r466",
      "r470",
      "r506",
      "r775",
      "r847",
      "r848",
      "r893"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "fulc_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ATM Offering",
        "documentation": "At-The-Market Offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-The-Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable securities, Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Marketable securities, Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Marketable securities, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r303",
      "r598"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r303",
      "r592",
      "r833"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_Camp4AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "Camp4AgreementMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAMP4 Agreement [Member]",
        "documentation": "CAMP4 Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases unpaid at end of period",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "fulc_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Lease Obligations, Current",
        "terseLabel": "Capital lease obligation, current portion",
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r142",
      "r143"
     ]
    },
    "fulc_CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CapitalLeasesFutureMinimumPaymentsDueAfterYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due after the second fiscal year, December 31, 2021.",
        "label": "Capital Leases Future Minimum Payments Due After Year Two",
        "terseLabel": "Future minimum lease payments, after 2021"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Leases, Future Minimum Payments Due, Next 12 Months",
        "terseLabel": "Future minimum lease payments, 2020",
        "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Leases, Future Minimum Payments Due in Two Years",
        "terseLabel": "Future minimum lease payments, 2021",
        "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized gains before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Gains Before Tax",
        "terseLabel": "Cash equivalents, Gross unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized losses before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Losses Before Tax",
        "negatedLabel": "Cash equivalents, Gross unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CashAndCashEquivalentsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CashAndCashEquivalentsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents amortized cost.",
        "label": "Cash And Cash Equivalents Amortized Cost",
        "totalLabel": "Cash equivalents, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r165",
      "r752"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "fulc_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Cash equivalents, Fair Value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r126"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r100",
      "r193"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r100"
     ]
    },
    "fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities accumulated gross unrealized gains before tax.",
        "label": "Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Gains Before Tax",
        "terseLabel": "Total cash equivalents and marketable securities, Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities accumulated gross unrealized gains before tax.",
        "label": "Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total cash equivalents and marketable securities, Gross Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities amortized cost basis.",
        "label": "Cash Equivalents And Marketable Securities Amortized Cost Basis",
        "totalLabel": "Total cash equivalents and marketable securities, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CashEquivalentsAndMarketableSecuritiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CashEquivalentsAndMarketableSecuritiesFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "fulc_CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities fair value disclosure.",
        "label": "Cash Equivalents And Marketable Securities Fair Value Disclosure",
        "verboseLabel": "Total cash equivalents and marketable securities, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CashPaidForOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CashPaidForOperatingLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for operating lease liabilities",
        "label": "Cash paid for operating lease liabilities",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ChangeInVariableConsiderationConstrained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ChangeInVariableConsiderationConstrained",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in variable consideration constrained",
        "label": "Change In Variable Consideration Constrained",
        "documentation": "Change in variable consideration constrained."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r170",
      "r171",
      "r172",
      "r196",
      "r218",
      "r219",
      "r221",
      "r223",
      "r229",
      "r230",
      "r287",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r342",
      "r343",
      "r346",
      "r349",
      "r357",
      "r506",
      "r634",
      "r635",
      "r636",
      "r637",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r669",
      "r690",
      "r712",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r800",
      "r825",
      "r830"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r229",
      "r342",
      "r343",
      "r344",
      "r346",
      "r349",
      "r355",
      "r357",
      "r634",
      "r635",
      "r636",
      "r637",
      "r765",
      "r800",
      "r825"
     ]
    },
    "fulc_ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ClinicalAndRegulatoryMilestoneDueUponInitiationOfPhaseTwoClinicalTrialAchievedAndPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestone due upon initiation of phase two clinical trial achieved and paid.",
        "label": "Clinical And Regulatory Milestone Due Upon Initiation Of Phase Two Clinical Trial Achieved And Paid",
        "terseLabel": "Clinical and regulatory milestone due upon phase two clinical trial achieved and paid"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ClinicalAndRegulatoryMilestonePayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ClinicalAndRegulatoryMilestonePayables",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestone payables.",
        "label": "Clinical And Regulatory Milestone Payables",
        "terseLabel": "Specified clinical and regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specified clinical and regulatory milestones phase two clinical trial",
        "label": "Clinical And Regulatory Milestone Payables Upon Phase Two Clinical Trial",
        "documentation": "Clinical and regulatory milestone payables upon phase two clinical trial."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ClinicalAndRegulatoryMilestonesDueUponInitiationOfPhaseTwoClinicalTrialRecordedAsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestones due upon initiation of phase two clinical trial recorded as expense.",
        "label": "Clinical And Regulatory Milestones Due Upon Initiation Of Phase Two Clinical Trial Recorded As Expense",
        "terseLabel": "Clinical and regulatory milestones due upon phase two clinical trial recorded as expense"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ClinicalAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ClinicalAndRegulatoryMilestonesMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestones.",
        "label": "Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ClinicalAndRegulatoryMilestonesPayableUponInitiationOfPhaseTwoClinicalTrial",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestones payable upon initiation of phase two clinical trial",
        "label": "Clinical And Regulatory Milestones Payable Upon Initiation Of Phase Two Clinical Trial",
        "terseLabel": "Specified clinical and regulatory milestones due upon phase two clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ClinicalProgram": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ClinicalProgram",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical program",
        "label": "Clinical program",
        "terseLabel": "Clinical program | Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r155"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Acceleron Collaboration Agreement",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "fulc_CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for commitment for office and laboratory space lease of current corporate headquarters.",
        "label": "Commitment For Office And Laboratory Space Lease Of Current Corporate Headquarters [Member]",
        "terseLabel": "Commitment for Office and Laboratory Space Lease of Current Corporate Headquarters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r80",
      "r600",
      "r668"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r321",
      "r322",
      "r737",
      "r842"
     ]
    },
    "fulc_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance",
        "verboseLabel": "Shares reserved for future issuance under the 2022 Inducement Stock Incentive Plan",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r827",
      "r828",
      "r884",
      "r905",
      "r906"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r669"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r89",
      "r669",
      "r687",
      "r906",
      "r907"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized; 61,915,367 and 52,099,211 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r602",
      "r775"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r181",
      "r183",
      "r189",
      "r594",
      "r614"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r755"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Process",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ConsultingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ConsultingServicesMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting services.",
        "label": "Consulting Services [Member]",
        "terseLabel": "Consulting Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r346",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of preferred stock converted into common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r60",
      "r88",
      "r114",
      "r352"
     ]
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Terms",
        "terseLabel": "Convertible preferred stock, terms of conversion",
        "documentation": "Description of conversion terms for preferred stock."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r60",
      "r63",
      "r88",
      "r113",
      "r115"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CorporateBondsMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Bonds",
        "label": "Corporate Bonds [Member]",
        "documentation": "Corporate bonds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Restructuring Expenses",
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r108",
      "r109"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_CumulativeCatchUpAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "CumulativeCatchUpAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative catch-up adjustment",
        "label": "Cumulative Catch Up Adjustment",
        "terseLabel": "Cumulative Catch-Up Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Aggregate fair value of securities, unrealized loss position for more than 12 months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r305",
      "r762"
     ]
    },
    "fulc_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Greater than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Greater than 12 Months",
        "terseLabel": "Debt Securities, Available-for-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Aggregate fair value of securities, unrealized loss position for less than 12 months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r305",
      "r762"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Deferred tax liability",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r128",
      "r446"
     ]
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRentCreditNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, excluding current portion",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r813",
      "r890"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue",
        "totalLabel": "Deferred Revenue, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Current, Total",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "fulc_DeferredRevenueCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "DeferredRevenueCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue current and noncurrent.",
        "label": "Deferred Revenue Current And Noncurrent",
        "terseLabel": "Deferred revenue current and non-current"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research And Development Costs",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "fulc_DeferredTaxAssetsLeaseIncentive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "DeferredTaxAssetsLeaseIncentive",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease incentive.",
        "label": "Deferred Tax Assets Lease Incentive",
        "terseLabel": "Deferred lease incentive"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "fulc_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating lease liability",
        "label": "Deferred Tax Assets, Operating lease liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r882"
     ]
    },
    "fulc_DeferredTaxAssetsOrphanDrugCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "DeferredTaxAssetsOrphanDrugCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets orphan drug credit carryforwards.",
        "label": "Deferred Tax Assets Orphan Drug Credit Carryforwards",
        "terseLabel": "Orphan drug credit carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent",
        "terseLabel": "Deferred rent",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_DefinedContributionPlanName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "DefinedContributionPlanName",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan Name",
        "label": "Defined Contribution Plan Name",
        "terseLabel": "Defined contribution plan name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r51"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation Expense",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r393",
      "r423",
      "r424",
      "r426",
      "r771"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Total",
        "label": "Dividends",
        "verboseLabel": "Dividends declared or paid",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r116"
     ]
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Common Stock, Total",
        "label": "Dividends, Common Stock",
        "terseLabel": "Common stock dividends declared",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r116"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794",
      "r796"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r216",
      "r218",
      "r221",
      "r222",
      "r223",
      "r227",
      "r494",
      "r495",
      "r595",
      "r615",
      "r757"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r218",
      "r221",
      "r222",
      "r223",
      "r227",
      "r494",
      "r495",
      "r595",
      "r615",
      "r757"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r224",
      "r225",
      "r226"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r440",
      "r457"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r883"
     ]
    },
    "fulc_EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation federal orphan drug credits.",
        "label": "Effective Income Tax Rate Reconciliation Federal Orphan Drug Credits",
        "terseLabel": "Federal orphan drug credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r883"
     ]
    },
    "fulc_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officers' compensation",
        "label": "Effective Income Tax Rate Reconciliation Officers Compensation Percent",
        "documentation": "Effective income tax rate reconciliation officers compensation percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent, Total",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationOwnershipChangePercent",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, ownership change, percent.",
        "label": "Effective Income Tax Rate Reconciliation, Ownership Change, Percent",
        "terseLabel": "Impact of ownership change"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r883"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal and state research and development credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r883"
     ]
    },
    "fulc_EmergingGrowthCompanyPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "EmergingGrowthCompanyPolicyPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company policy.",
        "label": "Emerging Growth Company Policy Policy [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "fulc_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation expense, weighted average period expect to recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Outstanding Stock Options",
        "verboseLabel": "Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r159",
      "r185",
      "r186",
      "r187",
      "r198",
      "r199",
      "r200",
      "r203",
      "r211",
      "r213",
      "r228",
      "r291",
      "r297",
      "r358",
      "r427",
      "r428",
      "r429",
      "r454",
      "r455",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r493",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r537",
      "r619",
      "r620",
      "r621",
      "r644",
      "r712"
     ]
    },
    "fulc_EstimatedUsefulLifeOfAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "EstimatedUsefulLifeOfAssetTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated useful life of asset.",
        "label": "Estimated Useful Life Of Asset Table [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Life of Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r502"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r502"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r123"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r499",
      "r548",
      "r549",
      "r550",
      "r763",
      "r764",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r500",
      "r501",
      "r503"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r372",
      "r377",
      "r499",
      "r548",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r372",
      "r377",
      "r499",
      "r549",
      "r763",
      "r764",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r548",
      "r549",
      "r550",
      "r763",
      "r764",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r503"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r17"
     ]
    },
    "fulc_FairValueTransfersBetweenLevels": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "FairValueTransfersBetweenLevels",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value transfers between levels.",
        "label": "Fair Value Transfers Between Levels",
        "terseLabel": "Fair value transfers between levels"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r306",
      "r307",
      "r340",
      "r355",
      "r483",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r613",
      "r762",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r835",
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_GSKAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "GSKAgreementMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK agreement.",
        "label": "G S K Agreement [Member]",
        "terseLabel": "GSK Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r692"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_GovernmentAgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "GovernmentAgencySecuritiesMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Agency Securities [Member]",
        "label": "Government Agency Securities [Member]",
        "terseLabel": "Government agency securities"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants outside of two thousand sixteen stock incentive plan and two thousand nineteen stock incentive plan.",
        "label": "Grants Outside Of Two Thousand Sixteen Stock Incentive Plan And Two Thousand Nineteen Stock Incentive Plan [Member]",
        "terseLabel": "Grants Outside of 2016 Stock Incentive Plan and 2019 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants under two thousand nineteen employee stock purchase plan.",
        "label": "Grants Under Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_GrantsUnderTwoThousandNineteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "GrantsUnderTwoThousandNineteenStockIncentivePlanMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants under two thousand nineteen stock incentive plan.",
        "label": "Grants Under Two Thousand Nineteen Stock Incentive Plan [Member]",
        "terseLabel": "2019 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "GrossProceedsThresholdOfAutomaticConversionOfPreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds threshold of automatic conversion of preferred stock to common stock.",
        "label": "Gross Proceeds Threshold Of Automatic Conversion Of Preferred Stock To Common Stock",
        "terseLabel": "Gross proceeds threshold of automatic conversion of preferred stock to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794"
     ]
    },
    "us-gaap_ImpairmentOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other than Temporary Impairment Losses, Investments, Total",
        "label": "Other than Temporary Impairment Losses, Investments",
        "terseLabel": "Securities with other-than-temporary impairment",
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r107"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r314",
      "r697"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r697"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r437",
      "r441",
      "r444",
      "r450",
      "r456",
      "r458",
      "r459",
      "r460",
      "r639"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r438",
      "r439",
      "r444",
      "r445",
      "r449",
      "r451",
      "r633"
     ]
    },
    "fulc_IncomeTaxesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "IncomeTaxesDisclosureLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_IncomeTaxesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "IncomeTaxesDisclosureTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Table]",
        "terseLabel": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Unbilled accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Operating Lease Assets And Liabilities",
        "label": "Increase Decrease In Operating Lease Assets And Liabilities",
        "terseLabel": "Operating lease assets and liabilities",
        "negatedLabel": "Operating lease assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "fulc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in common stock capital shares reserved for future issuance.",
        "label": "Increase In Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Increase in number of shares reserved for issuance (shares)"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in number of shares reserved for issuance, percent of common stock outstanding.",
        "label": "Increase In Number Of Shares Reserved For Issuance Percent Of Common Stock Outstanding",
        "terseLabel": "Increase in number of shares reserved for issuance, percent of common stock outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndemnificationGuaranteeMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Agreement",
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Other income, net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Interest income receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r908"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with private placement, net of placement agent fees and offering costs, Amount",
        "documentation": "Issuance of common stock in connection with private placement, net of placement agent fees and offering costs, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfPlacementAgentFeesAndOfferingCostsShares",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with private placement, net of placement agent fees and offering costs, Shares",
        "documentation": "Issuance of common stock in connection with private placement, net of placement agent fees and offering costs, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_LandsdowneStreetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "LandsdowneStreetMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "26 Landsdowne Street [Member]",
        "documentation": "26 Landsdowne Street [Member]",
        "label": "26 Landsdowne Street [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Leases, Rent Expense, Total",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Operating lease end date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseIncentivePayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseIncentivePayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Incentive, Payable, Current",
        "terseLabel": "Deferred lease incentive, current portion",
        "documentation": "This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r141",
      "r819"
     ]
    },
    "fulc_LeaseIncentivePayableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "LeaseIncentivePayableNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Incentive payable noncurrent.",
        "label": "Lease Incentive Payable Noncurrent",
        "terseLabel": "Deferred lease incentive, excluding current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements, Gross",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Capital Leases",
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesOperatingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_LegalProceedingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "LegalProceedingsMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for legal proceedings.",
        "label": "Legal Proceedings [Member]",
        "terseLabel": "Legal Proceedings"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_LessImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "LessImputedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "documentation": "Less: imputed interest",
        "label": "Less: imputed interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease option to extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease option to extend description",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "fulc_LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "LesseeOperatingLeaseWrittenNoticePeriodToExtendAdditionalLeaseTerm",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease written notice period to extend additional lease term.",
        "label": "Lessee Operating Lease Written Notice Period To Extend Additional Lease Term",
        "terseLabel": "Written notice period to extend additional lease term"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "LesseeOperatingLeasesAllowanceForNormalLeaseholdImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating leases, allowance for normal leasehold improvements.",
        "label": "Lessee Operating Leases Allowance For Normal Leasehold Improvements",
        "terseLabel": "Lessee, operating leases, allowance for normal leasehold improvements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeases1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_LessorOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, Operating Lease, Renewal Term",
        "label": "Lessor, Operating Lease, Renewal Term",
        "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, Operating Lease, Term of Contract",
        "label": "Lessor, Operating Lease, Term of Contract",
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r196",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r467",
      "r470",
      "r471",
      "r506",
      "r667",
      "r758",
      "r787",
      "r847",
      "r893",
      "r894"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r129",
      "r606",
      "r775",
      "r826",
      "r839",
      "r885"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r164",
      "r196",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r467",
      "r470",
      "r471",
      "r506",
      "r775",
      "r847",
      "r893",
      "r894"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r328",
      "r844",
      "r845"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Accrued liabilities for indemnification agreements",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r801"
     ]
    },
    "us-gaap_LossContingencyLossInPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyLossInPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Loss in Period",
        "terseLabel": "Expenses incurred for legal proceedings",
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r328",
      "r844",
      "r845"
     ]
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MA",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Cambridge, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable Securities, Total",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r811"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable Securities, Current, Total",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Marketable Securities",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r388",
      "r575",
      "r616",
      "r659",
      "r660",
      "r721",
      "r723",
      "r725",
      "r726",
      "r728",
      "r747",
      "r748",
      "r761",
      "r765",
      "r770",
      "r776",
      "r849",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "fulc_MilestonePaymentForCertainIdentifiedTargets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "MilestonePaymentForCertainIdentifiedTargets",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment For Certain Identified Targets.",
        "label": "Milestone Payment For Certain Identified Targets",
        "terseLabel": "Milestone payment for certain identified targets"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_MilestonePaymentForCertainOtherIdentifiedTargets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "MilestonePaymentForCertainOtherIdentifiedTargets",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment for certain Other Identified Targets.",
        "label": "Milestone Payment For Certain Other Identified Targets",
        "terseLabel": "Milestone payment for certain other identified targets"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r388",
      "r575",
      "r616",
      "r659",
      "r660",
      "r721",
      "r723",
      "r725",
      "r726",
      "r728",
      "r747",
      "r748",
      "r761",
      "r765",
      "r770",
      "r776",
      "r849",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "fulc_MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "MinimumPercentageOfOutstandingSharesOfPreferredStockForLiquidationPreference",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of outstanding shares of preferred stock for liquidation preference.",
        "label": "Minimum Percentage Of Outstanding Shares Of Preferred Stock For Liquidation Preference",
        "terseLabel": "Minimum percentage of outstanding shares of preferred stock for liquidation preference"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "MinimumPercentageOfShareholdersVoteOrWrittenConsentRequiredForAutomaticConversion",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of shareholders vote or written consent required for automatic conversion.",
        "label": "Minimum Percentage Of Shareholders Vote Or Written Consent Required For Automatic Conversion",
        "terseLabel": "Minimum percentage of shareholders vote or written consent required for automatic conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "fulc_MyoKardiaCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "MyoKardiaCollaborationAgreementMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MyoKardia Collaboration Agreement.",
        "label": "Myo Kardia Collaboration Agreement [Member]",
        "terseLabel": "MyoKardia Collaboration and License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_NatureOfBusinessAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "NatureOfBusinessAndBasisOfPresentationLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of business and basis of presentation.",
        "label": "Nature Of Business And Basis Of Presentation [Line Items]",
        "terseLabel": "Nature Of Business And Basis Of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_NatureOfBusinessAndBasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "NatureOfBusinessAndBasisOfPresentationTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of business and basis of presentation.",
        "label": "Nature Of Business And Basis Of Presentation [Table]",
        "terseLabel": "Nature Of Business And Basis Of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r102",
      "r130",
      "r162",
      "r179",
      "r182",
      "r187",
      "r196",
      "r202",
      "r206",
      "r207",
      "r208",
      "r209",
      "r212",
      "r213",
      "r220",
      "r231",
      "r241",
      "r245",
      "r247",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r495",
      "r506",
      "r611",
      "r689",
      "r710",
      "r711",
      "r759",
      "r785",
      "r847"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r214",
      "r227",
      "r254",
      "r255",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r309",
      "r427",
      "r428",
      "r429",
      "r452",
      "r453",
      "r454",
      "r455",
      "r461",
      "r462",
      "r463",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r577",
      "r578",
      "r579",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements-Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_NonRefundableUpfrontPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "NonRefundableUpfrontPaymentsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront payments received.",
        "label": "Non Refundable Upfront Payments Received",
        "terseLabel": "Non refundable upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_NumberOfCommonStockVotingRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "NumberOfCommonStockVotingRights",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock voting rights.",
        "label": "Number Of Common Stock Voting Rights",
        "terseLabel": "Number of common stock voting rights"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_NumberOfDirectorsStockholdersAreEntitledToElect": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "NumberOfDirectorsStockholdersAreEntitledToElect",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors stockholders are entitled to elect.",
        "label": "Number Of Directors Stockholders Are Entitled To Elect",
        "terseLabel": "Number of directors stockholders are entitled to elect"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "fulc_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Off-balance sheet risk and concentrations of credit risk.",
        "label": "Off Balance Sheet Risk And Concentrations Of Credit Risk Policy Policy [Text Block]",
        "terseLabel": "Off-Balance Sheet Risk and Concentrations of Credit Risk"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_OfficeAndLaboratorySpace": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "OfficeAndLaboratorySpace",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and laboratory space",
        "documentation": "Office and laboratory space",
        "label": "Office and laboratory space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Tax Year",
        "terseLabel": "Open tax year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r241",
      "r245",
      "r247",
      "r759"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, excluding current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r140"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r140"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r140"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r140"
     ]
    },
    "us-gaap_OperatingLeasesRentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesRentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "fulc_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration beginning year"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_OperatingLossCarryforwardsIndefinitely": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "OperatingLossCarryforwardsIndefinitely",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards indefinitely.",
        "label": "Operating Loss Carryforwards Indefinitely",
        "terseLabel": "Net operating loss carryforwards indefinitely"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Valuation Allowance, Total",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r122",
      "r629",
      "r630"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r775"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitment",
        "totalLabel": "Other Commitment, Total",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r16",
      "r180",
      "r183",
      "r188",
      "r511",
      "r512",
      "r517",
      "r593",
      "r612",
      "r820",
      "r821"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r286"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "fulc_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Liabilities, Current, Total",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r775"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities, excluding current portion",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "fulc_PatentCostPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "PatentCostPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent cost.",
        "label": "Patent Cost Policy [Text Block]",
        "terseLabel": "Patent-Related Costs"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_PaymentForPrepaidResearchFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "PaymentForPrepaidResearchFunding",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Prepaid Research Funding.",
        "label": "Payment For Prepaid Research Funding",
        "terseLabel": "Payment for prepaid research funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments for Operating Activities, Total",
        "label": "Payments for Operating Activities",
        "terseLabel": "Amounts paid during the period",
        "documentation": "Total amount of cash paid for operating activities during the current period."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Marketable Securities, Total",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined Contribution Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r769"
     ]
    },
    "fulc_PercentageOfCommissionOnGrossSalesPricePerShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "PercentageOfCommissionOnGrossSalesPricePerShare",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission on sales price per share",
        "documentation": "Commission as percentage of sale price per share.",
        "label": "Percentage Of Commission On Gross Sales Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "fulc_PreferredStockConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "PreferredStockConversionPricePerShare",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock conversion price per share.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Preferred stock conversion price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendRatePerDollarAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePerDollarAmount",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount",
        "terseLabel": "Preferred stock, dividend per share",
        "documentation": "The amount per share used to calculated dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r342"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r669"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r342"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r669",
      "r687",
      "r906",
      "r907"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r601",
      "r775"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "fulc_PrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "PrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses.",
        "label": "Prepaid Expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_PrepaidResearchFundingPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "PrepaidResearchFundingPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research funding payment received.",
        "label": "Prepaid Research Funding Payment Received",
        "terseLabel": "Prepaid research funding payment received"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_PrepaidSignOnBonusesSubjectToVestingProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "PrepaidSignOnBonusesSubjectToVestingProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid sign-on bonuses subject to vesting provisions.",
        "label": "Prepaid Sign On Bonuses Subject To Vesting Provisions",
        "terseLabel": "Prepaid sign-on bonuses subject to vesting provisions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds of common stock",
        "terseLabel": "Proceeds from initial public offering of common stock, net of underwriting discounts and commissions",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under benefit plans, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "fulc_ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's secondary offering of stock to the public.",
        "label": "Proceeds from Issuance of Common Stock in Connection with Follow-on Offering",
        "terseLabel": "Proceeds from issuance of common stock in connection with public offerings, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs",
        "verboseLabel": "Net proceeds of after deducting offering costs",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "fulc_ProceedsFromMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ProceedsFromMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from maturity of marketable securities.",
        "label": "Proceeds From Maturity Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ProceedsFromSaleOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of marketable securities.",
        "label": "Proceeds From Sale Of Marketable Securities",
        "verboseLabel": "Sale of marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r179",
      "r182",
      "r191",
      "r196",
      "r202",
      "r212",
      "r213",
      "r231",
      "r241",
      "r245",
      "r247",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r465",
      "r468",
      "r469",
      "r495",
      "r506",
      "r596",
      "r610",
      "r643",
      "r689",
      "r710",
      "r711",
      "r759",
      "r772",
      "r773",
      "r786",
      "r822",
      "r847"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r149",
      "r152",
      "r153"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "verboseLabel": "Total property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r166",
      "r609"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r597",
      "r609",
      "r775"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r149",
      "r152",
      "r607"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of asset",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_Propertyplantandequipmentusefullives": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "Propertyplantandequipmentusefullives",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment Estimated Useful Lives",
        "label": "PropertyPlantAndEquipmentUsefulLives",
        "documentation": "PropertyPlantAndEquipmentUsefulLives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Utilities, Inventory [Line Items]",
        "terseLabel": "Public Utilities Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Utilities, Inventory [Table]",
        "terseLabel": "Public Utilities Inventory [Table]",
        "documentation": "Detailed information about the type of inventory held by the utility and the carrying value of this inventory."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r370",
      "r388",
      "r419",
      "r420",
      "r421",
      "r551",
      "r575",
      "r616",
      "r659",
      "r660",
      "r721",
      "r723",
      "r725",
      "r726",
      "r728",
      "r747",
      "r748",
      "r761",
      "r765",
      "r770",
      "r776",
      "r779",
      "r840",
      "r849",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r370",
      "r388",
      "r419",
      "r420",
      "r421",
      "r551",
      "r575",
      "r616",
      "r659",
      "r660",
      "r721",
      "r723",
      "r725",
      "r726",
      "r728",
      "r747",
      "r748",
      "r761",
      "r765",
      "r770",
      "r776",
      "r779",
      "r840",
      "r849",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "fulc_RangeOfTieredRoyaltiesOnNetSales": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "RangeOfTieredRoyaltiesOnNetSales",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of tiered royalties on net sales.",
        "label": "Range Of Tiered Royalties On Net Sales",
        "terseLabel": "Range of tiered royalties on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently adopted accounting pronouncements.",
        "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ReimbursementPaymentRecieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ReimbursementPaymentRecieved",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Payment Recieved.",
        "label": "Reimbursement Payment Recieved",
        "terseLabel": "Reimbursement Payment Recieved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r541",
      "r542",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r686",
      "r688",
      "r720"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r892"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r694",
      "r697"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r541",
      "r542",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r686",
      "r688",
      "r720",
      "r892"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r640",
      "r641",
      "r642",
      "r695",
      "r696",
      "r697",
      "r717",
      "r719"
     ]
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-Term Capital Lease Obligations",
        "negatedLabel": "Principal payments on capital lease obligations",
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer)."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Assets Acquired Other than Through Business Combination [Line Items]",
        "terseLabel": "Research And Development Assets Acquired Other Than Through Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r436",
      "r901"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "fulc_ResearchContractCostsAndAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ResearchContractCostsAndAccrualsPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research contract costs and accruals.",
        "label": "Research Contract Costs And Accruals Policy [Text Block]",
        "terseLabel": "Research Contract Costs and Accruals"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research, development and sales arrangement aggregate amount receivable upon achievement of milestone.",
        "label": "Research Development And Sales Arrangement Aggregate Amount Receivable Upon Achievement Of Milestone",
        "terseLabel": "Aggregate amount receivable on achievement of milestone"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Development And Sales Arrangement Amount Received Upon Achievement Of Milestone",
        "documentation": "Research Development And Sales Arrangement Amount Received Upon Achievement Of Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "fulc_ResearchMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ResearchMilestoneMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research milestone.",
        "label": "Research Milestone [Member]",
        "terseLabel": "Research Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r810",
      "r824"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Unvested Restricted Stock Awards",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Activities",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r313",
      "r316",
      "r320"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesScheduleOfRestructuringChargesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring expenses",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r315",
      "r318",
      "r319"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restructuring Charges, Total",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r317",
      "r318",
      "r841"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r116",
      "r605",
      "r623",
      "r628",
      "r638",
      "r670",
      "r775"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r198",
      "r199",
      "r200",
      "r203",
      "r211",
      "r213",
      "r291",
      "r297",
      "r427",
      "r428",
      "r429",
      "r454",
      "r455",
      "r475",
      "r478",
      "r479",
      "r482",
      "r493",
      "r619",
      "r621",
      "r644",
      "r906"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r240",
      "r243",
      "r244",
      "r248",
      "r249",
      "r251",
      "r367",
      "r368",
      "r576"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r240",
      "r243",
      "r244",
      "r248",
      "r249",
      "r251",
      "r367",
      "r368",
      "r576"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r750"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_SalesMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "SalesMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone.",
        "label": "Sales Milestone",
        "terseLabel": "Specified sales milestone"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of minimum rental commitments",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Schedule of Accounting Standards Update and Change in Accounting Principle",
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r44",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents schedule of prepaid expenses and other current assets.",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r693",
      "r694",
      "r697"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table]",
        "terseLabel": "Schedule Of Research And Development Assets Acquired Other Than Through Business Combination [Table]",
        "documentation": "Disclosures of the amount of capitalized costs of a research and development nature acquired in a transaction other than a business combination, amount of costs charged to expense during the period, and identification of the income statement caption in which the charge is reflected."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Charges",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r392",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r67"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted Average Assumptions Used to Calculate Fair Value of Stock Option",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r113",
      "r115",
      "r116",
      "r170",
      "r171",
      "r172",
      "r229",
      "r342",
      "r343",
      "r344",
      "r346",
      "r349",
      "r355",
      "r357",
      "r634",
      "r635",
      "r636",
      "r637",
      "r765",
      "r800",
      "r825"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Potential Conversion of Preferred Stock and Future Issuance of Common Stock",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r56",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r88",
      "r89",
      "r113",
      "r115",
      "r116"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r656",
      "r657",
      "r658",
      "r722",
      "r724",
      "r727",
      "r729",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r751",
      "r766",
      "r779",
      "r851",
      "r904"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r249",
      "r760"
     ]
    },
    "fulc_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r850"
     ]
    },
    "fulc_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r850"
     ]
    },
    "fulc_SeriesBStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "SeriesBStockPurchaseAgreementMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series b stock purchase agreement.",
        "label": "Series B Stock Purchase Agreement [Member]",
        "terseLabel": "Series B Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Number of Shares, Cancelled",
        "negatedLabel": "Number of Shares, Cancelled",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Cancelled",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Unvested, Ending balance",
        "periodStartLabel": "Number of Shares, Unvested, Beginning balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested, Ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested, Beginning balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407"
     ]
    },
    "fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options repurchased in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period",
        "negatedLabel": "Number of Shares, Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options repurchased in period weighted average grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockBasedCompensationExpenseRecognizedDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r392",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Shares, Cancelled",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Outstanding, Ending balance",
        "periodStartLabel": "Number of Shares, Outstanding, Beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityOutsideOf2019And2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "Award Type",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r397",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate intrinsic value of restricted stock awards vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Outstanding",
        "verboseLabel": "Contractual term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Shares issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, Shares",
        "periodStartLabel": "Beginning balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_SidneyStreetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "SidneyStreetMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetailsOne",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesTables",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "125 Sidney Street [Member]",
        "label": "125 Sidney Street [Member]",
        "documentation": "125 Sidney Street [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r194"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfRelatedAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "terseLabel": "Software",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r170",
      "r171",
      "r172",
      "r196",
      "r218",
      "r219",
      "r221",
      "r223",
      "r229",
      "r230",
      "r287",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r342",
      "r343",
      "r346",
      "r349",
      "r357",
      "r506",
      "r634",
      "r635",
      "r636",
      "r637",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r669",
      "r690",
      "r712",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r800",
      "r825",
      "r830"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r29",
      "r159",
      "r185",
      "r186",
      "r187",
      "r198",
      "r199",
      "r200",
      "r203",
      "r211",
      "r213",
      "r228",
      "r291",
      "r297",
      "r358",
      "r427",
      "r428",
      "r429",
      "r454",
      "r455",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r493",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r537",
      "r619",
      "r620",
      "r621",
      "r644",
      "r712"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r656",
      "r657",
      "r658",
      "r722",
      "r724",
      "r727",
      "r729",
      "r736",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r751",
      "r766",
      "r779",
      "r851",
      "r904"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r228",
      "r576",
      "r632",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r691",
      "r692",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r712",
      "r780"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r228",
      "r576",
      "r632",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r691",
      "r692",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r712",
      "r780"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "negatedLabel": "Conversion of convertible preferred stock into common stock, Shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r28",
      "r60",
      "r116",
      "r339"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Issuance of common stock under employee benefit plans, Shares",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares initial public offering net of underwriting discounts, commissions and offering costs.",
        "label": "Stock Issued During Period Shares Initial Public Offering Net Of Underwriting Discounts Commissions And Offering Costs",
        "terseLabel": "Initial public offering net of underwriting discounts, commissions and offering costs, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Common stock shares issued in exchange for services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, Shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r88",
      "r89",
      "r116",
      "r634",
      "r712",
      "r731"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Shares issued for asset acquisition",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock awards, Shares",
        "verboseLabel": "Shares reserved for vesting of restricted stock units",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r116"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r88",
      "r89",
      "r116",
      "r403"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "negatedLabel": "Conversion of convertible preferred stock into common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r29",
      "r116"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance of common stock under employee benefit plans",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value Initial public offering net of underwriting discounts, commissions and offering costs.",
        "label": "Stock Issued During Period Value Initial Public Offering Net Of Underwriting Discounts Commissions And Offering Costs",
        "terseLabel": "Initial public offering, net of underwriting discounts, commissions and offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r88",
      "r89",
      "r116",
      "r644",
      "r712",
      "r731",
      "r786"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Shares issued for asset acquisition, estimated fair value",
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock awards",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r88",
      "r89",
      "r116"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Repurchase of unvested restricted stock awards",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r88",
      "r89",
      "r116",
      "r637",
      "r712",
      "r733"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r92",
      "r93",
      "r104",
      "r671",
      "r687",
      "r713",
      "r714",
      "r775",
      "r787",
      "r826",
      "r839",
      "r885",
      "r906"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r195",
      "r341",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r356",
      "r358",
      "r484",
      "r715",
      "r718",
      "r735"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Common Stock and Series B Convertible Preferred Stock",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r716"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r544"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r544"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r544"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureAdditionalBalanceSheetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Additional Balance Sheet Detail",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "fulc_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards, Expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]",
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r56"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Convertible preferred stock, Ending balance",
        "periodStartLabel": "Convertible preferred stock, Beginning balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r434",
      "r603"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_TemporaryEquityDividendsDeclared": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TemporaryEquityDividendsDeclared",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, dividends declared",
        "label": "Temporary Equity Dividends Declared",
        "documentation": "Temporary equity dividends declared"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, share price",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r56"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, share issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Convertible preferred stock, Ending balance, Shares",
        "periodStartLabel": "Convertible preferred stock, Beginning balance, Shares",
        "terseLabel": "Convertible preferred stock, share outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "fulc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities",
        "negatedLabel": "Conversion of convertible preferred stock into common stock, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B convertible preferred stock in connection with asset acquisition, net of issuance costs, Shares",
        "documentation": "Temporary equity, stock issued during period, shares, new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period value conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities",
        "negatedLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B convertible preferred stock in connection with asset acquisition, net of issuance costs",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "fulc_Thereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "Thereafter",
     "crdr": "credit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "documentation": "Thereafter",
        "label": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_ThirdRockVenturesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "ThirdRockVenturesLLCMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Rock Ventures LLC.",
        "label": "Third Rock Ventures L L C [Member]",
        "terseLabel": "TRV"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransactionDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r340",
      "r355",
      "r483",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r613",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r835",
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesRetired",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Shares, Retired",
        "negatedLabel": "Retirement of treasury shares",
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r89",
      "r116"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Treasury Stock, Value, Ending Balance",
        "periodStartLabel": "Treasury Stock, Value, Beginning Balance",
        "totalLabel": "Treasury Stock, Value, Total",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost; no shares as of December 31, 2020 and December 31, 2019",
        "terseLabel": "Treasury stock, at cost; no shares",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r64",
      "r65"
     ]
    },
    "fulc_TwoThousandAndTwentyTwoInducementStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TwoThousandAndTwentyTwoInducementStockIncentivePlanMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCommonStockScheduleOfPotentialConversionOfPreferredStockAndFutureIssuanceOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Stock Inducement Plan",
        "label": "Two Thousand And Twenty Two Inducement Stock Incentive Plan [Member]",
        "documentation": "Two Thousand And Twenty Two Inducement Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockActivityUnder2019PlanAnd2016PlanDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfWeightedAverageAssumptionsUsedToCalculateFairValueOfStockOptionDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen and two thousand sixteen stock incentive plan.",
        "label": "Two Thousand Nineteen And Two Thousand Sixteen Stock Incentive Plan [Member]",
        "terseLabel": "2019 Plan and 2016 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_TwoThousandNineteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TwoThousandNineteenStockIncentivePlanMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen stock incentive plan.",
        "label": "Two Thousand Nineteen Stock Incentive Plan [Member]",
        "terseLabel": "2019 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_TwoThousandSixteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TwoThousandSixteenStockIncentivePlanMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen stock incentive plan.",
        "label": "Two Thousand Sixteen Stock Incentive Plan [Member]",
        "verboseLabel": "2016 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_TwothousandtwentytwoinducementstockincentiveplanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "TwothousandtwentytwoinducementstockincentiveplanMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Stock Incentive Plan",
        "label": "TwoThousandTwentyTwoInducementStockIncentivePlan [Member]",
        "documentation": "TwoThousandTwentyTwoInducementStockIncentivePlan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r202",
      "r203",
      "r204",
      "r205",
      "r214",
      "r254",
      "r255",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r309",
      "r427",
      "r428",
      "r429",
      "r452",
      "r453",
      "r454",
      "r455",
      "r461",
      "r462",
      "r463",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r577",
      "r578",
      "r579",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U S Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r767",
      "r769",
      "r902"
     ]
    },
    "fulc_UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled accounts receivable related to reimbursable research and development cost.",
        "label": "Unbilled Accounts Receivable Related To Reimbursable Research And Development Cost",
        "terseLabel": "Unbilled Accounts Receivable Related To Reimbursable Research And Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnbilledReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled Receivables, Current",
        "terseLabel": "Unbilled accounts receivable",
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued",
        "terseLabel": "Accrued penalties related to uncertain tax positions",
        "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Penalties and interest expense related to income taxes",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Accrued interest related to uncertain tax positions",
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "fulc_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r146",
      "r148",
      "r150",
      "r151"
     ]
    },
    "us-gaap_VariableLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Lease, Payment",
        "label": "Variable Lease, Payment",
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r223"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r223"
     ]
    },
    "fulc_WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "WeightedAverageRemainingContractualTermInYearsOutstandingBeginningBalance",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning Balance",
        "documentation": "Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning Balance"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "WeightedAverageRemainingContractualTermInYearsOutstandingEndingBalance",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance",
        "documentation": "Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_WorkforceReduction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "WorkforceReduction",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/DisclosureRestructuringActivitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workforce reduction",
        "label": "Workforce reduction",
        "terseLabel": "Workforce reduction"
       }
      }
     },
     "auth_ref": []
    },
    "fulc_WorldwideNetSalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fulcrumtx.com/20231231",
     "localname": "WorldwideNetSalesMilestonesMember",
     "presentation": [
      "http://www.fulcrumtx.com/20231231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Worldwide net sales milestones.",
        "label": "Worldwide Net Sales Milestones [Member]",
        "terseLabel": "Worldwide Net Sales Milestones"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(d)-(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-8A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-6"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-7"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481475/840-20-55-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481192/840-30-45-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5.02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-11"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0000950170-24-021074-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-021074-xbrl.zip
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M4!L0L!:W/S3 2RPG.F5,1C+B1B?7-P2@SIM1-@ 9! <!),2*1;\RE3B*;,B
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M1NY+YQ[?P) %FT8!!M+YBJ>$1=('U!\($@72:$E5DOIQ7\GE3G[,7\W(%&(
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M18!NOACV!H,U$QLP247DA[U-7^ZC:%RGGL!\SJRO26RD"Z1)"*CEH)V#EJ
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M9E72)#6^T"1D(1Z74!')1$#BA&.&N\^U>717S;=.'H[TFIHV"\:2*)1 C!@
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M6]WP&YGR&LMB6!9R&3-% FN=6QK8,Z8^T0 K+X@DB%AOF7(OV\ZN$_ *RF*
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MU\YZ,/7,5U-,O4,T?&*/FJ_&>R<J49<&NL+<Y\_H@NBN?:#IC8V,_X1\]GY
MHUG\-@B#W9D! ? Y\/PQ%JUX;$Y?CW?&P$WYMT=CSW'*0SB (9J!@=4&/ 9$
MJP5)>) J^)^(@P>'K;:9[;.=PHUJN/66/6_9\^:PYRVR[XMH<+;@ 4S$>$(I
M$ T86J@=MT1#\&CIMQZ<9[+DAW(($@7>4;30$1C>$%9@NH,Z #P,@#,NV9EW
M5N07U7G[\RZH!,:-S)F=78U(ETB$Z1&!_W;5^-S/]&U[V:T7K!Y?>R'J <W%
M*\;:7MD:QFD@2=!J-EUU9O?;"6YCW6 ;&O(:P-O8/8-7.=N-@GO>"^\-[ALT
M&^SZT=U*#>U^8^3L R*0TN=U>:ZBU=^7\XUO##W8N&E[:YO@<_NR[Z[MO<R-
M7-].]G2&>]NS^1V=S1O$5;!+^9.)J^"I8=<]0^%@%_"7GUX%K[9SW,ZQKW-<
M8U1\'Z+@;^ZT@')E58%G):6@84J,"1+"F(F(8(H3$48VLM;&B7UP4YGWLUKG
MQ3Y(S;.\F"X)#'47.7FJFHO6&B.Z3/M?3Q#S5I[W;H;7XXQ>YD:^>*Q]LLKZ
M]=(GWO,SNJ)>%X]-(J@D221 ,# 9$Q$%$4E2%D3<#Z,HB=<C3!Q=_#(ILY$I
MR[4WY7E8U\&M]K#N1)KMO)[&R-X\_Z__ $:+;NWRKSLED+9]L;/>SFL[KS[,
M:]VGKQ_:;4^AU?OE3M*-0)3/>2J>$$@"7M0F >3(4XQ,BD1($BYB>)<4?NI;
M;LV:8NU;8OC5T<)^30H]!I1;BMS.:SNOYY:KVU3QC4X5/[0W!'9A%=L[INUA
MC+*+3#;:Y>]5N3<IZZ PF&?="[Z:=1!NHX Q.AC?-9CBRR\R>#6\UAO!L'.T
M='W-2F>@'HF1RL0 8T&P#11>7%9BI$6A2P\KSF=Z58)[^(/XV]+X+N^66.+[
MED/5W(0JC2B)M.\3%H# EC3AA$8R],,DID!<Z^J(/N_)7*=[/$Y/YO6&]C]C
M,_2-">OLY&HU]EXL<871C:*J#/990-H&,L<>DO!:<>9RFF;EJ$59FK+$KUK2
M-]8:%W0^:HJ\XYT9QJ*/X%SA.(M\X.4@OSK';6YJGL !+F:'BOFL4YOT1!12
MP&/)T>7 3%TJV ^4>U]V3W;W=[T8Z!HN_AM.?#[+IB"%',"QZ1QJFQ7#.C4
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MR].;4G':M/TIZS!1_51!7_O-:QW[^#1[]99IW,XTTBW3V""F\?(R7%-YFA>
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M,%[T'=>;!U18Z%J08+36HAT94^+G+CZ7N[XRF'!>6ZPF\^[X)^7=3@OPXWR
MA4N$-YH,)89:V)KPQ_/)#;)A5K4\O45%SH-="U13@R,X&6=HW*SA45T6J<Z+
M ?"#H]K%EC4K%M"M"L%5F=ZRF&=FA#J@D[\:GV'JW:HKH75.%G# $OB0&5W9
MQ29UNY7+KJ*(;/ <'*E.Y1!XY+3E!F<340"F,#74% H44*&FM4NBYIG.N0#+
MY^;;&4<MC1=V]98P49SFZD#1EJ@!:7QUVO ?9KJP9V@^T2TLG=$LUEL 87!F
M=I;3\<[2/>A69JDWHZTIU'#YV<L:9=XK!2Z'A^>Z.5; )D4VP&6NE\V)EQ9[
M+"?K?YR#X.J"IYG(0?Q8H*5J@4J=]!$E@#NW@Z,<Y]AT1ZJ:'7?T "N6V<S%
M(3FGT>P9*[GH#2PS>2ZE?<TUQTZ^?/B !<>.#T]^\P[V]C\?':^L*=85*OS%
MU=PZZCH*@75VE+(NAZP5,T>3F:V+0_ROJQ"%N*V#>X2K8++@?MSI. E1+C1E
MI[IA=AW?I,NHLH.\<:AC5D/I,-P@ S@ -T\=>L+BI+6N" <!M:A)B:=RF*-/
M<C*8ZRI-N:>NQM*6?&KTECL I9JAS7H9-:]NN5*MIPQ@S$OJ'_7$=(Q0Z-E,
MQRRES.<^B]*$<AZ^9--Q1S?'$@-Z(3H.-'U,-(1C@484Q]H1[,XDYLC4UW@7
MP+?_/8UW0P]>/D :1>&(=#8U6"G,E05[9Y1QQS.D.U[@!Z$[,/]._70W_9;[
M F=1J#43%Q6(0V_'BC$N33VSRVHF?_%IY4S6C?#;F5TJ+^;>&!#EL#R-GP:@
MFSOMU\:]4RMOF.OKY.5P4G<"U*XIJ5,A_IW#K.)V5G>P?F_/VG=QUIS7!8/W
M7)0UFL#JI,JKWCT XA:I#*7%Q$$FI/1"8)'K-B@0M->1>Q968[AHK5?2*>JJ
M!LW:P)Q1= % K4TXJ"F,G+;=0:[+JH$TN'DQR04+?H&L*:^<0+@?H/+"E!;B
M;!HXWWC+VZ)DKNS80(P0]F/_S*\.65ZQX#GMRVOK*"Z-_[FIF)G++&QO7ED!
MI2X>Z"JRF.YF7']3K5V5QORQK#9 74R@+E$X1^77]8,M/]CR@YH?X/DVK:G:
M%9/JD&5SV&96KWP$USEI75WDR]7.JR2[G(\L5FM9H<,VGIDBP_KT"[# <17W
M-NT.<IGO+,;OM;[E#LX^%\70Z"WA;PD?*VBW1.I*IW5)OF/M&IC1674^G?F@
M1BZS" A5.1W-&;YAX#._&T:F F&;VEC=T=96%<JJS]U5'M_Z+Z6KL(7%=/&U
M\)A%$[J3@'AMC3Z[0@.+$%\Y/792U,6+9B>G,4FYPE^81#6H;4\#9[%9.*G.
M<K53F\FOR*SK\GEE38;MR=N>/'CE+Z;V;C8BH2&HFHD/S6KRF>EE6':S:HML
M-O'=CJ!KDR-2N4&SC+-(FTY9A\YIJ&N)C>I7*N'R8E!TG#G/"RA]8_1*NC,T
M--5YKIOTK?H0?-D]V?4.\@;JO4,.LJ=AOIE+J7:F&KCQX-W>SLQ3LX#5)O#$
M)C*I/>LNSZN-8.J\WR[%FU7><@9\ 2(_N'=V%9S@H1%8^-%.9N[C[>G;GCYX
M)6"QTM2!(T)CG?6N3Q&8?ET1Q95A0I)JJRN[XNIUZB/:Q9M(OJL"8>797<B?
MP./@#(HT?KL"0N*#2X%'<R!J?XFKN;?3A@,X]17-K1)N0YE3U*?]&GY%3\N-
M7&4;%?AL48';L,"G"@O<\OCOBL=W0B EFL2</PBA0*/@-TJ]BU(I:^5[7C3:
M&9($XJ@<M.ELH#'_+AN[[:U5F2VNWU+=<JJS&/C:-<'.TMD0$L\C IHX)R1'
M!P9FY.=TT8Y&<,4 W)0R=\46@+0M>BX1H>=%E\P'T[J9D O2VA+GECAKXBS,
M8+K3"2>N;1N-71X]&^YW;!$"7Q;"19UTZV=UNS^4=9V8#T>H$.:="U>9,I<;
M0>?1K$VD25&(T5D;[EW.VT)A4&P3,[0PC#;N:&A,C7W+R7CLXF;FQ1IVKMIL
M7B]UJZS6NYL8'F<XVMI/MP?JFP_48C!C?94CLB6FC9TFT"\OS97[6DC3M)(#
M_;#*RCIX/\,7S35,#"1K4F/=P=!&:%RIN0FI-7W6=._.5?OZN91"?\&"4V%+
M^EO2[\2K..[M(FA=2\0FLJ--2FGBM6<<_FKB0Q,T>Z4Z6=E&TW<IOZ7:&4A?
M9.FKV/DM9IA;ZK3-LLAOJJ#FQ-KU)V6E.ZD=S0/&V$@_%S3?R+^VL\,2H=/&
M5C=O)]EH;ORI]9J9?Z*.17!NQ%$WQGD>.SOK([BL<&\SS9GG<!;#T-C'9A%Z
M6]FW90"M#?4:E*NCQW=F<5P[</1=$$P=#5( +0+=8<^O.L"E:@(IVPCN68VX
M:7O#$F=X5@>% Q<8FUF$^+5'S@+99\?08E"8<5U2)"CW>N=:R8@F,6_>:>6*
M@W[Y\,I9(TX<G#,/.TGN@FP:47ZM_T5'35O]OKLM28-,MP=U>U!O.*AM7H$#
M?=-Y&<5YOE;96L:6E[]M9%#3T[B.CEO4U:X+[9V%'*VNZQ$6II@T*0E-.-I,
M]M157>"7\VS<:9Q1#R ORDZ0':; KAAO@7;O<EY#<I[K>N5]VV.R/2;PRKW&
M$;A08*AFI:V7;QY+69KB:Z:<FZ[.#YJ75FL2/>?^1'B%,H4[7AA3@P^;I20@
MAK6B36P>Y2/2Z1&.*7#S5V8C6.5J,LO6K^#DE4+-@ETF"+)GYZX^'E=EPK46
M=O.6W;/3M[)[^2P%XUJQX]D=VZ.T/4I74X,P):'M:8[AE2YEOLWO7%*%<(4.
M*<W"K9U\^_;&*Z4&7;S)F<G'.5;[5_,CZ20"X*=9]OZR4.9:UVP,B>K<8=EN
M\<3C25EF^(S15]%V:?_R1R&<?PCC7-"I[)WG9=4V&X#I'):%,(-9(OJOXG^%
M=P)O'+>92<T(<?8=&]+.K)_9U1GCE3N=4][,R,#-^=#56<Z+@88M,JU)1S7Y
M\JWK81;^T#:0OK$"Y*KSW8\\ZB?S*6]#(YXF-&(;&]'ODDGWGG5+5DW%I*(Z
MS4[I*>U'BN^GO>.'U A:\V@^>X?W2+=>3RTKQ%:P+ZTPZ,\6'<+ /+KK_3+I
MT4Y=U2;OO%O/E/Z]YND??46=R%ST:$>\57OQ35QN([/SFY0F,4.VJ$6< 8S.
M\C&Z].!]DQH5MU4D;:XF37V*;C2Z*U0QS =&30:UWQ) )C;X<Q!V@$TWG)L%
M .+<"(2%1ZHF"+LM35DT"?>S0'6!92C:ZN7>9#0TZ,+7;E 8VEJG-@\!0M?-
M+E4GBKV9S35KZ,Y"0^ ,XV-P%LV$L*Q)@^P[34:Z@?16J"POE1A/!OGY9.AR
MEH>3TB5!>GH*FCXL7]UNY^#D[^_J(=:JQFU#P]',\B%W<"#P^$%=;&2$:L7!
MY_\AD<^3%JI_^^C+3/TQ,)Y"%6A6\AUN.=E_AVDR#ZY\=VL1C]O.X3. R":;
M5'O'[_?V_XX]E@J,EAYB%8H=3^<3.0 ,"7N'#:2Q9J',W>U%/AC@%4/,"")U
M^W-8[T_GL*A>>$5AO)+ZVL9NHQZFO3\G '#J8AB8--\F$;891=HS(WR9V\0F
MI/S$C*LZU1W3W.M$JOI%];5P4Q#YLT-W)0NXKA +G\8N7-%5.7+E?-P2S L&
M8B[4E=&QW>?;JN^86Q^.O/\2HPF66YS5-1"C43YQ3,_5\<F&G8U$%;VF1"J7
MD.(\[1KVNCG\R^FMH87(&]9IX %^T&A45_GY0LYK$V.%>>)UT!8^HYMNU]1_
M:3,7YH_ REM-E:B:[(?&3>OZ,.C5U[OLI ,CB]G2?&OFD3O2&+V+OK;Y4IT#
MPF@=Y8>NT&+C!('?<+OPF>XAAQ_?[73[U#L6/%]?6W/7EF6CK6N0V:JN*+8W
M.0-]OG.$5VW9C-,7Z.)O&59=J*M9E-PY342& A779X R8:=UN:!!RRW8/%BN
MLT<8RWS99C72.=MH]K;)$:X+T;36M<5$2O=H+'>VZE'M8 -_Y6!QQYI2-W7T
M47<O:HH?UG5&FL9Z50Z'K^9G7[.RQALN<J-L;=!-GSN,5BPRE^$\DY"KEAH>
M5P$',-45Q((8Q!2MU*SKE6#ID4UGAYM9J_!P3G]UEM]5+-5QTNS,*GC.<9)H
M$IJ7Q/.W]32!&>:U+QY0G<'R<S5<G;>V P+["@OAWH>0JL: ^-R:@CJ6Y!D>
MPZ1#&"N6H7$@&,\C]H=L)N+06H/XBAP3'C$)U('@6R%SC3673&E0GW9W/)KD
M-#4+?X)]/>]"$]L@UROE.69\K&-!!Z242V1@\W>V*1 @4%JO[+C(VBS.C@:Q
M+$EZ#EI7QMUB.84K.%J4I4%6M:JR2!-?T90RN<B+/UH;=C?=?%9,!=CR.>[V
M/*("X?U@OLP[;52+*U5V-FJCQ-H^P:WSJRFE(I3*78'_61G8FIM>9+6#7.-6
MMXGQ0 P#C YSZ:^S0BMSD3Y?Z+:\2P_9SPV\Y@%%_OIDR$!PU1#ZBS-F;*8\
M^%*VQ_ Z_YOS_[K<J8-.B\E:'>[<'',"? 28?(-%8)19&VT)<L<U]$4.MI11
M.Z;<<.L.<_[<K>6''L,"8\Z&L)PP\](5'NT67!4RG]2NQ^Y(.^4Q'.]S'GI#
MKK&QS>(+#W83/*.;[^FG]T3;Z,TV,@/$7A;JIU?P@;$DYC[CI_[NO\9GK["^
M[]+O%^(.HC@87[YMG&E!BG^\>KV!CM)-=^)M':./Z!CMG<7I$5#/28-Q>RA=
M7KX-\/-YX6QD=8,<-2F7Z5%HY%_TR%S-9KEKR:"9$NC4/A>?G@W1$H4%11H,
M5/MD7)D1K,GZC2Z>6>2M-B[RO>[4V-8<JKO,E [VN"$,,FM(=8YC-"-7>1,A
M%>(FM%SF(].I!#13QII*RG>NG1Q%WU&\842CR(]]3OTXC'B_ P[OR<WJ2_%5
M;USZDUIYO(X!X^M.ML45F\C2\_&<,!L=N' @7;'9>N2M 7_1>GJ%.]QE6G4&
MBNLBL*QX*O:>N,%_Y?2M![O56 );;OY8Y4]#ZS4,92*:Z1I,WL$F$J[JJ["F
MFMYUMC<Z/Q8=;5?2>)?YT>[F/+MK^/.6'6W949/\N6"*O4;(Z,3;/&9T^Z1N
M945-'$N3L^"*.C2\I_4CK?+T/('[K''Z/94#;<M=MMSE;MQE/Y\7H! NA6&I
M>\'UH2KRBUIQ@&^ A+-\>=;\\B-\N]?J>;G6=;_@2W()ML67Y_IBX\S"@7;<
M7',K-;+309G7A?.1QSF/E+G24,NUGW*U<^I&E*2M?E!S?=Q\C,>8I29GILV8
MJ2WI\U09)*PF%Z9QUJ.=?I!+X(HWE51 W0^>Y6(42V\_+\:[=;&ANM["EA-N
M.>'=..$' =+6Y>Z?FX[?>;$LQBU%49^1=16FJ6* -I\VH[E.7QY@S].E?'KF
MA>^ZJA:XR)R!--%=;5C78OT!UUS>03$S?Q7* 7>\;WUZ4TM:-,P1>ZV(@8O]
MM84HJV+B:H5U"KAW\_W&DZ*<F"6A I@N,C)%G1R.@VF]Z\O+FKQV;86P% IR
MH\K5\W4Q9"-7%ONDJ@N3;3G*EJ/<C:.<&"PU4">SFD[INMHDF:E% G5U\3HL
M"(T:LT+,2\"(<_FV43;/R(!^A0G6YQ'=2!J#?>R*MIO+JZ:VWR["HT[#GU48
M\V9^U50_NGWANYRA.X2=%55EVL@_EY6P"& 6RSHMK5AUI6P4VL,NSN&V*0%<
MUS29RN"'PIFM?BFR$J 97(]E/T\ :4FYZWWJ#A\GV5:T1V6R<L48$3V!6$!D
M;^O&%K,VTZ;3C'QY+-$J'O=]1?;\CF+S4T,"^S,2>'&!/AOI VMA3PU@5G/(
M4L&Y<Z%Y'4UVIJ8M<)R62ZV"2Z[JTLRZ]&U-G5RX9'F.JMO,+KP0 72/9, G
M#I:Y-1SL)07+W'>RSYB_='.4#ET1I4-OB]*A-&VB='KDXW]I423;Z*=M]--F
MK^F+BWZZNYKW^\RU_ S0\.[#O <S[34RO/O,VWH#SL^_)&W[0YNV_:Y-VWY\
M*;Z&?7OY('_99EW/L<=0-.%LC#MUV#NZ3+[6K@V0F4*ZXN:MUHXHO]OXKJZQ
M/#=>SIQ6H :[$)@,W26S\K&NR ":&NL$SZ%SORP9DZO#U53*<IE5I;F$.9L_
M)VBN:-PQ^:@TE5=-QZW["%0#T%9J56.:3] DJNO6E>U04%G TF:8*^#\Q]T9
MEW^8@:F:11J8NM&[\S/5GG!\1^,TN@"9Y\IV9:TK:-9(#+N2[*"R,AF #$/5
M!:?I2I$5D]$?;35 ]];:!;3B8>CC1M,#+.FP-@2U]<S&9O U4]Y9]O_8>]?F
MMK$D6_2O(&9.==@SH$JB7G;Y]HV09;O*4^4J'\O=U>=\N0$2H(@V"+#QD,SY
M,+_]YLK,_0)!^5%VB988,=-ED2"PL7?NW/E8N;).BVPONNB-V][/4 >B\Z#7
MS98FN&'GBIN8F0X3#MWHSPG/ :T1-LH25:,EWLY=*[$0?@U0.MA!> DZZ;](
M-YT4V4)!C1"!KM3RN9BD"[ C&NO*A+(Q9Y UKWH+;=DX4U_D5Z:;MO=#<D);
MP69R:&;"/<+QK 6BZS;]'_0=I6$([X.\6AMU2\6"=@*81'0IRPKPT@FV0D:P
MJ)1BV U/4)2+Y)\HTENM,W4(#!0I044[68Y6<6+KJN3(&OCODO)]#N"5!/%,
M$E.>D.;)95DUN1$I+T<\\$# 3.W^4,9+$?PRZVI.*3;;6?UV#XJMGB::/J('
MHS!^P3@_>L)54C!W[SJ.!5OY44R#HL6LEL(%SA^.]_U/'_Q7GD2D&Y,B!E[N
M(*;1T');1?LL;]C";AZ*II5"_V6U[ I;)AH^^?#P,**7*S@QQ _A$+$9MNQV
M;!P6.Y5$_XX0V/".,F*4;U[E:0<R2-6@O8S1[^"D+/+LRCVESAP9MP7_./&?
M5Y;[GPO!I!Z-]PUWDQ2X!O;#-,NOLD"-(*K+C.:24>MM-]'OK3^0FT[ L^"-
MV^MJQ*S-C06(<B]8O@7+#NE/DODY*N(%"HZ(=-=6#<E1$0'U64*!SY)F;B+D
M=+C*3;FLS=ZN(1V3I/E4CSYSEB*[F;5SJ)K+NNH,Z[/A52>]GJ>F8ZTGB=^\
M@O@F[;=SY0]>QQ5[[8891;-8TK !H\%AEPA-N'^@ZX'_?51-I]W2\&\(C&2%
MDN_K$;A/RH;/M(R.:KH565SUE/D@Z,RK:E?\KAM->ZIR.[6VSB>=T1S&_I"D
MMQ2+%GRT></S6]^8_(MYIPG]!#T$0,/#@KL7_:)?,0LZ&XV5J!5%4*NYI381
MVQV %DG)-PY:L8-)QOM&$N+5VK['7H/ LC$Q8#PA1Z5MFYN.)(4K1\W%L_R]
MJ#@\U!&^<B/865<:XFAE\^*E";+IAEMH"_?8]B6JOK1[R-OI:<[PK9W;NA5J
MS_IJ"6>G /*=9&A_T/J(/E(!V[1>S_[VCZ-;W,#0-STO4#01^VBE4OJPC;*L
M44^"P[TQ1N:?,_C/$/X_?R:YL0W[8,+[/ZWSI=!1<>LW%DJ# PBET?"@E[!9
M?U6S,^:Y':4UHSSZJ-3P&,\2L!1FBTF]8E\PH-[A^+J)O-"[\ "V:<UN>0/P
MU.;H$,0&:\JU5>L.<>QTB2:>=?5V6Z"_!89U"E>.9(TO[1%->&4"1_@EK"08
M/S %66#AD+3D!TV-!2FWDX"&6DSP.,W2;--"W+)<^]JBM,9_2@[!W(1.%8:>
MMPCX<0D@VYCH:9*0Y@C.@?Z"6BO8CTHB[L>17XYQK3O@Y IT'+4*%>!.(ZUK
M)+,P8*=JX,<MPF/%4<UHPP@+1=M(H,-0?8?2N:'FO!69L+4.>]'K;E+DS5RB
M3!9CPT4,';T,5U[&TJW"D<)MTYK2T*[RMJYN=T>")#2S'4X,*Y*VF47<N>DN
M+[-&PT0(/_.6,0[K-DTH-LDMGC6>!M& GN?[,P.H9=[%>>X);=-V::Y 52T^
M6E2E8%13/S['Z2U!@P0-S^A)[766V5(>(7-FQ?H@65;+%E&_AS;LQY6!V^AU
M;,7J:>><4,YW-I5]-(),4N[%7<HJY-W 0IU-:TZK0N4:F=N+SIHH+XK."+/Z
M;W1*+,F<PEE<78N6+G/$A>F$R J$O2'NV^TBWRI!^9KUDTM;N2E4-A:FIIE;
M5@+T-HE/$\'C1/8$[>BR5/R)O.3%XXNA')K=A&_0#H;H D#^ 9$E<?9F<*<U
M[*,3MY\AHE ",G^-E\O5W$W!!;7S+"E:QD_(95 27K8:B(-& @IJHHA=R77Y
MRC.PFW_[:.\TD][&=<;%ND*"DOC1?3%;VKWHF>6.%Y-:50W:@31 ,13YNXQ[
MM"+Q.77&BFH3^G.W &X#"+R",4ILNTFD[+JJ&ZE*T-DE*W'.(?P_LP[@<Z"C
M?W85P!]( +@Z@$%$_'@#(GX\@(@_'#_R>"OW]P41;][IVRAI^%P1_H__^(\?
MHM<C*4?\:_27HGVRO[>_?W O!?7/:7IWNW3Z13$8=]Y%QP;C]5UI(O9,.Y%F
MHSJS!H]PX]OXL,&17E<,V,D$'+%:!B0>T$BFBVKL)_>Q# >FG]3XB<!*Y4/X
MKOPIG+.KK ;"H&2/@(&J7O .!\UULD6\G;NREUW9R[<[IW_V*_Y9;H.7<7&-
M 1FA#JP4?=/ES3R9P'*=9^18D [K@P4?'W\78'HYQNG458BEW'3M>$]_$L I
MA*&EE$)W!7NB2V"=,/SQV:]GL6N6ET3/CO[O$3)+&;))[-E<,G<L\@X@,\E*
M_38"80%'N4KMSCW+ &'GCY'LPRB\YRJ6WNG\+0U:W9ZV!U=!WY08FPYAO,J+
M+($C-.L*?YW\:8ZC26<N[A3M#\'T6  YC8OJCQQ=%(K5UADK%Z_.28IOV5PQ
MB,720(IYDH%[S$Q>.Y3C;9O%;3#YKO($"H;DMIVO)!GS;0$?[X 7]E7"!=L$
MZGRYUIT+6Y';%[Z5GG2F.]<V;<][#/G\/8NZ-B^X*$^MF!%9PER;(0:,EZ1M
M/.MDL:K:;F+XU82M1!H;+K1&$"3V 9$_5Z(!:SZIF5MQ$Y^)@[K0#;=)3K8&
MD;07_3[/&41D^^$A'X&.C@'Q7\@*)66@J5=IU/8*YQC.8GBL4KI; QM72EBT
M:Z7D.81.2B,!N;V?+RM[T4_5-484<_C &XH%;WACMPWBUGEO7.$K>K3F*9M@
MFA THQ0,@8YMBO+4?W6(;33<KW1Y^.@O__[XZ/C)]W_Y]_'X\(FQ)^8)*AZR
M4B$-($;G4@PF/B-#3:!VENM/K#EY/O],Z@DE,LZ"7;Z3/W9".P2C,WT9.UKT
M0AKE*FYG>.6EY[-RY*?2IAHU=GVMTEM=6KEY/LG)OA9PG<T=,P*@(3<0T2N7
M83(M)'>+-K1HW'ZXCZ1V2#IUCS( XC8OA#8H,*L]0V<!VEE*-(S'!-@ND'26
ML[Q>F 0=WT;7RCY%"Y9M]%%Q>?2&AMFNR=^0P8LW.'_S\N+UFP@_*++190>@
M'WW72%VPMA=-MALLMA7RL!>=V;I/@.Q1RY#4-.NU-OF\2'+:7;]47=Z@G!3:
MF=.(MHH='&1+BX9L+0ZYD:IOJ.*528Q+ZYLT$ -L:U\,K$YW57>N9T;,U/L2
MU=ZZ!=T*A ASOAF>;XYO"4Z$-;6 13XCM7M7BM0<14YDR%CNKZ]PQI4PQF;G
MLH.^QN>PY:#]*47K'SS,;][D>]%S'#1BJ3;!U?-$RJ;SJFN888+.*O>X=6+#
M8?CV55+C!J'-5\**=10A^%)J^!DO&.3)R(S1AYJS4X"O5QRH$GOR!GLE[EG%
M?D?H1IO&9V1T PCC-R)Q7<,GAMD =*Q .N8*,_?H5?L(=-?;! B:.KM,N-VS
M-B&*H^4\J1?)M'J7\TG;<+[P]<_B^:E)[\[HV$+OR39/D%^,I-4K6$3<F/<B
M;V_!2"<GA$2>PWMNW2:KZ,>+GZ-E,>6'TK\9?EE*Q=9A?+R_CS?])Y?8#RQR
M,JV!)K32IM ?CL1JB;'];EIUB"JBB S/-)Z&;=+D+88I".'6 0PSEZ7M"0C)
M!_DCW/+.OZ/R?@\T@W$%@VZ8=C*"!N$!YCIDS\7*F"5+5R7M<;-DSV+36(I7
MCO9<K:4F<,UG>1$2S)26'"6M&FY7%Y[])*O6MLX',>)JHGGC'C#H6*S[>T+3
MO;LPP >-<R]'WJMRI/5:T]B^:<1-SDSCBU3# ZJ'V9:#T$XR81&ZMJ5(9A%I
MQV7O):EFQ(H5"!<TJ?QQ;XXYJ*!)RJ^YSL;C0\)6)[N?9"H3*EQ/I3%=/S<K
M*^<)5\NB::00YWL[AS;_(N>WW<HR_KMO%+PLH__JRDS);JXS%Q29=84>*2Q,
M;.EO:* WT#]/]++@Q\""GM6E8<^0=ECC?CLLUG%O,NQ.3_'*H8GT&BC5TV4%
M]P3G#33Q0NV20)LV2F^,\TJYUVQ]GNXY991(/8QZ&?#O-&)6&,"ZIP"!]DV4
MTD/?FD':OTW;2IOT2?]!*1/'+7@.6^V=^O@D0E?!QDUJ17Y55"2T.TW\"DQ!
MM :J7V5*3,P+7,YF"]O!VF.'R=:<232B7<RD/E@7=%M*I6D@D_?X;V4IM;!P
M"3.:)%KB+CPBZ^-'#)DFMZOEF*\10N#$_'55OV,YE07]_2+F7"L8Y,! PN]M
M>DKTCZ2 B8C/?EA#,-^$CD0F'"_AFU8S2:F["3AZQ(/4-FMX-;I,9\YG$^'0
M]P?$)7Q->IT;WF:GP6Y'@VUK*]!M[O]Y'^7DOY*RPT%",[$O^907S\Y0'L9Z
MNJJ7@.6PTYMFL',24\G[<:M(3WB%8)IW_^>OOO3]5WI4]T<_2U V2T[$N\^Z
M^?V-$9V;S?P6F_D'9YX\D)/WX?W>,H%QZ(R:GG7(7?0^0:=^CGD(P94E,9^
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M#6$)H_M_" DY ( $C*A<A4V"S"+=8Y#:RW7&B7 VW;86)1?W8T(^=0Z+(FW
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MGELK/2>4E@TD=\%+>B^3"@6>X("TOFL:+5@&$YK_3+@E7:-LF U*<=+OS<;
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M2J7#$/E7<?2N1(,6&,JT7&_IW_1$[SKM=IHW\F>LWVEC/8D)N+[K=<8- E4
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MPXJS*](LDH*.LZK(IAVI>SXI7ES\](R/$ X=_BX_T^=RX_L//UB *_ITW%/
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M8OEGDYMSB11PFTE$SC$ =8SL"X"7N "L/R/$MJ']NLU9,"^HP%&$7IQO**:
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M-<PC QIZ+WI%;X9)BCW9<?(R1X]ZG1LW_%CA6#CBY8&TL[5L2<&9P2EV02\
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M*;4821'W\O 1:9%Y/F$7Y^:';L^^V^'/=OBS;W=.[RJYEM5)L< /2'6(^8*
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MR\)\3P<NAA*"]#?D>MQ[_0S7$)JD!H+Q>/JH+Q]T5$A]?YX$;Z\R_P#Q: >
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M8''V'SVBM7W*+1S+0FJ)%WXT%@.?)VR-2.3'&[@[R.6, _L8;U!S8EK$L0]
MUAFP\FMF85K5M==0-N4V.MKV?8E3N>H:U,%RR:SIR7B-HT^@0BOS2]X0!L/6
M>U%FPQ2)V!T>MT1RJNO-X?]Y1<I),.MJ\IK$?QS@!!P9B:U.8G_:/V#VHM])
MUV^^5E1_X)Q;&YG$%V(#<R5 1AK3EGQH^@DW:B5[\@J:XH,/P]ML>J O^/R,
MK RQEW(707=DRE-HVBYM8"@(TEUKX5=5)P)R=>3779-YSTL:ZT\X%X+;U+K"
M!:6C[7/)B#+H/Y>[HBZ6"<T;]WH@4]GB\Q1.9Y!V-AL7)KXT6V1UC<63!MF\
M6C![92I*?YX52S>EF7!#6EAO+]PM+*5B  -$J,6;ZZLJ.%Z7/,6=?01K@!IT
MI1I,\DSORJ\ IOA:_(5@C+3L_6?;$N<@JL1,CS3^4INZ)K7I@\LWL;@93");
MWSI_.VUW.RPIAJ_<V&A87;&P^LJ&"561:UNOR?0J.?W(I"/6[9_GXE[U"#YT
M+Y"%H;N[']$T#E?>6M->F0*3H)K4(;PP7,W-BZ;6A*Z0L]CGDTWKC4!U38O^
M=0W\W;(#[85L<7O']>%OCI2&P57=C&N17F>#2.S)6B*P@/D.1B>0O5NZD51+
M;NG")GX/;B=1#*N([.^XB9\:U0QC$',H"Z"?:V889IE="6^F10W[ I"W3D*@
M](?JP,SY(QRNH?888#^@(7MZU1=)HSTQK['?3]S3\5)O,XQ.@NTXR7!2]ECB
MNU(:6H,)'T&-KHG >1BY;AP[G74[%IIML%"@5@-X$2^]43'J@]9SO=S\LJZZ
M99@FQA+7+"&724FCLD:_0O+% HI=NY!$K )UQ[TD!9>M:Y6,5'YI>$^>JENY
MZ05I$TY[F @=_9H;['E.#S<0(;WP_[/WKDUN(T?3Z%]AG'C]AA3!&>NR%Z\W
MXD3,2MI=V=9J0I?'<3Z")$C"(H$Q0,R(_O6G,ZNJNQH$1_+MT4CB%WLU)(%&
MH[NZ+EF9-[@Z(Q>D!KE*0[P^?S>Y"J8Z/,",.BD-=X\ PPK7DBECV ;?#/Z9
M ,@BV(</%-/DM#.GA?U)A.-<<B*99/4)/7V7YEV9GB>EMF\"<3E(*-*VILX
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M41[S\AS!A:F!8]6QLKKL-TJ-K'E_#1OA^BEG$)89*PX#WH9DO%7]*--NR^1
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M4#\1,UIVRBC A-8?[Z0IU$6!!1#.]^^^^_YWN1T<K*]1>Q>\TW;W(U?267B
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M#$T;'JA<V%3:55!-;X5TA3EMR""7\S K BTN(40FG&7)%S62>\R$TRWSY[J
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MI)T5ZYY%[6P8R<C2)LS4A6U2:NR=>HUF>\^JGJ;7CH[$\)(^6ZL0D4")40U
MP+FF.TNU(EG,TI"5B%'"^0BF_WC#F[5^,GA.CC*.\)QC?_CCR=/Y9/8/GN;1
M+6PX:;?[50_*,![("I'13%@<N!^-HR0LYPRF2F\%.A*M$?UR&6YC@D,_[Y52
M;FR/IF!!NPL'>TY"'8#6#:D\4?YSQ2W>9D@\H45*((B/E'-L^!V#B-18E"6O
M4ZM<L3GX"49<>H:?@Z-$+:8S_R,TF88#3M&)U$W().(:;1T2R-'I"4NP:#0(
M;00CCTS"/IOI? 0[-#S;F6!CI6U*_"V1-+Z== C3]:DL<Y.W=283Y.PKC9"T
M3T?N;Q_LUWN//"W?ARBVLPPK_%9VH771\/DKWPM7M@ZDE.4+(VMN[F=!N?0^
M[(<M$6KX.N$0U'3"$?N/U7$7@[@OW^^^F,VPIQG1X/<DW;D8*F4S=5/-^>G)
M*;\;AU((OQ_^\(=OIAH-%UU7K*()^;78S==G?RW>(Y5V 2&_:-+,TYQ.GC1H
M;^FZ= *PC6)2N#7AK >4@;8Q^_8/2XL/(!0K72I2,(CQ,+RU6BT]+;QX^+B>
M^&99JXV6AD1C?58U,.0DZ-VQF5>N/7;HN5:8J[[M>G61<8"[&H0TR9J'YHP>
M01QWQPZ=T.<G]/GG.Z=?*OK\U5^>@IK'&<GHVAW@P2[$\J3RZJ(1KF2E3/!^
M+K/T4:$(>F 0UO"Z2D<(P%'R#2:L6!SXVU1@T\C$D]&P-0]W@%D60UZ0P#DE
M3\R.D\1=!3]PF@JH4HZ1,!/6W22BS=;'<V#2IY.VZ7>2TG %*-%!X<&%P2'S
M&FSR2@M!J5#*#J1$&2"9A>AM1X&[J%23R='X$PF/,3Q/[%$\":%PL%,0[X,_
M+S@/U=+2"SQ=+/PCVZOPILZZIKWR[%6\HBX(9C/R,M2B6MH1%6..C[JNS[]H
MVF#REHH(CDH/?D'&EY0$OL8F+U()=NXQ3>2 *SM-BMW3K1*D<;"Z^EE,9^EE
M+NSHIN=Y:2E%+JLW3@?BF5T^3$=B/^FF=C.-^" 2K?DX.>?U-B^E"OA3T[R+
M<_+4\S9):7%3W-AV/?1A8NEU9E)$8T]O.(#@)S78;JIDAD1GA36U.*ATI/@+
M4Z4NC.,;N5H78>/.PUL59\_4O\CC>RWEB909U5"MO8OQU)?OE2<3<L0%SZGI
M' +(=J3*5R*B=L*9B2P:$!!ECTGQ_#Y;0D@*E.^OT)EN9O+)15):*=S5EC#4
M^[)HN\&U19!R<(/"93'$CQ==3OP5T8&2NH:%OA?%52Y)IWU CC,.I).B\MA/
M>7+^]N395/0/>+M(7$76AKJQ,V;;5#@3^3$>VP4%65K$1P;@0PBS*P7*,./"
M])==3[F>M\VFG$,,%8DXX6T"Q"TQ4N/QDK2+)*MTN\8_%?,#HZ]ECWE)M!88
MI6EU69>8K_'LV=3')(]RQT[C6G$X,\E/9CP#20B5JR$BT=U+5RI6GGF)C0[S
M/K>T&>>NF%P6;4%MB<GS_\FIDZ8)R$!R[,.DGS(WX C(9+F:OM5Q+!M4-RRF
M#/'E2O"G1KYUHK;YA%F6S)1=BGUXDI%G&;O5XP=G+\+/UBAHGV2\[LB1-.+Z
MP7:(4E?L;*%+4R*]@@^C*O:0Y@3.96YE0$1@?&;*S4\4KIKLZW)05'/5A$2H
MXRSU-GB?<CCUG<->2HK]6>'HFC5[K?ZN6G@W>M@QNIS,;&G2R7N"D[\R2Z_&
M--DLV-+NP%SE&N"YE1NH-XA]W#LJG8S_!D"O?/!VFJ2T5/2X#X8]Q>%07DG%
MVZ[#B2;Q&*<OADQYZ6#PG,H^T97E.VU[,@9%%6J4*",R!MZ2OI<9$ (=NM-2
M4TDE5J5(*C9MB%0/ZU3_]H2&FY>0BCLVL\,;CDSLQ.<E%:,G2FGYO-W%4^C+
MMV,YDF DTV%K9)B2\ 8*2_G45']JP?I$+5ABXM6LZ9+TB3G#E-#;IT=_:@X]
M+9VX=/1(TX7CPOS3*CFMDEM6"4R*KA2A2":/I/Q%))&(TY[WFZ)5]9HZ5ZU1
M&(?PD,7TDR453EW&IQ5X? 52*SZLHVJ!ACAM,F)6TQA--8453D*$,"F6R_!=
MIP;DBP%E>8S+/ PZ3JC-IKC*1\*NU*KI7YGVAYL^EOT1N0!]DX1W9>\2O3GH
M'UK<FBN,:,3DN\>.S_D:O[<1YP/*''Z-QM/"20W)DCO?;$8N(7F)I"VC@78*
M"-D*IF9R<L]ZJ4$][C(2*>V0.I2/0_4^&&K?/\62GU!PXT+S8*/=)P.HMY9/
M;E_>&7?R2(C**F4'<E@T(Z5>AP]?\3=E][53O=DLR("$5-%P:R10Z!QY(DV"
MA' "*R\50J0V=.3"$<-:U=6.2J&%"UAH6)@U1,6TKY3/4R6*=,BW/*)\I'V,
M,BZAZ;_E#JJ^]\VWP4/9=XX2E?*B5RJ&>LM,YA59E5CH8CY)U$&Y+\U(V/HX
MR'?Q>JZ\4K2;"FT(R\GC!R8+-#K (S,Q':G2I!3G5'*U"U-$TS15-DM:>1'E
M[F5QW;2TROHJ[FS^Z@1Q.T'</M\Y_8I.S%R,UE>3CIR>BGXS.,RB#+OX/^FA
M31U08AP3D0@OAC@&:=GR?EB2>3@ (^@81\H%!T4;/](N#;1II_9SFND/'E0B
M=B",L+O10Q$GXO0#)]"4(N5:W8N])7*8_KL'RET\2[ZBBOPEU=N!47N6EO:I
MWGXG+&5Z-][L %)3:TRIS;W.:B5BW>PW(QP!, Y3H$TC%BCBNF*E<[<KYFO;
M]46=];HEV4I0*<7;AHOLU(SK#@>45G\?96U&>\GVIJ7&QCVQY-K&'.YVQKME
M7]<301\ SZ*(!"O;"UPHA%QQ)@4.#6.T+*I6Z%3"EP7H.;EIT<I=&RM)@LO2
MK3?.*EQ#(@Y>38&WUH%( *Z#&BC.,S4/&PU7'--5<V4\;%+M7OP(?.X:K>&5
M*DUG++18 POPPXBVX<&#[ ;=EOHX&D@ZW?GTKIR>^-=K#%^V5\C2$$#\M 2$
M.AVC)_-XU\QC0LCZ]W9A"!!#QB[T199#DCT!9"BLNY%+&.D<4-TB2,B<<[CC
M0O6$0[2S(Q=42VAU23?,:77Z'HUM6=2N*4+E!H-]+6\L(_CHP8-IF"1F_H+Q
M[<&C-V:M&;FS[;LRG&?$2A)O)7E!J+ET86_#P4)_^'PW2/#.0;P!P8'RNMPT
M5T9WLRTDF9@FY[JH-I*.'3L[>$)@*KQ+.#8=3FB,P"*DD&!4NV)3#O5"3:8:
MCCB37,AQ3MR;B>\2%U9^1>7?D >A\;?3*[5'Q^MKML[,>S)Z [5G*-]L&D6@
M2K?*+G*&.,0^1;%V4=DIR3"0,>3ED9$G/>5UT^Y*F=_+IV]_OIBL&FG9<8=P
M)OAS(-%HHC@@SP"@?[7&0N,=PCNX+O=>N2T\:@%5+(MF=L7[I-TJS2#E5CI
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M%"<VTH4==18]:('=+.,OT]:HW0Z/H9Y&*KNVV70"",)JL%TZ\D"8<U)YI3D
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M_$"W(9)!J56.C,+]FNF^.$9X860+$J\K2XA*5CIFBK,;INN+G[&4,U1CCN@
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M7@?70N72Z9L-EU#,E-?XZ!+9NHVL)7?VIL>KG#=2M4XJGED=+4*LAZXZ?Z9
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M7%:)BA:TKPE0RT3OMF'2UJK>2-EU4\[U;0L*]97'J.$M;7PQ#]5+U"1FY;R
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M6/BC0@G(DVE))+N)'$?6R=,G+Z>.J,#>FLPR)7PCQ&R*66>+MGM"BN-">FW
MK^YA?<)9M:XVBW!JIXR'A-%E3?B&;\#B-=,N =PO*G'7IDVLG1'8' LTSNHS
MA^<9(NYE6>J[&0RS.#)(=1N 1Y4N&/V#HY-)2#3&X@8]YUN19DF.67([R(X
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M$M8'451$\,-<+WA22]!YU;=H06!159Z>689:-)+"2^ TA_]NVG<$J)%W45Q
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M@AO_]NW7%X^#Z*?*HI#1K* [1G3:3/ D,GF/84O_]O"+;R^^?9?O/=)VU^2
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MR&&N=UO5@]"-3&9\(8;M5X*,H)G7B?W1$EL1X5+C?^$#9<F]Y7CCG&?&HO)
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MY5-_+MKCY>&$/W/XJ>%"(9=]W=;75K^5+U!OAW9C__5CS_NN(#34YVG%T:!
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M":*6#\&80*4U0N&8XA_#U3+;IH$82UYQ><5-DC>JC6V[\B9A(!.:N+"KT&H
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MCU0T)$%"_C0GY%*9OEB]CLJ.V/.G<LW3@6B1Z^7<3&LP;.$IC^T,^];-%5%
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M*K?!-F'ZCGC0=T.6?O3 EX_2_KZ+-9M(>3%G33Q[,N5FF-)K+./OM*LBFM3
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MDY,(Q-P*CBX\%"Y\,^>UG4^-11WN G'^FTC9\ZSN_&%#[9X=!FH[0HA>4T2
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M0NB)*1*A#^7F)/Z2M@15HSNGY(OLW^KV1D$/7(B^<;8)4OCSU75Z5\[6__L
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M^3?"@H WP3]13-$F+G4:/ S!*)F-@"]=\OV$<^\%[J<_]U0WU-&5@MK)[@4
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M6@__9GZ*G90=\QY;%JY"%(V2Y"5,^?[<<FK1D8K.L<)=:I)J%A.3B=7??,A
M14]W!"ITMHV'GLK)L1&-*H0'7$0J&>J(F9@8G8OAO>_BH+1EBSBB$NWLY)@[
MIK<"%AD?4CC)4O,ELE4=YY:13+4)%9>B*D"M_96*?KD(R(]=V0-)+_^(K%5W
M[R(;]HXFJ3'7Y0>Z74O/D<C(L%?::ZE[QY/-BQ?5.?+5FXS787)<%L80%1E_
M1K%8JG<*-"4I;<1\^Z>7\*W;F4V^5S^MY+L6]W_FXOZLL/3V-AAW)0S^.>*R
M[5+ 97+07P[QUVK_$ST2OI]AN5JT#ASHD/3K3 8,H5\.\5C"4Y0\_4+3N3J@
MS(2$" 4G?(1%3KY_N0A8]OP#;+(,/GFA_YD-^,ZQ>]DAD%B]P<$8?2?UPF9_
MJ#EU3WA;]NFZ)$@8W#J57%O5?S1&;Y=\SY.$)8+;\GZ:BI!>4%=576X[(V4J
MWC;ES/:>;.VQFRR)ZF=,MOW/]]8N<ZUA;;0L8@PH*GU7QXA"6&[H8U.Q$.E,
M@$" CFKT)BZ+:2EE40XRXC5 U\'H9$:H22V'P'4_Y;B:>\5.NJKD!H\*YJ7+
M(.\X60I'L?RXI \B?\K<+@OHV-JCZ9A!AZ0D#JU3OGG32K5HI:Y;8XAX2ESG
M2BV<<7-((="^92_I8G=1YZ'>$N-9QYZ=#I%:',#NO"S<DNFTJ*S[PY<D#TD*
M0#.Z+]2$\\C(Y"0471\I*]@C7Y"=J1=<8F$7PH'@?:_BKWE87SG5J#&XAET?
M4]CUM4L)%_:"TNOK9H":(=6EB'J9H!+\-:K3A52=%5I5C4$H]DFQ*=SYR&@O
M8M5-JN?6LL@Y<SP:C6"N<[2KX30XD)#[#:8Q!HY"*N*UJQ[<YOFC276;>NC"
MGVR5JTR,R8:ZVKW&4]QM#GOIONW>2:7?8^,7PEA%^NWJNWHWDMB4<Q!3K["P
M4;T,V6S,L_ L12)D'>_"I#Z7W<R/"P7YT9_BZ?D,ZFZI3!KHE6J$A8@$V^ C
MS\R^S,2#[^,4;MM8Q(WY1$[.LSC92'OV!T)YI?C='J7?8-47,$$(?-,AE#1B
MY0O;58A%*&7T)!"QT!C1<U 7@T:AY,:7Y&Z'I2/P:O/-<D$<3R0UPY2:$"@0
M5Y(GS?D7\=Y;JW8JZCGA($W4[JZ[&:'Q:1@B&]2\D4X(=#ZZI[7%9F;P,7O&
M1\0""TG6VY@LK&,\S\/I1,)5QAKTSJ0_1%*-4$)%P'[,2)FO9!N+FY6TLY&^
MMP^B&4W>11IT$W(UV^A.".;'*6K[886,)Z;UJ#=>$[V@1U.:#%<V%OAT]M:*
M5UOQ:A_OFOYJI:II;KMM_-BP(84*AL9F'N=Z0@AZL2ZY?+#\8F5*\J!9J3(6
M*9^.0WS.]<&OS%KB:+J!US+!96GSXUQ,<8.)^(2,_4U[V39*0N6.G]AE7FM>
M_Y(L6(<9_3317CI L_0#PHJLPE=IL462XL2@4K9D/R$T-L:^HM6D(J= >*!V
M,V%RF)V&C+4AQ71FX+G(S>P'MK^O>,XSN^WI(T]OTK-VB!150>7X"G*W#"QN
MX=VEL*42H1=6#SFRH5!N59$41X#@4(^IPD=2NNA.U!>NTAYQ5"GK,91!(+/\
M$Z^__8;^]^MOT@I(0;E!;21,,YWFR*%=17V0R0,"V&R,/!%DN%PG2!Y-5RW>
M%DW'1(;KF[$$ZV@V0UT)(ASWE#/*Y#41HWUA*H(.I-.WY<XM_M0PVB6+N-I\
M7O$<.!<$(QVX-?7Z:N-U,[C>D=/PB,SXUMC8%W=)6E.>@83/#XQI7J6(1,-1
M[C5:D4),3X^D 'I4O*)14]7&-UR4<B>Y#8X<@#=#P,)1B@@3R4NH#T#4 _"E
MM>#\XE2#3R]<]Q%\7L2A1@:+!G?Y J9S-,@J:COCL*4YPYJ0=\'O$HB7UB0#
MSF$6,<1.'7"_V$1>Y&]NLA'G,!0X[FN;D1L;_0]_-/N7A,Z\ZU.DAH9V!-/_
M',I[;J;9,!N  2STBN% )V82W%'I^@AS<!&>)71C\$T;F^U^> L!K%#$$PTK
MHU'1V#B.)$).FL'A!2 S'WOK0*;IMV\Q.+%A;,?Q\:L0[8.,^*<NP")RSZ(=
M+S)#Y7Z#V_T,8= :"/]L@?"E"I3TO;1[4T,O:-<AVCT<7-]MN*5)C540[:F&
MMM^AWT*')";5F3')C=&6=-CN>/,OH_9UFH,.  T953G^XC<B<MG5W_5HU8/T
M<$[BR2B#@:HLP:]Y0FHQLC7<?P*E6[G^5X;-#T1#S/W_C%R+A8NGM!0F-ZDZ
ML$)^@\#=_I$V3"9B)TVSC%Q,P_KVOED9BE=[I!N]KXH4Q5I%[?!VCE(ORWB9
M,8LL$/[\NJJXD<^J0FK:$94?Q86CL:;"\W#M2[KST8;U;J75S6@R_FG<Z&K@
MJX'_2PQ\3\B8BQ+:&A8I#+TS'*7NB-585V/-HH/93-SKP9>'D$HWK'Z1$/A0
M0VMD.ZR2(H#_$!4*B-S*T>TLCDA<"N-7RUTMEVZ4H8&GMN^955S!M&Q07+EV
M0S<7#GBKCDFEE4[VQ"#3<Q[E0?CG0U6BC)6$$ZN!K@;*!II81>QPM-3/-[H[
MR<MNJ\-.61^X[FP3WH?*-PEH>D_A "0;"2(;'5BK>BV=. CZ:H^K/:H>D1]9
M,!9CU ""255E!P#R+E4LC3I$GA\I<N))>=93XRF1!O=L&AM9\#V$X#P[\M01
M#^A^R9'Z)>5]Y15"DZL\F'[OL?P'AJ*,?8.)B5;;7VU?<C)M.?O9&Q>JVE!N
MRD-Q(6P 40W[>-=@R_DK"HX6:J$*ERI9V"O<2F7UD9QW,9:?IQ6ZU:)7B[YL
MT1IP2/S!BMB3N7&8I3*NEYOP<IEIA090XC2W""@HZ"CA8;JK44R>*2+3B)B_
M_"BH#24 G+1*5JM>K?J"5:>FY^.$=LY%Q@3-]&3'DVBQ&W>A#D:NEK=:WK+E
MW4NV[SIGB734=&9ESAV")<[AMOMMB:1N+](4%$%<B_Z'E_Z:Z:(Y=C@"3-5K
MVV$U8#9@<+D+N\X2;!;-6XDOI1N6X@VIRWO$2%COF53YLP\.=R\PVWB9T4N0
M1LGXPD>V,N&;%.$>-O-UH.JGF]$Z4/4O7=/52<\X:=(396++/]W6NUW5O+_;
M?OK^.J9J,G66-M0NRC@0TS>G=JRP%=WT\BE _[)O#W7[V5. HJVARC,.5=SQ
M;VIU@MP7,Y\,9M0>FQ:WS1K\KA9E,N)Y:B]30=TQ0?*NZO.KV62.:'O;4NT>
MTKD"KS(F;VHP=1#E=IAOQ5=-ALK2-">AR< O415 I<"R'S+PUC*9T-62V3XG
MPI:WMQCM2>;Q,.L47L!V.W:%#C>M?)N_DC&BI2?_MN[?]9MO8S#\;=1\?14U
M7_&*WTA9[G6J??L-HNS_ HB"M.H.=7C]U>9K$O7H^@\P1_0SON4/-"+TBP]0
M.9X-:B8=*A%+CNQ^X8:VX5 !G6,_C#O5:+*_',@9B,!!E# RG> 3"<[T&#%R
M2IOI1"HN: -(D[*6CN?*);FUQI0.L6)L [>85@7"T@QVCODXTD5@8BF9!':2
MRQU_9A<VQAF@#?X$QFB-FFE&'YD9!*QYXBISCRES1W$$)T;-\DT83PYO;8S5
M=#>6J>H*Z]C>$SUQOY[ND&"DNVZ\F==@52-C)=D0\ASKOK?1<A+7HN]Z, 6,
M][\_?U5H2>.+SU_ICE)SY^D[\?32EZ8@ -<R,YR_H;$9Z@,Z*.FVU'&E\--$
MVTW_OSF&R)8)44]4,N'2-]3#T!$W'\+G?W0TX=?+@N!Y]R%P8TYT_8Z'/3$-
M(:KES#LK1!3;V^I(_#T0/FI&HG@<._4SX+)L#TS:8**H6%FL2-GXU>1V/4DK
M;:N:J"YG7-P^P[G,"A3/ZKR*UM-4[O4IQD"__LVI!M$VA[/)\M"IU=45A3)$
M%PJI:E9/9J-6*H@$!IVPXQ(KU8S=\#E*EV>J8&.:H3SG!><YMB,,4MAV-V4C
MQUVN?*%?2NG-PV&Q(Y0*"Y'5(/IDBR3,-Q_/5YNWU9;WR(R!7_!!<6/Z_9L$
M"+29\P5;8.U(=VM.@../V7&X;3O&+=#V4]J08 C@G@:_\=8(%JJ>*EPJG339
MH$:!W)?[2JA:*H*1E=LS4[S.[.DYX=]"(<BPH&.[PX%-S-E>&I@^@U8UW1J3
M/X==U=<=LRT28)E2UF8'(<^=7A_LK#_4VXQR>QM<7UBR8*-]>/ ^<KC@A1!0
M#DA^#5OFWB^0'\QQ@98X368[C,C85SDEQ<QZB(?L9WZ @\-RR^S?9Y;[NJX.
MS.9I.ES:P&=E:ZFYAQ,I)>[DSQ-@-4[(\MVL3O-#$1%HD$\O[8*A45,\&.W\
M<8@BSW77EB1;F"0+9"4##:)"P>T<_&#O !^DPM!''ACE&80+"FMQ1T[8 4;"
M9J2ZX8YA3"7]>UTQ'=R>&:X3BO5PF\/Y5!62'OV@3$Y-,-3#<,XL,#WSF1S[
M:O/ZML0XP>PIP&3<M*-W[/5R(FTZ?=H=!35V%9/"#3>L9-NNZ!\>=1@EPA"?
MR2#;MO-7<>Z4*/[#BS9/&J,A?; DP$2=#QP1,2^*&Y@=2E?]0P7=]UE,=>6+
M"]Z3PQ=Z< ]UW+H*5\E_0DU.>2>Z:C\R*0]Q59TXGO6!G#C>7;4EEVI8.)Q.
M-8B-(G(8$9W^$OV"\J0GK14[[XIXV)E;EEPYHU(B:U2Y98B01A4G5O0,-V.F
M##3_XK$:7O 0Q7#P(@IQCLZ?SWE[RAPF!LM2.S,?#Y%^"";J(Q]D$O3+,:<Q
M$FBR3/. M+8ZU8.%F$,?W)1>CPZ6>CA&,%970?4Q.0'T]I@<80*473W]AWCT
MS^N^&T^FANMS2U'J56U,B7 .K;K0\ LN)MY'Q]2R=Y:(LA=B*_9'/'KX/\.'
M-<_5?S<[">EDO.R,2J>&#DQAE>M#)@7K3*V-KH5[/Y3$*!MV4Q>,5PX?G%Y7
M;Z_\3Q)57G\[#IL=00OU"P/6%AM7^AP^BK6[5#)#6=."7>$MCT3NQ^X U9,M
M^4G:^RDI( 3&[=\BHI>#-GT18;7<W=*=XD:53DSJ_8C\:*V<$J_4E81'U<FD
MJ@50H2$\Y\$.$JGG<TPP+KWL'T/(;F_K WJ 9^P"N&KJ4N*9PF@2!M11$L 1
M+68-A;D":%K?=5JORZ2M-O\)-KK'E%#[7ZR&NA+=?YP8PA67^6&([C^N+NKC
M6QW?7R*<14JBU'?=*:1F7(&G8M!-8VF+CI"1$[O@_<*?"G3OQ>GNVH(#;/]]
MO1G':8HC7%+*OWS]BM,.=M$@%N$J$X^:4:E=YH;7%M,3/:,7DFO2.Z#6J&\S
M3&H=TY+,7T8"S(1G"/^DN;_:9R5!.<?S![#9A .T/X)*-/PGZA?M22L0H.N.
M=AX"U.]<#D&VAR 0RO3(*N>W1-A AS;\R*D^MCMK!@_$5ZK5D"_>_O5S-'@
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M4FUQ<[2'<FR(12HES@DN=.R3F 9!,\F=#35X"@<F\%E,X)=JL^_5;W\L?DD
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M6N>RCN2A^$K>A:I^E2T5KU'!5'KI>&_RSA^]P$FP.DLEXKUG?&+5J%?7&5>
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MS3H3RN30WK-?>$WUS8[_;"#__[<\GCXSF'\P&Y0S$ "$+*.EC6JG-L #4AI
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M-XO$QIT>3R6-^W#@5Y4=T:0G2BY6#B*#%?",\#XO:J_T"[^(,"UM,OA%$G[
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MMXE0#B'\#@=]131@N[+$?2B6. SV-]0BZ2*H\[[A6K"91(B9_[0,YI!'H\?
M.OW'OZ5(CFR59A$;P3:ZX3.LQXN:LJD_79<]BG63E8L/\[NKW_WG'__M0RWE
M[Z[^\(?__/U__O[E'W[_NT__^/N7[K'KAN[\!9[^PN-21/K'ER__W4)2MZC\
M&Y]^\DE^U0]C*4AI"@S)=PQ^9CQ_J7,<D8+@L[BA"#L1$12KR3PKDR&?$DZ^
MV]DTNR5Y5W^X?$96M1K.:CCB:U(G,QME%.BKZT1*ACT-D>6ULA8SPXYPG*!#
M)<,Y/NI"7:CJ:VI</FR'*X!Q!3!^9&OZZQMA>7Q^_\889;55OVV[4XMAUQ#
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M]:^Q]+OVNTMP0>:8P EU*;GCF!:2KE^NHC!DSHT4I[KX!12BQ.@CDN;4JM2
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M;(0DJFFEZ7@JK 'B,_JE--.@D5J)>4+2188$2[DU-JF3'^/S>!G]E\BG\4S
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M 8MI.AIQF)%%%6M4I6[=2C)(PD<UJYE19B R(RAR2S*##?S([7R=%AH3""1
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M U,/XQ;8Z)H8*DK54B).LRV!<0MV6%+5HC34DY(ZKB*4A:'&F4-V<087TU6
M%9Z^PUH+O'"L.(6NZ-(8HO,H VLTCR5R9+SXL.W"%]H>) >?HUE3TZB(;OI0
M@>U(Q4+8(Q1AB]#" E#SO\+&-TZ'T0QR_L%6VSK1,O[Y9J)RH;C%&-DHNH:O
MH->H<BK1-:(XZ@5O1SB/HRC-[!AT<7#'JYV71KK["EX6RMM"'8"@>BR\R2XJ
M-8> AH.)I)C@,(J_X"LHUZ*KK3IZ+^Y?JD0?.BY)H,@M98!!>KRS<JO">RB#
M*&VX60@-@.;])B5'&9V-%8^CB>IX'KP&#KOK!X)+^^KH^W[[SXI:EG1E<=Z
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M7/A[709H@R[N NQ@]T::\&';4)4F"MJURI.BK'K!>YU2D?@-2IE-0V,53ZN
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M #'W95"VQMOI'I)!]H*WH\[IP=+(JC4Y:54U+%@CEI"%>6E_"5L,*.P1]6^
MI$88&N?UH#]JQ#&WL!(\'I(#CORP5=FQ:$,U+Z2FW$H,[HXXG9$*YX" Z-2.
M!^#S44W"\D3749I1M3JQ.8O:E%4*<>IQFK-LPZFZZUZ!Y]]YJV@3D.4UU*$R
MVC)L)J4YS!WL?3BB&OH:$0D\.V#27+,[U&(OZ@1'J:(IC:S+9(=?CV$HIOBI
MPGECD3:%]C*UH^@:)H(FLP@:(VP1O*S)]>_7S*=63^6B6F(3 94;[BV9@J'I
M'"#C,0%'=H[Y&M 7&/^!CR$#&8>+*G#!*BU71T+5"+SNNK)?;R=4'N%HO=OJ
M=UCV:3??X(?SCE[Q'%@KV-O;9;KZ%@??XK"[<_K\NF173<(5GL18/'L9QW@8
MXB'RO@"EK=.';\0OJ![%!M_)7E1L H&_1WRN8ABN?_:JHMKEIJKH $?[ 4ZE
M>94:@\JF]>%)XI0M5M<;<X9.NV&K/P]^BR"\9*C89X%Y7VM#@2-KW-^FX)3C
MT#&#?D2PG&5"EA@YJNPBH \,?U$SLG[LBL_ I@>C*%/&:/@C3_&:CS6WH7ZB
M5@%\O/$(M)^X9ICZI*VDS6\:?5'!OYMD;(L@M.NIC57'1%78R&HM-8I!5962
M&\$ZHE(-8W3CDF1%)15D'!0:4["\\R;V;Q7&$Y6!2UH_[]I"[QJ=:5ET\ 'X
M.IIG<)Z*!.831<I^]M+B@\\-SCWM2WQ@F:(M'P9?<O J C"\T/2AF;NV(X);
M,6!2P#2S%X!)UZ*T-H5NZXS(BC,6+)>KTZ>G9=Q,T8&,]80ZPLK2!O8-(Q/
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MV\4EY!G [ (M:P0VUQ37!^T?.&7BR4$SDTB3C)YG@B))YD&]X(K,I$K+N_T
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M9RCZ%)870]_>JS-53N 8O27C)AER#7TK^<::[0"]F[FJ>4 X&7!%8E(GU%
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M^5=S1#$@F[=BO\0L4&=G608;9[:N!N-1/<J^;!80\&SWWV!XI.R,/;43;G#
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MAU4\.^\-?L18N=B/^9/5><_VX8IOOT4/-,RBAK',$^IH0E)ZCS@WLA18D5+
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M\._#0=U"E1ON$'7H^14 7H=.RIT'+W!F06ZW9[L@MP_,Y#2)$A(P2D25.ZQ
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MET(P:KDR>JFC?PR>.>$Q8LI2Q*U4R%$:D-6)<D>LQ QO'G1Y-G(9TP"\ +P
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MB325^P&67\,B_&"%*S@SP#W]:,^&949^=5?KEW"S=KKNY"/7'?K  6')U>Z
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M[]F>G2#J,.=^/X7M0[9M>*N>=HV$GMS@Y@X1E]?U8O7.M@J,A;"/MMXHX'L
M3B:!O7"N+&+9.V,X%X\!Z-G?FR4X,[ZS(A&?>:<"OSP6H/_0WBO"\C++NA(K
MWTL=4-+5'ZUK/G]W5.$I%Z4]V7IZO$=0<V_B!;^[OH@%4'?G-N)=.01X@AA
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M[?-+2JK/!O:$EHIC0Q#&16J!FV-4BCQ#/#59SJ7)2;(7/N3W1O]BO@^\=?,
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MY1$\JP!I(ML\$WVK7G<XH!IW7=D^GW-%?X1T, W4:;=]C(<,E*CRZ0)Y*+P
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M0P)SJ$$[Y]W]6]ZJ)ZY;=G4TGHOUGOC1!_4.0QI:9J654;T #;5Q%[ZV@>W
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MFNMZUUNU9J=M*H Y/M>+53.[:T6=-D_DO%G=!(8E<"4=&Z/ZP$7P6NRDN<'
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MY1<@;$8 #3Z/F;\L4)N1HEZ,YMMJ0AB&:CR9ET-G<&WXRI_#HL UL@+@9S'
ML\UB\:]70SAI.+LHF67YYWSKW>"4?\WWN<[L.1YIG6VY5G9Y3OY75?TK_'>%
MB:/X'84AK%+FRS?PE(N+\=LPK*<C>_DF__IV:D, U-C(WAPV#] F/.(SE;_Y
MQZ*>#]/E\F'*N0@6Z*V;?,]O!9=XL_)7?;^E4^HA=+YVF3[]/OR*CD<#1&P1
MP7+3SU>)JE/[)38YJ,@F6*(W=O3-7M9O?_C35>I8;GWQ#^[9]X=L[^.'-PZP
MGCM\EKL8:7VCFVAVI2.TG+DTQ+%+(J?;\21(FV[GL4'$2,-]U,[&3FNJN_C2
MEH;XI]ED&F?SRT\C.YZ_&X?L)9]FZ%O[P#_#'?XRFOA__E!%$/K3+)YFBWA+
MGM7'D4W?&K)T(#H.L>WBK%JN5)%.JV4:P,GSA[#W@1]T2YTX*$4FDKBD#$C0
M$YZG='KD>")(:1EIP-QB1A^5(F]!AW=2F^1SU)JVJ#"NJ7 <YWGMZV&=-1@P
MA[):DB:CT>1;-II^'([A&S#+X;3ZIS>GINZ>3N'!'?CD-J^XC%^UFF.W"L,N
MYI-EY"X_2I:<\![Y< 1*UV313M!ZV]R)8'R&_[@\ =YG9*=U?%/'J<W=[9<+
M4D*WS;5_V%6=\G58#QO]^LWR&GO*3IK;2GDF#3!3HQ3L.8B<47W3(3?]SLZ8
MO/$^3_,<^F[/<4,AD+ZVY=4N2KQ+<="-XU&6W+"#X_2!&&ZWAOU(:29W2:,Y
MU L^118-T$7^]?_Y 43IM:]ZI\K+H^W^?92@V_@Q_]7-_O3G3>/Z[K1RFRK$
M4UC"GH%Z!GH\!J(] YUBL>]]:GM/1X?>M[C_8=W:9.DS:)_AK+/C9,>^U,Q7
M8HQUC"/B<O=Y[ 2R*BFD#=:8)L)$Z+27Y"DXHJ1&(6**N!4QCQ%)B$21L*""
M^-R2\I8.E5)(<*@>R0.I'[E%\K/)7.TA[(2WM(>P0T)85,0IXI&.N7E[P %I
MP0C D<3"6N:Q35<A+')ON)4LMR*#<V2DR";#4>(V=WQGP09Q) C#0O40]@!-
M]QX=W%^FIOOK8@84N9C%XJ9/0&[PN6]&\WKXIQ<36_EN)%IG5412N3QGB5KD
M"(Z(.Z:E"_"1=1)3A>=4\&@!G[6#<Q1'&FN&3'3"!ZV<D^$H8D(^=FWL2R?R
M'K=>W):^4-PR2LO$!$=4AIA558%,8A(Y#N:V8=18T['0$Y><,LN1]!;.$1(.
MQXXASQGG444<PNU3'@Z)6_ N/6[U;MR'\TI.JEWD3/O>E_OZ>*<7$%L#[Q*U
M(<F(!(X4U-D@D0G,(6I4\)XR+3B^*B"8$C%Y$5&4104V#KED-$J.*1P\5XRG
MHP@(9AZY/]=+)_(>MU[<EKY8W J2F=R"4'K +<X%LH89E(RAA)CD")-7<4MQ
M$ZDC%%D9P2 /BN9F6 0Y"P8YL0D+PWO<>H:*;>^U;1?W]TF:?[.SV(N%5\,Q
MO5C8% M*$N-#,DAP A!/$D \$0F99*6E401E2*?$PV O!,,(@^AH0H#6>8N<
M9U(8@;70[BAB@1C3BX4>M_HM??FX976*R="(K \&U%DC04D%-$HV2ATYCU9U
MBR6UE0'^/\**)\ ZF\UPSU$&.DNPYYYVYL[WN/4,U-G>3[M,MXVVCDWOA(OI
M;/(UEHX&O9!X-?S3"XE-(<$%<U*HB!3)37=$(#F70,,G0H+%RK'4R54#]=4:
M&322 E1:'IE"(&8H GW7>^:-TTX>)Y@W(+A/M^V1J]_25X!<5"2=A(G(YR9A
MG%&#' L!$89M$LPK2T*G79@REJH0D6:Y17;$#!DF+++",1.<2<F;'KF>I8+;
M^VM7B0CC>CY;M*PRKJ:Y-73=:[C]8.-^L/&]4W699084VRPW&,B:_,D'CHR0
M)#A)D@T=%S#C+$K/)$HJ]YV5VB!M#$:8125L4E3()\EH*(U2T/_$V213A::$
MONTG&?=J= ^//3P>3!7GD4OB"#+!:U"K74):Y0B9C"3F"!CWG8Q@+"7S%HX4
M5GO$A6;(2J>1 N4]<.V),IW^^$^3./&D VF>.3SVSN@##&Z?[NQ>UTND5V/Q
M]HZ=K?)IIF/DV(!D$!%Q QJW)2P[=HC4*848\(/ZP#]MW%(-C.I+3'KHZK?T
M%4"7"B%%4'<1<]GF=TX@S5U 3-/$C>.6J@<-,7]JZ!)R__28UT7GO5/Z@5D7
M=?VFLNMQS4"(<)(?VDQ3O;SHG2^]\^5$QKL3&;CA$2.&B0=YI#UR(H \8@ZT
M;VM=Y ^:E[:481NSVW_>P +X/(KY XBU=Q<3V.K_*=_O%7F'DG9TH.23SG<_
M&==//]V]1^D>I9\72D=I%':)(D650EQ$@QRV$6G-B<:8!H4/8FF<&DKC@92/
MG"CS,E&Z]]0_B NOF3#3R\7#<AP]HYGEPF21I\,<43(>IRGJ;1;CV0O)W4(M
M$>6M"22/=S.(.[ @;,(&6<7S]-<4J'*/ZOG_:SR4H!(#2A[9[7\MH3R_4'(/
MESU<]G!YIT9\29.0%$8:2[ !O$W(F:!04(P+F8*(M%.[<]!HP^'@4@X,[N'R
MO@$)^)Q'X_UY]SCCT\#'C7O?=X1@=T'N-^+RB-,3[SL@<M/VKN+W:1S7<6O.
M=KUOT'8Q6#9G&CW]PU??;%W]8=?][W#QPR<M*DH-UP))B4%QM%$@;:U"&#.#
MG<(B^H/,$M[<NKUH*;?04MR E@!>>['R"-L+1X_RNF9*.[EMMM9A)9U#8 ?D
M;"+*D-.&P9\>\TA$9$QW"EP=$=QJCB)S$FP*#2(V2(Q4I-H088V2[$FVF9_@
M-@^J6:RG$1[G:QQ=GIW(T-R=DN_@\\>=CSS"YB-C@\\M-2ARA$NP/1EGCMC$
MN@;J?3#C]\5T.BJ=">SH+Q;4+A]_/X]Q8_QX_3GV\\?E6?4NA&%F##NJVH6J
MRDJ!()S;X>AUS" 7./@D+1+P'Y!DVB%-"$'1"&&B\T3Y3L3V+E29%B/_YG=_
M'L-B%#^F3[,XM</P2Z.%U& 0? 0M9/9^,9O!F[ZKZSBO/V=]]!8D>B>][9F.
M)B^KM53:ZB(E)WG!*M^L6&7+DO6#RD_&KCCT?')UK/'DYA;CR25]Z%AP>J8U
MP^O_W7C"R3_3$XTM[]+[J0PE?O%3EY_F!0\X=_D8R_',!Y6_! KJ6>1UL\@C
MCR)_YA34)[4\,*EEVS;I0[//L)ZE']U[R+1*0B+ERB(?#$><,(Z<-Q%);36+
M-$F+.T&!NV2@%%?*%0?*H?H6#*3HJ[5ZP#KY+>T!ZX" )27/(V@8"DZGG#?'
MD>5"(>=\THQY$OB#<D >%; X%3U@/4"1[<M+KRBR-5P; 6^XR7B1?>WUPOTC
M^GDUGU1?8SW/KO3<\WM8 Z7UVN[K8:]>9FS*#)9BXC$P)",-N7\W18Y9B[ 0
M,GH?HJ*=.6?W57)_A]?Z./Y+PX^_-^SX>?+WAAD_K7CQ4&UT'[EWUTLG^![#
M7MR6OE ,DYQH24"'Y8%&T&&M0R8YD>%))5!K!2#<H?3>I\4PT_<![YV[!^";
M#YG9@4:KX=A/+F(UBSX.O^84A5YH](7\?2'_?;L38JN9$1PIR1GB@@IDM%?(
M&9HX,9R %GV(&L4E^_ZV8MM#E= /%'F=%?2]*MVC8H^*CX**R2LBC68H:.D0
M!UP#A-,8$6]IC,0:U1V=?I]2Q$=#12UZ3.S=U4^DFB_;?M\R,[R73'W%?%\Q
M?Y Y/IZ0D+!$,CA0Q!7-(B<R>-YDL%).<-^)EMZOP<AFP'19(=.4QK1U,@?K
M,\+YDPZL>/:%\SUJ]JC9H^9=4%-(RJ)B&@DN$N*2:T!-85#4T5OF'7QSH*[F
M3X6:?,#D(\^3?V&HV;<;.735+@Z*^(AMUD $XM93I!TV""MAI.3<>/:@6O(K
M5;OOO)\MXKZJW?\8VE):.(R/4[K[#%NNM MVG7DV6J]:7[U[,FS:5^]N'=)7
M[U[Q3AVJ>O<NU;H[>.,YUUT=NS3Q*:RE Q8FGL+N/_-:WE-8PIZ!>@9ZMI6^
MI["$?>7OJ42@?OD.VY.;9LUB'>W,GQ?K)L2O<33II\\^USS+OK+ND!G&SC,9
M,4&<8(.X#!89;PBREBHGL)9<=S*,[UPET3H9?FNY\-TX_+SFP8/7VQ&YOZ'D
M<Z7Y/@C4PU@/8_MA+*BHE9,2)68!RWB0R%@JD"/!TD05C;[C9KYSH<13PA@?
M*/S(<_J>#8SU>5@/*QNVE[/):%1T7Q?'$7[MDZU>#_?T@F)+4&@5J,04"4X!
M]!T#T)>!(<-C$"0P[34^1&[4+Q?3T>0RQM]BF2JX$7D\=(S_T>L<7CJE]^#U
MXK;TA8*7L<1K)SF*.H"Q[@U&1E&-@O5&"<)H, _2<I\>O"CI>QGTKMY#*+FS
M28IUW<Q(J./LZ]#WG1Y?$?OT@F)K'! )@3D'DH$G$!0Z2&2--8B&@$U4($+,
M@WK?;,S-SAZ13>;[-1Y<2HC>G]OC5K^EKP"W$HXX:>(0C<F!LDH3,@(^*2^,
M8EHP[CK6^7T4W"?!+<'ZOH^] _< O%)2V'N9T#=NZ!LWW%.N*$NP5C(B$BS(
M%:(<,D[EL8::2<R29+@S'O,^^G#AU$=SES#SI,.CGWGWAAX8>V#L@?$F8.3"
M:$4P"AI3Q!W%R#EN .Z\LHJ(9 T_A,+]N,!(\"-KVB\*&'M/\P':VM@[U4WV
M,JKOTM!W:3A(EP;+6""!@R:/02NWQH$2#XJ]4<81FI)CW!PJ7WE#7NTO)#]4
M9[:!HD^JW3_[7@T]=O;8V6/GG?J"F< TL0Q)D23B22GD+"7(4XP9-5S:;JW'
M?9.DGQ([S4"(OCO8(_6YV?DMG'H:*'J =B&[.FOLZ8%STRWV],!ATA$;O43*
M<(]X!/O:,4F1<#@J8"[E,7M(#YR-SE(I H^%W^<3_\];-+?9OW-$W[2:C]/,
M9K.L^ ![J\ZJU:)4955V]H:Y4Y,?>9R5>6";GSHW[-DLR*YR-X-BM6Y693_]
MDPVJ7?>^PX4//S@*2\EC ,/"N( X,2D/&Z1("V^%%3@*]:#IJ+O9]?=S.P-9
MN9B?3V;PWF%+-M;EQTVA^.&OO]X@%??DOP,..:,]LI88Q(V3R&HK09Y'(1@E
MWI*#./P>^>7$ #8[_]\.L;]'#WAZTJZ:-\N<MP!PR6/[<CIM;HG<0E*=%Z?Z
M%F>QLJO%.3LYCK N1>? WG;>:*!N;)!E/"'!N"2P^RD)\E@<\:&N%W<F&%1'
MGXDF.R?K.-[[7EQJ)PD'2>QSFEPBR B;4)0T!,J#B4H]%C,\YGMIT Z$D09)
MJ?@RC88ZI+U+*00;HCI(D<NN]_JXF-=S$"O#\9?'>;D0 XY1,$2$!VU*. 9
M34";,IQJ8N#)W:-MV@%?[J^3VT#7LP"WG7@V+/1=36;59+UHE2TG'.^I]VM
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M4EPYJCS(&4*.[8AA R+40+!>8^Z!K-_25P!D5')MG#7(Q91+,24%/9@KI*,
M]5ESZUFGAY71427FX$A<P$]KY+Q0*$GF#;,>2VR.#61D8#@9X'Y&8N]1/I*^
MO)P6W2K.GQ8S?V[K7F]^98S7BYNM%GQ:*J>)02KDP3I*>.2HB4@EHN&R0GC9
MZ5)'/'&18XLPZ,_929V0ED)FK=LKG1A-_KIN 4\D;AB7 T+[T98]D/5;^@J
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M7Z(]L^F3=])1KJ_^/,FG?JTZRL>ECC(H G-PXY"?RDZSRK%67AKQN51'7/2
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M\<CG"L:?B)$4AE]W4/%--M /NR,-/,CH8AX?S1VH)I%J9'TR\(^0S#H5HNQ
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MN81M-[8.<-N?H\6T5<4+T;Q2++GE/*Q3F8=PRO.GM.'<YXBF$24>RA/2JA0
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MVZ/K]N+@-ESE00IP'"2B.&'$==1@D4J%='11.LNQ=:2KVU(?'"5("BJ $Y,
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M-P'4M:[O=:[N%7 ;KQ3:!SVN\B6CD9(DS!*?\)@)D@8B(RQ*6"84&''+W<R
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MMG:6E<+HF2M0 ZAJJU;("6AYH$PNZM- 37.Z@?D&4QI.+9_N' NIL#%0%P:
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M:@,&+%!#MPRVFT;SZ.]6M2_#^),FS^1-]XRW:_J2V;>&P2"-TN\QD'C]16S
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MMN^#&J<GJL&?)^IU^T]%<7I=OT#-Y:(X4$-0"RB-$L[F06U_$=EY58_G]##
MI"WCW%W1U[O!.5>+IE\XY_^G [KC7X .Z ZA>@'WE\#U#X8IAP#]0 "7$_&,
M &"[YMO><\\>D ]Q])J0L_CZA8,N]<'AX!H<W'M>V&:GF%N&P+M2PQP$]HK,
M=P2!+LW!0> :IU?4BS"VL\DEK,!-IRI.3SO?VP9H984H,S+#NCF._%*5YY6X
M?  $1OWUAW6-\(ZK_]NQ-PAS3=>VOZ:NN9A3:O:HU+@$IA>HU#PH1&M_OO+.
MOFL4%VNTS8RZ#/27#]] =[#&V^<LRY6IZH=&+;BP+8>+&^&B2UIZ@;BXF;&W
MMYC57\P85.D9!IYXVJ+<GP786F#G-0XB^!=@#_%%FO&U,</Y7A2V8T4I85N\
M/P^\G\M)\8#2G"SIK\'G8' O,.B2EQP,KH'!='\A%-9D73CFO V%_F90^%-U
M(U"CP^S+!^!@ZG#P6&A]1SCH,ID<#C8X&,1AG,[AX-ZLXU56<0>#OXH;CVV(
M@:>%^>:]&WAG8I17VZG3OH-L]M/)^:0>=RJNP\%^X*#OLID<#C8X&*9Q&/8-
M!UO4B-<@X:U&C0T:PG!/!]ZOD[HN>XN&T]H>L</#7N&A2X1ZV7@XJVW$:,SF
M\)!%?_?CM!=A(7<!YF<U1N^@YS<&)]T$,M]-8/=J[W,QAO5]R G,_N-'7"FD
M?L&EZ^;S N%R[6GSJAKJ;.]%U#_!E9?#IL_M8BK%'1AH!* +W)R/ZU6GTGA)
M%W7W$(0,>W(@[8JL]P\[72;:"\3.E::WS]*(SA_%[ LRWY7#>E*,8?%6F-ZC
M*B\\?YT3<@6&?JCAR\K[7?Q#7)EBL@B3MT'';<Y]F[/_2J1NCQYLBJTS5FX\
M%CK73J_D+>_VX8'/G\TTP8FN?UO GX% <Q)]9^VD]E<>]G=<MR:SLA,@**!_
M 6-F6)ME62]JO/BCD94-OFAC5Z<R7UR6H"$LRIL3[^="?"O/+D&4_ 4' W;7
MV!0%F$CH]_E2E2/8UQOO%5HP_@_P;KC2Z.7;?OGEG7V)_=[[&?!NU%V\I=*T
MSM@Z(O;;$?B'#OP=^._EY(#2T(\#?Z:-^H>MH69!\5'RX,R,QLTII1_<.DWH
MOT1X_('N3!; II(@2>/DD:)@>LK+:+-^3AST1!Q$3APX<7 8<<#VF(#W#K-\
M97O])I!O4]=\NOG9\:\WY5]$I7-Q@I583CSA75_ 2V](>3V$I]836>?P:U/$
MX*<*;BT+N G/5,[^.<FEM#4,Q/!F'VUX'++WB+=VA.RQ0W:'[ <*'=^;VWF%
MFK\1U)LLP\HI5Z:%^_:,AVY^QG-4>.\"U9\/KB<.UQVN'R@4?F^XO@%D6PT]
MW!RPWYW^^H5[7R\,C,A,8*MJP+L&=A'P^HK"+D"^ISB<'C]&.)#<W1'G_J#2
M8*,W+"+D1]XO@"2U1A74.QL#=$Z]&E,8:>*86+P2,O_Z9?$A)U,7]"U W1PM
M[X)+=QYY1+RR QCUV8#]Y_&CB(/1Q38D/MN?HGBV8&<OXHQC\1ZP>.!8_#FR
M>+#?V&RK%F3>AVI8C[W_+2Y';[W_ ?X\!_WDRXF7PS-&!OZ!JRK+_J"+:&\T
MD46N/*$47&ICN[.\NG2H<'A4")Z?X'_"RGC'OQ*WX"'8HP;P#E=BFN,&(/&E
M N,D'XEB.7\-&V/7$]$<%/P^*6":+!"$\5?B!VLZL%"W?S6M-FY9%U/+XE19
M/&)IP$_0'W6JRQ%:0O///VMJLWL!]3O=Y$Q44@Q-33Y_*\Q-]Q3L/.)0J1>H
MY#M4>M:HM+^ D_6H]#$?"O@(GQPJ.52Z'Y7\ ?L_Q\^+#I76H9)_!+H22[R_
M#LX&6%ROQ0\6A/1>D$EIY$"FKZQT"V1\!S+/&F3ZK_HXD.D1 >T 9-)XP%S;
M^>?G#$[C?3J#YQK]_0YWPM+<>%_*(E<W35Z7._TY+,<SR@:??CL[?BIWRL26
M5^*_?_K]%^_3L!X+C!-Y7ZH)AGNL6A[7_-(UOWQ>:^J:7SJANV.A>_;NOYZ7
MJ'F1NO4V9>U7\:T<EI<WWH=O\+6-@SQ3%^92;"1\':ONC%7?G?[RO"C5L>KV
M6?6=*-2D:"S=7_+A'Q+CO!WC'I1QWW_X^+SHUC'N]AGWO<GR8>[XMB?;A'S[
MR^E/SXML'=]NGV]_$=(4CF5[L$/(LE]^__"\*-:Q[/99]DME,#? *<E]V2A&
M^?,B6L>UCR>&=W@ZZWT1YTT%3&P/A@%F[\58>#:O]U565I=BW)9=^S2T52\M
MK]O<7C$:%; JZ#D?=[QOIKR?#YN[\3.^4^18>"<?=NG'M0=BY(=-CY=&MW>G
M71_6G05L8:6GIQ[MF90?CL9>71:Y7O3;)]$@BN+OGWB,$6WK%&-A>>R8<IMK
M]8;P0<S3[Z>D:@\T^" ,@N_O6#/_OG%MG3ZW<+3S;]A-"6.:,,?<@RN!J&VR
M.EZ"A.V5E8?5G%07H%!6-]ZH$,.3Q4NJ"D.U\=:!6^(5I8<\#!\#5O:P?@JP
M=MW$=N6UUS86]"X$8(C$D@7E96ZQ0QHE)B#W,02LFA4IN !,T09PY](BP_A"
MC/&2&]@$>$ ) #,LQ["7< 6&I&&D/;P&'S*^&1G;!&L.8KK;Y]\P!ID/. /O
M&57Y%3P(MQAFE.6X>?!0M\>+>_R?%O>U=V$J@Q#OUF=Q??Z/]W%2#?/ZXHXU
M<H$0+A#B>-=TEU-4!K7,QW+N=;-'LBST-M;@[-//OYU^_>OO'\XVP;A[X8P=
M)9[-QVLWLO.?$X K5'_:ROI=H#=*3A:^TC],8[DW2' 36/@3*^>ODOQ8'\[J
M!;K1'ZJF)!N,1!JOAG6!']",@)%(<R&*#.L8X8-L%&IS@7UR929#N,L^4$S&
M%V4%:S+M$=8#4ELK17L"(_>2[D,LD2.-I.+AW:%4X8!&=_P<#.A==_-HP%VP
MU?%$]#:C?-Z+ 0_%7_[O=_YW+W%A/DX*54TN%RJ.VEK1@P>ZI:,#<NQEKG5A
M'K(=43]WXR \Z];"K<6QKT5?=8GG(RC>@[;Y9M9STF\*/6_A&.WY+)'+H>I6
MXJ>;-ULCC/7'45XWMI4KMF)VO?3JK%O#U_5K[[0PWSS,-!>CO'*X=Z1,[1;C
M2;KZ,UZ,NRCCV/'+8==SIU"W&&XQGB=V8<"F#8YH>O)<Y"9;+CWVX)@M=Y+V
MF".SV9D8GI?9B)KV6$R:HKSNCL.RLH"_L'SVR%2UC<@9=B=F[8OGCM[RII.(
M$G@",VW)43;?:AL_E;>15-J=6_7_W"I('YG_SX-'WL@V.LA*=J;'/-I8W@R;
MDT-#\]()]#HR_@VPXCYI]O#%:K:(!CM>GJ<@]2:+<Z^<=V34KM37?%PX.G)T
M]-250C]Y;XY.5^_*9DN^K>.?W2_Y(XFSEZ=>NYZTVWNW]\]Z[P_C5=RQ^.NO
MIV2C4ZJ=JE!'ZV)["#+U=9*/=I0]MX5X$;N]4?1'GP#X2(R+1Q^A/9; #FQV
MOF@F>G5'-Y.5>>!NDY_'')T'H&\&42^M0#='-\=G.<<^*88OQC*'1_TZJ>O2
MF>4O2<=L#/'E/E:O[FARM57=LZ\+\R)V_ZEF^KZ#%H[>2G\:R!Z_9>/FZ.9X
M+'-T5KBSPOO"-VZ.;HX]PK^#6^&S0J//P?C^N3+G6%[S:SFQU33%9#M&^.8V
M^"[I<@<5AY^#[?4W,*6]Z:GX26MFFWG+^U0I8*\QIBKLPO1VF^X,[N=M<&\+
M6!W_/*.Y/>-M.X*IK0*W_B':;DUI1R5N:FYJ1S6U/AO#S_1(^B_8?^"_Q%5>
MB*%VI](OZ5SRW87(*WAEEX__4RFJQQ:H?M$+^2(FZ8SJO6+S%G#Y^ \'>\E#
M!U;C7L+^'=,<W0%V+TGHF,X W1S='(]ECLY$W[N)?E8._R&\G\3PC]H9Z$>G
M+CZEQKOMT5>ZA.WG,DEG0^\5/)\,G,=OG;@YNCD>RQR=)=U+$CHFZ\3-T<WQ
M6.;H+.F]6])_%OC^/P^\=V51Y$-G3K\HZ\N9T\]LDLZ<WBN"WD9/[\O%X/W*
MOK0OP5IQ<W1S/)8Y.LNZER1T3-:*FZ.;X[',T5G6AP@CSX?">U]6XW+HS.J7
M9(4YL_J93=*9U?N.]'XJ=!Z_A>+FZ.9X+'-TUG0O2>B8+!0W1S?'8YFCLZ;W
M;DW;$K8?_F7^**_S\;^<.?V2K"]G3C^S23IS>J_XN8B=)]ZO/[V[^.G$>S_P
MOESDQ4NU6=P<W1R/98[.ONXE"1V3S=+'.3[C\E\O8?N<67WT9G43P/BSJ02L
M\HTSJU^2%>;,ZF<V26=6'R#X^VG8>?RFB9NCF^.QS-&9T:ZS5E_XQLW1S;%'
M^'=P _MY==;ZO90P:\P,_+F<%%NJ(N[::O78^-J%->VVT=G0S]N&OH63)]M/
MH'[&/.2FYJ:VTZ8S\+]"%L9^[$5-^<55O/-MFTZZAW.S[][:Y'1^-9U>8;X1
M;165O 0T+XO)Y?"MSNM1(6[>X*]O1T+K?'@^IW3FS?M:^48',7[SCTD]SK.;
M[MWV7F*&&G36;S@)>,2;J?KZ[1 ZP-[6^,?7L,)VI2^FRL!(G)M&IA.1@<1\
M(XIK<5.__>XU7/CC:UGJFS_]KQ]?7XPOBS_]?U!+ P04    "  \@%M81;=U
M00%^ 0#S/Q< $0   &9U;&,M,C R,S$R,S$N>'-D[+U[<^PVEB?X_WP*K&=C
MVHZ5?*_DLKM=W=43J9=+4[I*A1ZNZ7%L5%!)9(IM)ID%DI*R8S_\XN!!@N\7
M"#!O::;:-Y5)'.  ('">O_-O__-]ZZ-73"(O#/[TS<GWG[]!.%B%KA=L_O3-
MT\/QXN'\^OJ;__GO_^W?_J_C8W1Q=7V+;O$;6JQB[Q5?>-'*#Z.$8/3MPY?O
MT/\^N[]!#ZL7O'701;A*MCB(T3%ZB>/='S]]>GM[^]Y=>T$4^DE,NXN^7X7;
M3^CX6! _)]B![]&%$V/TQ]//IW\X_GQZ?/K3X\GI'W_\_,>3T^\___B''_^?
MSY__^/FSTBS<[8FW>8G1MZOO$+2B?0<!]OT]NO(")UAYCH\>9*='Z#I8?8\6
MOH_NH56$[G&$R2MVO^<TWR/WCQ'G(7;(!L>WSA9'.V>%__2-PLDZ\5<DV<;O
MC O:[0\G]'_?(">.B?><Q/@J)-L+O'82/_[3-TGP]\3QO;6'73K!/H:9R3V@
M_$Q7)(C^Z,;D.-[O<)3K]?V9^-^'9/.)_OP)?H:>3X\__W ,??.6.$BVIVFK
MM 5]\/,G_![C(/*>?7P,CV'"9CPZ/H6%Y\TC$J>-UT[TS!K3+QF/Z4/QCN2[
MB/#J^TWX^@E^R3T*$]5IYOCC=/IS3[_]($;_^>33__YRPW>7?-CW@M^KYX<^
M_\,G^/G9B;!\/(F.-XZS*[,G?LB-V\5>-8?TA]R#\*,;5TWXYQ\_\1_51[V&
M =.7(Z8;-AWP>XE!,1TG/__\\R?VZS?__M\08IO6V^Y"$B.^=V_"%5O:AL[@
MKV/9XS%\=7QR2O?1]Y38-RBHW/4UP_TT;A!RG08-(EWDH8.0BP2]_UC7;^6J
M=NHQJML_\.$8/C3V6=IU_3JMW.*?L!]'\IO&(52_(9V'T'9DL;^C3FM==> -
MF__TA&*?NJ] =K(-7 )YB/+IIW]UF_KT[,VZ=8(@C%E?\)7\<K?S@G7(OZ'?
MP8OQ1Q+Z^)%.&X(/3_?7'4[B3['S'@;A=O\)VGRZI__YF[S-Y;^+P+T,8B_>
M7],>R98-Y1ODT:.[^^-RH'*H+J;"@<>8.OD,_X^*#HH4D7YT A=Q:D@A]V^?
MBD0*Y),(N\O@W]GG':%W?L!G\(9^(1J+1QH:KAQ_E?C]VV7#JFTFOI0+-LDR
M/E"6F>QQ'H(8YKGT3_?,\>$0?WC!.(Z41>SP<,L2GL 2IF00R&H9)21((4[K
M8_V:UR^3M6\PO>TB$(3<Q,?+]542TV^_T/%MDRW[\<[9PX1'%SAV/#\ZY8LZ
MBD++2I^RES53!XX1[P/67W2#PC7B':$M[PGY\ S:B;[0MZ(W*L5_[ 8M;_.=
M0^C/+SCV**N]7NU\RY;5_Z''>XZ^S9'^[F.EAZYT^F6T7"]W4I6C5^UYN*43
M]0**WBN^":/60[T'I9:=\(?&G9#U X=!UA.[TG-](>CL8VOHV!KT^U=,8M#Y
M[PA>8T+@]W#U.UU?]N]+Z+N81)=_3ZA(=4&Y6GEQGQTSK(.6C?1CCXVD# "E
M(T"L:[:SU$'\$^+#@,N&#>3C -*SRYSHY<H/WWJ=-5FCEMWP4Y_=0(DB1O5C
M9;MH=JG0=NN <+9<GR61%^ (SO\S)_+H.MTI<Z-J>7V;MJSR/Y>$2$X75I7*
M"TA29R\UHP^_J#U\K'BO%7](MEN'[)?K!V\3>/0X=*BJOEJ%"=6N@\T=?<%6
M'HXJ5[QCTY85_Y?2B@NZL+ *99211I+VQUKW6NLKQR._.GZ"OU"EB_[-SLO*
MI:U^LF4E?RZM))!!C Y2"7TL6U<]'RXR$%9>'1\FCIZI7QSR.U61J9SS@%<)
MH>/$T4E1N>_:K'E!3SZ7%I1=K IE=@QGM%%&_&.->[V:=R2DJE"\!RLIG=X=
MO">W.*Y\.>N>;5G-D])J2D+<G"I)'2%*[&/Y>BW?PG79<!Q?M:!P6U;E&C8V
M:%G(LJ$MHY:WM"!.\&,Q>[Z+J@9;\PKF'FE9L!\JWKR<BOJQ0+T6Z#S<;L.@
M?G74WUN6Y@_E*XXU_EB7(;H$S!E5RC S&N(@8CQ=OL-'7*U"-+9H6;L?RYH#
MD#N&2 !N2Y0$D:#XL9X]WS/?=YY#;J&ETL:-MX)97&P(;M =VENUK.M/%>^D
M0I))*X(HRJA^K&UGYV%Q04KZ0\43+6M6MMM\K-!8]VYY6<37+6M1MJCPAA_S
MWUO*\.*M4*#/0V9ZPD&M.:SI^985*UM.%&+",Z:0^UC(7@MY'=!G\:/S7K-P
MZN_-"W5:MHCPQHBU_EB77NL"WK< LS>%A4O3D=U1Y;5RC>J>;5FOLLU#$$(J
M)02D/A:OZ^UTCZ.8)*LX(?1$8ED S.)7O*WJ'FM9LK)U(T<(990^5JR?;P_'
M$%%QA\G#BT.J];'B,RUK539L4 (L;@/M,$&,QL<J]5JE>^R#0_O.(?'^D3A4
M@5VQ^)C*Y:I]N&7=RE8/0>F8D4(JK8_UF\"?JL&OVM&_>EIA)>GL7T7?RD\?
M(3)3;(-'<)J-V02"0,L6*!M4^FP!WL?'!M#@:V]8[Z;G6Y:W;'NI\;M_K.5$
M#GAU70>V;5GCLDVGNRO^8]FU^N0;7N+F%BU+7#8"-?CG/]94OZ.^86$[-&M>
MW1_*EJ,6I_W'"H]V#C<L:/FIEO4K6Y)41_''8DW@,6Z2CCNT:UG0LIVIS7O\
ML<@#'5G5XE'NMY;%*AN:1&[AQY+H]FVU')K-K5J6L3K:IM;/];&ZHQU>#:M9
M?JIE]<J6)-7Y];%8NAPIU<=E\\,M2U>V -4Y53Z648MWI>&]JWZR90$K\J)*
MGI:/I9LRZ2U3UQ3$$8%6,"(AKI%LRZ8H&X7Z)LOEU5!E!!D0P\=FFL#PG^%N
M7$:QMP77VU.$:7\WWII^*;QQBRB21H8Q3H(!G;5LO+*IJH=#(0\' OLT'1;B
MXT(P,/A1# VQL7ULR4FW9._S30/9YFWVA[+-K-<V^SC9IO=HI9L@A=ED[VHD
MGG$7<=IL&=R#2P+D378706@X?L4^;2L?^;.'B4-6+_NGV/.]_\)NT_ZS.9Z6
MC5LV%M9YY');.ATS/_ B^:B+G%BE0#=Q.G1QK[.8>!@]HY,]FG* ) L?^U_G
M_N]]:O:GTK+7RG;,^KWV<2*:]0NGIU'5C[E=,@GEEIU3-JKV\"GG#JX:M_/'
MMIIF6[4?.EHIMFRC"J-NGVWT<2:9"%K(=,":!YKNK+$T6S90V:[<%/B05Q\;
M0R0^MI#.+=1;U!E"IV6KE.W8S5OEXW Q%CVCG@9XYWBN\)K#E;.,7S YIPH+
MG3ZNVC3M&_V]M.RJLG&]+3:G> BQH<@X 7[?L=$@,1RIT'ULO"DWWF)%">.Z
M+7'C.<]4!2Z)WF:Z:MF"95-^ORTHQM.T!95!?>S#"?9A[_MQ,+&6O52VSK?O
MI8^+<D((H0&24^?FS7OAQ[()O8B.^['VTP6@]E[XKFU;5KTE6/5CR:=;<D5
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MOH/H"*$1#<I-*>A4O"<08IYEX2?@^!EZ8\7EE/ZFU:(FY%F\L8)7>CZE1:Y
M2V*]P+=J/T:2<R9D67V#9\<WY(70$1330PPF(<$>+V>#S"OGR-P,24$3)@1V
M1CG9:%8I1>8F)B>W%K:+3!%*3*8( <1'XH/'5T(L:@$WRLBF6(H3[V]-?*0J
M4CI^2<\,J) N/@KHB45FIJ]WYD28"E8>AW<!=\/)X)IFD'J4T6+.F$,8?U,F
M%::'HFN #ZYC*W[%,5ZWO(=R]D,O^J/S#F=C*!IZV% =QR7/L"E>^E0Q?'PA
M>)20>?KY] \'SU!ZA@VHR\@Z-&B/.W=V'M58^5:"D'SRRK"7>028#!K28G,4
M7<FT/=D9B]H7 6>ROX.?@)Q)B_-+5'[7G%_O:^'W%9/GL _'/(40Q2\8T7?^
M%%T';B+JSU>!.QJ ^I6B/_<DEEWMHT3+Q?+\NB9JP%CQ^<EX+$ ;ISJ>,'B9
M#2]8KM=G_()\>,$XOO>BWT'3"]EVXH)=M%QS2%OXD=<''5DEM* (T3$<BUL:
M13 *1&A/W%R0&P@+QN00N/#$M-J2E9D1^Y_VC43GB/6.H =N)LC/R'(ML8_9
M$Z)RK"PD:RK4P,I<Y70'NH4J)LPI3UB8F[#)8])K3@X(DAH9?24"*+K%8!TB
MGV4_@>D3LI0>=DX_+LEC^#8J*:F8'@94(3L,Z!X *[X]+EKRXV]&NI%K\^/G
MD/P_F+D\HN0<.*Q2*>]Q@-\<_Q&3K6X%4I!&0/O 6&NRCQ'!5FR K=J$M;&2
M3F-Y=>$70P;$F.D8K8N*3%,Z"Q7E;R<NMM[7F0-7.+;M"/39(&;K"1PY1^-<
M@;SSN?H"AT[-SWQJ E:G3IJG.[@#>7^S1EB$(7Z@>UJ;0?5MTP#NR0I+'@BV
MY[!YJWP5-8![3ONJ*A%L/,*:&4HOO%?/Q8%[3UFYP^0B]'V'\.*_PT,2102W
M,-S++A#T<01I<\>\FV,S188G8[@0H)BO,.A*KJE0PP.,)_<:)L\1W7ITVUT"
MN/,H@W-&"S%BQJS,6IC(B9@%3@PS\$C;+-Z]P2 #Q74 >N@WH&AZ*89RTK08
MC)VY9\9>A62-/7 _P063!7C4)<M>OF.R\B)\1[S!KD^=&<O*^+ENE7'0F,8L
M^4",D8]5:LMFKIXW<%P'*^S[!@K-NBXK2>WX$!%P'0A?[3C/8TJ3A1D<TPTC
M'?'&'(\ZV<HY&PN\7:>\F<N'R5O&7)Y(H*N&3,'RY\I*H8;*65P'+MX&WMI;
ML3?QE\2!/'\\SA5>((H6&X+Y<6AJ/^IE*P^;7,/;I$H41WZ :#,JL"[778I1
MYFM6RDJ6$Q4]%8@;(1\@[.O.Q4[+I5'3HJGF:Z/.;I[%&R7F5PP,/.C=BZ:6
M2JRFQ5?MU5B=W3RKKWAALNEF9H58*V=+E&G]V4I(TP,5FG!TEE>>Q^F4C"(Z
M0P4+@3G=4A]+.:5&\G4>!E0$C#TP]!1X-(BX*[(01T*C*P33'%*#H.CZ^,DE
M-91!6?YHMR8;W3)4/DOHN9,W2MZ%$1--3TZ_T"=>HB6Y":D>-/35ZY /?H2R
ML93,N7(X1^CD%/$106@#']/7/8,YA6%#!;)-'J8*CG#5JEMPTJ&=& >+8MTR
M;P*4KZ?SN&7C,HK5/_)0*.24VRJ2H/,HX'G4DY\"^3OGSB%+PD"P.4+G'2;,
MMJ'+XD[IP^O)>^#P<V#FX=:BPV2UT=:^<PQAQC%&0#41=55RJ/8C7ZZ4=EHN
M1E#_)X':;_!UJ\EN&8=5T93(8@BE0B]?'8M-&ZJE7>7YY!'% ]>KTO=[E,92
MBW\-QB+IXU!=N4HV)U50%563*9YT<^SI=UD.RQ2*)TN3D8IDFBPSI29IEE>Q
M:7/&"&Z=@"Z9D:(E2<B,=<+8A!2L:'.>F"S2]Q4'";XBX1;$>KCJ_NK%+^<)
MO>>WF-!1^0FDPX(T2/_G#@]V$3VA->T*R;[0&^T,R=Z@_K/H#\D.3:0.&)B$
M?**_3P<0BCQYPCLW6X54.%U 9[H799?H!KV@0_%#%@2JH_;F11E7D%[-6<]9
MQ2=X0=RL<Q,U- U-26H-J$"15'K,*GO!.:%T:J"XI:&9R&.J=-T$DW(NN9,O
M/>.+LLK08AT_TIMCF"[Q2AY^C$/&MR-ZG';/3\QO>M +/M-#GO7#=K;LR7AZ
MX,2LYQ-<JOEW%/ZMY1 ,@(LM G0TYDNPY(&T:L29F9((^KE5<3RZ\)MA?1P@
MRWY7/@^)J<K29< 2SE@*#HPE)1O5(DO<^;;0[Z9<6'93:F&IPDU9XFMR\!"E
M#O6HXHO%6MJ&ZB^.'W^YB+9D8GI=,HI)LHI92;#S%X=L!E0!4U[T'#TD"!K"
M,]?!B]_ QB&,OR#9F6?B<KW&JSB%,Z!:&N11W&/ )?%\C\?LQE?8Q<3QP:.1
MQ"'9YQX>FEXO>Y:@#J"\ CV4[_T(.3$2 T#I"(J-6!K*RH!5WL*$J9M$3H3'
MV6>VCQA%Z;00 WB"0K]NKD(YSK4D0Y);"E!"_4F0':F6E\8Q'#+WN97F+&\%
MR]P+M4LK;YY^/OT\>:5B^M!RK83LCTA\4<R2])57LQZ8YJK\S7%?6%!%OI&9
M+!DM3-<89 =R/CUFRCD#$/(A7OG]+WB4^TW I@B*B)%$E.;LF?#MC#_5Y6C#
M6V>+1XG4S+L#5(Q)T^.&G=.CY=B-"&[>*L8LR?^67MRC[JJ,',,UH/=12O%0
M."F)H9P=2'Z>U&YZ0T_ R W? OP0$XPU9(>>_H0RHHA3->,'UL-+P:I_Z.SX
M%E<E'VJ8%CJ]\**5'T;)X.@\Z6#+2L&BC.;!,),K]F="W=<W<L5^T;@6ANP8
M5+<C()Q?8/[O=<#DN#2 C(]Q#)>R!_2M[.,[2/3EXF(6J"8GXX"Y]@<P?&"<
M5H*-<,[,5+RJ0G#C.=>/X>5[C(.A)05K\>DX=8 XYO0/C\.FR- PY0XSVLC%
MT8IX[%NSL=G:JR64 M$%DG>N1KUI;^P$'.<=LAUXMN"1U<JVWYG7 V.L,:U
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MZ-JSS=L9:]<>G?-DU/IM?IIRXC!S;+7,U9F8*V1KKMIP6 =/Q4' YXY]'UI
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MT^)+"F_1+:8G+UW#,6D32E<HQ3@MG5#H6^CO.X9[!?-#.S642#'Q5/@C9^'
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M*D+:(+R&2(NN4]!X\QPG$9'%&=CX$3XY5@B!V'V@'T-C$F@C'C$U415H!-U
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MAR53WCA8#O6SXZ\@Q(8Q?_1LW:7N=B3<0<MKSB3.P52T=/HYFR1(F;10- 6
M\%9A"1P<3Z=,7=BP>5!)K>KP _"@%M1>/O&:[L+,E9C&OYC!8X"[<(%/J(!$
MA$7^*&BYLB$/6G)VR)')T>J(CP]8G$O#5<Z6';DLQJB*->3GJDOF=<QN6B-J
M9".\$!?FSR O8R;@/9=6A---1S2'\X<#52$63[C\B*>?T)('31EZ]DU 0#V2
MO4[%[,/WO]&L903Q#+^J8-9'I60#+R"6BTULTU0RM@D)JLT+IHHF8/-60L.S
M[P^9"^6A8-^"45#J,UH"EQLR!TY(6Z1#UA'1(RZ]KS8PAV_NEZ.< G%]8QZ
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M",!ZB YRYFA#1UC+%==1CQ<&WF@%HAX8U:  I$3EC^'QH7F+C&<#.PF.UD
M!ZS4(6MS=BA]N%*RD>""M!&3Z()ELKS::8G_@=(W=+ZG0C?DP9LRSWO]9&:=
M@:V7*"X))'=F-W7@;-Q097FOL^3BU4\W\Z)V4K^$:[RKJ.%I G\-:,RCK;D\
M\LCTH,E9>[5> ][/&[J)5\D6'N</6/J!HS->A1$[7]]CS-77<$>C9.]1NCI
MV&U<_67'^&*'GKW<_^:1I'IIK?,S+^'=>S1(^0Q\H&$$\][KYCC#9[[D".V1
M1.Y"G]Y#@R-EMRQN^<QC/7\0AM0T@-L=OG'@+&JN@_D-[1'^!1(]8IH%AQG
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M$E9!O1(O!G*PQ%D8( H<?;Z'5\D(!XFJ7:_6,!AR*-2/$2^)R<FKH]IVTVC
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MHAZFZ?P8$$P(<-7WQ4L4KI8058._WR'\ B;(!N^0!R7>P#%"[#P@3X09>/5
M/ (O3XZ1L:9X"F5!1ND%5(M-Y5'OC5RR;*3>C@P5/YAIWUZ,R.NY$(;K!7R\
M9^ $R4=,<7AY/;!L9C,;]YUD?"2<SQX=G4>'QQ)5,JF&,YP.T>-]>A!7L5Q[
MXC"]<IR>,%"B0"JKD;&>(+OK81C2-7PV;A'/'C/F?Z/!#B*\VPBS#H0TT@9K
MH'6&K#F345.+@).39"1'$5FK^5@@:BH;5&VY/O16RJNJ+9.)K@ZG(++#=QGV
M*#_V1CRHE5BCO&TCCV!%!HA13K\=62T,.?U.2I43F2UZ)?RL)U<U!=_BB:D;
MLCQ3-2/BVS[C RS3-3TP'#,A\WKK@<#'3(,"3IC_G<^H.I<88^=[/0& V"5[
MIH OQJ@03];.K$X=8P<<&1QK#6FV+;53-7@5J +ZJ]*QM\K0.?GCIU+_US,X
MB6[%YA*$&F+.GRES8F*LKD.A<?H[/.1!J9N0-TIE:J C-.941X(2"+-*;/,#
M\W4J'#S3*O2!TAQ5&.HL2'M>7<(\U++M4'/]I%32'5*V/W?6U1EI5$2PJ*9Q
M[EA[0FFI9210MG@S9><H?T<H)NA78W5I1,5(M68Y;]][H1UX$>EAWL4Z,7EL
ME0H6M[)=CS5,8</F/7 FIJJ%B-X]8^X DHS-WK."4+I?%QR(92? LX06<$KF
M(SRJ:!X(1#-O[+H&=M<U D?D:)GN7OWX,BTV5+LU]F2JX,U"^O;,_6_$% RN
M<4+WWIKV[R5D %Z 1^"MZ!!F!C(PR!RV/G0QWSS6KT<[]J!GIG7\. NF=BJJ
M%\'<A\)7/_TG(NBZA[\UQ'.O:D]X/1A25$Y!2]1!QC&,7UQ6 A'9[$20#=2(
MQ%[$@8RFQ18DSW]3MPP"B#KRM"67#JKZ);:CK8QZ<%"F?1.3DO<"O<][T)KB
M"5NYS?A]8IR4+F>O[)/8+"DT[8=@A7@@D9.'BF):*^2LP9;Y8: HQ/XEVB59
M..K1QYOR6%N.#STR.VJR K_ND[_X:1#Z0EJ6)%YL4D34P9. +91]>+5.O+*7
M><^;64CDU^(^\;II,P.S, N-M:M3,8<$W"]<@5]?1?/,@$;)"J$@NTZ3+2A(
MP9.*^#AR/^J;^"*)8T0P_GX)\]=K/.#D?1ES9XZ1J_GI%='3,XS7N%W/S[)D
M%9+ ]W?<FY>_-J)^\(<U'JN'F\"[^G]G<+8F /J]K]PYDC532^4):8#ZB<P-
M?F68D6S/\'XI5WC/K81P(63.XMU3UM(!_(#_R8?PL1A4A]42N10*7!+U[<"E
M58-+#1^CK'0R*ALQXCPTNS,GZ&JH5>18?&V)WH>9FTZ8_;4<GP7<3+ Z2^O;
MW*ZQ+G-(:H^SR".%BI1E^IA?15IV9$!%.C_-4GVXJ 5?E^3.KP4'EX$K(I)<
MAQ%*+_""VR3I*)@XVIQ'VO-X@XZ//[(P=&6F=JF+:L9#W,=BIXLYZ15^JQ0#
MD?1VY,0WC+\*D#/*@5I6Z7D5/OB7<.5'BSAX0)LB\G.\S$K(@0-3.C25?ZP/
M0FU:]E+!#,RMWYN#1J[,X[2!$J]JO<*:F#]!QWPTUN)WQ4F4$FH":_0:/V<@
MT0'^L[**QH'D*JSB#4<F[R#" /1+TSO OX0<%I@9,I' J[HWF,G#-(=J<G,2
M_\"T$")S9 +$?\WNIKS=^6%*X5,H$XA4/-ZSGSRBJA2E53_>;8*OC.S,$[HS
M9%.;B-CH8#J/A$")'AXV*M%0)$#U#T#U#WE)=5CV:_'DQL\\,'^,MK_U7<'>
MCG5D\RH^E%C=N]CC'1PAC;7ENT.K<!V"B;17M)K733);_>GW/XX7+A:/%QYN
MR(RH-&;039]<-NXM:6QFM]L1PX[,LKF,2RMCN_"M47M$@?,BU6Z!@AJ41Z,N
MYRK4"W?4?#^6?7EE9Z;B\F:D/SJ0]&.FN1$Q!KD>P7V/N*LRZ]_<9)*M^/2>
M/+TF188/W;LP1CE"W/P""4_#-P3HG),<,+@G+(S1KKR8]55:6EAOW@YW-^_A
M,R/%;"$#I;P+C_?!+&]E+P29U<PM,2/%XC+^_..G/TNIG)6XEJJ+A,B6 QBY
M:$O]'KC4^C3S=L3V*NMAWM4Z,7EJM24-+:YF[IBHDF9];$S3[$F$.,Q3LEC]
MJPA3-+6S*^\ W!A8%W)7.T,2P2P$1P-I/2XBI1;(>]S]*^0()G"U)KUH.9%E
M",[YGNS&BPB?=".@2&CV+M**(?B1R2BHO>0J,N;7=I)DT03$+:!06C<T!6YP
M7N1W2?Y7E-_[X:'.&#P7M=B^QSOP7HK<PUUX>TPM='*LQ#8\?$A*-Z),0#R?
MF[<K]UH1[W 7GI][B$#_,%BLV8%"6&3DX4>CT(+#@VT[14?FQOVX>D5!$:'E
M6IW9#X[8PWWL2*-G1+BE&/EEP][?2-/S)_2=B<::;H[U <!DY8:B-"],TLQS
M;<*.?0PW\3(^3^("[^+'XN4?:)4_)3]3,PUQ*R& 7N-SJ)+C(<.]@4OD"^W/
MRVB'()9PR]"N['/V=*HSTE\N;4HW].(M8X_UX[&.(/L4Z\JK^CIBLANY5H?/
M^5RT9_DN_?O7Q:&>\XO'Q\7%3\^/5T]/CXX-L6:(][<O:1ALT!F6[K/,7[UB
MCN?SF^&(9%?9X@Y,&B7><516%(R+K$U#;[%I"(JZ:3D.(FJ*U8J&B!A[(4%(
M!.EX(Q(Z0!4Z\R.-,;SO,D_)P:!I'/J\;,G]L=<5W8P %J>>&J.#J"5?DRC
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M'(TG#L=07(-5YC43F G+;EDM.P4'DSX.SGUDZ8!E$<1MX&BR\J.RW,%J$%T
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MZ^HU1&\,M+\$GFF)'],V[\1J8$HJ&OI.=:(@0UT4>(A;E-*@='SNP,V)_R_
MBUHN6P]NQOYJF2^"[ 'M6&1B&4;6T$1_P9WDER*L2&NUN34\)U8K#]]X1.E;
MN$)R#MTE\1N)L2/,R(AGB_@=I/V[)/\K@CV:;&+ JY7J,N?JS+HX=;-:I\PZ
MO<AS/'PRU.O(WS3E*G5))]9# ^*XH8=CF-9)D3W'*?(CX#TXZ_!T*2!:P:[X
M]%EMYIZV!R>8UADX27\'\NBJES)E6 M.$-U\]@A#U7DE"<6=((?[Q1"K4HX$
M_Y@[U.E((ZU@_RKF6E; 9")O]&6ZP_OF,BTV;;_<M@/9L.KVR7UZ3YY>\:GA
MX]D(8Y0C%..)$7Y]#+_!CTR_!98Q+$N"Z-W6 DW2H'V67+R"6',3_^RG(2Q+
M?+1F8<!"4^ ?6*C$E 4MTG4KVB?Q 87;ER+-B/#&!#:\#^%IT":KJ[ 31Y!"
M)=%C3^JKY 1I9)<(0G+[DE/>BIVUW""NU)&2 9_O+R(?2RG]*M56<2?(Z1;0
ME&1I5'."/*K2?,Z9_?4&OS9B2,6D)*RS@OTSL!&AB"\I61@'EE:*;4%"](F_
M;R5=?\%G>7:.\%6.&JJ(&9JWSZZV8",_0#4D(GE%^R1V/R9DB;F)0>]92"9^
MR7.)7U1IQ)OFO;9ZQ4R_3IPBY,QF)_@M![&4G1[2@DZ0P! [[OTTWXONU5UN
M#7UUG"",;L^N& BQ@/W]RF11?%,R#QFN%0=/5%D02U\%)V9!\'$"E3ZL?X@T
M0FE&-0!2TUQ/'>MZ/FH5700!/M$RXK"XQ'.0O(7QJB8[])5U8H:$#4R#<J5Z
MFV8A!_8+,YSMP'"&7^(E,F%!#&<1?H>W+R>=2D[,BJ;GV$W\])Z B5IZZPQN
MQ G2#W;!<-_G8H8D3#2 4<J.J3OY$*PC%KCL(.NAI2$XP7:@-$6OF-@R"(&(
M[0J[=4=Q^S='I7K!#]:T*'V0,^Z$S&1"00ZIYX=NOWG&MFA=I,$7/&STQ_WV
M)8F:,DSMHQ/+L?4,5YAG9.6<($#PL^VSF2F*.D&&L/"5P1J=#^-!#3A!,GML
M2>,6.EZ;&M7LGXQWD&('SP7WV,7#)"F-EVL\_ RQI$,M'>G0NO8)90AO3;7F
M&/7HX<TYP XLE101O!2X<X'"'JHJZ,3.Y BG+'DB"%'2(#M9.2<(H,>[ KA$
M6<B)H0]QIWYZ39%4L![<B!.D"_?SA;\+<S]J@<G0ES>/LNFYY/4:<8)TX83C
M0.1-L;\#Z4.WLOWS<;E>G].TPH^O".4/8?9/..X3XO#!4#Z7:^H2 Q^I?WJ'
M1_MTK3JQ#E3S!SY[7<]$G7K6GT8U#>X%)"!,GY+WFIJTHY@3\Z,PV'1*YGUU
MG"!,=F,\H!B]4_P1W4M&J.($6<J@D,[PF/Y:]D_2H9(RG 1H0LF[T9X;#!GC
M60$$S>>W46O=D:W!5#I$5KH,W\( Q0&@H=RC]#*)(C]M!SD/KNP$J8_%2T92
MR>57X&RDEJ2D!5TDX0EWU@1]Z2GJ!ADC-?Y8>E^C,"?I/>.@>GJJC !7WU"Z
M"C-TGX;RYX+5 3DQ)5C0(J$@?G3OA\%-S%Y-'<^-K@I.D%3I0NO224"UA!JN
MI.IZ3A!X$P=H&X?K<$46VY?"!V,7ZG@C=M>P?WM34QXH8_!-@I\K&H$!]?@!
M'E6@'9$P>X].K)1'? AA,:U^7W=<@.KB3I#3SH?5Y5ZG+NT$,>-"]WC(WC*]
M3?!=)9W.:7MP@FDU0T_7Y$L+.D%"?7?=^^DR)?YLU,&&YW+O%[M5-9T@LH0?
M9,ZZ-<?#KGG3JN@$B0K]>H?MLKN&$T3)GK544RHC2%W:OD@A7-7DXL8<WN/?
ML"144*2M0X(7A[7DQ(SV0%^4.;C&(6C(FK&_!EIN*^RQ E>='(%+'HMQ8#OV
M&< 'QZ>,(LGA=0SN57Z4]9E6!M9W8L$KU;<*WZ:N\DX01*7RQ3 A7EK<"7+$
M&!ZUIWR[E!.#)R"=Q2HG?M$76-S:R'VH9>6<($ ' 7N17R.(4(] &"L@.K-6
M6$;O!,TZP1YVL'<[^G>(>$/J.T$PZ(>7:Q$>3*%7EA9TQ*A\00S]$6BYOOT%
MU41592$GN ]W3I7&3WH[U4HX,>AZ/M=N0 556?NBT2T6Y[,@>8_18YXB)#$+
M=11S8AZH*"J!IE3K0R2%G2"E#6].7%K*!_,08'1932>(E'E,4#O24W+U+4>Q
MU&V]OY83Q-7%32T/S)XJ3I#5UB'K:9H=N1BQ:'43@%J"6W[:86Z]A9V8!U!1
M<WQ"/,YS%*-U",%?.8+$W<NX%"6)&T:JB $YH!DGR*],DS69\@'" 2(N65XG
M:2-251UN-6G#3K (SLGF.#5<V#JJV)=1+OSM[O>+#98[ME+'%64A)V9$N=DX
M^C2*_8CY30W>L(HVG"!<",;"IVD01@6\C"L5.84;1@%5IFYW!8WI6:ZO_!2R
MOV7<E*/AJC!%#TXP32+(\8W)'M5=9B/]V@[LZHAF2EG$P0/:@+]@DNY+V.T,
MG[HP*0#,36%^Z,S= VC;TWO":S^EH1^U#X/IVG9B51"/:2PE$@03$BJ%9Q1?
M5F'LQZL07O,EBC0H*#+YIQY CHG:=V!E)2G PN;H/)'F9U06<F*N*1AF0=SC
M(;]5LH$0 +6BNZN\$P013\$N7\U: 2>&+$UUWBE!=M=P@JA&9BWM%%P.+26N
M!E2M)/&[_7-(#J15H<22S!.M@TFKEGWBOB1O*(UYKJ[5OI*Z5*Z&/17LDW2/
M;P-JL^XS""M+VL^,BC;-=*?M:[^SH!,;77:<PF,44LK%:E?'WEI.$*=6XSJD
MIFWH \!_?[E^SA 9HFSLG16<(*G].F+/Y3I$8%US+GS3>W$-:],1#2E^)87P
M,(QSN#[EBM%Z&2=F%![U^$%'$I.WO).Z'LI:%9T@47:F76'Q!E] *Q*C<8CE
M1-F _4MXN5Z'*T"TN?5?X'V&'^Z/.W_51HA1%71BUL1P9_6SNUW*D<'G)!<#
MUY() 9UXKX2K4&'C[JME?W'=TB.:NZA2-9#<=*]3WHG9>BQVNX@HO?T(O NN
MH^3])EXGZ9:Z&W5YF>M5M3]O)([X/DU6" 498+5DX!"_7"^*/(&QKBX@P5>:
M435>S:#ZE A@*.U'R40-.[$2FCNPZX4O*^D$$67D@^CZJ(SR515V@Y394@.6
M^>QFP&L=VKGU)R\SUK97>^NC_8.,'S5@D?H*$'> [+*6!9!(]$*Z5=U8_.&&
M1MKB946SFH$6"[0E88\J5:^F$T1JY/GH*>H$&61(</'=;'=I0E/@9N1JE#\H
M5*6=((:>7^4#3RU]2PNZ00+/:0K7&3UUU7>YLK 3I#PFZQS?*D@("NJ(V5 5
M=H*41?"/(LNI$33A/OT 1%VAC&&9$(O1)"%#@(+S_3/)W5MY84)L %4)=<7L
MSM"/$PPLW6[/]U_Q&5*DY.BX3@E.RVJO$O(TJCFB16->CP]HEZ0$U10B/&HT
M]95U8IY:$-'X-?2:I*H,S!W%G2!''IK(H),5]D]U!2=(XBK+T@&L1TO=5=Z^
M4 SJH1C>*7&>AB\%W&#<D-N2@CO*.C$S8N33\B4*-Q0(23-6JEW#_NPTDRQW
M)603M27T[SSL?M5,VKH3*Z#?^."@E4%\7'),8&"R5'.F7<D)TGI"]CM,_8>U
M8'_'2N?B)L9CCQ%Q$X/1WZ?A&R 51CY%;R  N>6_P$4COT:HE2BQG5C74)=.
MK"7AU-&-0^^IX@A9Y9PITQ0URS@Q<)UX:YYYO&7F!3*H4C2*DG<5E/K$7=@_
M'1BZ&05/8EFP^X(K-.HXL1ZNBS0F.)3X#+D.OQ%$2O765)>V_IYDTM]UF*W\
M"!(47.&W2 -TH*N<$[,A-T'H&RNLS\*B",(\264N,<(G)WA=ZGXJ)5&G%KHJ
M9IW+5!]R]8T$(1#,/2KTR_4F[7+VCU2*HDER3DN@,6L*6GYZ]F)R'MB:$XNQ
M4X'2Z7?>5\W^7#^]HA3YZUR&D%9^<F(6J.,7C430>.5T%+?/]<<PB-&^$Z*B
M7<3^L*F%?+F^#%,L1"9I)H(Y+E)$CK0("XS)5816;?^C@?7M$SP.:_4+_C&G
MO@8<=E6B )RX!R?V:F7H?@3<!S\-LN==@(?Z^<=/?_CQ<V?:H_Z*3I#('T=,
MF]*EIF9%["]G4<,%R^L 5PUU-2=FA9[WE>6P"TA:7M0),F08#9455*J\[*SA
M!%$WVYT?I@0%.+T,LUV2^=%R#3#4MQ #1E4,&C?[(>TXP0"=A%[T#= ,P^A:
MQ^-;=8(Y3RDQAN\%P^L#RK&@(#72JDL[04RGW:<1CTJ\%)7>28>UY 831J9A
M$5"C;L \BM?V:K:T\\K.[-_:H*H.J0,-S8 (9SN*5SQ/>NN^[JO@Q.IH8I9H
M'/P]59P@JQ$RKP(+O8E)BE90<78KMO2;<8+\AOV[ B3LNL%Z*]G?@R78"F,^
M%K,N4 I1!^3ZY0AK8"M)-T@"-CZT 2=F4W,5:B='. KLW'+(3%/7Z?N@+.P$
M*4H0]"Z2>BO9WXV+_.D5T3<H-ZTKM&C*DD[,#P7>S[)D%4)<(3@57'T+A6=-
M]8);IC7P\8[T':,;=8(U<N4Y<S5:X269LL38H/O"EV!2;%[/BRR,(;]PLGT)
M8U\CB>^T?3AB>OHYB8HXQ]?I-;YS4H6_;J.0_3U]!S% :+GF#,:3@F7U,"-Q
MBAG$="KG\Y#Z3BSR#D%=3W(:U( 3))/]1+=8-\:XM* 3)+3<8O ?_#<F!L#)
MDKXA,:E*I0R6TSN^52>8,_8=3JW%/-&J6BTR?3=NL*^5'>TNR05<]^Y(0]W*
M]D_[UI./)IO&ZWD5^:D$1JRO@A.S=XEV*5J%2K\@\;L3 V[:&QO62&7F\R_X
MW2K-JSYIPTZPB#Q<"? JP$ITA-E("SI!PM!<C4XG:"S#YYB<'HO05"R@+EC&
M#[#8X%&#"V#Y(>7_)#)AYZM@T@Z<8)D,,JF,V!:T, OP]0%=XG7XIECB!S3D
M!@L2>+()XO'YGC\8JI^5(9OZM=T@5H* KX<VV%W+$>(D&$9=63PZRMN7@]1J
MX3$J93>UR4WS3=<EI"KK!"&=QR#',NG/TG% ,TZ0?U^\1.'J.6=7XDW\AE=;
MDNX[;]7>2O;W8I5^@6$6ESI]!GC)\XZSY[EJ?D<WYL0LER^LGJA)63DG"&B#
M[70&L2I+VU^8^!"$Z\O?L'C$,"-!PS%Y.\'K*KM/PY4TR?PA]>T3?)7EX19>
MA\\9PC_<AFO(B0([I6?7Z5:T3Z+L\/\%'_@YBN^2G,Y&F 0<R'01!,3AEP76
M-W,?3=2D$_M6*]GJ3?STGBB])P8V87\UZ,$&D%?I7)@$>HT[L4(.5OYV2BCC
M6[6_CCKL05+:M2O9)XT[KT(4?BEHL(U>>D.">23 [R"ZYWD4?XOB$6TYL0%D
M)_T# KPW\>&N^^9HUW2"R.83$!1K*QE-TH).D-"QLP9:<YT@A_J5ER"U/9G;
M9$6=($/IX*1I9AM2WPF"15QV$FWL$PR3['PO?E$I/_5K.T%L]?"^0^_"JRY-
M8OPGQ68AVXN 7&0DP459)L2;;1?U ;I.VH,33--/R!D'/*UNAREL1'/V!0T>
MI"HBQ"0P>20'C,3QJ+N\$_-;DVC!1 FA,O4CJR^]B&9UZ_#9#[#IY.#9PB<G
M9N4Y?@FC")QW( L:*"BZ@/74I9T@Y@[EFB"N,N+T:SM!+)$S7_K?BB^#T>@7
MFTV*-OA:K4<A_4P0ZI7/5O-#<6<:NI[LF>K-7N7HC ,.N*F&UIZC'^O.PI?)
MBLP[5?\H )FDA=PXXYOR:NV#$\N3^)!3H ;BE"^W.]3+.#%P+;?B3AEY6 M.
M$%T+A2!2#GG=P*S<4/]C\K?\B:15U0DRR3GU@'8<:@D2+/M;948:96DGB&FJ
M?B[#J%#<DXJB3I#1\OVN%'3@>>2GZ7Z=I'"5=,)A:U1W@EP=#$K\XP4F";\:
M>92.=%(/:LD))G2983@H&GLX@^ @W9S#FG""[-*[4LA]D)4__A3BA8MGJ"/)
MX* &G" 9[T98A&!JE!$D?'9BN&-#*ZZ^H7059B2UX/3IO%2=V-<;-?Q\VEX8
M]>].S+5"MZN7XK-5P0F2ZKZZS$]735!'<2?(D1YWI>]Y!QBP1CTG".3P1?RY
MH)XJ>4DGB&BL(O@GCRW36'1B<2?(J5R#[O&)=1,STWB/)V!_+?N'-'<#$CSB
MR#W#XEU^3G*T3)G3%)ZAC*0THI'@UTDJ2:/:.N8G[\&)%=%Z8@@Q,7=(+Z"U
M7L4)LIX?2R"QTL5)?::J2]M?V.4K1WSN85DC3(EDU10^=>LX,4N=&&A"GD N
M%2H4Y8-;<8)X.".2* S(E&B 9'65=X(@X1A8Q,&PV$3=NO;W8ZF0$!6>MTH?
MO.[B]LDABO7E^@D_KU'PD.RI^7X9XX.<.)"W".JKX,12[#P2QBEAE&W8G\M;
M_Z5T65+ )K6+6#=74=@:+&-BM@+^-98L_V^XNTB"ELU*7=(1(HC+BT_TEI=^
M[DML_GUEG=@]S?Q7:L%)7M()(IJ8N*6W5L9"167T]%9R@K3^Z]2U2_/I-4SQ
M9;'ZY\]XD4#ZHMO;"\4)I2[J!.\/UF_V>F74D6LFU:T.[-N1T_07%$5_B9/W
M^!%OQ21& ;F,4_EQJBCLQ)J9 GBB:[=/V;X3##O<+:?QTBN7]"\(?#91L'C#
ME^X&\>\D/'):QZ!#1N#(AH.W2@H194 !<?&_@+LOW:N%L<XJ3JPE\#X$3Q7\
M'S@&W_ ;)=;*1J!5T0D2RV@,>L[#BL4G('CHJ)P_NBHX09):$*N\9(<)<%4]
M)PA4>!95[K!=![YV92=(!4B(C%EVT L/K,D%76MWP)%N;2>(O8=,'<29GLA8
M\$I-2Z]Z'B^A&X]T8%M.,&(^897Z*2ON52+)@B]K*129E:0'#L[ZS7^;K/SH
M_A4?_VV?#MEW^V_)"XHP&+ZA"S]?O3[O%L$_"GI"M!Z3'66=V"3*B$.I0EF_
MEA/$/18O61B$?KJGN<5H*AN52*(J[ 8ITWDU3?X2F:9K)]C<EMXTDO'U5K)_
M9.EXLR[7:SP-:2;.,O,U:!UK(]MS8JZYSVY_FEV7M'_\X;1<P[OP.DK>.X77
MKO).$"1)+T=?N%H&:;VZ3A!:[I1%D;\F ,"G]D=3E76"D&6Z\>/PWSX-+!)<
M B 034B(L%Q?A[&/SP,_*E=A=\:;*1IV@D4""K5.#D6IR]NP)IP@6RD6:NQE
MW;K6WRL\;G$1QX4?/:!=DK8,K+(R]H4 DMD!!75/%Q$Q4OC2NO&'5'9B,0K.
MH?=^NDS)44$C6&1PA@.J.4&>6L_(YT6(YA^FJ)0TX C)%,^#GGXLVN$NB1,>
MDZ9P%]6IYP2!W*?G$:5O6'26/[SN$J*/1#0 /'M*J"-T^1W"0>^2_*\H?RB1
M4J@NZ#I)V4]0[I/4;&]T!$XP77GQG.])=+U"7:!1S?Z)+[<@+;;X.H)):08=
MZ]:Q3YC4J5&>LE9=U(GE5T$^'6[Q;1$^>>/V9_S+XU\6FQ0IW,$419R8X8LD
MPE^)A?H-"1S7QCO0KFX=/>.K_PTB5.082;6/3LP,/L-7" 79-?Z5HW "JGK=
MI5!Q^FO4=()(R<.1/QK[@+EZJCE!7A."F#A'"RG79;3UU7&"L!+]7D9!^=&)
MH2I"=P?"/EH7F2;10VF>ZE/W8?^";MAV2NC?"Y;BI_ C  "^(<%?XFX[1YLP
MCHD;8"3%5)ZL92=65V4 QB\G16"K''F-!'-F8<Y?9_1-)3RHE-X&<_?I!&.G
M<$)52M*3->X$J^!QUWC@$8^N< 784O0!6/]!=$ D2Z"M/EI%14#2U:\(.BT8
M!*F94"I>&!V!$TRO0Z-GD,R1Z:(ZC2*]M9P@[@N*\3@CR!\<;/'I#$.#!PL;
MJ]K&JE71_NT&NM XC_:+(-D11T<Y-G.'H6-$,T[,<&<TXCU#<6,I<10^OP,:
M<,;,@\6OQWR;7Z5IDEXD:8J(K'H=^;67A5X--^:QU DM\,H+ *L.;[?*F16?
MGO@810$\;4$2*+@@VH2YTT0RGZH7-YAWJ"^4*#\46^X8M4-PN_''',\@-*D3
MUI".K6^Z"X@9Q)>Y+-Q#_.;$6M 'ENZZWX>W8O\RA&D ;1>Q@."1_82BX#D.
M4"/%J\2(K%G1B?G50.GO*>H$&8(CB9@D'O\=(:9P8,8=ZJ&GLFOU.*F,:ML)
M1O5(H@<(KTZ0U=">\)P2+:6G,@G2H :<(/D![=B-MES?)O$&M$-BXK[E2Q1N
MR(I4Z">UJSM!;A.][K;+=5]9V E22O\#.$K5CT9),2>&K[C,F0IWI$C0T8H3
MQ'-O:7P:7J(W%"7D:&='(7W1RG=;;S4')![J_=8Y5J7/7'<M^\0]O2?Y:U)D
M^!C/W_'(]OE[$L9!P901L,?"F&6YW^&K6X6;<5 S3BS=/C^)2A-)3ISG.,PS
MFH2#;D6-E.P3=^$&V[A%2NV 4BOAQJ![)D+$ZYMN>OM;=8PY>KGY-#R/!C3D
M! M*]-P<[++X J;0$N#4IP[8Z*WD!&FR12KJBL1%"CHCJF.J]$:';8/#>["N
MCZI4NAD$(3,?UE51N^H["SHQ[[+4O-Q\N1?RELMF5+>N?3'F$7,=B\0757+Q
M^Y3%82J>$P.J.3&/JJ-4T^=D0'4GR-5=>N#V@87/,:N7->$$V>S5@)]_:SQZ
MXJAQC3KS-W;7<(*H4A#L5$ZT2SDQ^)$FK,46C+S2B9NB82=8=(OR'*79<DUA
MOP6UH)KZOCI.$-9P_)&X^A#?GN<X><E02J*E;F(\9?58^/,]J7X1^5E'&HJY
M^G*"D95HV(+OKWM3#9$R!S5E7T0A8Q3R,O9<W+IUG)A?P0:F5MRV"CDQ]*9.
M7/FJE19T@H2&2_N0B%?-JDZ0J0A.HVDF\/FH](#5JN@$B=7AIA6,N8CP"<#D
M@V:X)4G[JGF23MR9$ZPDVY7>"QW2<[N4$X._8+"FZ#R) YT<,IT5G"#IX(3B
M;22I>N)P:2SS?+TYP4QX]%$G"\'# DM$6#S@4?SW*=J&Q383$"Q5S\?A+5E7
MSE'\7T&BZ(S]TJOAQ,R6SP A^$< ?%2;4K4J.D%B(TT=46#XD<8]KE71"1+E
M;_L[?]MA1NBKXP1A=6U:P#.P=?F<=-9P@JBNA,<79<*\Y5I0$U<3)%=EC6C0
M_DOU#BS2ZR(.X/I[WN$O<<[UI107IIX*3;N2$[-=)MLC'INJLZ9=ROJ==Y'@
MQ2+S'6I]=(+/Y'Y]0#L6W'&?)IO4WZK/OZ[RUGE?M_&!Q4##%%@6L[^EP19R
M ]ID<":CB$BM'2PIX\+ -W[$$!= _:W*+"8MYL0^:*A8SO=$.<LPAI7:IOY:
M3A GP"6#I+)<:Z7[[J]E?^$U<2*Z MCNT#OYU/8"/*@5-V96J@2BSV/\*+SA
MWGS@S]_Q+#F@&8?)GS[;E6,)! 8.SOXV;2IUX^"KG_X3Y7Y-IBX'7!E06EOU
MX):L"R=L='L>^PYG:E,RD95Q8J/A4T\5";U,+\A82W1*4B*,5^$N:@.^3=*@
M$RS!5R"6O2!9.TEFI=;Z2@LZ04+')&@C? ]MPPG"Z_YC]&*G%[Z,1'5I9XEA
MJ.3_UB>HJN$(48I Q"]ID@V#^R0U[-^!\XD#U7,\D*4&-=^[?69?X!_"%8G[
M?$ ;B']-\,D;1O@@3F+$$O5FS[LDOH>1/[TGO,93&OI16^P8UYX36TIB<%#A
MORF*.D%&E]IV!,B)M+YUH9':PZZV*-W@D>*3[#U_A0WLQ[5W7$]1-^9MFB1%
M5;94@FI=M_M.^@P;T*\3#&YH,6Z[[#VJLDX0HG3T%T4O.&LK*XW<VV)P,];W
M^P*OOH#HIB7P1;6/3LQ4UUG:")<D6THIO!W4D!,L$)2B76#TDF)N#-__1GV[
MB7E^G:0DH%7I$-Y1W ER9,J@#L>RCN).D'-SOU3K%<J/3@QU\>:'$7#R.DG!
M<@")>(7\NQ4,#=FZSW&*_ A>F^ N<H[P2D*J-$M3-.P$BV#C8\D2@ 7Q,:">
M6%DY^T^J@S%^KQCVS,30P;5FG9C?GWW\UL,+E?C0,$E2-K^R<DX0T)LS7#N,
M<7@[]A=X]QL?8A!!6+P!4&7F?RE]ZX/7=1J #Y4$EFK6CIQ80Q0>K@L\IU["
MB4&+6 C"T@58F/0-T7Q!X B6Y9J^^MK-6']Q4+7!-5Y]\N3>S>_V]ZE69MOW
M&+_H7L,=-26-2I(K;<J)9:M*/)-1;/.5XK,86=ZI)9BR??OK9K'9I&A#YE?8
MG'A6TXT,&:JKM".SK]!O@+R4<;_5P=J15FTGB&V%D2I5"?*23A#Q)4F"]S"*
MB$L-%F,WP'TZR$HBZKHZ!S7@!,FJS+C5.^VG) )!_@L6^^')MHR%QUT:9OB3
MJ!'J2L@[5U].,)(]=!Y?$21MI("NY91WREMZ-9T@LAH7'$ B]!H9-@E@;$6$
M=1(_KD7[EU;W6T'WJ;!8O8;H#3\5 $D\;%N'9^G%B175@*V^+O ]CK[B06^+
MK8 N<Q-?)T5*5 S2DV5P*TX0S],%,_MT-SZ-I*031$CRT"B\_KJ3- YOQ@GR
MYW/<*),$.^;=JC\N)R:H)6]6J'E1E+PWE9X#JCE!7GGTR3!TE87L7YR_)&F$
M9>4 <F*"V2"K%&R*Z)3>&M9U-8LB"/'-?,L0'EKVX?IG^W/ ;TBJ,L%;>+D6
M%/@LM'M=?WY>8P)"?$0$+!\!?$,RP\&4C3NQTPY&0^A*( .O^6FQ%WI[<X*9
M*M55%SA'5PTGB")K^!6_85&:T6OT 8&2AJ+L/^ZB4"K<:51S@KRVYD:M[M#3
M_*CK.T%P_7!2BEJ28M:O(FH6>-SZ471>9"&^(UMAMI(B]J\D,4N(\AVW6.<H
ME6"6'M:"*W/UBJ*HTW=4+.'$_N");$KQ\A%ME!@YRL+V%UT[#VI=H2 #1FRM
MNT,:<6(6*4 J2LN C$[P05E1)\@8E%SQ@^9(9"]T+$:O49@3]7$<8.$OI&#Z
MF2S\Q%BG]O<YR0GDAP$>JAS06K:O=2HYL6H E0M<X2$K.1YH-X1HJZ CM^ B
M"/ "RMA_;K%4\DE^&4H*NC$+4IC,GM#IP96=('4D]O;Y7MZ RD5[QNZ<8"?1
MLPJ'2A_@9KNH$V0\%KM=1"X,/Q)-FX)-L]M):T!]^U<*?C\\L91=C^&W'"$*
MBUA#Y%!G^]*LZLB\OF3H7P4>V]4;.!%U9O-1%G:#E"K'#G"<P0+IIN6157&"
M+.I-466 8'IFU7G:4=P)<EKJ(OP'_XW9,9CG)@B<#,<R8YD\%!+=U&W;/X#J
M((&M0Z;^V8EYG341._B'3OJZT>W4"=9"_IHPOU4C,+"O3@RVM0?Y#_1@TMJV
M]2I.D#4D8=(UON9E= YMP_XQ5(T5X(6%X$/\_ _0.HS#'$7[UO&D5\V)>6U;
M:330=WHK.4%:><:17#C9+:38_:S6'W04=X*<2E:;P$%>(S_G5+W8W\44N.X9
M;[U4>)W<A3$:]+(YK!GK&BB.[O;I\\M3F$=*]#?^W8G%WD"*X"CN-.9[D>=I
M^%(0![JGY-Y7Z1,&-V)_J?Z2I/_$=\4*R^E!L6JZVRB*.#%CFCG*.N^5H6TX
M0?@B^$?!4E]<)VD',)U2 SBD 2=(U@E@PU=$0!<HWF"2F-2Q;3G!B!H2/,T?
MTA%@KRKL!"E$&@>9CAAS^3]NMKLT>:/+3TV9;ETG"+U#.3%^X;'A9VYPOG\F
M&'(T@PU<#V6\>%>$Q_!6G"">ORP?\*102!40Y=0J^:[R3A!$%'VPZI*5'_T?
M+,AD0;CJ!KKHJ>(&6=2+Y 'M(/,2O@AT@5&U*MJ7<Z2 <;U$#JQJG\RZ#UT5
MW'J?ABMI[D7]6DXL4R7Z:;<=1:.:$^3)#=<5,IC\NQKP?DQ[]A?S(TKQ=7:N
M#.%6/)OUJMDG[SE^":,(\&)H4!I-3 3/0Q:U^90\H'#[4J09_3%#N&F8KTM0
M%25D 4-D9]M:,57+]IG$;$5Z6 ;JLF[L;IXN#O,VSK 4E[(TV5V(>KV5G"#M
M$I3,8!2*J9(#+@]\UK)<KBDX'=#,CGZZ%PNI(?C&M6A_X?)-)>PHO+](P)6@
MO"SA-^BPJXT*D<@LT!C*+==EE%9KV<_6DQ,K:\+DJ9H8;'/G<-4=AA/LU\UJ
MJE/>"8(FM6 _A-D_KU.$>(HR(V9S6:=.L%8;A$(DLUM!.[)))]@R7PBYX"ON
M6'#[D)'9OZN[8)DI'$AT7[S@1]%RC=\1^#N!S"&&N7?P?HTW98IJ./_"#![/
MH)KDY<DZ;3]4C'3KQ!Z0 RJK0*15A9T@A<,O;<-<A7S:*.+$L&6^,'SYJ*ZM
MOCI.$*;POU0K@SHK.$%2[[F<]001=6;.XYD>B';OH&MANNZM.ROP)+GPFFXZ
M*HC?W%@771D[+R9,#J[9HOV;6U3Y5+D32A\_2>S'@&KVR2ME).+DA"_U[!SE
M[PC%Q%FL+5'TE'=B$>L;,L>90>W/GHZGP34"C5ZT3'=8>+Y,BPV5?-I3.Z8Q
M)^9=AD$FFV%9.?MSJ8>IMMB"$?3?]&%*7(=:\WAH0T[,(7?=NT2[)%.@L-2+
MV)^YK_OD+U@T"7W!OQ1+,YL4*9!R]&O9)XYEF<\@;!.N<0CS(YH2KH2[@;1/
M,2+N!K^$^>MU K!KRY@_$26VX)$MNK%0Y]9LR'-06NC>"78K;F667_' .UU2
MV_ISX:I,$Y!>X.MWDZ0*D)E:$2?F2!:KUU:S9-R:U.6<I=F$_>.Q)P6)XNS7
MJN7$G,*VN<:G+_C(X3\K*3@.)+M'#WQ];)M.,.9FN\-/(6K/I!0H 94415U?
MO#P9[\#5RZO9)V^1K?[T^Q\56U#\Z,2"4D?8Z>'@#JEO?V[&1"T=2Z@2&6SK
M1KNEF&-LJ"WB>LH[L51+*VBR6&%Q,D6Z+V^MBDZ06.JYSO=D&@B*A#++MZJP
M$Z0PG$429!)0B^D-=7@/SHO\+LG_BO)F,H.A=9T@M =*PA4TB'9<JMIYN#^F
MM;NN_?/O/D58^@D>PTV\C,^3N,A0]EB\_ ,_[Y^2GZG@1]YEQ+0L418,J6Z5
MW"S?I7__NA!)8#\YL=S(R52)HA(7U^Z23A!1>B25SH5R^VNSE!.#;V,,* UF
MM5+6=1+<3 EG?Y)" '(.2I0'COHN=; :5-&)^;G#JYZ8/E2X++4"3@Q9IDN5
M.O9(I3'=RO9OD<K5!= ]U^MP1<+=J-H<OSX?=_Z*I@%>KIEM]8(ON)^0'_RK
M\%-\)BCU,9,V[\3*T+'FU<(&RW+R2V%,>TXPI)F<L<,G5%'4"3)*KZ+EFBG+
M\&X%.QB\[SN4;CKU[._S>KJ8UCZM?W9B/AJ^1QP\_1+@2U&@Y=$^L DGR*X>
M(#H' WF+:,(V#F_/#8:0::*.3LI8V-["3I BGP$:)E;@!<@TC8WGVO#:3A"[
M>//#")83OOGA>+E$+[FNN\6A;3A!^#,(,U?X ;W%TR,EJU["B4&7:ZJR"G4>
M*UWEG2!H+)B_<"],[H0[3=?VA0JU9:1*?@  C2UQ0[>B?1*Y0;R4C10/'44Y
M)[;"H0@]CH'RU)/>EZ:!Y;JZ$60!F5_]G'BU+==?4H0K4I><&$D7YK3-.S'[
MY4F]*/+7!(;:#8?=+.D$$2,S']R&,;K!K[0YLBJ4;3O!*$FFC$YLJJ[R;A%T
MOB___"G$UP<^;/?$-U[#>-A1TRTB&8PA49BE)'W :J\.A]*HY@1Y+>NTTK:F
M9=M6UG:"V/D<2'\F.:?M.*_6^W:#T5T!4'?HG7P:'CI5UG2"R$8\JM)30E;.
M"0(8Z@N'+]++[M-;R0G2ZM&U';BETH).D  >HWT08_4?A))87L0B$HUEWR69
M'WU)DV('4%00:$S44BCHUFF9[-\)AE<@F6\(#Z]C#\A+.D&$1/G3)6-V%'>"
M'*DK_)V_[4 E[*GB!%DR%\!.G5YG!2=(4NN-NH_=9NDF,?_??U2TX/?</X4O
MY,,.RP5X\Y%S!+ZSSEJ$@0X!"U#YM]_B%8^I^_R[3_C__B/WOR5QLMW_!Z'S
M ?]/Z<#!_PMB+(D^N8GQ(+=^#<X=H/;_YU?-0?RJQG(\3PB0KW\EF:*D/CL1
MP"8DI?+C-45K2D6&R2!SDZ'5;S?)VW\$*"14P!\_P!^__98%_PL<4"Z2-Y0V
M-SWA'W50J7^7K9L9!B5#!!#&5/ML:$@+W&% WF61OY&,J?[=,)^HV'N%+TP!
M143"L'HYPX.\QI>&'Y$\/_B7K&.8S9)6!DIYI3=4L:RAP:HR? AC;!4Q-+2G
MU =A[G&_?4DBR;CJWPWSZ^K;ZA4>T7#'=_"L5LS0$.F]\8 V(9RV<:X8HK28
MT2%>(-":1Y#7ZMM?T%XYQF8YLX.D<G8)B@[N/=*MW%G<Z)")5ZY/7 /P >TW
MWA2M(2N*&QHRZZXZJ]77C[*H4>Y*(X9;3*V7,KMB-7 ^V^NVJY+1X3^^HBAB
MT/S*X=8*F1W>UH^B\R(+8Y2ICX%Z*:,#E.8X4 Y47MKL@+\1B"/B(%E79;='
MVRYJ?.]3K\'.C<^*&#[TN>,_]P^^ &P_0-0.U-=_=RVC!#SYWVX"B+U<AQ3%
MKX?1JO)&![T( GQ69NP_^!6./BD'+"MK8[ 7X)V0/B7O<=]0A9(V!DK6XS(E
M46="++9JM,WB-H9\G^!+,_J_X:YSUTD+FY*WH/\4^8H!UCX;&A*)8KA_36+U
MV=HJ8EJ#5%X[5++OTB8UBQH:ZLUJG2Z*(,3M+/(<950QJ% S=10VKB7!]\XV
MOTK3)+U(L("_ZABV1B7#PU_$<>%'O8NB5LSHP?1S$N$+W4_IBT0ML3;+&1WD
M+UB:_TN,[YE'Y&=XDP?$XJZ^^U7EC0Z:ANY=1XFO?EN+90RO3.T84LER[:]K
M2EU.SRB%"DO\:G9 UV&ZO9&]4^K?S0Z*PU^KAU66D Q,-"=-8K_;D;S(/ZQ>
MPZCD5!7J+#48R>":?^4E:8#2__G5[__\VQ]_Y>WPJP\TJ__SJ\^_\HH,#R0A
M'DE^!-^8C?R64JX<(AD?Q)$B4M)U=C2,1HP?__GCJ?)#8:_B?/ETZGQIF<@X
M9SY_YTS+)L=Y\[M3Y4W;!,A9\OM394G#],CY\9^GR@^YU9.SY0^GRA:YI96S
MY8^GS9:6=9?SY4\GSA>%09FSYV2EW&[C-6//'TY6Z%4;RCEK3E;NE1KF.5=.
M5N;5\0;@3#I9X5?F<\"9<K+BK]33@7/E9(7@3O<*SIT3EX5EOAR<-2<N#XN^
M(YPE)RX*]_BL<"Z=N$2L=(QA_/GCR8K$'3XXG#<G+A-+7'XX9TY<+E;Y&''V
MG+A$+/=GXLPY6<FX[CW%V7&R(G';<XNSY&3E8+7'&&?-R<K!71YJG#DG*Q'K
M^,-Q)DTL$$?'Q)^ZPQWCR)].7 1N.?EQOIRX^*OT*^3\.7$AN.;"R'ERLI+O
M ,])SJN3%81KCIF<&Q/+P4=Q+S4<0CDK)I9_CXD5E1LJ9\;$$F^+&0RNI0F(
M,C]J2YGKX2*)LR0* W)B^!$D>'E\14A(4VH<LV7M9R^$<0S^AOH.HRC/^"^5
M$[$D<QLS-RL@730J3.+[? @1B]4*M,@9RX\J#W_O*6QO\"05I1[SY66M#9W!
MLS5 V184$BN,-P295$&*7EW+LZ(U'?;GH9W7K&?@'16L$5'/#-2U=&0EK0U;
M. _Q<AX\$]K5+2XN_:Q(K66F4?50PN#._H%?U63$%+]]A6_R&F HYBO%1J7'
MIB25*1OV\/K6)J4K*W!C$J1%+>YR!7+S'5*MHLXJ]NZ^RLNJ\YIK%K,VX#H$
M+5_%^[N$)AU6RDO]]>R=O;7\W5K27V<5ZP)LE57U2PJ(E5J"K**2(POM =+7
M+-?/&2+2DM8B:]:Q1LI32F#U][W;7%+0'O_ALA)NJ?X=KJY@C8ANE.0& 8K"
MU@;_'&-61C >OC-[MG)'!6M$U$&W>Q>1LKB]0S4(0JINNO?#X":^\'=A[D?"
MC:PZ6/LK.K OXISB3_?.3&<51VZ)4JSHWB<]E6R^77=XJ3!<?_Y@J&EKU&_9
MWIIV;Q(Z%KU+I%76ID15; N2.X(GQMBEZ!4SN4R?"9C@^ FQ7#_YW]0BUJ!6
M)G[+2H55Y4QH57%!3](CH;<+NJ&;U=')VAYJYQAMRA*Y'\8HX)G3A'V%;Z=P
M%:JEBMZ*+JSH_J7LDG)86REL5[O"\QC% <UPO$'Q2LWKKAHN+!&I=O= I;!E
ML[#ZI.[* :,RTC&3\<?TJI!>$EU<TC2IG1#3.M>4G*TGP9U^4U,MA:+,NG82
M?!IJH*LE0NXXX4Z">4.,?^V->6+,TKL/#[!2,NY]^M#<T[XBY;;/$^)1]SG?
M95\]"28-.^+;=MR38-*86U'#DGP2/#ST<M3G_4FP<=@SLMOFSQCV^4,S3/NF
M[',K."%NZ9]G+8>%D^#2L!M YA=Q$FP:=6UV^&6<&O,T#B^5!PACU>\^-*NT
MC_@N5Y,3XE07B]2.+"?!H&&'E([3S$FP;<Q)W^VD<VKLTSC%^IR!>#Z(#\TR
M[3-?R]OHA%C6*W2U79A.@CL#3_ZA'E,GP<-#K@$]WZU38Y^.;D?B(\9!TB=E
M4X)%&I?8I*_1D1[RI\"<?JZ<"#N&G>HZGG>SL,WADVB,&\#W12;AC\RQC4/Y
M?F@VC5E4G2Z.LW#O(VU)#:O9'[\S[T #9(7C,__N=1C)YYY,PBO*PQ50R_AX
M%+ ^KH(V3(P2@F=HF9(!!\0*=8]2DO)$09IF94>(H\E;%D7^BC?@OU$S]ZQF
M):>((6",0PAA%9PBHI9.1YL2L98+H!4#MXY.31?(TMPT737<(:-SNZA*NS/\
M_HW26<4-.>M0)R_=B^HD/*.G86)[;Y^$?]R4S.,GRDGXFTS).%D.O8]MP3V4
M>UHRQDD8/R;@H/+(^]C*VLDXUSCO/K8^;3*NR0X[ ]HTMU1!Y8_9<LW\4_!7
MHJH5#.-@$C\NU9".<9\F<L2_@Y\OND3TOSV*HPD:MHMT(QG[<XP'&,')^U,2
MP7[XXH<Q$+2,J^"S11IF^-,E_F>\H13VX,K,UIU]."?FE=0'G:PN;Q/P#.'#
M%L+O+]$;BA(2-\?&IR"CNXXU4NAJ*D^PGKE0E;8X$\3E^QK?;F 7@\'\$N:O
M%T66XX&F>+Q1 ;L#[/[X_P+U1CND)9L*E.:!P#=VSPSJU+1&%AY)=1$H"*B7
M<>X:T( *FQ4?;#1A7U",S]L('U.+8!O&(:P)\$OK/MWZ:MG%IBQ6.;D"\? >
M$/%HN4@R6$;@'47^5A_:6K7M7Z:]^T96TL7S:_BYY0#WN6BB*\+8O._QBPIE
M[ QEX[G#SQP^1#6ZNE;5X[D[_OY[>X/E/G9<S77N9^%*,6AY66>&?AE&1:XT
M/:E*6QO^+PB"=E&P>,.+=L-2TR[7;%RZUJBAK;A&;FN$70MP6!MN*+BF4UVT
M0D1F>?N?A&VO]^7?B,7L>F.?!,-Z'N=U=AWP$#X))@YX*XL,;<@3)\$JLZ>F
M-$9L6@.]:U[@@T[ WI?X2?@T##@#.[A[$JPZ\*2;8M>?!'^'RB]ZBJ>3<+ Y
M9!=+KM]IF>3:[7#@_NU4IIT$XP9M3(G2;A8O+=>8-& +ZBD)3\*W;0#7FMK%
M>5S7CGA9*;2><_BI11^#0Z5R=0ZOM"/ET6 -[AQN:1^+=RIU\!RQG4?*.2W9
MC/'KSZ?L (E_QXLK#U\B5/>.E\8/-W(Z'8=?I. ].SB+NUY=^RG<GP"$J(\&
M6LB>%T'D9QGCXV6R]<-8Y3S0+CAQ_KU'E(*)1[GXOR(X:1O#&U+3GKV7K$PX
M_I(83WDGG^5E70@SE/)?7<[^_FNP,EM\"U5>#=UU[)%2O&1A$/KI_M&/$-M]
M760HR]LCH1K(G;_%?SZE?ISA QK?2YT;0:.B_26&;U9T@__L75=507OIU1%>
MU"E>&W2-Z_II]%:S"!<0OF'VWD?^BO"X\X!2%)[E#CL_^ [KK6EO]8@@]/2T
M[^2WNKS]72O*,CJ70JN\*WN8YRE<;"'SQ"+/T_"E(,F:GA**IZ.WJ37:F7BC
M+/*G5T1S2RW7>)GCSM5[0UW8M73WG5NBN\[WE+439QSOG@OM^O;F1?."=NA&
M;N)?=DZ!HO#$!PW$) /(&&A5RB<*WGM)'",B2X*+5U,X(&JI\E^+#?Z?:T2S
M!K+S!^S.&>6\[,0RT.L1\8E>*Z;YQ'JU>Z[2D'C1895@,]RA=_)%+7KHU'6-
M-+HR#Z2M6=D5&6O,-![4U,0;6V\,W5,WHB$KU!".TJ=4A@^1FD9=3&-Z*)&:
M[5N<R1F)U^W S=-I*&,F:M0U9ART0Z9I<VJ52\=@;F+<)7YN%2]1N.+" 1$?
MGF/\BGF'$<6;RS"CF1L)2'26,>21FC A5=F8Z=D,OQB"CPV&3=ZUDYOM:KN+
MDCU"YRA&ZS"'E-$';"]9*ZZ12^=S-+WJ9EPCF,Q,E?B.Z@G?_30@"6 /F&5U
M6ZZ13B=I(MK[&K-+_ /:%>GJU<]D@^XBM+NB&QI]SOH\3)6!R!T5+.IA_U%D
M-*_#4Z)0L)*AO@#[0<N'XHPXQ3P@+.1F88Y%D_0M7"$Z*0]HE6QBT@K+M*M0
MY<[<K7.@+-^QN309>$0 /#-9A/_^^3^=H<F<A>SOG_]PE#:<OW_^XQ':./[^
M^4^.., .\F2L)]6I^PF>1'BTVM^PS.6HZP=X$OSJ=!U4P,J>%(.TO/UJ\2%R
MCIX&L_K\"6OGDX;GWFEP3>K0+3W*Y8OPM+ATV_2)%#G5+W+.P:P=?7#G?IH[
MQ3)MW]AZP@2YV^-)K#)M^:'?!_,D\!:TY8<._\Z38-2 0[[M/GI:'!IRP.N\
MO^?@WH<X\?L\94]KV:F\MFNO(,GUP.$[?ONQ;T;MD[['=?DDL'0T3GOU4^FT
M.-1YVG=D,YZ4/8X>Y_I[3M]=_20@809(6\+Z.RW6=&\\,WGRCGW?J0(23BLC
MGG0E&8N.F(/7+B&@6&8S#Z[XZ!!0 P22?F_]T\I0> C'6@$!YC(3.L^RPR)$
MYD"".C(&C@E(,0<,]1'8I^O?SU5(T^A&_DS9&J,-O'0^)&.UHT@X9Z?1SATK
M9Z>*R>'<G$:K\$&Y.7333_-4/%9F&HT>XBP_^1>GL? CSO$3R=U^\'DAC=/A
MS/O^0#HDRHES[_M;Z>"0*<["4WXMC0V]XCP\Y2?3D @N;KCZV'9B315'1W 8
MY]/WEXV9"#3.[^\&9P/I(S]_MRZJ$O=]/N7'RY#@MY)AD[X]J"WV*C[",_*@
M8+J2BY,^0HZ8B_+8O9)-D[XVCIE-LEC!DDN3/BC47'(XN82?O5Y'R7O%NZ-(
M&.%<HH*/"/+<3$YY$Y>9WI@DVY.:8T ##A&Y6%%](B@10;[$(C@*W^ ^4@7P
M#VO#8OZ W2XB&]^/^+Z_B==)NJ7'=D^>%<W:$V\OZ I>3]=)6BZ>6V#R;>B_
MA)$2O4ZKGAM )?#&BU=AA&J"]E-"2$B3MQ"?M.?[9_Q>%#;08I6';_0=TSUO
MLW1EC7&7"-],JY L.07!M2+?DW5\3]:A2C55RC[Z&:;:5>P3<@R)I?!Q,\UI
M=D!#%C.2).LP[P#^$0JX-C/78>SCBV+\S'0U-+&H@+M>(11DU_B9J.5C>YU$
M>"\O8VXKELD1XQNU?T(<;X83&ZF5/FB.$L7^O,&/SVR*([BK(7M'L+_GMIC5
MOXHP97/BZ^ :Z]6UEXN/B2)W6*#'?U;LCP/)F0M>,E&2%2GJF=W1S5ID"%$I
MD.3J09@7Q(,(SU.*UVB1WR7Y7U$.+T(EX9K5'5155.J%P1H*H:I=W+?SID%4
M==++"UO,<K-C!\5R?9O$FR>4;ME:(OJ&Y4L4;L@850?-D!9F%)F^^CD<:OOE
M6N.0'%K;H4USGV)^A\$E4[62#9\AKJE;9!EJX96/;,QF7JP4$>W<-DGS\-]D
M$4%F]ZQ43V("MF&QS>A!3U:A2I%T6&,VGU_=DKOZ5=93SQUQ!H\5OWSS/7@:
MYG@"P!"X@R*Z,HVZ@:DS2JEM >20HUL%CZ!'KWM0.ZX)W1)UQ6A]AW-$2L3%
MT:H#N^(V_#]LD#<_0D1TXLZ6\ $ON?H/0DGJ7=1>NJNH )/TU;?5JQ]OT -^
MPU[AYV*G<&YP$*ZM*,D3<_0;U27)A,@,U=8>)HE(*Q_G=BG7))8M=DGF1U_2
MI-CA&D36B#%]!0H8J6JQVN@0'%I%_&6'[_J#7H2\WO>U8V8(?[>(CR]=!2D>
MGB ]\<=,)6<I);3)FG6((?QI]X#>4*Q, =)?S^IVPLQN+-)%SOTNNS*;Z-6U
MJ'L1MR"H+$%?IWS]*(N[X= X/9KMQXY=&>Z?)CJ&#G3\FI2C#D>Y#/,1*Q>F
MGIO622S+.7V[Q 5<=X4Z"=9^SU@PRE&^P^7IY%/1'.ZA5$?CKUQ^3IEM&NY#
MY=4Q@=O.2;!Z"DSZ$^'0;4\XX^"=?AKLFP.._F.S['"GJMJMH>>E=")/D*D<
MFVJ9 +1]@TYBV<[U<A;]D"9-1^'N:C7UVE/Y2)U$UH]IA/-YINJ4)T!3S#_(
M5>Y$SH\I<H]\[+4W2JKOE,1.@GWC1-3!7J(GP=.IY2<]E]1)4^D<P8GX/<67
M$Y+GH4[$)[)<IY%-AYPH)Y%Q;!J)4\,'_"2X.2K#UHFPYA#QLG,YG@3[9M*
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M(RMQN+2-0)W!=N?NB@4N>DX'!X(!V:^^2M5=%'1W[XW?SJGO.I]$'=U;U/F
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M?W!:=/E+B@YC%"/I?6S*;'W9#3UL2=19$G7\4_'-RHOSV)TE96=)V9G4#GC
M;^C"\2SR37P)T)_X+KAE=I?0=I:\";=85UM_TIHY,0VO2.OIJ^.#!]CGA[C^
M:O/C#U]^1EH4^L]/6%!:O"#]O"!E].\)51FEM*F['C5:%3>)^8\N?I3%CS(F
M*.JOVNO%3OG[BU]E\:M,VZ^B_-3[R">R]?GED8;ED08/#U'[;?.1#U'K\Q,$
MN$HFLHAQ=P83A-DQ^<SFHQ*,1Z>I@-#;3ID^)%X@M44ZXJFY0E.O291G3\^O
M*K35ZC-!&E-^>-JJQ.HPM8TE;[BW1:KSF^ 6U;*OW=L?I<E-<',F<8W^]K,C
M'B]!W-D(MOU9Q$0L@6GN>UO5%;RELO02IK:$J7FZ [YQG[:O81YQ4DNYZ:7<
MM#_H^L93VJZ7I4BU4S&P2["E2X>%XD9;RE4[N5-=3]A2QEIW&6N&B\],">N%
M=XUH-#51\]I5JX:=P]+V71X17PZ-4X=&V9EJHA+YLHMC^UN7"N4.[J*:2W:I
M7.[@%BIY1XV4,&<+[-[DM'%;/8%UNDVB/T'H92[;DD\D#8K20I=,'?'XUB"Z
M2Q"+0(<?\3\\I7O\$3QS=B8%K\>2<.1"PA%CA[C9(OP^UI;R%23HDHZ1EGL1
M[J(DPM#B")[JQN%&W\KUM1E0#)"T]8[F=PT^0)SN,? R"Y/I.3\9<2YQ R:=
M1]S;8!;P+H$QMG= 0B*1(-E913)*7?AUT"2OU5F YXLW?MJ!0<HD+"4^C0>=
M Q:<JS1&@F):OM2'8+F/UAB+BRT$)?5>A&%4KODNV:1P5R+LHZFF?B;12A_0
MFLZ_>4'_RM!EC(U^7#E:=11KJD)M9S] ;=;<U0DZ65L,]EJN-K4)<6P-]+9Z
MIY[!O#9M]--YRNB'WY[PIZE M_\ZZK2^!=^C7;%C3JSY]_$1HVQJ\V_6Z&\%
MMT$2_4E8VQ4ZW&D<A4>6^5AC>ZO-;90$R3H*XM.U)+(8Z1G; 7LIBWE4?'+-
M^'.=:<H93K5]R")S3O((32O)\8Y'2. @6XQ9%]?B)NZGN5#>46+Z%L4@R].$
MSM6X39V[ 17(1.2ET?H)S5OW@ T0FR(),:F_[I'HG.1'V\,36 ,TI795%?E^
MKIV<RX.@EI.XGW,GYS?=[V>(Q .DU'/%@\;?-<-UA9I$:V)>> );_/!;"@\G
M0.@RN4)'0YM;TR+1]Y\#]-6ZX+E%:A2.C+[8I462EX>G/%7H=D>*+>J-VZTV
MI_GRR$/_QS2C\NV0_F\ PRAH:I5'79*]AW(=-<_VUQ3&X2?B! \@)V#*4)NX
MDVY*P_N[VKQ$ (+P*3T$<1Z!;)4<OT\E&%$?B_ZK#Y 4X!:FN^.CLK]&^?M5
M@2#< 7CS?1T7^&'3BRP#Z/_"E^ [TY^E/I(]3W-E*ZHFS7(=MUKIYK#%#G-'
M='U?!?GZ_75_$?X+H84/&)6O<IHOW)3RL=]^THU+BR"N"@C+V6+1LOR!MD*9
M;MIW,-J]%3 CF%3"(L(,HT25,;GM[5!7;9]!:(2D9+^@>?VOR5L4QR"\6*_Q
M!+(S+5?^R9?TN!WE+VDV<NS#I"U=W^#V*L%64R<') >U):#[DF4%YO;1S;C?
M,0G=);\$,,*?:"@P^ =T^R$EDGK0I/OJ)KJ&WDBEG&8+S=^OAKU-X2,$^R *
MCY1W6Y"7TVDS$O;1+2X?3_SYPU< YF@_[D+T8[2)L-@"MR"G2GDJW4>;.0F@
M'CA]QABZ*82ZQ^>[B&D?D>OHAH>TI\^K[C,5^9%FX>_G^I\:]3E4 9\T? Q?
M& :,XH^:!Q1MRNE@-&D8C#C4Z)%S^MQ1L]@1:9?4J= BT\(]$[ST>Y=.T,KY
M;F:!LSG_<IUM,"[X62 L[5)KBH5"=C$+\ 9(V +?W[1C.$6B8=,7.6DH^M_
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M^CL(@_+W@]W^KQ*B';6=:]<H>>QJV"U*'V*"I<[T/*24E0@^0J2#(P#)[UB
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MZ"(\:=@8XAC&A"(2S0.*-G%T,)HT#$HRW3D:E"E@S1DL&39#P786D VR<4F
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MM@23\*_,LLGW"<3XK:S' **S?,[<%!F A=T<T.V:<79A&4W!-1++=+6VL'N
M9@'H14 .Q[0%*36^ST@6BRQ1*2V[/-3_PC'?*@S@Q"*Y!EY*0\W6RGLD#V5A
M^IF YQP"D+--C(R6/H+HDJ7\ML!YR]_0+;0K=D\DNN(8:=TI J1JMALRMNXG
M\J(P 0<1C5%:>6ORDKUJZ4(3[S;S7"GN TROV]!EG.0M)@H"3C.:0OXB=1DH
M18)BV Q8UYS3*Y>RH*H+3"PJF9"-53<H9JVP(UJ&AEU*@V25"2''J@-*D7%\
MLE6T0M=P;FA4)AWC$$425[\%R3H::L5@/?/*_A[+/B'?3_>3M )L%.=IV=9
M0MOKTV.KU]2FBY'$[GYQU5]&8X?U.V] Y-D1W%92E1GNN4*QD/.Y+#\*U2XE
M[EZ7DN@\U&4L.$)/+_*8K*XN(1WRF8D&"=&ZNL5107GB ^^(3$CA' :!JGKI
MI+KP@$\V4A(OBPQQAPSSC,L@B[+5YA&"#"N+9,_","H75,L=O 9Y$,6Z]0FY
M"7%5"]4A- M5<I]G*APJW>UY0HJW#/Q1H-G<?."X,/0ICOK!:NW2]+F")+N]
M_TMPP*U&(KJRK #A=8$+39<!)"3D)'L G^1/["PWJ<ZN[!-5R^*WM?L0=%9B
M^PBC-4#0DM^QIL]L[]2KLW?X?@WBQ^(MCM;GZO_4)<GWM[;$%[#;IS" !YR*
MG!_*3<!QEGF0A.R5";O9>XR,]2)3G;Y>]VE2-JQK@^VGR7J,9)<+OJ<Q$H2S
M<D]P[0&8E<G(SWNDA_%8H*"G4R<0BS+11Y#CZ-TUX#V0+-?9L<79?-2:];(\
M@#A@.MA6GXDR3.RKY"M,LPR78<YX#+[7$-:?Y:XJ2Q_Q)?&HK/W@=;$8*X44
MK 2$-P%,$$?.+M;K8E<0A]8U4A/73(8@T=%/VV=/Y?!DR5%2S5PV<,A91'MH
MHNU"[50ESV5DY%\DX^BO A0F9 +3 80?V6XBP_D WJ*JR'H*D[3I@4,UGN=J
M::,4MFKM:7*6+F04-'9/,[)T(256_#VM2:H+H%Z&!$^+CFJ]PD16"$\K9YID
M4323AJ<E(\W"9/SMBA&J16K1195-,IZ6D]1&3ERSCA%YTB/50\96Y'&8PG.Q
MVR%)!^U]M$TBM![\>$E9#QNK62F2"R.0U;+7LSS:X<6_9@!][S[: )RA3O @
M*3@#@Q=T6([IS[!T=KEK.A9U=" _DCE+N=1N07>;]G[ZO,YDIKIMM9[N+>OR
M((CLD.GIWK*$P1(R/:>YK,'1(,R,];?3UWC9ZIU6NAUA%01[# '2D\'Q<P4Y
MAW'TT8DTD>]GC21N"W3K8QF"%&K_3M[4YD::<#I8]/OO]D4.()].1*WM77[I
M)O]$@OHUTI?C5+P =GN+B3E!!K#R?[?;P_2#J+%\.N+U\,[%J"Z;T1,N1<*/
MY^;_?O!(B4Y.(R-7&E->E))"9V+N1G/P>.^$["'>U0HE=*4KEV'H44=#3J.4
M(IHZK7GJA^S'BQ4DX*GBPG=6\^1H3_VR Q%A"N6>.E\'PL$1\CUUM@X$A*LR
M3-[@;"(O;IX/1#V SQJ\$&U,D91^U&P%K\@;OJ<7,$F+*%E'^QCP[,G#QK0&
M!?%/H.,41!#/%4T4;IGI3XS&]B8?_JO(\F-Q(<X.<(S*:F/82[Q!8Z\V%V')
MT[AF$FI3>WMT@O,9"X !#+/7?8AXP8\_?/GIAQ^Y*Y'KZ^N>.) +2:^S#2'F
M5J7R0B]G?HLX 'EWLE;"'#]8B!\@N([P(]_)L3WS/ACEV_:NF )O<:TBXW-I
M.&3!P6[OK653K@C\P+O89<.#MD+YK$O:Y<5+6UVT"&,-M-2D I=!E* @WB74
M0$7N'G8:#2FC>"^AL!'J3$74$V!X]G CR$RF[JGDFR7CB$R>V_\DKWZVC.2Q
M,>>TT=] @'\F*SI9>*J7[8.XK,U=M0DO\E.W5?($\+/F" \2EWF1A/?8 (CZ
M'IO\(T* P?7[X36/8OP(CFTK4)VX :D%=ZSF%H'3&FL+0PT>T@0VUBDR(.G]
MAKWH&0W+X-FA](UO3Z_&5:<W .+)ER]"H8G5CLY=DB%-AIPK?"-E]#]Q@].T
M?L(:4-_2!!R^!?!WD-\62<B/GF$TMG\0+@\U3GD+2?[FFO=^CTQ/^\NB38U+
MDS(]I[DL^Y:PJR![QQ5,T7^P+^HCB(F4?)SZ^79G!0A*]W=J![.N2*&\E^PQ
M["_U+MD7>4;$IR_\$%5.#WO+Z%XY/*[(:+U<XW*?L,^$:O<:$=ZNXB#CN:[8
M[>TOH:G>M'6:UR1]R]!^83F3G#C\GB?:EC@BZG1]/7+\2/?G%@"'?<ZIP]2]
MH A_ESM9O,[V%S?67>[0?M:G>Z)2N<N=U]7:PEZ?7R"9U^$93ZG2TSG+X72P
MY^7_"*(8<X?;%.)T\O/,KL%;?OZ)Y>B7[6Z?_&H"(C]X@==#<Y[9U_0#P(1(
M?/CU!1$AR?6Q&Y*DH'NQV]O,+ML!B,7,QV /H"BWC-)6^V-4$)?OR<%ERK(3
ML=MY&X%@Q"S=".'69\QUVK\HX88VH.S5D6:9.IV&3<I?K6 'I9(>SR#G"3H\
MI[4Y>":3Q&6<S2E81Z<"I8IB1:4[FNG197"DX[6T.S"I\/%.N\LP2O)\OF6W
M$7.C]6+U!#KNA6 '.T]N"U61@VYHYLBX&BV2G@ I*9W80W*BI"EAMA5)?)RK
MVQ.H)(G/)%:>D%<_X8X1PR $JV-Y]CSZU;3^SK-R>PZ=<?5+WK@^%21U:E]&
M4QMT@>.<]M669CP/2#?%WB3=+YZC9Y[#L5T^+D/GR*EE*<2>5TTQ+9(PG'0N
MH^8(P4GJ'9X7J3%Z9] =LCZE/9V9=,LO@. J'768?LYWX2D%BO9'VPE,Y])O
M;&&[<X,Q*XK+C&$M-J&I,[2GRDLMDNDYTV!I5M@%U7%VL4MACM/V\',2U"@,
MB6Y+6/>2G:6+'L_/=Y#W8%Z1(!"0O-*O",#L$FQ2B([W=P52E1UQUE&7FC;I
M'OT$].Y2>\@E7G'>N6/VXAFU1R:WA)CZG4JT'E:0J>HP%O>JIEE(,C=^'U?W
MCGO)L/BAWK&]@P9S=E/0-,=V!AK7<A$XU[Y8BQ8RK&%CV5G30/E3XQ<<6S_O
MM!KX@)75BP6E@8-YF[[0RRA5-]1*F7I<#NJ0MG<K&+6LN4[&+"O9EW+DK5:>
M([3DJRRQRR/7%S1Q)J4E)\_!FUIXVIBU&$>ENXXQTG/T)A@X-&((QV )UG+F
MV1+MT@>U$6,T!A.8NGG8<\3,TQG7_&P"O?^:#KW)FK1-P/C3#&!L&=1,P/@W
MCV$<-[/@[QX@-= T;P*VGR<&FUT=UBNKG$9?@A$PO3*G]'1-^!2CVWJ:X/CL
M9OW%S0>0=]\];C6P'9TK__!PRY<KT='>XVN*KTTSHXT%W:TMD#DOPIA4=ZSL
MY-YBNF_)RZZHUM.]9>&I<6-T97IJ]B?3'I[O.HHIK6P^?GF\C:_!'H)U5#W:
MNX\!N4R3L)(:R>^9F+)"570-;R]JG_,&.G7)G [N'2)T=:J>'MS%9I@G_?UU
MZAI8K>W=J.SWTNE7*+.]M25P7SBG+H+7PR(A$5/A&G.=.\QWMNB8BD)0.5V\
M#>&1EUP;C\Q)BX9.AQ.(E;A^\(@$2Z=!D8JQ4) VI8"I2W-.HS. 9+H2ZTG;
MIPF.+L,@'?:FJD-*$4N=QCP/&^G'7_1)[5.%CW[69(1ZS\-!-%]81$&8*B1\
M(F'J&I['<?2$@Z.[>!YPT!,0KB;D>11![R/#TZJFYY>X",.H7,%=LDGAKKJ%
M%U_$XHM0+WIREN,8BV@T<<^6N/@9]/L9])GKRE?:>]ON1-W=VS<??7@>>V,6
M:^=LK9W-J\MI"!;;IEU527@+N8S/8O1TTT9ET*GB@I7**4NPD]KY60V_#-#"
MUN#Y'1QC MU4T8NW.%J_YE6YV[OD VU!"@]"#5W8SYX<SI@:3ROG]]&[E SF
MM66@G\Y+0#_\]A0D6YKNVOR;Q0IN^R@/8G)U9K<%=EA\0T=L5^P>@T.9[U2
MJP)"MO"O-,3XV%/5T/9?1YW6M^ [1H<YL>;?W43,_JOH4F1WE[Q\IO\$ 60Q
M/M51QB64<B9L0FG\77L)(PED+C8Y@!@9!%!K@CT'\=<"('OU-D1/_N4V":5%
MZ@+'H+2N2Y<7+R-V]Z$'M>O84X08%\V1!%K7H].+Y)I]J.)?@] ]6R/M13[9
M19I]2F],&X.Q<UT75CP%272TFP*-[X85%4KH*U-Y;#UY1.(E0%=5^)RGZ]^=
MM)>\@!TNV0$/V%Z5"\TDS.;VGJ1HSNCR0!ZN6VT(Y#P3B41'>ZI=;2I<#SFE
MH68MZ!E G%I^E:+##?,(P=*D:G8RGF1/>X$O>9 37:@.(B?(@MW>VA)*TL7A
ME&F")L8E%7I;J\\*I F;A-CM[!',>P#!$]@7</V.[B\2A!?L>!3#[N#8(KB4
MP^TRE878M^>=^$OKI&8R/(G:Q]Y2BK<L"B-TN>*B'!*LE=G>WA+.$WD(=NB?
MI'A:0 )P^40F[FCDBKXDGWRL:/MB"P'@)\O+=+,&_]WCBGLMG/_NBN1)F$MV
MEV7%68O@BYR-'O8(O20#":E.IH<KN_$8P!4DW#$D57P> 21PR^T,L[?-K&H%
M^5NVEV9&U*9O_*62O*\+_+0L@C%*PY+L'\ G^1/U#9-^ UD^0A?*1XC>PST:
M>P%PAQ2>\N]U/X<LN74'T/VJ' Y40O+<&H P>T%-,QP&M]I<%'F*#2WK\Z=Q
MZ%AC;FE-Q: 1H[:Q7>&-Y;E9%7F6!TF(CI/*=57OYAZEUJ_45R0*]R=9SD@6
M(_*[,T14^)Y"7.2/%0K$[^348KC2$Z>#4XL0'RQ1+\W,\:' ]\IJ<QU!L$:=
M,O)9S,1P*6@(;I(\RF,0OJ0W,6I XX&J0SBR(8I2H&1GS=O3_.J9SSS":,V:
ML4)'S;,]NFL 7",U,=AB71=_IZ*%7](<K."O,,IS@'EFAAH] 71_H&G>II!R
M9])6IO\CCA#D=?01A2 )GQ!5H=5=IW$<P(M=6C"#"^7[VTNPK":5L04I;E/S
M%%ICKA6W;0EJB&KN(T1 817+C?\&DC7UV&D=WZP&=H+[&JP1H72N5KD^WD:D
MB9R;C?>J)/R(3D>IB-WU;*_BR3\OZ^US&@FI5#2A]Z\1O4)!SFD(Q,3 =1VV
M'X]I.>J<7KK<[@M=>8TL5:ZKR1,T:+%K^N$P&^5FB47P'')U8!AG:@)(B/QY
M#?*0\)PY#8G$ P02ON?6G2IPS[D,B'2@NWPL5H->V#>QRZC(D(FT#[F.1\WU
MZ?GZ!\C?37N@I\' <H*WE"/6901,\P>.<.(R+&8/"-NTZ7E0N=QAL:*AZD+!
M](%A2VLNHZ+IO R)1/"\_JC*/<.(5G 9@;'D4+JZYS(RFJ\:E4 0SRO42G,4
M?1$FGA>P'2S4-_SCGC]FJ^54\8)6/'^E5@4?472+Y\_0#H7"I"X\XK.R0V$P
MSCW&?!56^O91#N'Q_8G7_F0RKF+\Q47M1S*BR @>CHFTIF*6C&#GF-S;(X3)
M""R."K?TL"<C"#@FT1H(LS("FV."KF2$EL<%+VHGH5:I%[%7))X$,5M#QH]%
MD6(@6,C%94:QC>$TE.T:&77K46=C.049[NU7QSCO IE190F3>\^CV\->$&T<
M)-B#RGL"H][$8@XWQ]#\!+(<26#YD>@_ QCRWE+H.9CU7>*_Z=%LI#O^]3-]
M>4^+#%U"B*>\?"+&<T"_NTO"8DULNR6F";ZRH@^ )\-.D.X_F+UG+C 9"!Z+
M:;:Q6[_A,D#7,K:T@R0+ROL<XNI9I!34Y>'<IBH/1>9^7D 22M&<D4\MP/7[
ME/U"&S>[?9P> "#'=T5D*VZR+KN]"]5SJI)JIUL!P ^BMC8%*I:XHCR.]L3=
M %'1*Y)$88W=/B#)*0<@:2!_C)WC,^UA UK;T-9U_HJD]NSI^95+E_P^HVZ4
MRK7:<R1OLU"XZ@/],22*L.YR*&"/YUN8ZDC#\-00^UU&0#$X@T\&/74(S_&A
M"R1GNTE_R=YI8*3B[ZEB?2=&4KM,Z EPO,P6*\A-*0F&9GJA\6@O:$8RL\.0
M<M5(%6+K("['-)NZZ5O'U&4(=%[U/=0XSZ$1W/(#U4'/P1F+^0B43<^#Q >1
MV% ITDFW7,F"VW1U\QW_$SA9EEYX$E@'H<-N52V:XH%=<.;U9A22KK^!XULM
M/ S^*' 0_T?U=JZ@[#"MM4O3Y]OGF>T7)R!AZ\_1=U7SI$+OQ<TW>6^5_8/D
M?,R#?[XHW=X:%2^-;=:QE.8W4II?KU-:WAWM CG5)!!^T6MJ6W.7?Q_GY$"/
MY)"9HT] _"[:73*4HPX>SHU38"4T0YZLB!M*DZ39;TQC!'A,-^K0R9%"JJCO
M1I@NN^ZQ[M&-A#;@#T0AOA0D-J"Y3_VC($Q^U%V1GRN&_X+DI9/3^XMN,P[M
M$_I915[M44[<U/EG&IW<U!G>KNBX77L1@^@SDMV-?Q/OREM[5TK.7<_M_!5$
MVW<D,U]\ !ALP1/ TAGZ_56:Y!!);$40XV($/_+H8^29^'?>JL66K.@N*<]#
M:[WDC]=!#FZ#")*$2MU'LN<LO(7[YCNZWJ(,G-;ZDN;8^(ZTQ"2+UB8QEOJT
M?^RC3*6Z2Y"B71#.N,K? 7QY#Y)JW1?;+01;1#[-I>)[@/G<A*W9V)>]D3@6
MK0&=UAYP#A>>)UEJ1NBG_O>K-,L?TOR?('\"ZW2;<!XF,?>]Z4%8GE8D(E>_
MPNU8LM'(D_ V+E>?CY$1Q#O42>=T*)5TW6"..ZY=M([A^G(:!YV!K4(;@M-(
M+)&L2QSF>*%0O9BS(_%V+N%H)J1L.@QK5J7O^X3WZ@E%FFS:3[\:\%1OH.](
MB(*;..+@1 )\Y45!7?&HSD*A]X(?[D"=.IQ+WHK]BVV$+!=WXNR'>\P]Q\<H
MAQONH7<973>.Z\CO*(Q8.5,J1<9H0(3G !JR'6L-G' 98G<..-4\[?FC!N*;
MN5> BN>H&#RS8\>\>/Z$A&/<LV\8C.=O5[BY"W+1,9X_B^$8*QH:/^/YRQQF
M=L-@.(WG3X!XAC<C]F:J]0">B]T.J;RK3;O4V!K)@VB]I'+"CS]\^;E2^] _
M?\+_7$H&+"4#?"P9X%;"NO_)14MR^Y+</IWD]M[,7RA3GT21TI2O^_)1_OZ2
M3.\2=32-$:,31^OS$P2XU%VM =SZO&:!PMR\G\"^JKO'PL["!"9(GB?N/'HZ
MGLZI37!C+"=+:I_?!+>HR5O=VR+5^?E\.:BB[^(,EPRW66:X330";LGW\@*X
M)=_+IC-:W7HS=?SGFR?F1JR:^:0HE[(5'#OM;6N<R_"[0:[32G7PC5[;QDV7
M0X'M9%*,;"%= C;M2&=+%*=K6^-$E.TT0CV=,$XNP9]V[Q9M.^1QI&(M&?D8
MI;A$(R[1B$LT8B__T!*-N$0C+M&(TXI&["8;FHDZ9'['?DE6:R]*6-_UILI5
MO19O9-]I7[('&[E+LJP X74!3YGQ9 %9;7M/*8?,*$#U@;REE=L4;D"$2R-E
MB$$C03N"9 1CH:C2W_46THHJL%QIE.EVO^,M9.RD^.,1>X01\R&YL;[N+KQ,
MZ4O&"*<%8HTS\!?F3BZ[#:35)N$NV$,O$ N,9-B<O-V*VD5D 739K_OWS,FL
M7TEB&*LDOWN7_!,$L#[A2["-$MSR,HA93RCJ&]R55=^4TS.PY.;(WAXN-O=@
M0<%]HF[DF7A[9=0(:92'L-C?FP+E-I<T H&V/[AD3"P9$]RH]B5C8LF86#(F
M' I<,>AAFCK.?E;67[(CENR(X5Y$EY%V@S*71 @)TNSAJ5U2&@R<<0GO[Y+)
M8 !WBHMX24LP*YWR/1-+TH%6Q;.'VWE)*S"Q XH>Z:70M(U+=OP]^3)[[4;:
M9VT$?O\E>!L^;2-;X:T.H-L=;@1=;Y_[T>IV-P+M-)2HL5WW1K9BT;/8[GPC
M@$]#M3+D_)]\^F_KM%]D6;$K87E%/5_2JR!>%W$])[J1,KRD"K,'7E*%EU3A
M)55X22.M*/[$0&L\]BG*?K^% -\[ ((L?T*,5C=#DO[N-"#%%QPND7@=?40A
MNE7'@I3Z7?\"(GE+,Q*Q*_[@M.CREQ1)4U&,9,JQ*;/UY27.=(DS7>),EW!)
M_PPE\I*4R[B[$6*U!/^-2Z=T\72);--IUY.089<(N+$(O2WO3MZBRGCZ&9OU
MT8E?;?#SS\O3SXL%=;&@#K6@EB%QIX,EHX(T-96C_J)B8C7_T:5<XU*N<;&S
M][X^EL>C92%>'H]>'H^6I(U7)&=G3\^O*C32ZC-!6IG&.]@. UR%>UO$N#N#
M"<*\/)CMZ,8L#V8[OT7+@]G.;U$M:<B]_5&:W.*S7WSV?7SV(UC*G 9P*1ZU
M1$-,U?FV/+=MJ*C4\MSV$E/BWVGWZ;EM=P][V][I,HIN'/JE5I?-4[\\6FX5
M?HJ=>JGU94?(75XM=VUKEE?+W=Z?Y=5RM_='S7P]^?A:;JLGL$ZW2?0G")>X
MVB6NUL>X6OK$E6C!WN3O$G3:T3E&+ GC>8\_@F%G!QOR>KBV#&Z8*+_/=);R
M&[H5@B+.[2WI*TC0[1=?).%%N$,7%+HX ^R-JJX ;HB:7%^;47< 23+O:'[7
MX /$Z1YO@,S"9'HNWN/%>VQ=(G8;+#=LJ=QKU&7XY/S%$E*"!!I>>)//>%2W
MIG% 3O>SV\"(F9*4Y%*'15(N<-F58P(6*9G"8ZO!51HC62@MZX"C1=Y':[RR
MBRT$)?N]",.H7,M=LDGAKL3+LGF@-NL/4+\LT H>4K3']#^_H']EP9K8A42&
M JV?<,!DH&$]<K8#;1^RE\G9F71 GR=7IU =Q=IR61O&79V@D[7%8!_Z:E.;
M$,=Z0F\[+[(S9)#(8%Y;,OKIO%STPV]/>$+49;3_.NJTO@7?HUVQ8TZL^??Q
M$:/0<O-O%GE(DD=H%DF._H7#I$N! I\PKK%,W$]SU8.C//<MBD&6IPF="KE-
M-<\(G= GL"F2$%]ZKWLDKR9YI>=F3V -$']M)^[)]W.-("X/@@H)XGZN+6DX
MC=OAP=^0GL%E=HV_:R;Z*]0D6A-U\PEL<8GT%!Y.!XU^PRET-,0T:AH@^OYS
M@+Y:EQZV2&G:(LWR8I<625Z>P?)P(M5J_1ZAWKC=:G.:+X_MZ/^89E2^'=+_
M#6 8!4T=\J@YLO=0KJ/FV?Z:PCC\1*?O >0$3!EJ$W?236EX?U>;EPA $#ZE
MAR#.(Y"MDN/WJ00CZF/1(?,!D@+<PG1W?/_DURA_ORH0A#L ;[ZOXP*_U'&1
M90#]7_@2?&<Z:-1'LK;L:[ !$.]%.6G&DMJM='/88H>Y(Y("KH)\_?ZZOPC_
MA="JNY8:?)737//,6@N_*M /A,=AZT#Y VV&,MVT\_UH]U; C+"E2K9"G!;S
M5JI(QFUOYTZJW0X@-'(1R7Y!\_I?D[<HCD%XL5[C"63G&_ )X!=7PI?TN!WE
M+VEVW*LTH]*:OL'M61.JJ9,#DH/:$M"]P+(=</OH9E#OF(3NDE\"&.%/-(1C
M_ /B\E%"/VC2?74374/-HE).LX7F[U?#WJ;P$8)]$(5'RKLMR)-7M!D)^^@6
M"X\G_OSA*P!SM!]W(?HQVD3X>H9;D%.E&97NH\V<!)4.G#YC#-T40MWC\UW$
M-"?(=?0V",:$QX@>#J//T>*Y"[JG/;N.JL@UX31"4M$<7']%(T-0%4U/L.%%
M=I@"Q_LH#X8/!4-"\6,XO4CN*:%Z/HZK; #@]!K%O%+:MGPJ2L-T9'B/A)F+
M6L'7XC*"/4(L=4=^U!DO@T.[C*#<O2SMOVJ**\)3[ DRO%O9##1F[^010@Q%
M=W+3W>;I(OO?5Y(>/^]Q,7A[&71#N@R[8U>>!/OSO'S+ ,5=Q3'L.4KJ+%#"
M!>T])B;9G] W[C)ZCG"QED;M>:4CTU;=7@$,)C#]ZW0P[41'>%[KR2C/XT9Q
M>%[IQRAP4D$FGI?B,:QL\&)?3"#W\V20TQN98T0WFXI%5V,8D!&<)V![D(PH
M,@+?5'07^6 G(S!.0"2GQE\9 6L"LK9DL)@1^*8B>BO%L1E!<L2JJ):09,75
M&8%S*JJ-9(B?3T4ISO4H_*@_01<CL14(37C]1Q$AS?-4B/3E':;%]OVRR-"6
M9ME5NGN+DJ!"DUN#0OMG'*A#H6E-<K4HM'[,'GC'<C57<9!E50U73@XMN[V]
ML@QGSL;-E>VVT_WJ_?/_2F0H4EK92SNN;2(_S[C;4#-XSP!&(+N\PM7B81ZA
M0X'NHM+.QGX#6Z6GQ2.&7V;+L@*$UP7$URDIYTTJSV6/!6(A088#G0CG8!X[
ME3&6>AM+O0TM_%104('6TH5IJUT#]NOF+L6972O./'JYWT'9CL%N_U<)R8/:
MSK5KD3R6,.Q6I \QP0(H>DK:9R6"CQ"IQPA \CL6X,SVH]9P>0P.6&NB)DE*
M]K0R7^R)>\1$^?*9'GN\P"B(^R^$/>2X576J^>#IW&%S#N'BJXVFU:H-KULS
M:83343609@N+>?E_%%$6E7Z?C,DV.\U&)97K0FX;*Y=UB!^)#")ZJKZ1#XU[
M<&1GB=_/@2&:95;)$CU.4?]O>9N;;<J:2L_/UFN =#F?IT?(J0GK;&,;V*9,
MEY&4</DP5=N3WX9F>O1\T6S;Y&G5LC9#IY&02AD4FND;6204Y)R&0$P,H[!Q
M-3NMIX@NZ?U>I??+%?I@6VP;"=7=:\23M7,+>?1<O">%.I9W>WQZA\6;+%;3
MPCCU5+J,H18QG&Z)]WS9%F4OAC/ 4T#M5W&PF'!JBN&,D'0Z8J+ *&>-[?1Q
M.677(9J3$KM<QM(R)2JY^#Q/>78$1X[KT?,<:<L *WH^38 ]8BZ'<;#;SE;/
M\]#'N,^[7E_/<\\MG^C>#FK/$]=M,](!GG!/\Y$ 6EUV%E=OBQS]ME(#R1^/
M]4/MYR21?/?' .:'FA6DL]6=6$A!-P=RAE9[DBF=; G@84GN<AE G*[6%M:<
M4]8@J1,UG6J6,):H.(C%*%TJ?667A_I?.&'4"@,XL4AN*#6EH>90IOL@";,P
M_4R0S@L!X(0:,UK:?KHW+*\%;@ WM:GMIW;067S.$:8!#)$J%Z)]_O&'+S_]
M\"/_N5ZIOO:6=BHWE=VF\ %\GN?["-&%623K*DV7?8#5QG"=*]\E2-;Y)Q+"
M6,M5'T=W+&P4)N @.OV45AY CSX(](!_'LG]9=^F!=2RZO- FFGN!:D<(-CD
M=%JK_=4:V/>X0"-H(G4?!6]1C'22&D@,B*6[Z[[.T7?O=OL""0UW"0(0T!^L
MHS5SA*Y/*$D1[[FUQ^',<HH8/3R9I^MX'O31!QA57<EEB'IXQ\2:;S-(1E[7
M<ADH15IB!'JP-"&G5RX52J:N4[.H9"+A9#S5D5+"4*2I.8V&%(7TTMLH#_NT
M$/4TJ&>$"ZBN%KJ,DO$[2)'R7,9*SS5$4\>]CX R>8YJ.K[W\3D&<:H9!;P/
MOY&'J6-M\#XR1IU$Y$T9WD>R*!(&U5KB?7C*4"92L\!,PPE?L<,G1.=!?)7N
M=E$I<+RBCT)<7S5 0D:,)92RY^*:7USS>JW$#XC$7SY!_ &^I4G^SMK!WL,M
M#K_%:>^%TWX6X1VV(A,8U'*1K?_^UQ_8--+XN_.L%.LP+Y_I0 YZ',6/Y6(5
M5\>"R3A>+!EKJQI63(;Q8\'1AXXM)L,XO^ +K(MK6G5S+.>7;B!>8'%S.^Q^
ML6O2Z>H=+H,U!V?#XO->?-Y.^KPIJH+3*U[\VD[>."?US&6,)A]9Y;ASMX?R
M.T/7KKJ^/"/';G\=>_$ R^KE,W('F_*5N^D:=?*11.H-V]DL;C9 I]/B\5P<
M.(NK3^=\5IM-M 8727A?ODB;PL/S/EA3GRY@MIU]!B,YT*1F!@Y)H;_^P&]K
M;>K')^GKQ2P8,Z<V=<I"_P3PF3W^] +@3L$^3^GL2 X=GZ#H;9W:%RRP8#O-
M$^*N"CO2Z&;O[@?K DN&UV"?9A'K<+1;V>5%[VD<WNWV,/TH[6%?89JQHY28
M':P240J;U(!/Y&ISE28Y1#(&AXP$'9U:%+H%P&<0"U@5KY<]'H4+39W#+UG<
MJ=7*6X>GG#XS+7?GY VKB_MN<=]9H09Y;B)0TUSVR_B503?BJM7O$H:&Z;FS
M21T'NKKJN3>I#SG(*;^>>Y#4@6$HSIX[B?002%,+]]P;U$,<;^OQGF<&]KQ$
M&*8!SPM2]SLA(A.#Y^6B]8#2,%$8$;R<E+N99@Z?/,5/Z']^.[N+:\FR2);$
M=(Z0 ,DZ,N-#9CVWS9Y%9R<:3V?+]-/]-#C[FS2GKUP?O2:[#.8U<QWZZ6RJ
MPR\OG=Z^^0K2+0SV[Z2^>]>ARV\[[I1+VUU]$E2W+;^M?U,^O7>I9>H96/_[
M-OWXCRS?PW+J^%^U::.??OMVT9Y@]5M[5O(4OU50.S.7AX< 5T$I+^;RU[R(
M!(4!'%ED-3]N: *OQS26,9CZ6?FR$ 2KS2-,]_@%<I#] \0A*171JK5#8^72
M?:UMP1V:S2Z)-E'YL-G7(H!!D@- #9R0[.2*2RGCDA*CL3$!X!8)Q@PS+"$"
MQ%[*,J17*=SCOX)_@"#\ V&; YBQ UDT?\&9S>.P:&I3NQ[SF^_[")9"+\+U
M"\]7WFZJO>;S-H@1RUD#$"(&PZ$<1LLE'(MB_%H1'>TEO2%ZE4(02JNC4XNZ
M0><&S6I-_*X]U\<>PZFER@5*\'H9*,W>_MRO,,H1= ]I7K[9&J7A$<VS?LV*
M3=,UJE/;YE*-?2,+E(Y*$G0<@3JSBSA./W%Q-)P\B6T\,=4B+$N7TN-9W+ <
M2T8(9HANR'Q5Y!DN_(P6<+'#GA#F=@FZ+8'&@W7%B_4:%D%\D5\%$![0+\E#
M\G):(Z.O*TO#/]XE):.66U"CAW<1<LI&W?-SDT+KJM-A/MS0)RG;*T9"8#[T
M!('*=F, @I-=R&THV+XG*?LP@>%HD75YH<*84"6_R6GWV63B,AART8_J)NV&
M3Y9G9/4$'!IW,(Z.]XRC_\4J;_/V%!H%#T2=6D36<L_1X-O/*6*7'INVTZA)
M<6B>[9H3#)*99,.C5<=1OK#YJ+F,A6YFRW<A>(J$(F_E.BT\AT"2H?KVR(\Y
MEJ BS+F,D#E&(79->9K-H!T7CG?+T[P&[1 9C\T=(<FAOY:CPP7G:1J$=DH:
M[P6I$5(DM*,S1F+ "-D2>H^:O#_1TSR*@60D\CWZFDLQ7%,:)Y'UB_-:HYQ+
MU @VS@O*/)^J3RDX4MDWY_H9C1<_ZUG.QV?L5@FP5].QI0YW=E 0YWEOOY)C
M>TJ\THWTMLY,W8'HZ&G$AL[JB3^/P[27%\66%\5F_>B2\/[E>6=\B*CRSB)O
M<>5:3#P3?5&**^79<6$N#FV+?CLM9\7H6SAC5MTR!LXDWG8Q H]?-HM6V9"[
M!+4%+\'W4<N$U+Y:>_""5R!$T$.S[DO]&K,H"*>U U7&L;$-&QW1EGX&,,RP
MY9%L[<G$SU(158:PF"1?@7]1Y._D%')M)\SFUA: O@^R/%I?8<\!/'"3^^EM
M'<*>8W%@-+8V>323TGU3)VW._-GMW5K"0[#CU^D0]9K6<O06WK'(H>POY ED
M2!)<OW-95*N1@Q>@\G5G\7T*G#J#X[?1Z/'_*V"4A1&IKLW= E$OW>\,,8$[
M1\UB%8(F.DGW'6W..(V B. @/JC-N-'3+2;*38GF]= ,._538BJ1Z:9YIM=@
M R#Z)N;#I)#D"N[?@^0:%MON5*@:B^((-AEE@N9(P9[6PMHT7Q,(UNDVB?XD
MD%Z"!!VV'!VZ'$ D$Z^2NB:+HRT *T&[STCN+;N:XB- ^CI. ^NY9M8P'BPX
M"8];QB^6,&1$[]Q)"N:5DT.%9^UPVEPNB$^2AZ&?U<13;&3UDCHP#".%RPC(
M)<*(+7W-'%.ZP<-E'.2<2D)K2!T&H:+N"1Z\U'6=@'B2K2Y%*'R;'_^P3(@\
MAL/@"5&([Q%)LUWSU:^F)<E3E[1V*<-;)/K(%$+CELM8F) N.%>.IV$)?;01
M>7.BI\$(>D%IVBM]3IY59Z1<6Z?/*;.*U"%E5O4Y&U81#U7CK<^IL+W$C[/!
MU^=L5_6E]S(B^YSAJA$BIL'9ZUQ7DP!1#-0>1PH^@!P+'X\ /K\'$)S3&B^2
M/ JCN,BC#U ]Q(A6?_-]'1=H#K<(ZZL@7A<QN8M6FVO<%(2MX2[R'$9O18YE
MXY<4AVBFR7.>KG_'&>< 9@/C$ >[)206F>[V:/[E(F\"B)]K/2VO0U$M'X6V
MX>V%*JC0 V\MO*Q-S1^Q!M; V5\>Z -PHM=,?M$Q&(418\)NUA9TL]O'Z0$
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M;'&4KM+3;F)F!M*'G#E!V1&LEWJ3"-3H-'3AG43!0S)<6O5:N*BB+!C"12W
MP@T)H_<KGJ>+M^K,K>[HA?0Q"(HC9=_L]G%Z * JQD=[S]I]R4,+$E5_'.4-
MLHRLZQ9T87!8%M$" R,N?Z!TX@T,+191I;J1Z/'NHV/=N@N3PJ)Q^W$X@V(!
MAB$"E1?O-_/G+KIXF),6=+0F14E<(52A2MS/:KH&[RY@V:UXG2S&-? Y.B.8
M@=O)V-'@,US>V>#V=.;I4PD]@W\07%$V!KQ_Z(B1LO?[?R]HDT"P07JL#VK"
MD.6>Z++1*VOL<*VK1RK#B*C<)2^(F8!_HLO;J^)_XT#SF3:!<5BQ&!68V[2
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MI"X<3(^ _$R&-<[>S\K00RY01,+LM_<3<MS\3=HI_Y88\@PP&^;A1II5XL)
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MD166KM;3Y)!N QD-03C.%^F*P; 4_#:S8:D>/IV^$Y#4COTJ>]"M5YN+VJ]
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MX:0X#C8CT5RP=?#]/-!8?W.C%ZA[7FYZ:>/_?D#\4E"S]L'__P%02P,$%
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M=757IM^R-VS.7O5;U=V<;U!+ P04    "  \@%M8G:[7/NL'  #++@  #P
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MAW?(N &?2$R,B"50P!D@>F(I;$XC2*Q JB&ZH>M4V$1J6^$X<L%H&3):&IU
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MB6\\7"'U1.Q#4I/D'#>1-R#KO>:&?./I47H4HR]_0W#\E V!/\Y)%W!NK'B
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MD"M>HV/5=3K/#6Q-'=_!T'7;Q_>PM-WCHWM8.D?NRVT>_*)N&[Z<MVQ@Y@B
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MT(P!^F!H-BZ[W<N&907,Y '%JE3Q[AQ"RLL)59GZ7&3S#4)NP@70<\U$T["
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MTZ?8L>'-7TZ?SFP2O_DO4$L#!!0    ( #R 6UB-0ZZ\T)0  &$B 0 1
M:6UG-#0X-S4P-#5?,"YJ<&?L?'=45.FR[R9+%B5G!05!0'*F026)B&3)(" Y
MY]@$04&@!00$"0*2!20V.6<$).><<X8&FN[7GIDY9\8SY[TY][YUUWGKV:SZ
M8]>N_>WZ5=5786^ZD6/(.>#J(QEY&0 -'0#04'\ <A)X %S!QL;!QKJ"@X.#
MBWL%CX"4D  ?GX#JVG5B4CIJ!GHZ:EI:1F9.%L:;=YEH:5D%[]R]Q\W'Q\?
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M+/!6*Y% 4^->_246Z$#? '$; GLF08$$/F8A%+J10,MHL/*31J<I)#!O"#-
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M6,?P:\TV08(]AXEX_;CY:GP:M7WBUSO;(_/;G+=(F CF(N3/$_V3AZWNCRS
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MR#:*EU,<31ATVI%EYK+"G@>Z20B:3SR=8!;LR7Z=E7"=3>>]TQ$-U&T12E5
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M^9QQ*N?57S0UK:K6A@X,W(ZR("*3O%0JLX1UR[^1V1<?SJ_:]EN0&[U(#7:
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M)I7;S1S-%"D6NY/'5#QG",C1$I5%9H&")A6"4H?M2O6402-/R)9F-\/?+Q[
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MR@]]ADVN#6WE\_>(<(5 \FK;[A(4-.F%?TO%"#,K++/5<N^3AAB,:NB$7!N
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MDN.Y\OQNB.MY_AB[J1/]("</VF0I0A9G74<;-4\=70JT,BA5E-=51?K)I?O
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MDVVK^X;,J[1^2J*[#N#-_OI_Q.H_LY,K_BX'J2P(PA+R@M K8&3L+\TN_"
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M"]/1E]9S/NW"]62?JE^*]'K5>@B'&A\EB#._ZV CJGYOCQR+8$,;%F P37C
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MV!79\T$YR9^9UG3J0WGCQ27[-UCZ-X5CF-^9,02,7CP@BI_6Y5;ILQL/U'U
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MT+W8);<9*MZLN](!G?';'G"YD(JMYJP8U>-B/W6[6M9@RVZ)$,*KT!)+/\6
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M%W3/+-\@@(J&Z26AIU!8-O@WL*H?\<Z.+"_6P:%91D6:)PC@3*V!! $DKB&
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M*OCBFU&LK<QI0C]=8 ./UWG;%6<]>"U)VPWQ/A8N%2FI*7LP$B,]-;_KT=X
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M49\'-L727I,3?6TR2U<Z6)A2?,BRQ[*L!1=-T];+N0@-56H/.HXL:JB7V$W
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MY]=Y,L@K\L_28__/_,0@[4J_4!4X$A?B&JKR4/7J-:1>G(.2@>5ZT::F#T(
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MWQ],1 #A') #.\COQ'?XM!(7X+I7B:HU\ ;Q/D+5ZVEB/Z^.$@$(!\.B8Q'
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MK-YZ%;9@J^SG/7H6^BP5\WVRDCN0A/=88D>QI<)ZMF)+>>RSA#[O-P\$X(0
M^(;K[D#VPZ3L$NFZ2/7G3"Z%N.W..8(XM"Q/[*,BJ2_)&YI691H4EIPWQ]NU
MY82.BXQ/5(H%5$XB]]L0@#MU +UE%DH,"XAMH0>9/QAOXRA>6BF@3&J*NM9
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MN:Z4O23>W?3,#'RLKNMKFVOMW "YEXDT\,>Y9Q<$E<AEOMZ%NE\>P8*?PVB
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M.X=^2&<Z.5 GI#W!D(DMKY%]$$U##(%>-P3HI4+KDW)J)4;;=_YW]$G6KA\
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M2VE%_87+=WN?K_SJX0E7/.ES>ND]GM/?-\$:6"#U7ORIYCIC]CNTI;\NIOX
M6-;++II1=BD #SJ5U&#S6_]"OZG;C?PB\^1LZST$21R,'<,:]4&+F+W@'#U7
M6:ZC\ % N'A"Y>3Q 7D=1R)8?\BRL[A6XF'_39K4&)0T(!Y?(8G/]5N2MUVY
M/R+H!WIF6Y<GE%@OKE AIEK]K>L',^IW2*";E\<?7\DA]_TO#<DA8?( B!+J
MN?V3%LJ29!L@#V^_ELHLR5P_*^$S:TW/O@W_Y$<J77PJ^"D+,M?[SZA2CD%)
MN=5A\FWD^GY09,<L3.47RPSUK]XV2V.7[HZS,M52LI7]R:[\CIL?MD*@LX9
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M^/@H7P@%;0)M&2];3J34WPJC7\87 A$SD66G,LSY7HG2%$?,\2$\LX=,MG)
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M).@#Y![CCG8-+'=9@3)+S)8GUMN0]UJO]U)497F3<E1RAU5FKL_7-)1<.F,
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M8W_/J@.=MEQF7<6*]O,,J<UYFR]N^G\0FAI)-'I7-^ZO&X\#G!Z9"O)CR*Z
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M5_E'P-':BY/K'FGSSULPPC%"P.%P8+ H\6G''3>'W,(?6*GD11P@/I; 5%&
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MKCRW?L\2YK>*$%3]?<*3A68I#M#;=VZ(_:F# W#O3/S[PZ, O\[_Z/S2&QR
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M H8:4[#_5QK0E"55-5(L@;H@Z.CWX!&B-GMQX8DCXS(B3JBG(%B5R-5<>N>
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MO;9.\X=<'ZOM9[%YCRL!WZNV3+IY<<B]X!;K5VN+_&(AZ1E!)KSTFZ", AK
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M?V$.]TL:$.9! Z(@A 1ZA3 -&!6$H?+_J7]-JQOPO4THF74._6];&Y'/F/+
M^[(*:4 H787/+I?\OC]47G<>>#_X,@UH5*,!S<E7C#85JK51IC1 QX$&A(N_
M_-T=?MMNZL2M[VV.0->'Z4_%!_UON@-OEL>M[P.+<!(80C+KC*7:[X*K.FG
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MK/>SUD'WJBQ#;EH.(W/,N4NGK+4^B3'9L4@[,"4>9"SK_(-^_N^BGYTH3AJ
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MWQ<#H\A*;0X^E1</3KO\,A0K;3<TWQL;K#3W@(TW!3#&Q/N/7GS0'Z$D-X_
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MK-"_F+/FEC"TQ4BZ>$C$)K=:8D&_629=C!#@,NG[[LRM)W.NC!I$>L0;V+8
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MIR)L&VPR;I5628YZW<KZ[AAKF^&CKG%9S5L#?8G1A\&RB88I^H5W]\?&@Y.
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M \5T+2TA-=6!$QXL=,^F#F<3-^^3!WZP\YAPS//9^[PE#T+0Y)(DVLB@#-.
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MA[\@ST4"DG=C2,#+]R0@U#VI>4U'?6"F[Y@_(6\DI O1%FM*-O2_@SA/VY&
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M-GOJ(SQCD;*3R(,'D^T9OQEV;QV<ZRJ76NJ8.]1TRS'092)AA8 WX<PA0U^
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M2J;/%#KH%CUP%F]/Q.5IGQ //AJQ*3(DO"XGGK.N*YH:(0AC[K9Y10UR]3$
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M,3,02!VK_$07VQ1=6K?(C9]R@99)F $+9")D=P_0UB(7MD'ZLH()\]M(T_0
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M5>:U0V,MOZV?9(9!_OILGJ.52$,UN,2P4O:- L\>'N*P[0.=HSEVM\H2%1C
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M":D! /E<9F)Q+8H,/7+1TY^K&X(VWR5*;OK_=V6;TX3FBCHT9UF@$4=?2BA
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M"NC=XC@JSGKL.ZN&$UZ!(D$"TQ82):OP5'=W5G 1/7O_/G)$<2B;F#M!SF<
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M(7)_Y:ZU?JF8M^L\KW%<D?W%0^M_);[Z[Q_?\.<HU;1D\'.0ZK$E5[)89CZ
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M>W/'(JG+,5XF-FHK+,F)97>$-I#&6G%/[DSM:CZ][MRC,Y=255\C RVNO92
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MZ@6SDXD.A6L/C*?,B(EB7@EI>(1^@0S^*P- __'[][\_#>N_O#S6A=]?&S[
MWYSAO5<?DA&')UV+X5QNU@5SMQB [3MIA',"9H\6Y>BLX**]@/-C-YU>_6"J
MY&N[RXHM%PW]'-S*\M :D1.PRBT>)@2N"G)V-^A?<*[(EL+",0(C4W&T#_=F
M[6L8P+*5OCO=M'KF_;U.66:'C;Y#9<//%91L1@1W.N-5*,9U805;;7M!]@^#
M!-A'Y?7;"BB7/QXNY(<'L;V+6>B$A/6R MWNZ6T5=_!M^R0B[W)O%)]'IS
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ML',*SLZTJ\99:J6COX8@E]9/R$6:MMS,RX<4A-OVN:XWJYM'CT=XY=OZFC
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MK/KY_[7WWD%-?MO^\$.1H" ( M*# H(@HO0>$!$0$4613D1 2J2#M$ HTIN
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M42U3^>Q5@,LW$P1'S/(1*..X1V$@>;[I*LP(MB'W)M37W>;S^=8S1@ZN=T3
M!]-O96"DE/G=:/*AT_%5OD?.7UEX$$9GU=JEU2,2?<8<!N,R(HL&2VJL %F
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M1C$_%Y&+F6BG$8S*>>LN8*SU7O&BQ7O'_->R!R*;NB1@P*$ +5H[]C9=,N"
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M^O33)7.'OLEBFKL3=0\[%X148%CTB19:9@D]MZIH=[[] ./7&%LC>=1[/GR
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M2YF501YQ\J4=P=E@E8/[\J*DRH?^!GK'P&+&,:'2(" AW:Z/"(3X8[N.#X@
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M8J/PDJY94'BA0#]3!LEEG!4KI>?S>630IRJ1P]A-TZ,<)!IUY5WJ/E[G\?K
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M&C6P*L3J[QKCB40J<7?P@>D5%)F&*USXWPMU+UUX,MP"R@'@I5AKPJ.T)B(
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M3FGZ189;N4()@JS;=TXEO> $QG!SR MVS-YEXK@>05;D-G3SQDW&O<\4G/0
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M<#B@/CNG1#',G=&]CG$3'-/I)+P-B@O5T1@%ZB8H!:@')>K>E4F];7PW BM
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M)=$J^4/ARAG0$351K]VW<]<!TBB7$@-*<GA\7J#DX4LRPC%P&3B(_AL@1 6
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M@MNK_:)Y3RYE+.@82(TUC*G![X*68 KXJ2:.M$8PLU3[?AY#?%M!(6=H_QN
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M 6IU)YKY*0;@J"+A$+25OVO572$)1[9&+H/U)HENL*XV]A@(WX8P-<LG7_S
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M_.2=GIH2E;(26)'8>PS@]M!=>Z*09+V-D6RB<BH/27N[CX&+GZ:**AFM&Y(
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M.@TZH""!=?\XDB'3RT-/!7,S8;-R*U)C'_.Q/CY-91O&^6AG.DZ0?';JG)!
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M)(Z)QZ AC:!S'JD8_8JR7OVK;D8W=T,:=4^XH<97.M77U5'J>!,L$4+FX=@
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M?Q#T'2T)=ERAI*/(=_)^(-5@<VHF7D0 WW&4_H[VX=_"_R.$*U]OEA-+"D8
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MOXR76*5?F/?8_3R1TKUSO@P)7P]FGD K M >.7;%.-XRH8A:R $==($B!Q%
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M@Q]']I+3BIL3K6:B(^W+?=C5-3.VGX8L4I^)?@R\Z.84Y_[ZQ*;U7.5=AH+
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ML8^']", 3]J=K))G"*!U:DMD6@]^K;J*H8+J.I0IEQ;^8IL3OOM/*$2V4Q$
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MIVD9 >&*G)F]#'FD\^C%N6OC >[Z2;JY.56O>C#9*8I"WWY88;)$7^@ORC\
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M.\9F0V;!%%L5'/DR1XU82S5(ZBKJTCBUPXEZ:C.1I7A0(T4KD0DQ 3JQZ"R
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M?\DP44G7^7LA@9N4V\>P"@10EPOG<I72:3Q5H^WH$4^J@7PO8YQW9N_4"@&
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MJT]N22X;MHS:,G$(S]L;+6+\]#1N./L9!^S$Z\,4GFGA5XT+= 6=EZ.>/[I
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M^6:26_HM9:[R#5T*/$;P#"5V&1(23UP!'(G;YR=K!/O#V1(U:.7V1]P'B0J
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MMHVX]YP\UHVEYJ3#6N(X2$R!]5?5P.9B7IQ\9N<@OJ;W+>X2R]/*#"\G ?$
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M<@48/U=Y?=&B424^!=W)IJL]M@[BJTF#\L&"6HE-3$WK8"?'0@LPDJI6&T)
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M^-O#S.T?2N>#I3\MS#M51?6F3^QC>KD=332J3#C\T!N39D8= 16+*4J-JX/
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M5FV30>T6E8;VQ1W:"ZWY[O31WC J&M%!!W5AI]0%-0.Q*4[&KM-3?HX=M_Y
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M5M,IS#_L%*=$XA7ZI&!3&VOFI$4QD_NVVIV54U]0-D=IJL8,1<4,P0F-!M<
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M G??]=>LJ48[/:D;FWF"].PK2Q RXV,%(/=W?DB%4=!RPW<FLU..ED%@\3D
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M[Y\J4?&X+S+_F5W]OU](SR?^!U!+ P04    "  \@%M8@_Q%.TAC   <=0
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M=,W]=O"2%<8(!UHQX$!X%HQ<;O.&& X0PH'%(#C0,5FD*4VG#@=P/A_#PN%
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M\G!7NFK$W:G2+W:YUOEN!.DKCHCV2#J*U?K-',#MO:;BC_S(_:\Z\BK$ 6@
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M:72?<DT4W.U8'O90KMY=BGE&8&$J\<1H8D[?H+_8K"15]PC'05W,/X^(UY*
M! Z\DI8Q]WB]G7Q2BB)G11"*;#!C^RIO(#9/58.^2C![?;KGJB,^-1KO=Q*
M5(4/0(I3MP4,.:,/\SK\!#K)WZ*GY=H1=@Q7A;L[VU208;^4]GVG!H[-@V:M
M<,<LJ\K9.^Y5XQ2\H;?)^*D+,Z\)?;7(+QL;/)@+3@#<Q]<N1:Y3)\/ /S$S
M!K!/5;Q6&FHB5C"(9#DPHB:SV"E1_4G7O?^E!W :\2O.*<(Q(_WJ58!C+;@G
MMV?H46,B_2AW/OMQ""5>(Z66".EL;.00.N37L1+74SLIYAC%YBNQ[>2HZ]C9
ME/"6'BI"$B]&Y_M]&0USW.JT[!F'"5U2F8D-C@G@@B GO+Y!^Z?ZJTH>]H,?
M[Q&]S%Y"Z92T1LG\7-^^ZL AW@BU,@JSJ(CP,O30F;X;G/!\.E!-)TWAKF6Z
M@-[^Z:P/GE3G_C[6\I5E[*.R.@U(Y?&QZ^LJRQJLMB<(BG*TZD8$=PN['3?+
M:^,V6'#CJLPK8H<VB]7.7PU'-G<H2U2R&+1=H/,ORL0.-DL+^0D522TT!'^J
MP$AYS7]A4;LPP%[P8.=#LKI+3/A]H<)93VK9L8G>%=;[LB6Z,EN>H+YFUI -
M",F[.845:A7/[*B "'T:0K9-ILC45R>[(Z5PP-XF1-P+5.4@;$Q;)I)>]WZ3
MXDFZUTEA=5[US6*EC?>L6>OUCYNDUH&4DZWGLBNJ9'X/C3!/.<'5CS9$PE-L
MYO Q*7=<MPVK@XH\!60FF6R<[M]1ZV*Q#E=@G8MNC;;=_T1ZFOOF<"L<JS%"
M2)%L*:Z.@B;#V KRY;V-E [Z_GGK!1QH(WFN:9;&Z59[085WFQ5.K%?%Z# <
MW_ATDU)L330]0 Z>(?Z@AGG03?^Q)'7P3MI3_LR$D&7*IW4QQMK:.1PNZ^"0
MG"<%E%T?P;',))H&R6BW*UUKU.S&R _O/TY^W[F15-VF;!&6\G<-JNFMBU(U
M=I6W TX3^WW<(C/>TCJ2E;BS0' Z^IW^:A_C^ O!"AX=T>PIIVEK.YO3NB;'
MNYB.$<$HCGCHL\7NL<]ES)"2U^37+4E2X<3TVSH$,6Z=XN8US6FM4V'@J*?W
M'6G]JL_3"/L@6C,I5\47:3JDO>!O)F">:V^H(TQFIRT?#@RITL_ [F?<R ?A
M^A_U/KB1XRD9 >,M?@:OZ9WY/8<8>/> /X[_#LLGN",OK^:59ZI>Q7ZO7-=7
MFD^]4:>ULVU@'TR7F+ ;6R]4G^Y+W+ZTC?F?'DP7"OQB-V)C!F?6P,'QF5+F
M1UP7^56.'7E,QKKO*G* A;44\5 3_PLQX132+/77C.SW?V#(Q"FU]:SFV _+
M :0_H$%J$.;^L2/]'0TX\():3V&T@^'YQ]ZR;S]<*YE*Q=7X3(1(D)9;"8I+
M!6/NS*IF;<%8*T?V!'O U0Y"> -T3^/",1EDI;P=4(*&+,?2[R=IB0U4?Y%;
M[K?5]U59'K:RHZAB4601I6;63 O%$-H;T\!([#DT>SQA+UC@;O)$O[:Y=K2X
M^+F*2@[AQH-Q-23=+K7.,BEZ3]O);QGT0LUT RL[G@S#YPBPZ._V/2G6 C#
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M"G=:R)(^JQP]XO,DEHTYD!5L/>@%YW+,29$,K; ZIA!^7?5ZL;=O<PB-[G3
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M<SU(/;B5_W4 @@,J11Q/+JZ;H>G8\3A9Z;"C! ?(^ZG@  (V'( LRJ#>;^R
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M(PO2)LC-2S]:CM[)>YOJ3L+N"[J$:ITAIGY?7V3PK^#]_?2<O[$P+J\(N."
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M/=*+X61^& F?+O<6^[FTT)QX4.MM.Y=$/(+=VKX>$6^OD 67%)HV=+%T@.6
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M(B Q.]=FWE&)5/G2:A2B82\\EJ>4RQ\@73B]J@N;\RHH2*RFB_TQ'ECDX!:
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MST,R.%YKY\6#2RT&MI_3?3JHO$NEUW<Z; :G+)J-WFJ9#+Y93<'E["433Z9
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MVGUF.Z*C,?)^:D_AZK SL>"+[$D.N2&Q5\CL=302GU,!C7HCHZI0MS7EVCQ
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M:JFLV,A&V,G<R<F\MU)YHJ\>U)'!R[249:G<E-\@+2"M Q7+F0,PX9X=S5X
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M,H.+G#6TQ4[&]%E6/Q'9U&6BIZ?8V-X3^-UEF:G%Z8%O,/3,@2-\15F4T7'
M:)MG6<\^#U0H P0?)QL3CWNV$[63[(FJ,"P:8DKY^CLO:Y1MA9P@P,*67NY/
M"9!<SBQ?+[D&J*=!:J$84Z(^P] ?E3*:<*0F3S'H J#NK@IS,[AZX%I]-0G9
MZ?A%7:STX-0\KC(9))7L87"5GI4?M,9#4@3L<[V-<$WO5V. 5)<ELR8#R^*$
MDH&E#&7)0*W$_YYSL.YX$Z3@ AK'RVHP.B7FMPIA,^>[/ACOGZ'C97+-NWMD
MH6M0KSE+<N?;Z)RK'/SN,DQ!GQHY:GKM03'6JR#PD]>(9(.=PX*T2:]_' RZ
M@IV(=]8Y1FH@[/TQ^HA8-6;C6>NWU[]GJ.JMU<\*9#- [4/W=A3N,\3W92="
MDE^+4)FRXMAF:BG.XH=ZUI,NQ.1+TYK,_[*^9K>2I>[@$>@S(TA<]VGSRX>]
M03"(,S\?"^QRHJ#(?D;C6AV;;%.-X-[]*,/V."WLD<I$ _'-_,68VP#1UBBA
MF&[QCDJ)E0,%KP]/-),^VQDRA5L#]?Z[P921I5?<OOMMADVNO7!,\/7/ZAO@
MPV#6MBL^$]@\\UFA#X*P3B;DO4I'_]$G@52PIN@^N 2:<\-LTXJJ1>/.E$%6
M<WF;M-^;D6<J0)/A #PC!DH@ TGH4[ GS_1,]N!"'<TW)4']5^=)K=Y*75Z_
MDP(J*K_L")"B>-)B'FI=*,7?*!(5U>7?J2H9I+=W,6,_ W!*VA"(ON9X"(2K
MXS['@E(,(C&S4_T1%-U:V!'C7Q$T!<(-'[2WDT?#@EHB/)IV)?D6L\>Y"G_P
M.'L@*"0T,B>1HB"+Z744 ,2*/5@5"\;5^72 T UI\)*NPUS? ]7"4["5?PYG
M&2\,6G%.4SPN0*&K<(B0JGOL);8[F!%P,IDW8&+56A,OO3V9/3.H'%T:@:U1
MYKDWL&LG:)5W'!6N?6?H#.-2?P,VX=,%<'. UA8D6B*D@G5*&2 ,@UW@!CH0
MT?!$RO(PJ3UW?W%6YX#Y%(:M6'Q+FU $%]?B4[6Z8F@ '56SQCX!",KWEY\%
M.#R.0 8$V)>&!)RF@(+8A@:V\I9%KA/:(_"=A&A-<Z6*-R:'8_4WL^9#BI-8
M+RT<3Y+2B8SW-@Y=2Y1ZQT&6#UWK]:DG,0!/!-&&]*2RNW>L  FI-\(*M2>I
M8A8>YHI^B[ML)\.+9%.+URE-:K;6JA^_/Y)OICUWV&M)K$[=L/0RAA7OU<"G
MH4PYV.A[Y7V>0?K6V_0&ATO'XI[8-8%*B;:G3"KN6#9!B2'F>&=W%-.M 0O0
M:V4R:"*A(R5^/K%EN_/VSE'F-NGZO4Z1EZ#@88&[S65F=YX/1H];SO GGR?K
M>O]\-\[R2(K-KQFZ\$1ZB)-S(F#I-N@*W#V4A#HV7+%*S5QO"]/8>EK>K<8D
MHIR=LP@J%1R;?&-?D/Z*:]_Z9E7>HH=$";N!T@.K6 /S@KRYL.,E;L&D0QR'
M&6>E$98FIJ(%7W>5T(HO?NT),H0^6XX&G72KM[G>^ZMVZ>H0\DR9FV/< [E4
MX"$Z0K1/QLV^IZY_<5>0R=3,F![<P>;^ZHJQP;YFJ] NXBPV?<+S+7J[_]D0
M;-  MDL/T*/"[7[,6BI;*A;QXI%\D4PZJ!MUJ&3_%&KV"M=B#4(<(XV0('7S
M>^,@BM2'.TP.<UY82/,AC\1';:\G6.-^!YK@[#S^(!D7?<LY-.5'N*6IPC5C
M>HKOEFO59PMDX7Y.XI%6^R-BD?-(A4_"+1G^_1L6!%]QA&HD#L67SBS]0:FW
MIL%<F+3(?WU29,1MU*>I:9NLE!  ;6F4RFO=>/A3Q[T9GWY2]GM\:5ZF;GY&
M&WP6:_(\U]G(V3<;YA BAH2B]OV5Z$MM(#H+^S=,CX 6QP9:9+(#!SN;EV4'
MU;;%#CUCKBN^<1I02$%A?A!WK.99KJ,<O/A^64MN8CO[G(W-1K<7:2,!I1(]
M91C\BLU1ING852)B\5;O]9!T^Q%+F'I%D6$/3L"1C[:9+*Y5P<#^PM?P](5G
M$^XA 'A6JWAF7ERM]XW<?\;3)Z1[,/8,<6/%\Z'@^QB'-7PF\$Z[%3Z<R>>J
MR"<EJ.=4BGI'P(5 /_^&';IZ(A12A)6F;AY'S[(@[%$5Y)Y68-"8TZ:-"4#0
MHL/H!JNK=/1.2K)]^A$:R393Y81HW4RRO::XZ 5-;FG8Y,%H?#QJH+T\UO3H
MT DX%@JK\P-=B1>1GA--X&((W0"P0QEA^KD/JQ'*'+ZS6AP@59,C3A<)3\4D
MF1W&8=Q=).BJD0S')LF?X]D8,\VFL,#5&(Q)R.H=^[.WC9!T7U7^T&$B^VVQ
MNQ]V^Y@X]CZVJ> EQ,0'F:YG-BUNVZZH P0M@R5D:Q&&V<?--J&U[+R(]N(N
M"4UC<789/9OU(3^!'; :)<1,]Y[,_(]TEBI9*9_Q'<$D'_VP1X/9// ZB=:H
M.*3&DP>Z(!T7FO/:@.;6"*#6%,!"BTT78!YGH0OX<ROJ,EC\/S_*/3IAC)9/
M#\V33=>[L(II;]1>+96 -L.%VR+QKJEGPAV0:/]XLD"_9W>QH%[;,"$E:Y *
M(3[.<:4*9'08\7LIRCH4R;@C&_G0,7OK3A_M8R49_@R^0,7T=,*,N.&'M$Z:
M(!BE@)44IXC3[R3;3UKG'2];H,^^W-)U5<")X/&LX:G!+R6*_&I=EM\+]E_G
M!-\&0/.FR"A57X&: -Y0@_$,G=0:"N9+\W=^*0EL;3Y)"A^!P3@A(Y#;SDAJ
M'3AWHD*J#>NK)-A_=P5=9AG_1&X0\.P!CW[$U8OC!_?P".I'_BK/TA>U9(<<
M'W"OX/70)-Q(FZC/]\KD(@R-P'[B"AL.7(3-)(B-0R,65=YS>G>V?:B4#T7O
M$%CP6(65S&T^Z RK0JF&6#5QC\G *$7D"5VF>-.EYZBJONDJF+(U=5,@Z)U?
MU,A+(F=+MU3"^[?"&EE'</OD*W-4:Y($4P<G$C5V5Z==AHY*4YX]J:%-CDOF
M.M66))NK@ZM$ 7;)BAA@A1XT'[=LMC6DU1^EM*"I:@8(^C!"K$G4GX_U7I,I
MGKXL):],F)/8%<<B)A];Q?=Z>UU)-%9+@S"W=VC^$C"'<,22-C6B-2H"Y?=:
M.G2?6@H8(88GW B_K^)UM4U;T61RA:W64CE:<T5:A;<>X^@8@;\,NR:E.=_F
MGITQS'>Z4IO+W?(KC6'UA&QU-HPMVTC\X#^>#+#,C*MZMP &\9C.IS\ONU@U
MJ;VMZPQ=#9C<!C*K?[/=!\%EMBHNV$VCZ)HZ[F9^*OGU+<EZ=<+,#'BP\.38
M5D)0(P:M_X;#QO_EP5/C2@%2A:H"SY?U[)A36K";(19/XT>NP\>^;S0M4K&"
MTL3IA";.5XV^J"K$)/C=@,V*R\QMZJ1*?P2+F_+N9J41QK6>,Y0R?0\#0_.1
M?T@EMS^@7IPBGDI:L[*6):OU ,6;X?,\=XI04K$)L8/1L<N4F5+<I&ZZ>%2C
M(+42L\@N]][XDKM!!AY$:(%]U$;KL%> AG9$?@/8RR*( UST ,()M;4AZOMJ
MP_>4U'"?4';[G,.ZP 52R+1H2W$14Y'_D]?")8>R1J[@;0^2J4IQW%;?89?N
M[Y_T9NL[/1UBO6Z=@.J.&]Z8L@J)>F?0K>F5-@I+4DGXJ05\KW_IBVW:I%M*
M +I*:!2S+2+GVE[TQA-DDSEU0$TM]BA:(-,@/GC6RN1]XL5/X[SJ +A"#@\F
M7NYU8I5.FZ06C[U,0PVCX<<P=U2X2+(1U<G+1T--0V''=^]RW):KZ''A.RZ9
M1);-+018X43*E8]^4 ZPME,E-Q#,7I*[TD7'%(-J]K<)&6\$B^'*4$,HJS_'
MKO!+&!KO2F46UNRA!?S_*>S_) !C_]O+TNI02U/3'P34_9O&\HQL%I?+4YI=
M^<!Q]@Z!H5K58I'=,^>@VA3-<+234$2U[97$5[MW!X0N2VFYRF4[%P:LF"\7
M5@>-O?Y,FJN/Q)>ND^WM]GU.R.*/]XK#T_6-XJ\&.$UOZ3<3JJI\,LTS71[Z
M%KY_=$-H/ !'>S4V\]1FQ2O5EZ5E'H53]%)DG8R?A,\NS8"2,VQ3.;7,K0"V
M\&0*7Y&KS]#B=OQ/\;$53W9JQ ON+I%#\NT2^P+*^+TL.UN*]KF\Q3S$>!+Y
MO-1?ZKHN28.=[!;SA^_ZFBJK?%F=HU$H#$TH%]!SIA,J##(%^U)''PM<7_>E
MI+6JF>CK"EOE0UW:Q'KY^^E\0&/=3B>  IPS'T3K=VV_QF7-HTC<<,$'K=:N
M@T'>]C96X_N385\[)2O!X@@!A3DKBCL"J:[XZK2AG>/J+.X"ZZ^?38BK_>_2
M<09)C'Y:$\<]''P&>Q1HRQUX',>SS,*S83$=\/[JESJQ[<)%[H*^3M2E_YYB
M1)JG?P642IBCFT_(=)'.[ XM.%OSC;.VKX&X.7XE,LW1<[XE76K4630[U\V$
M1@*$,AH/W:V0J'&#HUP%7'T_T@5PCMH<<^A[[AZ-S6[?1V:&>(Z0DKB,07'M
MN/8.)^UI(&):.Z+-71U*>5'X\\MJ6-DB:AXM>F7^?(&8Y[Q@[-$NC'W+L] &
MNAGXI225#'DM/(X/K6%W=.3)6G!U7[<E89#%Y0<ORZQQ1V=IU\##W8$I+S&G
MQS); Y2RYNPP=,28$24-]<Q5;M>V-SW:6[J_K8X5_8OH/I$J7>E8*W_)L#-H
M.[])CU*6*#4T-V?FD%!W7-5Y>8"9#(\+OAG*/)K^E8ES90#*F343<TWKFI>1
M>PO\VR=+3AI8J3X)!ET>$-LRZ]E@^;VASF%[X"&#L(&'">L%R)JM.SE8=0*&
M;G.7N2U\E5;V@,P]6_8U9R+79?_E?<WZ059D.] I.^D*9OYDQ?6V=#+G"Q8[
M6[,\KYLD&4/:J0$*8 O'<B>S8DR5.5K?9)SZ?EG?X"P!#U(VX.(Z_O)R[Q\4
MI6L]2#H27B>ZUL?(!APY0A)5+/;_*CR)CD?P_?CVUA1'W^M94 ,KTP'?J]J9
M>+3#Z12#5Q^SAUDD&0BRHRL0C#XQ^)CB<C<&&]UY,SOR]6T',<W47P3"KOI7
MNIVK.T'J&V&IYVKZ]B&&3!2QZ+ 8M3.3PZG[*">\<0HIZ@%\KAOI/]AVIZ.9
M!0*F+:EB^@*+01*%J_JPIJC'.9ODD@+*SB5@PVJ>=>_S#Y3G+O5+/+;:$'K?
MW1L0<WV3[9)IH&%$0_V/2R9:'>J%8 Z]Z6YOUVY*0DUOS?,*46.53X]@OP*!
M(@D8GH\ETUNA\6*>AHSB4T*QM^SM[GPIU;[Q^%$[5E[2:%)B#&1N51Z';:^H
M5^UTU!"F5=.PD!.%4^M:V"?3=7;:2AZ$F2R^W[VM(Z^?/&?OEW,XT]0^PH0I
M%V!EV5[4E;\]QRY/_6/D@-V>/&WOY!R1),-])W'#ASD5=!,Z*BYH:*?&\DUD
M*PXL#V'D$J$\D2]ZH_3N0;QE"][[@\*E,>21'BNV7EP;:&&?;^MF.,*B7265
M7L1^=RZ_=:UX(3LE+B]SM4_PXV<]UPY!U2Q!\<ZQO7@.,3#$UA_XAZJ6!'YA
M;7RZ>B1O>D+UN"[81ERT76T,-AS7TJHPBTS(ATOZP;2D"\$>ARUUVQ1B];)V
M6]X<<(D9H8D%"\3DX*FRD H/6N2VH&A?]3GULYXGA_4#[$"MOH\OQ2,G$ME=
M#)#E(8\_M:*W)88,4N=I\0"),FC ^>FBLAB1AH(6U*VQ-#7:R="ANI*/",SB
M%:U<Q+:^\4K5_("QVMM\L1_$5ZW5-4;=.?RXV@X:5/397&XAU\:,8B<[^UNP
MK>C5FIIF;#RM#T1#(L$Z#L=</EG_AB/R7[Q.A^N_'SZ7[=J*FORLT0*I_DWL
MHJOB/R77$EY42W'V0GABNKN;ME?X"H\4@FVU!C&'EKV:"Y@2NC QL=*/84RM
M%K9&S#<P%R!>LLUWDW*4;%'GY]2?+]F+:TJ'P*N=0TDYE:(=GLQ.#=!'[9CY
M\PL>CU 6M>B*OJ8P7FF5BU*5"7/-/"J=H^X4-X;GG<S#=W CEH=,H-#X"O$@
M$0D0)!^F-S^#+236K?PY)0MT;HXB3.@ <2UHP/)J'%N&>\T!L>;[^U=+\(B\
MYETU.MFY\JHO4H1QJ^T'A]6I&8LFIMSBZP^..K,+3M&E;4SW4*[$H6E/_MM>
M_(&TS *I0(2FF5.5V$WB8HL8EU\6XH1S.!\0-.8SZFG6I>U<RO7V_-A0G*3L
MK/R1Y=.SF>3V/7N!R1?<QHG(=<S8K^O3<CB)_BB<CFL0Q;?OT)!LL#?OQF*7
ML !A:W'"F9%4)EW!RX*/T53_XEEC_4AI"B6D#4[PRA#-?;X#^X6KP-T=]=R8
M,Y5Q_"4I2V04?]L5C_3]]$Y=&Q8"\K+$9'*TW8.'YT[4"TN2!R&)@1]H>$O$
MU'VSXXBTS=]$)8EE][#U;2)*@P"J!)PX%]_ QVM=O<6OX#NB0ZITLHF"X9AV
MJ%;'S]#1H^[UDXN9>"N-K?H?NY%NA,J54^@OP.-E)$O':*@W-@<;0)5^3UTA
M<^;;NYYR&R[R!1R+<A&Z;I&:V!*:R&21R3;X'0BQ?A_0J>V5:!J8UL_SK)NC
M#?<6V1T!6WH#YX;:&4C@49"P)_PN,Q'>8T7*GEH.P+9!37BI%Y&/.B"V(";#
MM"JXX#Y_Z^U5S=9_4'#L.[2F'5Y*3K(*:OF&,R!>)T!;09KT-<*^*HTW!798
MXBQ="IUZA@N"W3XJU-2\:A:WRGFHWI: GK^;S;YNFGQ;C\600G@]OV5M'M6F
M443):I?&C82*W!8/%9T:.V6WB"7\"I\SD2T[5H'PU VD4HIZPQNB*^K0E&-O
M?02IJ:G'@:;6;>_3%'EHBXUS$,CK*DHH[3'PRBVW5CG("  5%<<XOF"J(2@"
MKJJ]9]NOT]E+.6I!]JU\TL:A^/R$CST%Z,,!I&A2P?&FU]P\?5S7CSFW>L6O
M] I^R0P:;E^/UUL _M05ODGS\V0-JUIU[*N2< .1V,%^H0:V9!"5=&7>V%X9
MH%;[P<1::G'V:;;L>2EFB'-G-+?:O\!'J2]^:T[S L=>>,RC_]!@Q#/Y[4A*
MT6:V:,$3&BT$,A?#_@.[B=Q?<P&.6$97QG1EH<MDYV]_")NEL^YY$\8;[%R[
MDMZ.@:L%+HJX]#^8=S*V/1[5@ B,(.B]DJ'C&J,BL422H?"W?-9:N-@-7RF#
MMC94$IU4G;"LG-+\X3+1=SARIP1'B:.5U@MG;<S/E8H()/1Z&B8NV/X6IUK(
M8P:2,T2TV,/\/O:XWV04H&+Y'.0HT_I7BTYD!KRL9YGAC:\,3FRLJ(CAMZ^I
M.M>!D]&\0@8GKT(U),@$>^/J$]\5NIG"[2::U#^V9=R)F"/I4\<U2K^ .^:#
M]>2>;;+S!>97TZPV:(214IQ>[2):.FQ>AU^2]/E$*-Y></B&F-V7C'<A=%Q7
MC&HI9Q@MS'<V>$4X@"SQ\EX3+0,$B/.8^3+FB/]Q82B^QJ0P%HM10?'U<6Q^
M]9W;EK6W;F![;-2]H^!2[CT^'7S'93+PLYR@U?EOL.-:(?SA4.[.A\%[D>^R
M^/#U%I:[( .PP5Y=[,R+ C7.@6W=:=?ER=OCXV\,-'+Q?:PQ;4I'X07VB8.:
M'L4E61C5]/87-1LYXSV\D9OPF$O#49N<!N1ZV=/J[S8YU<=E1M=^]$FII?VJ
M"@61U@S%5Y"9&%/DNIR@WG?/AEM+V1\@N?-L^WKVU*FONAD@,[BJFG$K:5,
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MF=B8.5,8FUE8V8O0G3:UT5%8F8K0:?#(L\L[2IA96LF\=S)3>:^@:O+>QD3
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M"H&32UG5V"\#]Y5:3&Q%Q\0D'G4TD%O""5QYQJ/BW[E!PV>2>?Y4&?$3R+]
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MJXT/OS!QZ42J2JC8HS2D+*5L^@'7:O,5TU&ROTU3\^A-$-%;<T-&&@B?M)O
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MDNZOA-3?C0%L8GG\W9Z_NF8<#;C?5O%I1L5;B^7=& 1"1KW[.?%+M=+/KD=
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M2J"H]>9F?&:S><N,:C+JVP1)X#V1FER)M*5-CX#K@CF@L>4>Y^86Z M&HZL
M'9<L[H,:)V\2.!$'<,[?9\V*Y*B;>"J&;#EQS*<ITIO,A-M(:$YU<[L4'\U0
M\S:VA8X(7-O-5TI@\PLFM9/>TSL>[&UHGI ;$**Z<!]'[^7#E T>L&IPV6^9
M$7Z\KI)4?-O%/=E$3; B%[*,BTEWX-I2R5%FD;Q.LKI5>*UF=$60RJ_'K,:?
M$CC1V=N,2&#[<L6G>HRG](?26I#QO.K_JQ[!B-FM6;,6.AN6_K,<S+)L*4[J
M)J6'5=I@.:@N590%2)N\VQ+NB;JX3C+533K ):LMCH -0GB%RL7SQNAJ9ACR
M1B54F,@MOIK(%3O&4_[^ZB'V^6[WY\! _O"A!Q;R>WM(M?D/Y-#%N#(S+F)@
M:E: B\\[MC-$V/.0%<4W!@3-@::?02!>\K1?+P3?:'XKH,X+U(JJ7=GS$-E>
MSK5^8@QJPA'1P[X)ID-[@K/P/Y/O"AK*6KTPD"FY1D0> =$">6T7+YFKA!RJ
M1OL<XT732EWDF<*V#._73TD/#?ZP*&N[>#=3B  =@^P),W^WO "HH]4$&S0X
M"*<>Q2;2"-_%>=E#*O--;>W72 S7]*=:'$:(Y0)"X+I +/@&NM/O]SK 0:()
MIO.5V,)3:]^IDY_(+,VTGRFMQQ.R-/?M+QFX6#6<<;5.X\(@@2S7F_ZEP-MG
M[6[Z(V  *L&U>YW5982Z<O4[;.G0BOV+Z\^F2C51',4FDLFS80!^0,IO.Y*G
MFNEE60&5,A_R>A&).$N2VJ[K/H1]V%=??LJA*2P_YS?+9O9R0#?I<C 6 SEF
M0V/31AJ,_>$-$+K_[:7BAVV(U>E#Y'_H%UFQ#"=9,6JN7AU/@Q*)WWJH?^]X
M9-+?Z!2XX.39!.&@FLSM](P>\&<'XW-;ZU+=-['MDCK#X:81+& B-Y@S/<;2
M@%0544RFI"^O7AX<DF-F)BKSE*":5-9DMD/5.ZK%JL:O;UQ^9UF4%>Z0?7)M
M[\-9=MX%4VC_A0W(6J;4K;M/3#$\P>YO5,9BT.N%$4NO\'4,CM1?N945Z\Z-
MQKPQ\_!9/99G+9\6ALDR!4-1&&FG7SN0C-&,66TB:=O;G#XD-#^59;K*?OGO
MQX1""RG]J0>B_N?-Q),=^?4%-\AN.*TY8*R9Q^+7QKGZ<VTT!^4;*@HF.W*D
MCKO"?.K\I(@OW0/'N#?_GF+IP>-U#9*_*T\*[V]?N4%$S_[[_QM_;D/][R;0
M'Q?^'U!+ P04    "  \@%M8'@/5/].E  "%U   $0   &EM9S0T.#<U,#0U
M7S8N:G!G[+L%6%Q-MB[<!$WP(,$:"!((&MPA!'=M7(,VTD@W$C1I @$"!$AP
M:-S=W8)#<'=W"^YP^6;.S#GWS/PRY]SGE^=^;^]=>ZVJVK5J5]6N>JMJ]\/4
MPQ( 3UY:3AJ A(0$<'_\ 1Z6\:ZEW,&6 ("2$H )  !@ %"0A !/'B6\1T7^
M"QB \B@C/<IZB4E_7 '4CT$C.Q0 ]$<_K$==]/$$4.S\Y=X_\2?^Q)_X$W_B
M3_QO"AEG"RMJ30<79U.(E86I"P" &H[\%T9!^,@<<L)1_BXW1$;\14;FYP(
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MW]OJXYW4_P_@3R-_&OG3R)]&_C3RIY$_C?Q_R\B_\UT+R"/)=7MDLP^S  D
M.BHJ&BH*.AHJ&@8Z.L8S?,Q'CO&,"!</"Y^$B(R4A(CD!3DEPTMR(#WP!0D-
M&PT]XVMF%F8R:G8N=B9.!B9FIC\204+'P'CV]!DA)B8A$P4)!=._C(<6 #X&
M4C>*$#(2#> )/A(R/M)#.X "@ 1X@OS'=N;?@8J&C(+^! GC,?0]'@ )&1D9
M"1D%$Q/MZ5,T-.0_8J.@XJ,]?\E!(*Z&3DAC2D3\@E,3Y/0IHG2$A/:=>N3W
M'ZGIK:-</,[0LF$ZK??P@*CVL65N&0VSM)\KOX_H)21E+6$8?-J?,\M=_-L>
M;9 A_24'_W&*@H3\! 45[3&,"Q_I40$\14)'14+Z:R:1GB#CHSPG('S)(:ZF
M'H'*:>J4.OR;YE-IZS(MUQ'1NX<9 -8?F<1'Q@>( >YH @,Q C_^_])IB"0;
MD6M!IDLY81EN)?4:M+,#&JQ^3%L?J[H<(-NF/RM-7O37KS>8UQ=:CY@UL73E
M1I )@YB6<]<YH_5_3R#?I@<H-)D#;5@5',(_;LI1%>[=[^7R6P6[MRU%E/%U
M9#-_4;,)CEU_4O'43$1!#_G+@;8"3Y^%(A%W&23X'5+K<O_@2W1Q24D4R;>/
MCLX:-($@B=RMYHD$-"09*T\J[4K[0UJ8O(@,@8/R!_:*L3+^5=M/?>FSY94M
M$&]J%5K1C!<5H!<VM=8.9'[39+H=J(7AT;'MYB%^D=XLD7MP8>0/K;LT+K3B
M\)>V12Z&LM#5C"=LH^4 2QG@C=Y<N @#\O<0ZB0IM=QQN\AM*R^>5_'!*H)$
MI0,MD]);L4]M3X8J-E-;S_R;YC4P4S(\6<\&HBL/""MN2*9?F4DKQK(A%;92
M7OIUKX;#O0F]BS:Q)^*.6WIH8>IUI.]_F!XU-NHYRO[>DEV7I::A>4+SO];!
M#19M.I%[NQ]9TZ32;D7GU83YX7#FYR%25,_9J[3L4OWUXB+7BYJD"+]M^9/Y
M!P!1%+>2BQ3WB1E(3=$6U..< .KU73O]97WD&71=TL %&D>^Z'[I^ !@H+TH
M[G?K-W9M5E22DDCS$PW!BYSX=G@UX8^ZL&R;0Z *ZD-NO7WAZ*,V=+M;J%)F
M&P_E<8(RS&A*Z02[B^FK[C#I=06NH9'B*G6QBA;D^O\\A51]52OOMYF9@N!7
MTZ<O] KK[QY170$]5;2:BN:KU TNDZJ=#H%],:[CKGGC1?QUO <:SDDV5G!#
M?"+;OS:*?]'16;>R10FA^CPB&EY&@\.5MT.%30%;9>6L.;A"=QMYEYL_D%'9
MM,M^*33UL\= ^B!6[!H5=5^]_#X>-^,!X(QCBMJL7:TWIK)I6K4IL!Z@[1IA
MMVF-_P4YHDL8MN-YC?-#,.Y,.2.[=F8&AU)(P2NLM9OBO>E*=6.>UH62RI7R
M_3I7MCW:J Y#;D2QDR.)U=NYM92&#XCJRPN5!T"NU0/ 0X5KX@% N?T .&-Y
M !S*]P8R&UD5WHN,/@!V=!\ "]_[>9J[!'WOU,1N>LO2GDW&V_J&P1X UVF^
M%S].E!R.!I(? )HJ]\<%.7#*>>+4,,%DBWS[2D[B!X#?525%>$!]LG>=]@%0
MT*QYPZ]1?]>%*&E,&R@X,7?N:E>#WOX^:+;YAUFU:VJ#%3ETS@LTC*?&[DI>
M\&NL1&-$3F,OBOL):;UL"S0=@B'@2(UHY-C5T'XFV*L$0MT(CC@;KHL:*V\E
MF)HFW7:P[3PFDW;&Z!:&<_66I.%X\@;GUHT/UQTI>CZ+KZNKB^YZ@Y90829I
MWRWZ_9/U=D3$ K';=#%44S^_"%9)Q*7&*2\PJZ _U:/Z"SX]M71^UL4*_=(S
M;#2L+(D37Z7@$% FE]LP/0Y"$R?/]AJQ;P%T;XJT-",G90,%<]>D /^%7J[I
M.>"ML290-#,EMU[0OZAUJ^?IJ='!;[&3P4F^3F*0!DCTU-3P!6,M:9;S=>!7
M(OC_X7N'"[F<6\1[=]NU;GKL*2+9AOBE89%>+Q3FD]*L.";_>MLB:I[6U&WH
M!7N=[OY%CC[12%04EFTUGZLX^ R_6U^0=:O<F3F/<W*$56D6JJAPTLNV>."=
MQ95LAKZY=J-P6 'D.M+W%6&8,2Q^ *A/@J\%J.[M%X[.;@1X?\3K\'@7#@G9
MABJ0J%RQ\3M>/S7.JV@72<H=H2R35?G%?W_6GU-A#Y_7!1H"&TL'\?NH9H27
M;C\OP^9Y[R8L<3L\O^P.'AH4\LFFR^:]BEW;MHX7T0+'YJEO!5;HI_W7>J%G
M4BOC]'7V[8?![UR%VL8T;>J-MV]7^OE(8>[A'J639Q;JJB]R5KW*>/EG#"XH
M $*3418C8R:<\EUA<E.#JH>,#$NV<4KDP,/X%MP^_RA\)'P\_/^.\^+G6PQ1
MQ^'>]!U[I4WR+?O!FTDY>O#%0NK.]7U5UMB"4U/ W .@$1:IZGV1X]'47)17
M%\_V]0%PH3_H*3%#VI^OT5:0),A<%3LVW]3+['=_,R)@X/T R+F^;XXII!>$
MZ4_N:;@F*L2D@WFVSG8U;MI*B_/2LUPX<EC2BGT7/61HOS6?41E/'I]5%6'W
MN>CE:V47E?I\/;55O0X,KESYYX78JHV>I-:').0I';W9JL:T_2HU!\:#/;,\
M",0XPDQE9%61G;9&E:5,9$"YK$CT=A?7D)0DCZY#=BRR$V"UY!,.6RJJ^%&J
MIE&%01[ U[Z6K.<_$HZD(B*^LXF&FY"\4"#[7V8&?LJ;M#15FG426[%SHNK2
M;W+DVW)W+[IG& >Q3C.ZOCF"UE"AH\Y5"MSV#CIS&_7K [X>6:_OF#7*BO3<
M*.D@R\??+JG&X&/_78+BMZ&IM ,O6U:DSL@QQW)KI@,.4%*F9-;'C/\ <0^8
M^L.D8/U<O9K/0HG45)3H!O)# J<,WH(WD9DJZCI&K[+RKV/NI)Q=IH<.M5T9
M=#>\T]/U2T$<DM 7$WR>,PMQ_,8O:GQCOEU+[.J/K(\>LB*_ YD%=S\ Z/*5
MRN++$*$EDP/3"PLHH2C/17R:]1: 3RP^],7DUQZ*1"41SR.X'3TDI13L_OE0
MA(J9FU=/;OV92MX*Z01'Y4!#/B8G'Q7TJXH/709O!D.88/$!D*R.D2$I;CDR
M;@?C5*>D!,[P3?"C/P!$*\T,#J(S3Z/4!O';8IU%?#(]THO@=?CTPJ&NT@K0
M/F])ZIE_?6!\S%(Q2!>5T#!3\5/HP:#&,>IQ7>D/0@>$LFL8>M#!LZ_:VCSV
M$EDYKIM4*;@ >)M:W@J8)AY=[#8[T2<3J)9S0  G._^)>T?^X5H^2)+*8.7B
M!7\,?V*D"N@('\DS /QZPZZDIG1?  ?8!T!PJ6XA-UU.?"%>K347%T#+RS-Y
MXF[VP_V;9)0 I$'#0-SN@WDA*4=]<:\P".@9K-W&;![4\0W<[7@@/APAI<?.
M4M,UW1.@R>V\V'GFS_3?9+D\;+[]/+YCS3?TSA83D/\@G_LR(=QF[L^H:AK;
M;AM\1ZCT?O]-V%:I6]$X%'P (.4'U_?-A8P')$SE]&>H3#O@BE3-K?I^*8:(
MZ!X:%L P(X#H)J)&**)6P4YVYRHE.$)8=TUSJT>>YZ>#^?ZMP^?&^;:D2^?:
MY['9ZDX=DU\D)?4*2_^QZR)F"@[,?3W/?3#3&2:/JR[?;0:+K.$()65C2,N?
MW/F0_-(> []34*2-36RN A+SH8C3+/KMZ%;7S6"A3,HT8E57'2,^2P9YO+[F
MFKB,Y@GC;L?D5/1P?<F^OH8VD"OLKA%Q$CHOT 6/T%7BPB>8Q]=47#+66YE\
M,B(.Q&#>D'9:7/I*0=^(O;&,Q@N2E?$;."R4'=G)C9>P6;:=7=BZ%).Y#T;"
M@Y'I=3.G/A_MIEPX6A"19/5_6SVI(*XYG28,@T+;OL ;.Y@M@R*EG2<K^*G4
MQ"/^Q=Y;^TS7+:[5;^O\"^UDF)A'/G- CN6NK-M*+^X.[46>QY,C[@+XB[[7
M,YU8D8TY]FIB5C;X?K^* ;=^R7-XDB ;FVES43M]3*& (95==2WOMTRTGFRX
M9E0D<Y3N<V*-('S4)OESU2[ZWI3GUXD8I@,8UMMG:[?Y]$4/ .Q.Y9Z]/8M;
MXAASH351IFK7&M$FZZ^QNM.=Y!5A]\>U!W%I$S^TZ^)V\V.G6G]!<FY.*/9;
MX)U?G@R?>B&0%O&U<Z6S\S+#7 T+;LRM^<\YC42,C_T3^BNU.ZN@C\2M1^9Q
M@!$7(2R&6_81?#5J"Y=Q;E;3_#"/Q17A1XM$VU(DLW&=ORHD=EUGO)J?6?5-
M#]."S\J]).#<Y..N8OO) ^  SP!?JV%2_];>Y &@I7+_&^%0>,_]!U_L>0"$
MP7N#7XT"[P7HSEV+YE5_HEMMP,K>B1\.;%,ECV6&_Z5DM?(MB_,F2F>6:E6D
ME/:<<F@P5N@'GZ.=>0([GXW[J<O9U!LP0D $VFTHIT-M_&;(;1LH=C[SA4L?
MW4G;ZB?&[3_% &V!%C\7L0V163>HK<PH41I3:(>%-TDWG^:PO)S 2"D9:B7-
MS@_.K1BJ+'W*V_ <_>U3X+IL1]X9<^&I-ID>NARV-PN^,CT+V-IV';MEX,/N
M7!G(5IY)6SMF:%*0&?93L':JT^XK?UNM(QO%Q1-I >20GT9[U?4=ABM90K9+
M]DH4>*T4WV4:HI5JI]L"*<S/:$D.E^PFMV\2)UAUE8AXMXMXI.6USD.!Z:XE
M5@*KJ;N?WUG$E_F7*3(OYU8'@AL.733(O[0E0L@5PJ#?))?GPO#KTH@/[%U0
M79#[A?+>6RB08/VR[O-SK?FXQ!%=CQ[192"]XRU@Z-&@"&[3)8RN?CN-6*Y0
MF.78!P,=7<^0O&M5YUVPAOIY*D^?A$4Z3?=Q.W IL$A]*IQ9X0W[X,H5T:4I
M_\X/-#+9+]DU/*'>X1@THMZOVHDF3S;?[K@B/OM]&X"!CE(<OM,KER3[ .#.
MMP#:_7QF,\F3E%@L,/L1V(!<L13]:;3#NL>J]JKHAQW^N?/LZJSZ_O[-\!ZF
ML#>[0AAG:B>B3F%/N)+8)@BB&17>IVNLH=.C,-5%$5AV+*&\LE]CO9K*Z.\?
M/Q F[S;^(11JO9I[ F9*G#KGN&D3(+\PHZ-8I1)[IL><P664QUK**:.@1$ 7
M=4E.WI!4. !-?.(!4]6J1VD:9=.J+T<52U10WZM="J@<H"_N%IDC.A27T-Q%
MJC,HLSEPV%]83=S#QK8RVB]$\95[WN["HX23UBRA)J>KJR YE?$DGO<]&DE;
MHAQ]QMK:DOEO=_73Z[  C_C8:A$X(B[*4KL:._+%$[?JAD]P7.0HRETE<-&X
MNBNZ_4_&644WOL//$A471X,4R^*++./VU=MYLO-3H+'1LG&=SL3Z4A;;#&$*
MO/FPS>P,N'.R;JOZ"391VK8:,S@]#^;41:E/WJD_OF1%!1?XC8Y.;J4QHD3/
MXMIMP^:LV;:)9<%HW:[;N?FB-@7:^71 ?-4?'Q5D@5/3S+EHZV*+*O(&R_^H
MJ[2U: 9G!6UTD);.Q%$KB3(ROVQ<O?O2Y@ __E4;?VJAB]!JN,A ]^ET+2*"
M(C'$BB*-X&"\(NQ<J/^US2Z5DUT8G#]VHH;DJ+%H82,@XOO8!?YR$K-E?L1I
MM4U^(\OO*D3CV-@13P';AU.]*3VR%86>W?EMEY95HGR5275#.ZAH)+\NH,!;
MP2QN$%_0T#^E]H#-B5^ -F3=%@2>_5&BW3XCQP5<FEMFS<$/CC:+YMEWW1 J
MID-*A"[ (>E:(ZK#$TJ.F?D9T4$%7A4C/ 'ONNIMC>:+6!T'9-!#J+14QG_\
MZ,\[?Q=9]&GL="7?? _,*9-4"YFDA'[R@W/RJ_*Q"N@[IM;)R=DA2.G@_"\M
M[&VS<[X_KSP0X*P-M:+ VJ0^W;*$5/7VN'#MIE6W&2KM:8:36$84FA=S5K9^
MH3X#G(30Z-JZO+"P+8PN"MBT/_'P670*8^"OYN_#V>1RO-6&=B_3C6L.Q<6A
M NVM,X+*0 J8.I+4U6Z9,5CU%.%#()]TE7DJ2.V([I:M=0Z5_1LI<5V=:3>E
M>NKRPV]82+7H(X UIX7J7&L'8C$+FLPJT1(#WC["D'C>0'.. ($R"/42?F*%
MT.=W<M=54>-%F2EIA37=K^.TL+E(OT@NMWV")B .!!-_X_)'5VNWPJI:]:57
MMIA(*']*X^!^*]3F[DS*+S,RHH?LN.J#MV=YE[]TS\^6"'X:=%?7$X7G36<4
MGH*.SD%X'572$)P99\_6E^\T O\)[1!EO,[O+PNN(V/J"V4A<B'9 Z\G%48J
M)F(7,C PA!'"-YLT].U=$^MZ"+:\=O!18C#29V:"TG#!9GS'NI%H3VT; )O,
M0K .D!37N&%O5K"E*0RQ[Y!5TR$N\C.>:3JACLFJ=YC.#R$AUT-!B4"EK9_-
MBBP,GQSIWF&_4M#GDO,K;MX<WO)8334(/F,Y4<I]-4WG]I2]:E6YASR(O$WH
M#;JJ$P)169E3H#C* U(D4I]HXQ$>'42FG=K:2N#*CBAR55ZYJ"WU"UC.G*/,
M-W,+PT=PW:N<3\Z.=SK]!,K7::E8('0H)TM_"_1[*DM\ K>B-[!I%4?;OW68
ML5EFJ;#/C(XZUI C,-\GC:Z@DIH"T^( VQK50R4?1\//'UUN&>XR:U,M0ZT?
MV6T^A\$PAPC)WXBXKO *^Z?6Q4N5H_N87XTRPI"H%/6?(X:MJ%<4U_,GK%=Q
M70R4\6;Z"85\"]\BU)JO/CX I)MG0$LP*IH-P8";/?3HK9W&D!J#:O 1E1G$
MKRJB-H?!"2*3WLFU\NYD(LTF+G"?'>SZ/C;+JD$0SL17Y_!XO\WAF?8]_<D\
MWP,@G<?M.O\!\#PTRCO./N>@X<P8)-U?I+2QCXI;&2HC/G/P , H3-E+M213
MR=CO(NU$+_"/,3;,JMRZCI"GVHSZK*Z!,;59[Y5HSM,0B;9I8K60$\R@]WKW
M]8Q&/H\,H_*P >,![-X)D@\OPHH^#Y>EG M+IUZV+[+(8DHP:S"TB_<A;6-(
MM;>H(]L!@_VR0N%\U<]Y,M8"YYRZ&#:FRN</H@I=4&)N_$4VT@*4*MP48$XB
MWZO#1AC0T$3B;JE4A@6Z6W65<H,25= (%X("!_FD>MG,1*OJ#>P*<BL'7F=D
MEF@:,+\-+6I?+C(CA>-PT-*)-J8+.[JFYH\Y-$UMF8]Q$1MN&6MPS2IAO*FM
M!P8VXB#-?U/Q)3UL)2B)W>3 F!T53C,DB J06_D"CI?F\O0C;VR!.&VA%URR
M.8G[C+VPZ>,IC7$;;3SC.3T#J8VV&S.#%X8F 7IZDWA.HQ0(05:%?E#OJG/U
MK"T;]'RB7P'(Q?0^C'I;YQ)(2[FDH]^8$OT;65F.=3MH2MF)"V4QQ/+E!#ZT
M>I$]2L_U(C<7XOW9]2I[CQ%(Z!T2T;)"0><$]ME$2_980J(M%A@I'G/;WN8Q
M' @[I.<F_D114;$/9T"N(Q:N>K<1*<.0BOZ]9PE%)\\JT<?L0.G:+./>]VA,
M#=J;).%6.A?+S#:L6975SP-A6K5S'/WU<[35S.W<)X)<>=-1@-[Z1L3=92%Z
MYGJW8FR23#Y:-*LL@,QIAO-5,XR5Q;:EA_5F55:D?96)ID-C+.&T"TOP3<UP
MDRQ-6!FZ:&81#/MY19R$4TV%U0@R+?]V5.5B5(]=S/6^0":LU$)C,],ENJQ,
MQ]Q68.^]6>R0A#C _/IJ#4$TJS*RL!ZPZ%S8))@9A><:Q?TM*[2TH@&=KXP5
MJ7_&_?3KL8A73M%$MO&OP6G>@]W?/W_ES12YQ<>:HNQA+7XCB!1SKLBK*H P
MY<ZO_!3U>P 0J9]YX^.]$)F(O[=Y-LT:_8Y<6(9 4R!E7RQXR/U*3IMY?SC:
M%@CRBKWY95Y!]=-I.7W[I8]OM'8?\WI4QZ#GU\35!16ZHNKR"AO(KTD#RY>_
M1BN""]O5%(]BWHV295ZGCDSQ<'V^=WX*=ZW@Z'=<PP&0KE)?AMT6)AS4YU?J
M,]D__\)[@GE#H#K$6QO;'>[^G*,K:# 7VF>6I^N2X=)\#YKE*MTD]9%&'ZFN
M)$*=CDGX/*DC YFL/*D3U9N_K=XX,"2K4- WXN\2]O+IQQB!V%U:"9?_EJI+
M<].,^S5"&M3SW6E.)4Q;_M@M/R_?)LFZ[M?V&BL['(QCX"@ %KF%)JL9M,KI
M,-^%CFD2F2^7*H^<W"L['H[)-\N5*O5I*/.?:J0OY,UW)_[>N7L2^+6[\6UQ
M5=:Y:[S6 V"<^XZ6R7\R;6N8J]P_Y%;KH]_,O[A*%MK,Y1V9WFYRA\+TKF9'
M]Y<6O'5".^!VWM<YFYJIJO [C^;1!8__HMP# %YILL] @1R2!\GVV>T4(^;]
M5G!_BK?K ^>M"\CM2$D:YB:8C_%MM7XMY,!-9#S1=I?FQY9][RXV7BF1ZZUT
M>^R;;Y-OO%&C,66S7B$S,U'YL7UHOBMG /T#,@,&^XP6E!ZEI&:SS$<FA^H2
MGJW]^MC*97Q439YI_T?9KP.HMNJ.-G&(271@TH+*EYY5SY-&M2/6_#M;AINZ
MIY5#U@EE\*0F?&Z?S.[;$TTO!9L'@%[/_4%QZ>0NKV3GC7ZYXQ!_8\_]'GP@
MN'HOK/P!0+SW -BM%9O_/@VTNF>=?@!,.OO64Y?1?*T8,\H3,K;<'_M!7[/7
M,%,Y3GZ]*1 :VT4I,.C\0[Q87Q>[">[1&V,?C#%/.YB#%95KUJBQ:+_P08&B
MM-HSW0L*F.S<2,1[2^=Q?9$3:KUMJRO^/L.6+GY9=)LV4BGT3==VPPN [ "9
M(&7>\W5=U])QXY4W4@JL T%G/]*BK611"JSM/C_OO-9W/$B:UPP++NVA?1\T
M(NO8^63%"Z#9YU_6(9-APU!=AF&3QW(2:$A^WE38&"9'[<OH09&(N#\K=N8^
MBR+3BMMX[:G@+1$":?L$SB:A<_=UQLPL6\:>F%8Q5*@OS3'QY NA\/IJ[SPK
MQ1&=K*#*"P_ST,VARR$\8]]+RTG^J%#2Y>!HJ8QQMNEO-UP8*>0-0Y,%$A*-
MR!#"CD6EW\YA=5)L5+_,0/@!Y[OYLIJZ-D=&5-7&YRP_KC@IDI _I<;#1&S
M9460Z-Q6_5>2-51!?9"PY"IH$4Y42!]O;!*Y\WD#071$B!EZ<J8-^(.NBJY7
M6HZGKGK?YW$<L["G09<LOCUA7#MJ1.7Z/+RIHQN"D!'_,Q=[H2ED)DS:BU7*
MJXRP^YK?XMY2?1FPTHFZ090W"2;-36*\D1*$#!Q?RF@D# ->1+KNMPJ[%6;/
M6D9-"MF!B(/1JO+BCO1#BB,3^[Y0=DR;(>&V&5;6KL'6WS;,'<#.X]TW\MAF
MZ7[YIQ;VL'GZR4R4:4^,SEI;Y!>$2V"QSEV$*Z-W"XA1&QQLHQ+^&)U-LLA.
MCPP[E)MIHX!;<[RD**>V[UZJMCXXTK8]=:T"Y\4ZH+1!]MJ=B<WM4#YR5#CY
M?5.](@S5A8Q5WCO(>)5I:K3I+4TUW#,F4WS;(9$PV"_:D5X2I+PG^E1H9X]M
M@FTK#4 &H*KXEEU[U$U/+22Y5H^/R<A/,4U-RD_4F'?30S"/0HX%O9D$(U\D
MK E*V-8_$_JZ*]LIDX E1ZZ27^$CUB\^-":U8NL=B<BZ TE/]J#H> U+CG)8
MRJ0][:(LR&.E)Q*A_%HUO^P/;S#L9.+8#KCJB]4#3H(AWI2)B!<)^R+81H'-
M<VPAWZ:M=S-#?AT+R0[<%81F%\W'GGK@R9VE 3DJ?G>IT1VUD5O^X):CU4-&
MH"LBLDGYK[1<!FRV^Q@FJLETR*ZOU4=5V%HVVRXB(MLN&8"K+>[L;L_TO6NK
MM+?/2R.U-!1?<5!=28I\HC\4^RQ1%:[RX2QER[HVM*KG[25,UH7Y:4&PBH"K
M0"*&6T##/8'S\%9B"!;,2/1Z9F+F9<"+66]$3J!Z_^O@Q @"\[ _*CWF!=XO
MD_!8H)2UX#I&?=D<V<7 EN(@*[*=W0"2$T/#&I95JNJ,%M_HI.'6[$;):!L7
M)N,VG5=(%C0AIH*_-.6)XW[AEMQV5"[VD.ZN2VAO,9J\5:?>Z,(PWMYL5Y"8
M'-/SN)2Q']KD=X9I2.P.\D^A<T,DMWC BDT&L"/ZI]X+#6]ST&%J>GI>C68[
M<I8%OPD^\B@4L5'-4(3$0+'Z+&F#SY#'KMS0-O>U#NM)S(2FC/IF][GRGJQ!
M&\F6 6X3_^S)5^)$&L253VKNRTJ'(AXEL'#3"X[4(DIJ/)F<7'*CZ2U#2' >
M[R#M>G)_@BQM^WRUE_ES &UBI-.GQ-6H _(;8UT>NE,BV'C(QS$9)79+0RZD
MKA2]XY''*21ZQ'QO8%%!B0VC61;L9'ACQ2RS\--/T9'4=+K.HW#GIQ##R7!.
MQ_+9C8;92D77_-#6&!TFZDC7OBG>UR8S&Q\IR%O!@P98B9>F*&=U=9A)*#P_
MPM@"+ \@TAAG^',R[XAGBJQOJYC[R)P(V,:Q W$^FC]'O^KH[4SYQV4T&9!N
M8=3XT,3$;"X34VXWAPH+ME?$TIJ]$RF)\-%"AAJ-I0#->X8$:5NEIK1U(J_S
M:UU;4\A4GC&F(9T9 CFPFP*!H#?WQF8IEV/Y,=0D]W[/Z$(:$S&@_--S=IM2
MT-E+:^3UK]C/BA6$T?-B:DJ0K(#HI%+A*D9:+)-NNB4<P:+W=1V#5UG%US'>
M4LXNXT-<UUE&;C.W3.EK[(X/ ':JTR\3#7^7ZD">1:RB)R5_Y?&;#X [L@<
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MICB;/PQ#%S8U+YSX 8-.DFSE[X#M!["+"N"\L;F#VL@QZ$+6;4FE12VB IA
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M>:>JJ'_TM?1PP_KI"EK@G+L :R>N^"EK5BLYN!T[-(UZ'OX&;6C.C.3WS]Y
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M42<RVU).DTR6MO8[=CL*H+@7]^>G?V!N5-[)^RIY'",Q?5Y2V;40_I;:JW9
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M3A=E+U\O;V=G;6NHDU5F#'(GFF"!ED=@6ORL-JLX8>G.LQ*+G"?"Z-(*;EB
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M5NAH4;@+%-A*O[&"'-KFP9N""3<S3$59L/Q,KREDI25]J[(\ARB/=AIS=>8
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M#&Z;G!GLOI'P!&,4L=+ )?/!89<+W^/0X)7Z.4A46:QL\D0')%1I.:EY?W\
M5IR?X;>7_$ Q[^< 8*!YTH09Y+P[1'\6*,0Z%7&W[!#ZG30T/!4(2FPPB+30
M.JV)X@B.3G!]&QVP-$[E]M(TFFOMJ<I3#XWM,&[N02(BX#<IJ7!T$&K ],YX
M/..G:H&/,LVMH-L],-+M\'Z;I2<T8"??\J!D%'>C6Y%@/*,@B+4X1<4.J?G\
MT,']^H^XFC8/YH?Z812_4)A7VEE4M(.XFLXTWB!]G@S72T$ZQ&^:S)7,/SGG
M][*?/"*(@_MP"(;'+_SJ"J=Y'[:%NQ2#&H>\\)%B(5;IC17KRQFI6?O:>5\:
MQZ)NIC(R-^U,1O>JBDNG2/1:E?=WSTUBB,#E_]V:Z*-M6BK[!]JPC.QXONQR
MA\NI(O]UJI8<()O&1*^B),.)U$X&R9>8BMKB'@J =S.I2>]#38-Q85$CF&22
M.L+O^9M%*H,A=]&2R VS.GCS@B7*(_0 '++2F)%N62492M7-_V+SC;'S4E9#
MET50Z:C.K$3O0F_!!Y$,RF@M9,WWUC]A!>+B7QX!GAHUGE_Y$)K()7J*:X?:
M"<:A"['LAIXYUU89X]4O.3Z"!2JJ-*2,.O?PND= N%O4T.@C@-JY5!D+;'.
MI6M,,.!^OZI%^-%+U%&4)WW]K/HK4J<'P3CW)JG])R]6ULCRYL']\L/.1W7D
MO(X$.<HYDK;4F8>T%?+RZPFQFJ_O\L,Y?([C$;#&E'EWWWJ_HT>$^65>>OE.
M:H(VH_81T,S\[^]46TJ"V+I!VS"BQ>-SG;ZP"(2W4K.Q>LCGR(SMQJR56H:[
M#UG\QK)NARV7G0UG*S9]GERHSC\:JV0=VX90XYU;.,YA?/BT72',<S>_G3S7
MK(K!7+3,]?+"VMJFE\X,F]6D>3>E(<7_ 4W9USR>PZTYZHB.\_#8VA$(Q\)T
M_BTA,4&JQ>M2_1)':J(%C.=E9* _@QL=QD=$O+25$!(<R^7FR4QQK)Y(5E.B
MK>6QP#NB9?1&_YIEQTO(@X8ZA(QF]!;V'N@C.=403@=KF1):_E12&+&F_5M*
M]\AC-? T5.^@&E([MV,]MQ_NGDKC[< 97QTJ"(G-"ZZ2L>GW*1RERG&)4?AL
MYB/PZZY%%O]GH]<P!B%9[EB-(,]\A0DI_;SCTJV2^I9U!@JC01Y^BHJ+ZCB7
MD:-!<]X3+:)BSX(O*ES3X@F[5HP1&LI AP#4#S@^*FI;=I&QMI2N/2,KO$J'
M -@)(=W=[R<EE[BRQ2XB=F@EI(3BUN04SG@,=SG%K&_D_M?E%<_]5_YG HM?
M!)YBTA?>-.?>WW=/CSS^F08XCBSSF\2")M_%PRVT^PI^NU-X20" @<@<3[--
MC?2^EVJVV!!A/(9XG@OBE+Z$L2YJ8?0T<ZCARGNYO>J(/S%P+JGQM..M[E)#
MWS)E,"PNN*REJ#)EU<@^MH&3VC3'"]T* ,$X,JNIXX\<G'-<;C-A&/U!-(AS
M .+5#I%58"%(%LRN_N8UU>AEU(/")W=CCL]F_L&JFU7F7>-5K(R8*?]B170F
MX2>9)I7D0!>W_9(0K0=HY52EKZ$)FI!4E#1RL""F8C2?B/E5DR9@3[&PE4C=
MDD .=%PH[>I9*>;+_VZ<^F%436.>'F'(MFU9@V1X/R&UO7 E2U\K"",P2Y'Q
M]!0D-RZL)FT)3TC_01I_?D$R2:R*:6 !SOWTXP9RGJ*_!1=P$$4;\M![6I4+
M/WS#KGTSGQ:<P/KKYA/AIW"E ]<=FN7L<A&K-)F=0:BH=CQBTK# -K]^P3S^
MU_B'F<X\/(9$_G=X8$J!_AX1MPWBQ'M+;NYKP4> [B.@CYGH.H+1)'O%/?_'
M(L?'566&6%E';MYQ3]_K.JB2US/T$5P\<@R A[%,6&W-CV>[K.ME%NHE+YGJ
M6QSG!3X-]=H/D-TP-KJN1SAP4IN4,!3[9,QTL@/+6G!\7$3V/WEQ F%O!3B
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MWR2>I&H83#'WRI]XXO]N"BQ"ME07NVMA>%)<-&V^N15.2?*2@9HU82[N;/Y
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M/*II3@VUP[SHMJN;+@!M<L[LDQI@[PM 4."D7'4(Y3_5_U3_(^JU(8/=-\O
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MAWI"]J$*=:&IH/H,Q"V4"UX3F/_=/32N//2D70#14XFLG',3<^_(V9SWBI.
MCW6>TY!G_?*/K:/WV'-64%UG-_:LX#]14T9?MX&U:I'*S%2Y\/*N6\!"DYST
MC4RD1)NR:"4C/8\H+OINGO^-N9BV\1\V1\3B?JGTQ1/J]/^\^PY9;1:70, K
MF9#EW/I:4'1A_%*8]1= ?=3('$:26\2#8A&=G!/ON )>H^-ZKI3ELRYX4Y>C
MZ<GC.NL0K[F&LH]427CKQ5KV#(]>%K\\?'!EES$,#A"7KA@VE#,ICM@Q1<K3
M&E!.4@Z2']51;$C4G@EAH9:\(\:KY V<@*D=6ATXODC7O(Q6]*1%W@[?N?[M
MT).WQ]*_0+",'7?& \20T"[?2S8(<X*?R\]^SWBW?+A2SZR:>54V;,B]Q*TJ
MU.<D:_#=F<N53<BP(D[0QZ"@_XF X1+^2B;KG8=@!;]J3\.T=;Q-&*!M$]S7
MV[DG+!AASXM# XNJ>7.#)NWZ#36.=44JPYPW6J$Q(NEBNZ91*^(F5]35(P.P
M1-_9G1DL]^7]E[M&[\F"QT;)N)SP_"7]_M]2Y#I^6EL6GR:&F9;'7A62&KZ6
MJFS%EZ$]OX5B,VY%ZGV-#]H0L@SZ&**66\%5_$HO%=ZHZ? \8>T[T? 9J%_$
M&CR$7/9Z,#A9G67<:$1?7HN;7%2;*S(B!T_SD@IJ[II4>PG[E?0MD8%+>E00
M.M8[\DEY)?7EUN'>55)V)R,(OL!-P^MO&_+.J58!DAT,@:!0&%$= *B@O()@
MPXQ,$$V" -+3;Y*>@4ME[0X@\\&I)@Y;0FS%D 9?Q,3%-F8Q@O!;JP'\X$2Z
M4A;,[J4/*1BK$+,-SE2#9>20DN*%YQMCMJ052:IN)S<<'N$(Y_ZWE8RKE;NW
MKK:I7[@JO0Q*5@"^8_7NM^#Z?.7R?D6DW5Y[C,AUN2[(!V5!>VRV/I72RZL]
M./S;[7IWQBKDS'9Z8:"=;[4!43_3+G4YO,%S57=3*;?)],^'$S6K8W? 5ICE
M-M#"/_T+\A4E]9E$<N& \<@ C<YKUUWD+-"E):<KMPE+9%Z#!VF1/@@)D^^3
M43P33:I9;H[\MNJTH]"\>/NY2;V!2UD%.H9771Q\I-P^0J!.+-?[WW\<$NTR
MHM;''*P801*..Q7OV+DB2A#</#8JX0LP2;-^6#,ZP'>"@I\YO]2;YSQQ8'DB
M<&%7%)2S=%35[K"RD,HUXVP[<U9E,3];^:]5Q)"X[_54K#/[:D&69B/H8\G6
MS-LM/4R,2/X,NBC'7N[W4D0XK,<%GU3]2I=5A&I\"+EWLU!I\>W/&J(U2_EU
M%*KM\%E>2O;#1RIA8VYE,@IN40;3 4GSW Q9GS\]D'&_^CEY5=WO36$TK^LX
MWOWH5;S5<[:\Q123>+-@EHIAG] 779?%F0<+M"=<0J])@EE#]JG@^P3"/W]:
M)D]/ZSII6)D G2KC6JKA5*1,A3"[E(<1'[U#?%9#8HXJRZ==ODY-I-,5Y]J<
ML7.HT(SO;:L85W< BPH SEJ\(E49OI#-:N.YWY[CB'W]7,'=[H[SK9FGWRK[
MX'XI*>F4.AIC&IH2.PCM]G5040O(.>(%*\5.#MF<E/7H^!=HW"5Y?NYJB^/;
M<+Y)/S'_0W)VT/LEH= 181%NH3J%G5I8$%-N+M+[Q>X>=G7 =7-WR*B=VJQN
M/^TAM]Y6\\%92*MR,NNNX6EX8.P3]R'CS#'W.-G!N3VM-W)"GWV'9?#VOIRD
M')M^KW=J?P$#^#E?FNG&&9%8]O1_RVTPL.F-+<WTUOUB-*ZX0T2K2S"\2"@3
MNE[LG;^U\J.!V3D[+6#%QC'L6U7IW&M/6=_!'S^&YXH(,$2>AGO44&"G/<.T
M>WL9 @+.J+XU0&WM.GOI6"$0>NO\H+"(]K/6IKY"&"-V[HYVXV+/6O'8= JJ
M3/6='4&5(6M:>F[5_)1\-_F*B+&-:;AKJ$3U*O5GT"@EN[(70?*P.Z-*)94R
M=_3)F)-?6B%4_$-,,7-+AV>X/?DE06-BG\R/0AH4#[\ASU.$F<$W(<BS7"0)
M+PW U>2CBW1H2O6&W\-7W."M7QGEIQ7%N7X/.:.TM4J#"^ZU/ 6C";YC9)((
M%O):\(R#SN!@7VU82GE:[D=M(W&><<[!R$3-7D: ;LH*.?V>)8M0-<FHZ>()
M^T#C!CY?'N>Q<UUA-NO;0>A!6% MJ\8B )WZ!ZX\8(- C%#N\V7TQDA6$UFB
MY0/_GX_*OJRNQ7><M;+L7GU7[/>@=I;F"DX0L9QZW>QF$RJ/!NL?Y%NH+>(4
M$C=/72D8O^+"$]0,'2XA?L+5S#36A?3LDC0]8>\,8&G!90@7-[&T=GFL"NB
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MVR?"IDPOE7Y/2[YSMLM,Y7['DH[/8^YG+  =E#2>ANCU1MVPFMX!Q&:P@(4
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M,DPI/SM4V2XAID1]I,Y1<R:1&SP2FA)FJQ:/">Y&RQ#\/-S1I@)W+2860EZ
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M29660P*^UO%17B$+A-8G:7"Y0#_0V_HY,:E@VW^X;A#7,9\.>>76U_;0TLC
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M1?B 1SQK8?5PQ6,OO;U<%XA3L#S=FI*_N7? OHOY]!L@!*KW!W1.&0INRII
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M!]B>'"Y1!$217W49&,1D&- MV[[*HSU4TVAJ1-4HJ4I5]^O)3O6Y&S)A]]'
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MGTM%(^245VA>L_%J(&@@YZ-HZLS\RQ\JS"U,0->GII$HQ?CUF$NM5>%KN]^
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M92M] QUMMN+]U]P6W(TV_E%>>\C'XQ-2&G[+DE4S^AN0+']0(?(;X.UR?Q&
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M2XM?:_.A'P58;<@2SN60+K_WDD@M?RBUG+0[=G)X3/=?$=4B=Y ^T%WI<\V
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M%G,0C=T[]V #'WG>1?>'%L-*, 3#>LKW_!344M,ZX/.U '*XT+[QA>/]O:T
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MF5&> W#K9CT"X&%A/@#)>&O-(/[%$LG#<8QJ?@F)7KN&KU0^7-+FK?"!2*Q
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M?I8A@M.0=M>,C#M)L-1!GU_\V!SSDX%$H'1C125!\I>\N0D=SNE1S.#5N<&
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M#N<G^-RV(DY4-][RP<G';]0J<>\+5C<!6> 8)'D>@-63B_HZ%(PA$":*3;-
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M R[EPCU:N-+\5';LN;:XA-1SHT3+&6=:+_Y-"LEN8'CIJ5\ N/M8\AS^O,\
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M5U6QZFEY)I_WF';N7/65#6S"2$^6*=E0_P+/='Q\+QYW$B:0FSS,9DKM97%
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M1]603$&%[VV*J^$1J]!G6VX%Y>G#]^P?QV.GZU$;:'[#9/@V;(I0M233OW'
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MRDN9@H !Z_%'2A<<G;:_ 8?K#;\!*ZJ_ 7V,2G:Q#$KD]]_E)_>,3DOX 2@
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MR'$ZZH+N&+/H[TF7(?H,>*G@M_!V56$@G"C UU2U EX#F]+3>U7C^[7B(<F
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MD7LUI-X:3[A^7,;7F'X<.T6@I\U,V^$#)L-R42Q?5A_W-)+U@Q"6&ZFC:U)
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M7&/,-=;(G+^QYLR/Z1]+  H-%745  X.#L#G^@7XL4QQH>SC] P T-0$< $
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M?",@(*)IB>>V_N0<&V\QU,G&AZ6K7W*7<* [YS+XL5\7)OVIOJ]ES8IK#=M
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M"3W'"G'X!]?!M-R%'X QN7D&??U^J2\A+7UI2PQ$WBZA,M#F]A(Z#-^=&=+
M06!P44&T(^X*1):.C=Z3HGL4E[ 8^[S:%,;8E5RB?D)=T;#8*G_A8_M&C"@/
MTD7\RO1X$1$R."CDQY<<.49%]UA3V3[K0!3#Y>V*3'!,I7_WBPA!]]>SKIN]
MVU.["I2K!&EU0)=G[XI<JJ<^62E222:K2K[9$16,>#XS4[# UZ7ML@R'7Y7J
MSYV0):< .]P3A[FXN.P#/^I-K[Y@[Z:OK<-X22(DF%ANJ#S/EZK3$C8T>=D
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M7EK_1MTY=_>LT$59 \UD'R!Q*GT&;G D@QV\G4B6Z%5_!O\2=?+DG!@:2UP
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M;U\"0U;DK;"AP\/A#;E^C39U!F/F[/YTHXP?$NH<MV-(PA#=S,#\N @ZM<U
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M 9\W%_]?24@0AI2=<4,EE>;X3O0D2I+XP]) -P67KBX!]#YFZSBK[\:1^;>
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M=R+P=(0N_#^_9_R]C(_Y'XKW_'M##)JQS\U)GA@3>. ^7Y&@%%J+.]:(77Q
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MY.PLR]HX1&HUY[G31&$$I/%OW(IR(=VVM-X(WL:K5M!2M8+%IDA=R=M(*B[
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MP,9@K!H9"?6+(!ND2SLF>7ZOPR 55^:MPNM&/;L'D5>H:N_6ZMS&AO@#5\D
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MZ>(I6$16*OUJ\8BAS=7!BQRKF!$@<W(&2NOQ/)PI*'+BD7SJK&RW[]_P,_&
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M4$L! A0#%     @ /(!;6%J&8Z1C#00 #/@G !$              ( !
M &9U;&,M,C R,S$R,S$N:'1M4$L! A0#%     @ /(!;6$6W=4$!?@$ \S\7
M !$              ( !D@T$ &9U;&,M,C R,S$R,S$N>'-D4$L! A0#%
M  @ /(!;6#*=VB;% P  PPX  !               ( !PHL% &9U;&,M97@Q
M,%\Q,BYH=&U02P$"% ,4    "  \@%M8E=B90<("  #*#@  #P
M    @ &UCP4 9G5L8RUE>#(Q7S$N:'1M4$L! A0#%     @ /(!;6/ILF>](
M!   HB,   \              ( !I)(% &9U;&,M97@R,U\Q+FAT;5!+ 0(4
M Q0    ( #R 6UB=KM<^ZP<  ,LN   /              "  1F7!0!F=6QC
M+65X,S%?,2YH=&U02P$"% ,4    "  \@%M8/5DANML'   K+@  #P
M        @ $QGP4 9G5L8RUE>#,Q7S(N:'1M4$L! A0#%     @ /(!;6%HX
MVZ;'!   NQD   \              ( !.:<% &9U;&,M97@S,E\Q+FAT;5!+
M 0(4 Q0    ( #R 6UA+G,)]N00  )89   /              "  2VL!0!F
M=6QC+65X,S)?,BYH=&U02P$"% ,4    "  \@%M8F4[Q.^83  !9HP  #P
M            @ $3L04 9G5L8RUE>#DW7S$N:'1M4$L! A0#%     @ /(!;
M6(U#KKS0E   82(! !$              ( !)L4% &EM9S0T.#<U,#0U7S N
M:G!G4$L! A0#%     @ /(!;6.)AGI(P.@  LFH  !$              ( !
M)5H& &EM9S0T.#<U,#0U7S$N:G!G4$L! A0#%     @ /(!;6(+U"+/3?0
MF9(  !(              ( !A)0& &EM9S0T.#<U,#0U7S$P+FIP9U!+ 0(4
M Q0    ( #R 6UCRZBA_5P4! "S5 0 2              "  8<2!P!I;6<T
M-#@W-3 T-5\Q,2YJ<&=02P$"% ,4    "  \@%M8I"H$G&F*  ""+P$ $@
M            @ $.& @ :6UG-#0X-S4P-#5?,3(N:G!G4$L! A0#%     @
M/(!;6#-%#T 7.@  <&<  !(              ( !IZ(( &EM9S0T.#<U,#0U
M7S$S+FIP9U!+ 0(4 Q0    ( #R 6UC^%1"$7)4  *&X   1
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M-5\V+FIP9U!+ 0(4 Q0    ( #R 6UC/+#<D%=$  /'U   1
M  "  8,>"P!I;6<T-#@W-3 T-5\W+FIP9U!+ 0(4 Q0    ( #R 6UA*,T<_
M!(H  .6R   1              "  <?O"P!I;6<T-#@W-3 T-5\X+FIP9U!+
M 0(4 Q0    ( #R 6UA@.B/ZDX\  $:Y   1              "  ?IY# !I
F;6<T-#@W-3 T-5\Y+FIP9U!+!08     &  8 -T%  "\"0T    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>fulc-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:fulc="http://www.fulcrumtx.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fulc-20231231.xsd" xlink:type="simple"/>
    <context id="C_bc43a13b-90f8-4ef8-89c3-5e47e6633f21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_30e3fda8-1f2a-42d1-bbf1-8d7c093ac7d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6b2cb0ed-bc13-4280-b556-83c472d55900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b63474af-44cc-4faf-b216-6548e22c9832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_830548a4-6251-494e-acc6-0972515e7069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e5fa44bd-3098-4335-bd36-e6a28c5c81f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:Camp4AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_98a6da6d-074f-41ab-bfc4-6a2ea10c4c2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17ffb108-fe7e-476c-83d5-3f1c63e048af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b517f554-4042-404a-9af4-f3387f4737b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwothousandtwentytwoinducementstockincentiveplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_375efc5e-e60e-4b9b-bf98-fb370dc4734f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_62175780-5393-425b-aa05-cee4f721a128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_79eda3da-f82b-42a7-9282-e10d0fdfbdf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-02</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="C_630894ba-94c3-4b2d-a63f-cbe1dd1d4533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_331bbcc1-90e8-4bf6-9dcd-ca73f84cc749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_0e910a3d-1e4f-4b7c-85cc-e29372e692ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_4ce2bbff-4474-45cb-9d57-0f72591eb0e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3bf28ad-b304-4305-a570-1122422d798b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c3e57f9c-5c4a-427a-ae13-ff85b90fbe11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3f962abd-0c59-46b0-942a-62bedb1c8907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c9395349-8914-4a65-9d57-bc8e29bb62e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_5418e51c-11bd-4ab1-86e5-58e2085729af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f3a948e1-3f74-4748-b84d-2b0696114a7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_874dc0df-15d5-4f39-8253-51d6179f2225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1553121b-ab45-495e-b5a0-c6324fbe71f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ef714543-18c5-47fb-aabb-747b27cc8411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsUnderTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6d813c32-3ade-4f1e-a7d9-3519e68f4cac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_63c6c909-d955-4771-8848-2cdb7bda457f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_1b2a8270-a42f-4a33-8218-0bc08d831c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_3a2cdb21-6525-45f5-bf28-66b9a5ce67b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3d0c7846-78b1-4df1-8b8d-1b707923fa89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandAndTwentyTwoInducementStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_98d7485a-ca98-4800-86e5-94959550472d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fb5c742b-1082-4c9f-adea-cdf8661b486d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1e35e38c-6f43-4880-aab5-7ba1d31d8d24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1ba2348b-df57-42f0-b766-38e72c616f8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a3bad76-7c81-4609-ae81-f7496ee21338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_edc3b5c0-37a2-4a67-b22d-a8f24b1a6030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_94054f0d-7eb4-4308-b9a8-6595c31dccc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_000f7fb2-957c-4f01-b3cf-38256d89b74f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_22c69f38-8bae-4283-a815-fd207b1f78a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">fulc:LegalProceedingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_94104f8d-cdd1-47a0-bd4b-ab3238e5307d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_465c59ff-4b61-4b2d-8eaa-5ac890630a2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a87177cb-5bc3-41bf-971c-4854bb97a946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1084719-244f-4e97-8f34-58c058846345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwothousandtwentytwoinducementstockincentiveplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="C_6a8b9b58-5d94-486d-a1c0-5e1919ae1ab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_3e373bc4-17ca-40e0-beff-f412a277967e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="C_343e6c36-f77a-4689-8990-03e75af7256f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ddb6c423-a9fc-4d5d-b7bc-80dc1e5b3113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7c3c4af6-ca10-4044-9408-a2cfdd8766f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:LandsdowneStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5b154a84-e3b6-4d80-8d60-7e28915a9763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a79a27de-8391-4e03-935a-a5b39db9ffc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_67ea3264-4f09-49a3-8fab-3cdfe1108e54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fae73cbe-4594-47e0-a56a-d04732d2b464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ddc92748-af69-48e3-ad4c-c0752140c842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5df36d60-952e-4b70-a43a-be90787573aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2034a62c-8291-4271-afc4-d4d11578f7a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f46423a4-6cae-4566-b0b3-c4344e7e0ddc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_71bc03af-5035-47a1-a103-ae996647c88e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9a8da089-33c9-42b0-ba2e-0a03c031f084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-02</instant>
        </period>
    </context>
    <context id="C_fd317054-d5af-4b47-89c2-049b6bdcf482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:Camp4AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1db948c7-31b2-4309-a481-9cda796e4d8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_51307bed-9fb2-4853-8cce-0c34673cf5f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_69b9c54c-e52c-4afc-b0d8-7b44074f2ffe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_85e16b30-1163-467d-8e7c-c5891589de08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_40257969-ac48-44c3-9ca7-ffe11592ae76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c4f28692-ee59-4c99-998d-16b6c76ed96d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:CorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b18d8319-eea3-4201-bf6f-cdbb16015369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_508a96d8-65ca-4e37-92e2-530cc3c9b8b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_19b2e307-2653-4c2d-ac68-2e2064f71c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1e7d6101-2b2e-4757-966e-e38a693e1fe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e9320667-4317-4880-b542-adec903ee354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e746306c-e757-4570-81a1-01d41ff4c7c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:LandsdowneStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f8a31241-faea-4738-8c70-9704d5b4aa96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fbda6a93-4094-47c4-ac19-6cebaec8a93d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_990c5530-0921-4d0d-abca-bc365950858b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b7d85ad2-5aaa-4c27-af4c-3ddc57509e92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e04dd368-3fa8-45c2-825d-2725b8979f16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_45f470b7-37af-4351-8f8c-c8ecfdfc36bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_184f93c0-caca-423f-93d2-bab19e3e2a1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1f634eef-7981-4392-81a6-c6c15de65892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bbc1c709-9a9f-4ee8-ae35-e6e93fd2f8f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dbd2599a-812b-4ac3-94fe-e6eac2633ccd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2fbda0dc-8dce-4255-a8df-39239cbf99b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">fulc:CommitmentForOfficeAndLaboratorySpaceLeaseOfCurrentCorporateHeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cca8e9eb-dd24-4750-983a-2de55f115638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_98e7f3b2-a03a-4688-bc57-f63c93ac0609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsUnderTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cb406b69-1f55-4cbb-aacf-ebebc94b8c0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandAndTwentyTwoInducementStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5854b7db-5036-4f5d-b484-aa8238657b18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5c4254ea-de8b-4774-8083-9eb5cd87bb6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a18d155f-7a8d-4b6c-9a25-f1314028d766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_2b05eccd-bd38-4e74-aadd-9cd13b5c1a5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:CorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cf9e5807-85a6-4487-b3cc-e06892d1b91c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4fb06a81-59b1-410a-943c-d31a633e10ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4c94a63-164c-46e2-af94-f4aa5ed3dad5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fulc:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3ccff940-b46f-49f2-a0ba-1cf5bf8580ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_542d5873-acb9-4a0a-8e2d-dac0c67b8056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8ddbacbc-0594-4cc9-a6ac-745a13b49459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eb41ec6a-6f90-42d8-a1d9-14d1685b4dbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5298f167-d10a-434d-ac4b-5d0e08769dd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwothousandtwentytwoinducementstockincentiveplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="C_4ba02dc0-884d-416e-855c-afa71a9532cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-02</instant>
        </period>
    </context>
    <context id="C_884143a7-2e26-4a93-ac13-566cb4dd0eaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0663cabf-5a8c-4583-a6b8-7af5d48c1798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8a1f01be-46f9-44b7-9528-8152dca6e10e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ea0f142c-6216-4014-90e1-aa57c23c6c6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fulc:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a2846897-76a3-4206-9f4d-846065573bee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fulc:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1189e0ad-3433-423c-b4a2-785ddc505de5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2704081c-8b8e-46dd-97fd-b538434d0d04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7354e229-40c7-40da-a524-c89e5cf4d63b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_11995c32-99cc-441f-9c07-7fd5a7ad4859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3e7c4269-98eb-4914-9616-c8e3cd7260bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a2062e16-6f62-4e3b-89f8-c083e9ea8bfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cfcc2344-b6f1-4e48-98ac-862abef9fa95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_18e2c630-6ac6-421f-9bc1-23e2b22a1afb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwothousandtwentytwoinducementstockincentiveplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_43ee8347-1c34-42ba-9abd-dcdc1b5cbd11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_34147407-27d4-48db-9e5a-99ff76257ddc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-02</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="C_848b9802-2af7-4a3a-b897-56f5907cf9a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a247c0da-5748-4ee1-809e-b40ff34a7c07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cf990f8e-d292-4776-92bd-5fa5305cf788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="C_c4c8c6c6-98f6-489e-a40d-a5ff2e15f073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_37fbfbef-7505-46ab-bce6-acf025a24bb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f027d984-8450-4048-9d00-1f28f5700faa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3409faec-0230-4835-b5e3-04aae93d50b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc2dcbed-a530-47fe-b591-af8023e6e6ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fulc:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:GSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_91aa4910-0766-4281-855f-db89fadd437e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:GSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d0796c66-5faa-42cb-bb2a-9806d8b59cc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f435b74c-2ffc-441d-adc0-12a5eda8264a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fa1479d0-71e2-465d-899e-3a286e2d39c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f1a6601c-64be-4399-85ae-db7867216139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aa92b40b-ab4d-458f-9b44-218ef3a76113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d6c403c7-c450-4827-9fce-058e2ee7e5b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae3bba65-b6cd-4d0b-9844-04bfbfe465a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_307f7d91-6fab-4f2c-b389-665c233bce30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:LandsdowneStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_944dfc71-acfe-4731-851c-eec85eb1064c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b9eb8757-a555-4809-8e7b-95ed236c0f69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fulc:GSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_87e20816-2f34-485e-b3e4-7088d4e8e968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_78fb4e2e-0240-4074-b54f-749132177dc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:CorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_36c5b7d8-3257-4975-88e1-ef21c0684b9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_96c49986-10b9-4fb3-ac44-74df5efad901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:LandsdowneStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_84b31042-326d-4a8d-bb3a-1fab245f12f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenAndTwoThousandSixteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_55fd13cf-5a49-4af6-b31e-8f8a1b4bf952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ea348ed2-fdcc-4579-91c5-808f2dfce003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1c1be40a-0714-4b4f-8656-46ec78f32fc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsUnderTwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_16f0f75c-5dfd-4809-a32b-10469163a156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d3376273-a29c-48cf-8511-32060db0b560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fulc:CorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5186a5a2-f3b1-4be3-90f3-23ff2a2bd44a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7022a87d-e56e-48d8-8868-7ed1b8f6cd32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fulc:ResearchMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e3d54fc7-6a3d-43de-9e32-8e241187c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7baf9985-59a2-4afb-b460-9750260fe38c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fulc:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fulc:MyoKardiaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_909e565e-556f-4785-a3a2-94aa703eda4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8919af49-dcdf-4a7e-89e1-427cdf1d9a7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_96906aae-d485-4fa9-8d8d-c0baeaee0dc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_da574656-31f4-41eb-8cfa-bc58b33e0fa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_477d49f1-72c7-42b4-91d0-1ea14d3bf239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e83c356b-9ff3-413e-a403-598979417ee5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_04824925-8561-4f56-bff5-d30316c83058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fulc:GrantsOutsideOfTwoThousandSixteenStockIncentivePlanAndTwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_57f214bc-60d6-4c5d-b206-28aa46d3644a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3ce307f7-639d-48f2-8416-d63934e3040e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="C_749e2b12-a6eb-4d72-8bf1-bab5c1af0594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bca61fa2-7113-472f-975c-b0f57452da67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3bf64331-d750-4ee0-8b5b-6d241408072d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680581</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fulc:SidneyStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Vote">
        <measure>fulc:Vote</measure>
    </unit>
    <unit id="U_SquareFeet">
        <measure>fulc:SquareFeet</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>fulc:Segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_a151601b-25e5-4dce-a7af-59adc7c0046e">0001680581</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_418f39dc-1c32-4f25-a4ea-883e4e1ecce1">false</dei:AmendmentFlag>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_f027d984-8450-4048-9d00-1f28f5700faa"
      decimals="0"
      id="F_147a6ca8-da94-428a-949b-b233bda25635"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_2fbda0dc-8dce-4255-a8df-39239cbf99b4"
      id="F_7ea1fc65-b56a-4dfb-832a-ef4cfbdfdbe6">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_6b56879a-8609-407b-a0e6-9933f8568a75">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_30e3fda8-1f2a-42d1-bbf1-8d7c093ac7d6"
      decimals="0"
      id="F_1a1e02a0-4db7-4a97-ad0d-1f182f01916f"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_5371ab0a-259c-42e8-a3f8-9e6fae93b21c">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      id="F_f5f1606d-dc3f-4973-a9fa-9933609a1b1d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      id="F_766f3400-711f-4ffa-babd-fbc7095320eb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_1a68b880-8a0c-4fb5-9af0-f610de17e8b2"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:OpenTaxYear
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_34f687fe-c7b7-4d4d-a574-1aceb3c54fb6">2016 2017 2018 2019 2020</us-gaap:OpenTaxYear>
    <dei:DocumentType
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_ea02c8c4-74f6-4c6c-ba67-e49aeccd869f">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_3a89f8b5-5c7f-497b-9df0-d9f41a6e0852">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_ff152776-33ac-4a4a-a6ab-30d9d7488525">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_0ab3f932-7b6f-4ac6-8b88-91f0986571e9">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityExTransitionPeriod
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_e47c69cf-a8a4-4725-8c1c-59b4ca56992e">false</dei:EntityExTransitionPeriod>
    <dei:EntityFileNumber
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_7320a356-58b6-49f9-9ba9-462b5b258261">001-38978</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_f7b6be00-5567-45e5-9746-0eba9e60b7e4">FULCRUM THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_b00fc233-2eb9-4126-ad43-c070c59d143d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_adfdcee4-e6e6-4ed9-9ff2-a8ed88ec8306">47-4839948</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_2d77796c-a243-465c-95b3-bdf03720c16d">26 Landsdowne Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_f7d08653-1ffa-451c-8a41-62f8290c3fe8">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_1f8c0526-220d-46cb-b2e1-8e60414c0a78">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_829ccd6b-53cd-4c25-9403-e96122c78c5b">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_599de067-e50f-4a35-85d1-020a837e3f1c">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_af1201bf-c545-4a78-9e4f-2a7ed191ff6b">651-8851</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_211cb59a-e998-4fa7-b8c7-acd162b218a2">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_e0be92d4-8d3a-405f-b015-dd4485c25916">FULC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_9bd99d7c-a040-4916-8a18-18e5645e475f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_609aff12-9a82-49b3-9043-315404895ec8">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_cb737feb-d0ee-467f-b0c5-73e737631413">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_b4e5857c-60c6-4ede-b90d-5543307eff1f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_79537463-18ea-4257-b0da-8529c29ca72c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_fcbba139-ee28-44e6-a4c5-a36f6fff78f5">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_857e8a1b-86aa-44b7-a626-894265036687">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_942de826-59ea-46a3-85a7-faba090f5fe3">true</dei:EntityEmergingGrowthCompany>
    <dei:DocumentTransitionReport
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_d5e3c961-6d00-42a3-b185-16b303871160">false</dei:DocumentTransitionReport>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_178de865-d60a-4c98-aadb-9a15650e01ed">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_87b34972-5fd8-4459-b715-23ea697d54c6">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_3faba763-610e-484d-b59b-25ba0a54d6ba">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_1189e0ad-3433-423c-b4a2-785ddc505de5"
      decimals="-3"
      id="F_617fa759-1985-45f6-9924-4b2a673e232a"
      unitRef="U_USD">163559530000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_3e373bc4-17ca-40e0-beff-f412a277967e"
      decimals="INF"
      id="F_88c457a9-3246-435d-9714-1efbdb85ffa6"
      unitRef="U_shares">61935171</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_70b38388-17d0-4c8d-906a-5c6bf79ec10e">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2024 Annual Meeting of Stockholders within 120 days of the end of the registrant&#x2019;s fiscal year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_0b40b602-da45-4b82-9ed0-f06b07b12972">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_20e2bec9-76ab-4122-b3dc-b8be86e3511e">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_70e1fc64-39fd-47b7-a2aa-14d05f4cef62">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_f7b55bf0-355c-46ab-8720-dd38ce6ebae8"
      unitRef="U_USD">25563000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_3e62898e-a63e-43c7-bfea-1535709f0c29"
      unitRef="U_USD">35098000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_ba1b5e26-ec88-44ee-a911-c7ac2eb7840a"
      unitRef="U_USD">210658000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_e4677c03-a312-4d1f-9419-b12bf7e235f8"
      unitRef="U_USD">167823000</us-gaap:MarketableSecurities>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a0f09afd-2cdb-4a48-bf62-5aa9a9e8f6d6"
      unitRef="U_USD">537000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_f1d72ea1-e0b6-4e4f-ba33-a6a907ca9de3"
      unitRef="U_USD">229000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_1a717cb9-d1bb-4a7b-87d8-eb0d2e87c9aa"
      unitRef="U_USD">5441000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_dcd6dc27-1047-4a70-9bc2-56c6d2322f8e"
      unitRef="U_USD">4369000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a6800d0f-3af5-4c5f-88ac-bce954859070"
      unitRef="U_USD">242199000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_28760d49-6bd8-4717-8f0a-b004ec22a2d4"
      unitRef="U_USD">207519000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_d1fc2bf4-1612-4169-a7a6-0fdb872de439"
      unitRef="U_USD">5216000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_bb660212-aad8-48cb-a265-3aa8cb94dde5"
      unitRef="U_USD">6906000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a0c835df-faca-48aa-9307-eff837ac5682"
      unitRef="U_USD">7176000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_a0c0fafe-8649-4c24-ac10-52de3345a633"
      unitRef="U_USD">9063000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_2db271dd-5337-4bf9-9545-6c95612d4f3c"
      unitRef="U_USD">1092000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_962a9d38-98e5-4bf8-95de-f17edb2686da"
      unitRef="U_USD">1092000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_e0145b8f-29cf-48ea-b65b-c02f5699eda6"
      unitRef="U_USD">2011000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_ef27ae72-a4a0-4929-bf00-594576273838"
      unitRef="U_USD">2105000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_52cf794e-4e82-4ee0-bcd0-a99a2e923fd4"
      unitRef="U_USD">257694000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_284e3667-0efd-4928-8929-09acf754932b"
      unitRef="U_USD">226685000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_abafc4fd-3a67-4580-8816-c58a5b16d128"
      unitRef="U_USD">2757000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_ee624c53-fab6-4fe0-9a52-a10397b789c2"
      unitRef="U_USD">3638000</us-gaap:AccountsPayableCurrent>
    <fulc:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_e2470f77-a580-4ae2-a3f3-9cb18dd99927"
      unitRef="U_USD">8726000</fulc:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <fulc:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_5c01ba62-91ae-4a48-993a-bc6775229729"
      unitRef="U_USD">9551000</fulc:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_8761609e-0050-45eb-b6d0-bf4b68791580"
      unitRef="U_USD">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_9c28ae14-f86c-4a0a-8e1c-a00289347031"
      unitRef="U_USD">934000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_2e610820-cfb6-4dd2-a840-a3363ac175c0"
      unitRef="U_USD">2192000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_88a0c25e-04f0-42b5-bd6a-b02f9b007643"
      unitRef="U_USD">2602000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_9f820ee3-c70f-4016-b604-96fe39515ea7"
      unitRef="U_USD">13675000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_2a48620d-a0db-4321-b1ba-c3c126ac7433"
      unitRef="U_USD">16725000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_cc3d5799-a26e-43f6-8674-910a3af89033"
      unitRef="U_USD">8629000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_bbdc0167-0788-4fdd-a8b9-a1fabf247278"
      unitRef="U_USD">10821000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a42372db-d046-4ccc-bf87-a79c76e89d83"
      unitRef="U_USD">197000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_cac8c9d5-3392-4be2-b089-104df94acc5c"
      unitRef="U_USD">197000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_33b5326a-8680-4b0c-8a3b-23f7879bd20c"
      unitRef="U_USD">22501000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_ef0f0647-ed4f-492e-912e-4809b547e73a"
      unitRef="U_USD">27743000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_a3f4b0de-4467-4c6a-8ec2-d3b0df5390b2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_64a58510-e458-4609-9334-ca0317543db1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_7e0d3bed-6c8f-4250-a5a6-1f26187151b0"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_cdc91ff9-e431-4bf6-a1eb-b104a2acac25"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_f1e7fd3a-27f5-4f82-a97b-9b826faf4e96"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_531d3a13-2060-4109-b6f1-fad153f0a719"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_7e24add3-83b3-4c84-bfed-d7102b0b0cb8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_429a7793-ebb3-4b2a-a72c-115325f584a4"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_eac7f2df-addd-4463-9cad-d306d73659ab"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_7ed92e28-5e3b-4663-8046-192ef0c4482f"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_9a3dc5ce-88ea-4dbd-a7a2-296f7fb73d0c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_394a5a36-8883-46f4-ab7f-ad0aed7651b7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_3555aa0d-2daf-4a54-a6a2-8996c3a482c7"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_82aa2157-0a6a-40fe-b488-4c37398a586e"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_cda6ce50-9b23-4468-a454-bf57aa6ba2c0"
      unitRef="U_shares">61915367</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_c50b5d29-5289-4c7e-a1e2-a4b331c8220c"
      unitRef="U_shares">61915367</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_23b0feb6-8755-48b7-9eb9-5ca7ab008e3b"
      unitRef="U_shares">52099211</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_7bab9097-5c29-422d-8a70-ed14eeffbc1b"
      unitRef="U_shares">52099211</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_54203ff8-a84d-414d-9e49-1995449f0923"
      unitRef="U_USD">62000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_67429593-08ef-42cc-828c-b0acbb6a8623"
      unitRef="U_USD">52000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_4d8d02b1-7823-449f-b43d-2d4ceab31b5e"
      unitRef="U_USD">744940000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_2280f138-9ee0-4f4e-8eac-1ac0c03f3e3c"
      unitRef="U_USD">612025000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_1b660fcb-6ba0-4c1d-9109-56f48249f579"
      unitRef="U_USD">-136000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_7db86fa1-bb06-4723-987e-2ce81b725b9a"
      unitRef="U_USD">-797000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_0bbe546c-9c85-492d-84f6-080058e538f9"
      unitRef="U_USD">-509673000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_8616c886-d926-4fbe-9673-8793df10df76"
      unitRef="U_USD">-412338000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a18940f9-148d-4c48-a3be-1b7c283631a6"
      unitRef="U_USD">235193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_6999ac6c-9293-4a32-889a-361209901bd6"
      unitRef="U_USD">198942000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_3b81fb3f-f2a6-44d8-ab0a-f7a721bd1464"
      unitRef="U_USD">257694000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_69db5a5c-55df-4c86-b2da-01564fd5ddbe"
      unitRef="U_USD">226685000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_5a2db02c-b0dd-4168-9fcd-255b3a031baf"
      unitRef="U_USD">2805000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_07098fde-a401-465f-8273-a180fed410d1"
      unitRef="U_USD">6342000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_5a879eb8-1677-40ae-867a-e245ca344289"
      unitRef="U_USD">71801000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_2e2f3b29-ca8b-40cf-94a9-404b8eec57a1"
      unitRef="U_USD">76782000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_4ddb9beb-bdfc-4e81-81cc-6ff77ed6ffdd"
      unitRef="U_USD">41668000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_c4650f3d-2df1-4dc5-8cea-85ceaae13ced"
      unitRef="U_USD">41694000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_c82e7ae8-827d-48f8-8984-67d30f5d8a26"
      unitRef="U_USD">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_d1e3d223-2ed4-4734-84f9-b29636824c7d"
      unitRef="U_USD">427000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:OperatingExpenses
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_92a3c45c-0c45-4a3b-8167-e6ed088816ed"
      unitRef="U_USD">113469000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_6fe39b14-7b08-475f-9ac7-9891dd5edcdb"
      unitRef="U_USD">118903000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_dd63ce32-88b9-4080-a689-b8bdfc4a6f4a"
      unitRef="U_USD">-110664000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_e2587692-e41f-47f3-a2c2-25a925a7a784"
      unitRef="U_USD">-112561000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_91a410a8-55eb-4fd6-87b6-7e37df0e6d63"
      unitRef="U_USD">13329000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_dac4da0b-57f4-41c4-ae3c-ac0fcadb1e7f"
      unitRef="U_USD">2690000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_d4510d6b-dcbd-447b-96d0-bf5a105c3afe"
      unitRef="U_USD">-97335000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_8ef21e64-4f47-46de-959f-a6e40487e689"
      unitRef="U_USD">-109871000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="2"
      id="F_b40dcc3d-2204-4084-9327-7c417fd7920d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="2"
      id="F_cce06d28-151b-4f4d-9654-fe26f3f3068a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="2"
      id="F_a8be8302-c9d0-4399-ae9b-5e95dacbad05"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="2"
      id="F_e3bf18fb-9c59-4060-8250-bf791f85a165"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_c201371c-64f1-42ee-a24d-58f99385063a"
      unitRef="U_shares">61310</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_c3a2f877-c6a7-4152-ba0a-505fac16a41a"
      unitRef="U_shares">61310</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_05db2d71-ebfb-41dd-8cdc-38c5df06b2dc"
      unitRef="U_shares">44991</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_d10c649a-48df-48ec-ad35-1513d386dc22"
      unitRef="U_shares">44991</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_8e61051c-9f4c-41a9-893a-22cad5595d56"
      unitRef="U_USD">-97335000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_591f7824-88f1-499b-a45b-e3cce91a99db"
      unitRef="U_USD">-109871000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_a27ac672-1234-4ee4-849d-2ed18b9b0fbd"
      unitRef="U_USD">661000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_14d1a153-5e13-47f3-a975-fc344a548125"
      unitRef="U_USD">-400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_963d4ed7-9ea7-4b26-a15e-2a4fab7f62e7"
      unitRef="U_USD">661000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_32b5a071-7f96-4702-bcf9-5c3469fc9c80"
      unitRef="U_USD">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_dfa9fbea-e9f3-45bd-a258-32da009ddaae"
      unitRef="U_USD">-96674000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_c5127829-fc05-4f29-b20c-9b170e3260c2"
      unitRef="U_USD">-110271000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_ae3bba65-b6cd-4d0b-9844-04bfbfe465a7"
      decimals="INF"
      id="F_b8930882-56a6-40d5-8e54-fcf4c0a84a5a"
      unitRef="U_shares">40626224</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ae3bba65-b6cd-4d0b-9844-04bfbfe465a7"
      decimals="-3"
      id="F_0e7dc88d-2a72-4db7-9cd3-c3b8dde501c5"
      unitRef="U_USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e83c356b-9ff3-413e-a403-598979417ee5"
      decimals="-3"
      id="F_42fa9de4-9855-4f82-8d83-9b48ff3e2a24"
      unitRef="U_USD">514362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cf9e5807-85a6-4487-b3cc-e06892d1b91c"
      decimals="-3"
      id="F_bae38940-2cdb-4b5e-91a2-3d9bf77b2a1e"
      unitRef="U_USD">-397000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1e35e38c-6f43-4880-aab5-7ba1d31d8d24"
      decimals="-3"
      id="F_f03324c0-7e9b-4a07-899d-274a99fd8857"
      unitRef="U_USD">-302467000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_57f214bc-60d6-4c5d-b206-28aa46d3644a"
      decimals="-3"
      id="F_b3881198-ebc2-41d1-816d-bded0e4d4cdb"
      unitRef="U_USD">211539000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e3bf28ad-b304-4305-a570-1122422d798b"
      decimals="INF"
      id="F_ce92a678-fcbb-4e3f-818a-ac2383da58f0"
      unitRef="U_shares">11029410</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e3bf28ad-b304-4305-a570-1122422d798b"
      decimals="-3"
      id="F_7fb24fa2-226b-4b25-b02a-a27805390dd2"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2"
      decimals="-3"
      id="F_1ab31b0a-2b4f-440a-8092-4775713c3fa0"
      unitRef="U_USD">80793000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_26e5acfa-c936-4c78-b9dd-d807aae29c7c"
      unitRef="U_USD">80804000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="C_e3bf28ad-b304-4305-a570-1122422d798b"
      decimals="INF"
      id="F_a3c12b2f-66cc-4496-b6c1-a40599c3045a"
      unitRef="U_shares">433403</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2"
      decimals="-3"
      id="F_07b4137c-fa48-415a-a50c-5823fd11d3c2"
      unitRef="U_USD">3519000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_8f870157-85dc-411e-9a54-4abc9ac8eb76"
      unitRef="U_USD">3519000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_e3bf28ad-b304-4305-a570-1122422d798b"
      decimals="INF"
      id="F_3a41ce53-d0c9-4760-9bb9-1783705f99bf"
      unitRef="U_shares">10174</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2"
      decimals="-3"
      id="F_29f211d0-f17a-4ed1-b2ca-11db5ff3b07b"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_07f92cb3-2912-4990-9b27-e16f38b14291"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_02064de1-3b8a-4e39-aa1b-178d4ee4cba2"
      decimals="-3"
      id="F_e4422a81-aafb-4129-ac3c-5073491bf0b6"
      unitRef="U_USD">13350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_04f9b722-f61f-45e3-a167-6e46b9172fe4"
      unitRef="U_USD">13350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_bca61fa2-7113-472f-975c-b0f57452da67"
      decimals="-3"
      id="F_15235345-8d3e-4efb-afb5-27fb429f1857"
      unitRef="U_USD">-400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_bc584789-a70f-447d-b419-ef4490e4f35f"
      unitRef="U_USD">-400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_71bc03af-5035-47a1-a103-ae996647c88e"
      decimals="-3"
      id="F_2f865581-46b4-41a8-bdf2-c77c6d924b5a"
      unitRef="U_USD">-109871000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_3a95c9b9-1f43-46be-b34c-9f66025e02ee"
      unitRef="U_USD">-109871000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_a87177cb-5bc3-41bf-971c-4854bb97a946"
      decimals="INF"
      id="F_aadee3d3-f65b-4a7d-86a3-b5de77de8772"
      unitRef="U_shares">52099211</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a87177cb-5bc3-41bf-971c-4854bb97a946"
      decimals="-3"
      id="F_4e845932-6b89-432d-bfc1-6dae07a9fe73"
      unitRef="U_USD">52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fae73cbe-4594-47e0-a56a-d04732d2b464"
      decimals="-3"
      id="F_31435457-c386-4dc1-aee8-94963895c712"
      unitRef="U_USD">612025000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bbc1c709-9a9f-4ee8-ae35-e6e93fd2f8f1"
      decimals="-3"
      id="F_df6c9fec-5b3b-477d-b45e-418ae2694d7b"
      unitRef="U_USD">-797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_edc3b5c0-37a2-4a67-b22d-a8f24b1a6030"
      decimals="-3"
      id="F_c2c1bb9e-226b-4cb3-bc1f-c65532a47986"
      unitRef="U_USD">-412338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_9586bffd-9503-492e-bba7-853a6e577fa2"
      unitRef="U_USD">198942000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a"
      decimals="INF"
      id="F_415bcc82-89e2-43d8-97bc-c5f01a155469"
      unitRef="U_shares">9615384</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a"
      decimals="-3"
      id="F_f5a7a68b-670a-4c00-8119-b4b8af157530"
      unitRef="U_USD">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1"
      decimals="-3"
      id="F_67d529eb-048c-4c6a-913d-662b760d7db1"
      unitRef="U_USD">117336000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_59b09fa6-6ced-466a-bec7-f38b6d819aab"
      unitRef="U_USD">117346000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a"
      decimals="INF"
      id="F_8d71914b-3e8a-4b41-9f11-df3b52e7d0ff"
      unitRef="U_shares">182628</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a"
      decimals="-3"
      id="F_f1d81b05-4600-4da6-bdce-14b11c71df1c"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1"
      decimals="-3"
      id="F_d7f0385d-dcb0-4dbd-8264-1191788603f6"
      unitRef="U_USD">777000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_f6a8ef44-87e4-4485-be07-3c3b4dd12914"
      unitRef="U_USD">777000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_184f93c0-caca-423f-93d2-bab19e3e2a1a"
      decimals="INF"
      id="F_680622f7-38b6-419e-ae4d-2a3574eaf43b"
      unitRef="U_shares">18144</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1"
      decimals="-3"
      id="F_1f720489-30b8-4cc0-896f-c05ff56f65e7"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_ebba9278-4ad1-4c9e-bffc-15aeef1340ab"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a26b7a9a-b187-43df-8a31-2ddf18c790c1"
      decimals="-3"
      id="F_52e223d5-e659-4cce-a1d6-212829694f7b"
      unitRef="U_USD">14802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_c7ebd902-04ad-4bd0-a0a6-78f94db73844"
      unitRef="U_USD">14802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ea348ed2-fdcc-4579-91c5-808f2dfce003"
      decimals="-3"
      id="F_ba745d5e-2ba4-45b2-919c-5ac2a45971ed"
      unitRef="U_USD">661000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_5190daf6-01d9-4325-9683-8f44eaeb15c5"
      unitRef="U_USD">661000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_465c59ff-4b61-4b2d-8eaa-5ac890630a2c"
      decimals="-3"
      id="F_781b28ef-e937-40f1-9088-568b902d5959"
      unitRef="U_USD">-97335000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_62d84c27-24c2-4347-9b59-450df47c377d"
      unitRef="U_USD">-97335000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_fbda6a93-4094-47c4-ac19-6cebaec8a93d"
      decimals="INF"
      id="F_25d0d1b5-ae16-4581-b4b3-5f690d4036bc"
      unitRef="U_shares">61915367</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_fbda6a93-4094-47c4-ac19-6cebaec8a93d"
      decimals="-3"
      id="F_61c838bc-753b-4917-aca6-125b77c62da2"
      unitRef="U_USD">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8919af49-dcdf-4a7e-89e1-427cdf1d9a7e"
      decimals="-3"
      id="F_9d956c4a-f79a-4c6f-9653-8e40661fe0dc"
      unitRef="U_USD">744940000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_45f470b7-37af-4351-8f8c-c8ecfdfc36bf"
      decimals="-3"
      id="F_b0beb74a-ca7e-49b3-aff4-058bc3a5e049"
      unitRef="U_USD">-136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aa92b40b-ab4d-458f-9b44-218ef3a76113"
      decimals="-3"
      id="F_d2c8d7ee-9cd1-42c4-ab98-3672f2a6e080"
      unitRef="U_USD">-509673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_e09e67a7-d01b-449e-89a5-6b1b5c268938"
      unitRef="U_USD">235193000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_1684dfb9-077f-4778-aafe-e48c696111c0"
      unitRef="U_USD">-97335000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_9ebd2d47-c576-481e-929e-6a2a0298a098"
      unitRef="U_USD">-109872000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_c34c300f-3738-4026-8608-75876dfc8b34"
      unitRef="U_USD">2172000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_ffbf6e18-d516-4cdb-9365-d86b1b3dd51e"
      unitRef="U_USD">2414000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_cac9a478-84bc-4e0f-9d1c-c597486f3c9a"
      unitRef="U_USD">14802000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_0f75e940-5dc6-44b5-b6cc-3fe1bcaa529b"
      unitRef="U_USD">13350000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_e0158e48-0ee4-4710-8743-f8b8b597a9ed"
      unitRef="U_USD">5991000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_1cf1aa88-b2b8-47d6-af04-7e36ffe6632d"
      unitRef="U_USD">-152000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_c2f8d36e-d20a-4675-b0de-e35b791ca68f"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_2f782b3e-a215-4814-9ca7-ed1052b0b36c"
      unitRef="U_USD">-2500000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_d3d0f75a-7eb2-4517-adf3-948ecc0033d4"
      unitRef="U_USD">308000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_2914351b-962b-4335-ab8a-5f92e2e5caac"
      unitRef="U_USD">-908000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_62f18481-08ab-4b2e-a0b2-e11a38a4da0c"
      unitRef="U_USD">1072000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_69fabd89-2887-466e-9457-97c5deaa383c"
      unitRef="U_USD">170000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <fulc:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_b175f863-9ad4-43c3-828b-05e20e742eb2"
      unitRef="U_USD">715000</fulc:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities>
    <fulc:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_ef42bca5-421f-4c16-b6df-b0df33861649"
      unitRef="U_USD">372000</fulc:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_1de0ead9-c097-45a5-ae94-ae641b334f7f"
      unitRef="U_USD">-94000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_c87e6f1c-2b73-4d5d-b9c1-e3eb2ff37e29"
      unitRef="U_USD">1562000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_c27cd942-668a-464a-85e2-67bcd2dd95c4"
      unitRef="U_USD">-853000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_0b97d928-2eee-4e76-b988-9ea1a3ae0dfb"
      unitRef="U_USD">-1176000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_e88e61d0-4e47-4b3c-88fb-1ebbda0ac553"
      unitRef="U_USD">-825000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_2ec3943b-2b04-4a8f-b058-0d91840935f2"
      unitRef="U_USD">555000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_7c57b7cf-4461-4fc1-9186-5d260ef490cf"
      unitRef="U_USD">-934000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_f7ee3c5d-7b0d-4eb6-9227-3530ad0ef00e"
      unitRef="U_USD">-3777000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_9729c94b-5a71-4ca4-b259-5f3aa4ea6853"
      unitRef="U_USD">-90965000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_45dfc76c-24fe-47b9-8191-ef31a3214fb5"
      unitRef="U_USD">-97050000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_34f0d9d3-e47b-4ac5-b656-d28bb9ca55e8"
      unitRef="U_USD">194892000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_eadef223-8c64-4d82-a8f4-9e0ffa683ba8"
      unitRef="U_USD">151153000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <fulc:ProceedsFromMaturityOfMarketableSecurities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_0679ac34-00a7-4a54-82da-2839b6f7a82c"
      unitRef="U_USD">158708000</fulc:ProceedsFromMaturityOfMarketableSecurities>
    <fulc:ProceedsFromMaturityOfMarketableSecurities
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_730a6405-d024-4e68-a112-7025505b5ef5"
      unitRef="U_USD">165529000</fulc:ProceedsFromMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_2b37ada8-d152-45e3-a025-1c6738c495b1"
      unitRef="U_USD">508000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_fde9db4a-8f78-4ea4-8d6d-ab597a2d63db"
      unitRef="U_USD">1963000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_31e4a361-7d2e-477f-beca-df7c8cfcfe16"
      unitRef="U_USD">-36692000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_1a340afe-8ceb-4db7-a1d4-6293a32f5a92"
      unitRef="U_USD">12413000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <fulc:ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_04d86b98-c472-4b49-b1e0-1d4eb5793011"
      unitRef="U_USD">117345000</fulc:ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering>
    <fulc:ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_04038a93-8cac-421c-9a6c-4ba63bbcf7a5"
      unitRef="U_USD">80804000</fulc:ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_46f52518-b2c4-4ea2-b549-8fa8263ea771"
      unitRef="U_USD">777000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_1b20ec3e-77b4-471a-bdae-5b0941f548e9"
      unitRef="U_USD">3519000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_f0732bd3-42d0-4262-b4a7-5d955ae35727"
      unitRef="U_USD">118122000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_efb66392-3dc7-4748-b6cb-f3219c61a824"
      unitRef="U_USD">84323000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_5173a367-482b-48f7-900e-406b8d1cf61a"
      unitRef="U_USD">-9535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_845f2e06-0a21-433e-ab1a-2c864372dd14"
      unitRef="U_USD">-314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_609e0bed-bb46-4e7f-b5bb-51ec3dbca19d"
      unitRef="U_USD">36190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_57f214bc-60d6-4c5d-b206-28aa46d3644a"
      decimals="-3"
      id="F_f7d01b95-d9b9-4f71-9f32-fdbabb637b09"
      unitRef="U_USD">36504000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_cc464f91-ebc3-46a9-9d15-5bf46b2d4900"
      unitRef="U_USD">26655000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_af236a14-fc15-4318-ae09-efc32ea7aff8"
      unitRef="U_USD">36190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <fulc:CashPaidForOperatingLeaseLiabilities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_7aa651ae-a3e7-4c6d-aee0-d6824c93a194"
      unitRef="U_USD">3333000</fulc:CashPaidForOperatingLeaseLiabilities>
    <fulc:CashPaidForOperatingLeaseLiabilities
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_c03f6bc8-28f6-4b31-be70-3ed042ade783"
      unitRef="U_USD">2219000</fulc:CashPaidForOperatingLeaseLiabilities>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_3f93096e-3da2-428b-a403-f692416e67a6"
      unitRef="U_USD">26000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_605d4372-e65a-426d-9ee8-125d28caafa9"
      unitRef="U_USD">25563000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_2efd1c25-5cd4-4a68-a326-bf52f8c50763"
      unitRef="U_USD">35098000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_8c308d85-78c0-412f-8d6b-413a00236198"
      unitRef="U_USD">1092000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_09a347d5-54d3-461c-9d54-8eb625631261"
      unitRef="U_USD">1092000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a0c67889-d17d-4bd4-aea5-7dd0580ad338"
      unitRef="U_USD">26655000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_bc919db5-4fcd-4592-b348-1cb02388989f"
      unitRef="U_USD">36190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_f2caf29d-9de8-4dd2-90b7-423ebd0f89f6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Nature of the Business and Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fulcrum Therapeutics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Fulcrum&#x201d;) was incorporated in Delaware on August 18, 2015. The Company is focused on developing small molecules to improve the lives of patients with genetically-defined rare diseases in areas of high unmet medical need.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sales of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2022, the Company completed a public offering of its common stock and issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,029,410&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2023, the Company completed a public offering of its common stock and issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,615,384&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the sale of shares of its capital stock and from upfront payments received from the collaboration and license agreements with Acceleron Pharma Inc. (&#x201c;Acceleron&#x201d;), a wholly-owned subsidiary of Merck &amp;amp; Co., Inc., (&#x201c;Merck&#x201d;) and MyoKardia, Inc. (&#x201c;MyoKardia&#x201d;), a wholly-owned subsidiary of Bristol Myers Squibb Company. As of December 31, 2023, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;509.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to expand its research and development efforts. The Company expects to finance its future cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these financial statements. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. As a result, the Company could deplete its capital resources sooner than it currently expects. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate development or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c9395349-8914-4a65-9d57-bc8e29bb62e9"
      decimals="INF"
      id="F_edd9cda2-f069-4b58-ac2a-f186e564c289"
      unitRef="U_shares">11029410</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cf990f8e-d292-4776-92bd-5fa5305cf788"
      decimals="2"
      id="F_71391dca-4767-48cb-8ef6-eaaee611f1af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.82</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_c9395349-8914-4a65-9d57-bc8e29bb62e9"
      decimals="-5"
      id="F_fb6d3d2d-1ed1-40e5-a4c8-528dbdb22c89"
      unitRef="U_USD">80800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1b2a8270-a42f-4a33-8218-0bc08d831c80"
      decimals="INF"
      id="F_ca54a7aa-c16f-4c49-92e6-6453ee4aa232"
      unitRef="U_shares">9615384</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_3ce307f7-639d-48f2-8416-d63934e3040e"
      decimals="2"
      id="F_914d376f-537c-47b8-80fc-5ed254758ba3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_1b2a8270-a42f-4a33-8218-0bc08d831c80"
      decimals="-5"
      id="F_5ae57e45-46ca-4583-8bcb-d2c2497959e1"
      unitRef="U_USD">117300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-5"
      id="F_59c70a7d-2ce6-4801-b7a6-ee8eeb3f6927"
      unitRef="U_USD">-509700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_3d7e110b-5607-4529-b4a4-bb24d39478ed">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Fulcrum Therapeutics Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;date of the financial statements, and the reported amount of expenses during the reported periods. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ from those estimates or assumptions.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. Cash equivalents include investments in money market funds that invest in U.S. Treasury obligations, and commercial paper. The Company maintains its bank accounts at major financial institutions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash represents cash held to secure a letter of credit associated with the Company&#x2019;s facility lease for its corporate headquarters.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects the Company&#x2019;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#x2019;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: Unobservable inputs based on the Company&#x2019;s assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents and marketable securities are carried at fair value and are classified according to the fair value hierarchy described above (Note 3). The cash equivalents and marketable securities are initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, to determine fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies securities with a remaining maturity when purchased of greater than three months as marketable securities. As of December 31, 2023, the Company&#x2019;s marketable securities consisted of investments in U.S. Treasury securities, government agency securities, corporate bonds, and commercial paper. Marketable securities are classified as current assets on the consolidated balance sheets if the marketable securities are available to be converted into cash to fund current operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable securities classified as available-for-sale are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, which is a component of stockholders&#x2019; equity, until such gains and losses are realized. Any premium arising at purchase is amortized to interest expense (a component of other income, net) over the period of the earliest call date, and any discount arising at purchase is accreted to interest income (a component of other income, net) over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income, net.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#x201c;other-than-temporary&#x201d; and, if so, marks the investment to market through a charge to the Company&#x2019;s statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost, net of accumulated depreciation. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:34.84%;"&gt;&lt;/td&gt;
          &lt;td style="width:65.16%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful Life (in years)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment. The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use or disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record any impairment losses on long-lived assets during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2022, the Company adopted ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2016-02&#x201d;). For contracts entered into on or after the effective date, at the inception of a contract, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than twelve months are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. The Company does not recognize leases with terms of twelve months or less on the balance sheet. Options to renew a lease are not included in the Company&#x2019;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset or (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For all operating leases, a lease liability and corresponding right-of-use asset are recognized. The lease liability represents the present value of the lease payments over the expected remaining lease term, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#x2019;s incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate the Company&#x2019;s incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating and yield curve analysis, since the Company does not have a rating agency-based credit rating. The right-of-use asset represents the right to use the leased asset for the lease term. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred if any, less any lease incentives received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease payments included in the measurement of the lease liability comprise (i) the fixed noncancelable lease payments, (ii) payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and (iii) payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease expense for operating leases consists of the lease payments plus any initial direct costs, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. The Company accounts for lease and non-lease components together as a single lease component.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;1) Identify the contract with the customer&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#x2019;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2) Identify the promises and performance obligations in the contract&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other readily available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are capable of being distinct and distinct in the context of the contract. In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;3) Determine the transaction price&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Changes to the constraint of variable consideration can have a material effect on the amount of revenue recognized in the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If an arrangement includes research and development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are based on the occurrence of events not within the Company&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until the underlying events occur or the associated approvals are received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company assesses its revenue generating arrangements in order to determine whether a significant financing component exists.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;4) Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis, except for any variable consideration that meets the criteria to be allocated entirely to a single performance obligation or to a distinct service that forms part of a single performance obligation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;5) Recognize revenue when or as the Company satisfies a performance obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may satisfy performance obligations over time or at a point in time, depending on the nature of the performance obligation. Revenue is recognized over time if the customer simultaneously receives and consumes the benefits provided by the entity&#x2019;s performance, the entity&#x2019;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or the entity&#x2019;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For revenue that the Company recognizes over time, the Company assesses whether an input or an output method is the appropriate measure of progress associated with the satisfaction of the performance obligation. In determining the appropriate method for measuring progress, the Company considers the nature of the good or service that it has promised to transfer to the customer. Output methods recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract. Input methods recognize revenue on the basis of the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation. Estimates inherent to the measurement of progress associated with the satisfaction of performance obligations based on an input method include the total estimated costs to satisfy the associated performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 10, &#x201c;Collaboration and License Agreements&#x201d;, for further information on the application of ASC 606 to the collaboration and license agreement with Acceleron (the &#x201c;Acceleron Collaboration Agreement&#x201d;) and the collaboration and license agreement with MyoKardia (the &#x201c;MyoKardia Collaboration Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and development expenses include costs directly attributable to the conduct of research and development programs, including personnel-related expenses such as salaries, payroll taxes, benefits, and stock-based compensation expense, manufacturing and external costs related to outside vendors engaged to conduct both preclinical studies and clinical&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;trials, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;laboratory supplies, depreciation on and maintenance of research equipment, and the allocable portions of facility costs, such as rent, utilities, repairs and maintenance, depreciation, and general support services. Expenditures relating to research and development are expensed in the period incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research Contract Costs and Accruals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with research institutions and other companies. The Company records accruals for estimated ongoing research costs that have not yet been invoiced&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials or the extent of services provided during the reporting periods, including invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at each reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent-Related Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures stock-based awards based on the fair value on the date of grant. Compensation expense associated with those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each restricted stock award is based on the fair value of the Company&#x2019;s common stock on the grant date, less any applicable purchase price. The fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The historical volatility is calculated based on a period of time commensurate with the assumption used for the expected term. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its stock-based awards. The expected dividend yield is assumed to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as the Company has never paid dividends and has no current plans to pay any dividends on common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient&#x2019;s payroll or service costs are classified.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restructuring Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records costs and liabilities associated with exit and disposal activities in accordance with Accounting Standards Codification 420, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. For the years ended December 31, 2023 and 2022, comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;consists of net loss and unrealized losses on investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock and unvested restricted stock awards are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company&#x2019;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities, U.S. Treasury securities, and commercial paper. The Company&#x2019;s marketable securities consist of U.S. Treasury securities, corporate bonds, and commercial paper, and potentially subject the Company to concentrations of credit risk.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s interim chief executive officer, view the Company&#x2019;s operations and manage its business as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1a68b880-8a0c-4fb5-9af0-f610de17e8b2;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is an emerging growth company (&#x201c;EGC&#x201d;), as defined in the Jumpstart Our Business Startups Act (the &#x201c;JOBS Act&#x201d;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates for ASUs. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its initial public offering or such earlier time that it is no longer an EGC.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&#x2014;Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_cd4972b6-4d23-4106-9d4d-00d9f978b642">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Fulcrum Therapeutics Securities Corp., which is a Massachusetts subsidiary created to buy, sell, and hold securities. All intercompany transactions and balances have been eliminated.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_459da1f4-1172-4ca1-9b63-a2f36acf640d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;date of the financial statements, and the reported amount of expenses during the reported periods. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ from those estimates or assumptions.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_eeb71113-3d39-477f-a066-10fbe2c5d2b0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. Cash equivalents include investments in money market funds that invest in U.S. Treasury obligations, and commercial paper. The Company maintains its bank accounts at major financial institutions.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_e512b5e7-9f15-49cb-81fe-865a076f0e43">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash represents cash held to secure a letter of credit associated with the Company&#x2019;s facility lease for its corporate headquarters.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_78f11fa5-ec62-401b-a90e-6a309c359ee9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects the Company&#x2019;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#x2019;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: Unobservable inputs based on the Company&#x2019;s assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents and marketable securities are carried at fair value and are classified according to the fair value hierarchy described above (Note 3). The cash equivalents and marketable securities are initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, to determine fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_0d70a3f5-26b7-45ab-8a93-5d5a062b3b68">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies securities with a remaining maturity when purchased of greater than three months as marketable securities. As of December 31, 2023, the Company&#x2019;s marketable securities consisted of investments in U.S. Treasury securities, government agency securities, corporate bonds, and commercial paper. Marketable securities are classified as current assets on the consolidated balance sheets if the marketable securities are available to be converted into cash to fund current operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable securities classified as available-for-sale are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, which is a component of stockholders&#x2019; equity, until such gains and losses are realized. Any premium arising at purchase is amortized to interest expense (a component of other income, net) over the period of the earliest call date, and any discount arising at purchase is accreted to interest income (a component of other income, net) over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income, net.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#x201c;other-than-temporary&#x201d; and, if so, marks the investment to market through a charge to the Company&#x2019;s statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_90182429-a4a3-4f17-ba75-1b55825f4bcb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost, net of accumulated depreciation. Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:34.84%;"&gt;&lt;/td&gt;
          &lt;td style="width:65.16%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful Life (in years)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Construction-in-progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. Depreciation expense is not recorded on construction-in-progress until the relevant assets are completed and put into use. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <fulc:EstimatedUsefulLifeOfAssetTableTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_6c3652f8-1652-4935-9f74-d181487b7929">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset as follows: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:34.84%;"&gt;&lt;/td&gt;
          &lt;td style="width:65.16%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful Life (in years)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="text-indent:12pt;vertical-align:top;"&gt;&lt;p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</fulc:EstimatedUsefulLifeOfAssetTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e"
      id="F_2b4046c4-dcb6-4e85-a7d4-fbb4612e0718">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_5c4254ea-de8b-4774-8083-9eb5cd87bb6d"
      id="F_6be48353-a9fe-458b-851f-e288d6d74361">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_375efc5e-e60e-4b9b-bf98-fb370dc4734f"
      id="F_e956b45e-430c-4502-885a-37577fb02698">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_990c5530-0921-4d0d-abca-bc365950858b"
      id="F_4ea8d928-19ed-4a97-a188-163496a10e69">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <fulc:Propertyplantandequipmentusefullives
      contextRef="C_e04dd368-3fa8-45c2-825d-2725b8979f16"
      id="F_ef1253b7-df46-4f90-81ff-89e9d9b8e1ad">Shorter of useful life or remaining lease term</fulc:Propertyplantandequipmentusefullives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_63ffe8a0-ebff-4a05-ba84-b121c4d9a9f4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment. The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use or disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record any impairment losses on long-lived assets during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_95b2e08e-b11b-47ae-b7ac-85a84ed4750f"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_1853967c-c336-407a-a4fa-035b6f05cb37"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_c5fabc73-3496-47cb-abde-f798941a08c4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2022, the Company adopted ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2016-02&#x201d;). For contracts entered into on or after the effective date, at the inception of a contract, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than twelve months are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. The Company does not recognize leases with terms of twelve months or less on the balance sheet. Options to renew a lease are not included in the Company&#x2019;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset or (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For all operating leases, a lease liability and corresponding right-of-use asset are recognized. The lease liability represents the present value of the lease payments over the expected remaining lease term, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#x2019;s incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate the Company&#x2019;s incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating and yield curve analysis, since the Company does not have a rating agency-based credit rating. The right-of-use asset represents the right to use the leased asset for the lease term. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred if any, less any lease incentives received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease payments included in the measurement of the lease liability comprise (i) the fixed noncancelable lease payments, (ii) payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and (iii) payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease expense for operating leases consists of the lease payments plus any initial direct costs, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. The Company accounts for lease and non-lease components together as a single lease component.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_03b2f503-6e0d-48fb-a3c5-e5a49155a1af">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;1) Identify the contract with the customer&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#x2019;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2) Identify the promises and performance obligations in the contract&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other readily available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are capable of being distinct and distinct in the context of the contract. In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;3) Determine the transaction price&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Changes to the constraint of variable consideration can have a material effect on the amount of revenue recognized in the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If an arrangement includes research and development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are based on the occurrence of events not within the Company&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until the underlying events occur or the associated approvals are received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company assesses its revenue generating arrangements in order to determine whether a significant financing component exists.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;4) Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis, except for any variable consideration that meets the criteria to be allocated entirely to a single performance obligation or to a distinct service that forms part of a single performance obligation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;5) Recognize revenue when or as the Company satisfies a performance obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may satisfy performance obligations over time or at a point in time, depending on the nature of the performance obligation. Revenue is recognized over time if the customer simultaneously receives and consumes the benefits provided by the entity&#x2019;s performance, the entity&#x2019;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or the entity&#x2019;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For revenue that the Company recognizes over time, the Company assesses whether an input or an output method is the appropriate measure of progress associated with the satisfaction of the performance obligation. In determining the appropriate method for measuring progress, the Company considers the nature of the good or service that it has promised to transfer to the customer. Output methods recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract. Input methods recognize revenue on the basis of the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation. Estimates inherent to the measurement of progress associated with the satisfaction of performance obligations based on an input method include the total estimated costs to satisfy the associated performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;See Note 10, &#x201c;Collaboration and License Agreements&#x201d;, for further information on the application of ASC 606 to the collaboration and license agreement with Acceleron (the &#x201c;Acceleron Collaboration Agreement&#x201d;) and the collaboration and license agreement with MyoKardia (the &#x201c;MyoKardia Collaboration Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_48c821f8-9605-4655-9c82-8314d9bdcc4d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and development expenses include costs directly attributable to the conduct of research and development programs, including personnel-related expenses such as salaries, payroll taxes, benefits, and stock-based compensation expense, manufacturing and external costs related to outside vendors engaged to conduct both preclinical studies and clinical&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;trials, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;laboratory supplies, depreciation on and maintenance of research equipment, and the allocable portions of facility costs, such as rent, utilities, repairs and maintenance, depreciation, and general support services. Expenditures relating to research and development are expensed in the period incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <fulc:ResearchContractCostsAndAccrualsPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_a31469b1-1b02-4526-a444-332bed0536ce">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research Contract Costs and Accruals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with research institutions and other companies. The Company records accruals for estimated ongoing research costs that have not yet been invoiced&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials or the extent of services provided during the reporting periods, including invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at each reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;</fulc:ResearchContractCostsAndAccrualsPolicyTextBlock>
    <fulc:PatentCostPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_e55053dd-2269-4bfd-b7c8-1bc086d6d951">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent-Related Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;</fulc:PatentCostPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_65eb842b-3ec4-4fca-83ee-01a33c6e3368">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures stock-based awards based on the fair value on the date of grant. Compensation expense associated with those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each restricted stock award is based on the fair value of the Company&#x2019;s common stock on the grant date, less any applicable purchase price. The fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The historical volatility is calculated based on a period of time commensurate with the assumption used for the expected term. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its stock-based awards. The expected dividend yield is assumed to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as the Company has never paid dividends and has no current plans to pay any dividends on common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient&#x2019;s payroll or service costs are classified.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="0"
      id="F_3209ba7c-608d-4ba2-9f24-16096ffc9596"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_97a9f808-9e01-41d8-b7b3-52aaf6fd6628">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_52dbf44e-92de-4a6a-81fa-bd9e81656f44">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restructuring Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records costs and liabilities associated with exit and disposal activities in accordance with Accounting Standards Codification 420, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_4369700a-7e92-406b-ba93-7a1ccc771abb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. For the years ended December 31, 2023 and 2022, comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;consists of net loss and unrealized losses on investments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_73ad1174-5a17-41df-9f41-4a34c783cfa4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding options to purchase common stock and unvested restricted stock awards are considered potential dilutive common shares. The Company has generated a net loss in all periods presented, and therefore the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <fulc:OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_b43e7914-9fae-45ca-ba05-c65bf27f623a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company&#x2019;s cash, cash equivalents, and restricted cash are deposited in accounts at large financial institutions. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, cash equivalents and restricted cash are held. The Company maintains its cash equivalents in money market funds that invest in U.S. Treasury securities, U.S. Treasury securities, and commercial paper. The Company&#x2019;s marketable securities consist of U.S. Treasury securities, corporate bonds, and commercial paper, and potentially subject the Company to concentrations of credit risk.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds.&lt;/span&gt;&lt;/p&gt;</fulc:OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_e7cde6e7-88a7-4d95-a343-ab47ce8e0cc6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s interim chief executive officer, view the Company&#x2019;s operations and manage its business as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1a68b880-8a0c-4fb5-9af0-f610de17e8b2;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <fulc:EmergingGrowthCompanyPolicyPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_12ab5095-d304-4c92-894a-ae3745bdf5d9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is an emerging growth company (&#x201c;EGC&#x201d;), as defined in the Jumpstart Our Business Startups Act (the &#x201c;JOBS Act&#x201d;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates for ASUs. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its initial public offering or such earlier time that it is no longer an EGC.&lt;/span&gt;</fulc:EmergingGrowthCompanyPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_fee7dc74-39f0-47d5-85c2-8494e1ff8c01">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&#x2014;Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this guidance effective January 1, 2023. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_0e1e106e-2186-4393-abc7-159e26f33c11">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the fair value hierarchy classification of such fair values as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;177,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; transfers between fair value levels during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_10321103-d038-4ee3-aaec-9693e0e94bb5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the fair value hierarchy classification of such fair values as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;177,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_bc43a13b-90f8-4ef8-89c3-5e47e6633f21"
      decimals="-3"
      id="F_fb17082c-87c6-4d96-b66b-d13f2646ed5e"
      unitRef="U_USD">25563000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1f634eef-7981-4392-81a6-c6c15de65892"
      decimals="-3"
      id="F_b03733c7-3335-401a-8a9d-60db062d70f1"
      unitRef="U_USD">25563000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_51307bed-9fb2-4853-8cce-0c34673cf5f7"
      decimals="-3"
      id="F_ec37346f-8bcc-419a-b104-bea288c6842c"
      unitRef="U_USD">14215000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d6c403c7-c450-4827-9fce-058e2ee7e5b5"
      decimals="-3"
      id="F_593e8cdb-2d3b-443d-a84f-5f34dafc0837"
      unitRef="U_USD">14215000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3e7c4269-98eb-4914-9616-c8e3cd7260bd"
      decimals="-3"
      id="F_beff8da9-a2ec-4cdb-b1c5-75bf884eb21f"
      unitRef="U_USD">65107000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_16f0f75c-5dfd-4809-a32b-10469163a156"
      decimals="-3"
      id="F_be7e279e-8528-44a3-ba92-88b3986234dd"
      unitRef="U_USD">65107000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5854b7db-5036-4f5d-b484-aa8238657b18"
      decimals="-3"
      id="F_d6c9c506-c571-4c41-9725-35668873af0b"
      unitRef="U_USD">17889000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7354e229-40c7-40da-a524-c89e5cf4d63b"
      decimals="-3"
      id="F_caf5fef9-c7b8-4abf-9f32-3d8a10925d33"
      unitRef="U_USD">17889000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d3376273-a29c-48cf-8511-32060db0b560"
      decimals="-3"
      id="F_be8f8638-2718-4c9c-9e51-bb20b5581a3b"
      unitRef="U_USD">113447000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_78fb4e2e-0240-4074-b54f-749132177dc0"
      decimals="-3"
      id="F_4e5d3521-7416-4c7e-9309-ae6127a4cec5"
      unitRef="U_USD">113447000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_542d5873-acb9-4a0a-8e2d-dac0c67b8056"
      decimals="-3"
      id="F_5074a177-8663-42bd-ab69-01f54a0a8829"
      unitRef="U_USD">236221000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87e20816-2f34-485e-b3e4-7088d4e8e968"
      decimals="-3"
      id="F_bfb2af73-852b-40ab-aa16-4fb2854b33ed"
      unitRef="U_USD">25563000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fa1479d0-71e2-465d-899e-3a286e2d39c4"
      decimals="-3"
      id="F_ea4fe32c-ca59-4e64-9829-e5874ca9166c"
      unitRef="U_USD">210658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5186a5a2-f3b1-4be3-90f3-23ff2a2bd44a"
      decimals="-3"
      id="F_e118d0c2-bdd8-4444-a306-0f83af997b18"
      unitRef="U_USD">25174000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cca8e9eb-dd24-4750-983a-2de55f115638"
      decimals="-3"
      id="F_fce42646-1573-46e7-b75e-aeb5a38c429e"
      unitRef="U_USD">25174000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_62175780-5393-425b-aa05-cee4f721a128"
      decimals="-3"
      id="F_c2a4cf71-8a2e-4824-b6e6-53cf6a4d1697"
      unitRef="U_USD">9924000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8a1f01be-46f9-44b7-9528-8152dca6e10e"
      decimals="-3"
      id="F_89ee2c43-0acc-4824-af90-9eed5deebc11"
      unitRef="U_USD">9924000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_da574656-31f4-41eb-8cfa-bc58b33e0fa1"
      decimals="-3"
      id="F_0988a8a5-d927-46cb-a908-c5fe437547ac"
      unitRef="U_USD">10231000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_944dfc71-acfe-4731-851c-eec85eb1064c"
      decimals="-3"
      id="F_119f77fc-144d-40ab-8e6e-f43ccdacac0b"
      unitRef="U_USD">10231000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c3e57f9c-5c4a-427a-ae13-ff85b90fbe11"
      decimals="-3"
      id="F_bd040bf8-b74a-439a-866a-d601f1b2ad50"
      unitRef="U_USD">12444000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ddb6c423-a9fc-4d5d-b7bc-80dc1e5b3113"
      decimals="-3"
      id="F_7966bd63-93f9-4dfd-909e-0ca937a45544"
      unitRef="U_USD">12444000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_62175780-5393-425b-aa05-cee4f721a128"
      decimals="-3"
      id="F_44ccdce4-ded3-4ad2-993a-e5cf170847d9"
      unitRef="U_USD">48476000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8a1f01be-46f9-44b7-9528-8152dca6e10e"
      decimals="-3"
      id="F_30c59fbc-a62b-463f-82dd-b114858415b8"
      unitRef="U_USD">48476000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c4f28692-ee59-4c99-998d-16b6c76ed96d"
      decimals="-3"
      id="F_af79de19-084d-40cd-ab69-f270d4af6306"
      unitRef="U_USD">96672000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2b05eccd-bd38-4e74-aadd-9cd13b5c1a5f"
      decimals="-3"
      id="F_8081aa36-1570-4340-b71f-d209233ae64e"
      unitRef="U_USD">96672000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_85e16b30-1163-467d-8e7c-c5891589de08"
      decimals="-3"
      id="F_b98ff466-d53f-443a-8358-b677dd882a31"
      unitRef="U_USD">202921000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_43ee8347-1c34-42ba-9abd-dcdc1b5cbd11"
      decimals="-3"
      id="F_440fccbe-fac8-4d57-8ac1-3ffb3560d85b"
      unitRef="U_USD">25174000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_37fbfbef-7505-46ab-bce6-acf025a24bb3"
      decimals="-3"
      id="F_5e84cfd8-6f92-4c0a-823c-7092a2fb9b8f"
      unitRef="U_USD">177747000</us-gaap:AssetsFairValueDisclosure>
    <fulc:FairValueTransfersBetweenLevels
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a50d38b6-93c1-4371-8c4f-f4bda3ae5719"
      unitRef="U_USD">0</fulc:FairValueTransfersBetweenLevels>
    <fulc:FairValueTransfersBetweenLevels
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_deaf1f96-3560-438c-b287-4cfb511ff826"
      unitRef="U_USD">0</fulc:FairValueTransfersBetweenLevels>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_b44b7277-9f86-49ae-b866-cd3fe4834124">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents and marketable securities consisted of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; sales of marketable securities during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the held 46 debt securities that were in an unrealized loss position for less than 12 months with an aggregate fair value of  $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company held 18 debt securities that were in an unrealized loss position for greater than 12 months with an aggregate fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the aggregate fair value of marketable securities with a remaining contractual maturity of greater than one year was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has the intent and ability to hold its debt securities until recovery. As a result, the Company did not record any charges for credit-related impairments for its marketable securities for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_508873a5-f24a-4bde-ba94-3c8669676c34">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents and marketable securities consisted of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <fulc:CashAndCashEquivalentsAmortizedCost
      contextRef="C_a2846897-76a3-4206-9f4d-846065573bee"
      decimals="-3"
      id="F_66d415a4-ac2e-45b6-85fd-fa0957d323d9"
      unitRef="U_USD">25563000</fulc:CashAndCashEquivalentsAmortizedCost>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax
      contextRef="C_a2846897-76a3-4206-9f4d-846065573bee"
      decimals="-3"
      id="F_c471c1c8-8301-40c7-b753-017a4b4bda02"
      unitRef="U_USD">0</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax
      contextRef="C_a2846897-76a3-4206-9f4d-846065573bee"
      decimals="-3"
      id="F_4eb1d12c-1763-4cc3-bbb4-891f54337f10"
      unitRef="U_USD">0</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a2846897-76a3-4206-9f4d-846065573bee"
      decimals="-3"
      id="F_dbade28f-3f49-4d85-a119-c170ee03e41d"
      unitRef="U_USD">25563000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <fulc:CashAndCashEquivalentsAmortizedCost
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_5515494b-e8de-4306-8b06-c99dcedec12b"
      unitRef="U_USD">25563000</fulc:CashAndCashEquivalentsAmortizedCost>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_184fcd76-3232-4562-bb67-309f0a077f01"
      unitRef="U_USD">0</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_4d21fea8-a942-4993-9af6-f9daa3ab696e"
      unitRef="U_USD">0</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_03c56b8a-df1c-4183-8518-f3ab35bbce71"
      unitRef="U_USD">25563000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d"
      decimals="-3"
      id="F_576cef89-8d5b-4961-ba03-9a7226c48a43"
      unitRef="U_USD">14229000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d"
      decimals="-3"
      id="F_6948d46c-1ef5-4596-ac73-471832a89369"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d"
      decimals="-3"
      id="F_a0731310-6e81-4993-aec2-2e8a0133c24b"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4043d4c3-2cc1-47d6-b554-63f3cfc4f19d"
      decimals="-3"
      id="F_6a53a1c5-ee49-47ca-8899-b7124d01fa7f"
      unitRef="U_USD">14215000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f1a6601c-64be-4399-85ae-db7867216139"
      decimals="-3"
      id="F_fbcacd44-ac6a-40bb-8694-89052c163b6f"
      unitRef="U_USD">65182000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f1a6601c-64be-4399-85ae-db7867216139"
      decimals="-3"
      id="F_8c70653f-6518-42b3-bbb7-2469c30cc4ef"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f1a6601c-64be-4399-85ae-db7867216139"
      decimals="-3"
      id="F_3e0207fd-5b0e-4b95-8f67-8c4812de2f87"
      unitRef="U_USD">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f1a6601c-64be-4399-85ae-db7867216139"
      decimals="-3"
      id="F_d5e19ece-8db7-4709-a15a-ff2534d84ca3"
      unitRef="U_USD">65107000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_874dc0df-15d5-4f39-8253-51d6179f2225"
      decimals="-3"
      id="F_18120e83-6b98-4ce2-bb80-777712eea1bb"
      unitRef="U_USD">17891000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_874dc0df-15d5-4f39-8253-51d6179f2225"
      decimals="-3"
      id="F_a7d60395-606e-406e-b24b-0b7e1da34315"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_874dc0df-15d5-4f39-8253-51d6179f2225"
      decimals="-3"
      id="F_115df96d-77ce-4226-b713-4903c8608832"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_874dc0df-15d5-4f39-8253-51d6179f2225"
      decimals="-3"
      id="F_becbf605-83b3-440d-a97e-1166a67fd7cf"
      unitRef="U_USD">17889000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b18d8319-eea3-4201-bf6f-cdbb16015369"
      decimals="-3"
      id="F_08ad4836-00b2-40c9-95dd-1d77af2d4d8e"
      unitRef="U_USD">113492000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b18d8319-eea3-4201-bf6f-cdbb16015369"
      decimals="-3"
      id="F_7770e584-481c-4efa-8894-688f9e845e8f"
      unitRef="U_USD">90000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b18d8319-eea3-4201-bf6f-cdbb16015369"
      decimals="-3"
      id="F_f08ff81f-2a20-4a36-a020-925693bb2a9d"
      unitRef="U_USD">135000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b18d8319-eea3-4201-bf6f-cdbb16015369"
      decimals="-3"
      id="F_518bc0a3-7b14-4599-bf23-954185bbf2da"
      unitRef="U_USD">113447000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_12d7056f-dcbc-47c8-805a-f62374f6e141"
      unitRef="U_USD">210794000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_f0dffa0d-bcd1-40e8-80e2-cbbfcac98d3a"
      unitRef="U_USD">131000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_d6c6f968-2391-4dcb-b5dd-638ef58b531f"
      unitRef="U_USD">267000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_5ca738b1-aa95-4d0c-af81-af409a4c4d64"
      unitRef="U_USD">210658000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fulc:CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a386aa33-d8b5-4eea-aefb-bbaf25195732"
      unitRef="U_USD">236357000</fulc:CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis>
    <fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_5daba9f0-df3e-4dde-a434-3de2f1c4b619"
      unitRef="U_USD">131000</fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax>
    <fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_19c50895-4d4f-44bd-aa50-5c2ecc54a74c"
      unitRef="U_USD">267000</fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fulc:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_2eecdc5f-c4c2-4845-954c-5535d0fb194f"
      unitRef="U_USD">236221000</fulc:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
    <fulc:CashAndCashEquivalentsAmortizedCost
      contextRef="C_5418e51c-11bd-4ab1-86e5-58e2085729af"
      decimals="-3"
      id="F_24e0e221-3ced-4fb3-9b3f-cc8237acd674"
      unitRef="U_USD">25174000</fulc:CashAndCashEquivalentsAmortizedCost>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax
      contextRef="C_5418e51c-11bd-4ab1-86e5-58e2085729af"
      decimals="-3"
      id="F_cb656689-9e14-47c4-8b40-ef73f68e44f4"
      unitRef="U_USD">0</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax
      contextRef="C_5418e51c-11bd-4ab1-86e5-58e2085729af"
      decimals="-3"
      id="F_4ca1623c-0b83-4739-a6aa-f4e45b763019"
      unitRef="U_USD">0</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5418e51c-11bd-4ab1-86e5-58e2085729af"
      decimals="-3"
      id="F_2d1ea54e-8dfd-4a3b-91ea-f4f6f4e65257"
      unitRef="U_USD">25174000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <fulc:CashAndCashEquivalentsAmortizedCost
      contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"
      decimals="-3"
      id="F_7cbae5ec-b0c0-43e3-a0b8-2da96b3b321e"
      unitRef="U_USD">9928000</fulc:CashAndCashEquivalentsAmortizedCost>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax
      contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"
      decimals="-3"
      id="F_d874e870-6b4c-45fc-b2bd-5fdbe79bb6e0"
      unitRef="U_USD">0</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax
      contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"
      decimals="-3"
      id="F_e0b04575-abaf-4383-b58e-15864cf7426a"
      unitRef="U_USD">-4000</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"
      decimals="-3"
      id="F_1ab366e3-f00f-4aee-a201-31ea6b801f43"
      unitRef="U_USD">9924000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <fulc:CashAndCashEquivalentsAmortizedCost
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_17e5f826-63c0-49bf-93c1-59723f259f44"
      unitRef="U_USD">35102000</fulc:CashAndCashEquivalentsAmortizedCost>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_fe2728b5-5d03-4be1-ad0a-a7108543bfe3"
      unitRef="U_USD">0</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainsBeforeTax>
    <fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_92bb087b-589a-4d0e-b08d-9a660afb5b04"
      unitRef="U_USD">-4000</fulc:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_3a7b4be4-eae7-428e-b741-ea391a143dbd"
      unitRef="U_USD">35098000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f"
      decimals="-3"
      id="F_9aabdb1c-0d12-4674-9602-14dc727b5cd0"
      unitRef="U_USD">10267000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f"
      decimals="-3"
      id="F_a6ab8a06-5c77-4ed2-bade-bd164a9bc856"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f"
      decimals="-3"
      id="F_458e495d-e72a-465b-81b9-f10e6f54fa55"
      unitRef="U_USD">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c3093075-2cd8-4daa-b4d0-ffdb9e06926f"
      decimals="-3"
      id="F_afa499c4-2f6c-4d84-9cbb-809b0a768378"
      unitRef="U_USD">10231000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb"
      decimals="-3"
      id="F_7dc7595b-277d-4980-bd39-4dbffd10ba23"
      unitRef="U_USD">12493000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb"
      decimals="-3"
      id="F_1c168132-833e-49e2-a2fb-25c785885bb8"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb"
      decimals="-3"
      id="F_4a61d5be-e215-409d-9b9a-1db558bc7cbb"
      unitRef="U_USD">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_24a2ceb1-4320-444f-b2e8-c63fa4c57beb"
      decimals="-3"
      id="F_5634255c-394c-4c9e-aa5a-f82530bdfa9d"
      unitRef="U_USD">12444000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"
      decimals="-3"
      id="F_6eb00453-8c63-459c-98ce-d532a93762d8"
      unitRef="U_USD">48661000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"
      decimals="-3"
      id="F_daa8d89c-08da-4127-91ad-1a3623fd14cc"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"
      decimals="-3"
      id="F_13c0c223-98f9-4630-b3c3-238a64d47db7"
      unitRef="U_USD">185000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4681212b-55bd-4fde-9aaa-56be5bfa9b10"
      decimals="-3"
      id="F_752e58b5-2105-4444-844f-a41d959b9f76"
      unitRef="U_USD">48476000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f435b74c-2ffc-441d-adc0-12a5eda8264a"
      decimals="-3"
      id="F_900e5638-5f1b-4445-96b6-7f797c8a7066"
      unitRef="U_USD">97195000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f435b74c-2ffc-441d-adc0-12a5eda8264a"
      decimals="-3"
      id="F_713acf75-dcd4-4ba7-a2d4-f8709ea75641"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f435b74c-2ffc-441d-adc0-12a5eda8264a"
      decimals="-3"
      id="F_c532fb3f-e6af-47c5-a326-c8577f00314c"
      unitRef="U_USD">526000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f435b74c-2ffc-441d-adc0-12a5eda8264a"
      decimals="-3"
      id="F_2945ae3b-f1a6-4a70-bcf1-a25c99808e27"
      unitRef="U_USD">96672000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_cdbe9396-bfd1-469f-af06-1921b1fa207e"
      unitRef="U_USD">168616000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_ce56c8b9-2acb-42a1-a021-bd63d753f2f3"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_6bb98a21-1643-4f80-bc46-7b95353d880a"
      unitRef="U_USD">796000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_8259c56e-02aa-40cb-8707-07655404f0ab"
      unitRef="U_USD">167823000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fulc:CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_6ab19816-bfcb-4022-b5b6-5074c3890074"
      unitRef="U_USD">203718000</fulc:CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis>
    <fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_0e948fb0-d92d-4c9c-b3ea-f01ec9c6b89a"
      unitRef="U_USD">3000</fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax>
    <fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_39c870bc-3b52-4505-8bff-c9c6fe1c43bb"
      unitRef="U_USD">800000</fulc:CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fulc:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_bdfb3b59-efb2-43fb-b69e-ec69b73c55d9"
      unitRef="U_USD">202921000</fulc:CashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
    <fulc:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_809657ba-5c72-4d4d-8833-4e50dfa92daa"
      unitRef="U_USD">0</fulc:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-5"
      id="F_d627204e-3e8d-485a-b696-263b4c52ecd4"
      unitRef="U_USD">130200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <fulc:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-5"
      id="F_977fd516-8a7a-4cf8-a358-42cc946f0f95"
      unitRef="U_USD">33800000</fulc:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months>
    <fulc:AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-5"
      id="F_05f50402-1dc1-4744-9b6f-ca152fc74573"
      unitRef="U_USD">25100000</fulc:AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_d0bf5816-4f51-4022-bc09-19694ce8baec">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.693%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.363%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_f1f46239-1c14-432c-b4f1-786e2d04a032">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.693%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.363%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4fdb1768-de02-4a5e-a2df-1e5f05251c7e"
      decimals="-3"
      id="F_b199ab34-1baf-40b5-a7f7-890802f135de"
      unitRef="U_USD">9682000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e4c94a63-164c-46e2-af94-f4aa5ed3dad5"
      decimals="-3"
      id="F_be71b71c-8efc-4d0d-8531-1e605aa3c0af"
      unitRef="U_USD">9057000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5c4254ea-de8b-4774-8083-9eb5cd87bb6d"
      decimals="-3"
      id="F_01eaba7e-67bf-472a-b10e-4b386bd10e35"
      unitRef="U_USD">600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f46423a4-6cae-4566-b0b3-c4344e7e0ddc"
      decimals="-3"
      id="F_9786f354-26de-46e5-9f36-b4e5f9329a9e"
      unitRef="U_USD">786000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_375efc5e-e60e-4b9b-bf98-fb370dc4734f"
      decimals="-3"
      id="F_2f2adf6e-50e2-4bd6-9d3b-297dcc238540"
      unitRef="U_USD">393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_749e2b12-a6eb-4d72-8bf1-bab5c1af0594"
      decimals="-3"
      id="F_2fd639b0-d6c2-4445-a939-f992119fb136"
      unitRef="U_USD">393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_990c5530-0921-4d0d-abca-bc365950858b"
      decimals="-3"
      id="F_7619cdf9-541b-41f2-815f-9fa6a2e5d791"
      unitRef="U_USD">199000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_98a6da6d-074f-41ab-bfc4-6a2ea10c4c2a"
      decimals="-3"
      id="F_a8fef92e-acd9-4496-a621-fae68e44ea7c"
      unitRef="U_USD">199000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_508a96d8-65ca-4e37-92e2-530cc3c9b8b6"
      decimals="-3"
      id="F_453b657e-71c1-45d1-9eb8-4511da07b3ff"
      unitRef="U_USD">7102000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a79a27de-8391-4e03-935a-a5b39db9ffc9"
      decimals="-3"
      id="F_25f8f59e-cb6f-4329-b3dd-130af53c7a1d"
      unitRef="U_USD">7102000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_343e6c36-f77a-4689-8990-03e75af7256f"
      decimals="-3"
      id="F_03a39c9b-8393-439b-8cd4-9561db61fad1"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0663cabf-5a8c-4583-a6b8-7af5d48c1798"
      decimals="-3"
      id="F_24e461b1-9dc8-4ebf-875f-96e1e09214ce"
      unitRef="U_USD">31000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_b38ee409-5a5e-4993-a13d-13168ffded03"
      unitRef="U_USD">17976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_7ddfe214-3b7a-4bb5-84bd-382f49b4a27a"
      unitRef="U_USD">17568000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_16d494e0-301c-428c-b5d4-d3b8ffaabe45"
      unitRef="U_USD">12760000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_e6970bf2-7277-45e9-b0ae-88418002d70a"
      unitRef="U_USD">10662000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_f17ca9d1-4f59-4bf5-af09-a747457fd27b"
      unitRef="U_USD">5216000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_9f81df70-8067-4caf-b9d7-d73456fd5e2f"
      unitRef="U_USD">6906000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-5"
      id="F_27229485-6600-4ae5-8aa7-00390b705ecc"
      unitRef="U_USD">2200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-5"
      id="F_aab076bb-ed8e-4923-b893-edc04e15e338"
      unitRef="U_USD">2400000</us-gaap:Depreciation>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_bce4e763-9adc-4492-b146-08343b1af37b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Additional Balance Sheet Detail&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid sign-on bonuses subject to vesting provisions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest income receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;External research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payroll and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <fulc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_f50dcf6a-5dcf-4a8b-8111-e9559ebc17c5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid sign-on bonuses subject to vesting provisions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest income receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fulc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <fulc:PrepaidExpenses
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_e11e247a-cd94-4134-bc9e-68a83e2f6a0c"
      unitRef="U_USD">3658000</fulc:PrepaidExpenses>
    <fulc:PrepaidExpenses
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_664749e3-db8f-4f54-a457-bbcf833c1d4f"
      unitRef="U_USD">3425000</fulc:PrepaidExpenses>
    <fulc:PrepaidSignOnBonusesSubjectToVestingProvisions
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_3fef4ed3-6e2d-4e32-b3aa-0556eccde726"
      unitRef="U_USD">71000</fulc:PrepaidSignOnBonusesSubjectToVestingProvisions>
    <fulc:PrepaidSignOnBonusesSubjectToVestingProvisions
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_6418612c-4d2e-42ab-9fb5-08f7f2915f4e"
      unitRef="U_USD">92000</fulc:PrepaidSignOnBonusesSubjectToVestingProvisions>
    <us-gaap:InterestReceivable
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_b0a83954-7643-4525-98c7-b92f41941055"
      unitRef="U_USD">1712000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_fc716983-d86b-4944-b280-1ca2ee1a9736"
      unitRef="U_USD">852000</us-gaap:InterestReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_0c11df06-6db0-4721-afe3-faf9077b54cf"
      unitRef="U_USD">5441000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_5623e738-545f-4648-af59-e8eca3cb464a"
      unitRef="U_USD">4369000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <fulc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_0d71ce0a-afe5-4ac2-8b09-075966449c3b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;External research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payroll and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fulc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <fulc:AccruedResearchAndDevelopmentExpenses
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_6bc36e01-4109-46da-9c91-aa27b508648e"
      unitRef="U_USD">3164000</fulc:AccruedResearchAndDevelopmentExpenses>
    <fulc:AccruedResearchAndDevelopmentExpenses
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_d7e87b66-f3a1-44d6-9a25-b1da2f272ecb"
      unitRef="U_USD">4700000</fulc:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_d87d2602-5421-4b31-a6d3-94ed51d38c80"
      unitRef="U_USD">4712000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_9a1c8b64-e8d9-4c90-9728-dac975132d9b"
      unitRef="U_USD">4211000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a1dd3bb8-d4f9-48d6-a9a9-2dd09e7b6496"
      unitRef="U_USD">454000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_f0e0f81b-2efb-422f-95fb-7c59738534b0"
      unitRef="U_USD">535000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_7a10876e-1dab-417b-9b72-b183603f6308"
      unitRef="U_USD">396000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_74598710-d802-4b20-bb49-4dc7a715fa94"
      unitRef="U_USD">105000</us-gaap:OtherLiabilitiesCurrent>
    <fulc:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_5a33d1d4-1d00-4a9b-b16e-979b12ffb349"
      unitRef="U_USD">8726000</fulc:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <fulc:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_09d381a3-65f6-4f77-ba21-c20032946a8e"
      unitRef="U_USD">9551000</fulc:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_36b1aec6-794c-4e49-b362-5b0e7a627c03">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of undesignated preferred stock were authorized. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock were issued or outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends have been declared since inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_30664edb-b9bd-419f-a452-85ca5a50e57c"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_dec6b98c-aa19-49b6-a8a6-d4e55321ca14"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_abfebb00-bc98-4d09-a34f-53461f7aff51"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_a468b614-5bc9-48f1-95af-e62dd24d9e77"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_86535969-6674-422f-952b-8cbffddade70"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_ded0ee53-15cc-45b3-b912-59428194d3b7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <fulc:TemporaryEquityDividendsDeclared
      contextRef="C_000f7fb2-957c-4f01-b3cf-38256d89b74f"
      decimals="INF"
      id="F_2d98784f-9513-4655-b974-d83bb8330325"
      unitRef="U_USD">0</fulc:TemporaryEquityDividendsDeclared>
    <fulc:TemporaryEquityDividendsDeclared
      contextRef="C_f3a948e1-3f74-4748-b84d-2b0696114a7f"
      decimals="INF"
      id="F_7ac21e01-d2c2-4cad-adb9-30ad78d21376"
      unitRef="U_USD">0</fulc:TemporaryEquityDividendsDeclared>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_f6e52853-6727-40a1-9fda-65b76dc2cf02">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value per share, were authorized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each share of common stock entitles the holder to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vote on all matters submitted to a vote of the Company&#x2019;s stockholders&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Common stockholders are not entitled to receive dividends, unless declared by the Company&#x2019;s board of directors, subject to the preferential dividend rights of any preferred stock then outstanding. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends have been declared or paid by the Company since its inception.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, the Company has reserved for future issuance the following number of shares of common stock:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for exercises of outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,972,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,504,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for vesting of restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for future issuance under the 2019 Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,157,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,941,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for future issuance under the 2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,346,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,061,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for future issuance under the 2022 Inducement Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;837,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;329,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,388,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,913,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="0"
      id="F_1d87a370-dbcc-4ec9-b50c-3aa2596345d6"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="0"
      id="F_1e2ecca1-ffb1-4011-9ba1-eb3fe28916c9"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="3"
      id="F_9cad333d-84aa-49d1-a657-9671f8a9bfee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="3"
      id="F_c03f0bd0-c464-4408-8254-f65fcda4d0c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_af6320d3-c1bb-4876-8b01-d4bfca2d9f8f">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders</us-gaap:CommonStockVotingRights>
    <fulc:NumberOfCommonStockVotingRights
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_99b4c042-e6fd-4cc3-b0a8-ace2cbd96c13"
      unitRef="U_Vote">1</fulc:NumberOfCommonStockVotingRights>
    <us-gaap:Dividends
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="0"
      id="F_9f46b5a9-e573-4003-998c-ab929ab8061f"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_fd5cc117-757d-4f1c-ae17-e16631e53d64">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, the Company has reserved for future issuance the following number of shares of common stock:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for exercises of outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,972,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,504,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for vesting of restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for future issuance under the 2019 Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,157,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,941,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for future issuance under the 2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,346,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,061,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares reserved for future issuance under the 2022 Inducement Stock Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;837,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;329,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,388,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,913,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1553121b-ab45-495e-b5a0-c6324fbe71f5"
      decimals="0"
      id="F_c25a4a27-eb39-4af2-bbc2-0530cb26f99a"
      unitRef="U_shares">9972217</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c4c8c6c6-98f6-489e-a40d-a5ff2e15f073"
      decimals="0"
      id="F_f16c318d-af7f-4a36-8217-a7011abb5be6"
      unitRef="U_shares">6504080</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_909e565e-556f-4785-a3a2-94aa703eda4a"
      decimals="0"
      id="F_336829b8-4b40-4cea-8a99-1d975d479e5c"
      unitRef="U_shares">75017</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_ddc92748-af69-48e3-ad4c-c0752140c842"
      decimals="0"
      id="F_2ce26678-5c3c-4807-bde9-72711e03c549"
      unitRef="U_shares">76718</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ef714543-18c5-47fb-aabb-747b27cc8411"
      decimals="0"
      id="F_6a26ea78-463a-46e6-b938-702ac46f9369"
      unitRef="U_shares">3157537</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_98e7f3b2-a03a-4688-bc57-f63c93ac0609"
      decimals="0"
      id="F_26489ba9-bef1-4262-af47-8e548084ac31"
      unitRef="U_shares">1941054</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1c1be40a-0714-4b4f-8656-46ec78f32fc0"
      decimals="0"
      id="F_8867b819-7d02-475c-b29e-7f18ace55c67"
      unitRef="U_shares">1346125</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_69b9c54c-e52c-4afc-b0d8-7b44074f2ffe"
      decimals="0"
      id="F_3cbe6295-6518-4219-838b-9d1bc68b101f"
      unitRef="U_shares">1061279</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cb406b69-1f55-4cbb-aacf-ebebc94b8c0b"
      decimals="0"
      id="F_4d0cc0ae-d15c-4303-aa00-9e67facc1a8c"
      unitRef="U_shares">837877</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3d0c7846-78b1-4df1-8b8d-1b707923fa89"
      decimals="0"
      id="F_530a29bf-fc44-41d5-8579-c5464bafc541"
      unitRef="U_shares">329880</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="0"
      id="F_d1e972ba-20b1-4e57-b257-60d9a681af78"
      unitRef="U_shares">15388773</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="0"
      id="F_1edbfe61-728c-4231-a6ef-e27df6e9fee2"
      unitRef="U_shares">9913011</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_a1034a58-34bb-438c-bcd2-11f5d704b23a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2016 Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2016, the Company adopted the 2016 Stock Incentive Plan (the &#x201c;2016 Plan&#x201d;), which provided for the grant of restricted stock awards, restricted stock units, incentive stock options, non-statutory stock options, and other stock-based awards to the Company&#x2019;s eligible employees, officers, directors, consultants, and advisors. As of the effective date of the 2019 Stock Incentive Plan (the &#x201c;2019 Plan&#x201d;), and as of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares remained available for future issuance under the 2016 Plan. Any options or other awards outstanding under the 2016 Plan remain outstanding and effective.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 2, 2019, the Company&#x2019;s stockholders approved the 2019 Plan, which became effective on July 17, 2019. The 2019 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards to the Company&#x2019;s officers, employees, directors, consultants and advisors. The number of shares initially reserved for issuance under the 2019 Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,017,142&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, plus the shares of common stock remaining available for issuance under the 2016 Plan as of July 17, 2019. The number of shares reserved was annually increased on January 1, 2020 and will be increased each January 1 thereafter through January 1, 2029 by the least of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of each such year or (iii) an amount determined by the Company&#x2019;s board of directors. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;3,157,537&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for future issuance under the 2019 Plan. On January 1, 2024, the number of shares reserved for issuance under the 2019 Plan was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The shares of common stock underlying any awards that expire, terminate, or are otherwise surrendered, cancelled, forfeited or repurchased by the Company under the 2016 Plan or the 2019 Plan will be added back to the shares of common stock available for issuance under the 2019 Plan. As of July 17, 2019, no further awards will be made under the 2016 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2022 Inducement Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2022, the Company's board of directors adopted the 2022 Inducement Stock Incentive Plan (the "Inducement Plan"), pursuant to which the Company may grant&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, subject to the terms of the Inducement Plan and Nasdaq rules, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The Company initially reserved a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for the issuance of awards under the Inducement Plan. The number of shares reserved and available for issuance under the Inducement Plan can be increased at any time with the approval of the Company&#x2019;s board of directors. The Inducement Plan permits the board of directors, a delegated committee of the board of directors, or a delegated officer of the Company to grant the stock-based awards available under the Inducement Plan to attract key employees for the growth of the Company. Effective March 8, 2023, the Company&#x2019;s board of directors amended the Inducement Plan to increase the number of shares reserved for issuance by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares. Effective May 18, 2023, the Company&#x2019;s board of directors amended the Inducement Plan to increase the number of shares reserved for issuance by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,400,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;837,877&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for future issuance under the Inducement Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock options granted by the Company typically vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period and have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; contractual term. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Shares issued upon the exercise of stock options are issued from the Company&#x2019;s pool of authorized but unissued common stock. In addition to stock options granted under the 2019 Plan and 2016 Plan, the Company has granted stock options as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4), which were granted outside of the 2019 Plan and 2016 Plan. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:81.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.272%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.581000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.926%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.346%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.939%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,504,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.55&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,885,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,089,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,582,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,972,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,114,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,225,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock as of the balance sheet date for those options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average grant date fair value of stock options granted in the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.62&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. The total intrinsic value of stock options exercised in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022 has been calculated on the date of grant using the following weighted average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.788%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.555%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.663%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.389%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.607%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year&lt;br/&gt;Ended&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year&lt;br/&gt;Ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has also granted restricted stock units. The shares of common stock underlying restricted stock units typically vest over a four-year period. The shares of common stock are recorded in stockholders&#x2019; equity as they vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s restricted stock unit activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.656%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.698%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.914%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.497%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of all restricted stock units and restricted stock awards that vested during the years ended December 31, 2023 and 2022 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total compensation cost recognized in the statements of operations &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and comprehensive loss associated with all stock-based compensation awards granted by the Company is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.91&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 2, 2019, the Company&#x2019;s stockholders approved the 2019 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on July 17, 2019. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252,142&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock reserved under the ESPP was increased on January 1, 2020, and will be increased annually on each January 1 thereafter through January 1, 2029, by the least of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;428,571&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of each such year or (iii) an amount determined by the Company&#x2019;s board of directors. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,346,125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for future issuance under the ESPP. On January 1, 2024, the number of shares reserved for issuance under the 2019 ESPP was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;428,571&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_11995c32-99cc-441f-9c07-7fd5a7ad4859"
      decimals="INF"
      id="F_6fdfb2ba-e7d1-445e-949d-a77386cac4cb"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_94104f8d-cdd1-47a0-bd4b-ab3238e5307d"
      decimals="INF"
      id="F_f3927417-66d4-4f29-82b5-d356f97712a5"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4ba02dc0-884d-416e-855c-afa71a9532cf"
      decimals="INF"
      id="F_59fc1b2a-bc41-4956-9257-cf7148d2d131"
      unitRef="U_shares">2017142</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_79eda3da-f82b-42a7-9282-e10d0fdfbdf1"
      decimals="INF"
      id="F_ada5bcbd-3faa-425e-a63b-7c98037a9959"
      unitRef="U_shares">2000000</fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <fulc:IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding
      contextRef="C_79eda3da-f82b-42a7-9282-e10d0fdfbdf1"
      decimals="2"
      id="F_05f505e5-b8fb-4fe7-84ce-8f6677f02fd3"
      unitRef="U_pure">0.04</fulc:IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4fb06a81-59b1-410a-943c-d31a633e10ff"
      decimals="INF"
      id="F_7bc925d2-7e4c-4c4d-913c-ffeb1eedbdb3"
      unitRef="U_shares">3157537</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0e910a3d-1e4f-4b7c-85cc-e29372e692ec"
      decimals="INF"
      id="F_fc9f268d-fdf9-48db-823e-915df95734e1"
      unitRef="U_shares">2000000</fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b517f554-4042-404a-9af4-f3387f4737b9"
      decimals="INF"
      id="F_1ed2a4af-05ed-4ead-a450-5bf85357f24f"
      unitRef="U_shares">1750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e1084719-244f-4e97-8f34-58c058846345"
      decimals="INF"
      id="F_520d1a31-f9b5-4243-b6cd-cbe50acaf60e"
      unitRef="U_shares">2000000</fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5298f167-d10a-434d-ac4b-5d0e08769dd7"
      decimals="INF"
      id="F_e5f0ea02-d3fc-4471-9c22-29af6e4caf7e"
      unitRef="U_shares">1400000</fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_18e2c630-6ac6-421f-9bc1-23e2b22a1afb"
      decimals="INF"
      id="F_be1b1c1b-9ad0-4a43-a36f-ba415364bbbb"
      unitRef="U_shares">837877</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_6b2cb0ed-bc13-4280-b556-83c472d55900"
      id="F_52bfc8d1-b1a0-4544-a222-ec7a0742c468">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6b2cb0ed-bc13-4280-b556-83c472d55900"
      id="F_c4563870-4368-4b6b-8494-c53b99aa1883">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_9f4c877b-61ad-4b2b-8997-8ab75f929ab3">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:81.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.272%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.581000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.926%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.346%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.939%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,504,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.55&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,885,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,089,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,582,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,972,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,114,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,225,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_84b31042-326d-4a8d-bb3a-1fab245f12f7"
      decimals="INF"
      id="F_ae2088b6-c8e7-407c-99af-b69b1e68bdd0"
      unitRef="U_shares">6504080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_84b31042-326d-4a8d-bb3a-1fab245f12f7"
      decimals="2"
      id="F_2e86a276-740a-4e22-b8ab-fa256667068b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_2704081c-8b8e-46dd-97fd-b538434d0d04"
      id="F_39b59d17-bef0-4798-a0f1-f59012896033">P8Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_84b31042-326d-4a8d-bb3a-1fab245f12f7"
      decimals="0"
      id="F_c0e62dd4-f4f6-4b9f-afa7-3aa1494c2556"
      unitRef="U_USD">1885160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_830548a4-6251-494e-acc6-0972515e7069"
      decimals="INF"
      id="F_feb9d404-3739-47d6-941f-84a00e8f9fd5"
      unitRef="U_shares">6089933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_830548a4-6251-494e-acc6-0972515e7069"
      decimals="2"
      id="F_f9bf619b-32de-4594-b217-3f4d3244a455"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_830548a4-6251-494e-acc6-0972515e7069"
      decimals="INF"
      id="F_4544fa51-e065-4b75-99f0-de04838f688a"
      unitRef="U_shares">38903</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_830548a4-6251-494e-acc6-0972515e7069"
      decimals="2"
      id="F_3643a9e2-20bd-4151-8795-91ab71b85e68"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_830548a4-6251-494e-acc6-0972515e7069"
      decimals="INF"
      id="F_23c5ae36-30dd-48be-8475-d143834e1383"
      unitRef="U_shares">2582893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_830548a4-6251-494e-acc6-0972515e7069"
      decimals="2"
      id="F_03aad399-fe5d-4dc0-94e7-07383cee9a64"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af"
      decimals="INF"
      id="F_8b0df4b7-d127-46b8-a819-6e42e5b80a13"
      unitRef="U_shares">9972217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af"
      decimals="2"
      id="F_d82f0a58-4282-44ac-8d46-116515a0309a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_830548a4-6251-494e-acc6-0972515e7069"
      id="F_8dd40fba-1b02-479c-94c3-88d3b69e5371">P8Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af"
      decimals="0"
      id="F_13df0298-91aa-4621-82fe-ffd333537c31"
      unitRef="U_USD">15114074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af"
      decimals="INF"
      id="F_481a0c29-e815-4fdf-821b-8e703dc884d0"
      unitRef="U_shares">3225146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af"
      decimals="2"
      id="F_a9a8395e-bcfb-4886-9965-2b4005e591e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_830548a4-6251-494e-acc6-0972515e7069"
      id="F_6762641a-e633-4c0d-9f89-8b0c0c09cdd0">P7Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_17ffb108-fe7e-476c-83d5-3f1c63e048af"
      decimals="0"
      id="F_75ec2d17-c876-44c5-a3ec-a1d2290fbb44"
      unitRef="U_USD">407817</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_67ea3264-4f09-49a3-8fab-3cdfe1108e54"
      decimals="2"
      id="F_5d3a11c1-3a71-4171-a124-269231b7f5db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_55fd13cf-5a49-4af6-b31e-8f8a1b4bf952"
      decimals="2"
      id="F_706b2744-de33-4a22-8c17-c7d9aa8714a3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_67ea3264-4f09-49a3-8fab-3cdfe1108e54"
      decimals="-5"
      id="F_7f626d3e-9437-4ed2-b239-37fa54bcfcbc"
      unitRef="U_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_55fd13cf-5a49-4af6-b31e-8f8a1b4bf952"
      decimals="-5"
      id="F_4daab2b5-b305-4cea-bc5a-c28487dbcc09"
      unitRef="U_USD">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_4d6ebefd-b4b3-4e28-acf9-ac563ab7de6c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022 has been calculated on the date of grant using the following weighted average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.788%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.555%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.663%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.389%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.607%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year&lt;br/&gt;Ended&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year&lt;br/&gt;Ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_fb5c742b-1082-4c9f-adea-cdf8661b486d"
      decimals="3"
      id="F_0d47260b-cfc9-4a57-bad8-a03552bb5104"
      unitRef="U_pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9a3bad76-7c81-4609-ae81-f7496ee21338"
      decimals="3"
      id="F_f5a0d9b0-a71d-4916-ad79-2e015c53ca65"
      unitRef="U_pure">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_fb5c742b-1082-4c9f-adea-cdf8661b486d"
      decimals="3"
      id="F_477f22c3-2612-4015-9481-a1a6c489deb2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9a3bad76-7c81-4609-ae81-f7496ee21338"
      decimals="3"
      id="F_42a2557a-c4dc-4106-9ff2-de78c6d676e0"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fb5c742b-1082-4c9f-adea-cdf8661b486d"
      id="F_b0ba673e-00de-49f7-9e77-9a1331b7920e">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9a3bad76-7c81-4609-ae81-f7496ee21338"
      id="F_6bc83985-0940-4850-ac56-58c2fc19aacf">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_fb5c742b-1082-4c9f-adea-cdf8661b486d"
      decimals="3"
      id="F_394dff0d-593b-4ae0-b1b4-bdeb1483fdef"
      unitRef="U_pure">0.986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9a3bad76-7c81-4609-ae81-f7496ee21338"
      decimals="3"
      id="F_61be77dd-9964-4dea-8eac-2d0bc7f9f95d"
      unitRef="U_pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_96906aae-d485-4fa9-8d8d-c0baeaee0dc8"
      id="F_377a7387-32ae-4f0c-ab6f-d72f17f44113">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s restricted stock unit activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.656%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.698%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.914%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.497%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_04824925-8561-4f56-bff5-d30316c83058"
      decimals="INF"
      id="F_ec43b9b9-4ea7-40bb-b0ac-18ec01a97d54"
      unitRef="U_shares">76718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_04824925-8561-4f56-bff5-d30316c83058"
      decimals="2"
      id="F_7eab8562-501b-4791-b973-6920d252826f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5"
      decimals="INF"
      id="F_c93a4f9c-f020-4175-a8d6-c0847faa9fdf"
      unitRef="U_shares">37045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5"
      decimals="2"
      id="F_fc5134ad-5958-4248-b859-2fe69c5a2858"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5"
      decimals="INF"
      id="F_ceb4d597-61ba-4489-955f-a7f59c88a03a"
      unitRef="U_shares">18144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5"
      decimals="2"
      id="F_59dbeffa-57e2-4a71-b51c-00c8b8f1c5c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5"
      decimals="INF"
      id="F_da7aff0b-e982-4c81-93fc-cd70afce42f3"
      unitRef="U_shares">20602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_02da4ec1-b3f6-409c-b15f-30d32ea0a1f5"
      decimals="2"
      id="F_be0433a4-2a66-466e-a72b-6e81c6f0e060"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_5df36d60-952e-4b70-a43a-be90787573aa"
      decimals="INF"
      id="F_0b00f2f7-80b5-4486-920d-c621ba5e4bd6"
      unitRef="U_shares">75017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_5df36d60-952e-4b70-a43a-be90787573aa"
      decimals="2"
      id="F_0c09e4c4-fccd-451c-bbd9-4dd79dfb1143"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_96906aae-d485-4fa9-8d8d-c0baeaee0dc8"
      decimals="-5"
      id="F_365c7841-2b4e-4a20-bf94-5f6b480992de"
      unitRef="U_USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_36c5b7d8-3257-4975-88e1-ef21c0684b9e"
      decimals="-5"
      id="F_e77f4363-ba72-4196-8624-9768d5e2714c"
      unitRef="U_USD">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_9bb8d83c-0a35-40ee-84e5-652ed6c3b59a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total compensation cost recognized in the statements of operations &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and comprehensive loss associated with all stock-based compensation awards granted by the Company is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3f962abd-0c59-46b0-942a-62bedb1c8907"
      decimals="-3"
      id="F_c2aead14-8319-4b2d-b80e-05038c9c1539"
      unitRef="U_USD">11026000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f8a31241-faea-4738-8c70-9704d5b4aa96"
      decimals="-3"
      id="F_c55ec37f-6447-48f2-983b-bcc2e6c32463"
      unitRef="U_USD">9652000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_b63474af-44cc-4faf-b216-6548e22c9832"
      decimals="-3"
      id="F_8c538ff1-638e-427b-9561-43056a30568e"
      unitRef="U_USD">3776000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_40257969-ac48-44c3-9ca7-ffe11592ae76"
      decimals="-3"
      id="F_87535653-2f66-4b79-ab7c-b094036fad9c"
      unitRef="U_USD">3698000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-3"
      id="F_5c9342cc-0b9f-4924-9ef1-e4b3eb9af494"
      unitRef="U_USD">14802000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-3"
      id="F_021e3b9e-4029-4002-89d7-19b4a05c2611"
      unitRef="U_USD">13350000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-5"
      id="F_ff1ef594-87ce-4bd0-ab51-60ad81995171"
      unitRef="U_USD">30400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_0f98a150-4501-4d70-a794-677ef7714827">P2Y10M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9a8da089-33c9-42b0-ba2e-0a03c031f084"
      decimals="INF"
      id="F_4c9f7592-555e-4168-97b1-b696dba5753f"
      unitRef="U_shares">252142</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_34147407-27d4-48db-9e5a-99ff76257ddc"
      decimals="INF"
      id="F_1abed8a0-1b57-4f8d-a7e6-5414e06b30df"
      unitRef="U_shares">428571</fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <fulc:IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding
      contextRef="C_34147407-27d4-48db-9e5a-99ff76257ddc"
      decimals="2"
      id="F_5afab60f-b21d-4410-9221-d5080c3ba99d"
      unitRef="U_pure">0.01</fulc:IncreaseInNumberOfSharesReservedForIssuancePercentOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_98d7485a-ca98-4800-86e5-94959550472d"
      decimals="INF"
      id="F_cec7b221-727d-4d33-b8f9-5287c6d68399"
      unitRef="U_shares">1346125</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_331bbcc1-90e8-4bf6-9dcd-ca73f84cc749"
      decimals="INF"
      id="F_284ca7ba-22d9-40c9-80af-2e130aa8afb5"
      unitRef="U_shares">428571</fulc:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_46edbb76-07e8-4a88-9b7a-a21b3f933eff">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Collaboration and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Acceleron Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 20, 2019, the Company entered into the Acceleron Collaboration Agreement to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space (the &#x201c;Indication&#x201d;). Under the terms of the Acceleron Collaboration Agreement, the Company granted Acceleron an exclusive worldwide license under certain intellectual property rights to make, have made, use, sell, have sold, import, export, distribute and have distributed, market, have marketed, promote, have promoted, or otherwise exploit molecules and products directed against or expressing certain biological targets identified by the Company for the treatment, prophylaxis, or diagnosis of the Indication.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 3, 2022, Acceleron notified the Company of its termination of the Acceleron Collaboration Agreement for convenience, which became effective 120 days after the Company's receipt of the notice, or October 1, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2023, the Company recognized no collaboration revenue associated with the Acceleron Collaboration Agreement. During the year ended December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of collaboration revenue associated with the Acceleron Collaboration Agreement, which includes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of revenue recognized that was included in deferred revenue as of  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021. As of December 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; deferred revenue, unbilled accounts receivable, or accounts receivable associated with the Acceleron Collaboration Agreement. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cost reimbursement payments under the Acceleron Collaboration Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million associated with the achievement of specified research milestones&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;MyoKardia Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 20, 2020, the Company entered into the MyoKardia Collaboration Agreement, pursuant to which the Company granted to MyoKardia an exclusive worldwide license under certain intellectual property rights to research, develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export, have exported, distribute, have distributed, market, have marketed, promote, have promoted, or otherwise exploit products directed against certain biological targets identified by the Company that are capable of modulating up to a certain number of genes of interest with relevance to certain genetically defined cardiomyopathies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to a mutually agreed research plan, the Company will perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets (&#x201c;Identified Targets&#x201d;) for further research, development, manufacture and commercialization by MyoKardia. The Company and MyoKardia will work together to determine how best to advance at each stage of the research activities under the research plan and to identify which of the Identified Targets, if any, meet the criteria set forth in the research plan (the &#x201c;Cardiomyopathy Target Candidates&#x201d;). Upon completion of the research plan, the parties will work together to prepare a final data package and MyoKardia may designate certain Cardiomyopathy Target Candidates for MyoKardia&#x2019;s further exploitation under the MyoKardia Collaboration Agreement (the &#x201c;Cardiomyopathy Targets&#x201d;). If MyoKardia does not designate any Cardiomyopathy Targets during the designated period, then the MyoKardia Collaboration Agreement will automatically terminate. If MyoKardia designates one or more Cardiomyopathy Targets, then MyoKardia will be obligated to use commercially reasonable efforts to seek regulatory approval for and to commercialize one product directed against an Identified Target in certain specified countries.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the period in which the Company is performing the research activities pursuant to the research plan (the &#x201c;Research Term&#x201d;) and for a specified period beyond the Research Term if MyoKardia designates a Cardiomyopathy Target, the Company may only use the data generated from such research activities for MyoKardia in accordance with the MyoKardia Collaboration Agreement. During the Research Term and for a specified period thereafter, the Company may not research, develop, manufacture, commercialize, use, or otherwise exploit any compound or product (a) that is a Compound or Product under the MyoKardia Collaboration Agreement that is directed against the Cardiomyopathy Target Candidates for the treatment, prophylaxis, or diagnosis of any indication or (b) for the treatment of any genetically defined cardiomyopathies shown to be related to certain specified genes of interest that are modulated by the Cardiomyopathy Targets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the MyoKardia Collaboration Agreement, MyoKardia made a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upfront payment and a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;payment as prepaid research funding to the Company in July 2020. MyoKardia will also reimburse the Company for the costs of the research activities not covered by the prepaid research funding, up to a maximum amount of total research funding (including the prepaid research funding). Upon the achievement of specified preclinical, development and sales milestones, the Company will be entitled to preclinical milestone payments, development milestone payments and sales milestone&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;payments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;298.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate per target for certain Identified Targets, and of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate per target for certain other Identified Targets. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To date, the Company has achieved a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million specified preclinical milestone. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;MyoKardia will also pay the Company tiered royalties ranging from a mid single-digit percentage to a low double-digit percentage based on MyoKardia&#x2019;s, and any of its affiliates&#x2019; and sublicensees&#x2019;, annual worldwide net sales of products under the MyoKardia Collaboration Agreement directed against any Identified Target. The royalties are payable on a product-by-product basis during a specified royalty term, and may be reduced in specified circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The MyoKardia Collaboration Agreement continues on a country-by-country and product-by-product basis until the last to expire royalty term for a product, at which time the MyoKardia Collaboration Agreement expires with respect to such product in such country. Either party has the right to terminate the MyoKardia Collaboration Agreement if the other party has materially breached in the performance of its obligations under the MyoKardia Collaboration Agreement and such breach has not been cured within the applicable cure period. MyoKardia also has the right to terminate the MyoKardia Collaboration Agreement for convenience in its entirety or on a target-by-target, product-by-product or molecule-by-molecule basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Analysis&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Identification of the Contract&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed the MyoKardia Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Identification of the Promises and Performance Obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that the MyoKardia Collaboration Agreement contains the following promises: (i) an exclusive worldwide license under certain intellectual property rights, including rights to a specified number of potential cardiomyopathy gene targets identified by the Company for further research, development, manufacture and commercialization for the treatment, prophylaxis, or diagnosis of certain genetically defined cardiomyopathies that was conveyed at the inception of the arrangement (the &#x201c;MyoKardia License&#x201d;), (ii) research services to identify and validate potential biological targets (the &#x201c;MyoKardia Research Services&#x201d;), and (iii) participation in the joint steering committee (the &#x201c;MyoKardia JSC&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed the above promises and concluded that the MyoKardia License is not capable of being distinct from the MyoKardia Research Services given that the MyoKardia License has limited value without the performance of the MyoKardia Research Services and the MyoKardia Research Services can only be performed by the Company due to their specialized nature. Therefore, the Company has concluded that the MyoKardia License and the MyoKardia Research Services represent a single combined performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also assessed the participation on the MyoKardia JSC and concluded that the promise is quantitatively and qualitatively immaterial in the context of the MyoKardia Collaboration Agreement. Accordingly, the Company has disregarded its participation on the MyoKardia JSC as a performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Determination of the Transaction Price&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company received a non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which the Company included in the transaction price. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2021, the Company achieved a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million specified preclinical milestone associated with the MyoKardia Collaboration Agreement, which was previously constrained due to the significant uncertainty regarding whether such preclinical milestone would be achieved. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company included this amount in the transaction price as of December 31, 2021. Based on the continued uncertainty associated with the achievement of any of the remaining preclinical and development milestone payments that the Company is eligible to receive, the Company has constrained the variable consideration associated with those milestone payments and excluded them from the transaction price. As part of its evaluation of constraining the preclinical and development milestones, the Company considered numerous factors, including the fact that the achievement of the preclinical and development milestones are contingent upon the results of the underlying preclinical and development activities and are thus outside of the control of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also included in the transaction price the expected amount of costs to be reimbursed for the MyoKardia Research Services, which includes the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million prepaid research funding payment that the Company received in the third quarter of 2020.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reassesses the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the transaction price. There was no change in the amount of variable consideration constrained during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Any consideration related to sales milestone payments (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to MyoKardia and therefore are recognized at the later of when the related sales occur or the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Allocation of the Transaction Price to Performance Obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As noted above, the Company has identified a single performance obligation associated with the MyoKardia Collaboration Agreement. Therefore, the Company will allocate the entire amount of the transaction price to the identified single performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recognition of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenue related to the MyoKardia Collaboration Agreement over time as the MyoKardia Research Services are rendered. The Company has concluded that an input method is a representative depiction of the transfer of services under the MyoKardia Collaboration Agreement. The method of measuring progress towards the delivery of the services incorporates actual cumulative internal and external costs incurred relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs are estimated reflects the Company&#x2019;s estimate of the period over which it will perform the MyoKardia Research Services. Changes in estimates of total internal and external costs expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of collaboration revenue associated with the MyoKardia Collaboration Agreement, which includes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of revenue recognized that was included in deferred revenue as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022. During the year ended December 31, 2022, the Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of collaboration revenue associated with the MyoKardia Collaboration Agreement, which includes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of revenue recognized that was included in deferred revenue as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021. As of December 31, 2023, the Company recorded no deferred revenue associated with the MyoKardia Collaboration Agreement. As of December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million associated with the MyoKardia Collaboration Agreement, which is classified as either current or net of current portion in the accompanying consolidated balance sheets based on the period over which the revenue is expected to be recognized. The aggregate deferred revenue balance represents the aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. As of December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company had received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cost reimbursement payments under the MyoKardia Collaboration Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million associated with the achievement of a preclinical milestone. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company had received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cost reimbursement payments under the MyoKardia Collaboration Agreement and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million associated with the achievement of a preclinical milestone. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded unbilled accounts receivable of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to reimbursable research and development costs under the MyoKardia Collaboration Agreement for activities performed during the three months ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. As of December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded unbilled accounts receivable of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;related to reimbursable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;research &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and development costs under the MyoKardia Collaboration Agreement for activities performed during the three months ended December 31, 2022. As of December 31, 2023 and 2022, the Company recorded no accounts receivable under the MyoKardia Collaboration Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e9320667-4317-4880-b542-adec903ee354"
      decimals="-5"
      id="F_c032797b-00f7-43c2-8a10-3e5cda328196"
      unitRef="U_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_eb41ec6a-6f90-42d8-a1d9-14d1685b4dbb"
      decimals="-5"
      id="F_5306dc97-8b1d-45ea-8622-fbc2c0514ef9"
      unitRef="U_USD">600000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_6d813c32-3ade-4f1e-a7d9-3519e68f4cac"
      decimals="-6"
      id="F_7088611c-3048-4d8e-99c4-02d49175c88b"
      unitRef="U_USD">0</us-gaap:DeferredRevenue>
    <fulc:ReimbursementPaymentRecieved
      contextRef="C_884143a7-2e26-4a93-ac13-566cb4dd0eaa"
      decimals="-5"
      id="F_f8084776-1119-4f79-94c3-9d0d8d5a5792"
      unitRef="U_USD">4900000</fulc:ReimbursementPaymentRecieved>
    <fulc:ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone
      contextRef="C_7022a87d-e56e-48d8-8868-7ed1b8f6cd32"
      decimals="-5"
      id="F_fefac233-4a26-4799-a72e-ee3432d6096d"
      unitRef="U_USD">2000000</fulc:ResearchDevelopmentAndSalesArrangementAmountReceivedUponAchievementOfMilestone>
    <fulc:UpfrontPayment
      contextRef="C_1db948c7-31b2-4309-a481-9cda796e4d8a"
      decimals="-5"
      id="F_3a664ed6-bd1d-4dc8-a647-06247736b5bc"
      unitRef="U_USD">10000000</fulc:UpfrontPayment>
    <fulc:PaymentForPrepaidResearchFunding
      contextRef="C_1db948c7-31b2-4309-a481-9cda796e4d8a"
      decimals="-5"
      id="F_5a530ef9-b949-481a-b256-42d55d5db100"
      unitRef="U_USD">2500000</fulc:PaymentForPrepaidResearchFunding>
    <fulc:MilestonePaymentForCertainIdentifiedTargets
      contextRef="C_a18d155f-7a8d-4b6c-9a25-f1314028d766"
      decimals="-5"
      id="F_3ff95216-8a04-4415-85dc-b16471316963"
      unitRef="U_USD">298500000</fulc:MilestonePaymentForCertainIdentifiedTargets>
    <fulc:MilestonePaymentForCertainOtherIdentifiedTargets
      contextRef="C_a18d155f-7a8d-4b6c-9a25-f1314028d766"
      decimals="-5"
      id="F_24d4f1d1-9c31-4e96-8370-37ddfe8f1ceb"
      unitRef="U_USD">150000000</fulc:MilestonePaymentForCertainOtherIdentifiedTargets>
    <fulc:ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone
      contextRef="C_ea0f142c-6216-4014-90e1-aa57c23c6c6b"
      decimals="-5"
      id="F_8898f3f8-c10d-4afb-8044-b20a1de13f47"
      unitRef="U_USD">2500000</fulc:ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone>
    <fulc:NonRefundableUpfrontPaymentsReceived
      contextRef="C_a2062e16-6f62-4e3b-89f8-c083e9ea8bfa"
      decimals="-5"
      id="F_2e71a7b4-87a2-4585-9b27-79c3e2979a2d"
      unitRef="U_USD">10000000</fulc:NonRefundableUpfrontPaymentsReceived>
    <fulc:ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone
      contextRef="C_7baf9985-59a2-4afb-b460-9750260fe38c"
      decimals="-5"
      id="F_bcf11d46-2a1f-4f53-94a8-dec39a2e4bcd"
      unitRef="U_USD">2500000</fulc:ResearchDevelopmentAndSalesArrangementAggregateAmountReceivableUponAchievementOfMilestone>
    <fulc:PrepaidResearchFundingPaymentReceived
      contextRef="C_a247c0da-5748-4ee1-809e-b40ff34a7c07"
      decimals="-5"
      id="F_d0d1dfd9-7f0b-4bd4-95aa-e96962604794"
      unitRef="U_USD">2500000</fulc:PrepaidResearchFundingPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a2062e16-6f62-4e3b-89f8-c083e9ea8bfa"
      decimals="-5"
      id="F_8944ce3b-95a2-454f-876c-9a060cedc3b5"
      unitRef="U_USD">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391"
      decimals="-5"
      id="F_8d0d5a7f-9534-4197-8146-d1dd6cb951e6"
      unitRef="U_USD">900000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1e7d6101-2b2e-4757-966e-e38a693e1fe6"
      decimals="-5"
      id="F_85f1df7b-f9d6-4b06-8606-e942cfd6df1a"
      unitRef="U_USD">5300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_d0796c66-5faa-42cb-bb2a-9806d8b59cc7"
      decimals="-5"
      id="F_4213087d-a3f4-47ad-a88f-8ad50cf1447d"
      unitRef="U_USD">3200000</us-gaap:DeferredRevenue>
    <fulc:DeferredRevenueCurrentAndNoncurrent
      contextRef="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391"
      decimals="-5"
      id="F_bfd14e2a-e784-478f-af32-2e5dbe389730"
      unitRef="U_USD">900000</fulc:DeferredRevenueCurrentAndNoncurrent>
    <fulc:ReimbursementPaymentRecieved
      contextRef="C_a2062e16-6f62-4e3b-89f8-c083e9ea8bfa"
      decimals="-5"
      id="F_5b1cab70-9247-4275-aa82-bf8c650b9a6b"
      unitRef="U_USD">7200000</fulc:ReimbursementPaymentRecieved>
    <fulc:PaymentForPrepaidResearchFunding
      contextRef="C_19b2e307-2653-4c2d-ac68-2e2064f71c76"
      decimals="-5"
      id="F_88dcb756-d67f-454b-a928-e865767ca209"
      unitRef="U_USD">2500000</fulc:PaymentForPrepaidResearchFunding>
    <fulc:ReimbursementPaymentRecieved
      contextRef="C_3a2cdb21-6525-45f5-bf28-66b9a5ce67b6"
      decimals="-5"
      id="F_c24740d6-20f0-48e8-bb67-8ebe6ba40ab1"
      unitRef="U_USD">5600000</fulc:ReimbursementPaymentRecieved>
    <fulc:PaymentForPrepaidResearchFunding
      contextRef="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391"
      decimals="-5"
      id="F_83e1c9cb-3114-46a2-ae6e-4b586676fb47"
      unitRef="U_USD">2500000</fulc:PaymentForPrepaidResearchFunding>
    <fulc:UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost
      contextRef="C_19b2e307-2653-4c2d-ac68-2e2064f71c76"
      decimals="-5"
      id="F_054128a8-ba91-45f3-bb94-da03125816ca"
      unitRef="U_USD">500000</fulc:UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost>
    <fulc:UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost
      contextRef="C_3a44863b-a2bd-4da3-b1e3-b5bac4b5f391"
      decimals="-5"
      id="F_8ee53e8e-488c-4b95-b125-04ead424551f"
      unitRef="U_USD">200000</fulc:UnbilledAccountsReceivableRelatedToReimbursableResearchAndDevelopmentCost>
    <fulc:AssetAcquisitionDisclosureTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_4d615888-3a42-4e62-8e53-5477733a209b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;GSK Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2019, the Company entered into the right of reference and license agreement, as amended (the &#x201c;GSK Agreement&#x201d;), with subsidiaries of GlaxoSmithKline plc (collectively referred to as &#x201c;GSK&#x201d;), pursuant to which the Company has been granted an exclusive worldwide license to develop and commercialize losmapimod. Under the GSK Agreement, the Company also acquired reference rights to relevant regulatory and manufacturing documents and GSK&#x2019;s existing supply of losmapimod drug substance and product. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize losmapimod at its sole cost. The Company is also responsible for costs related to the filing and maintenance of the licensed patent rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the GSK Agreement, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series B Preferred Stock to GSK. In addition, the Company may owe GSK up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in certain specified clinical and regulatory milestones, including a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone that was achieved during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2022 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone previously achieved and paid during 2019, and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in certain specified sales milestones. The Company agreed to pay tiered royalties on annual net sales of losmapimod that range from mid single-digit percentages to a low double-digit, but less than teens, percentage. The royalties are payable on a product-by-product and country-by-country basis, and may be reduced in specified circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The GSK Agreement may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the GSK Agreement will continue in effect until the expiration of the Company&#x2019;s royalty obligations, which expire on a country-by-country basis on the later of (i) ten years after the first commercial sale in the country or (ii) approval of a generic version of losmapimod by the applicable regulatory agency.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes clinical and regulatory milestone payments when the underlying contingency is resolved and the consideration is paid or becomes payable. The milestone payments are capitalized or expensed depending on the nature of the associated asset as of the date of recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;CAMP4 Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2023, the Company entered into a license agreement (the &#x201c;CAMP4 Agreement&#x201d;) with CAMP4 Therapeutics Corporation (&#x201c;CAMP4&#x201d;) pursuant to which the Company received a worldwide exclusive license (including the right to sublicense) from CAMP4 to rights under its Diamond Blackfan Anemia (&#x201c;DBA&#x201d;) program, which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how for the Company to research, develop, manufacture, use, commercialize or otherwise exploit therapeutic products in any indication, including the grant of a sublicense under certain intellectual property rights that CAMP4 has licensed under an agreement with Children&#x2019;s Medical Center Corporation (&#x201c;CMCC&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company made an undisclosed upfront non-refundable, non-creditable payment to CAMP4. If the Company succeeds in developing and commercializing licensed products, CAMP4 will be eligible to receive (i) up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in development and regulatory milestone payments, and (ii) up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in sales milestone payments. CAMP4 is also eligible to receive royalties on worldwide net sales of licensed products ranging from mid-single digit to low-double digit, subject to potential reduction following loss of patent coverage, the launch of certain generic products or royalty stacking for licenses of third party intellectual property. The royalties will expire on a product-by-product and country-by-country basis upon the latest to occur of (i) the expiration of all valid patent claims covering the compounds in such country, (ii) the expiration of all regulatory exclusivities in such country, and (iii) 10 years following the first commercial sale in such country. The Company is responsible for the costs associated with the development and regulatory approvals of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unless earlier terminated in accordance with its terms, the license agreement continues on a country-by-country and licensed product-by-licensed product basis until the expiration of the royalty term in each country, at which time the license agreement expires with respect to such licensed product in such country and the Company will have a fully-paid up, royalty-free and perpetual license to the licensed patent rights and know-how with respect to such licensed product in such country.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CAMP4 has the right to terminate the license agreement in the event of the Company&#x2019;s non-payment (subject to cure periods and tolling for bona fide disputes). CAMP4 may also terminate the license agreement if the Company challenges certain patents sublicensed to the Company by CAMP4. Either party may terminate the license agreement in its entirety for the other party&#x2019;s material breach if such other party fails to cure the breach. Either party may also terminate the agreement in its entirety upon certain insolvency events involving the other party. The Company has the right to terminate the license agreement with CAMP4 for any or no reason upon prior written notice to CAMP4.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes development and regulatory milestone payments when the underlying contingency is resolved and the consideration is paid or becomes payable. The milestone payments are capitalized or expensed depending on the nature of the associated asset as of the date of recognition.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</fulc:AssetAcquisitionDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="C_dc2dcbed-a530-47fe-b591-af8023e6e6ca"
      decimals="INF"
      id="F_8c6ab2af-961c-4c2a-af11-85ab0442cbaf"
      unitRef="U_shares">12500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <fulc:ClinicalAndRegulatoryMilestonePayables
      contextRef="C_b9eb8757-a555-4809-8e7b-95ed236c0f69"
      decimals="-5"
      id="F_16af583f-765b-4cf6-a78e-3e4be19c6bd7"
      unitRef="U_USD">37500000</fulc:ClinicalAndRegulatoryMilestonePayables>
    <fulc:ClinicalAndRegulatoryMilestonePayables
      contextRef="C_91aa4910-0766-4281-855f-db89fadd437e"
      decimals="-5"
      id="F_7c0b44f6-0b3e-47e1-aa7a-df102623b4ed"
      unitRef="U_USD">5000000</fulc:ClinicalAndRegulatoryMilestonePayables>
    <fulc:ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial
      contextRef="C_91aa4910-0766-4281-855f-db89fadd437e"
      decimals="-5"
      id="F_cb990585-553d-4ff3-9ed1-3c1f4b394c64"
      unitRef="U_USD">2500000</fulc:ClinicalAndRegulatoryMilestonePayablesUponPhaseTwoClinicalTrial>
    <fulc:SalesMilestone
      contextRef="C_b9eb8757-a555-4809-8e7b-95ed236c0f69"
      decimals="-5"
      id="F_d52ab741-65e7-4459-9063-c829e7ba7e3e"
      unitRef="U_USD">60000000</fulc:SalesMilestone>
    <fulc:ClinicalAndRegulatoryMilestonePayables
      contextRef="C_fd317054-d5af-4b47-89c2-049b6bdcf482"
      decimals="-5"
      id="F_51de192b-a99e-43f0-acc8-48c7fb740be5"
      unitRef="U_USD">35000000</fulc:ClinicalAndRegulatoryMilestonePayables>
    <fulc:ClinicalAndRegulatoryMilestonePayables
      contextRef="C_e5fa44bd-3098-4335-bd36-e6a28c5c81f2"
      decimals="-5"
      id="F_8e0986c5-5ccd-493d-9a23-b0ea09ce7d7b"
      unitRef="U_USD">35000000</fulc:ClinicalAndRegulatoryMilestonePayables>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_3949344b-2193-40b4-bf14-6c2bb1b3345c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;26 Landsdowne Street&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2017, the Company entered into a lease agreement for its current corporate headquarters comprising approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,731&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office and laboratory space at 26 Landsdowne Street  in Cambridge, Massachusetts, commencing December 2017. The Company began to occupy and use the leased space for its intended purpose in June 2018. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The lease ends on June 30, 2028. The Company has the option to extend the term of the lease for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;period, at the market rate, by giving the landlord written notice of its election to exercise the extensio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;n at least nine months prior to the original expiration of the lease term. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The lease has a total commitment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; term, and includes escalating rent payments. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The lease provides the Company with an allowance for normal leasehold improvements of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The lease agreement requires the Company to either pay a security deposit or maintain a letter of credit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company maintains a letter of credit for this lease and has recorded the cash held to secure the letter of credit as restricted cash on the consolidated balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and December 31, 2022. Operating lease and variable lease expense associated with this lease for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Operating lease expense and variable lease expense associated with this lease for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The future minimum lease payments associated with the 26 Landsdowne Street lease as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;125 Sidney Street&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, the Company entered into a lease agreement comprising approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,196&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office space at 125 Sidney Street in Cambridge, Massachusetts, commencing November 2021. The Company began recognizing rent expense associated with this lease during November 2021. The lease ends on March 31, 2024. The Company has the option to extend the term of the lease for two successive one-year periods, at the market rate, by giving the landlord written notice of its election to exercise the extension at least nine months prior to the original expiration of the lease term. The lease has a total commitment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million over the initial term, and includes escalating rent payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease expense associated with this lease for each of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; variable lease expense was recorded associated with this lease for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022. The future minimum lease payments associated with this lease as of December 31, 2023, are as follows (in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <fulc:OfficeAndLaboratorySpace
      contextRef="C_7c3c4af6-ca10-4044-9408-a2cfdd8766f8"
      decimals="0"
      id="F_413e5cf2-0845-4372-8eff-b00f3e6abf1a"
      unitRef="U_SquareFeet">28731</fulc:OfficeAndLaboratorySpace>
    <us-gaap:LessorOperatingLeaseRenewalTerm
      contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901"
      id="F_f1b806f6-04cc-44b0-a600-f55da1e5cc5d">P5Y</us-gaap:LessorOperatingLeaseRenewalTerm>
    <us-gaap:OtherCommitment
      contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901"
      decimals="-5"
      id="F_e05764b8-7731-478a-a46d-03f7bd4e50c8"
      unitRef="U_USD">25100000</us-gaap:OtherCommitment>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901"
      id="F_c1e0924d-d1a0-4fa0-8ed4-16d27345586e">P10Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901"
      decimals="-5"
      id="F_a2a89bb7-8f6c-435e-94d2-9529bdf77fb1"
      unitRef="U_USD">5000000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:SecurityDeposit
      contextRef="C_96c49986-10b9-4fb3-ac44-74df5efad901"
      decimals="-5"
      id="F_fc626c98-e273-444b-bd72-ed40537e6fd0"
      unitRef="U_USD">1100000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-5"
      id="F_c74682e5-3595-40a7-8fa9-cc2aa7ee54eb"
      unitRef="U_USD">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeasePayment
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-5"
      id="F_1a38d27a-6440-4064-87a0-0ed92825d8b9"
      unitRef="U_USD">900000</us-gaap:VariableLeasePayment>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-5"
      id="F_7aed25f7-399f-4952-8763-6b3111aa7447"
      unitRef="U_USD">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeasePayment
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-5"
      id="F_f00c2d30-ef85-42b2-8ba7-60c359e0b530"
      unitRef="U_USD">1000000</us-gaap:VariableLeasePayment>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_307f7d91-6fab-4f2c-b389-665c233bce30"
      id="F_4ae5e658-5e80-49a5-bcfa-600dfeface66">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The future minimum lease payments associated with the 26 Landsdowne Street lease as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1"
      decimals="-3"
      id="F_01b6ddf8-bf28-418a-bc0f-9fcf2fca69aa"
      unitRef="U_USD">2572000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1"
      decimals="-3"
      id="F_4eaf70c2-9260-4b12-9e02-0385a3c29013"
      unitRef="U_USD">2649000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1"
      decimals="-3"
      id="F_4fd88fe2-8774-4130-9bd7-b3d20ba25a7c"
      unitRef="U_USD">2729000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1"
      decimals="-3"
      id="F_380a3bed-bf5e-4fb4-b0f6-49c6f5cd1175"
      unitRef="U_USD">2811000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <fulc:Thereafter
      contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1"
      decimals="-3"
      id="F_82a45766-5637-4935-9c0c-7daeb2c171f7"
      unitRef="U_USD">1426000</fulc:Thereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1"
      decimals="-3"
      id="F_b43e7edf-0e20-4670-a230-7b39bf9c3f2d"
      unitRef="U_USD">12187000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <fulc:LessImputedInterest
      contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1"
      decimals="-3"
      id="F_3fdca038-6eed-41b5-a987-841834ddeeb9"
      unitRef="U_USD">-1575000</fulc:LessImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e746306c-e757-4570-81a1-01d41ff4c7c1"
      decimals="-3"
      id="F_fd97193a-f6c8-4bce-9af2-d87c875cab1d"
      unitRef="U_USD">10612000</us-gaap:OperatingLeaseLiability>
    <fulc:OfficeAndLaboratorySpace
      contextRef="C_63c6c909-d955-4771-8848-2cdb7bda457f"
      decimals="0"
      id="F_1f9712d4-47e8-4472-8552-36f8b30225df"
      unitRef="U_SquareFeet">12196</fulc:OfficeAndLaboratorySpace>
    <us-gaap:OtherCommitment
      contextRef="C_6a8b9b58-5d94-486d-a1c0-5e1919ae1ab3"
      decimals="-5"
      id="F_5af8acfb-7764-4a38-a5b8-f796d68f3fe2"
      unitRef="U_USD">1700000</us-gaap:OtherCommitment>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_3ccff940-b46f-49f2-a0ba-1cf5bf8580ae"
      id="F_b92c66e9-2552-4d68-b1b4-25e1d4d77a5e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease expense associated with this lease for each of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; variable lease expense was recorded associated with this lease for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022. The future minimum lease payments associated with this lease as of December 31, 2023, are as follows (in thousands): &lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_3ccff940-b46f-49f2-a0ba-1cf5bf8580ae"
      decimals="-5"
      id="F_fa4777a3-beea-4cd1-b3e6-8e36b4c7459b"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_3bf64331-d750-4ee0-8b5b-6d241408072d"
      decimals="-5"
      id="F_57a6accf-c0f6-4517-ab4b-4e8626d7423d"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeasePayment
      contextRef="C_3ccff940-b46f-49f2-a0ba-1cf5bf8580ae"
      decimals="-3"
      id="F_9182ebcf-b7ad-4050-8e04-07c22ba12cd7"
      unitRef="U_USD">0</us-gaap:VariableLeasePayment>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241"
      decimals="-3"
      id="F_11c2465f-db8b-426a-a12c-623023658cbc"
      unitRef="U_USD">210000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241"
      decimals="-3"
      id="F_f5b9ec8a-8c8f-46d1-a9e3-2526c7cf46d5"
      unitRef="U_USD">210000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <fulc:LessImputedInterest
      contextRef="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241"
      decimals="-3"
      id="F_823a9c1d-6131-41ec-a9b0-441fc7dd2384"
      unitRef="U_USD">-1000</fulc:LessImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_a28bfc62-3c7d-4d95-ae61-8bb974e5b241"
      decimals="-3"
      id="F_103a26da-edad-4217-b77a-1f7d1e97bc61"
      unitRef="U_USD">209000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_5a36b5ad-90bd-478c-8281-1c076e362265">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters arising out of the relationship between such parties and the Company. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t accrued any liabilities related to such obligations as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 or 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 28, 2023, a class action complaint was filed in the United States District Court for the District of New Jersey against the Company and current and former officers (the &#x201c;Securities Action&#x201d;). On May 19, 2023, the Securities Action was transferred to the United States District Court for the District of Massachusetts, captioned &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Celano v. Fulcrum Therapeutics, Inc., et al&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;., Case No. 1:23-cv-11125-IT. On July 31, 2023, the court appointed a lead plaintiff, who filed an amended complaint on September 29, 2023. The Securities Action alleges violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder against all defendants and control person violations of Section 20(a) against the individuals, related to the Company&#x2019;s February 2023 announcement that the U.S. Food and Drug Administration issued a clinical hold regarding the investigational new drug application for pociredir (formerly known as FTX-6058) for the potential treatment of sickle cell disease. The Securities Action alleges that the defendants made misleading statements and omitted to disclose material information related to the clinical hold and seeks, among other things, compensatory damages in connection with an allegedly inflated stock price between March 3, 2022, and March 8, 2023, as well as attorneys&#x2019; fees and costs. On November 28, 2023, all defendants filed a motion to dismiss the Securities Action, which motion is currently pending. The Company intends to defend vigorously against this litigation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At each reporting date, the Company eva&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;luates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as they are incurred. Other than attorneys&#x2019; fees and costs related to the defense of the Securities Action, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such costs have been incurred during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_f027d984-8450-4048-9d00-1f28f5700faa"
      decimals="-3"
      id="F_9c380771-8a46-4e1b-9557-6c5e0164433c"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_30e3fda8-1f2a-42d1-bbf1-8d7c093ac7d6"
      decimals="-3"
      id="F_d32887a9-c1c1-4754-9dc3-6b0223f0cf50"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="C_22c69f38-8bae-4283-a815-fd207b1f78a2"
      decimals="-3"
      id="F_df0a93e7-bfb4-4908-8c59-a9de478dad0c"
      unitRef="U_USD">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_3fd76c55-2be7-49c6-bb4c-44de9335cc75">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.545%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.321%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.907%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.321%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.907%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal orphan drug credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Officers' compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impact of ownership change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the years ended December 31, 2023 and 2022, the Company incurred book and tax losses and, because it maintains a full valuation allowance on its net deferred tax assets, did not recognize federal or state income tax expense or benefit.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.440000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.440000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Orphan drug credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;132,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;164,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the net deferred tax assets. The Company considered its history of cumulative net losses incurred since inception and its lack of commercialization of any products since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, which is primarily attributable to increases in net operating loss carryforwards as a result of current year net losses, increases in capitalized research and development costs, and the generation of research and development and orphan drug tax credit carryforwards. The Company reevaluates the positive and negative evidence at each reporting period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;312.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, a portion of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;288.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the federal net operating losses can be carried forward indefinitely. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company also had state net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;317.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had federal orphan drug credits of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had federal research and development tax credit carryforwards of approximately $7.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company also had state research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended (the &#x201c;Internal Revenue Code&#x201d;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2021 would limit or otherwise restrict the Company's ability to utilize its pre-change net operating losses and research and development tax credit carryforwards to offset future taxable income. As a result of the analysis, the Company does not believe that there are any significant limitations on its ability to utilize its net operating losses and research and development tax credit carryforwards to offset future taxable income. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since December 31, 2021. If the Company has experienced a change of control, as defined by Section 382, subsequent to December 31, 2021, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company&#x2019;s tax years are still open under statute from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_34f687fe-c7b7-4d4d-a574-1aceb3c54fb6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2016&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to the present.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;It is the Company&#x2019;s policy to include penalties and interest expense related to income taxes as a component of the provision for income taxes. As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accrued interest or penalties related to uncertain tax positions and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; amounts have been recognized in the Company&#x2019;s statements of operations. For the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company generated research and development tax credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#x2019;s research and development tax credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development tax credit carryforwards and, if an adjustment is required, this adjustment would result in an adjustment to the deferred tax asset established for the research and development tax credit carryforwards and the valuation allowance.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_d31d1de1-9c9d-407b-866b-98f777c63e04">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.545%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.321%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.907%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.321%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.907%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal orphan drug credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Officers' compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impact of ownership change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_7c3d3c91-d7fa-4366-9b07-5180b9a46074"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_db1e67a3-0306-4407-972f-696f9e385d9d"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_d8b532aa-1716-46f6-a0b5-6eac3ce7e045"
      unitRef="U_pure">-0.0071</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_181f5258-ebe1-4807-b632-5a4cf2024ed2"
      unitRef="U_pure">-0.0046</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_9c40b210-055b-4fbe-90ab-86576924522e"
      unitRef="U_pure">0.0147</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_1f431da3-b4e6-4746-bc59-f2790a9daa42"
      unitRef="U_pure">0.0144</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <fulc:EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_72f8c3b0-053e-4679-84c3-09cf6fe60cd5"
      unitRef="U_pure">0.0941</fulc:EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits>
    <fulc:EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_d4f859c4-b824-4e53-99d7-932ff25d3cd4"
      unitRef="U_pure">0.0723</fulc:EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_9828961a-6d43-464e-acc1-dd4b15b58141"
      unitRef="U_pure">0.0592</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_d661e0c8-d283-43b4-a7bb-3713977b8d41"
      unitRef="U_pure">0.0578</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <fulc:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_34084f92-a398-4c00-bfc4-20e19aa465e7"
      unitRef="U_pure">-0.0106</fulc:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent>
    <fulc:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_b759c243-5902-4468-8896-683a860dc2db"
      unitRef="U_pure">-0.0023</fulc:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent>
    <fulc:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_a1b05a15-e143-4ee2-b700-fecc1b30a44c"
      unitRef="U_pure">-0</fulc:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent>
    <fulc:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_12d4786a-ed85-44e4-a22e-30df807ad2cc"
      unitRef="U_pure">0.0292</fulc:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_a27c445f-9c52-4bc2-a5ff-d79cee3e40c2"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_5683da60-5306-41b9-97b9-6564082f5508"
      unitRef="U_pure">-0.0013</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_01d35edb-5634-4a57-8e73-e3fa66ae5e2b"
      unitRef="U_pure">-0.3593</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_f11b1152-5ae7-4104-a053-46e42b82f9f6"
      unitRef="U_pure">-0.3171</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="2"
      id="F_51ad5fcb-3d0f-43ec-a298-77c5bf132a68"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="2"
      id="F_755c010e-1598-480a-ac8b-13e1c05d59f2"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_7836b155-312c-45d9-9429-1454938ebbd6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.440000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.440000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Orphan drug credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;132,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;164,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_c5c5993f-2bb2-49b6-b557-6a8dbe57d4ac"
      unitRef="U_USD">85622000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_dae9f351-6e3d-4e25-a65e-6f69f2d4788a"
      unitRef="U_USD">75005000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <fulc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_f2261d01-a7e5-44a6-93e6-ad72e8a94a28"
      unitRef="U_USD">30019000</fulc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <fulc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_d445e18d-1123-4da7-9ac9-988d308d15a1"
      unitRef="U_USD">16911000</fulc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_b16458cc-2933-41a6-a924-7fe1d3b95bd9"
      unitRef="U_USD">23790000</fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards>
    <fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_2ab99df4-a2df-485d-8358-018adf5065d5"
      unitRef="U_USD">14628000</fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_c096bd95-9f1a-4847-afd7-d7beb16183ec"
      unitRef="U_USD">11569000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_8602eb32-9102-4e45-9ed6-013d6ba399b5"
      unitRef="U_USD">10140000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_73535e15-b1a8-4d0a-bd10-cdb5557dd2ae"
      unitRef="U_USD">6291000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_0188bb73-de8b-4898-bcbf-598d69ffdb39"
      unitRef="U_USD">6918000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_fdffd483-1dcd-40cd-a464-e64dfba24553"
      unitRef="U_USD">6740000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_2b7e2ced-4964-4bd1-85f6-6aa7ec7bd6ff"
      unitRef="U_USD">5232000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <fulc:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_701d2047-3c96-4d24-9d4a-f85c4c01babf"
      unitRef="U_USD">2911000</fulc:DeferredTaxAssetsOperatingLeaseLiability>
    <fulc:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_fd601f7a-ece4-4689-a3f8-8f4e8a694f31"
      unitRef="U_USD">3613000</fulc:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_e8ad2c53-a7d5-487d-b0f8-b745aab1b081"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_d9aa9e91-cc45-4bf6-8919-33142beb73d7"
      unitRef="U_USD">251000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_5e32c7e0-98fd-4d68-9fdb-81347a51a9a5"
      unitRef="U_USD">166942000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_2d2c072b-b0ff-4fa7-be96-51077e7af93e"
      unitRef="U_USD">132698000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_35985c09-b5c3-46d0-a7aa-30881bc74116"
      unitRef="U_USD">164483000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_406c0d8e-ac3f-4cb9-82f1-045f5648be60"
      unitRef="U_USD">129512000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_392345be-d202-4bfc-ba5f-a9fc87576d1b"
      unitRef="U_USD">2459000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a2326433-68ae-40fd-84d8-2ab30e33cc1d"
      unitRef="U_USD">3186000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_ec7d7a4a-a7d7-4c9d-8e85-e32ed86fe4a8"
      unitRef="U_USD">2459000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_274908d0-ffdb-4828-8467-1c06ef1e83eb"
      unitRef="U_USD">3186000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="-3"
      id="F_ca58174c-b40f-406f-a204-a53391306274"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-3"
      id="F_a28ac2e1-17de-4fdc-aee2-08b95f6d666b"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="-5"
      id="F_3f1ce589-70eb-47e8-85d0-de344ad2e5d9"
      unitRef="U_USD">35000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e3d54fc7-6a3d-43de-9e32-8e241187c233"
      decimals="-5"
      id="F_18bc6b47-a267-4c4a-87ca-d0c78544d388"
      unitRef="U_USD">312300000</us-gaap:OperatingLossCarryforwards>
    <fulc:OperatingLossCarryforwardsExpirationYear
      contextRef="C_477d49f1-72c7-42b4-91d0-1ea14d3bf239"
      id="F_c93bdc6f-c3ef-4d54-bcb7-5b9fe720e44b">2036</fulc:OperatingLossCarryforwardsExpirationYear>
    <fulc:OperatingLossCarryforwardsIndefinitely
      contextRef="C_477d49f1-72c7-42b4-91d0-1ea14d3bf239"
      decimals="-5"
      id="F_a9de034f-a0ce-44c9-9500-41de6779712e"
      unitRef="U_USD">288700000</fulc:OperatingLossCarryforwardsIndefinitely>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_848b9802-2af7-4a3a-b897-56f5907cf9a6"
      decimals="-5"
      id="F_887d90c2-6779-425d-83df-c5d46a165c13"
      unitRef="U_USD">317100000</us-gaap:OperatingLossCarryforwards>
    <fulc:OperatingLossCarryforwardsExpirationYear
      contextRef="C_8ddbacbc-0594-4cc9-a6ac-745a13b49459"
      id="F_0e048132-786c-49b6-a0e6-d957700959f2">2036</fulc:OperatingLossCarryforwardsExpirationYear>
    <fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards
      contextRef="C_e3d54fc7-6a3d-43de-9e32-8e241187c233"
      decimals="-5"
      id="F_73b65394-4688-482e-80f0-0d650a4c7cee"
      unitRef="U_USD">23800000</fulc:DeferredTaxAssetsOrphanDrugCreditCarryforwards>
    <fulc:TaxCreditCarryforwardExpirationYear
      contextRef="C_477d49f1-72c7-42b4-91d0-1ea14d3bf239"
      id="F_5931b6de-6971-40a6-a559-cb46fccc1baf">2040</fulc:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1ba2348b-df57-42f0-b766-38e72c616f8c"
      decimals="-6"
      id="F_32b106cb-5f82-471a-93af-1681facdefbf"
      unitRef="U_USD">6000000</us-gaap:TaxCreditCarryforwardAmount>
    <fulc:TaxCreditCarryforwardExpirationYear
      contextRef="C_630894ba-94c3-4b2d-a63f-cbe1dd1d4533"
      id="F_1c4ddd80-67a2-4772-b49d-7c1e3944a831">2035</fulc:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_3409faec-0230-4835-b5e3-04aae93d50b9"
      decimals="-5"
      id="F_8e545f98-4255-4583-9887-68dcf528a4fd"
      unitRef="U_USD">4900000</us-gaap:TaxCreditCarryforwardAmount>
    <fulc:TaxCreditCarryforwardExpirationYear
      contextRef="C_4ce2bbff-4474-45cb-9d57-0f72591eb0e3"
      id="F_1a7f06b0-a16b-4150-9baa-00d098f083b2">2030</fulc:TaxCreditCarryforwardExpirationYear>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_b4343bf1-0618-4250-a1a4-6799705cbed5"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_a3610ea2-62e0-46e6-9752-012909c1517b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
      contextRef="C_ace913de-08f0-4d3e-b2f5-d944b6b65ed8"
      decimals="INF"
      id="F_e584d35e-def5-4198-88ac-3f26f0a3e2c7"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
      contextRef="C_2034a62c-8291-4271-afc4-d4d11578f7a0"
      decimals="INF"
      id="F_d7dcc4f9-2713-424d-a654-5fd4fd02a4f8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_9ed2afa5-3e4c-46d2-8e47-5ed02e4c26fc"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_9c0f7c5e-3628-4702-9cea-70b939c964fc"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_32c0c5a5-bafd-4765-9fd5-e4a30248c1e9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15. Defined Contribution Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a defined contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#x201c;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;401(k)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants the option to elect to defer a portion of their annual compensation on a pretax basis. As currently established, the Company is not required to make contributions to the 401(k) Plan. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;he Company made $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in contributions to the 401(k) Plan for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <fulc:DefinedContributionPlanName
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_fad43420-5693-4e54-817d-88c615c81818">401(k)</fulc:DefinedContributionPlanName>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="-5"
      id="F_765f9dec-b171-4be3-99bf-fe59bd4ba22d"
      unitRef="U_USD">700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="-5"
      id="F_47784b2a-6409-41b4-8068-414c41267837"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_c510f09c-536c-4839-b2a9-47ec7c0a243f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;16. Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.969%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.836%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.836%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,972,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,504,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,047,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,580,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      id="F_d97977cb-ac7f-4ac4-b840-4e11102853c2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.969%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.836%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.836%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,972,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,504,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,047,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,580,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b7d85ad2-5aaa-4c27-af4c-3ddc57509e92"
      decimals="INF"
      id="F_c3e8a1b8-ea57-4c75-8191-0bf1e7c6c25e"
      unitRef="U_shares">9972217</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_dbd2599a-812b-4ac3-94fe-e6eac2633ccd"
      decimals="INF"
      id="F_f18b0349-707e-48ee-a8e4-3fb0d3d60cc9"
      unitRef="U_shares">6504080</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_94054f0d-7eb4-4308-b9a8-6595c31dccc1"
      decimals="INF"
      id="F_bf3ee3f1-724d-4801-ad4c-74ff38b65e94"
      unitRef="U_shares">75017</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cfcc2344-b6f1-4e48-98ac-862abef9fa95"
      decimals="INF"
      id="F_19fd4a7b-bf14-4e82-92e2-197c5a4dfcb3"
      unitRef="U_shares">76718</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9b4d2622-dc4a-4c45-9c70-9fc18b93653c"
      decimals="INF"
      id="F_d2666cbc-9d73-42b9-ae51-9f29691b7be4"
      unitRef="U_shares">10047234</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5b154a84-e3b6-4d80-8d60-7e28915a9763"
      decimals="INF"
      id="F_ce5d1630-c979-4e68-9569-36a3acf46d76"
      unitRef="U_shares">6580798</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
